--DOCSTART-- (10070173)

Comparison	NN	O	O
of	NN	O	O
budesonide	NN	O	B-INT
Turbuhaler	NN	O	I-INT
with	NN	O	O
budesonide	NN	O	B-INT
aqua	NN	O	I-INT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
seasonal	NN	O	B-PAR
allergic	NN	O	I-PAR
rhinitis	NN	O	I-PAR
.	NN	O	O

Rhinocort	NN	O	O
Study	NN	O	O
Group	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
budesonide	NN	O	B-INT
Turbuhaler	NN	O	I-INT
400	NN	O	O
microg/day	NN	O	O
with	NN	O	O
budesonide	NN	O	B-INT
aqua	NN	O	I-INT
256	NN	O	O
microg/day	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
seasonal	NN	O	O
allergic	NN	O	O
rhinitis	NN	O	O
(	NN	O	O
SAR	NN	O	O
)	NN	O	O
.	NN	O	O

Secondarily	NN	O	O
to	NN	O	O
ascertain	NN	O	O
patients	NN	O	B-OUT
'	NN	O	I-OUT
preferences	NN	O	I-OUT
for	NN	O	O
the	NN	O	O
two	NN	O	O
nasal	NN	O	O
devices	NN	O	O
and	NN	O	O
to	NN	O	O
assess	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
.	NN	O	O

DESIGN	NN	O	O
Randomized	NN	O	O
,	NN	O	O
multicentre	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
double-	NN	O	O
dummy	NN	O	O
,	NN	O	O
parallel	NN	O	O
groups	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
Private	NN	O	O
practices	NN	O	O
and	NN	O	O
hospital	NN	O	O
clinics	NN	O	O
in	NN	O	O
Ontario	NN	O	B-PAR
,	NN	O	I-PAR
Quebec	NN	O	I-PAR
and	NN	O	I-PAR
Manitoba	NN	O	I-PAR
.	NN	O	O

POPULATION	NN	O	O
Two	NN	O	B-PAR
hundred	NN	O	I-PAR
and	NN	O	I-PAR
eighty-four	NN	O	I-PAR
out-patients	NN	O	I-PAR
with	NN	O	I-PAR
SAR	NN	O	I-PAR
,	NN	O	I-PAR
who	NN	O	I-PAR
were	NN	O	I-PAR
symptomatic	NN	O	I-PAR
during	NN	O	I-PAR
the	NN	O	I-PAR
ragweed	NN	O	I-PAR
season	NN	O	I-PAR
,	NN	O	I-PAR
volunteered	NN	O	I-PAR
for	NN	O	I-PAR
enrolment	NN	O	I-PAR
(	NN	O	I-PAR
243	NN	O	I-PAR
randomized	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

RESULTS	NN	O	O
Mean	NN	O	B-OUT
daily	NN	O	I-OUT
nasal	NN	O	I-OUT
symptom	NN	O	I-OUT
scores	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
changes	NN	O	O
from	NN	O	O
baseline	NN	O	O
for	NN	O	O
eye	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
(	NN	O	O
more	NN	O	O
than	NN	O	O
80	NN	O	O
%	NN	O	O
)	NN	O	O
achieved	NN	O	O
substantial	NN	O	O
control	NN	O	O
of	NN	O	O
their	NN	O	O
symptoms	NN	O	O
with	NN	O	O
budesonide	NN	O	B-INT
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
nasal	NN	O	B-OUT
and	NN	O	I-OUT
non-nasal	NN	O	I-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
for	NN	O	O
both	NN	O	O
groups	NN	O	O
were	NN	O	O
epistaxis	NN	O	B-OUT
and	NN	O	O
headache	NN	O	B-OUT
.	NN	O	O

Turbuhaler	NN	O	B-INT
was	NN	O	O
easier	NN	O	O
to	NN	O	O
use	NN	O	O
and	NN	O	O
more	NN	O	O
convenient	NN	O	O
to	NN	O	O
carry	NN	O	O
,	NN	O	O
had	NN	O	O
less	NN	O	O
of	NN	O	O
an	NN	O	O
unpleasant	NN	O	O
taste	NN	O	O
,	NN	O	O
and	NN	O	O
caused	NN	O	O
less	NN	O	O
nasal	NN	O	B-OUT
irritation	NN	O	I-OUT
than	NN	O	O
the	NN	O	O
aqua	NN	O	O
spray	NN	O	O
.	NN	O	O

More	NN	O	O
than	NN	O	O
twice	NN	O	O
as	NN	O	O
many	NN	O	O
patients	NN	O	O
preferred	NN	O	O
Turbuhaler	NN	O	B-INT
to	NN	O	O
the	NN	O	O
aqua	NN	O	B-INT
spray	NN	O	I-INT
(	NN	O	O
69	NN	O	O
%	NN	O	O
versus	NN	O	O
31	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Improvement	NN	O	O
in	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
clinic	NN	O	O
visits	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Once	NN	O	O
daily	NN	O	O
use	NN	O	O
of	NN	O	O
256	NN	O	O
mg	NN	O	O
of	NN	O	O
budesonide	NN	O	B-INT
aqua	NN	O	I-INT
and	NN	O	O
400	NN	O	O
mg	NN	O	O
of	NN	O	O
budesonide	NN	O	B-INT
Turbuhaler	NN	O	I-INT
are	NN	O	O
equally	NN	O	O
safe	NN	O	B-OUT
and	NN	O	O
efficacious	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
SAR	NN	O	B-PAR
.	NN	O	O

Patients	NN	O	O
preferred	NN	O	O
the	NN	O	O
budesonide	NN	O	B-INT
powder	NN	O	I-INT
formulation	NN	O	O
delivered	NN	O	O
via	NN	O	O
Turbuhaler	NN	O	B-INT
two	NN	O	O
to	NN	O	O
one	NN	O	O
over	NN	O	O
the	NN	O	O
aqua	NN	O	B-INT
formulation	NN	O	O
.	NN	O	O



--DOCSTART-- (10390665)

Anti-emetic	NN	O	B-OUT
efficacy	NN	O	I-OUT
of	NN	O	O
prophylactic	NN	O	O
granisetron	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
perphenazine	NN	O	B-INT
for	NN	O	O
the	NN	O	O
prevention	NN	O	B-OUT
of	NN	O	O
post-operative	NN	O	O
vomiting	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
.	NN	O	O

We	NN	O	O
have	NN	O	O
compared	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
granisetron	NN	O	B-INT
with	NN	O	O
perphenazine	NN	O	B-INT
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
vomiting	NN	O	O
after	NN	O	O
tonsillectomy	NN	O	B-PAR
with	NN	O	I-PAR
or	NN	O	I-PAR
without	NN	O	I-PAR
adenoidectomy	NN	O	I-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
.	NN	O	O

In	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
study	NN	O	O
,	NN	O	O
90	NN	O	B-PAR
paediatric	NN	O	I-PAR
patients	NN	O	I-PAR
,	NN	O	I-PAR
ASA	NN	O	I-PAR
I	NN	O	I-PAR
,	NN	O	I-PAR
aged	NN	O	I-PAR
4-10	NN	O	I-PAR
years	NN	O	I-PAR
,	NN	O	O
received	NN	O	O
granisetron	NN	O	B-INT
40	NN	O	O
mg	NN	O	O
kg-1	NN	O	O
or	NN	O	O
perphenazine	NN	O	B-INT
70	NN	O	O
mg	NN	O	O
kg-1	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
45	NN	O	O
each	NN	O	O
)	NN	O	O
intravenously	NN	O	O
immediately	NN	O	O
after	NN	O	O
an	NN	O	O
inhalation	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

A	NN	O	O
standard	NN	O	O
general	NN	O	O
anaesthetic	NN	O	O
technique	NN	O	O
was	NN	O	O
employed	NN	O	O
throughout	NN	O	O
.	NN	O	O

A	NN	O	O
complete	NN	O	B-OUT
response	NN	O	I-OUT
,	NN	O	I-OUT
defined	NN	O	I-OUT
as	NN	O	I-OUT
no	NN	O	I-OUT
emesis	NN	O	I-OUT
with	NN	O	I-OUT
no	NN	O	I-OUT
need	NN	O	I-OUT
for	NN	O	I-OUT
another	NN	O	I-OUT
rescue	NN	O	I-OUT
antiemetic	NN	O	I-OUT
,	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
3	NN	O	O
h	NN	O	O
(	NN	O	O
0-3	NN	O	O
h	NN	O	O
)	NN	O	O
after	NN	O	O
anesthesia	NN	O	O
was	NN	O	O
87	NN	O	O
%	NN	O	O
with	NN	O	O
granisetron	NN	O	B-INT
and	NN	O	O
78	NN	O	O
%	NN	O	O
with	NN	O	O
perphenazine	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.204	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
corresponding	NN	O	B-OUT
incidence	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
next	NN	O	O
21	NN	O	O
h	NN	O	O
(	NN	O	O
3-24	NN	O	O
h	NN	O	O
)	NN	O	O
after	NN	O	O
anaesthesia	NN	O	O
was	NN	O	O
87	NN	O	O
%	NN	O	O
and	NN	O	O
62	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.007	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
clinically	NN	O	O
serious	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
were	NN	O	O
observed	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
granisetron	NN	O	B-INT
is	NN	O	O
a	NN	O	O
better	NN	O	O
anti-emetic	NN	O	O
than	NN	O	O
perphenazine	NN	O	B-INT
for	NN	O	O
the	NN	O	O
long-term	NN	O	B-OUT
prevention	NN	O	I-OUT
of	NN	O	O
post-operative	NN	O	B-OUT
vomiting	NN	O	I-OUT
in	NN	O	O
children	NN	O	B-PAR
undergoing	NN	O	I-PAR
general	NN	O	I-PAR
anaesthesia	NN	O	I-PAR
for	NN	O	I-PAR
tonsillectomy	NN	O	I-PAR
.	NN	O	I-PAR


--DOCSTART-- (10475150)

The	NN	O	O
role	NN	O	O
of	NN	O	O
somatostatin	NN	O	B-INT
(	NN	O	I-INT
octreotide	NN	O	I-INT
)	NN	O	I-INT
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
melatonin	NN	O	B-OUT
secretion	NN	O	I-OUT
in	NN	O	O
healthy	NN	O	B-PAR
volunteers	NN	O	I-PAR
and	NN	O	I-PAR
in	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
hypothyroidism	NN	O	I-PAR
.	NN	O	I-PAR
Somatostatin	NN	O	I-INT
has	NN	O	O
been	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
pineal	NN	O	O
gland	NN	O	O
of	NN	O	O
several	NN	O	O
animal	NN	O	O
species	NN	O	O
,	NN	O	O
which	NN	O	O
suggests	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
melatonin	NN	O	B-OUT
secretion	NN	O	I-OUT
.	NN	O	O

Whether	NN	O	O
somatostatin	NN	O	B-INT
has	NN	O	O
regulatory	NN	O	O
influence	NN	O	O
on	NN	O	O
melatonin	NN	O	B-OUT
secretion	NN	O	I-OUT
in	NN	O	O
man	NN	O	O
has	NN	O	O
never	NN	O	O
been	NN	O	O
unequivocally	NN	O	O
shown	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
nocturnal	NN	O	B-OUT
melatonin	NN	O	I-OUT
secretion	NN	O	I-OUT
in	NN	O	O
8	NN	O	B-PAR
healthy	NN	O	I-PAR
volunteers	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
6	NN	O	I-PAR
women	NN	O	I-PAR
with	NN	O	I-PAR
untreated	NN	O	I-PAR
primary	NN	O	I-PAR
hypothyroidism	NN	O	I-PAR
,	NN	O	O
a	NN	O	O
disease	NN	O	O
state	NN	O	O
that	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
nocturnal	NN	O	O
secretion	NN	O	O
of	NN	O	O
melatonin	NN	O	O
.	NN	O	O

The	NN	O	O
participants	NN	O	O
were	NN	O	O
given	NN	O	O
subcutaneous	NN	O	O
injections	NN	O	O
at	NN	O	O
18:00	NN	O	O
h	NN	O	O
and	NN	O	O
23:00	NN	O	O
h	NN	O	O
of	NN	O	O
either	NN	O	O
saline	NN	O	B-INT
or	NN	O	O
octreotide	NN	O	B-INT
(	NN	O	I-INT
Sandostatin	NN	O	I-INT
;	NN	O	O
each	NN	O	O
injection	NN	O	O
50	NN	O	O
microg	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
nights	NN	O	O
when	NN	O	O
the	NN	O	O
healthy	NN	O	B-PAR
volunteers	NN	O	I-PAR
were	NN	O	O
given	NN	O	O
octreotide	NN	O	B-INT
,	NN	O	O
melatonin	NN	O	B-OUT
secretion	NN	O	I-OUT
was	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
recorded	NN	O	O
during	NN	O	O
administration	NN	O	O
of	NN	O	O
saline	NN	O	B-INT
.	NN	O	O

Also	NN	O	O
the	NN	O	O
urinary	NN	O	B-OUT
excretion	NN	O	I-OUT
of	NN	O	I-OUT
melatonin	NN	O	I-OUT
was	NN	O	O
of	NN	O	O
similar	NN	O	O
magnitude	NN	O	O
at	NN	O	O
these	NN	O	O
two	NN	O	O
occasions	NN	O	O
.	NN	O	O

By	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
GH	NN	O	B-OUT
secretion	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
the	NN	O	O
nights	NN	O	O
the	NN	O	O
healthy	NN	O	O
controls	NN	O	O
were	NN	O	O
given	NN	O	O
octreotide	NN	O	B-INT
(	NN	O	O
GH	NN	O	O
AUC	NN	O	O
22.6+/-5.4	NN	O	O
mU/l	NN	O	O
x	NN	O	O
h	NN	O	O
during	NN	O	O
octreotide	NN	O	B-INT
and	NN	O	O
126.6+/-21.9	NN	O	O
mU/l	NN	O	O
x	NN	O	O
h	NN	O	O
during	NN	O	O
saline	NN	O	B-INT
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
hypothyroidism	NN	O	I-PAR
also	NN	O	O
showed	NN	O	O
similar	NN	O	O
nocturnal	NN	O	B-OUT
melatonin	NN	O	I-OUT
secretion	NN	O	I-OUT
during	NN	O	O
octreotide	NN	O	B-INT
and	NN	O	O
saline	NN	O	B-INT
.	NN	O	O

Urinary	NN	O	B-OUT
excretion	NN	O	I-OUT
of	NN	O	I-OUT
melatonin	NN	O	I-OUT
also	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
,	NN	O	O
as	NN	O	O
did	NN	O	O
GH	NN	O	O
secretion	NN	O	O
.	NN	O	O

The	NN	O	O
total	NN	O	B-OUT
nocturnal	NN	O	I-OUT
secretion	NN	O	I-OUT
of	NN	O	I-OUT
TSH	NN	O	I-OUT
was	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
octreotide	NN	O	B-INT
(	NN	O	O
TSH	NN	O	O
AUC	NN	O	O
562+/-136	NN	O	O
mU/l	NN	O	O
x	NN	O	O
h	NN	O	O
during	NN	O	O
octreotide	NN	O	B-INT
and	NN	O	O
851+/-185	NN	O	O
mU/l	NN	O	O
x	NN	O	O
h	NN	O	O
during	NN	O	O
saline	NN	O	B-INT
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
thus	NN	O	O
suggesting	NN	O	O
that	NN	O	O
100	NN	O	O
microg	NN	O	O
of	NN	O	O
octreotide	NN	O	B-INT
should	NN	O	O
be	NN	O	O
sufficient	NN	O	O
to	NN	O	O
inhibit	NN	O	O
also	NN	O	O
the	NN	O	O
pinealocytes	NN	O	O
if	NN	O	O
their	NN	O	O
function	NN	O	O
were	NN	O	O
regulated	NN	O	O
by	NN	O	O
somatostatin	NN	O	B-INT
.	NN	O	O

Since	NN	O	O
exogenous	NN	O	O
somatostatin	NN	O	B-INT
--	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
octreotide	NN	O	B-INT
--	NN	O	O
fails	NN	O	O
to	NN	O	O
influence	NN	O	O
nocturnal	NN	O	B-OUT
secretion	NN	O	I-OUT
and	NN	O	I-OUT
urinary	NN	O	I-OUT
excretion	NN	O	I-OUT
of	NN	O	I-OUT
melatonin	NN	O	I-OUT
in	NN	O	O
normal	NN	O	B-PAR
subjects	NN	O	I-PAR
and	NN	O	I-PAR
in	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
hypothyroidism	NN	O	I-PAR
,	NN	O	O
it	NN	O	O
is	NN	O	O
reasonable	NN	O	O
to	NN	O	O
assume	NN	O	O
that	NN	O	O
endogenous	NN	O	O
somatostatin	NN	O	B-INT
may	NN	O	O
not	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
regulator	NN	O	O
of	NN	O	O
melatonin	NN	O	O
secretion	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O



--DOCSTART-- (10578479)

Effects	NN	O	O
of	NN	O	O
soy	NN	O	B-INT
intake	NN	O	O
on	NN	O	O
sex	NN	O	B-OUT
hormone	NN	O	I-OUT
metabolism	NN	O	I-OUT
in	NN	O	O
premenopausal	NN	O	B-PAR
women	NN	O	I-PAR
.	NN	O	O

Studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
phytoestrogens	NN	O	O
in	NN	O	O
soy	NN	O	B-INT
products	NN	O	O
may	NN	O	O
impart	NN	O	O
hormonal	NN	O	O
effects	NN	O	O
that	NN	O	O
protect	NN	O	O
women	NN	O	O
against	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

Limited	NN	O	O
research	NN	O	O
suggests	NN	O	O
that	NN	O	O
intake	NN	O	O
of	NN	O	O
soy	NN	O	B-INT
products	NN	O	O
high	NN	O	O
in	NN	O	O
isoflavonoid	NN	O	O
phytoestrogens	NN	O	O
affects	NN	O	O
sex	NN	O	B-OUT
hormone	NN	O	I-OUT
metabolism	NN	O	I-OUT
,	NN	O	O
but	NN	O	O
it	NN	O	O
is	NN	O	O
unknown	NN	O	O
whether	NN	O	O
phytoestrogens	NN	O	O
in	NN	O	O
soy	NN	O	O
have	NN	O	O
any	NN	O	O
effect	NN	O	O
on	NN	O	O
menstrual	NN	O	O
function	NN	O	O
or	NN	O	O
serum	NN	O	O
sex	NN	O	O
hormones	NN	O	O
in	NN	O	O
women	NN	O	B-PAR
on	NN	O	O
common	NN	O	O
hormone	NN	O	O
therapies	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
(	NN	O	O
OC	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
soy	NN	O	B-INT
in	NN	O	O
36	NN	O	B-PAR
premenopausal	NN	O	I-PAR
women	NN	O	I-PAR
,	NN	O	I-PAR
20	NN	O	I-PAR
of	NN	O	I-PAR
whom	NN	O	I-PAR
used	NN	O	I-PAR
OC	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	O
consumed	NN	O	O
their	NN	O	O
normal	NN	O	O
diet	NN	O	O
for	NN	O	O
two	NN	O	O
menstrual	NN	O	O
cycles	NN	O	O
and	NN	O	O
added	NN	O	O
a	NN	O	O
soy	NN	O	B-INT
beverage	NN	O	I-INT
containing	NN	O	O
20	NN	O	O
g	NN	O	O
of	NN	O	O
protein	NN	O	O
and	NN	O	O
38	NN	O	O
mg	NN	O	O
of	NN	O	O
total	NN	O	O
isoflavones	NN	O	O
to	NN	O	O
their	NN	O	O
usual	NN	O	O
diet	NN	O	O
for	NN	O	O
another	NN	O	O
two	NN	O	O
menstrual	NN	O	O
cycles	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
serum	NN	O	B-OUT
estrone	NN	O	I-OUT
,	NN	O	I-OUT
estradiol	NN	O	I-OUT
,	NN	O	I-OUT
sex	NN	O	I-OUT
hormone-binding	NN	O	I-OUT
globulin	NN	O	I-OUT
,	NN	O	I-OUT
dehydroepiandrosterone	NN	O	I-OUT
sulfate	NN	O	I-OUT
,	NN	O	I-OUT
prolactin	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
progesterone	NN	O	I-OUT
concentrations	NN	O	I-OUT
with	NN	O	O
soy	NN	O	B-INT
feeding	NN	O	O
in	NN	O	O
the	NN	O	O
non-OC	NN	O	O
or	NN	O	O
the	NN	O	O
OC	NN	O	O
group	NN	O	O
.	NN	O	O

No	NN	O	O
changes	NN	O	O
in	NN	O	O
menstrual	NN	O	B-OUT
cycle	NN	O	I-OUT
length	NN	O	I-OUT
or	NN	O	I-OUT
the	NN	O	I-OUT
urinary	NN	O	I-OUT
estrogen	NN	O	I-OUT
metabolite	NN	O	I-OUT
ratio	NN	O	I-OUT
of	NN	O	I-OUT
2-hydroxyestrone	NN	O	I-OUT
to	NN	O	I-OUT
16	NN	O	I-OUT
alpha-hydroxyestrone	NN	O	I-OUT
were	NN	O	O
seen	NN	O	O
with	NN	O	O
soy	NN	O	O
feeding	NN	O	O
in	NN	O	O
the	NN	O	O
non-OC	NN	O	O
or	NN	O	O
the	NN	O	O
OC	NN	O	O
group	NN	O	O
.	NN	O	O

Levels	NN	O	O
of	NN	O	O
urinary	NN	O	B-OUT
estrogen	NN	O	I-OUT
metabolites	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
non-OC	NN	O	O
and	NN	O	O
the	NN	O	O
OC	NN	O	O
group	NN	O	O
.	NN	O	O

Thus	NN	O	O
soy	NN	O	B-INT
consumption	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
menstrual	NN	O	B-OUT
cycle	NN	O	I-OUT
,	NN	O	I-OUT
serum	NN	O	I-OUT
sex	NN	O	I-OUT
hormones	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
urinary	NN	O	I-OUT
estrogen	NN	O	I-OUT
metabolite	NN	O	I-OUT
ratio	NN	O	I-OUT
in	NN	O	O
premenopausal	NN	O	B-PAR
OC	NN	O	I-PAR
or	NN	O	O
non-OC	NN	O	B-PAR
users	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (10589810)

Clinical	NN	O	B-OUT
effects	NN	O	I-OUT
of	NN	O	O
root	NN	O	O
instrumentation	NN	O	O
using	NN	O	O
conventional	NN	O	O
steel	NN	O	O
or	NN	O	O
non-tooth	NN	O	O
substance	NN	O	O
removing	NN	O	O
plastic	NN	O	O
curettes	NN	O	O
during	NN	O	O
supportive	NN	O	O
periodontal	NN	O	O
therapy	NN	O	O
(	NN	O	O
SPT	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
root	NN	O	O
instrumentation	NN	O	O
has	NN	O	O
been	NN	O	O
accepted	NN	O	O
as	NN	O	O
the	NN	O	O
most	NN	O	O
important	NN	O	O
cause-related	NN	O	O
treatment	NN	O	O
of	NN	O	O
periodontal	NN	O	O
diseases	NN	O	O
,	NN	O	O
repeated	NN	O	O
scaling	NN	O	O
and	NN	O	O
root	NN	O	O
planing	NN	O	O
may	NN	O	O
over	NN	O	O
time	NN	O	O
result	NN	O	O
in	NN	O	O
substantive	NN	O	O
loss	NN	O	O
of	NN	O	O
tooth	NN	O	O
substance	NN	O	O
and	NN	O	O
increased	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
teeth	NN	O	O
.	NN	O	O

In	NN	O	O
an	NN	O	O
effort	NN	O	O
to	NN	O	O
minimize	NN	O	O
these	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
non-root	NN	O	O
substance	NN	O	O
removing	NN	O	O
curettes	NN	O	O
have	NN	O	O
been	NN	O	O
developed	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
clinical	NN	O	B-OUT
effects	NN	O	I-OUT
of	NN	O	O
such	NN	O	O
plastic	NN	O	O
curettes	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
periodontal	NN	O	O
infection	NN	O	O
has	NN	O	O
not	NN	O	O
yet	NN	O	O
been	NN	O	O
established	NN	O	O
.	NN	O	O

The	NN	O	O
aims	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
root	NN	O	O
instrumentation	NN	O	O
using	NN	O	O
plastic	NN	O	B-INT
curettes	NN	O	I-INT
(	NN	O	O
Universal	NN	O	O
Perio	NN	O	O
Soft	NN	O	O
Scaler	NN	O	O
,	NN	O	O
Hawe-Neos	NN	O	O
Dental	NN	O	O
,	NN	O	O
Bioggio	NN	O	O
,	NN	O	O
TI	NN	O	O
,	NN	O	O
Switzerland	NN	O	O
)	NN	O	O
versus	NN	O	O
conventional	NN	O	B-INT
steel	NN	O	I-INT
curettes	NN	O	I-INT
on	NN	O	O
the	NN	O	O
periodontal	NN	O	O
conditions	NN	O	O
during	NN	O	O
supportive	NN	O	O
periodontal	NN	O	O
therapy	NN	O	O
.	NN	O	O

40	NN	O	B-PAR
subjects	NN	O	I-PAR
participated	NN	O	O
in	NN	O	O
this	NN	O	O
parallel	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
blind	NN	O	O
,	NN	O	O
prospective	NN	O	O
longitudinal	NN	O	O
clinical	NN	O	O
study	NN	O	O
following	NN	O	O
active	NN	O	O
peridontal	NN	O	O
therapy	NN	O	O
.	NN	O	O

20	NN	O	B-PAR
subjects	NN	O	I-PAR
served	NN	O	I-PAR
as	NN	O	I-PAR
a	NN	O	I-PAR
control	NN	O	I-PAR
group	NN	O	I-PAR
and	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
conventional	NN	O	B-INT
steel	NN	O	I-INT
curettes	NN	O	I-INT
during	NN	O	O
a	NN	O	O
supportive	NN	O	B-PAR
periodontal	NN	O	I-PAR
care	NN	O	I-PAR
visit	NN	O	O
(	NN	O	O
SPT	NN	O	B-PAR
)	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
20	NN	O	B-PAR
subjects	NN	O	I-PAR
,	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
,	NN	O	O
were	NN	O	O
treated	NN	O	O
using	NN	O	O
plastic	NN	O	B-INT
curettes	NN	O	I-INT
during	NN	O	O
a	NN	O	O
similar	NN	O	O
SPT	NN	O	O
visit	NN	O	O
.	NN	O	O

Clinical	NN	O	O
parameters	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
bleeding	NN	O	B-OUT
on	NN	O	I-OUT
probing	NN	O	I-OUT
(	NN	O	I-OUT
BOP	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	I-OUT
probing	NN	O	I-OUT
pocket	NN	O	I-OUT
depth	NN	O	I-OUT
(	NN	O	I-OUT
PPD	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
3-6	NN	O	O
months	NN	O	O
later	NN	O	O
at	NN	O	O
the	NN	O	O
next	NN	O	O
regular	NN	O	O
SPT	NN	O	O
visit	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
BOP	NN	O	B-OUT
percentage	NN	O	I-OUT
was	NN	O	O
determined	NN	O	O
10	NN	O	O
days	NN	O	O
following	NN	O	O
baseline	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
2	NN	O	O
treatment	NN	O	O
modalities	NN	O	O
regarding	NN	O	O
BOP	NN	O	B-OUT
and	NN	O	I-OUT
PPD	NN	O	I-OUT
at	NN	O	O
any	NN	O	O
observation	NN	O	O
time	NN	O	O
.	NN	O	O

Both	NN	O	O
treatments	NN	O	O
were	NN	O	O
effective	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
BOP	NN	O	B-OUT
percentage	NN	O	I-OUT
which	NN	O	O
ranged	NN	O	O
from	NN	O	O
17-42	NN	O	O
%	NN	O	O
at	NN	O	O
baseline	NN	O	O
by	NN	O	O
about	NN	O	O
40	NN	O	O
%	NN	O	O
after	NN	O	O
10	NN	O	O
days	NN	O	O
(	NN	O	O
mean	NN	O	O
BOP	NN	O	B-OUT
baseline	NN	O	O
:	NN	O	O
26	NN	O	O
%	NN	O	O
,	NN	O	O
mean	NN	O	O
BOP	NN	O	B-OUT
after	NN	O	O
10	NN	O	O
days	NN	O	O
:	NN	O	O
16	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
clinical	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
non-root	NN	O	B-INT
substance	NN	O	I-INT
removing	NN	O	I-INT
curettes	NN	O	I-INT
may	NN	O	O
be	NN	O	O
valuable	NN	O	O
instruments	NN	O	O
for	NN	O	O
periodontally	NN	O	O
treated	NN	O	O
patients	NN	O	O
during	NN	O	O
maintenance	NN	O	O
care	NN	O	O
,	NN	O	O
thus	NN	O	O
minimizing	NN	O	O
trauma	NN	O	O
on	NN	O	O
the	NN	O	O
hard	NN	O	O
structures	NN	O	O
of	NN	O	O
the	NN	O	O
teeth	NN	O	O
.	NN	O	O



--DOCSTART-- (10752495)

Prediction	NN	O	O
of	NN	O	O
creatinine	NN	O	B-OUT
clearance	NN	O	I-OUT
from	NN	O	I-OUT
serum	NN	O	I-OUT
creatinine	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
rheumatoid	NN	O	I-PAR
arthritis	NN	O	I-PAR
:	NN	O	O
comparison	NN	O	O
of	NN	O	O
six	NN	O	O
formulae	NN	O	O
and	NN	O	O
one	NN	O	O
nomogram	NN	O	O
.	NN	O	O

The	NN	O	O
estimation	NN	O	O
of	NN	O	O
glomerular	NN	O	B-OUT
filtration	NN	O	I-OUT
rate	NN	O	I-OUT
is	NN	O	O
important	NN	O	O
for	NN	O	O
the	NN	O	O
medical	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
rheumatoid	NN	O	I-PAR
arthritis	NN	O	I-PAR
(	NN	O	I-PAR
RA	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
determination	NN	O	O
of	NN	O	O
endogenous	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
(	NN	O	O
Clcr	NN	O	O
)	NN	O	O
from	NN	O	O
a	NN	O	O
24-h	NN	O	O
urine	NN	O	O
collection	NN	O	O
is	NN	O	O
an	NN	O	O
unreliable	NN	O	O
and	NN	O	O
time-consuming	NN	O	O
procedure	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
tested	NN	O	O
the	NN	O	O
accuracy	NN	O	O
of	NN	O	O
six	NN	O	O
equations	NN	O	O
and	NN	O	O
one	NN	O	O
nomogram	NN	O	O
for	NN	O	O
the	NN	O	O
prediction	NN	O	B-OUT
of	NN	O	I-OUT
Clcr	NN	O	I-OUT
from	NN	O	I-OUT
serum	NN	O	I-OUT
creatinine	NN	O	I-OUT
(	NN	O	I-OUT
Scr	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
38	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
RA	NN	O	I-PAR
and	NN	O	I-PAR
20	NN	O	I-PAR
controls	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
positive	NN	O	O
correlation	NN	O	B-OUT
was	NN	O	O
found	NN	O	O
for	NN	O	O
all	NN	O	O
methods	NN	O	O
in	NN	O	O
the	NN	O	O
controls	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.83-0.94	NN	O	O
)	NN	O	O
and	NN	O	O
RA	NN	O	O
patients	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.51-0.69	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
methods	NN	O	O
did	NN	O	O
not	NN	O	O
overestimate	NN	O	O
Clcr	NN	O	O
in	NN	O	O
RA	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
RA	NN	O	O
group	NN	O	O
the	NN	O	O
simple	NN	O	O
formula	NN	O	O
published	NN	O	O
by	NN	O	O
Cockcroft	NN	O	O
[	NN	O	O
Clcr	NN	O	O
=	NN	O	O
(	NN	O	O
(	NN	O	O
140	NN	O	O
-	NN	O	O
age	NN	O	O
)	NN	O	O
x	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
/	NN	O	O
(	NN	O	O
72	NN	O	O
x	NN	O	O
Scr	NN	O	O
)	NN	O	O
,	NN	O	O
x	NN	O	O
0.85	NN	O	O
for	NN	O	O
females	NN	O	O
]	NN	O	O
showed	NN	O	O
the	NN	O	O
best	NN	O	O
correlation	NN	O	O
with	NN	O	O
the	NN	O	O
measured	NN	O	O
Clcr	NN	O	O
.	NN	O	O

In	NN	O	O
RA	NN	O	O
the	NN	O	O
Cockroft	NN	O	O
formula	NN	O	O
can	NN	O	O
reliably	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
predict	NN	O	B-OUT
Clcr	NN	O	I-OUT
from	NN	O	I-OUT
Scr	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (10763172)

[	NN	O	O
Improving	NN	O	O
wound	NN	O	B-OUT
healing	NN	O	I-OUT
after	NN	O	I-PAR
nose	NN	O	I-PAR
surgery	NN	O	I-PAR
by	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
xylometazoline	NN	O	B-INT
and	NN	O	O
dexpanthenol	NN	O	B-INT
]	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
the	NN	O	O
examination	NN	O	O
of	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
an	NN	O	O
application-form	NN	O	O
of	NN	O	O
the	NN	O	O
new	NN	O	O
combination	NN	O	O
of	NN	O	O
Xylometazoline	NN	O	B-INT
with	NN	O	O
Dexpanthenol	NN	O	B-INT
(	NN	O	I-INT
Nasic	NN	O	I-INT
)	NN	O	I-INT
versus	NN	O	O
Xylometazoline	NN	O	B-INT
alone	NN	O	I-INT
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Randomized	NN	O	O
verum	NN	O	O
controlled	NN	O	O
parallel-group-comparison	NN	O	O
of	NN	O	O
two	NN	O	O
weeks	NN	O	O
treatment	NN	O	O
of	NN	O	O
a	NN	O	O
nasal-spray	NN	O	O
.	NN	O	O

61	NN	O	B-PAR
inpatients	NN	O	I-PAR
with	NN	O	I-PAR
the	NN	O	I-PAR
diagnosis	NN	O	I-PAR
Rhinitis	NN	O	I-PAR
following	NN	O	I-PAR
nasal	NN	O	I-PAR
operation	NN	O	I-PAR
were	NN	O	O
included	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
and	NN	O	O
30	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
verum	NN	O	B-INT
and	NN	O	O
placebo	NN	O	B-INT
each	NN	O	O
.	NN	O	O

The	NN	O	O
assessment	NN	O	O
of	NN	O	O
nasal-breathing-resistance	NN	O	B-OUT
according	NN	O	I-OUT
to	NN	O	I-OUT
scores	NN	O	I-OUT
was	NN	O	O
defined	NN	O	O
as	NN	O	O
target-parameter	NN	O	O
.	NN	O	O

Confirmatory	NN	O	O
statistical	NN	O	O
analysis	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
according	NN	O	O
to	NN	O	O
Wilcoxon-Mann-Whitney-U	NN	O	O
two-sided	NN	O	O
at	NN	O	O
alpha	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0.05	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURE	NN	O	O
The	NN	O	O
superiority	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
Xylometazoline-Dexpanthenol	NN	O	B-INT
nasal-spray	NN	O	O
versus	NN	O	O
Xylometazoline	NN	O	B-INT
nasal	NN	O	O
spray	NN	O	O
could	NN	O	O
be	NN	O	O
proven	NN	O	O
for	NN	O	O
the	NN	O	O
target-parameter	NN	O	O
as	NN	O	O
clinically	NN	O	O
relevant	NN	O	O
and	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

The	NN	O	O
clinically	NN	O	O
proven	NN	O	O
efficacy	NN	O	B-OUT
is	NN	O	O
emphasized	NN	O	O
by	NN	O	O
good	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
both	NN	O	O
treatments	NN	O	O
.	NN	O	O

Due	NN	O	O
to	NN	O	O
easy	NN	O	O
handling	NN	O	O
of	NN	O	O
the	NN	O	O
nasal-spray	NN	O	O
a	NN	O	O
good	NN	O	O
compliance	NN	O	B-OUT
was	NN	O	O
confirmed	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Distinct	NN	O	O
improvement	NN	O	B-OUT
of	NN	O	O
symptoms	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
following	NN	O	I-PAR
nasal	NN	O	I-PAR
operations	NN	O	I-PAR
underlines	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
both	NN	O	O
medications	NN	O	O
.	NN	O	O

With	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
tolerability	NN	O	B-OUT
therapy	NN	O	O
with	NN	O	O
the	NN	O	O
combination	NN	O	O
is	NN	O	O
more	NN	O	O
beneficial	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
the	NN	O	O
alternative	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
result	NN	O	O
of	NN	O	O
this	NN	O	O
controlled	NN	O	O
clinical	NN	O	O
study	NN	O	O
confirms	NN	O	O
that	NN	O	O
the	NN	O	O
combination	NN	O	O
Xylometazoline-Dexpanthenol	NN	O	B-INT
is	NN	O	O
an	NN	O	O
enlargement	NN	O	O
and	NN	O	O
improvement	NN	O	O
of	NN	O	O
effective	NN	O	O
medicinal	NN	O	O
treatment	NN	O	O
of	NN	O	O
rhinitis	NN	O	B-PAR
following	NN	O	I-PAR
nasal	NN	O	I-PAR
operation	NN	O	I-PAR
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
therapy	NN	O	O
with	NN	O	O
Xylometazoline	NN	O	B-INT
alone	NN	O	O
.	NN	O	O



--DOCSTART-- (10764172)

Intrathecal	NN	O	O
morphine	NN	O	B-INT
suppresses	NN	O	O
NK	NN	O	B-OUT
cell	NN	O	I-OUT
activity	NN	O	I-OUT
following	NN	O	O
abdominal	NN	O	O
surgery	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
The	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	B-INT
on	NN	O	O
natural	NN	O	B-OUT
killer	NN	O	I-OUT
(	NN	O	I-OUT
NK	NN	O	I-OUT
)	NN	O	I-OUT
cell	NN	O	I-OUT
activity	NN	O	I-OUT
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
who	NN	O	I-PAR
underwent	NN	O	I-PAR
hysterectomy	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Forty	NN	O	B-PAR
patients	NN	O	I-PAR
were	NN	O	I-PAR
divided	NN	O	I-PAR
into	NN	O	I-PAR
four	NN	O	I-PAR
groups	NN	O	I-PAR
of	NN	O	I-PAR
ten	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
groups	NN	O	O
received	NN	O	O
intrathecal	NN	O	O
0.5	NN	O	O
mg	NN	O	O
morphine	NN	O	B-INT
(	NN	O	O
Group	NN	O	O
IT0.5	NN	O	O
)	NN	O	O
,	NN	O	O
intrathecal	NN	O	O
0.1	NN	O	O
mg	NN	O	O
morphine	NN	O	B-INT
(	NN	O	O
Group	NN	O	O
IT0.1	NN	O	O
)	NN	O	O
or	NN	O	O
10	NN	O	O
mg	NN	O	O
morphine	NN	O	B-INT
i.v	NN	O	O
.	NN	O	O

(	NN	O	O
Group	NN	O	O
IV	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
ten	NN	O	O
patients	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
and	NN	O	O
received	NN	O	O
inhalation	NN	O	O
anesthesia	NN	O	O
alone	NN	O	O
(	NN	O	O
Group	NN	O	O
C	NN	O	O
)	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
withdrawn	NN	O	O
before	NN	O	O
and	NN	O	O
two	NN	O	O
hours	NN	O	O
after	NN	O	O
surgery	NN	O	O
and	NN	O	O
on	NN	O	O
postoperative	NN	O	O
days	NN	O	O
one	NN	O	O
and	NN	O	O
two	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
blood	NN	O	O
NK	NN	O	O
cell	NN	O	O
activity	NN	O	O
using	NN	O	O
a	NN	O	O
chromium	NN	O	O
release	NN	O	O
assay	NN	O	O
with	NN	O	O
K562	NN	O	O
cells	NN	O	O
as	NN	O	O
targets	NN	O	O
,	NN	O	O
plasma	NN	O	O
catecholamines	NN	O	O
and	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
postoperative	NN	O	B-OUT
pain	NN	O	I-OUT
score	NN	O	I-OUT
and	NN	O	I-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
were	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
four	NN	O	O
groups	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
In	NN	O	O
Group	NN	O	O
IT0.5	NN	O	O
,	NN	O	O
the	NN	O	O
NK	NN	O	B-OUT
cell	NN	O	I-OUT
activity	NN	O	I-OUT
was	NN	O	O
lower	NN	O	O
on	NN	O	O
postoperative	NN	O	O
day	NN	O	O
1	NN	O	O
(	NN	O	O
23.9	NN	O	O
+/-	NN	O	O
8.4	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
the	NN	O	O
baseline	NN	O	O
level	NN	O	O
(	NN	O	O
45.7	NN	O	O
+/-	NN	O	O
13	NN	O	O
%	NN	O	O
)	NN	O	O
before	NN	O	O
surgery	NN	O	O
,	NN	O	O
and	NN	O	O
recovered	NN	O	O
on	NN	O	O
postoperative	NN	O	O
day	NN	O	O
2	NN	O	O
.	NN	O	O

In	NN	O	O
Groups	NN	O	O
IT0.1	NN	O	O
,	NN	O	O
C	NN	O	O
and	NN	O	O
IV	NN	O	O
,	NN	O	O
the	NN	O	O
NK	NN	O	B-OUT
cell	NN	O	I-OUT
activities	NN	O	I-OUT
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
changes	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
four	NN	O	O
groups	NN	O	O
,	NN	O	O
neither	NN	O	O
plasma	NN	O	B-OUT
adrenaline	NN	O	I-OUT
nor	NN	O	O
noradrenaline	NN	O	B-OUT
concentrations	NN	O	I-OUT
changed	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
four	NN	O	O
groups	NN	O	O
,	NN	O	O
the	NN	O	O
plasma	NN	O	B-OUT
cortisol	NN	O	I-OUT
levels	NN	O	I-OUT
increased	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
on	NN	O	O
postoperative	NN	O	O
days	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O

The	NN	O	O
pain	NN	O	B-OUT
score	NN	O	I-OUT
was	NN	O	O
lower	NN	O	O
two	NN	O	O
hours	NN	O	O
after	NN	O	O
surgery	NN	O	O
and	NN	O	O
on	NN	O	O
postoperative	NN	O	O
day	NN	O	O
1	NN	O	O
in	NN	O	O
Group	NN	O	O
IT0.5	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
long-lasting	NN	O	O
analgesic	NN	O	O
effects	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
0.5	NN	O	O
mg	NN	O	O
morphine	NN	O	B-INT
suppress	NN	O	O
the	NN	O	O
immune	NN	O	O
response	NN	O	O
following	NN	O	O
abdominal	NN	O	O
surgery	NN	O	O
.	NN	O	O



--DOCSTART-- (10912743)

Effects	NN	O	O
of	NN	O	O
low-dose	NN	O	O
aspirin	NN	O	B-INT
on	NN	O	O
clinic	NN	O	B-OUT
and	NN	O	I-OUT
ambulatory	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
in	NN	O	O
treated	NN	O	B-PAR
hypertensive	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

Collaborative	NN	O	O
Group	NN	O	O
of	NN	O	O
the	NN	O	O
Primary	NN	O	O
Prevention	NN	O	O
Project	NN	O	O
(	NN	O	O
PPP	NN	O	O
)	NN	O	O
--	NN	O	O
Hypertension	NN	O	O
study	NN	O	O
.	NN	O	O

Nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
drugs	NN	O	O
may	NN	O	O
affect	NN	O	O
blood	NN	O	B-OUT
pressure	NN	O	I-OUT
(	NN	O	I-OUT
BP	NN	O	I-OUT
)	NN	O	I-OUT
control	NN	O	I-OUT
in	NN	O	O
hypertensive	NN	O	B-PAR
patients	NN	O	I-PAR
receiving	NN	O	I-PAR
drug	NN	O	I-PAR
treatment	NN	O	I-PAR
,	NN	O	O
but	NN	O	O
data	NN	O	O
on	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
low-dose	NN	O	O
aspirin	NN	O	B-INT
are	NN	O	O
scanty	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
assessed	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
with	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
aspirin	NN	O	B-INT
(	NN	O	O
100	NN	O	O
mg/day	NN	O	O
)	NN	O	O
on	NN	O	O
clinic	NN	O	B-OUT
and	NN	O	I-OUT
ambulatory	NN	O	I-OUT
systolic	NN	O	I-OUT
(	NN	O	I-OUT
SBP	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
(	NN	O	I-OUT
DBP	NN	O	I-OUT
)	NN	O	I-OUT
BP	NN	O	I-OUT
in	NN	O	O
hypertensives	NN	O	O
on	NN	O	O
chronic	NN	O	O
,	NN	O	O
stable	NN	O	O
antihypertensive	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
the	NN	O	O
framework	NN	O	O
of	NN	O	O
the	NN	O	O
Primary	NN	O	O
Prevention	NN	O	O
Project	NN	O	O
(	NN	O	O
PPP	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
factorial	NN	O	O
trial	NN	O	O
on	NN	O	O
the	NN	O	O
preventive	NN	O	O
effect	NN	O	O
of	NN	O	O
aspirin	NN	O	B-INT
or	NN	O	O
vitamin	NN	O	B-INT
E	NN	O	I-INT
in	NN	O	O
people	NN	O	B-PAR
with	NN	O	I-PAR
one	NN	O	I-PAR
or	NN	O	I-PAR
more	NN	O	I-PAR
cardiovascular	NN	O	I-PAR
risk	NN	O	I-PAR
factors	NN	O	I-PAR
.	NN	O	O

Fifteen	NN	O	B-PAR
Italian	NN	O	I-PAR
hypertension	NN	O	I-PAR
units	NN	O	I-PAR
studied	NN	O	I-PAR
142	NN	O	I-PAR
hypertensive	NN	O	I-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
76	NN	O	I-PAR
men	NN	O	I-PAR
,	NN	O	I-PAR
66	NN	O	I-PAR
women	NN	O	I-PAR
;	NN	O	I-PAR
mean	NN	O	I-PAR
age	NN	O	I-PAR
59	NN	O	I-PAR
+/-	NN	O	I-PAR
5.9	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	I-PAR
treated	NN	O	I-PAR
with	NN	O	I-PAR
different	NN	O	I-PAR
antihypertensive	NN	O	I-PAR
drugs	NN	O	I-PAR
:	NN	O	O
71	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
aspirin	NN	O	B-INT
and	NN	O	O
71	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
underwent	NN	O	O
a	NN	O	O
clinic	NN	O	B-OUT
BP	NN	O	I-OUT
evaluation	NN	O	O
with	NN	O	O
an	NN	O	O
automatic	NN	O	O
sphygmomanometer	NN	O	O
and	NN	O	O
a	NN	O	O
24-h	NN	O	B-OUT
ambulatory	NN	O	I-OUT
BP	NN	O	I-OUT
monitoring	NN	O	I-OUT
,	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
aspirin	NN	O	B-INT
treatment	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
clinic	NN	O	B-OUT
SBP	NN	O	I-OUT
and	NN	O	I-OUT
DBP	NN	O	I-OUT
were	NN	O	O
not	NN	O	O
statistically	NN	O	O
different	NN	O	O
in	NN	O	O
treated	NN	O	O
and	NN	O	O
untreated	NN	O	O
subjects	NN	O	O
.	NN	O	O

Ambulatory	NN	O	B-OUT
SBP	NN	O	I-OUT
and	NN	O	I-OUT
DBP	NN	O	I-OUT
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
aspirin	NN	O	B-INT
treatment	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
baseline	NN	O	O
:	NN	O	O
deltaSBP	NN	O	O
-0.5	NN	O	O
mmHg	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
from	NN	O	O
-1.9	NN	O	O
to	NN	O	O
+2.9	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
and	NN	O	O
deltaDBP	NN	O	O
-1.1	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
from	NN	O	O
-2.5	NN	O	O
to	NN	O	O
+0.3	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
pattern	NN	O	O
was	NN	O	O
similar	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

No	NN	O	O
interaction	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
aspirin	NN	O	B-INT
and	NN	O	O
the	NN	O	O
most	NN	O	O
used	NN	O	O
antihypertensive	NN	O	O
drug	NN	O	O
classes	NN	O	O
(	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
and	NN	O	O
calcium	NN	O	O
antagonists	NN	O	O
)	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
relatively	NN	O	O
small	NN	O	O
sample	NN	O	O
size	NN	O	O
our	NN	O	O
results	NN	O	O
seem	NN	O	O
to	NN	O	O
exclude	NN	O	O
any	NN	O	O
significant	NN	O	O
influence	NN	O	O
of	NN	O	O
low-dose	NN	O	O
aspirin	NN	O	B-INT
on	NN	O	O
BP	NN	O	B-OUT
control	NN	O	O
in	NN	O	O
hypertensives	NN	O	O
under	NN	O	O
treatment	NN	O	O
.	NN	O	O



--DOCSTART-- (10934569)

Randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
intensive	NN	O	B-INT
early	NN	O	I-INT
intervention	NN	O	I-INT
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

Young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorder	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
intensive	NN	O	B-INT
treatment	NN	O	I-INT
or	NN	O	O
parent	NN	O	B-INT
training	NN	O	I-INT
.	NN	O	O

The	NN	O	O
intensive	NN	O	B-INT
treatment	NN	O	I-INT
group	NN	O	O
(	NN	O	O
7	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
,	NN	O	I-PAR
8	NN	O	I-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorder	NN	O	I-PAR
not	NN	O	I-PAR
otherwise	NN	O	I-PAR
specified	NN	O	I-PAR
--	NN	O	I-PAR
NOS	NN	O	I-PAR
)	NN	O	O
averaged	NN	O	O
24.52	NN	O	O
hours	NN	O	O
per	NN	O	O
week	NN	O	O
of	NN	O	O
individual	NN	O	O
treatment	NN	O	O
for	NN	O	O
one	NN	O	O
year	NN	O	O
,	NN	O	O
gradually	NN	O	O
reducing	NN	O	O
hours	NN	O	O
over	NN	O	O
the	NN	O	O
next	NN	O	O
1	NN	O	O
to	NN	O	O
2	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
parent	NN	O	B-INT
training	NN	O	I-INT
group	NN	O	O
(	NN	O	O
7	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
,	NN	O	I-PAR
6	NN	O	I-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorder	NN	O	I-PAR
NOS	NN	O	I-PAR
)	NN	O	O
received	NN	O	O
3	NN	O	O
to	NN	O	O
9	NN	O	O
months	NN	O	O
of	NN	O	O
parent	NN	O	B-INT
training	NN	O	I-INT
.	NN	O	O

The	NN	O	O
groups	NN	O	O
appeared	NN	O	O
similar	NN	O	O
at	NN	O	O
intake	NN	O	O
on	NN	O	O
all	NN	O	O
measures	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
at	NN	O	O
follow-up	NN	O	O
the	NN	O	O
intensive	NN	O	B-INT
treatment	NN	O	I-INT
group	NN	O	O
outperformed	NN	O	O
the	NN	O	O
parent	NN	O	B-INT
training	NN	O	I-INT
group	NN	O	O
on	NN	O	O
measures	NN	O	O
of	NN	O	O
intelligence	NN	O	B-OUT
,	NN	O	I-OUT
visual-spatial	NN	O	I-OUT
skills	NN	O	I-OUT
,	NN	O	I-OUT
language	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
academics	NN	O	I-OUT
,	NN	O	O
though	NN	O	O
not	NN	O	O
adaptive	NN	O	B-OUT
functioning	NN	O	I-OUT
or	NN	O	O
behavior	NN	O	B-OUT
problems	NN	O	I-OUT
.	NN	O	O

Children	NN	O	B-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorder	NN	O	I-PAR
NOS	NN	O	O
may	NN	O	O
have	NN	O	O
gained	NN	O	O
more	NN	O	O
than	NN	O	O
those	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O



--DOCSTART-- (10940525)

Efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
selamectin	NN	O	B-INT
against	NN	O	O
fleas	NN	O	O
and	NN	O	O
heartworms	NN	O	O
in	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
presented	NN	O	I-PAR
as	NN	O	I-PAR
veterinary	NN	O	I-PAR
patients	NN	O	I-PAR
in	NN	O	I-PAR
North	NN	O	I-PAR
America	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
series	NN	O	O
of	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
masked	NN	O	O
field	NN	O	O
studies	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
selamectin	NN	O	B-INT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
flea	NN	O	O
infestations	NN	O	O
on	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
heartworm	NN	O	O
infection	NN	O	O
in	NN	O	O
dogs	NN	O	B-PAR
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
observations	NN	O	O
were	NN	O	O
made	NN	O	O
on	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
selamectin	NN	O	B-INT
treatment	NN	O	O
on	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
showing	NN	O	I-PAR
signs	NN	O	I-PAR
of	NN	O	I-PAR
flea	NN	O	I-PAR
allergy	NN	O	I-PAR
dermatitis	NN	O	I-PAR
(	NN	O	I-PAR
FAD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

In	NN	O	O
all	NN	O	O
studies	NN	O	O
selamectin	NN	O	B-INT
was	NN	O	O
applied	NN	O	O
topically	NN	O	O
,	NN	O	O
once	NN	O	O
per	NN	O	O
month	NN	O	O
,	NN	O	O
in	NN	O	O
unit	NN	O	O
doses	NN	O	O
providing	NN	O	O
a	NN	O	O
minimum	NN	O	O
dosage	NN	O	O
of	NN	O	O
6mgkg	NN	O	O
(	NN	O	O
-1	NN	O	O
)	NN	O	O
.	NN	O	O

Dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
with	NN	O	I-PAR
naturally	NN	O	I-PAR
occurring	NN	O	I-PAR
flea	NN	O	I-PAR
infestations	NN	O	I-PAR
,	NN	O	I-PAR
some	NN	O	I-PAR
of	NN	O	I-PAR
which	NN	O	I-PAR
also	NN	O	I-PAR
had	NN	O	I-PAR
signs	NN	O	I-PAR
associated	NN	O	I-PAR
with	NN	O	I-PAR
FAD	NN	O	I-PAR
,	NN	O	O
were	NN	O	O
assigned	NN	O	O
randomly	NN	O	O
to	NN	O	O
receive	NN	O	O
three	NN	O	O
months	NN	O	O
of	NN	O	O
topical	NN	O	O
treatment	NN	O	O
with	NN	O	O
selamectin	NN	O	B-INT
(	NN	O	O
220	NN	O	B-PAR
dogs	NN	O	I-PAR
,	NN	O	I-PAR
189	NN	O	I-PAR
cats	NN	O	I-PAR
)	NN	O	I-PAR
or	NN	O	O
a	NN	O	O
positive-control	NN	O	O
product	NN	O	O
(	NN	O	O
dogs	NN	O	O
:	NN	O	O
fenthion	NN	O	B-INT
,	NN	O	O
n=81	NN	O	O
;	NN	O	O
cats	NN	O	O
:	NN	O	O
pyrethrins	NN	O	B-INT
,	NN	O	O
n=66	NN	O	O
)	NN	O	O
.	NN	O	O

Selamectin	NN	O	B-INT
was	NN	O	O
administered	NN	O	O
on	NN	O	O
days	NN	O	O
0	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
and	NN	O	O
60	NN	O	O
.	NN	O	O

Day	NN	O	O
0	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
the	NN	O	O
day	NN	O	O
that	NN	O	O
the	NN	O	O
animal	NN	O	O
first	NN	O	O
received	NN	O	O
treatment	NN	O	O
.	NN	O	O

Flea	NN	O	O
burdens	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
flea	NN	O	B-OUT
comb	NN	O	I-OUT
counts	NN	O	I-OUT
and	NN	O	O
clinical	NN	O	B-OUT
evaluations	NN	O	I-OUT
of	NN	O	I-OUT
FAD	NN	O	I-OUT
were	NN	O	O
performed	NN	O	O
before	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
days	NN	O	O
14	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
and	NN	O	O
90	NN	O	O
.	NN	O	O

On	NN	O	O
days	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
and	NN	O	O
90	NN	O	O
,	NN	O	O
mean	NN	O	B-OUT
flea	NN	O	I-OUT
counts	NN	O	I-OUT
in	NN	O	O
selamectin-treated	NN	O	B-INT
dogs	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
92.1	NN	O	O
,	NN	O	O
99.0	NN	O	O
,	NN	O	O
and	NN	O	O
99.8	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
mean	NN	O	B-OUT
flea	NN	O	I-OUT
counts	NN	O	I-OUT
in	NN	O	O
fenthion-treated	NN	O	O
dogs	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
81.5	NN	O	O
,	NN	O	O
86.8	NN	O	O
,	NN	O	O
and	NN	O	O
86.1	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
day	NN	O	O
0	NN	O	O
counts	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
on	NN	O	O
days	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
and	NN	O	O
90	NN	O	O
,	NN	O	O
mean	NN	O	B-OUT
flea	NN	O	I-OUT
counts	NN	O	I-OUT
in	NN	O	O
selamectin-treated	NN	O	O
cats	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
92.5	NN	O	O
,	NN	O	O
98.3	NN	O	O
,	NN	O	O
and	NN	O	O
99.3	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
mean	NN	O	B-OUT
flea	NN	O	I-OUT
counts	NN	O	I-OUT
in	NN	O	O
pyrethrin-treated	NN	O	O
cats	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
66.4	NN	O	O
,	NN	O	O
73.9	NN	O	O
,	NN	O	O
and	NN	O	O
81.3	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
day	NN	O	O
0	NN	O	O
counts	NN	O	O
.	NN	O	O

Selamectin	NN	O	B-INT
also	NN	O	O
was	NN	O	O
beneficial	NN	O	O
in	NN	O	O
alleviating	NN	O	O
signs	NN	O	O
in	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
diagnosed	NN	O	I-PAR
clinically	NN	O	I-PAR
with	NN	O	I-PAR
FAD	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
397	NN	O	B-PAR
dogs	NN	O	I-PAR
free	NN	O	I-PAR
of	NN	O	I-PAR
adult	NN	O	I-PAR
heartworm	NN	O	I-PAR
infection	NN	O	I-PAR
from	NN	O	I-PAR
four	NN	O	I-PAR
heartworm-endemic	NN	O	I-PAR
areas	NN	O	I-PAR
of	NN	O	I-PAR
the	NN	O	I-PAR
USA	NN	O	I-PAR
were	NN	O	O
allocated	NN	O	O
randomly	NN	O	O
to	NN	O	O
six	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
selamectin	NN	O	B-INT
(	NN	O	O
n=298	NN	O	O
)	NN	O	O
or	NN	O	O
ivermectin	NN	O	B-INT
(	NN	O	O
n=99	NN	O	O
)	NN	O	O
.	NN	O	O

Selamectin	NN	O	B-INT
achieved	NN	O	O
a	NN	O	O
heartworm	NN	O	B-OUT
prevention	NN	O	I-OUT
rate	NN	O	I-OUT
of	NN	O	O
100	NN	O	O
%	NN	O	O
,	NN	O	O
with	NN	O	O
all	NN	O	O
dogs	NN	O	O
testing	NN	O	O
negative	NN	O	O
for	NN	O	O
microfilariae	NN	O	O
and	NN	O	O
adult	NN	O	O
heartworm	NN	O	O
antigen	NN	O	O
on	NN	O	O
days	NN	O	O
180	NN	O	O
and	NN	O	O
300	NN	O	O
.	NN	O	O

Selamectin	NN	O	B-INT
was	NN	O	O
administered	NN	O	O
to	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
673	NN	O	B-PAR
dogs	NN	O	I-PAR
and	NN	O	I-PAR
347	NN	O	I-PAR
cats	NN	O	I-PAR
having	NN	O	O
an	NN	O	O
age	NN	O	O
range	NN	O	O
of	NN	O	O
6	NN	O	O
weeks	NN	O	O
to	NN	O	O
19	NN	O	O
years	NN	O	O
(	NN	O	O
3954	NN	O	O
doses	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	B-PAR
included	NN	O	I-PAR
19	NN	O	I-PAR
purebred	NN	O	I-PAR
or	NN	O	I-PAR
crossbred	NN	O	I-PAR
Collies	NN	O	I-PAR
(	NN	O	I-PAR
Bearded	NN	O	I-PAR
,	NN	O	I-PAR
Border	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
unspecified	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
serious	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
.	NN	O	O

Results	NN	O	O
of	NN	O	O
these	NN	O	O
studies	NN	O	O
indicated	NN	O	O
that	NN	O	O
selamectin	NN	O	B-INT
was	NN	O	O
highly	NN	O	O
effective	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
flea	NN	O	O
infestations	NN	O	O
in	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
without	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
simultaneous	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
environment	NN	O	O
or	NN	O	O
of	NN	O	O
in-contact	NN	O	O
animals	NN	O	O
and	NN	O	O
also	NN	O	O
was	NN	O	O
beneficial	NN	O	O
in	NN	O	O
alleviating	NN	O	O
signs	NN	O	B-OUT
associated	NN	O	I-OUT
with	NN	O	I-OUT
FAD	NN	O	I-OUT
.	NN	O	O

Selamectin	NN	O	B-INT
also	NN	O	O
was	NN	O	O
100	NN	O	O
%	NN	O	O
effective	NN	O	O
in	NN	O	O
preventing	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
canine	NN	O	O
heartworms	NN	O	B-OUT
and	NN	O	O
was	NN	O	O
safe	NN	O	B-OUT
for	NN	O	O
topical	NN	O	O
use	NN	O	O
in	NN	O	O
dogs	NN	O	B-PAR
and	NN	O	I-PAR
cats	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (11099086)

Oral	NN	O	O
ciprofloxacin	NN	O	B-INT
vs.	NN	O	O
intramuscular	NN	O	O
ceftriaxone	NN	O	B-INT
as	NN	O	O
empiric	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	B-PAR
invasive	NN	O	I-PAR
diarrhea	NN	O	I-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Acute	NN	O	O
invasive	NN	O	O
diarrhea	NN	O	O
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
serious	NN	O	O
condition	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
increasing	NN	O	O
resistance	NN	O	O
of	NN	O	O
enteric	NN	O	O
pathogens	NN	O	O
to	NN	O	O
commonly	NN	O	O
used	NN	O	O
oral	NN	O	O
antibiotics	NN	O	O
,	NN	O	O
intramuscular	NN	O	O
ceftriaxone	NN	O	B-INT
has	NN	O	O
become	NN	O	O
the	NN	O	O
routine	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
invasive	NN	O	O
diarrhea	NN	O	O
requiring	NN	O	O
an	NN	O	O
emergency	NN	O	O
visit	NN	O	O
in	NN	O	O
southern	NN	O	O
Israel	NN	O	O
.	NN	O	O

The	NN	O	O
inconvenience	NN	O	O
of	NN	O	O
this	NN	O	O
parenteral	NN	O	O
regimen	NN	O	O
created	NN	O	O
an	NN	O	O
increased	NN	O	O
need	NN	O	O
for	NN	O	O
oral	NN	O	O
pediatric	NN	O	O
formulations	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
invasive	NN	O	O
diarrhea	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
suspension	NN	O	O
formulation	NN	O	O
of	NN	O	O
ciprofloxacin	NN	O	B-INT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	B-PAR
invasive	NN	O	I-PAR
diarrhea	NN	O	I-PAR
in	NN	O	I-PAR
infants	NN	O	I-PAR
and	NN	O	I-PAR
children	NN	O	I-PAR
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
From	NN	O	O
July	NN	O	O
1996	NN	O	O
through	NN	O	O
December	NN	O	O
1997	NN	O	O
,	NN	O	O
201	NN	O	B-PAR
evaluable	NN	O	I-PAR
children	NN	O	I-PAR
ages	NN	O	I-PAR
6	NN	O	I-PAR
months	NN	O	I-PAR
to	NN	O	I-PAR
10	NN	O	I-PAR
years	NN	O	I-PAR
(	NN	O	I-PAR
35	NN	O	I-PAR
%	NN	O	I-PAR
<	NN	O	I-PAR
1	NN	O	I-PAR
year	NN	O	I-PAR
;	NN	O	I-PAR
70	NN	O	I-PAR
%	NN	O	I-PAR
<	NN	O	I-PAR
3	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	I-PAR
presenting	NN	O	I-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
invasive	NN	O	I-PAR
diarrhea	NN	O	I-PAR
at	NN	O	I-PAR
the	NN	O	I-PAR
Pediatric	NN	O	I-PAR
Emergency	NN	O	I-PAR
Room	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
ciprofloxacin	NN	O	B-INT
suspension	NN	O	O
(	NN	O	O
10	NN	O	O
mg/kg	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
+	NN	O	O
im	NN	O	O
placebo	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
95	NN	O	O
)	NN	O	O
or	NN	O	O
im	NN	O	O
ceftriaxone	NN	O	B-INT
(	NN	O	O
50	NN	O	O
mg/kg/day	NN	O	O
+	NN	O	O
placebo	NN	O	O
suspension	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
106	NN	O	O
)	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
manner	NN	O	O
.	NN	O	O

Stool	NN	O	B-OUT
cultures	NN	O	I-OUT
for	NN	O	I-OUT
Shigella	NN	O	I-OUT
,	NN	O	I-OUT
Salmonella	NN	O	I-OUT
,	NN	O	I-OUT
Campylobacter	NN	O	I-OUT
spp	NN	O	I-OUT
.	NN	O	I-OUT
and	NN	O	I-OUT
diarrheagenic	NN	O	I-OUT
Escherichia	NN	O	I-OUT
coli	NN	O	I-OUT
were	NN	O	O
obtained	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
to	NN	O	O
5	NN	O	O
and	NN	O	O
21	NN	O	O
+/-	NN	O	O
5	NN	O	O
.	NN	O	O

Clinical	NN	O	B-OUT
response	NN	O	I-OUT
and	NN	O	I-OUT
safety	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
to	NN	O	O
5	NN	O	O
and	NN	O	O
21	NN	O	O
+/-	NN	O	O
5	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
We	NN	O	O
isolated	NN	O	O
127	NN	O	O
pathogens	NN	O	O
from	NN	O	O
121	NN	O	O
(	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
:	NN	O	O
73	NN	O	O
(	NN	O	O
57	NN	O	O
%	NN	O	O
)	NN	O	O
Shigella	NN	O	O
;	NN	O	O
23	NN	O	O
(	NN	O	O
18	NN	O	O
%	NN	O	O
)	NN	O	O
Salmonella	NN	O	O
;	NN	O	O
18	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
E.	NN	O	O
coli	NN	O	O
;	NN	O	O
and	NN	O	O
13	NN	O	O
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
Campylobacter	NN	O	O
.	NN	O	O

Overall	NN	O	O
bacteriologic	NN	O	O
eradication	NN	O	O
on	NN	O	O
Day	NN	O	O
4	NN	O	O
to	NN	O	O
5	NN	O	O
was	NN	O	O
99	NN	O	O
%	NN	O	O
for	NN	O	O
Shigella	NN	O	O
,	NN	O	O
77	NN	O	O
%	NN	O	O
for	NN	O	O
Salmonella	NN	O	O
and	NN	O	O
77	NN	O	O
%	NN	O	O
for	NN	O	O
Campylobacter	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
.	NN	O	O

Clinical	NN	O	B-OUT
cure	NN	O	I-OUT
or	NN	O	I-OUT
improvement	NN	O	I-OUT
was	NN	O	O
observed	NN	O	O
in	NN	O	O
100	NN	O	O
and	NN	O	O
99	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
ciprofloxacin	NN	O	B-INT
and	NN	O	O
ceftriaxone	NN	O	B-INT
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Serum	NN	O	O
ciprofloxacin	NN	O	B-INT
values	NN	O	O
determined	NN	O	O
on	NN	O	O
Day	NN	O	O
3	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
were	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
patients	NN	O	O
than	NN	O	O
were	NN	O	O
the	NN	O	O
MIC50	NN	O	O
and	NN	O	O
MIC90	NN	O	O
values	NN	O	O
for	NN	O	O
the	NN	O	O
Shigella	NN	O	O
and	NN	O	O
Salmonella	NN	O	O
spp	NN	O	O
.	NN	O	O

isolated	NN	O	O
.	NN	O	O

Possible	NN	O	O
drug-related	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
occurred	NN	O	O
in	NN	O	O
13	NN	O	O
patients	NN	O	O
[	NN	O	O
ciprofloxacin	NN	O	B-INT
,	NN	O	O
8	NN	O	O
(	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
ceftriaxone	NN	O	B-INT
,	NN	O	O
5	NN	O	O
(	NN	O	O
4.7	NN	O	O
%	NN	O	O
)	NN	O	O
]	NN	O	O
and	NN	O	O
were	NN	O	O
mild	NN	O	O
and	NN	O	O
transient	NN	O	O
.	NN	O	O

Joint	NN	O	B-OUT
examination	NN	O	I-OUT
was	NN	O	O
normal	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
completion	NN	O	O
of	NN	O	O
therapy	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Oral	NN	O	O
ciprofloxacin	NN	O	B-INT
was	NN	O	O
as	NN	O	O
safe	NN	O	B-OUT
and	NN	O	O
effective	NN	O	B-OUT
as	NN	O	O
intramuscular	NN	O	O
ceftriaxone	NN	O	B-INT
for	NN	O	O
the	NN	O	O
empiric	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
invasive	NN	O	O
diarrhea	NN	O	O
in	NN	O	O
ambulatory	NN	O	B-PAR
pediatric	NN	O	I-PAR
patients	NN	O	I-PAR
requiring	NN	O	I-PAR
an	NN	O	I-PAR
emergency	NN	O	I-PAR
room	NN	O	I-PAR
visit	NN	O	I-PAR
.	NN	O	I-PAR


--DOCSTART-- (11229858)

Effect	NN	O	O
of	NN	O	O
antipyretic	NN	O	B-INT
drugs	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
malaria	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
comparison	NN	O	O
of	NN	O	O
different	NN	O	O
antipyretics	NN	O	B-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
malaria	NN	O	I-PAR
showed	NN	O	O
a	NN	O	O
small	NN	O	O
effect	NN	O	O
of	NN	O	O
naproxen	NN	O	B-INT
,	NN	O	O
but	NN	O	O
not	NN	O	O
of	NN	O	O
metamizol	NN	O	B-INT
,	NN	O	O
on	NN	O	O
the	NN	O	O
reduction	NN	O	B-OUT
of	NN	O	I-OUT
fever	NN	O	I-OUT
peaks	NN	O	I-OUT
.	NN	O	O

Antipyretic	NN	O	B-INT
treatment	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
fever	NN	O	B-OUT
clearance	NN	O	I-OUT
and	NN	O	O
therefore	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
cautiously	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
malaria	NN	O	B-PAR
.	NN	O	O



--DOCSTART-- (1131298)

Effect	NN	O	O
of	NN	O	O
the	NN	O	O
essential	NN	O	B-INT
oils	NN	O	I-INT
of	NN	O	I-INT
garlic	NN	O	I-INT
and	NN	O	I-INT
onion	NN	O	I-INT
on	NN	O	O
alimentary	NN	O	O
hyperlipemia	NN	O	O
.	NN	O	O

SUMMARY	NN	O	O
The	NN	O	O
effect	NN	O	O
of	NN	O	O
garlic	NN	O	B-INT
and	NN	O	I-INT
onion	NN	O	I-INT
on	NN	O	O
alimentary	NN	O	O
hyperlipemia	NN	O	O
,	NN	O	O
induced	NN	O	O
by	NN	O	O
feeding	NN	O	O
100	NN	O	O
g	NN	O	O
butter	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
studied	NN	O	O
in	NN	O	O
10	NN	O	B-PAR
healthy	NN	O	I-PAR
subjects	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
freshly	NN	O	O
extracted	NN	O	O
juice	NN	O	O
of	NN	O	O
50	NN	O	O
g	NN	O	O
of	NN	O	O
garlic	NN	O	B-INT
or	NN	O	I-INT
onion	NN	O	I-INT
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
an	NN	O	O
equivalent	NN	O	O
amount	NN	O	O
of	NN	O	O
their	NN	O	O
ether-extracted	NN	O	O
essential	NN	O	B-INT
oils	NN	O	I-INT
,	NN	O	O
was	NN	O	O
administered	NN	O	O
randomly	NN	O	O
on	NN	O	O
four	NN	O	O
different	NN	O	O
days	NN	O	O
during	NN	O	O
a	NN	O	O
one-week	NN	O	O
period	NN	O	O
.	NN	O	O

Garlic	NN	O	B-INT
and	NN	O	I-INT
onion	NN	O	I-INT
have	NN	O	O
a	NN	O	O
significant	NN	O	O
protective	NN	O	O
action	NN	O	O
against	NN	O	O
fat-induced	NN	O	O
increases	NN	O	O
in	NN	O	O
serum	NN	O	B-OUT
cholesterol	NN	O	I-OUT
and	NN	O	I-OUT
plasma	NN	O	I-OUT
fibrinogen	NN	O	I-OUT
and	NN	O	O
decreases	NN	O	O
in	NN	O	O
coagulation	NN	O	B-OUT
time	NN	O	I-OUT
and	NN	O	O
fibrinolytic	NN	O	B-OUT
activity	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
essential	NN	O	O
oil	NN	O	O
fraction	NN	O	O
,	NN	O	O
which	NN	O	O
contains	NN	O	O
all	NN	O	O
the	NN	O	O
taste	NN	O	O
and	NN	O	O
odour	NN	O	O
,	NN	O	O
exactly	NN	O	O
duplicated	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	B-OUT
of	NN	O	O
whole	NN	O	O
garlic	NN	O	B-INT
and	NN	O	O
onion	NN	O	B-INT
.	NN	O	O

It	NN	O	O
is	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
concluded	NN	O	O
that	NN	O	O
the	NN	O	O
active	NN	O	O
principle	NN	O	O
of	NN	O	O
garlic	NN	O	B-INT
and	NN	O	I-INT
onion	NN	O	I-INT
is	NN	O	O
the	NN	O	O
essential	NN	O	O
oil	NN	O	O
,	NN	O	O
which	NN	O	O
chemically	NN	O	O
is	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
sulphur-containing	NN	O	O
compounds	NN	O	O
,	NN	O	O
mainly	NN	O	O
allyl	NN	O	O
propyl	NN	O	O
disulphide	NN	O	O
and	NN	O	O
diallyl	NN	O	O
disulphide	NN	O	O
.	NN	O	O



--DOCSTART-- (11317090)

Economic	NN	O	B-OUT
evaluation	NN	O	I-OUT
of	NN	O	O
aquatic	NN	O	B-INT
exercise	NN	O	I-INT
for	NN	O	O
persons	NN	O	B-PAR
with	NN	O	I-PAR
osteoarthritis	NN	O	I-PAR
.	NN	O	O

OBJECTIVES	NN	O	O
To	NN	O	O
estimate	NN	O	O
cost	NN	O	B-OUT
and	NN	O	O
outcomes	NN	O	B-OUT
of	NN	O	O
the	NN	O	O
Arthritis	NN	O	O
Foundation	NN	O	O
aquatic	NN	O	B-INT
exercise	NN	O	I-INT
classes	NN	O	I-INT
from	NN	O	O
the	NN	O	O
societal	NN	O	O
perspective	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
Randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
20-week	NN	O	O
aquatic	NN	O	B-INT
classes	NN	O	I-INT
.	NN	O	O

Cost	NN	O	B-OUT
per	NN	O	I-OUT
quality-adjusted	NN	O	I-OUT
life	NN	O	I-OUT
year	NN	O	I-OUT
(	NN	O	I-OUT
QALY	NN	O	I-OUT
)	NN	O	I-OUT
gained	NN	O	O
was	NN	O	O
estimated	NN	O	O
using	NN	O	O
trial	NN	O	O
data	NN	O	O
.	NN	O	O

Sample	NN	O	O
size	NN	O	O
was	NN	O	O
based	NN	O	O
on	NN	O	O
80	NN	O	O
%	NN	O	O
power	NN	O	O
to	NN	O	O
reject	NN	O	O
the	NN	O	O
null	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
cost/QALY	NN	O	B-OUT
gained	NN	O	O
would	NN	O	O
not	NN	O	O
exceed	NN	O	O
$	NN	O	O
50,000	NN	O	O
.	NN	O	O

SUBJECTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Recruited	NN	O	O
249	NN	O	B-PAR
adults	NN	O	I-PAR
from	NN	O	I-PAR
Washington	NN	O	I-PAR
State	NN	O	I-PAR
aged	NN	O	I-PAR
55	NN	O	I-PAR
to	NN	O	I-PAR
75	NN	O	I-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
doctor-confirmed	NN	O	I-PAR
diagnosis	NN	O	I-PAR
of	NN	O	I-PAR
osteoarthritis	NN	O	I-PAR
to	NN	O	O
participate	NN	O	O
in	NN	O	O
aquatic	NN	O	B-INT
classes	NN	O	I-INT
.	NN	O	O

The	NN	O	O
Quality	NN	O	B-OUT
of	NN	O	I-OUT
Well-Being	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
QWB	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
Current	NN	O	B-OUT
Health	NN	O	I-OUT
Desirability	NN	O	I-OUT
Rating	NN	O	I-OUT
(	NN	O	I-OUT
CHDR	NN	O	I-OUT
)	NN	O	I-OUT
were	NN	O	O
used	NN	O	O
for	NN	O	O
economic	NN	O	O
evaluation	NN	O	O
,	NN	O	O
supplemented	NN	O	O
by	NN	O	O
the	NN	O	O
arthritis-specific	NN	O	B-OUT
Health	NN	O	I-OUT
Assessment	NN	O	I-OUT
Questionnaire	NN	O	I-OUT
(	NN	O	I-OUT
HAQ	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
Center	NN	O	B-OUT
for	NN	O	I-OUT
Epidemiologic	NN	O	I-OUT
Studies-Depression	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
CES-D	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
Perceived	NN	O	B-OUT
Quality	NN	O	I-OUT
of	NN	O	I-OUT
Life	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
PQOL	NN	O	I-OUT
)	NN	O	I-OUT
collected	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
postclass	NN	O	O
.	NN	O	O

Outcome	NN	O	O
results	NN	O	O
applied	NN	O	O
to	NN	O	O
life	NN	O	O
expectancy	NN	O	O
tables	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
estimate	NN	O	O
QALYs	NN	O	B-OUT
.	NN	O	O

Use	NN	O	B-OUT
of	NN	O	I-OUT
health	NN	O	I-OUT
care	NN	O	I-OUT
facilities	NN	O	I-OUT
was	NN	O	O
assessed	NN	O	O
from	NN	O	O
diaries/questionnaires	NN	O	O
and	NN	O	O
Medicare	NN	O	B-OUT
reimbursement	NN	O	I-OUT
rates	NN	O	I-OUT
used	NN	O	O
to	NN	O	O
estimate	NN	O	O
costs	NN	O	O
.	NN	O	O

Nonparametric	NN	O	O
bootstrap	NN	O	O
sampling	NN	O	O
of	NN	O	O
costs/QALY	NN	O	B-OUT
ratios	NN	O	I-OUT
established	NN	O	O
the	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
around	NN	O	O
the	NN	O	O
estimates	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Aquatic	NN	O	B-INT
exercisers	NN	O	I-INT
reported	NN	O	O
equal	NN	O	O
(	NN	O	O
QWB	NN	O	B-OUT
)	NN	O	O
or	NN	O	O
better	NN	O	O
(	NN	O	O
CHDR	NN	O	B-OUT
,	NN	O	I-OUT
HAQ	NN	O	I-OUT
,	NN	O	I-OUT
PQOL	NN	O	I-OUT
)	NN	O	O
health-related	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
improved	NN	O	O
with	NN	O	O
regular	NN	O	O
class	NN	O	O
attendance	NN	O	O
.	NN	O	O

Costs/QALY	NN	O	B-OUT
gained	NN	O	O
discounted	NN	O	O
at	NN	O	O
3	NN	O	O
%	NN	O	O
were	NN	O	O
$	NN	O	O
205,186	NN	O	O
using	NN	O	O
the	NN	O	O
QWB	NN	O	B-OUT
and	NN	O	O
$	NN	O	O
32,643	NN	O	O
using	NN	O	O
the	NN	O	O
CHRD	NN	O	B-OUT
.	NN	O	O

CONCLUSION	NN	O	O
Aquatic	NN	O	B-INT
exercise	NN	O	I-INT
exceeded	NN	O	O
$	NN	O	O
50,000	NN	O	O
per	NN	O	O
QALY	NN	O	B-OUT
gained	NN	O	O
using	NN	O	O
the	NN	O	O
community-weighted	NN	O	O
outcome	NN	O	O
but	NN	O	O
fell	NN	O	O
below	NN	O	O
this	NN	O	O
arbitrary	NN	O	O
budget	NN	O	O
constraint	NN	O	O
when	NN	O	O
using	NN	O	O
the	NN	O	O
participant-weighted	NN	O	O
measure	NN	O	O
.	NN	O	O

Confidence	NN	O	O
intervals	NN	O	O
around	NN	O	O
these	NN	O	O
ratios	NN	O	O
suggested	NN	O	O
wide	NN	O	O
variability	NN	O	O
of	NN	O	O
cost	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
aquatic	NN	O	B-INT
exercise	NN	O	I-INT
.	NN	O	O



--DOCSTART-- (11381289)

Why	NN	O	O
were	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
Heart	NN	O	O
Outcomes	NN	O	O
Prevention	NN	O	O
Evaluation	NN	O	O
(	NN	O	O
HOPE	NN	O	O
)	NN	O	O
trial	NN	O	O
so	NN	O	O
astounding	NN	O	O
?	NN	O	O
The	NN	O	O
Heart	NN	O	O
Outcomes	NN	O	O
Prevention	NN	O	O
Evaluation	NN	O	O
(	NN	O	O
HOPE	NN	O	O
)	NN	O	O
study	NN	O	O
was	NN	O	O
important	NN	O	O
because	NN	O	O
it	NN	O	O
showed	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
ramipril	NN	O	B-INT
-	NN	O	O
an	NN	O	O
angiotensin-converting	NN	O	B-INT
enzyme	NN	O	I-INT
(	NN	O	I-INT
ACE	NN	O	I-INT
)	NN	O	I-INT
inhibitor	NN	O	I-INT
-	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
at	NN	O	I-PAR
high	NN	O	I-PAR
risk	NN	O	I-PAR
for	NN	O	I-PAR
cardiovascular	NN	O	I-PAR
events	NN	O	I-PAR
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
ramipril	NN	O	B-INT
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
rates	NN	O	B-OUT
of	NN	O	I-OUT
death	NN	O	I-OUT
,	NN	O	I-OUT
myocardial	NN	O	I-OUT
infarction	NN	O	I-OUT
,	NN	O	I-OUT
stroke	NN	O	I-OUT
,	NN	O	I-OUT
coronary	NN	O	I-OUT
revascularization	NN	O	I-OUT
,	NN	O	I-OUT
cardiac	NN	O	I-OUT
arrest	NN	O	I-OUT
and	NN	O	I-OUT
heart	NN	O	I-OUT
failure	NN	O	I-OUT
,	NN	O	I-OUT
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
risk	NN	O	B-OUT
of	NN	O	I-OUT
diabetes-related	NN	O	I-OUT
complications	NN	O	I-OUT
and	NN	O	I-OUT
of	NN	O	I-OUT
diabetes	NN	O	I-OUT
itself	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
vitamin	NN	O	B-INT
E	NN	O	I-INT
were	NN	O	O
also	NN	O	O
evaluated	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
statistical	NN	O	O
benefits	NN	O	O
were	NN	O	O
shown	NN	O	O
.	NN	O	O

The	NN	O	O
benefits	NN	O	O
of	NN	O	O
ACE	NN	O	B-INT
inhibitor	NN	O	I-INT
therapy	NN	O	O
that	NN	O	O
were	NN	O	O
observed	NN	O	O
were	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
not	NN	O	O
just	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O



--DOCSTART-- (11401641)

Additive	NN	O	O
IOP-reducing	NN	O	B-OUT
effect	NN	O	O
of	NN	O	O
latanoprost	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
insufficiently	NN	O	I-PAR
controlled	NN	O	I-PAR
on	NN	O	I-PAR
timolol	NN	O	I-PAR
.	NN	O	O

PURPOSE	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
on	NN	O	O
intraocular	NN	O	B-OUT
pressure	NN	O	I-OUT
(	NN	O	I-OUT
IOP	NN	O	I-OUT
)	NN	O	I-OUT
of	NN	O	O
switching	NN	O	O
from	NN	O	O
timolol	NN	O	B-INT
to	NN	O	O
latanoprost	NN	O	B-INT
or	NN	O	O
adding	NN	O	O
latanoprost	NN	O	B-INT
to	NN	O	O
timolol	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
open	NN	O	I-PAR
angle	NN	O	I-PAR
glaucoma	NN	O	I-PAR
or	NN	O	I-PAR
ocular	NN	O	I-PAR
hypertension	NN	O	I-PAR
where	NN	O	I-PAR
IOP	NN	O	I-PAR
is	NN	O	I-PAR
not	NN	O	I-PAR
adequately	NN	O	I-PAR
controlled	NN	O	I-PAR
with	NN	O	I-PAR
timolol	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
6-week	NN	O	O
,	NN	O	O
double-masked	NN	O	O
,	NN	O	O
randomised	NN	O	O
multi-centre	NN	O	O
study	NN	O	O
.	NN	O	O

53	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
open	NN	O	I-PAR
angle	NN	O	I-PAR
glaucoma	NN	O	I-PAR
,	NN	O	I-PAR
capsular	NN	O	I-PAR
glaucoma	NN	O	I-PAR
,	NN	O	I-PAR
or	NN	O	I-PAR
ocular	NN	O	I-PAR
hypertension	NN	O	I-PAR
with	NN	O	I-PAR
an	NN	O	I-PAR
IOP	NN	O	I-PAR
of	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
21	NN	O	I-PAR
mmHg	NN	O	I-PAR
on	NN	O	I-PAR
current	NN	O	I-PAR
therapy	NN	O	I-PAR
were	NN	O	O
recruited	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
run-in	NN	O	O
period	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
2	NN	O	O
weeks	NN	O	O
on	NN	O	O
timolol	NN	O	B-INT
,	NN	O	O
5	NN	O	O
mg/ml	NN	O	O
twice	NN	O	O
daily	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

One	NN	O	O
group	NN	O	O
continued	NN	O	O
on	NN	O	O
timolol	NN	O	B-INT
,	NN	O	O
one	NN	O	O
switched	NN	O	O
from	NN	O	O
timolol	NN	O	B-INT
to	NN	O	O
latanoprost	NN	O	B-INT
,	NN	O	O
50	NN	O	O
microg/ml	NN	O	O
once	NN	O	O
daily	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
third	NN	O	O
group	NN	O	O
received	NN	O	O
latanoprost	NN	O	B-INT
in	NN	O	O
addition	NN	O	O
to	NN	O	O
timolol	NN	O	B-INT
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
comparing	NN	O	O
IOP	NN	O	B-OUT
at	NN	O	O
9	NN	O	O
AM	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
IOP	NN	O	B-OUT
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
mean	NN	O	O
+/-	NN	O	O
SEM	NN	O	O
)	NN	O	O
were	NN	O	O
24.2	NN	O	O
+/-	NN	O	O
0.9	NN	O	O
and	NN	O	O
23.8	NN	O	O
+/-	NN	O	O
1.0	NN	O	O
mmHg	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
16	NN	O	O
)	NN	O	O
for	NN	O	O
patients	NN	O	O
continuing	NN	O	O
on	NN	O	O
timolol	NN	O	O
,	NN	O	O
26.3	NN	O	O
+/-	NN	O	O
1.2	NN	O	O
and	NN	O	O
19.6	NN	O	O
+/-	NN	O	O
1.1	NN	O	O
mmHg	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
)	NN	O	O
for	NN	O	O
patients	NN	O	O
switching	NN	O	O
to	NN	O	O
latanoprost	NN	O	O
,	NN	O	O
and	NN	O	O
23.2	NN	O	O
+/-	NN	O	O
1.0	NN	O	O
and	NN	O	O
17.5	NN	O	O
+/-	NN	O	O
0.8	NN	O	O
mmHg	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
)	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
combined	NN	O	O
treatment	NN	O	O
.	NN	O	O

Adding	NN	O	O
latanoprost	NN	O	O
to	NN	O	O
timolol	NN	O	O
reduced	NN	O	O
IOP	NN	O	B-OUT
with	NN	O	O
5.9	NN	O	O
+/-	NN	O	O
0.9	NN	O	O
mmHg	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
and	NN	O	O
switching	NN	O	O
from	NN	O	O
timolol	NN	O	O
to	NN	O	O
latanoprost	NN	O	O
reduced	NN	O	O
IOP	NN	O	B-OUT
with	NN	O	O
5.0	NN	O	O
+/-	NN	O	O
0.9	NN	O	O
mmHg	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
caused	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
a	NN	O	O
significant	NN	O	O
IOP	NN	O	B-OUT
reduction	NN	O	O
of	NN	O	O
about	NN	O	O
25	NN	O	O
%	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
effect	NN	O	O
of	NN	O	O
latanoprost	NN	O	O
was	NN	O	O
additive	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
timolol	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
good	NN	O	O
effect	NN	O	O
on	NN	O	O
IOP	NN	O	B-OUT
reduction	NN	O	O
was	NN	O	O
also	NN	O	O
achieved	NN	O	O
by	NN	O	O
switching	NN	O	O
from	NN	O	O
timolol	NN	O	O
to	NN	O	O
latanoprost	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
a	NN	O	O
switch	NN	O	O
in	NN	O	O
many	NN	O	O
patients	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
alternative	NN	O	O
to	NN	O	O
combination	NN	O	O
treatment	NN	O	O
.	NN	O	O



--DOCSTART-- (11454878)

Recurrent	NN	O	O
epithelial	NN	O	O
ovarian	NN	O	O
carcinoma	NN	O	O
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
phase	NN	O	O
III	NN	O	O
study	NN	O	O
of	NN	O	O
pegylated	NN	O	B-INT
liposomal	NN	O	I-INT
doxorubicin	NN	O	I-INT
versus	NN	O	O
topotecan	NN	O	B-INT
.	NN	O	O

PURPOSE	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
pegylated	NN	O	B-INT
liposomal	NN	O	I-INT
doxorubicin	NN	O	I-INT
(	NN	O	I-INT
PLD	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
topotecan	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
epithelial	NN	O	I-PAR
ovarian	NN	O	I-PAR
carcinoma	NN	O	I-PAR
that	NN	O	I-PAR
recurred	NN	O	I-PAR
after	NN	O	I-PAR
or	NN	O	I-PAR
did	NN	O	I-PAR
n't	NN	O	I-PAR
respond	NN	O	I-PAR
to	NN	O	I-PAR
first-line	NN	O	I-PAR
,	NN	O	I-PAR
platinum-based	NN	O	I-PAR
chemotherapy	NN	O	I-PAR
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Patients	NN	O	B-PAR
with	NN	O	I-PAR
measurable	NN	O	I-PAR
and	NN	O	I-PAR
assessable	NN	O	I-PAR
disease	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
PLD	NN	O	B-INT
50	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
as	NN	O	O
a	NN	O	O
1-hour	NN	O	O
infusion	NN	O	O
every	NN	O	O
4	NN	O	O
weeks	NN	O	O
or	NN	O	O
topotecan	NN	O	B-INT
1.5	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/d	NN	O	O
for	NN	O	O
5	NN	O	O
consecutive	NN	O	O
days	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
stratified	NN	O	O
prospectively	NN	O	O
for	NN	O	O
platinum	NN	O	O
sensitivity	NN	O	O
and	NN	O	O
for	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
bulky	NN	O	O
disease	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
474	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
treated	NN	O	O
(	NN	O	O
239	NN	O	O
PLD	NN	O	B-INT
and	NN	O	O
235	NN	O	O
topotecan	NN	O	B-INT
)	NN	O	O
.	NN	O	O

They	NN	O	O
comprised	NN	O	O
the	NN	O	O
intent-to-treat	NN	O	O
population	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	B-OUT
progression-free	NN	O	I-OUT
survival	NN	O	I-OUT
rates	NN	O	I-OUT
were	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
arms	NN	O	O
(	NN	O	O
P	NN	O	O
=.095	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	B-OUT
response	NN	O	I-OUT
rates	NN	O	I-OUT
for	NN	O	O
PLD	NN	O	B-INT
and	NN	O	O
topotecan	NN	O	B-INT
were	NN	O	O
19.7	NN	O	O
%	NN	O	O
and	NN	O	O
17.0	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
=.390	NN	O	O
)	NN	O	O
.	NN	O	O

Median	NN	O	B-OUT
overall	NN	O	I-OUT
survival	NN	O	I-OUT
times	NN	O	I-OUT
were	NN	O	O
60	NN	O	O
weeks	NN	O	O
for	NN	O	O
PLD	NN	O	B-INT
and	NN	O	O
56.7	NN	O	O
weeks	NN	O	O
for	NN	O	O
topotecan	NN	O	B-INT
.	NN	O	O

Data	NN	O	O
analyzed	NN	O	O
in	NN	O	O
platinum-sensitive	NN	O	O
patients	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
benefit	NN	O	O
from	NN	O	O
PLD	NN	O	B-INT
for	NN	O	O
progression-free	NN	O	O
survival	NN	O	O
(	NN	O	O
P	NN	O	O
=.037	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
medians	NN	O	O
of	NN	O	O
28.9	NN	O	O
for	NN	O	O
PLD	NN	O	B-INT
versus	NN	O	O
23.3	NN	O	O
weeks	NN	O	O
for	NN	O	O
topotecan	NN	O	B-INT
.	NN	O	O

For	NN	O	O
overall	NN	O	B-OUT
survival	NN	O	I-OUT
,	NN	O	O
PLD	NN	O	B-INT
was	NN	O	O
significantly	NN	O	O
superior	NN	O	O
to	NN	O	O
topotecan	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=.008	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
108	NN	O	O
weeks	NN	O	O
versus	NN	O	O
71.1	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
platinum-refractory	NN	O	O
subgroup	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
nonstatistically	NN	O	O
significant	NN	O	O
survival	NN	O	O
trend	NN	O	O
in	NN	O	O
favor	NN	O	O
of	NN	O	O
topotecan	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=.455	NN	O	O
)	NN	O	O
.	NN	O	O

Severe	NN	O	B-OUT
hematologic	NN	O	I-OUT
toxicity	NN	O	I-OUT
was	NN	O	O
more	NN	O	O
common	NN	O	O
with	NN	O	O
topotecan	NN	O	B-INT
and	NN	O	O
was	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
dosage	NN	O	O
modification	NN	O	O
,	NN	O	O
or	NN	O	O
growth	NN	O	O
factor	NN	O	O
or	NN	O	O
blood	NN	O	O
product	NN	O	O
utilization	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
comparable	NN	O	O
efficacy	NN	O	B-OUT
,	NN	O	O
favorable	NN	O	O
safety	NN	O	B-OUT
profile	NN	O	O
,	NN	O	O
and	NN	O	O
convenient	NN	O	O
dosing	NN	O	O
support	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
PLD	NN	O	B-INT
as	NN	O	O
a	NN	O	O
valuable	NN	O	O
treatment	NN	O	O
option	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
population	NN	O	O
.	NN	O	O



--DOCSTART-- (11495215)

Oral	NN	O	B-INT
contraceptive	NN	O	I-INT
use	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
cardiovascular	NN	O	B-OUT
reactivity	NN	O	I-OUT
in	NN	O	O
nonsmokers	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
smoke	NN	O	O
and	NN	O	O
take	NN	O	O
oral	NN	O	B-INT
contraceptives	NN	O	I-INT
(	NN	O	I-INT
OCs	NN	O	I-INT
)	NN	O	I-INT
have	NN	O	O
significantly	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
disease	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
exact	NN	O	O
mechanismsfor	NN	O	O
the	NN	O	O
increased	NN	O	O
risk	NN	O	O
are	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

Cardiovascular	NN	O	O
reactivity	NN	O	O
to	NN	O	O
psychological	NN	O	O
stress	NN	O	O
may	NN	O	O
be	NN	O	O
one	NN	O	O
mechanism	NN	O	O
for	NN	O	O
the	NN	O	O
enhanced	NN	O	O
risk	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
small	NN	O	O
number	NN	O	O
of	NN	O	O
studies	NN	O	O
examining	NN	O	O
whether	NN	O	O
OC	NN	O	O
users	NN	O	O
who	NN	O	O
smoke	NN	O	O
have	NN	O	O
greater	NN	O	O
reactivity	NN	O	O
have	NN	O	O
produced	NN	O	O
mixed	NN	O	O
results	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
cigarette	NN	O	O
smoking	NN	O	O
,	NN	O	O
acute	NN	O	O
nicotine	NN	O	O
administration	NN	O	O
,	NN	O	O
and	NN	O	O
OC	NN	O	O
use	NN	O	O
on	NN	O	O
cardiovascular	NN	O	B-OUT
and	NN	O	I-OUT
lipid	NN	O	I-OUT
reactivity	NN	O	I-OUT
.	NN	O	O

Sixty	NN	O	B-PAR
healthy	NN	O	I-PAR
women	NN	O	I-PAR
,	NN	O	I-PAR
half	NN	O	I-PAR
of	NN	O	I-PAR
whom	NN	O	I-PAR
had	NN	O	I-PAR
been	NN	O	I-PAR
using	NN	O	I-PAR
OCs	NN	O	I-PAR
for	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
the	NN	O	I-PAR
previous	NN	O	I-PAR
6	NN	O	I-PAR
months	NN	O	I-PAR
,	NN	O	I-PAR
participated	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Approximately	NN	O	O
two	NN	O	B-PAR
thirds	NN	O	I-PAR
were	NN	O	I-PAR
smokers	NN	O	I-PAR
and	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
be	NN	O	O
tested	NN	O	O
after	NN	O	O
either	NN	O	O
a	NN	O	O
12-hr	NN	O	O
nicotine	NN	O	B-INT
deprivation	NN	O	I-INT
or	NN	O	O
administration	NN	O	O
of	NN	O	O
nicotine	NN	O	B-INT
gum	NN	O	O
.	NN	O	O

One	NN	O	B-PAR
third	NN	O	I-PAR
were	NN	O	I-PAR
nonsmokers	NN	O	I-PAR
.	NN	O	O

Heart	NN	O	B-OUT
rate	NN	O	I-OUT
,	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
lipid	NN	O	I-OUT
measures	NN	O	I-OUT
were	NN	O	O
taken	NN	O	O
at	NN	O	O
rest	NN	O	O
,	NN	O	O
during	NN	O	O
a	NN	O	O
videotaped	NN	O	O
speech	NN	O	O
task	NN	O	O
,	NN	O	O
and	NN	O	O
during	NN	O	O
recovery	NN	O	O
from	NN	O	O
the	NN	O	O
task	NN	O	O
.	NN	O	O

Results	NN	O	O
indicated	NN	O	O
that	NN	O	O
,	NN	O	O
among	NN	O	O
OC	NN	O	B-INT
nonusers	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
effect	NN	O	O
of	NN	O	O
smoking	NN	O	O
status	NN	O	O
or	NN	O	O
nicotine	NN	O	B-INT
administration	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
reactivity	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
among	NN	O	O
OC	NN	O	B-INT
users	NN	O	O
,	NN	O	O
nonsmokers	NN	O	O
had	NN	O	O
significantly	NN	O	O
greater	NN	O	O
heart	NN	O	B-OUT
rate	NN	O	I-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
reactivity	NN	O	I-OUT
to	NN	O	O
stress	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
acute	NN	O	O
nicotine	NN	O	B-INT
administration	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
nicotine	NN	O	B-INT
gum	NN	O	O
,	NN	O	O
has	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
cardiovascular	NN	O	B-OUT
or	NN	O	I-OUT
lipid	NN	O	I-OUT
stress	NN	O	I-OUT
reactivity	NN	O	I-OUT
in	NN	O	O
women	NN	O	O
.	NN	O	O

However	NN	O	O
OC	NN	O	B-INT
use	NN	O	O
among	NN	O	O
nonsmoking	NN	O	O
women	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
greater	NN	O	O
cardiovascular	NN	O	B-OUT
reactivity	NN	O	I-OUT
to	NN	O	O
stress	NN	O	O
.	NN	O	O



--DOCSTART-- (11642083)

[	NN	O	O
Neoton	NN	O	B-INT
and	NN	O	O
thrombolytic	NN	O	B-INT
therapy	NN	O	I-INT
of	NN	O	O
myocardial	NN	O	B-PAR
infarction	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

AIM	NN	O	O
To	NN	O	O
evaluate	NN	O	O
neoton	NN	O	B-INT
therapy	NN	O	O
effects	NN	O	O
in	NN	O	O
acute	NN	O	B-PAR
myocardial	NN	O	I-PAR
infarction	NN	O	I-PAR
(	NN	O	I-PAR
MI	NN	O	I-PAR
)	NN	O	I-PAR
on	NN	O	O
systolic	NN	O	B-OUT
function	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
left	NN	O	I-OUT
ventricle	NN	O	I-OUT
,	NN	O	I-OUT
arrhythmia	NN	O	I-OUT
and	NN	O	I-OUT
clinical	NN	O	I-OUT
symptoms	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
on	NN	O	I-PAR
thrombolytic	NN	O	I-INT
therapy	NN	O	I-INT
(	NN	O	I-PAR
TLT	NN	O	I-INT
)	NN	O	I-PAR
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
106	NN	O	B-PAR
males	NN	O	I-PAR
with	NN	O	I-PAR
Q-MI	NN	O	I-PAR
entered	NN	O	I-PAR
the	NN	O	I-PAR
study	NN	O	I-PAR
.	NN	O	O

47	NN	O	O
received	NN	O	O
treatment	NN	O	O
without	NN	O	O
TLT	NN	O	B-INT
and	NN	O	O
neoton	NN	O	B-INT
,	NN	O	O
30	NN	O	O
patients	NN	O	O
received	NN	O	O
TLT	NN	O	B-INT
with	NN	O	O
streptokinase	NN	O	B-INT
preparations	NN	O	O
,	NN	O	O
29	NN	O	O
patients	NN	O	O
were	NN	O	O
given	NN	O	O
streptokinase	NN	O	B-INT
preparations	NN	O	I-INT
and	NN	O	O
neoton	NN	O	B-INT
.	NN	O	O

Left	NN	O	B-OUT
ventricular	NN	O	I-OUT
systolic	NN	O	I-OUT
function	NN	O	I-OUT
was	NN	O	O
measured	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
21	NN	O	O
and	NN	O	O
28	NN	O	O
;	NN	O	O
arrhythmia	NN	O	B-OUT
was	NN	O	O
analysed	NN	O	O
at	NN	O	O
Holter	NN	O	O
monitoring	NN	O	O
in	NN	O	O
day	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
of	NN	O	O
MI	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
TLT	NN	O	O
failed	NN	O	O
to	NN	O	O
arrest	NN	O	O
progression	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
dilation	NN	O	O
by	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
hospital	NN	O	O
stay	NN	O	O
.	NN	O	O

Patients	NN	O	O
given	NN	O	O
neoton	NN	O	B-INT
in	NN	O	O
acute	NN	O	O
period	NN	O	O
of	NN	O	O
MI	NN	O	O
had	NN	O	O
no	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
end	NN	O	O
systolic	NN	O	B-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
volumes	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
left	NN	O	O
ventricle	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
months	NN	O	O
after	NN	O	O
MI	NN	O	O
onset	NN	O	O
.	NN	O	O

Antiarrhythmic	NN	O	O
action	NN	O	O
of	NN	O	O
neoton	NN	O	B-INT
manifested	NN	O	O
on	NN	O	O
MI	NN	O	O
day	NN	O	O
2	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Neoton	NN	O	B-INT
given	NN	O	O
to	NN	O	O
MI	NN	O	O
patients	NN	O	O
receiving	NN	O	O
TLT	NN	O	O
prevents	NN	O	O
progression	NN	O	O
of	NN	O	O
left	NN	O	B-OUT
ventricular	NN	O	I-OUT
systolic	NN	O	I-OUT
dysfunction	NN	O	I-OUT
and	NN	O	O
establishment	NN	O	O
of	NN	O	O
predictors	NN	O	O
of	NN	O	O
unfavourable	NN	O	O
outcome	NN	O	O
.	NN	O	O



--DOCSTART-- (11737955)

Antioxidant	NN	O	B-INT
supplementation	NN	O	I-INT
and	NN	O	O
exercise-induced	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
the	NN	O	B-PAR
60-year-old	NN	O	I-PAR
as	NN	O	O
measured	NN	O	O
by	NN	O	O
antipyrine	NN	O	B-INT
hydroxylates	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
antioxidant	NN	O	B-INT
supplementation	NN	O	I-INT
on	NN	O	O
exercise-induced	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
older	NN	O	B-PAR
adults	NN	O	I-PAR
(	NN	O	I-PAR
60	NN	O	I-PAR
(	NN	O	I-PAR
SE	NN	O	I-PAR
1	NN	O	I-PAR
)	NN	O	I-PAR
years	NN	O	I-PAR
;	NN	O	I-PAR
BMI	NN	O	I-PAR
26	NN	O	I-PAR
(	NN	O	I-PAR
SE	NN	O	I-PAR
1	NN	O	I-PAR
)	NN	O	I-PAR
kg/m	NN	O	I-PAR
(	NN	O	I-PAR
2	NN	O	I-PAR
)	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
in	NN	O	O
two	NN	O	O
groups	NN	O	O
:	NN	O	O
supplementation	NN	O	O
(	NN	O	O
n	NN	O	O
11	NN	O	O
)	NN	O	O
with	NN	O	O
100	NN	O	O
mg	NN	O	O
dl-alpha-tocopheryl	NN	O	B-INT
acetate	NN	O	I-INT
,	NN	O	O
200	NN	O	O
mg	NN	O	O
ascorbic	NN	O	B-INT
acid	NN	O	I-INT
,	NN	O	O
and	NN	O	O
2	NN	O	O
mg	NN	O	O
beta-carotene	NN	O	B-INT
,	NN	O	O
and	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
n	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

Before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
12	NN	O	O
week	NN	O	O
supplementation	NN	O	O
period	NN	O	O
,	NN	O	O
subjects	NN	O	O
cycled	NN	O	O
for	NN	O	O
45	NN	O	O
min	NN	O	O
at	NN	O	O
submaximal	NN	O	O
intensity	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
maximal	NN	O	O
workload	NN	O	O
capacity	NN	O	O
)	NN	O	O
.	NN	O	O

Antipyrine	NN	O	B-INT
was	NN	O	O
used	NN	O	O
as	NN	O	O
marker	NN	O	O
for	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Antipyrine	NN	O	O
reacts	NN	O	O
quickly	NN	O	O
with	NN	O	O
hydroxyl	NN	O	O
radicals	NN	O	O
to	NN	O	O
form	NN	O	O
para-	NN	O	O
and	NN	O	O
ortho-hydroxyantipyrine	NN	O	O
.	NN	O	O

The	NN	O	O
latter	NN	O	O
metabolite	NN	O	O
is	NN	O	O
not	NN	O	O
formed	NN	O	O
in	NN	O	O
man	NN	O	O
through	NN	O	O
the	NN	O	O
mono-oxygenase	NN	O	O
pathway	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
.	NN	O	O

Daily	NN	O	O
supplementation	NN	O	O
significantly	NN	O	O
increased	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
alpha-tocopherol	NN	O	O
and	NN	O	O
beta-carotene	NN	O	O
in	NN	O	O
the	NN	O	O
supplemented	NN	O	O
group	NN	O	O
(	NN	O	O
Delta	NN	O	O
14.4	NN	O	O
(	NN	O	O
SE	NN	O	O
3.2	NN	O	O
)	NN	O	O
and	NN	O	O
0.4	NN	O	O
(	NN	O	O
se	NN	O	O
0.1	NN	O	O
)	NN	O	O
micromol/l	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
and	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
,	NN	O	O
within	NN	O	O
and	NN	O	O
between	NN	O	O
groups	NN	O	O
,	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
exercise-induced	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
ratios	NN	O	O
para-	NN	O	B-OUT
and	NN	O	I-OUT
ortho-hydroxyantipyrine	NN	O	I-OUT
to	NN	O	I-OUT
antipyrine	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
supplementation	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
exercise-induced	NN	O	O
increase	NN	O	O
in	NN	O	O
thiobarbituric	NN	O	B-OUT
acid	NN	O	I-OUT
reactive	NN	O	I-OUT
substances	NN	O	I-OUT
in	NN	O	I-OUT
plasma	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
in	NN	O	O
60-year-old	NN	O	B-PAR
subjects	NN	O	I-PAR
antioxidant	NN	O	I-INT
supplementation	NN	O	I-INT
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
exercise-induced	NN	O	O
increase	NN	O	O
in	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
free	NN	O	B-OUT
radical	NN	O	I-OUT
products	NN	O	I-OUT
of	NN	O	I-OUT
antipyrine	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (11750293)

The	NN	O	O
course	NN	O	O
of	NN	O	O
depression	NN	O	O
in	NN	O	O
recent	NN	O	B-PAR
onset	NN	O	I-PAR
rheumatoid	NN	O	I-PAR
arthritis	NN	O	I-PAR
:	NN	O	O
the	NN	O	O
predictive	NN	O	O
role	NN	O	O
of	NN	O	O
disability	NN	O	B-OUT
,	NN	O	I-OUT
illness	NN	O	I-OUT
perceptions	NN	O	I-OUT
,	NN	O	I-OUT
pain	NN	O	I-OUT
and	NN	O	I-OUT
coping	NN	O	I-OUT
.	NN	O	O

BACKGROUND	NN	O	O
This	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
depression	NN	O	O
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
recently	NN	O	I-PAR
diagnosed	NN	O	I-PAR
rheumatoid	NN	O	I-PAR
arthritis	NN	O	I-PAR
(	NN	O	I-PAR
RA	NN	O	I-PAR
)	NN	O	I-PAR
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
predictors	NN	O	O
of	NN	O	O
depression	NN	O	B-OUT
.	NN	O	O

METHODS	NN	O	O
Twenty-two	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
history	NN	O	I-PAR
of	NN	O	I-PAR
recently	NN	O	I-PAR
diagnosed	NN	O	I-PAR
RA	NN	O	I-PAR
of	NN	O	I-PAR
less	NN	O	I-PAR
than	NN	O	I-PAR
2	NN	O	I-PAR
years	NN	O	I-PAR
were	NN	O	O
assessed	NN	O	O
on	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
clinical	NN	O	B-OUT
outcome	NN	O	I-OUT
and	NN	O	I-OUT
process	NN	O	I-OUT
measures	NN	O	I-OUT
on	NN	O	O
six	NN	O	O
assessment	NN	O	O
occasions	NN	O	O
over	NN	O	O
a	NN	O	O
21-month	NN	O	O
period	NN	O	O
.	NN	O	O

These	NN	O	O
22	NN	O	B-PAR
patients	NN	O	I-PAR
constituted	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
of	NN	O	O
a	NN	O	O
controlled	NN	O	O
trial	NN	O	O
and	NN	O	O
received	NN	O	O
standard	NN	O	B-INT
outpatient	NN	O	I-INT
clinic	NN	O	I-INT
treatment	NN	O	I-INT
during	NN	O	O
follow-up	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Patients	NN	O	O
became	NN	O	O
significantly	NN	O	O
more	NN	O	O
depressed	NN	O	O
over	NN	O	O
time	NN	O	O
.	NN	O	O

A	NN	O	O
set	NN	O	O
of	NN	O	O
five	NN	O	O
factors	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
consistently	NN	O	O
predict	NN	O	B-OUT
depression	NN	O	I-OUT
at	NN	O	O
the	NN	O	O
following	NN	O	O
assessment	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
initial	NN	O	O
level	NN	O	O
of	NN	O	O
depression	NN	O	B-OUT
,	NN	O	I-OUT
disability	NN	O	I-OUT
,	NN	O	I-OUT
pain	NN	O	I-OUT
,	NN	O	I-OUT
beliefs	NN	O	I-OUT
about	NN	O	I-OUT
the	NN	O	I-OUT
consequences	NN	O	I-OUT
of	NN	O	I-OUT
arthritis	NN	O	I-OUT
and	NN	O	I-OUT
coping	NN	O	I-OUT
strategies	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
results	NN	O	O
confirm	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
psychological	NN	O	O
factors	NN	O	O
in	NN	O	O
early	NN	O	O
RA	NN	O	O
and	NN	O	O
their	NN	O	O
relative	NN	O	O
independence	NN	O	O
from	NN	O	O
physical	NN	O	O
findings	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
study	NN	O	O
to	NN	O	O
document	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
illness	NN	O	O
perceptions	NN	O	O
in	NN	O	O
recent	NN	O	O
onset	NN	O	O
RA	NN	O	O
.	NN	O	O



--DOCSTART-- (11829043)

A	NN	O	O
pilot	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
progressive	NN	O	B-INT
muscle	NN	O	I-INT
relaxation	NN	O	I-INT
training	NN	O	I-INT
of	NN	O	O
patients	NN	O	B-PAR
after	NN	O	I-PAR
stoma	NN	O	I-PAR
surgery	NN	O	I-PAR
.	NN	O	O

Eighteen	NN	O	B-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
undergone	NN	O	I-PAR
stoma	NN	O	I-PAR
surgery	NN	O	I-PAR
were	NN	O	O
assessed	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
their	NN	O	O
anxiety	NN	O	B-OUT
level	NN	O	I-OUT
and	NN	O	I-OUT
self-reported	NN	O	I-OUT
quality	NN	O	I-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
(	NN	O	I-OUT
QoL	NN	O	I-OUT
)	NN	O	I-OUT
on	NN	O	O
three	NN	O	O
occasions	NN	O	O
;	NN	O	O
namely	NN	O	O
,	NN	O	O
immediately	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
5	NN	O	O
weeks	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
weeks	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
randomised	NN	O	O
into	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
and	NN	O	O
an	NN	O	O
experimental	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
20-min	NN	O	O
set	NN	O	O
of	NN	O	O
audiotaped	NN	O	O
instructions	NN	O	O
on	NN	O	O
progressive	NN	O	B-INT
muscle	NN	O	I-INT
relaxation	NN	O	I-INT
training	NN	O	I-INT
(	NN	O	I-INT
PMRT	NN	O	I-INT
)	NN	O	I-INT
was	NN	O	O
given	NN	O	O
to	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
for	NN	O	O
home	NN	O	O
practice	NN	O	O
.	NN	O	O

Assessment	NN	O	O
instructions	NN	O	O
included	NN	O	O
the	NN	O	O
Chinese	NN	O	B-OUT
State-Trait	NN	O	I-OUT
Anxiety	NN	O	I-OUT
Inventory	NN	O	I-OUT
(	NN	O	I-OUT
C-STAI	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
the	NN	O	I-OUT
Quality	NN	O	I-OUT
of	NN	O	I-OUT
Life	NN	O	I-OUT
Index	NN	O	I-OUT
for	NN	O	I-OUT
Colostomy	NN	O	I-OUT
(	NN	O	I-OUT
QoL-Colostomy	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	I-OUT
the	NN	O	I-OUT
Hong	NN	O	I-OUT
Kong	NN	O	I-OUT
Chinese	NN	O	I-OUT
version	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
World	NN	O	I-OUT
Health	NN	O	I-OUT
Organisation	NN	O	I-OUT
Quality	NN	O	I-OUT
of	NN	O	I-OUT
Life	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
WHOQoL	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Results	NN	O	O
indicated	NN	O	O
that	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
C-STAI	NN	O	B-OUT
score	NN	O	I-OUT
(	NN	O	O
F	NN	O	O
=	NN	O	O
4.66	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
WHOQoL	NN	O	B-OUT
score	NN	O	I-OUT
(	NN	O	O
F	NN	O	O
=	NN	O	O
4.74	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
domains	NN	O	O
of	NN	O	O
WHOQoL	NN	O	B-OUT
,	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
was	NN	O	O
shown	NN	O	O
in	NN	O	O
physical	NN	O	O
health/independence	NN	O	O
and	NN	O	O
general	NN	O	O
perception	NN	O	O
of	NN	O	O
QoL	NN	O	B-OUT
,	NN	O	O
with	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
demonstrating	NN	O	O
better	NN	O	O
functioning	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
QoL-Colostomy	NN	O	B-OUT
,	NN	O	O
however	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
experimental	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
PMRT	NN	O	B-INT
could	NN	O	O
enhance	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
and	NN	O	O
decrease	NN	O	O
state	NN	O	O
anxiety	NN	O	B-OUT
in	NN	O	O
patients	NN	O	B-PAR
after	NN	O	I-PAR
stoma	NN	O	I-PAR
surgery	NN	O	I-PAR
.	NN	O	I-PAR


--DOCSTART-- (11891832)

Comparison	NN	O	O
of	NN	O	O
weakness	NN	O	B-OUT
progression	NN	O	I-OUT
in	NN	O	O
inclusion	NN	O	B-PAR
body	NN	O	I-PAR
myositis	NN	O	I-PAR
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
methotrexate	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
whether	NN	O	O
5	NN	O	O
to	NN	O	O
20mg	NN	O	O
per	NN	O	O
week	NN	O	O
oral	NN	O	O
methotrexate	NN	O	B-INT
could	NN	O	O
slow	NN	O	O
down	NN	O	O
disease	NN	O	B-OUT
progression	NN	O	I-OUT
in	NN	O	O
44	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
inclusion	NN	O	I-PAR
body	NN	O	I-PAR
myositis	NN	O	I-PAR
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
double-blind	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
over	NN	O	O
48	NN	O	O
weeks	NN	O	O
.	NN	O	O

Mean	NN	O	B-OUT
change	NN	O	I-OUT
of	NN	O	I-OUT
quantitative	NN	O	I-OUT
muscle	NN	O	I-OUT
strength	NN	O	I-OUT
testing	NN	O	I-OUT
sum	NN	O	I-OUT
scores	NN	O	I-OUT
was	NN	O	O
the	NN	O	O
primary	NN	O	O
study	NN	O	O
outcome	NN	O	O
measure	NN	O	O
.	NN	O	O

Quantitative	NN	O	B-OUT
muscle	NN	O	I-OUT
strength	NN	O	I-OUT
testing	NN	O	I-OUT
sum	NN	O	I-OUT
scores	NN	O	I-OUT
declined	NN	O	O
in	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
-0.2	NN	O	O
%	NN	O	O
for	NN	O	O
methotrexate	NN	O	B-INT
and	NN	O	O
-3.4	NN	O	O
%	NN	O	O
for	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
=	NN	O	O
-2.5	NN	O	O
%	NN	O	O
to	NN	O	O
+9.1	NN	O	O
%	NN	O	O
for	NN	O	O
difference	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
also	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
manual	NN	O	B-OUT
muscle	NN	O	I-OUT
testing	NN	O	I-OUT
sum	NN	O	I-OUT
scores	NN	O	I-OUT
,	NN	O	I-OUT
activity	NN	O	I-OUT
scale	NN	O	I-OUT
scores	NN	O	I-OUT
and	NN	O	I-OUT
patients	NN	O	I-OUT
'	NN	O	I-OUT
own	NN	O	I-OUT
assessments	NN	O	I-OUT
after	NN	O	O
48	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Serum	NN	O	B-OUT
creatine	NN	O	I-OUT
kinase	NN	O	I-OUT
activity	NN	O	I-OUT
decreased	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
methotrexate	NN	O	B-INT
group	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
oral	NN	O	O
methotrexate	NN	O	B-INT
did	NN	O	O
not	NN	O	O
slow	NN	O	O
down	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
muscle	NN	O	I-OUT
weakness	NN	O	I-OUT
but	NN	O	O
decreased	NN	O	O
serum	NN	O	B-OUT
creatine	NN	O	I-OUT
kinase	NN	O	I-OUT
activity	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (12139812)

[	NN	O	O
Limbal	NN	O	B-INT
epithelial	NN	O	I-INT
autograft	NN	O	I-INT
transplantation	NN	O	I-INT
in	NN	O	O
treatment	NN	O	O
of	NN	O	O
pterygium	NN	O	B-PAR
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
observe	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
effects	NN	O	O
of	NN	O	O
limbal	NN	O	B-INT
epithelial	NN	O	I-INT
autograft	NN	O	I-INT
transplantation	NN	O	I-INT
and	NN	O	O
pterygium	NN	O	B-INT
excision	NN	O	I-INT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
pterygium	NN	O	B-PAR
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
paired-eye	NN	O	O
trial	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
208	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
229	NN	O	I-PAR
eyes	NN	O	I-PAR
)	NN	O	I-PAR
with	NN	O	I-PAR
initial	NN	O	I-PAR
pterygium	NN	O	I-PAR
,	NN	O	O
and	NN	O	O
they	NN	O	O
were	NN	O	O
allocated	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
:	NN	O	O
excision	NN	O	B-INT
of	NN	O	I-INT
pterygium	NN	O	I-INT
with	NN	O	O
limbal	NN	O	B-INT
epithelial	NN	O	I-INT
autograft	NN	O	I-INT
transplantation	NN	O	I-INT
surgery	NN	O	I-INT
(	NN	O	O
A	NN	O	O
group	NN	O	O
,	NN	O	O
106	NN	O	O
cases	NN	O	O
and	NN	O	O
124	NN	O	O
eyes	NN	O	O
)	NN	O	O
and	NN	O	O
simple	NN	O	B-INT
pterygium	NN	O	I-INT
excision	NN	O	I-INT
(	NN	O	O
B	NN	O	O
group	NN	O	O
,	NN	O	O
102	NN	O	O
cases	NN	O	O
and	NN	O	O
105	NN	O	O
eyes	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
criteria	NN	O	O
for	NN	O	O
recovery	NN	O	O
were	NN	O	O
corneal	NN	O	O
transparency	NN	O	O
with	NN	O	O
stable	NN	O	O
epithelial	NN	O	B-OUT
healing	NN	O	I-OUT
and	NN	O	O
no	NN	O	O
abnormal	NN	O	B-OUT
proliferation	NN	O	I-OUT
of	NN	O	I-OUT
pterygium-like	NN	O	I-OUT
tissue	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
post-operative	NN	O	O
follow-up	NN	O	O
periods	NN	O	O
ranged	NN	O	O
from	NN	O	O
18	NN	O	O
approximately	NN	O	O
28	NN	O	O
(	NN	O	O
22.4	NN	O	O
+/-	NN	O	O
4.9	NN	O	O
)	NN	O	O
months	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Some	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
lost	NN	O	O
follow-up	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
eyes	NN	O	O
followed	NN	O	O
up	NN	O	O
,	NN	O	O
5	NN	O	O
of	NN	O	O
11	NN	O	O
2	NN	O	O
eyes	NN	O	O
(	NN	O	O
4.5	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
A	NN	O	O
group	NN	O	O
and	NN	O	O
41	NN	O	O
of	NN	O	O
96	NN	O	O
eyes	NN	O	O
(	NN	O	O
42.7	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
B	NN	O	O
group	NN	O	O
were	NN	O	O
recurred	NN	O	O
,	NN	O	O
the	NN	O	O
difference	NN	O	O
being	NN	O	O
very	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
To	NN	O	O
provide	NN	O	O
a	NN	O	O
new	NN	O	O
stem	NN	O	O
cell	NN	O	O
source	NN	O	O
,	NN	O	O
limbal	NN	O	B-INT
epithelial	NN	O	I-INT
autograft	NN	O	I-INT
transplantation	NN	O	I-INT
,	NN	O	O
for	NN	O	O
an	NN	O	O
injured	NN	O	O
limb	NN	O	O
us	NN	O	O
is	NN	O	O
a	NN	O	O
reasonable	NN	O	O
therapeutic	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
pterygium	NN	O	O
.	NN	O	O



--DOCSTART-- (12477021)

Clinical	NN	O	B-OUT
performance	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
Reichert	NN	O	B-INT
AT550	NN	O	I-INT
:	NN	O	O
a	NN	O	O
new	NN	O	O
non-contact	NN	O	O
tonometer	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
level	NN	O	B-OUT
of	NN	O	I-OUT
accuracy	NN	O	I-OUT
for	NN	O	O
measurements	NN	O	B-OUT
of	NN	O	O
intra-ocular	NN	O	O
pressure	NN	O	O
(	NN	O	O
IOP	NN	O	O
)	NN	O	O
obtained	NN	O	O
with	NN	O	O
a	NN	O	O
new	NN	O	O
non-contact	NN	O	O
tonometer	NN	O	O
(	NN	O	O
NCT	NN	O	O
)	NN	O	O
the	NN	O	O
Reichert	NN	O	B-INT
AT550	NN	O	I-INT
.	NN	O	O

Measurements	NN	O	O
were	NN	O	O
compared	NN	O	O
against	NN	O	O
those	NN	O	O
obtained	NN	O	O
with	NN	O	O
the	NN	O	O
Reichert	NN	O	B-INT
Xpert	NN	O	I-INT
Plus	NN	O	I-INT
,	NN	O	O
Goldmann	NN	O	B-INT
applanation	NN	O	I-INT
tonometer	NN	O	I-INT
and	NN	O	O
Perkins	NN	O	B-INT
tonometer	NN	O	I-INT
.	NN	O	O

Thirty-five	NN	O	B-PAR
university	NN	O	I-PAR
students	NN	O	I-PAR
were	NN	O	O
assessed	NN	O	O
with	NN	O	O
the	NN	O	O
four	NN	O	O
tonometers	NN	O	O
in	NN	O	O
a	NN	O	O
randomised	NN	O	O
order	NN	O	O
,	NN	O	O
with	NN	O	O
non-contact	NN	O	O
tonometry	NN	O	O
performed	NN	O	O
first	NN	O	O
.	NN	O	O

Each	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
measurement	NN	O	O
devices	NN	O	O
had	NN	O	O
its	NN	O	O
own	NN	O	O
trained	NN	O	O
clinical	NN	O	O
observer	NN	O	O
.	NN	O	O

Plots	NN	O	O
of	NN	O	O
differences	NN	O	O
of	NN	O	O
IOP	NN	O	O
as	NN	O	O
a	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
mean	NN	O	O
for	NN	O	O
each	NN	O	O
pair	NN	O	O
of	NN	O	O
instruments	NN	O	O
were	NN	O	O
obtained	NN	O	O
.	NN	O	O

No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
when	NN	O	O
comparing	NN	O	O
the	NN	O	O
AT550	NN	O	B-INT
NCT	NN	O	I-INT
with	NN	O	O
contact	NN	O	O
applanation	NN	O	O
tonometry	NN	O	O
(	NN	O	O
AT	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
displaying	NN	O	O
the	NN	O	O
closest	NN	O	O
level	NN	O	O
of	NN	O	O
agreement	NN	O	O
(	NN	O	O
as	NN	O	O
represented	NN	O	O
by	NN	O	O
the	NN	O	O
lowest	NN	O	O
mean	NN	O	O
difference	NN	O	O
and	NN	O	O
the	NN	O	O
narrowest	NN	O	O
confidence	NN	O	O
interval	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
Goldmann	NN	O	B-INT
tonometer	NN	O	I-INT
(	NN	O	O
limits	NN	O	O
of	NN	O	O
agreement	NN	O	O
,	NN	O	O
0.12+/-2.17	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
readings	NN	O	O
of	NN	O	O
IOP	NN	O	B-OUT
with	NN	O	O
the	NN	O	O
AT550	NN	O	B-INT
NCT	NN	O	I-INT
are	NN	O	O
clinically	NN	O	O
comparable	NN	O	O
with	NN	O	O
those	NN	O	O
obtained	NN	O	O
with	NN	O	O
Goldmann	NN	O	B-INT
tonometry	NN	O	I-INT
in	NN	O	O
a	NN	O	O
population	NN	O	O
with	NN	O	O
IOP	NN	O	O
within	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
.	NN	O	O



--DOCSTART-- (12576806)

Is	NN	O	O
a	NN	O	O
2-week	NN	O	O
duration	NN	O	O
sufficient	NN	O	O
for	NN	O	O
stenting	NN	O	B-INT
in	NN	O	O
endopyelotomy	NN	O	O
?	NN	O	O
PURPOSE	NN	O	O
Internal	NN	O	B-INT
stenting	NN	O	I-INT
is	NN	O	O
an	NN	O	O
integral	NN	O	O
part	NN	O	O
of	NN	O	O
endopyelotomy	NN	O	O
.	NN	O	O

Studies	NN	O	O
in	NN	O	O
animals	NN	O	O
show	NN	O	O
good	NN	O	O
healing	NN	O	O
after	NN	O	O
1	NN	O	O
to	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
ureterotomy	NN	O	O
.	NN	O	O

Inherent	NN	O	O
stent	NN	O	O
related	NN	O	O
problems	NN	O	O
warrant	NN	O	O
a	NN	O	O
minimum	NN	O	O
possible	NN	O	O
duration	NN	O	O
of	NN	O	O
stenting	NN	O	O
without	NN	O	O
compromising	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
endopyelotomy	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
trial	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
optimum	NN	O	B-OUT
duration	NN	O	I-OUT
of	NN	O	I-OUT
stenting	NN	O	I-OUT
after	NN	O	O
endopyelotomy	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
57	NN	O	I-PAR
consecutive	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
ureteropelvic	NN	O	I-PAR
junction	NN	O	I-PAR
obstruction	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
undergo	NN	O	O
7/14Fr	NN	O	B-INT
internal	NN	O	I-INT
endopyelotomy	NN	O	I-INT
stent	NN	O	I-INT
placement	NN	O	I-INT
for	NN	O	O
2	NN	O	O
(	NN	O	O
group	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
4	NN	O	O
(	NN	O	O
group	NN	O	O
2	NN	O	O
)	NN	O	O
weeks	NN	O	O
.	NN	O	O

A	NN	O	O
symptom	NN	O	O
based	NN	O	O
questionnaire	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
all	NN	O	O
patients	NN	O	O
at	NN	O	O
stent	NN	O	O
removal	NN	O	O
.	NN	O	O

Followup	NN	O	O
was	NN	O	O
done	NN	O	O
with	NN	O	O
diuretic	NN	O	O
scanning	NN	O	O
at	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
9	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
and	NN	O	O
then	NN	O	O
yearly	NN	O	O
,	NN	O	O
and	NN	O	O
thereafter	NN	O	O
with	NN	O	O
diuretic	NN	O	O
renography	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
In	NN	O	O
each	NN	O	O
group	NN	O	O
26	NN	O	O
patients	NN	O	O
were	NN	O	O
available	NN	O	O
for	NN	O	O
evaluation	NN	O	O
.	NN	O	O

The	NN	O	O
2	NN	O	O
groups	NN	O	O
were	NN	O	O
comparable	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
symptoms	NN	O	B-OUT
and	NN	O	O
ipsilateral	NN	O	B-OUT
glomerular	NN	O	I-OUT
filtration	NN	O	I-OUT
rate	NN	O	I-OUT
.	NN	O	O

Mean	NN	O	O
followup	NN	O	O
was	NN	O	O
22.3	NN	O	O
(	NN	O	O
range	NN	O	O
12	NN	O	O
to	NN	O	O
36	NN	O	O
)	NN	O	O
and	NN	O	O
21.3	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
12	NN	O	O
to	NN	O	O
35	NN	O	O
)	NN	O	O
in	NN	O	O
groups	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
1	NN	O	O
year	NN	O	O
24	NN	O	O
group	NN	O	O
1	NN	O	O
(	NN	O	O
92.3	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
23	NN	O	O
group	NN	O	O
2	NN	O	O
(	NN	O	O
90.3	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
an	NN	O	O
improved	NN	O	O
drainage	NN	O	B-OUT
pattern	NN	O	I-OUT
.	NN	O	O

This	NN	O	O
difference	NN	O	O
was	NN	O	O
not	NN	O	O
significant	NN	O	O
.	NN	O	O

Stent	NN	O	B-OUT
related	NN	O	I-OUT
symptoms	NN	O	I-OUT
were	NN	O	O
present	NN	O	O
in	NN	O	O
a	NN	O	O
good	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
groups	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
but	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
urinary	NN	O	B-OUT
tract	NN	O	I-OUT
infections	NN	O	I-OUT
(	NN	O	O
11.5	NN	O	O
%	NN	O	O
versus	NN	O	O
38.1	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
group	NN	O	O
2	NN	O	O
patients	NN	O	O
64	NN	O	O
%	NN	O	O
preferred	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
stenting	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Two	NN	O	O
weeks	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
sufficient	NN	O	O
duration	NN	O	B-OUT
to	NN	O	O
allow	NN	O	O
functional	NN	O	O
restoration	NN	O	O
across	NN	O	O
the	NN	O	O
ureteropelvic	NN	O	O
junction	NN	O	O
after	NN	O	O
endopyelotomy	NN	O	O
and	NN	O	O
decrease	NN	O	O
stent	NN	O	B-OUT
related	NN	O	I-OUT
complications	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (12586799)

Phase	NN	O	O
III	NN	O	O
study	NN	O	O
of	NN	O	O
concurrent	NN	O	B-INT
chemoradiotherapy	NN	O	I-INT
versus	NN	O	O
radiotherapy	NN	O	B-INT
alone	NN	O	O
for	NN	O	O
advanced	NN	O	B-PAR
nasopharyngeal	NN	O	I-PAR
carcinoma	NN	O	I-PAR
:	NN	O	O
positive	NN	O	O
effect	NN	O	O
on	NN	O	O
overall	NN	O	B-OUT
and	NN	O	I-OUT
progression-free	NN	O	I-OUT
survival	NN	O	I-OUT
.	NN	O	O

PURPOSE	NN	O	O
Nasopharyngeal	NN	O	B-PAR
carcinoma	NN	O	I-PAR
(	NN	O	I-PAR
NPC	NN	O	I-PAR
)	NN	O	I-PAR
is	NN	O	O
a	NN	O	O
radiosensitive	NN	O	O
and	NN	O	O
chemosensitive	NN	O	O
tumor	NN	O	O
.	NN	O	O

This	NN	O	O
randomized	NN	O	O
phase	NN	O	O
III	NN	O	O
trial	NN	O	O
compared	NN	O	O
concurrent	NN	O	B-INT
chemoradiotherapy	NN	O	I-INT
(	NN	O	I-INT
CCRT	NN	O	I-INT
)	NN	O	I-INT
versus	NN	O	O
radiotherapy	NN	O	B-INT
(	NN	O	I-INT
RT	NN	O	I-INT
)	NN	O	I-INT
alone	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
advanced	NN	O	I-PAR
NPC	NN	O	I-PAR
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
From	NN	O	B-PAR
December	NN	O	I-PAR
1993	NN	O	I-PAR
to	NN	O	I-PAR
April	NN	O	I-PAR
1999	NN	O	I-PAR
,	NN	O	I-PAR
284	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
1992	NN	O	I-PAR
American	NN	O	I-PAR
Joint	NN	O	I-PAR
Committee	NN	O	I-PAR
on	NN	O	I-PAR
Cancer	NN	O	I-PAR
stage	NN	O	I-PAR
III	NN	O	I-PAR
to	NN	O	I-PAR
IV	NN	O	I-PAR
(	NN	O	I-PAR
M0	NN	O	I-PAR
)	NN	O	I-PAR
NPC	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
into	NN	O	O
two	NN	O	O
arms	NN	O	O
.	NN	O	O

Similar	NN	O	O
dosage	NN	O	O
and	NN	O	O
fractionation	NN	O	O
of	NN	O	O
RT	NN	O	O
was	NN	O	O
administered	NN	O	O
in	NN	O	O
both	NN	O	O
arms	NN	O	O
.	NN	O	O

The	NN	O	O
investigational	NN	O	O
arm	NN	O	O
received	NN	O	O
two	NN	O	O
cycles	NN	O	O
of	NN	O	O
concurrent	NN	O	O
chemotherapy	NN	O	B-INT
with	NN	O	O
cisplatin	NN	O	B-INT
20	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/d	NN	O	O
plus	NN	O	O
fluorouracil	NN	O	B-INT
400	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/d	NN	O	O
by	NN	O	O
96-hour	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
during	NN	O	O
the	NN	O	O
weeks	NN	O	O
1	NN	O	O
and	NN	O	O
5	NN	O	O
of	NN	O	O
RT	NN	O	O
.	NN	O	O

Survival	NN	O	B-OUT
analysis	NN	O	I-OUT
was	NN	O	O
estimated	NN	O	O
by	NN	O	O
the	NN	O	O
Kaplan-Meier	NN	O	O
method	NN	O	O
and	NN	O	O
compared	NN	O	O
by	NN	O	O
the	NN	O	O
log-rank	NN	O	O
test	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Baseline	NN	O	O
patient	NN	O	O
characteristics	NN	O	O
were	NN	O	O
comparable	NN	O	O
in	NN	O	O
both	NN	O	O
arms	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
median	NN	O	O
follow-up	NN	O	O
of	NN	O	O
65	NN	O	O
months	NN	O	O
,	NN	O	O
26.2	NN	O	O
%	NN	O	O
(	NN	O	O
37	NN	O	O
of	NN	O	O
141	NN	O	O
)	NN	O	O
and	NN	O	O
46.2	NN	O	O
%	NN	O	O
(	NN	O	O
66	NN	O	O
of	NN	O	O
143	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
developed	NN	O	O
tumor	NN	O	B-OUT
relapse	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
CCRT	NN	O	B-INT
and	NN	O	O
RT-alone	NN	O	B-INT
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
5-year	NN	O	B-OUT
overall	NN	O	I-OUT
survival	NN	O	I-OUT
rates	NN	O	I-OUT
were	NN	O	O
72.3	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
CCRT	NN	O	B-INT
arm	NN	O	O
and	NN	O	O
54.2	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
RT-only	NN	O	B-INT
arm	NN	O	O
(	NN	O	O
P	NN	O	O
=.0022	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
5-year	NN	O	B-OUT
progression-free	NN	O	I-OUT
survival	NN	O	I-OUT
rates	NN	O	I-OUT
were	NN	O	O
71.6	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
CCRT	NN	O	B-INT
group	NN	O	O
compared	NN	O	O
with	NN	O	O
53.0	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
RT-only	NN	O	B-INT
group	NN	O	O
(	NN	O	O
P	NN	O	O
=.0012	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
significantly	NN	O	O
more	NN	O	O
toxicity	NN	O	B-OUT
was	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
CCRT	NN	O	B-INT
arm	NN	O	O
,	NN	O	O
including	NN	O	O
leukopenia	NN	O	B-OUT
and	NN	O	O
emesis	NN	O	B-OUT
,	NN	O	O
compliance	NN	O	O
with	NN	O	O
the	NN	O	O
combined	NN	O	O
treatment	NN	O	O
was	NN	O	O
good	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
cycle	NN	O	O
of	NN	O	O
concurrent	NN	O	O
chemotherapy	NN	O	O
was	NN	O	O
refused	NN	O	O
by	NN	O	O
nine	NN	O	O
patients	NN	O	O
and	NN	O	O
was	NN	O	O
delayed	NN	O	O
for	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
1	NN	O	O
week	NN	O	O
for	NN	O	O
another	NN	O	O
nine	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
treatment-related	NN	O	B-OUT
deaths	NN	O	I-OUT
in	NN	O	O
either	NN	O	O
arm	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
We	NN	O	O
conclude	NN	O	O
that	NN	O	O
CCRT	NN	O	B-INT
is	NN	O	O
superior	NN	O	O
to	NN	O	O
RT	NN	O	B-INT
alone	NN	O	O
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
advanced	NN	O	I-PAR
NPC	NN	O	I-PAR
in	NN	O	O
endemic	NN	O	O
areas	NN	O	O
.	NN	O	O



--DOCSTART-- (12595499)

Development	NN	O	O
of	NN	O	O
renal	NN	O	O
disease	NN	O	O
in	NN	O	O
people	NN	O	B-PAR
at	NN	O	I-PAR
high	NN	O	I-PAR
cardiovascular	NN	O	I-PAR
risk	NN	O	I-PAR
:	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
HOPE	NN	O	O
randomized	NN	O	O
study	NN	O	O
.	NN	O	O

In	NN	O	O
people	NN	O	B-PAR
with	NN	O	I-PAR
diabetes	NN	O	I-PAR
,	NN	O	O
renal	NN	O	O
disease	NN	O	O
tends	NN	O	O
to	NN	O	O
progress	NN	O	O
from	NN	O	O
microalbuminuria	NN	O	O
to	NN	O	O
clinical	NN	O	O
proteinuria	NN	O	O
to	NN	O	O
renal	NN	O	O
insufficiency	NN	O	O
.	NN	O	O

Little	NN	O	O
evidence	NN	O	O
has	NN	O	O
been	NN	O	O
published	NN	O	O
for	NN	O	O
the	NN	O	O
nondiabetic	NN	O	O
population	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
retrospectively	NN	O	O
analyzed	NN	O	O
changes	NN	O	O
of	NN	O	O
proteinuria	NN	O	O
over	NN	O	O
4.5	NN	O	O
yr	NN	O	O
in	NN	O	O
the	NN	O	O
HOPE	NN	O	O
(	NN	O	O
Heart	NN	O	O
Outcomes	NN	O	O
and	NN	O	O
Prevention	NN	O	O
Evaluation	NN	O	O
)	NN	O	O
study	NN	O	O
,	NN	O	O
which	NN	O	O
compared	NN	O	O
ramipril	NN	O	B-INT
's	NN	O	I-INT
effects	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
9297	NN	O	O
participants	NN	O	O
,	NN	O	O
including	NN	O	O
3577	NN	O	O
with	NN	O	O
diabetes	NN	O	O
and	NN	O	O
1956	NN	O	O
with	NN	O	O
microalbuminuria	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
is	NN	O	O
restricted	NN	O	O
to	NN	O	O
7674	NN	O	B-PAR
participants	NN	O	I-PAR
with	NN	O	I-PAR
albuminuria	NN	O	I-PAR
data	NN	O	I-PAR
at	NN	O	I-PAR
baseline	NN	O	I-PAR
and	NN	O	I-PAR
at	NN	O	I-PAR
follow-up	NN	O	I-PAR
.	NN	O	O

Inclusion	NN	O	O
criteria	NN	O	O
were	NN	O	O
known	NN	O	O
vascular	NN	O	O
disease	NN	O	O
or	NN	O	O
diabetes	NN	O	O
plus	NN	O	O
one	NN	O	O
other	NN	O	O
cardiovascular	NN	O	O
risk	NN	O	O
factor	NN	O	O
,	NN	O	O
exclusion	NN	O	O
criteria	NN	O	O
included	NN	O	O
heart	NN	O	O
failure	NN	O	O
or	NN	O	O
known	NN	O	O
impaired	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
,	NN	O	O
dipstick-positive	NN	O	O
proteinuria	NN	O	O
(	NN	O	O
>	NN	O	O
1+	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
>	NN	O	O
2.3	NN	O	O
mg/dl	NN	O	O
(	NN	O	O
200	NN	O	O
microM	NN	O	O
)	NN	O	O
.	NN	O	O

Baseline	NN	O	O
microalbuminuria	NN	O	O
predicted	NN	O	O
subsequent	NN	O	O
clinical	NN	O	B-OUT
proteinuria	NN	O	I-OUT
for	NN	O	O
the	NN	O	O
study	NN	O	O
participants	NN	O	O
overall	NN	O	O
(	NN	O	O
adjusted	NN	O	O
odds	NN	O	O
ratio	NN	O	O
[	NN	O	O
OR	NN	O	O
]	NN	O	O
,	NN	O	O
17.5	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
,	NN	O	O
12.6	NN	O	O
to	NN	O	O
24.4	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
participants	NN	O	O
without	NN	O	O
diabetes	NN	O	O
(	NN	O	O
OR	NN	O	O
,	NN	O	O
16.7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
8.6	NN	O	O
to	NN	O	O
32.4	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
participants	NN	O	O
with	NN	O	O
diabetes	NN	O	O
(	NN	O	O
OR	NN	O	O
,	NN	O	O
18.2	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
12.4	NN	O	O
to	NN	O	O
26.7	NN	O	O
)	NN	O	O
.	NN	O	O

Any	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
albuminuria	NN	O	I-OUT
(	NN	O	O
defined	NN	O	O
as	NN	O	O
new	NN	O	O
microalbuminuria	NN	O	O
or	NN	O	O
new	NN	O	O
clinical	NN	O	O
proteinuria	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
1859	NN	O	O
participants	NN	O	O
;	NN	O	O
1542	NN	O	O
developed	NN	O	O
new	NN	O	O
microalbuminuria	NN	O	B-OUT
,	NN	O	O
and	NN	O	O
317	NN	O	O
participants	NN	O	O
developed	NN	O	O
clinical	NN	O	B-OUT
proteinuria	NN	O	I-OUT
.	NN	O	O

Ramipril	NN	O	B-INT
reduced	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
any	NN	O	O
progression	NN	O	B-OUT
(	NN	O	O
OR	NN	O	O
,	NN	O	O
0.87	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0.78	NN	O	O
to	NN	O	O
0.97	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.0146	NN	O	O
)	NN	O	O
.	NN	O	O

People	NN	O	O
without	NN	O	O
and	NN	O	O
with	NN	O	O
diabetes	NN	O	O
who	NN	O	O
are	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
for	NN	O	O
cardiovascular	NN	O	O
disease	NN	O	O
are	NN	O	O
also	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
a	NN	O	O
progressive	NN	O	O
rise	NN	O	O
in	NN	O	O
albuminuria	NN	O	B-OUT
.	NN	O	O

Microalbuminuria	NN	O	O
itself	NN	O	O
predicts	NN	O	O
clinical	NN	O	O
proteinuria	NN	O	O
in	NN	O	O
nondiabetic	NN	O	B-PAR
and	NN	O	I-PAR
in	NN	O	I-PAR
diabetic	NN	O	I-PAR
people	NN	O	I-PAR
.	NN	O	O

Ramipril	NN	O	B-INT
prevents	NN	O	O
or	NN	O	O
delays	NN	O	O
the	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
albuminuria	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (12709693)

Conscious	NN	O	O
analgesia/sedation	NN	O	O
with	NN	O	O
remifentanil	NN	O	B-INT
and	NN	O	O
propofol	NN	O	B-INT
versus	NN	O	O
total	NN	O	O
intravenous	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
fentanyl	NN	O	B-INT
,	NN	O	O
midazolam	NN	O	B-INT
,	NN	O	O
and	NN	O	O
propofol	NN	O	B-INT
for	NN	O	O
outpatient	NN	O	B-PAR
colonoscopy	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
This	NN	O	O
study	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
,	NN	O	O
for	NN	O	O
colonoscopy	NN	O	O
,	NN	O	O
analgesia/sedation	NN	O	O
with	NN	O	O
remifentanil	NN	O	B-INT
and	NN	O	O
propofol	NN	O	B-INT
might	NN	O	O
be	NN	O	O
more	NN	O	O
effective	NN	O	O
compared	NN	O	O
with	NN	O	O
anesthesia	NN	O	O
by	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
midazolam	NN	O	B-INT
,	NN	O	O
fentanyl	NN	O	B-INT
,	NN	O	O
and	NN	O	O
propofol	NN	O	B-INT
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
trial	NN	O	O
,	NN	O	O
100	NN	O	B-PAR
adult	NN	O	I-PAR
patients	NN	O	I-PAR
received	NN	O	O
either	NN	O	O
conscious	NN	O	O
analgesia/sedation	NN	O	O
(	NN	O	O
Sedation	NN	O	O
group	NN	O	O
)	NN	O	O
or	NN	O	O
total	NN	O	O
intravenous	NN	O	O
anesthesia	NN	O	O
(	NN	O	O
TIVA	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

Analgesia/sedation	NN	O	O
was	NN	O	O
achieved	NN	O	O
by	NN	O	O
infusion	NN	O	O
of	NN	O	O
remifentanil	NN	O	B-INT
(	NN	O	O
0.20	NN	O	O
to	NN	O	O
0.25	NN	O	O
microg/kg/min	NN	O	O
)	NN	O	O
and	NN	O	O
propofol	NN	O	B-INT
in	NN	O	O
titrated	NN	O	O
doses	NN	O	O
.	NN	O	O

TIVA	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
fentanyl	NN	O	B-INT
(	NN	O	O
2	NN	O	O
microg/kg	NN	O	O
)	NN	O	O
,	NN	O	O
midazolam	NN	O	B-INT
(	NN	O	O
0.05	NN	O	O
mg/kg	NN	O	O
)	NN	O	O
and	NN	O	O
propofol	NN	O	B-INT
(	NN	O	O
dosage	NN	O	O
titrated	NN	O	O
)	NN	O	O
.	NN	O	O

Cardiorespiratory	NN	O	B-OUT
parameters	NN	O	I-OUT
and	NN	O	O
bispectral	NN	O	B-OUT
index	NN	O	I-OUT
were	NN	O	O
monitored	NN	O	O
and	NN	O	O
recorded	NN	O	O
.	NN	O	O

The	NN	O	O
quality	NN	O	O
of	NN	O	O
the	NN	O	O
analgesia	NN	O	O
was	NN	O	O
assessed	NN	O	O
with	NN	O	O
a	NN	O	O
Numerical	NN	O	B-OUT
Pain	NN	O	I-OUT
Rating	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
NRS	NN	O	I-OUT
)	NN	O	I-OUT
;	NN	O	I-OUT
recovery	NN	O	I-OUT
level	NN	O	I-OUT
and	NN	O	O
return	NN	O	B-OUT
of	NN	O	I-OUT
psychomotor	NN	O	I-OUT
efficiency	NN	O	I-OUT
were	NN	O	O
evaluated	NN	O	O
with	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
the	NN	O	O
Aldrete	NN	O	B-OUT
scale	NN	O	I-OUT
and	NN	O	O
a	NN	O	O
Modified	NN	O	B-OUT
Post	NN	O	I-OUT
Anesthesia	NN	O	I-OUT
Discharge	NN	O	I-OUT
Scoring	NN	O	I-OUT
(	NN	O	I-OUT
MPADS	NN	O	I-OUT
)	NN	O	I-OUT
system	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
Both	NN	O	O
groups	NN	O	O
of	NN	O	O
50	NN	O	O
patients	NN	O	O
were	NN	O	O
comparable	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
demographic	NN	O	O
data	NN	O	O
,	NN	O	O
initial	NN	O	O
parameters	NN	O	O
,	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
colonoscopy	NN	O	B-PAR
.	NN	O	O

All	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
TIVA	NN	O	O
group	NN	O	O
found	NN	O	O
the	NN	O	O
colonoscopy	NN	O	O
painless	NN	O	O
(	NN	O	O
NRS	NN	O	O
score	NN	O	O
0	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
Sedation	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
average	NN	O	O
pain	NN	O	B-OUT
intensity	NN	O	I-OUT
score	NN	O	I-OUT
was	NN	O	O
0.4	NN	O	O
(	NN	O	O
0.8	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
marked	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
Sedation	NN	O	O
and	NN	O	O
TIVA	NN	O	O
groups	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
time	NN	O	O
from	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
procedure	NN	O	O
until	NN	O	O
the	NN	O	O
maximum	NN	O	B-OUT
MPADS	NN	O	I-OUT
score	NN	O	I-OUT
was	NN	O	O
reached	NN	O	O
:	NN	O	O
respectively	NN	O	O
,	NN	O	O
-6.9	NN	O	O
(	NN	O	O
4.0	NN	O	O
)	NN	O	O
versus	NN	O	O
25.7	NN	O	O
(	NN	O	O
8.4	NN	O	O
)	NN	O	O
minutes	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
TIVA	NN	O	O
group	NN	O	O
,	NN	O	O
changes	NN	O	O
in	NN	O	O
mean	NN	O	B-OUT
arterial	NN	O	I-OUT
pressure	NN	O	I-OUT
and	NN	O	I-OUT
heart	NN	O	I-OUT
rate	NN	O	I-OUT
and	NN	O	I-OUT
signs	NN	O	I-OUT
of	NN	O	I-OUT
respiratory	NN	O	I-OUT
depression	NN	O	I-OUT
were	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Combined	NN	O	O
administration	NN	O	O
of	NN	O	O
remifentanil	NN	O	B-INT
and	NN	O	O
propofol	NN	O	B-INT
for	NN	O	O
colonoscopy	NN	O	O
provides	NN	O	O
sufficient	NN	O	O
analgesia	NN	O	B-OUT
,	NN	O	O
satisfactory	NN	O	O
hemodynamic	NN	O	B-OUT
stability	NN	O	I-OUT
,	NN	O	O
minor	NN	O	O
respiratory	NN	O	B-OUT
depression	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
rapid	NN	O	B-OUT
recovery	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
allows	NN	O	O
patients	NN	O	O
to	NN	O	O
be	NN	O	O
discharged	NN	O	O
approximately	NN	O	O
15	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
.	NN	O	O



--DOCSTART-- (1286547)

Reduced	NN	O	O
platelet	NN	O	B-OUT
thromboxane	NN	O	I-OUT
formation	NN	O	I-OUT
after	NN	O	O
long-term	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
dihydropyridine	NN	O	B-INT
calcium	NN	O	I-INT
channel	NN	O	I-INT
blocker	NN	O	I-INT
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
with	NN	O	O
nitrendipine	NN	O	B-INT
in	NN	O	O
borderline	NN	O	B-PAR
hypertensive	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
IDDM-type	NN	O	I-PAR
diabetes	NN	O	I-PAR
mellitus	NN	O	I-PAR
.	NN	O	O

Twenty-nine	NN	O	B-PAR
IDDM	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
borderline	NN	O	I-PAR
hypertension	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
or	NN	O	O
nitrendipine	NN	O	B-INT
treatment	NN	O	O
.	NN	O	O

Nitrendipine	NN	O	B-INT
was	NN	O	O
given	NN	O	O
orally	NN	O	O
at	NN	O	O
a	NN	O	O
dosage	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
once	NN	O	O
daily	NN	O	O
over	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Stimulated	NN	O	B-OUT
platelet	NN	O	I-OUT
thromboxane	NN	O	I-OUT
formation	NN	O	I-OUT
at	NN	O	O
rest	NN	O	O
and	NN	O	O
after	NN	O	O
standardized	NN	O	O
,	NN	O	O
non	NN	O	O
exhausting	NN	O	O
exercise	NN	O	O
was	NN	O	O
measured	NN	O	O
by	NN	O	O
standard	NN	O	O
methods	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
plasma	NN	O	B-OUT
levels	NN	O	I-OUT
of	NN	O	I-OUT
platelet	NN	O	I-OUT
factor	NN	O	I-OUT
4	NN	O	I-OUT
and	NN	O	I-OUT
aggregation	NN	O	I-OUT
responses	NN	O	I-OUT
to	NN	O	I-OUT
collagen	NN	O	I-OUT
and	NN	O	I-OUT
ADP	NN	O	I-OUT
were	NN	O	O
determined	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
treatment	NN	O	O
group	NN	O	O
thromboxane	NN	O	B-OUT
formation	NN	O	I-OUT
after	NN	O	O
stimulation	NN	O	O
with	NN	O	O
collagen	NN	O	O
(	NN	O	O
0.3	NN	O	O
and	NN	O	O
1.0	NN	O	O
micrograms/ml	NN	O	O
)	NN	O	O
and	NN	O	O
1	NN	O	O
mM	NN	O	O
arachidonic	NN	O	O
acid	NN	O	O
(	NN	O	O
AA	NN	O	O
)	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
resting	NN	O	O
state	NN	O	O
.	NN	O	O

Exercise	NN	O	B-OUT
induced	NN	O	I-OUT
change	NN	O	I-OUT
of	NN	O	I-OUT
thromboxane	NN	O	I-OUT
synthesis	NN	O	I-OUT
in	NN	O	O
response	NN	O	O
to	NN	O	O
1.0	NN	O	O
micrograms/ml	NN	O	O
collagen	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
parallel	NN	O	O
,	NN	O	O
PF4	NN	O	B-OUT
plasma	NN	O	I-OUT
levels	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
lowered	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Whole	NN	O	B-OUT
blood	NN	O	I-OUT
aggregation	NN	O	I-OUT
after	NN	O	I-OUT
collagen	NN	O	I-OUT
stimulation	NN	O	I-OUT
(	NN	O	O
1.0	NN	O	O
micrograms/ml	NN	O	O
)	NN	O	O
was	NN	O	O
reduced	NN	O	O
after	NN	O	O
4	NN	O	O
weeks	NN	O	O
of	NN	O	O
nitrendipine	NN	O	B-INT
treatment	NN	O	O
,	NN	O	O
but	NN	O	O
ADP	NN	O	O
(	NN	O	O
5	NN	O	O
microM	NN	O	O
)	NN	O	O
induced	NN	O	O
aggregation	NN	O	B-OUT
was	NN	O	O
not	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
of	NN	O	O
nitrendipine	NN	O	B-INT
were	NN	O	O
not	NN	O	O
seen	NN	O	O
in	NN	O	O
platelet	NN	O	O
rich	NN	O	O
plasma	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
long-term	NN	O	O
nitrendipine	NN	O	B-INT
treatment	NN	O	O
may	NN	O	O
inhibit	NN	O	O
collagen	NN	O	B-OUT
dependent	NN	O	I-OUT
platelet	NN	O	I-OUT
activation	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
blood	NN	O	O
of	NN	O	O
diabetic	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
borderline	NN	O	I-PAR
hypertension	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (12960652)

Gastric	NN	O	O
dysrhythmia	NN	O	O
in	NN	O	O
infants	NN	O	B-PAR
with	NN	O	I-PAR
gastrointestinal	NN	O	I-PAR
diseases	NN	O	I-PAR
measured	NN	O	O
by	NN	O	O
epigastric	NN	O	O
impedance	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Gastrointestinal	NN	O	O
symptoms	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
myoelectrical	NN	O	O
dysrhythmia	NN	O	O
,	NN	O	O
where	NN	O	O
different	NN	O	O
types	NN	O	O
of	NN	O	O
gastric	NN	O	O
electrical	NN	O	O
activity	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
.	NN	O	O

These	NN	O	O
types	NN	O	O
of	NN	O	O
gastric	NN	O	O
myoelectrical	NN	O	O
activity	NN	O	O
and	NN	O	O
dysrhythmia	NN	O	O
can	NN	O	O
be	NN	O	O
measured	NN	O	O
by	NN	O	O
electrogastrography	NN	O	O
using	NN	O	O
cutaneous	NN	O	O
electrodes	NN	O	O
.	NN	O	O

Epigastric	NN	O	B-INT
impedance	NN	O	I-INT
is	NN	O	O
a	NN	O	O
non-invasive	NN	O	O
method	NN	O	O
used	NN	O	O
to	NN	O	O
study	NN	O	O
gastric	NN	O	O
emptying	NN	O	O
time	NN	O	O
and	NN	O	O
gastric	NN	O	O
phasic	NN	O	O
activity	NN	O	O
.	NN	O	O

At	NN	O	O
present	NN	O	O
no	NN	O	O
study	NN	O	O
of	NN	O	O
gastric	NN	O	O
dysrhythmia	NN	O	O
,	NN	O	O
measured	NN	O	O
with	NN	O	O
epigastric	NN	O	B-OUT
impedance	NN	O	I-OUT
,	NN	O	O
has	NN	O	O
been	NN	O	O
presented	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
gastric	NN	O	O
rhythms	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
impedance	NN	O	O
gastrography	NN	O	O
in	NN	O	O
control	NN	O	O
infants	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
infants	NN	O	B-PAR
with	NN	O	I-PAR
different	NN	O	I-PAR
gastrointestinal	NN	O	I-PAR
diseases	NN	O	I-PAR
,	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
treatment	NN	O	O
of	NN	O	O
their	NN	O	O
disease	NN	O	O
.	NN	O	O

METHOD	NN	O	O
21	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
age	NN	O	I-PAR
0-2	NN	O	I-PAR
months	NN	O	I-PAR
)	NN	O	I-PAR
and	NN	O	I-PAR
40	NN	O	I-PAR
healthy	NN	O	I-PAR
infants	NN	O	I-PAR
(	NN	O	I-PAR
age	NN	O	I-PAR
0-2	NN	O	I-PAR
months	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	B-PAR
suffered	NN	O	I-PAR
from	NN	O	I-PAR
partial	NN	O	I-PAR
or	NN	O	I-PAR
total	NN	O	I-PAR
intestinal	NN	O	I-PAR
obstruction	NN	O	I-PAR
,	NN	O	I-PAR
necrotizing	NN	O	I-PAR
enterocolitis	NN	O	I-PAR
or	NN	O	I-PAR
pyloric	NN	O	I-PAR
stenosis.All	NN	O	I-PAR
infants	NN	O	I-PAR
were	NN	O	I-PAR
fasting	NN	O	I-PAR
and	NN	O	O
studied	NN	O	O
during	NN	O	O
periods	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
hour	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
state	NN	O	O
and	NN	O	O
after	NN	O	O
treatment	NN	O	O
when	NN	O	O
possible	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	O
pathologic	NN	O	O
result	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
90	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
persistent	NN	O	O
phasic	NN	O	B-OUT
activity	NN	O	I-OUT
pattern	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
19	NN	O	O
of	NN	O	O
the	NN	O	O
21	NN	O	O
patients	NN	O	O
,	NN	O	O
high	NN	O	O
frequency	NN	O	B-OUT
phasic	NN	O	I-OUT
activity	NN	O	I-OUT
in	NN	O	O
11	NN	O	O
of	NN	O	O
the	NN	O	O
21	NN	O	O
patients	NN	O	O
.	NN	O	O

Short-term	NN	O	O
phasic	NN	O	B-OUT
activity	NN	O	I-OUT
was	NN	O	O
only	NN	O	O
found	NN	O	O
in	NN	O	O
13	NN	O	O
out	NN	O	O
of	NN	O	O
40	NN	O	O
of	NN	O	O
the	NN	O	O
normal	NN	O	O
infants	NN	O	O
(	NN	O	O
32.5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Using	NN	O	O
epigastric	NN	O	B-INT
impedance	NN	O	I-INT
we	NN	O	O
found	NN	O	O
that	NN	O	O
infants	NN	O	O
with	NN	O	O
partial	NN	O	O
or	NN	O	O
total	NN	O	O
intestinal	NN	O	O
obstruction	NN	O	O
had	NN	O	O
gastric	NN	O	O
phasic	NN	O	O
activity	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
infants	NN	O	O
.	NN	O	O

The	NN	O	O
origin	NN	O	O
of	NN	O	O
the	NN	O	O
gastric	NN	O	O
phasic	NN	O	O
activity	NN	O	O
patterns	NN	O	O
is	NN	O	O
unknown	NN	O	O
,	NN	O	O
but	NN	O	O
they	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
electrical	NN	O	O
control	NN	O	O
activity	NN	O	O
.	NN	O	O



--DOCSTART-- (1459268)

Prospective	NN	O	O
study	NN	O	O
of	NN	O	O
short	NN	O	O
and	NN	O	O
ultrashort	NN	O	O
regimens	NN	O	O
of	NN	O	O
gonadotropin-releasing	NN	O	B-INT
hormone	NN	O	I-INT
agonist	NN	O	I-INT
in	NN	O	O
an	NN	O	O
in	NN	O	O
vitro	NN	O	O
fertilization	NN	O	O
program	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
usefulness	NN	O	B-OUT
of	NN	O	O
the	NN	O	O
ultrashort	NN	O	O
regimen	NN	O	O
of	NN	O	O
gonadotropin-releasing	NN	O	B-INT
hormone	NN	O	I-INT
agonist	NN	O	I-INT
(	NN	O	I-INT
GnRH-a	NN	O	I-INT
)	NN	O	I-INT
in	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
in	NN	O	O
an	NN	O	O
in	NN	O	B-PAR
vitro	NN	O	I-PAR
fertilization	NN	O	I-PAR
(	NN	O	I-PAR
IVF	NN	O	I-PAR
)	NN	O	I-PAR
program	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
A	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
trial	NN	O	O
comparing	NN	O	O
short	NN	O	O
and	NN	O	O
ultrashort	NN	O	O
regimens	NN	O	O
of	NN	O	O
GnRH-a	NN	O	B-INT
.	NN	O	O

SETTING	NN	O	O
Aberdeen	NN	O	O
Assisted	NN	O	O
Reproduction	NN	O	O
Unit	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
Forty-eight	NN	O	B-PAR
patients	NN	O	I-PAR
having	NN	O	I-PAR
IVF	NN	O	I-PAR
for	NN	O	I-PAR
the	NN	O	I-PAR
first	NN	O	I-PAR
time	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
protocols	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURES	NN	O	O
Response	NN	O	B-OUT
to	NN	O	I-OUT
ovarian	NN	O	I-OUT
stimulation	NN	O	I-OUT
and	NN	O	I-OUT
occurrence	NN	O	I-OUT
of	NN	O	I-OUT
spontaneous	NN	O	I-OUT
luteinizing	NN	O	I-OUT
hormone	NN	O	I-OUT
(	NN	O	I-OUT
LH	NN	O	I-OUT
)	NN	O	I-OUT
surges	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
In	NN	O	O
ovulation	NN	O	B-OUT
induction	NN	O	I-OUT
,	NN	O	I-OUT
fertilization	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
pregnancy	NN	O	I-OUT
rates	NN	O	I-OUT
the	NN	O	O
ultrashort	NN	O	O
regimen	NN	O	O
produces	NN	O	O
results	NN	O	O
that	NN	O	O
were	NN	O	O
no	NN	O	O
different	NN	O	O
to	NN	O	O
the	NN	O	O
short	NN	O	O
regimen	NN	O	O
but	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
always	NN	O	O
prevent	NN	O	O
an	NN	O	O
LH	NN	O	B-OUT
surge	NN	O	I-OUT
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
ultrashort	NN	O	O
regimen	NN	O	O
can	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
alternative	NN	O	O
for	NN	O	O
ovarian	NN	O	O
stimulation	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
undergoing	NN	O	I-PAR
IVF	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (14679127)

Long-term	NN	O	O
survival	NN	O	O
in	NN	O	O
a	NN	O	O
phase	NN	O	O
III	NN	O	O
,	NN	O	O
randomised	NN	O	O
study	NN	O	O
of	NN	O	O
topotecan	NN	O	B-INT
versus	NN	O	O
paclitaxel	NN	O	B-INT
in	NN	O	O
advanced	NN	O	B-PAR
epithelial	NN	O	I-PAR
ovarian	NN	O	I-PAR
carcinoma	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
We	NN	O	O
have	NN	O	O
continued	NN	O	O
to	NN	O	O
monitor	NN	O	O
the	NN	O	O
survival	NN	O	O
of	NN	O	O
patients	NN	O	O
randomised	NN	O	O
in	NN	O	O
a	NN	O	O
previously	NN	O	O
reported	NN	O	O
multicentre	NN	O	O
phase	NN	O	O
III	NN	O	O
study	NN	O	O
of	NN	O	O
topotecan	NN	O	B-INT
versus	NN	O	O
paclitaxel	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
advanced	NN	O	I-PAR
epithelial	NN	O	I-PAR
ovarian	NN	O	I-PAR
cancer	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
failed	NN	O	I-PAR
one	NN	O	I-PAR
prior	NN	O	I-PAR
platinum-based	NN	O	I-PAR
regimen	NN	O	I-PAR
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Patients	NN	O	B-PAR
with	NN	O	I-PAR
bidimensionally	NN	O	I-PAR
measurable	NN	O	I-PAR
disease	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
topotecan	NN	O	B-INT
(	NN	O	O
1.5	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/day	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
)	NN	O	O
or	NN	O	O
paclitaxel	NN	O	B-INT
(	NN	O	O
175	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/day	NN	O	O
as	NN	O	O
a	NN	O	O
3-h	NN	O	O
infusion	NN	O	O
)	NN	O	O
every	NN	O	O
21	NN	O	O
days	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
eligible	NN	O	O
for	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
alternate	NN	O	O
therapy	NN	O	O
at	NN	O	O
third	NN	O	O
line	NN	O	O
.	NN	O	O

The	NN	O	O
European	NN	O	B-OUT
Organisation	NN	O	I-OUT
for	NN	O	I-OUT
Research	NN	O	I-OUT
and	NN	O	I-OUT
Treatment	NN	O	I-OUT
of	NN	O	I-OUT
Cancer	NN	O	I-OUT
Quality	NN	O	I-OUT
of	NN	O	I-OUT
Life	NN	O	I-OUT
(	NN	O	I-OUT
EORTC	NN	O	I-OUT
QOL	NN	O	I-OUT
)	NN	O	I-OUT
-C30	NN	O	I-OUT
questionnaire	NN	O	I-OUT
was	NN	O	O
also	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
eight	NN	O	O
symptoms	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
during	NN	O	O
each	NN	O	O
course	NN	O	O
(	NN	O	O
pain	NN	O	B-OUT
,	NN	O	I-OUT
anorexia	NN	O	I-OUT
,	NN	O	I-OUT
diarrhoea	NN	O	I-OUT
,	NN	O	I-OUT
fatigue	NN	O	I-OUT
,	NN	O	I-OUT
nausea	NN	O	I-OUT
and	NN	O	I-OUT
vomiting	NN	O	I-OUT
,	NN	O	I-OUT
dyspnea	NN	O	I-OUT
,	NN	O	I-OUT
constipation	NN	O	I-OUT
and	NN	O	I-OUT
insomnia	NN	O	I-OUT
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
226	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
.	NN	O	O

Demographic	NN	O	O
characteristics	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
as	NN	O	O
were	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
EORTC	NN	O	O
QOL-30	NN	O	O
questionnaire	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
topotecan	NN	O	B-INT
group	NN	O	O
,	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	B-OUT
was	NN	O	O
18.9	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
<	NN	O	O
1	NN	O	O
to	NN	O	O
92.6+	NN	O	O
weeks	NN	O	O
;	NN	O	O
25	NN	O	O
%	NN	O	O
censored	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
,	NN	O	O
for	NN	O	O
paclitaxel	NN	O	B-INT
,	NN	O	O
14.7	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
<	NN	O	O
1	NN	O	O
to	NN	O	O
137.3+	NN	O	O
weeks	NN	O	O
;	NN	O	O
12.3	NN	O	O
%	NN	O	O
censored	NN	O	O
)	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.076	NN	O	O
.	NN	O	O

At	NN	O	O
4	NN	O	O
years	NN	O	O
post-randomisation	NN	O	O
,	NN	O	O
median	NN	O	B-OUT
survival	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
topotecan	NN	O	B-INT
group	NN	O	O
was	NN	O	O
63.0	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
<	NN	O	O
1	NN	O	O
to	NN	O	O
238.4+	NN	O	O
weeks	NN	O	O
;	NN	O	O
20.5	NN	O	O
%	NN	O	O
censored	NN	O	O
)	NN	O	O
and	NN	O	O
,	NN	O	O
for	NN	O	O
paclitaxel	NN	O	B-INT
,	NN	O	O
53.0	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
<	NN	O	O
1	NN	O	O
to	NN	O	O
226.3+	NN	O	O
weeks	NN	O	O
;	NN	O	O
12.3	NN	O	O
%	NN	O	O
censored	NN	O	O
)	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.44	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Topotecan	NN	O	B-INT
continues	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
comparable	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
survival	NN	O	B-OUT
to	NN	O	O
paclitaxel	NN	O	B-INT
with	NN	O	O
manageable	NN	O	O
and	NN	O	O
non-cumulative	NN	O	O
haematological	NN	O	B-OUT
toxicity	NN	O	I-OUT
.	NN	O	O

Non-haematological	NN	O	B-OUT
toxicity	NN	O	I-OUT
was	NN	O	O
generally	NN	O	O
mild	NN	O	O
for	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
long-term	NN	O	O
survival	NN	O	O
rate	NN	O	O
indicates	NN	O	O
substantial	NN	O	O
therapeutic	NN	O	O
benefit	NN	O	O
for	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
topotecan	NN	O	B-INT
at	NN	O	O
relapse	NN	O	B-PAR
of	NN	O	I-PAR
ovarian	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (14739125)

Raising	NN	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
in	NN	O	O
humans	NN	O	O
through	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
transfer	NN	O	O
protein	NN	O	O
:	NN	O	O
an	NN	O	O
initial	NN	O	O
multidose	NN	O	O
study	NN	O	O
of	NN	O	O
torcetrapib	NN	O	B-INT
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
ability	NN	O	O
of	NN	O	O
the	NN	O	O
potent	NN	O	O
cholesteryl	NN	O	B-INT
ester	NN	O	I-INT
transfer	NN	O	I-INT
protein	NN	O	I-INT
(	NN	O	I-INT
CETP	NN	O	I-INT
)	NN	O	I-INT
inhibitor	NN	O	I-INT
torcetrapib	NN	O	I-INT
(	NN	O	O
CP-529,414	NN	O	O
)	NN	O	O
to	NN	O	O
raise	NN	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
(	NN	O	O
HDL-C	NN	O	O
)	NN	O	O
levels	NN	O	O
in	NN	O	O
healthy	NN	O	B-PAR
young	NN	O	I-PAR
subjects	NN	O	I-PAR
was	NN	O	O
tested	NN	O	O
in	NN	O	O
this	NN	O	O
initial	NN	O	O
phase	NN	O	O
1	NN	O	O
multidose	NN	O	O
study	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
Five	NN	O	B-PAR
groups	NN	O	I-PAR
of	NN	O	I-PAR
8	NN	O	I-PAR
subjects	NN	O	I-PAR
each	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
n=2	NN	O	O
)	NN	O	O
or	NN	O	O
torcetrapib	NN	O	B-INT
(	NN	O	O
n=6	NN	O	O
)	NN	O	O
at	NN	O	O
10	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
and	NN	O	O
120	NN	O	O
mg	NN	O	O
daily	NN	O	O
and	NN	O	O
120	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Torcetrapib	NN	O	B-INT
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
with	NN	O	O
all	NN	O	O
treated	NN	O	O
subjects	NN	O	O
completing	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
correlation	NN	O	O
of	NN	O	O
plasma	NN	O	B-OUT
drug	NN	O	I-OUT
levels	NN	O	I-OUT
with	NN	O	O
inhibition	NN	O	O
(	NN	O	O
EC50=43	NN	O	O
nM	NN	O	O
)	NN	O	O
was	NN	O	O
as	NN	O	O
expected	NN	O	O
based	NN	O	O
on	NN	O	O
in	NN	O	O
vitro	NN	O	O
potency	NN	O	O
(	NN	O	O
IC50	NN	O	O
approximately	NN	O	O
50	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
increases	NN	O	O
in	NN	O	O
CETP	NN	O	O
mass	NN	O	O
were	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
proposed	NN	O	O
mechanism	NN	O	O
of	NN	O	O
inhibition	NN	O	O
.	NN	O	O

CETP	NN	O	O
inhibition	NN	O	O
increased	NN	O	O
with	NN	O	O
escalating	NN	O	O
dose	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
elevations	NN	O	O
of	NN	O	O
HDL-C	NN	O	O
of	NN	O	O
16	NN	O	O
%	NN	O	O
to	NN	O	O
91	NN	O	O
%	NN	O	O
.	NN	O	O

Total	NN	O	B-OUT
plasma	NN	O	I-OUT
cholesterol	NN	O	I-OUT
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
nonHDL-C	NN	O	B-OUT
,	NN	O	O
including	NN	O	O
a	NN	O	O
21	NN	O	O
%	NN	O	O
to	NN	O	O
42	NN	O	O
%	NN	O	O
lowering	NN	O	O
of	NN	O	O
low-density	NN	O	B-OUT
lipoprotein	NN	O	I-OUT
cholesterol	NN	O	I-OUT
at	NN	O	O
the	NN	O	O
higher	NN	O	O
doses	NN	O	O
.	NN	O	O

Apolipoprotein	NN	O	B-OUT
A-I	NN	O	I-OUT
and	NN	O	I-OUT
E	NN	O	I-OUT
were	NN	O	O
elevated	NN	O	O
27	NN	O	O
%	NN	O	O
and	NN	O	O
66	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
apoB	NN	O	B-OUT
was	NN	O	O
reduced	NN	O	O
26	NN	O	O
%	NN	O	O
with	NN	O	O
120	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
.	NN	O	O

Cholesteryl	NN	O	B-OUT
ester	NN	O	I-OUT
content	NN	O	I-OUT
decreased	NN	O	O
and	NN	O	O
triglyceride	NN	O	B-OUT
increased	NN	O	O
in	NN	O	O
the	NN	O	O
nonHDL	NN	O	O
plasma	NN	O	O
fraction	NN	O	O
,	NN	O	O
with	NN	O	O
contrasting	NN	O	O
changes	NN	O	O
occurring	NN	O	O
in	NN	O	O
HDL	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
These	NN	O	O
effects	NN	O	O
of	NN	O	O
CETP	NN	O	O
inhibition	NN	O	O
resemble	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
partial	NN	O	O
CETP	NN	O	O
deficiency	NN	O	O
.	NN	O	O

This	NN	O	O
work	NN	O	O
serves	NN	O	O
as	NN	O	O
a	NN	O	O
prelude	NN	O	O
to	NN	O	O
further	NN	O	O
studies	NN	O	O
in	NN	O	O
subjects	NN	O	O
with	NN	O	O
low	NN	O	O
HDL	NN	O	O
,	NN	O	O
or	NN	O	O
combinations	NN	O	O
of	NN	O	O
dyslipidemia	NN	O	O
,	NN	O	O
in	NN	O	O
assessing	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
CETP	NN	O	O
in	NN	O	O
atherosclerosis	NN	O	O
.	NN	O	O



--DOCSTART-- (14763035)

A	NN	O	O
selective	NN	O	O
angiotensin	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
Valsartan	NN	O	B-INT
,	NN	O	O
produced	NN	O	O
regression	NN	O	O
of	NN	O	O
left	NN	O	B-PAR
ventricular	NN	O	I-PAR
hypertrophy	NN	O	I-PAR
associated	NN	O	O
with	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
arterial	NN	O	O
stiffness	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
whether	NN	O	O
a	NN	O	O
selective	NN	O	B-INT
angiotensin	NN	O	I-INT
II	NN	O	I-INT
receptor	NN	O	I-INT
blocker	NN	O	I-INT
(	NN	O	I-INT
ARB	NN	O	I-INT
)	NN	O	I-INT
would	NN	O	O
have	NN	O	O
a	NN	O	O
regressive	NN	O	O
effect	NN	O	O
on	NN	O	O
left	NN	O	O
ventricular	NN	O	O
hypertrophy	NN	O	O
(	NN	O	O
LVH	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
on	NN	O	I-PAR
continuous	NN	O	I-PAR
ambulatory	NN	O	I-PAR
peritoneal	NN	O	I-PAR
dialysis	NN	O	I-PAR
(	NN	O	I-PAR
CAPD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

In	NN	O	O
a	NN	O	O
double-blind	NN	O	O
study	NN	O	O
,	NN	O	O
24	NN	O	B-PAR
CAPD	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
LVH	NN	O	I-PAR
[	NN	O	I-PAR
left	NN	O	I-PAR
ventricular	NN	O	I-PAR
mass	NN	O	I-PAR
index	NN	O	I-PAR
(	NN	O	I-PAR
LVMi	NN	O	I-PAR
)	NN	O	I-PAR
>	NN	O	I-PAR
110	NN	O	I-PAR
g/m2	NN	O	I-PAR
for	NN	O	I-PAR
women	NN	O	I-PAR
and	NN	O	I-PAR
LVMi	NN	O	I-PAR
>	NN	O	I-PAR
137	NN	O	I-PAR
g/m2	NN	O	I-PAR
for	NN	O	I-PAR
men	NN	O	I-PAR
]	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
12	NN	O	O
months	NN	O	O
'	NN	O	O
administration	NN	O	O
of	NN	O	O
either	NN	O	O
the	NN	O	O
ARB	NN	O	B-INT
valsartan	NN	O	I-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
14	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
target	NN	O	O
blood	NN	O	B-OUT
pressure	NN	O	I-OUT
(	NN	O	I-OUT
BP	NN	O	I-OUT
)	NN	O	I-OUT
was	NN	O	O
140/90	NN	O	O
mmHg	NN	O	O
or	NN	O	O
lower	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
parameters	NN	O	O
were	NN	O	O
measured	NN	O	O
before	NN	O	O
and	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
:	NN	O	O
aortic	NN	O	B-OUT
and	NN	O	I-OUT
large-artery	NN	O	I-OUT
compliance	NN	O	I-OUT
and	NN	O	O
arterial	NN	O	B-OUT
wave	NN	O	I-OUT
reflections	NN	O	I-OUT
[	NN	O	I-OUT
pulse	NN	O	I-OUT
wave	NN	O	I-OUT
velocity	NN	O	I-OUT
(	NN	O	I-OUT
PWV	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
augmentation	NN	O	B-OUT
index	NN	O	I-OUT
(	NN	O	I-OUT
AI	NN	O	I-OUT
)	NN	O	I-OUT
application	NN	O	I-OUT
tonometry	NN	O	I-OUT
]	NN	O	I-OUT
and	NN	O	O
cardiac	NN	O	B-OUT
echocardiography	NN	O	I-OUT
.	NN	O	O

Periodically	NN	O	O
recorded	NN	O	O
were	NN	O	O
body	NN	O	B-OUT
weight	NN	O	I-OUT
,	NN	O	I-OUT
BP	NN	O	I-OUT
(	NN	O	I-OUT
mercury	NN	O	I-OUT
sphygmomanometer	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
serum	NN	O	I-OUT
creatinine	NN	O	I-OUT
,	NN	O	I-OUT
electrolytes	NN	O	I-OUT
,	NN	O	I-OUT
complete	NN	O	I-OUT
blood	NN	O	I-OUT
cell	NN	O	I-OUT
counts	NN	O	I-OUT
,	NN	O	I-OUT
urine	NN	O	I-OUT
volume	NN	O	I-OUT
,	NN	O	I-OUT
drainage	NN	O	I-OUT
volume	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
weekly	NN	O	I-OUT
creatinine	NN	O	I-OUT
clearance	NN	O	I-OUT
.	NN	O	O

Two-way	NN	O	O
analysis	NN	O	O
of	NN	O	O
variance	NN	O	O
for	NN	O	O
repeated	NN	O	O
measurements	NN	O	O
was	NN	O	O
used	NN	O	O
for	NN	O	O
statistical	NN	O	O
analysis	NN	O	O
.	NN	O	O

Systolic	NN	O	B-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
BP	NN	O	I-OUT
were	NN	O	O
both	NN	O	O
reduced	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
ARB	NN	O	B-INT
.	NN	O	O

The	NN	O	O
LVMi	NN	O	B-OUT
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
ARB	NN	O	B-INT
(	NN	O	O
to	NN	O	O
121	NN	O	O
+/-	NN	O	O
4	NN	O	O
from	NN	O	O
145	NN	O	O
+/-	NN	O	O
5	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
those	NN	O	O
receiving	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
to	NN	O	O
137	NN	O	O
+/-	NN	O	O
3	NN	O	O
from	NN	O	O
152	NN	O	O
+/-	NN	O	O
3	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
LVMi	NN	O	B-OUT
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
PWV	NN	O	B-OUT
and	NN	O	O
AI	NN	O	B-OUT
.	NN	O	O

In	NN	O	O
CAPD	NN	O	O
patients	NN	O	O
with	NN	O	O
LVH	NN	O	O
,	NN	O	O
ARB	NN	O	B-INT
reduced	NN	O	O
LVMi	NN	O	B-OUT
in	NN	O	O
association	NN	O	O
with	NN	O	O
alterations	NN	O	O
in	NN	O	O
arterial	NN	O	O
hemodynamics	NN	O	O
.	NN	O	O



--DOCSTART-- (15014018)

A	NN	O	O
pooled	NN	O	O
analysis	NN	O	O
of	NN	O	O
eastern	NN	O	O
cooperative	NN	O	O
oncology	NN	O	O
group	NN	O	O
and	NN	O	O
intergroup	NN	O	O
trials	NN	O	O
of	NN	O	O
adjuvant	NN	O	O
high-dose	NN	O	O
interferon	NN	O	B-INT
for	NN	O	O
melanoma	NN	O	B-PAR
.	NN	O	O

PURPOSE	NN	O	O
Nearly	NN	O	B-PAR
2000	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
stage	NN	O	I-PAR
IIB	NN	O	I-PAR
and	NN	O	I-PAR
III	NN	O	I-PAR
melanoma	NN	O	I-PAR
have	NN	O	O
participated	NN	O	O
in	NN	O	O
four	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
trials	NN	O	O
,	NN	O	O
conducted	NN	O	O
by	NN	O	O
the	NN	O	O
Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
and	NN	O	O
the	NN	O	O
Intergroup	NN	O	O
,	NN	O	O
investigating	NN	O	O
adjuvant	NN	O	O
high-dose	NN	O	O
IFN-alpha	NN	O	B-INT
2b	NN	O	I-INT
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
objectives	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
to	NN	O	O
update	NN	O	O
the	NN	O	O
analyses	NN	O	O
of	NN	O	O
each	NN	O	O
individual	NN	O	O
trial	NN	O	O
and	NN	O	O
to	NN	O	O
analyze	NN	O	O
prognostic	NN	O	O
factors	NN	O	O
and	NN	O	O
treatment	NN	O	O
effects	NN	O	O
based	NN	O	O
on	NN	O	O
pooled	NN	O	O
data	NN	O	O
.	NN	O	O

EXPERIMENTAL	NN	O	O
DESIGN	NN	O	O
Survival	NN	O	O
and	NN	O	O
disease	NN	O	O
status	NN	O	O
were	NN	O	O
updated	NN	O	O
to	NN	O	O
April	NN	O	O
2001	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
prognostic	NN	O	O
factors	NN	O	O
using	NN	O	O
optimized	NN	O	O
statistical	NN	O	O
models	NN	O	O
was	NN	O	O
based	NN	O	O
on	NN	O	O
data	NN	O	O
from	NN	O	O
patients	NN	O	O
in	NN	O	O
E1684	NN	O	O
,	NN	O	O
E1690	NN	O	O
,	NN	O	O
E1694	NN	O	O
,	NN	O	O
and	NN	O	O
E2696	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
treatment	NN	O	O
effects	NN	O	O
versus	NN	O	O
observation	NN	O	O
(	NN	O	O
Obs	NN	O	O
)	NN	O	O
was	NN	O	O
based	NN	O	O
on	NN	O	O
data	NN	O	O
from	NN	O	O
713	NN	O	O
patients	NN	O	O
randomized	NN	O	O
to	NN	O	O
high-dose	NN	O	O
IFN-alpha	NN	O	B-INT
2b	NN	O	I-INT
(	NN	O	I-INT
HDI	NN	O	I-INT
)	NN	O	I-INT
or	NN	O	O
Obs	NN	O	B-INT
in	NN	O	O
Trials	NN	O	O
E1684	NN	O	O
and	NN	O	O
E1690	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Updated	NN	O	O
analysis	NN	O	O
of	NN	O	O
E1684	NN	O	O
,	NN	O	O
E1690	NN	O	O
,	NN	O	O
and	NN	O	O
E1694	NN	O	O
confirmed	NN	O	O
their	NN	O	O
original	NN	O	O
conclusions	NN	O	O
,	NN	O	O
now	NN	O	O
at	NN	O	O
median	NN	O	O
follow-up	NN	O	O
intervals	NN	O	O
of	NN	O	O
2.1-12.6	NN	O	O
years	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
two-sided	NN	O	O
univariate	NN	O	O
log-rank	NN	O	O
analysis	NN	O	O
of	NN	O	O
pooled	NN	O	O
data	NN	O	O
from	NN	O	O
E1684	NN	O	O
and	NN	O	O
E1690	NN	O	O
(	NN	O	O
median	NN	O	O
follow-up	NN	O	O
,	NN	O	O
7.2	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
relapse-free	NN	O	B-OUT
survival	NN	O	I-OUT
(	NN	O	I-OUT
RFS	NN	O	I-OUT
)	NN	O	I-OUT
-but	NN	O	O
not	NN	O	O
overall	NN	O	B-OUT
survival	NN	O	I-OUT
(	NN	O	I-OUT
OS	NN	O	I-OUT
)	NN	O	I-OUT
-was	NN	O	O
significantly	NN	O	O
prolonged	NN	O	O
(	NN	O	O
two-sided	NN	O	O
log-rank	NN	O	O
P	NN	O	O
value	NN	O	O
=	NN	O	O
0.006	NN	O	O
)	NN	O	O
for	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
HDI	NN	O	B-INT
versus	NN	O	O
Obs	NN	O	B-INT
.	NN	O	O

Among	NN	O	O
all	NN	O	O
patients	NN	O	O
,	NN	O	O
prognostic	NN	O	O
factors	NN	O	O
that	NN	O	O
significantly	NN	O	O
negatively	NN	O	O
impacted	NN	O	O
RFS	NN	O	O
and	NN	O	O
OS	NN	O	O
included	NN	O	O
ulceration	NN	O	O
,	NN	O	O
recurrent	NN	O	O
disease	NN	O	O
at	NN	O	O
entry	NN	O	O
,	NN	O	O
enrollment	NN	O	O
in	NN	O	O
E1684	NN	O	O
,	NN	O	O
and	NN	O	O
age	NN	O	O
>	NN	O	O
49	NN	O	O
years	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
statistical	NN	O	O
models	NN	O	O
adjusting	NN	O	O
for	NN	O	O
these	NN	O	O
factors	NN	O	O
confirmed	NN	O	O
the	NN	O	O
statistically	NN	O	O
significant	NN	O	O
RFS	NN	O	B-OUT
benefit	NN	O	O
of	NN	O	O
HDI	NN	O	B-INT
versus	NN	O	O
Obs	NN	O	B-INT
but	NN	O	O
did	NN	O	O
not	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
significant	NN	O	O
OS	NN	O	B-OUT
benefit	NN	O	O
in	NN	O	O
the	NN	O	O
pooled	NN	O	O
populations	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
In	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
high-risk	NN	O	I-PAR
resected	NN	O	I-PAR
melanoma	NN	O	I-PAR
,	NN	O	O
HDI	NN	O	O
is	NN	O	O
effective	NN	O	O
adjuvant	NN	O	O
therapy	NN	O	O
with	NN	O	O
strong	NN	O	O
evidence	NN	O	O
for	NN	O	O
improved	NN	O	O
RFS	NN	O	B-OUT
and	NN	O	O
evidence	NN	O	O
for	NN	O	O
moderate	NN	O	O
improvement	NN	O	O
in	NN	O	O
OS	NN	O	B-OUT
based	NN	O	O
on	NN	O	O
two	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
studies	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
pooled	NN	O	O
analysis	NN	O	O
.	NN	O	O

Analyses	NN	O	O
of	NN	O	O
predictors	NN	O	O
of	NN	O	O
relapse	NN	O	O
and	NN	O	O
response	NN	O	O
are	NN	O	O
now	NN	O	O
needed	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
value	NN	O	O
of	NN	O	O
this	NN	O	O
modality	NN	O	O
.	NN	O	O



--DOCSTART-- (15133359)

A	NN	O	O
randomized	NN	O	O
comparison	NN	O	O
of	NN	O	O
alternative	NN	O	O
techniques	NN	O	O
to	NN	O	O
achieve	NN	O	O
coronary	NN	O	B-PAR
sinus	NN	O	I-PAR
cannulation	NN	O	I-PAR
during	NN	O	I-PAR
biventricular	NN	O	I-PAR
implantation	NN	O	I-PAR
procedures	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
Biventricular	NN	O	O
pacing	NN	O	O
system	NN	O	O
implantation	NN	O	O
is	NN	O	O
a	NN	O	O
time-consuming	NN	O	O
and	NN	O	O
challenging	NN	O	O
procedure	NN	O	O
.	NN	O	O

A	NN	O	O
critical	NN	O	O
step	NN	O	O
in	NN	O	O
biventricular	NN	O	O
pacemaker	NN	O	O
implantation	NN	O	O
is	NN	O	O
coronary	NN	O	B-PAR
sinus	NN	O	I-PAR
(	NN	O	I-PAR
CS	NN	O	I-PAR
)	NN	O	I-PAR
cannulation	NN	O	I-PAR
.	NN	O	O

CS	NN	O	O
cannulation	NN	O	O
can	NN	O	O
be	NN	O	O
achieved	NN	O	O
either	NN	O	O
using	NN	O	O
dedicated	NN	O	O
guiding	NN	O	O
catheters	NN	O	B-INT
(	NN	O	O
guiding	NN	O	B-INT
catheter	NN	O	I-INT
alone	NN	O	I-INT
positioning	NN	O	O
strategy	NN	O	O
,	NN	O	O
GCA	NN	O	O
)	NN	O	O
or	NN	O	O
with	NN	O	O
the	NN	O	O
aid	NN	O	O
of	NN	O	O
an	NN	O	O
electrophysiology	NN	O	B-INT
catheter	NN	O	I-INT
advanced	NN	O	I-INT
inside	NN	O	O
the	NN	O	O
guiding	NN	O	O
catheter	NN	O	O
(	NN	O	O
electrophysiology	NN	O	B-INT
catheter	NN	O	I-INT
aided	NN	O	I-INT
positioning	NN	O	O
strategy	NN	O	O
,	NN	O	O
EPA	NN	O	O
)	NN	O	O
.	NN	O	O

AIM	NN	O	O
OF	NN	O	O
THE	NN	O	O
STUDY	NN	O	O
To	NN	O	O
evaluate	NN	O	O
whether	NN	O	O
the	NN	O	O
EPA	NN	O	B-INT
technique	NN	O	O
is	NN	O	O
useful	NN	O	O
for	NN	O	O
reducing	NN	O	O
CS	NN	O	B-OUT
cannulation	NN	O	I-OUT
time	NN	O	I-OUT
compared	NN	O	O
to	NN	O	O
a	NN	O	O
conventional	NN	O	O
GCA	NN	O	B-INT
technique	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Thirty-four	NN	O	B-PAR
consecutive	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
GCA	NN	O	B-INT
(	NN	O	O
18	NN	O	O
patients	NN	O	O
)	NN	O	O
or	NN	O	O
EPA	NN	O	B-INT
(	NN	O	O
16	NN	O	O
patients	NN	O	O
)	NN	O	O
CS	NN	O	O
cannulation	NN	O	O
strategy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Time	NN	O	B-OUT
to	NN	O	I-OUT
successful	NN	O	I-OUT
catheterization	NN	O	I-OUT
of	NN	O	I-OUT
CS	NN	O	I-OUT
was	NN	O	O
5.0	NN	O	O
+/-	NN	O	O
2.4	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
EPA	NN	O	B-INT
group	NN	O	O
versus	NN	O	O
10.1	NN	O	O
+/-	NN	O	O
5.4	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
GCA	NN	O	B-INT
group	NN	O	O
p	NN	O	O
=	NN	O	O
0.004	NN	O	O
.	NN	O	O

Fluoroscopy	NN	O	B-OUT
time	NN	O	I-OUT
was	NN	O	O
4.6	NN	O	O
+/-	NN	O	O
2.3	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
EPA	NN	O	B-INT
group	NN	O	O
versus	NN	O	O
9.2	NN	O	O
+/-	NN	O	O
4.9	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
GCA	NN	O	B-INT
group	NN	O	O
p	NN	O	O
=	NN	O	O
0.004	NN	O	O
.	NN	O	O

Total	NN	O	O
contrast	NN	O	B-OUT
dye	NN	O	I-OUT
volume	NN	O	I-OUT
to	NN	O	O
search	NN	O	O
and	NN	O	O
engage	NN	O	O
the	NN	O	O
CS	NN	O	O
ostium	NN	O	O
was	NN	O	O
0.0	NN	O	O
ml	NN	O	O
in	NN	O	O
the	NN	O	O
EPA	NN	O	B-INT
group	NN	O	O
versus	NN	O	O
14.3	NN	O	O
+/-	NN	O	O
3.4	NN	O	O
ml	NN	O	O
in	NN	O	O
the	NN	O	O
GCA	NN	O	B-INT
group	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Cannulation	NN	O	B-PAR
of	NN	O	I-PAR
CS	NN	O	I-PAR
with	NN	O	O
the	NN	O	O
adjunct	NN	O	O
of	NN	O	O
an	NN	O	O
electrophysiology	NN	O	O
catheter	NN	O	O
to	NN	O	O
dedicated	NN	O	O
delivery	NN	O	O
systems	NN	O	O
significantly	NN	O	O
reduces	NN	O	O
procedural	NN	O	B-OUT
time	NN	O	I-OUT
,	NN	O	I-OUT
fluoroscopy	NN	O	I-OUT
time	NN	O	I-OUT
and	NN	O	O
contrast	NN	O	B-OUT
dye	NN	O	I-OUT
volume	NN	O	I-OUT
compared	NN	O	O
to	NN	O	O
a	NN	O	O
conventional	NN	O	O
strategy	NN	O	O
.	NN	O	O



--DOCSTART-- (15193668)

Combined	NN	O	O
descriptive	NN	O	O
and	NN	O	O
explanatory	NN	O	O
information	NN	O	O
improves	NN	O	O
peers	NN	O	B-OUT
'	NN	O	I-OUT
perceptions	NN	O	I-OUT
of	NN	O	O
autism	NN	O	O
.	NN	O	O

Authors	NN	O	O
examined	NN	O	O
the	NN	O	O
combined	NN	O	O
effects	NN	O	O
of	NN	O	O
descriptive	NN	O	O
and	NN	O	O
explanatory	NN	O	O
information	NN	O	O
on	NN	O	O
peers	NN	O	B-OUT
'	NN	O	I-OUT
perceptions	NN	O	I-OUT
and	NN	O	I-OUT
behavioral	NN	O	I-OUT
intentions	NN	O	I-OUT
toward	NN	O	O
an	NN	O	O
unfamiliar	NN	O	O
child	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O

Children	NN	O	B-PAR
(	NN	O	I-PAR
N	NN	O	I-PAR
=	NN	O	I-PAR
576	NN	O	I-PAR
;	NN	O	I-PAR
M	NN	O	I-PAR
age	NN	O	I-PAR
=	NN	O	I-PAR
10.06	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
view	NN	O	O
two	NN	O	O
videotapes	NN	O	O
of	NN	O	O
a	NN	O	O
boy	NN	O	O
engaging	NN	O	O
in	NN	O	O
typical	NN	O	O
and	NN	O	O
autistic	NN	O	O
behaviors	NN	O	O
receiving	NN	O	O
either	NN	O	O
descriptive	NN	O	B-INT
(	NN	O	I-INT
AUT-D	NN	O	I-INT
)	NN	O	I-INT
or	NN	O	O
descriptive	NN	O	B-INT
and	NN	O	I-INT
explanatory	NN	O	I-INT
information	NN	O	I-INT
(	NN	O	I-INT
AUT-D	NN	O	I-INT
+	NN	O	I-INT
E	NN	O	I-INT
)	NN	O	I-INT
.	NN	O	O

Children	NN	O	O
responded	NN	O	O
to	NN	O	O
measures	NN	O	O
of	NN	O	O
attitudes	NN	O	O
(	NN	O	B-OUT
Adjective	NN	O	I-OUT
Checklist	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
behavioral	NN	O	O
intentions	NN	O	O
(	NN	O	B-OUT
Shared	NN	O	I-OUT
Activities	NN	O	I-OUT
Questionnaire	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Children	NN	O	O
rated	NN	O	O
the	NN	O	O
typical	NN	O	O
boy	NN	O	O
more	NN	O	O
favorably	NN	O	O
than	NN	O	O
the	NN	O	O
boy	NN	O	O
showing	NN	O	O
autistic	NN	O	O
symptoms	NN	O	O
.	NN	O	O

When	NN	O	O
compared	NN	O	O
to	NN	O	O
descriptive	NN	O	O
information	NN	O	O
alone	NN	O	O
,	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
descriptive	NN	O	O
and	NN	O	O
explanatory	NN	O	O
information	NN	O	O
resulted	NN	O	O
in	NN	O	O
improved	NN	O	O
third-	NN	O	O
and	NN	O	O
fourth-graders	NN	O	O
'	NN	O	O
but	NN	O	O
not	NN	O	O
fifth-graders	NN	O	O
'	NN	O	O
attitudes	NN	O	O
toward	NN	O	O
the	NN	O	O
child	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O

Combined	NN	O	O
information	NN	O	O
improved	NN	O	O
behavioral	NN	O	O
intentions	NN	O	O
across	NN	O	O
grades	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
girls	NN	O	O
(	NN	O	O
vs.	NN	O	O
boys	NN	O	O
)	NN	O	O
were	NN	O	O
more	NN	O	O
responsive	NN	O	O
to	NN	O	O
information	NN	O	O
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
differences	NN	O	O
in	NN	O	O
academic	NN	O	O
intentions	NN	O	O
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
descriptive	NN	O	B-INT
and	NN	O	I-INT
explanatory	NN	O	I-INT
information	NN	O	I-INT
about	NN	O	O
autism	NN	O	O
appears	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
positive	NN	O	O
effect	NN	O	O
on	NN	O	O
children	NN	O	B-OUT
's	NN	O	I-OUT
attitudes	NN	O	I-OUT
and	NN	O	I-OUT
behavioral	NN	O	I-OUT
intentions	NN	O	I-OUT
.	NN	O	O

Implications	NN	O	O
of	NN	O	O
the	NN	O	O
findings	NN	O	O
are	NN	O	O
briefly	NN	O	O
discussed	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
study	NN	O	O
limitations	NN	O	O
and	NN	O	O
recommendations	NN	O	O
for	NN	O	O
future	NN	O	O
research	NN	O	O
.	NN	O	O



--DOCSTART-- (15358868)

Superior	NN	O	O
visual	NN	O	O
search	NN	O	O
in	NN	O	O
adults	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O

Recent	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	O
perform	NN	O	O
better	NN	O	O
than	NN	O	O
matched	NN	O	O
controls	NN	O	O
on	NN	O	O
visual	NN	O	O
search	NN	O	O
tasks	NN	O	O
and	NN	O	O
that	NN	O	O
this	NN	O	O
stems	NN	O	O
from	NN	O	O
a	NN	O	O
superior	NN	O	O
visual	NN	O	O
discrimination	NN	O	O
ability	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
assessed	NN	O	O
whether	NN	O	O
these	NN	O	O
findings	NN	O	O
generalize	NN	O	O
from	NN	O	O
children	NN	O	O
to	NN	O	O
adults	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O

Experiments	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
showed	NN	O	O
that	NN	O	O
,	NN	O	O
like	NN	O	O
children	NN	O	O
,	NN	O	O
adults	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
were	NN	O	O
superior	NN	O	O
to	NN	O	O
controls	NN	O	O
at	NN	O	O
searching	NN	O	B-OUT
for	NN	O	I-OUT
targets	NN	O	I-OUT
.	NN	O	O

Experiment	NN	O	O
3	NN	O	O
showed	NN	O	O
that	NN	O	O
increases	NN	O	O
in	NN	O	O
target-distractor	NN	O	O
similarity	NN	O	O
slowed	NN	O	O
the	NN	O	O
visual	NN	O	B-OUT
search	NN	O	I-OUT
performance	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
significantly	NN	O	O
more	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
autism	NN	O	O
group	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
the	NN	O	O
adults	NN	O	O
with	NN	O	O
autism	NN	O	O
have	NN	O	O
a	NN	O	O
superior	NN	O	O
visual	NN	O	B-OUT
discrimination	NN	O	I-OUT
ability	NN	O	I-OUT
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
these	NN	O	O
experiments	NN	O	O
replicate	NN	O	O
in	NN	O	O
adults	NN	O	O
previous	NN	O	O
findings	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O

Superior	NN	O	O
unique	NN	O	B-OUT
item	NN	O	I-OUT
detection	NN	O	I-OUT
in	NN	O	O
adults	NN	O	O
with	NN	O	O
autism	NN	O	O
,	NN	O	O
stemming	NN	O	O
from	NN	O	O
enhanced	NN	O	O
discrimination	NN	O	O
,	NN	O	O
is	NN	O	O
discussed	NN	O	O
in	NN	O	O
the	NN	O	O
light	NN	O	O
of	NN	O	O
the	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
stimulus	NN	O	O
processing	NN	O	O
disturbances	NN	O	O
in	NN	O	O
the	NN	O	O
disorder	NN	O	O
in	NN	O	O
general	NN	O	O
.	NN	O	O



--DOCSTART-- (15848261)

[	NN	O	O
Postural	NN	O	O
biofeedback	NN	O	O
and	NN	O	O
locomotion	NN	O	O
reeducation	NN	O	O
in	NN	O	O
stroke	NN	O	B-PAR
patients	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

AIMS	NN	O	O
To	NN	O	O
compare	NN	O	O
,	NN	O	O
in	NN	O	O
post-acute	NN	O	B-PAR
hemiparetic	NN	O	I-PAR
patients	NN	O	I-PAR
,	NN	O	O
gait	NN	O	B-OUT
improvement	NN	O	I-OUT
after	NN	O	O
conventional	NN	O	B-INT
physical	NN	O	I-INT
therapy	NN	O	I-INT
alone	NN	O	I-INT
or	NN	O	O
with	NN	O	B-INT
a	NN	O	I-INT
specialised	NN	O	I-INT
balance	NN	O	I-INT
retraining	NN	O	I-INT
program	NN	O	I-INT
.	NN	O	O

PATIENTS	NN	O	O
Twenty-six	NN	O	B-PAR
patients	NN	O	I-PAR
within	NN	O	I-PAR
3	NN	O	I-PAR
months	NN	O	I-PAR
of	NN	O	I-PAR
onset	NN	O	I-PAR
of	NN	O	I-PAR
stroke	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
receive	NN	O	O
physical	NN	O	B-INT
therapy	NN	O	I-INT
(	NN	O	O
control	NN	O	O
group	NN	O	O
)	NN	O	O
or	NN	O	O
therapy	NN	O	B-INT
and	NN	O	I-INT
retraining	NN	O	I-INT
(	NN	O	O
experimental	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
with	NN	O	O
left	NN	O	O
hemiplegia	NN	O	O
.	NN	O	O

The	NN	O	O
experimental	NN	O	O
group	NN	O	O
was	NN	O	O
significantly	NN	O	O
older	NN	O	O
than	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

METHOD	NN	O	O
Thirteen	NN	O	O
patients	NN	O	O
received	NN	O	O
early	NN	O	O
conventional	NN	O	B-INT
therapy	NN	O	I-INT
,	NN	O	O
and	NN	O	O
13	NN	O	O
received	NN	O	O
therapy	NN	O	B-INT
combined	NN	O	I-INT
with	NN	O	I-INT
standing	NN	O	I-INT
balance	NN	O	I-INT
training	NN	O	I-INT
by	NN	O	I-INT
biofeedback	NN	O	I-INT
(	NN	O	I-INT
BPM	NN	O	I-INT
Monitor	NN	O	I-INT
)	NN	O	I-INT
.	NN	O	O

Clinical	NN	O	O
measures	NN	O	O
were	NN	O	O
collected	NN	O	O
at	NN	O	O
entry	NN	O	O
(	NN	O	O
J0	NN	O	O
)	NN	O	O
,	NN	O	O
once	NN	O	O
when	NN	O	O
subjects	NN	O	O
began	NN	O	O
to	NN	O	O
walk	NN	O	O
(	NN	O	O
JM	NN	O	O
)	NN	O	O
and	NN	O	O
30	NN	O	O
days	NN	O	O
later	NN	O	O
(	NN	O	O
JM	NN	O	O
+	NN	O	O
30	NN	O	O
)	NN	O	O
.	NN	O	O

Gait	NN	O	B-OUT
spatiotemporal	NN	O	I-OUT
parameters	NN	O	I-OUT
were	NN	O	O
collected	NN	O	O
by	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
Vicon	NN	O	O
system	NN	O	O
at	NN	O	O
JM	NN	O	O
and	NN	O	O
JM	NN	O	O
+	NN	O	O
30	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Whatever	NN	O	O
the	NN	O	O
method	NN	O	O
of	NN	O	O
rehabilitation	NN	O	O
,	NN	O	O
the	NN	O	O
clinical	NN	O	B-OUT
scores	NN	O	I-OUT
improved	NN	O	O
significantly	NN	O	O
between	NN	O	O
J0	NN	O	O
and	NN	O	O
JM	NN	O	O
+	NN	O	O
30	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
spasticity	NN	O	O
.	NN	O	O

The	NN	O	O
time	NN	O	B-OUT
between	NN	O	I-OUT
stroke	NN	O	I-OUT
and	NN	O	I-OUT
the	NN	O	I-OUT
beginning	NN	O	I-OUT
of	NN	O	I-OUT
walking	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Gait	NN	O	B-OUT
velocity	NN	O	I-OUT
increased	NN	O	O
significantly	NN	O	O
between	NN	O	O
JM	NN	O	O
and	NN	O	O
JM	NN	O	O
+	NN	O	O
30	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
walking	NN	O	B-OUT
pattern	NN	O	I-OUT
was	NN	O	O
improved	NN	O	O
for	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
paretic	NN	O	I-OUT
limb	NN	O	I-OUT
single	NN	O	I-OUT
stance	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
experimental	NN	O	O
group	NN	O	O
significantly	NN	O	O
improved	NN	O	O
the	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
reception	NN	O	I-OUT
double	NN	O	I-OUT
stance	NN	O	I-OUT
on	NN	O	I-OUT
the	NN	O	I-OUT
paretic	NN	O	I-OUT
limb	NN	O	I-OUT
between	NN	O	O
JM	NN	O	O
and	NN	O	O
JM	NN	O	O
+	NN	O	O
30	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Both	NN	O	O
groups	NN	O	O
demonstrated	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
rehabilitation	NN	O	O
unit	NN	O	O
.	NN	O	O

The	NN	O	O
benefits	NN	O	O
of	NN	O	O
visual	NN	O	O
biofeedback	NN	O	O
by	NN	O	O
forceplate	NN	O	O
system	NN	O	O
training	NN	O	O
suggest	NN	O	O
particular	NN	O	O
improvement	NN	O	O
of	NN	O	O
anticipation	NN	O	O
equilibrium	NN	O	O
with	NN	O	O
conventional	NN	O	B-INT
therapy	NN	O	I-INT
.	NN	O	O



--DOCSTART-- (15854186)

Cophenylcaine	NN	O	B-INT
spray	NN	O	O
vs.	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
flexible	NN	O	B-PAR
nasendoscopy	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
double-blind	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

Practices	NN	O	O
vary	NN	O	O
across	NN	O	O
the	NN	O	O
UK	NN	O	O
on	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
topical	NN	O	O
preparation	NN	O	O
prior	NN	O	O
to	NN	O	O
flexible	NN	O	O
fibreoptic	NN	O	O
nasendoscopy	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
double-blind	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
randomised	NN	O	O
98	NN	O	B-PAR
patients	NN	O	I-PAR
to	NN	O	O
receive	NN	O	O
cophenylcaine	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
nasal	NN	O	O
spray	NN	O	O
before	NN	O	O
flexible	NN	O	B-PAR
nasendoscopy	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
(	NN	O	O
1-100	NN	O	O
)	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
record	NN	O	O
pain	NN	O	B-OUT
,	NN	O	I-OUT
unpleasantness	NN	O	I-OUT
of	NN	O	I-OUT
taste	NN	O	I-OUT
and	NN	O	I-OUT
overall	NN	O	I-OUT
discomfort	NN	O	I-OUT
experienced	NN	O	I-OUT
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
the	NN	O	O
procedure	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
minimal	NN	O	O
pain	NN	O	B-OUT
and	NN	O	I-OUT
discomfort	NN	O	I-OUT
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
pain	NN	O	B-OUT
or	NN	O	I-OUT
overall	NN	O	I-OUT
discomfort	NN	O	I-OUT
experienced	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
sensation	NN	O	B-OUT
of	NN	O	I-OUT
bad	NN	O	I-OUT
taste	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
worse	NN	O	O
in	NN	O	O
the	NN	O	O
cophenylcaine	NN	O	B-INT
group	NN	O	O
.	NN	O	O

In	NN	O	O
linear	NN	O	O
regression	NN	O	O
,	NN	O	O
factors	NN	O	O
that	NN	O	O
predicted	NN	O	O
the	NN	O	O
overall	NN	O	O
unpleasantness	NN	O	B-OUT
of	NN	O	O
the	NN	O	O
experience	NN	O	O
were	NN	O	O
primarily	NN	O	O
pain	NN	O	B-OUT
experienced	NN	O	O
and	NN	O	O
secondarily	NN	O	O
unpleasantness	NN	O	B-OUT
of	NN	O	I-OUT
taste	NN	O	I-OUT
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
routine	NN	O	O
use	NN	O	O
of	NN	O	O
cophenylcaine	NN	O	B-INT
for	NN	O	O
nasal	NN	O	O
preparation	NN	O	O
is	NN	O	O
not	NN	O	O
justified	NN	O	O
before	NN	O	O
flexible	NN	O	B-PAR
nasendoscopy	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (15858959)

Effects	NN	O	O
of	NN	O	O
Saccharomyces	NN	O	B-INT
boulardii	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
diarrhoea	NN	O	I-PAR
.	NN	O	O

AIM	NN	O	O
Certain	NN	O	O
probiotic	NN	O	O
agents	NN	O	O
,	NN	O	O
e.g	NN	O	O
.	NN	O	O

Lactobacillus	NN	O	O
GG	NN	O	O
,	NN	O	O
have	NN	O	O
shown	NN	O	O
efficacy	NN	O	O
in	NN	O	O
clinical	NN	O	O
trials	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
childhood	NN	O	O
diarrhoea	NN	O	O
,	NN	O	O
but	NN	O	O
few	NN	O	O
studies	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
Saccharomyces	NN	O	B-INT
boulardii	NN	O	I-INT
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
diarrhoea	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Two	NN	O	B-PAR
hundred	NN	O	I-PAR
children	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
in	NN	O	O
a	NN	O	O
granulated	NN	O	O
form	NN	O	O
in	NN	O	O
a	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
250	NN	O	O
mg	NN	O	O
(	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
group	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
)	NN	O	O
for	NN	O	O
5	NN	O	O
d.	NN	O	O
Clinical	NN	O	O
and	NN	O	O
demographic	NN	O	O
characteristics	NN	O	O
on	NN	O	O
admission	NN	O	O
were	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
study	NN	O	O
groups	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
medians	NN	O	O
of	NN	O	O
the	NN	O	O
average	NN	O	B-OUT
stool	NN	O	I-OUT
frequency	NN	O	I-OUT
after	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.003	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
diarrhoea	NN	O	I-OUT
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
group	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
(	NN	O	O
4.7	NN	O	O
vs	NN	O	O
5.5	NN	O	O
d	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
on	NN	O	O
watery	NN	O	O
diarrhoea	NN	O	O
became	NN	O	O
apparent	NN	O	O
after	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
hospital	NN	O	I-OUT
stay	NN	O	I-OUT
was	NN	O	O
shorter	NN	O	O
in	NN	O	O
the	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
(	NN	O	O
2.9	NN	O	O
vs	NN	O	O
3.9	NN	O	O
d	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Four	NN	O	O
children	NN	O	O
from	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
versus	NN	O	O
only	NN	O	O
one	NN	O	O
child	NN	O	O
from	NN	O	O
the	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
group	NN	O	O
had	NN	O	O
persisting	NN	O	O
diarrhoea	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
suggested	NN	O	O
that	NN	O	O
S.	NN	O	B-INT
boulardii	NN	O	I-INT
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
acute	NN	O	I-OUT
diarrhoea	NN	O	I-OUT
and	NN	O	O
the	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
hospital	NN	O	I-OUT
stay	NN	O	I-OUT
.	NN	O	O

S.	NN	O	B-INT
boulardii	NN	O	I-INT
seems	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
promising	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
amelioration	NN	O	O
of	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
acute	NN	O	B-PAR
diarrhoea	NN	O	I-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
when	NN	O	O
used	NN	O	O
therapeutically	NN	O	O
.	NN	O	O



--DOCSTART-- (16055807)

Interventions	NN	O	O
in	NN	O	O
the	NN	O	O
initial	NN	O	B-PAR
prodromal	NN	O	I-PAR
states	NN	O	I-PAR
of	NN	O	I-PAR
psychosis	NN	O	I-PAR
in	NN	O	O
Germany	NN	O	B-PAR
:	NN	O	O
concept	NN	O	O
and	NN	O	O
recruitment	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
Early	NN	O	O
Detection	NN	O	O
and	NN	O	O
Intervention	NN	O	O
Programme	NN	O	O
of	NN	O	O
the	NN	O	O
German	NN	O	O
Research	NN	O	O
Network	NN	O	O
on	NN	O	O
Schizophrenia	NN	O	O
(	NN	O	O
GRNS	NN	O	O
)	NN	O	O
investigates	NN	O	O
the	NN	O	O
initial	NN	O	B-PAR
prodromal	NN	O	I-PAR
phase	NN	O	I-PAR
of	NN	O	I-PAR
psychosis	NN	O	I-PAR
in	NN	O	O
a	NN	O	O
multidimensional	NN	O	O
approach	NN	O	O
.	NN	O	O

Two	NN	O	O
intervention	NN	O	O
strategies	NN	O	O
are	NN	O	O
being	NN	O	O
studied	NN	O	O
by	NN	O	O
two	NN	O	O
large-scale	NN	O	O
multicentre	NN	O	O
projects	NN	O	O
.	NN	O	O

AIMS	NN	O	O
To	NN	O	O
present	NN	O	O
the	NN	O	O
concept	NN	O	O
of	NN	O	O
the	NN	O	O
intervention	NN	O	O
studies	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
provide	NN	O	O
an	NN	O	O
interim	NN	O	O
report	NN	O	O
of	NN	O	O
the	NN	O	O
recruitment	NN	O	O
procedure	NN	O	O
.	NN	O	O

METHOD	NN	O	O
Comprehensive	NN	O	B-INT
cognitive-behavioural	NN	O	I-INT
therapy	NN	O	I-INT
has	NN	O	O
been	NN	O	O
developed	NN	O	O
for	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	B-PAR
initial	NN	O	I-PAR
prodromal	NN	O	I-PAR
state	NN	O	I-PAR
.	NN	O	O

For	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
late	NN	O	B-PAR
initial	NN	O	I-PAR
prodromal	NN	O	I-PAR
state	NN	O	I-PAR
the	NN	O	O
atypical	NN	O	B-INT
neuroleptic	NN	O	I-INT
amisulpride	NN	O	I-INT
is	NN	O	O
explored	NN	O	O
.	NN	O	O

Both	NN	O	O
interventions	NN	O	O
are	NN	O	O
evaluated	NN	O	O
in	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trials	NN	O	O
using	NN	O	O
clinical	NN	O	O
management	NN	O	O
as	NN	O	O
the	NN	O	O
control	NN	O	O
condition	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Between	NN	O	O
January	NN	O	O
2001	NN	O	O
and	NN	O	O
March	NN	O	O
2003	NN	O	O
,	NN	O	O
1212	NN	O	B-PAR
individuals	NN	O	I-PAR
seeking	NN	O	I-PAR
help	NN	O	I-PAR
for	NN	O	I-PAR
mental	NN	O	I-PAR
health	NN	O	I-PAR
problems	NN	O	I-PAR
were	NN	O	O
screened	NN	O	O
for	NN	O	O
putative	NN	O	O
prodromal	NN	O	O
symptoms	NN	O	O
at	NN	O	O
four	NN	O	O
university	NN	O	O
centres	NN	O	O
.	NN	O	O

More	NN	O	B-PAR
than	NN	O	I-PAR
388	NN	O	I-PAR
individuals	NN	O	I-PAR
fulfilled	NN	O	I-PAR
criteria	NN	O	I-PAR
for	NN	O	I-PAR
both	NN	O	I-PAR
interventions	NN	O	I-PAR
and	NN	O	I-PAR
188	NN	O	I-PAR
(	NN	O	I-PAR
48.5	NN	O	I-PAR
%	NN	O	I-PAR
)	NN	O	I-PAR
gave	NN	O	I-PAR
informed	NN	O	I-PAR
consent	NN	O	I-PAR
to	NN	O	I-PAR
participate	NN	O	I-PAR
in	NN	O	I-PAR
the	NN	O	I-PAR
trials	NN	O	I-PAR
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
screening	NN	O	O
procedure	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
feasible	NN	O	O
and	NN	O	O
trial	NN	O	O
participation	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
acceptable	NN	O	O
to	NN	O	O
a	NN	O	O
relevant	NN	O	O
proportion	NN	O	O
of	NN	O	O
people	NN	O	O
at	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
psychosis	NN	O	O
.	NN	O	O



--DOCSTART-- (16167234)

[	NN	O	O
Effect	NN	O	O
of	NN	O	O
branch	NN	O	O
chain	NN	O	O
amino	NN	O	B-INT
acid	NN	O	I-INT
enriched	NN	O	I-INT
formula	NN	O	I-INT
on	NN	O	O
postoperative	NN	O	B-OUT
fatigue	NN	O	I-OUT
and	NN	O	O
nutritional	NN	O	B-OUT
status	NN	O	I-OUT
after	NN	O	I-PAR
digestive	NN	O	I-PAR
surgery	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
branch	NN	O	B-INT
chain	NN	O	I-INT
amino	NN	O	I-INT
acid	NN	O	I-INT
(	NN	O	I-INT
BCAA	NN	O	I-INT
)	NN	O	I-INT
enriched	NN	O	I-INT
formula	NN	O	I-INT
on	NN	O	O
nutritional	NN	O	B-OUT
status	NN	O	I-OUT
and	NN	O	O
postoperative	NN	O	B-OUT
fatigue	NN	O	I-OUT
for	NN	O	O
digestive	NN	O	B-PAR
surgery	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Forty	NN	O	B-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
underwent	NN	O	I-PAR
digestive	NN	O	I-PAR
surgery	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
received	NN	O	O
parenteral	NN	O	O
nutrition	NN	O	O
with	NN	O	O
either	NN	O	O
BCAA	NN	O	B-INT
enriched	NN	O	I-INT
(	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
n=20	NN	O	O
)	NN	O	O
or	NN	O	O
routine	NN	O	B-INT
amino	NN	O	I-INT
acid	NN	O	I-INT
(	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
n=20	NN	O	O
)	NN	O	O
for	NN	O	O
seven	NN	O	O
consecutive	NN	O	O
days	NN	O	O
.	NN	O	O

Nitrogen	NN	O	B-OUT
balance	NN	O	I-OUT
,	NN	O	I-OUT
serum	NN	O	I-OUT
total	NN	O	I-OUT
protein	NN	O	I-OUT
,	NN	O	I-OUT
albumin	NN	O	I-OUT
,	NN	O	I-OUT
prealbumin	NN	O	I-OUT
,	NN	O	I-OUT
transferrin	NN	O	I-OUT
,	NN	O	I-OUT
retinol	NN	O	I-OUT
binding	NN	O	I-OUT
protein	NN	O	I-OUT
and	NN	O	I-OUT
postoperative	NN	O	I-OUT
fatigue	NN	O	I-OUT
score	NN	O	I-OUT
were	NN	O	O
monitored	NN	O	O
during	NN	O	O
the	NN	O	O
postoperative	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
cumulative	NN	O	B-OUT
postoperative	NN	O	I-OUT
fatigue	NN	O	I-OUT
scores	NN	O	I-OUT
were	NN	O	O
lower	NN	O	O
in	NN	O	O
BCAA	NN	O	B-INT
group	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
at	NN	O	O
the	NN	O	O
4th	NN	O	O
,	NN	O	O
5th	NN	O	O
and	NN	O	O
7th	NN	O	O
day	NN	O	O
after	NN	O	O
operation	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
achieved	NN	O	O
positive	NN	O	O
nitrogen	NN	O	B-OUT
balance	NN	O	I-OUT
2	NN	O	O
days	NN	O	O
earlier	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
group	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
cumulative	NN	O	B-OUT
nitrogen	NN	O	I-OUT
balance	NN	O	I-OUT
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
elevation	NN	O	O
of	NN	O	O
serum	NN	O	B-OUT
total	NN	O	I-OUT
protein	NN	O	I-OUT
,	NN	O	I-OUT
albumin	NN	O	I-OUT
,	NN	O	I-OUT
prealbumin	NN	O	I-OUT
,	NN	O	I-OUT
transferrin	NN	O	I-OUT
at	NN	O	O
the	NN	O	O
7th	NN	O	O
day	NN	O	O
after	NN	O	O
operation	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
at	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
after	NN	O	O
operation	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	B-OUT
level	NN	O	I-OUT
of	NN	O	I-OUT
retinol	NN	O	I-OUT
binding	NN	O	I-OUT
protein	NN	O	I-OUT
was	NN	O	O
higher	NN	O	O
in	NN	O	O
BCAA-enriched	NN	O	B-INT
group	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P=0.004	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
TPN	NN	O	O
with	NN	O	O
BCAA	NN	O	B-INT
enriched	NN	O	I-INT
formula	NN	O	I-INT
can	NN	O	O
reduce	NN	O	O
postoperative	NN	O	B-OUT
fatigue	NN	O	I-OUT
score	NN	O	I-OUT
and	NN	O	O
improve	NN	O	O
the	NN	O	O
nutritional	NN	O	B-OUT
status	NN	O	I-OUT
for	NN	O	O
digestive	NN	O	B-PAR
surgery	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (16295154)

Intervention	NN	O	B-INT
pilot	NN	O	O
for	NN	O	O
parents	NN	O	B-PAR
of	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

Parents	NN	O	B-PAR
of	NN	O	I-PAR
children	NN	O	I-PAR
who	NN	O	I-PAR
receive	NN	O	I-PAR
the	NN	O	I-PAR
diagnosis	NN	O	I-PAR
of	NN	O	I-PAR
autistic	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
experience	NN	O	O
a	NN	O	O
situational	NN	O	O
crisis	NN	O	O
related	NN	O	O
to	NN	O	O
receiving	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
,	NN	O	O
which	NN	O	O
causes	NN	O	O
feelings	NN	O	O
of	NN	O	O
distress	NN	O	O
and	NN	O	O
urgency	NN	O	O
to	NN	O	O
access	NN	O	O
services	NN	O	O
for	NN	O	O
the	NN	O	O
affected	NN	O	O
child	NN	O	O
.	NN	O	O

This	NN	O	O
paper	NN	O	O
describes	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
(	NN	O	O
n	NN	O	B-PAR
=	NN	O	I-PAR
31	NN	O	I-PAR
)	NN	O	O
that	NN	O	O
was	NN	O	O
conducted	NN	O	O
at	NN	O	O
a	NN	O	O
regional	NN	O	O
diagnostic	NN	O	O
center	NN	O	O
of	NN	O	O
a	NN	O	O
large	NN	O	O
metropolitan	NN	O	O
children	NN	O	O
's	NN	O	O
hospital	NN	O	O
to	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
refine	NN	O	O
a	NN	O	O
nursing	NN	O	B-INT
intervention	NN	O	I-INT
designed	NN	O	O
for	NN	O	O
parents	NN	O	B-PAR
of	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	O
(	NN	O	O
b	NN	O	O
)	NN	O	O
to	NN	O	O
identify	NN	O	O
methodological	NN	O	O
revisions	NN	O	O
for	NN	O	O
a	NN	O	O
larger	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
secondary	NN	O	O
purpose	NN	O	O
was	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
post-diagnosis	NN	O	B-INT
nursing	NN	O	I-INT
intervention	NN	O	I-INT
on	NN	O	O
parents	NN	O	B-OUT
'	NN	O	I-OUT
reports	NN	O	I-OUT
of	NN	O	I-OUT
stress	NN	O	I-OUT
,	NN	O	I-OUT
impact	NN	O	I-OUT
of	NN	O	I-OUT
event	NN	O	I-OUT
(	NN	O	I-OUT
diagnosis	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
use	NN	O	B-OUT
of	NN	O	I-OUT
services	NN	O	I-OUT
after	NN	O	O
a	NN	O	O
child	NN	O	O
is	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
ASD	NN	O	O
.	NN	O	O

The	NN	O	O
intervention	NN	O	O
consisted	NN	O	O
of	NN	O	O
usual	NN	O	B-INT
care	NN	O	I-INT
plus	NN	O	O
3	NN	O	O
hours	NN	O	O
contact	NN	O	B-INT
with	NN	O	I-INT
a	NN	O	I-INT
pediatric	NN	O	I-INT
nurse	NN	O	I-INT
practitioner	NN	O	I-INT
(	NN	O	I-INT
PNP	NN	O	I-INT
)	NN	O	I-INT
for	NN	O	I-INT
counseling	NN	O	I-INT
,	NN	O	I-INT
instruction	NN	O	I-INT
,	NN	O	I-INT
and	NN	O	I-INT
assistance	NN	O	I-INT
with	NN	O	I-INT
implementation	NN	O	I-INT
of	NN	O	I-INT
the	NN	O	I-INT
recommended	NN	O	I-INT
treatment	NN	O	I-INT
plan	NN	O	I-INT
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
received	NN	O	O
only	NN	O	O
the	NN	O	O
usual	NN	O	B-INT
care	NN	O	I-INT
post-diagnosis	NN	O	O
,	NN	O	O
which	NN	O	O
consisted	NN	O	O
of	NN	O	O
a	NN	O	O
1-hour	NN	O	O
consultation	NN	O	B-INT
session	NN	O	I-INT
to	NN	O	I-INT
receive	NN	O	I-INT
the	NN	O	I-INT
results	NN	O	I-INT
of	NN	O	I-INT
diagnostic	NN	O	I-INT
tests	NN	O	I-INT
and	NN	O	I-INT
a	NN	O	I-INT
written	NN	O	I-INT
copy	NN	O	I-INT
of	NN	O	I-INT
the	NN	O	I-INT
recommended	NN	O	I-INT
treatment	NN	O	I-INT
plan	NN	O	I-INT
provided	NN	O	O
by	NN	O	O
a	NN	O	O
developmental	NN	O	O
pediatrician	NN	O	O
and/or	NN	O	O
PNP	NN	O	O
.	NN	O	O

Between	NN	O	O
group	NN	O	O
differences	NN	O	O
in	NN	O	O
measures	NN	O	O
of	NN	O	O
impact	NN	O	B-OUT
of	NN	O	I-OUT
event	NN	O	I-OUT
and	NN	O	O
perceived	NN	O	B-OUT
stress	NN	O	I-OUT
were	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
attributed	NN	O	O
to	NN	O	O
a	NN	O	O
small	NN	O	O
sample	NN	O	O
size	NN	O	O
.	NN	O	O

A	NN	O	O
larger	NN	O	O
study	NN	O	O
is	NN	O	O
feasible	NN	O	O
and	NN	O	O
recommended	NN	O	O
with	NN	O	O
an	NN	O	O
expanded	NN	O	O
nursing	NN	O	O
intervention	NN	O	O
and	NN	O	O
a	NN	O	O
significantly	NN	O	O
larger	NN	O	O
sample	NN	O	O
recruited	NN	O	O
from	NN	O	O
an	NN	O	O
additional	NN	O	O
recruitment	NN	O	O
site	NN	O	O
.	NN	O	O

Nurses	NN	O	O
working	NN	O	O
with	NN	O	O
this	NN	O	O
special	NN	O	O
population	NN	O	O
must	NN	O	O
recognize	NN	O	O
that	NN	O	O
parents	NN	O	O
have	NN	O	O
information	NN	O	O
and	NN	O	O
counseling	NN	O	O
needs	NN	O	O
that	NN	O	O
begin	NN	O	O
after	NN	O	O
they	NN	O	O
receive	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
ASD	NN	O	O
for	NN	O	O
their	NN	O	O
child	NN	O	O
and	NN	O	O
can	NN	O	O
address	NN	O	O
these	NN	O	O
needs	NN	O	O
with	NN	O	O
a	NN	O	O
standardized	NN	O	O
nursing	NN	O	O
intervention	NN	O	O
.	NN	O	O



--DOCSTART-- (16427787)

Sleep-anticipating	NN	O	O
effects	NN	O	B-OUT
of	NN	O	O
melatonin	NN	O	B-INT
in	NN	O	O
the	NN	O	O
human	NN	O	B-PAR
brain	NN	O	O
.	NN	O	O

Melatonin	NN	O	O
,	NN	O	O
the	NN	O	O
hormone	NN	O	O
produced	NN	O	O
nocturnally	NN	O	O
by	NN	O	O
the	NN	O	O
pineal	NN	O	O
gland	NN	O	O
,	NN	O	O
is	NN	O	O
an	NN	O	O
endogenous	NN	O	O
regulator	NN	O	O
of	NN	O	O
the	NN	O	O
sleep-wake	NN	O	O
cycle	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
melatonin	NN	O	B-INT
on	NN	O	O
brain	NN	O	O
activities	NN	O	O
and	NN	O	O
their	NN	O	O
relation	NN	O	O
to	NN	O	O
induction	NN	O	O
of	NN	O	O
sleepiness	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
controlled	NN	O	O
functional	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
fMRI	NN	O	O
)	NN	O	O
study	NN	O	O
.	NN	O	O

Melatonin	NN	O	B-INT
,	NN	O	O
but	NN	O	O
not	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
reduced	NN	O	O
task-related	NN	O	B-OUT
activity	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
rostro-medial	NN	O	O
aspect	NN	O	O
of	NN	O	O
the	NN	O	O
occipital	NN	O	O
cortex	NN	O	O
during	NN	O	O
a	NN	O	O
visual-search	NN	O	O
task	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
auditory	NN	O	O
cortex	NN	O	O
during	NN	O	O
a	NN	O	O
music	NN	O	O
task	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
correlated	NN	O	O
with	NN	O	O
subjective	NN	O	B-OUT
measurements	NN	O	I-OUT
of	NN	O	I-OUT
fatigue	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
melatonin	NN	O	B-INT
enhanced	NN	O	O
the	NN	O	O
activation	NN	O	B-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
left	NN	O	I-OUT
parahippocampus	NN	O	I-OUT
in	NN	O	O
an	NN	O	O
autobiographic	NN	O	O
memory	NN	O	O
task	NN	O	O
.	NN	O	O

Results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
melatonin	NN	O	B-INT
modulates	NN	O	O
brain	NN	O	B-OUT
activity	NN	O	I-OUT
in	NN	O	O
a	NN	O	O
manner	NN	O	O
resembling	NN	O	O
actual	NN	O	O
sleep	NN	O	O
although	NN	O	O
subjects	NN	O	O
are	NN	O	O
fully	NN	O	O
awake	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
fatigue	NN	O	B-OUT
inducing	NN	O	O
effect	NN	O	O
of	NN	O	O
melatonin	NN	O	B-INT
on	NN	O	O
brain	NN	O	O
activity	NN	O	O
is	NN	O	O
essentially	NN	O	O
different	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
sleep	NN	O	O
deprivation	NN	O	O
thus	NN	O	O
revealing	NN	O	O
differences	NN	O	O
between	NN	O	O
fatigues	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
circadian	NN	O	O
sleep	NN	O	O
regulation	NN	O	O
as	NN	O	O
opposed	NN	O	O
to	NN	O	O
increased	NN	O	O
homeostatic	NN	O	O
sleep	NN	O	O
need	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
highlight	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
melatonin	NN	O	B-INT
in	NN	O	O
priming	NN	O	O
sleep-associated	NN	O	O
brain	NN	O	O
activation	NN	O	O
patterns	NN	O	O
in	NN	O	O
anticipation	NN	O	O
of	NN	O	O
sleep	NN	O	O
.	NN	O	O



--DOCSTART-- (16505427)

Phase	NN	O	O
III	NN	O	O
study	NN	O	O
of	NN	O	O
two	NN	O	O
different	NN	O	O
dosing	NN	O	O
schedules	NN	O	O
of	NN	O	O
erythropoietin	NN	O	B-INT
in	NN	O	O
anemic	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O

PURPOSE	NN	O	O
To	NN	O	O
compare	NN	O	O
maintenance	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
administered	NN	O	O
once	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
with	NN	O	O
continued	NN	O	O
weekly	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
cancer-associated	NN	O	I-PAR
anemia	NN	O	I-PAR
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Eligible	NN	O	O
patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
at	NN	O	O
enrollment	NN	O	O
to	NN	O	O
receive	NN	O	O
three	NN	O	O
weekly	NN	O	O
doses	NN	O	O
of	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
40,000	NN	O	O
U	NN	O	O
subcutaneously	NN	O	O
(	NN	O	O
SC	NN	O	O
)	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
either	NN	O	O
standard	NN	O	O
weekly	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
(	NN	O	O
40K	NN	O	O
arm	NN	O	O
)	NN	O	O
or	NN	O	O
120,000	NN	O	O
U	NN	O	O
of	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
(	NN	O	O
120K	NN	O	O
arm	NN	O	O
)	NN	O	O
SC	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
for	NN	O	O
18	NN	O	O
additional	NN	O	O
weeks	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Three	NN	O	B-PAR
hundred	NN	O	I-PAR
sixty-five	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

One	NN	O	O
hundred	NN	O	O
eighty-three	NN	O	O
patients	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
40K	NN	O	O
arm	NN	O	O
,	NN	O	O
and	NN	O	O
182	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
120K	NN	O	O
arm	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
requiring	NN	O	B-OUT
transfusions	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
23	NN	O	O
%	NN	O	O
in	NN	O	O
40K	NN	O	O
arm	NN	O	O
and	NN	O	O
18	NN	O	O
%	NN	O	O
in	NN	O	O
120K	NN	O	O
arm	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.22	NN	O	O
)	NN	O	O
or	NN	O	O
specifically	NN	O	O
during	NN	O	O
the	NN	O	O
maintenance	NN	O	O
phase	NN	O	O
(	NN	O	O
13	NN	O	O
%	NN	O	O
in	NN	O	O
40K	NN	O	O
arm	NN	O	O
v	NN	O	O
15	NN	O	O
%	NN	O	O
in	NN	O	O
120K	NN	O	O
arm	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.58	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
40K	NN	O	O
arm	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
2	NN	O	O
or	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
3	NN	O	O
g/dL	NN	O	O
hemoglobin	NN	O	B-OUT
(	NN	O	I-OUT
Hb	NN	O	I-OUT
)	NN	O	I-OUT
increment	NN	O	I-OUT
,	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
drug	NN	O	B-OUT
dose	NN	O	I-OUT
held	NN	O	O
because	NN	O	O
of	NN	O	O
high	NN	O	O
Hb	NN	O	B-OUT
,	NN	O	O
and	NN	O	O
had	NN	O	O
higher	NN	O	O
mean	NN	O	O
end-of-study	NN	O	O
Hb	NN	O	B-OUT
levels	NN	O	O
.	NN	O	O

Toxicities	NN	O	B-OUT
,	NN	O	O
including	NN	O	O
thromboembolism	NN	O	B-OUT
,	NN	O	O
and	NN	O	O
overall	NN	O	B-OUT
survival	NN	O	I-OUT
were	NN	O	O
similar	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
40K	NN	O	O
arm	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
global	NN	O	B-OUT
quality	NN	O	I-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
(	NN	O	I-OUT
QOL	NN	O	I-OUT
)	NN	O	I-OUT
at	NN	O	O
baseline	NN	O	O
for	NN	O	O
unclear	NN	O	O
reasons	NN	O	O
,	NN	O	O
whereas	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
120K	NN	O	O
arm	NN	O	O
had	NN	O	O
a	NN	O	O
greater	NN	O	O
global	NN	O	B-OUT
QOL	NN	O	I-OUT
improvement	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
so	NN	O	O
end-of-study	NN	O	O
QOL	NN	O	B-OUT
was	NN	O	O
equivalent	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
After	NN	O	O
three	NN	O	O
weekly	NN	O	O
doses	NN	O	O
of	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
40,000	NN	O	O
U	NN	O	O
,	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
120,000	NN	O	O
U	NN	O	O
can	NN	O	O
be	NN	O	O
administered	NN	O	O
safely	NN	O	O
once	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
without	NN	O	O
increasing	NN	O	O
transfusion	NN	O	B-OUT
needs	NN	O	I-OUT
or	NN	O	O
sacrificing	NN	O	O
QOL	NN	O	B-OUT
.	NN	O	O

The	NN	O	O
Hb	NN	O	B-OUT
increment	NN	O	I-OUT
is	NN	O	O
somewhat	NN	O	O
greater	NN	O	O
with	NN	O	O
continued	NN	O	O
weekly	NN	O	O
epoetin	NN	O	B-INT
alfa	NN	O	I-INT
.	NN	O	O

Lack	NN	O	O
of	NN	O	O
blinding	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
different	NN	O	O
treatment	NN	O	O
schedules	NN	O	O
may	NN	O	O
have	NN	O	O
confounded	NN	O	O
results	NN	O	O
.	NN	O	O



--DOCSTART-- (1669598)

Local	NN	O	O
immunotherapy	NN	O	O
by	NN	O	O
inhalation	NN	O	O
of	NN	O	O
a	NN	O	O
powder	NN	O	O
extract	NN	O	O
in	NN	O	O
asthma	NN	O	O
due	NN	O	O
to	NN	O	O
house	NN	O	O
dust	NN	O	O
mite	NN	O	O
Dermatophagoides	NN	O	O
pteronyssinus	NN	O	O
:	NN	O	O
a	NN	O	O
double-blind	NN	O	O
comparison	NN	O	O
with	NN	O	O
parenteral	NN	O	O
immunotherapy	NN	O	O
.	NN	O	O

To	NN	O	O
verify	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
the	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
local	NN	O	B-INT
immunotherapy	NN	O	I-INT
(	NN	O	O
LI	NN	O	O
)	NN	O	O
by	NN	O	O
inhalation	NN	O	O
of	NN	O	O
a	NN	O	O
powder	NN	O	B-INT
extract	NN	O	I-INT
of	NN	O	I-INT
house	NN	O	I-INT
dust	NN	O	I-INT
mite	NN	O	I-INT
(	NN	O	I-INT
HDM	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
parenteral	NN	O	B-INT
immunotherapy	NN	O	I-INT
(	NN	O	I-INT
PI	NN	O	I-INT
)	NN	O	I-INT
by	NN	O	O
injection	NN	O	O
,	NN	O	O
10	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
asthma	NN	O	I-PAR
due	NN	O	I-PAR
to	NN	O	I-PAR
HDM	NN	O	I-PAR
were	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
blind	NN	O	O
fashion	NN	O	O
.	NN	O	O

5	NN	O	O
patients	NN	O	O
(	NN	O	O
Group	NN	O	O
A	NN	O	O
)	NN	O	O
underwent	NN	O	O
LI	NN	O	O
and	NN	O	O
subcutaneous	NN	O	O
injections	NN	O	O
of	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
5	NN	O	O
patients	NN	O	O
(	NN	O	O
Group	NN	O	O
B	NN	O	O
)	NN	O	O
underwent	NN	O	O
PI	NN	O	O
and	NN	O	O
inhalation	NN	O	O
of	NN	O	O
lactose	NN	O	B-INT
for	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
groups	NN	O	O
each	NN	O	O
inhalation	NN	O	O
was	NN	O	O
preceded	NN	O	O
by	NN	O	O
premedication	NN	O	O
with	NN	O	O
disodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
(	NN	O	I-INT
DSCG	NN	O	I-INT
)	NN	O	I-INT
(	NN	O	O
40	NN	O	O
mg	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
Group	NN	O	O
A	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
symptoms	NN	O	B-OUT
score	NN	O	I-OUT
and	NN	O	O
in	NN	O	O
peak	NN	O	B-OUT
expiratory	NN	O	I-OUT
flow	NN	O	I-OUT
(	NN	O	I-OUT
PEF	NN	O	I-OUT
)	NN	O	I-OUT
-derived	NN	O	I-OUT
parameters	NN	O	I-OUT
was	NN	O	O
observed	NN	O	O
already	NN	O	O
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	O
patients	NN	O	O
lost	NN	O	O
the	NN	O	O
late	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
bronchial	NN	O	B-OUT
response	NN	O	I-OUT
to	NN	O	O
the	NN	O	O
challenge	NN	O	O
with	NN	O	O
HDM	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
variation	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
bronchial	NN	O	B-OUT
responsiveness	NN	O	I-OUT
to	NN	O	O
methacholine	NN	O	O
and	NN	O	O
ultrasonically	NN	O	O
nebulized	NN	O	O
distilled	NN	O	O
water	NN	O	O
(	NN	O	O
UNDW	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
immunologic	NN	O	B-OUT
humoral	NN	O	I-OUT
and	NN	O	I-OUT
cellular	NN	O	I-OUT
parameters	NN	O	I-OUT
in	NN	O	I-OUT
peripheral	NN	O	I-OUT
blood	NN	O	I-OUT
after	NN	O	O
treatment	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

No	NN	O	O
local	NN	O	B-OUT
important	NN	O	I-OUT
adverse	NN	O	I-OUT
reactions	NN	O	I-OUT
were	NN	O	O
observed	NN	O	O
in	NN	O	O
Group	NN	O	O
A	NN	O	O
and	NN	O	O
no	NN	O	O
systemic	NN	O	B-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
were	NN	O	O
observed	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
LI	NN	O	O
is	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
PI	NN	O	O
,	NN	O	O
but	NN	O	O
more	NN	O	O
rapid	NN	O	O
in	NN	O	O
its	NN	O	O
action	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
asthma	NN	O	O
due	NN	O	O
to	NN	O	O
HDM	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
LI	NN	O	O
is	NN	O	O
locally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
providing	NN	O	O
DSCG	NN	O	O
is	NN	O	O
inhaled	NN	O	O
before	NN	O	O
each	NN	O	O
therapeutic	NN	O	O
inhalation	NN	O	O
,	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
induce	NN	O	O
systemic	NN	O	B-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (17293018)

The	NN	O	O
safety	NN	O	O
of	NN	O	O
whey	NN	O	B-INT
protein	NN	O	I-INT
concentrate	NN	O	I-INT
derived	NN	O	O
from	NN	O	O
the	NN	O	O
milk	NN	O	O
of	NN	O	O
cows	NN	O	O
immunized	NN	O	O
against	NN	O	O
Clostridium	NN	O	O
difficile	NN	O	O
.	NN	O	O

A	NN	O	O
whey	NN	O	B-INT
protein	NN	O	I-INT
concentrate	NN	O	I-INT
prepared	NN	O	O
from	NN	O	O
the	NN	O	O
milk	NN	O	O
of	NN	O	O
cows	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
immunized	NN	O	B-INT
against	NN	O	I-INT
Clostridium	NN	O	I-INT
difficile	NN	O	I-INT
(	NN	O	I-INT
C.	NN	O	I-INT
difficile	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	I-INT
its	NN	O	I-INT
toxins	NN	O	I-INT
,	NN	O	I-INT
toxin	NN	O	I-INT
A	NN	O	I-INT
and	NN	O	I-INT
toxin	NN	O	I-INT
B	NN	O	I-INT
,	NN	O	O
is	NN	O	O
produced	NN	O	O
for	NN	O	O
use	NN	O	O
as	NN	O	O
a	NN	O	O
medical	NN	O	O
food	NN	O	O
for	NN	O	O
the	NN	O	O
dietary	NN	O	O
management	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
C.	NN	O	I-PAR
difficile-associated	NN	O	I-PAR
diarrhea	NN	O	I-PAR
(	NN	O	I-PAR
CDAD	NN	O	I-PAR
)	NN	O	I-PAR
to	NN	O	O
prevent	NN	O	O
a	NN	O	O
relapse	NN	O	O
of	NN	O	O
the	NN	O	O
infection	NN	O	O
.	NN	O	O

The	NN	O	O
safety	NN	O	O
of	NN	O	O
anti-C.	NN	O	B-INT
difficile	NN	O	I-INT
whey	NN	O	I-INT
protein	NN	O	I-INT
concentrate	NN	O	I-INT
(	NN	O	I-INT
anti-CD	NN	O	I-INT
WPC	NN	O	I-INT
)	NN	O	I-INT
is	NN	O	O
supported	NN	O	O
by	NN	O	O
analytical	NN	O	O
data	NN	O	O
comparing	NN	O	O
the	NN	O	O
composition	NN	O	O
of	NN	O	O
raw	NN	O	O
milk	NN	O	O
from	NN	O	O
immunized	NN	O	O
cows	NN	O	O
versus	NN	O	O
that	NN	O	O
from	NN	O	O
non-immunized	NN	O	O
cows	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
composition	NN	O	O
of	NN	O	O
anti-CD	NN	O	B-INT
WPC	NN	O	I-INT
versus	NN	O	O
that	NN	O	O
of	NN	O	O
regular	NN	O	B-INT
whey	NN	O	I-INT
protein	NN	O	I-INT
concentrate	NN	O	I-INT
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
a	NN	O	O
prospective	NN	O	O
clinical	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
77	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
CDAD	NN	O	I-PAR
to	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
consuming	NN	O	O
anti-CD	NN	O	B-INT
WPC	NN	O	I-INT
to	NN	O	O
prevent	NN	O	O
relapse	NN	O	O
of	NN	O	O
the	NN	O	O
infection	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
adverse	NN	O	O
event	NN	O	O
monitoring	NN	O	O
,	NN	O	O
physical	NN	O	O
examinations	NN	O	O
,	NN	O	O
and	NN	O	O
extensive	NN	O	O
hematological	NN	O	O
and	NN	O	O
biochemical	NN	O	O
assessments	NN	O	O
,	NN	O	O
showed	NN	O	O
that	NN	O	O
anti-CD	NN	O	B-INT
WPC	NN	O	I-INT
is	NN	O	O
safe	NN	O	B-OUT
to	NN	O	O
consume	NN	O	O
by	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
CDAD	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
available	NN	O	O
analytical	NN	O	O
and	NN	O	O
clinical	NN	O	O
evidence	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
anti-CD	NN	O	B-INT
WPC	NN	O	I-INT
is	NN	O	O
safe	NN	O	B-OUT
for	NN	O	O
use	NN	O	O
by	NN	O	O
individuals	NN	O	B-PAR
with	NN	O	I-PAR
CDAD	NN	O	I-PAR
,	NN	O	O
under	NN	O	O
the	NN	O	O
described	NN	O	O
conditions	NN	O	O
of	NN	O	O
use	NN	O	O
.	NN	O	O



--DOCSTART-- (17321989)

The	NN	O	O
prophylactic	NN	O	O
effect	NN	O	O
of	NN	O	O
itraconazole	NN	O	B-INT
capsules	NN	O	O
and	NN	O	O
fluconazole	NN	O	B-INT
capsules	NN	O	O
for	NN	O	O
systemic	NN	O	O
fungal	NN	O	O
infections	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
myeloid	NN	O	I-PAR
leukemia	NN	O	I-PAR
and	NN	O	I-PAR
myelodysplastic	NN	O	I-PAR
syndromes	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
Japanese	NN	O	B-PAR
multicenter	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
study	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
study	NN	O	O
comparing	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
effects	NN	O	O
of	NN	O	O
capsule	NN	O	O
forms	NN	O	O
of	NN	O	O
fluconazole	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
110	NN	O	O
)	NN	O	O
and	NN	O	O
itraconazole	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
108	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
myeloid	NN	O	I-PAR
leukemia	NN	O	I-PAR
(	NN	O	I-PAR
AML	NN	O	I-PAR
)	NN	O	I-PAR
or	NN	O	I-PAR
myelodysplastic	NN	O	I-PAR
syndromes	NN	O	I-PAR
(	NN	O	I-PAR
MDS	NN	O	I-PAR
)	NN	O	I-PAR
during	NN	O	I-PAR
and	NN	O	I-PAR
after	NN	O	I-PAR
chemotherapy	NN	O	I-PAR
.	NN	O	O

There	NN	O	O
were	NN	O	O
4	NN	O	O
cases	NN	O	O
with	NN	O	O
possible	NN	O	O
systemic	NN	O	O
fungal	NN	O	O
infection	NN	O	O
in	NN	O	O
the	NN	O	O
itraconazole	NN	O	B-INT
group	NN	O	O
,	NN	O	O
and	NN	O	O
there	NN	O	O
were	NN	O	O
8	NN	O	O
possible	NN	O	O
and	NN	O	O
3	NN	O	O
probable	NN	O	O
cases	NN	O	O
in	NN	O	O
the	NN	O	O
fluconazole	NN	O	B-INT
group	NN	O	O
.	NN	O	O

Adverse	NN	O	B-OUT
events	NN	O	I-OUT
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
differ	NN	O	O
in	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
MDS	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
remission-induction	NN	O	O
phase	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
the	NN	O	O
numbers	NN	O	O
of	NN	O	O
cases	NN	O	O
with	NN	O	O
probable	NN	O	B-OUT
or	NN	O	I-OUT
possible	NN	O	I-OUT
infections	NN	O	I-OUT
were	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
itraconazole	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
fluconazole	NN	O	O
group	NN	O	O
,	NN	O	O
whereas	NN	O	O
no	NN	O	O
difference	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
AML	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
consolidation	NN	O	O
phase	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
neutrophil	NN	O	O
counts	NN	O	O
of	NN	O	O
>	NN	O	O
0.1	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/L	NN	O	O
lasting	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
4	NN	O	O
weeks	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	B-OUT
of	NN	O	I-OUT
infection	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
fluconazole	NN	O	O
group	NN	O	O
(	NN	O	O
5	NN	O	O
of	NN	O	O
9	NN	O	O
patients	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
itraconazole	NN	O	O
group	NN	O	O
(	NN	O	O
0	NN	O	O
of	NN	O	O
7	NN	O	O
patients	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.03	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
both	NN	O	O
drugs	NN	O	O
were	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
AML	NN	O	I-PAR
or	NN	O	I-PAR
MDS	NN	O	I-PAR
who	NN	O	I-PAR
received	NN	O	I-PAR
chemotherapy	NN	O	I-PAR
and	NN	O	O
that	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
itraconazole	NN	O	O
for	NN	O	O
prophylaxis	NN	O	O
against	NN	O	O
systemic	NN	O	O
fungal	NN	O	O
disease	NN	O	O
is	NN	O	O
not	NN	O	O
inferior	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
fluconazole	NN	O	O
.	NN	O	O



--DOCSTART-- (17616069)

[	NN	O	O
Intravenous	NN	O	O
treatment	NN	O	O
of	NN	O	O
postpartum	NN	O	B-PAR
anemia	NN	O	O
with	NN	O	O
trivalent	NN	O	B-INT
ferrum	NN	O	I-INT
preparation	NN	O	I-INT
]	NN	O	O
.	NN	O	O

AIM	NN	O	O
OF	NN	O	O
THE	NN	O	O
STUDY	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
effectivity	NN	O	B-OUT
and	NN	O	O
safeness	NN	O	B-OUT
of	NN	O	O
intravenous	NN	O	O
treatment	NN	O	O
of	NN	O	O
pospartal	NN	O	O
anemia	NN	O	O
with	NN	O	O
trivalent	NN	O	B-INT
ferrum	NN	O	I-INT
preparation	NN	O	I-INT
.	NN	O	O

TYPE	NN	O	O
OF	NN	O	O
THE	NN	O	O
STUDY	NN	O	O
Prospective	NN	O	O
randomized	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
Department	NN	O	O
of	NN	O	O
Obstetric	NN	O	O
and	NN	O	O
Gynecology	NN	O	O
2nd	NN	O	O
Medical	NN	O	O
Faculty	NN	O	O
Charles	NN	O	O
University	NN	O	O
and	NN	O	O
Teaching	NN	O	O
Hospital	NN	O	O
Motol	NN	O	O
,	NN	O	O
Prague	NN	O	B-PAR
,	NN	O	O
and	NN	O	O
Department	NN	O	O
of	NN	O	O
Obstetric	NN	O	O
and	NN	O	O
Gynecology	NN	O	O
1st	NN	O	O
Medical	NN	O	O
Faculty	NN	O	O
and	NN	O	O
Teaching	NN	O	O
Hospital	NN	O	O
Bulovka	NN	O	O
,	NN	O	O
Prague	NN	O	B-PAR
.	NN	O	O

METHODS	NN	O	O
500	NN	O	O
mg	NN	O	O
of	NN	O	O
sacharose	NN	O	B-INT
ferric	NN	O	I-INT
oxide	NN	O	I-INT
(	NN	O	I-INT
Venofer	NN	O	I-INT
)	NN	O	I-INT
was	NN	O	O
intravenously	NN	O	O
administered	NN	O	O
in	NN	O	O
two	NN	O	O
days	NN	O	O
regimen	NN	O	O
to	NN	O	O
50	NN	O	B-PAR
women	NN	O	I-PAR
with	NN	O	I-PAR
clinical	NN	O	I-PAR
and	NN	O	I-PAR
lab	NN	O	I-PAR
signs	NN	O	I-PAR
of	NN	O	I-PAR
postpartal	NN	O	I-PAR
anemia	NN	O	I-PAR
.	NN	O	I-PAR
The	NN	O	O
effect	NN	O	O
of	NN	O	O
administered	NN	O	O
drug	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
comparsion	NN	O	O
of	NN	O	O
values	NN	O	B-OUT
of	NN	O	I-OUT
red	NN	O	I-OUT
blood	NN	O	I-OUT
count	NN	O	I-OUT
recovered	NN	O	O
before	NN	O	O
the	NN	O	O
treatment	NN	O	O
,	NN	O	O
2nd	NN	O	O
or	NN	O	O
3rd	NN	O	O
day	NN	O	O
post	NN	O	O
administration	NN	O	O
and	NN	O	O
two	NN	O	O
weeks	NN	O	O
later	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	B-OUT
values	NN	O	I-OUT
of	NN	O	I-OUT
soluble	NN	O	I-OUT
transferrin	NN	O	I-OUT
receptors	NN	O	I-OUT
and	NN	O	I-OUT
ferritin	NN	O	I-OUT
were	NN	O	O
observed	NN	O	O
as	NN	O	O
markers	NN	O	O
of	NN	O	O
iron	NN	O	B-OUT
cell	NN	O	I-OUT
saturation	NN	O	I-OUT
and	NN	O	O
body	NN	O	B-OUT
iron	NN	O	I-OUT
reserves	NN	O	I-OUT
,	NN	O	O
too	NN	O	O
.	NN	O	O

Integral	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
the	NN	O	O
monitoring	NN	O	O
of	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Venofer	NN	O	B-INT
came	NN	O	O
in	NN	O	O
sight	NN	O	O
as	NN	O	O
effective	NN	O	B-OUT
drug	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
pospartal	NN	O	O
anemia	NN	O	O
and	NN	O	O
could	NN	O	O
become	NN	O	O
as	NN	O	O
the	NN	O	O
alternative	NN	O	O
to	NN	O	O
blood	NN	O	O
transfusion	NN	O	O
in	NN	O	O
mid-severe	NN	O	O
cases	NN	O	O
.	NN	O	O

It	NN	O	O
should	NN	O	O
be	NN	O	O
emphasized	NN	O	O
that	NN	O	O
we	NN	O	O
have	NN	O	O
not	NN	O	O
encountered	NN	O	O
any	NN	O	O
serious	NN	O	B-OUT
adverse	NN	O	I-OUT
event	NN	O	I-OUT
with	NN	O	O
intravenous	NN	O	O
trivalent	NN	O	B-INT
saccharose	NN	O	I-INT
ferric	NN	O	I-INT
oxide	NN	O	I-INT
treatment	NN	O	O
.	NN	O	O



--DOCSTART-- (1780092)

[	NN	O	O
Clinical	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
and	NN	O	O
tolerance	NN	O	B-OUT
to	NN	O	O
nimesulide	NN	O	B-INT
in	NN	O	O
suppository	NN	O	O
formulation	NN	O	O
in	NN	O	O
pain-inflammatory	NN	O	O
pathologies	NN	O	O
of	NN	O	O
the	NN	O	O
ear	NN	O	O
,	NN	O	O
nose	NN	O	O
,	NN	O	O
and	NN	O	O
throat	NN	O	O
]	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
new	NN	O	O
pharmaceutical	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
non-steroid	NN	O	O
anti-inflammatory	NN	O	O
drug	NN	O	O
.	NN	O	O

Nimesulide	NN	O	B-INT
have	NN	O	O
been	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
study	NN	O	O
compared	NN	O	O
with	NN	O	O
flurbiprofen	NN	O	B-INT
,	NN	O	O
in	NN	O	O
98	NN	O	B-PAR
patients	NN	O	I-PAR
aged	NN	O	I-PAR
between	NN	O	I-PAR
18	NN	O	I-PAR
and	NN	O	I-PAR
75	NN	O	I-PAR
suffering	NN	O	I-PAR
from	NN	O	I-PAR
pain-inflammatory	NN	O	I-PAR
pathologies	NN	O	I-PAR
of	NN	O	I-PAR
ENT	NN	O	I-PAR
nature	NN	O	I-PAR
.	NN	O	O

Both	NN	O	O
drugs	NN	O	O
,	NN	O	O
administered	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
one	NN	O	O
suppository	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
showed	NN	O	O
marked	NN	O	O
anti-inflammatory	NN	O	B-OUT
,	NN	O	I-OUT
analgesic	NN	O	I-OUT
and	NN	O	I-OUT
antipyretic	NN	O	I-OUT
activity	NN	O	I-OUT
and	NN	O	O
produced	NN	O	O
a	NN	O	O
significant	NN	O	O
,	NN	O	O
progressive	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
typical	NN	O	O
symptoms	NN	O	B-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
inflammatory	NN	O	I-OUT
state	NN	O	I-OUT
up	NN	O	O
to	NN	O	O
their	NN	O	O
complete	NN	O	O
remission	NN	O	O
.	NN	O	O

Nimesulide	NN	O	B-INT
evidenced	NN	O	O
greater	NN	O	O
speed	NN	O	O
and	NN	O	O
duration	NN	O	B-OUT
of	NN	O	O
therapeutic	NN	O	O
action	NN	O	O
.	NN	O	O

Assessment	NN	O	O
on	NN	O	O
the	NN	O	O
effectiveness	NN	O	B-OUT
and	NN	O	O
tolerability	NN	O	B-OUT
as	NN	O	O
expressed	NN	O	O
separately	NN	O	O
by	NN	O	O
the	NN	O	O
physician	NN	O	O
and	NN	O	O
patient	NN	O	O
were	NN	O	O
positive	NN	O	O
in	NN	O	O
almost	NN	O	O
all	NN	O	O
cases	NN	O	O
of	NN	O	O
both	NN	O	O
treatments	NN	O	O
.	NN	O	O



--DOCSTART-- (17897478)

Salmeterol	NN	O	B-INT
plus	NN	O	O
fluticasone	NN	O	B-INT
propionate	NN	O	I-INT
versus	NN	O	O
fluticasone	NN	O	B-INT
propionate	NN	O	I-INT
plus	NN	O	O
montelukast	NN	O	B-INT
:	NN	O	O
a	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trial	NN	O	O
investigating	NN	O	O
the	NN	O	O
effects	NN	O	O
on	NN	O	O
airway	NN	O	B-OUT
inflammation	NN	O	I-OUT
in	NN	O	O
asthma	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Few	NN	O	O
studies	NN	O	O
have	NN	O	O
compared	NN	O	O
treatment	NN	O	O
strategies	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
asthma	NN	O	I-PAR
poorly	NN	O	O
controlled	NN	O	O
on	NN	O	O
low	NN	O	O
dose	NN	O	O
inhaled	NN	O	O
corticosteroids	NN	O	O
,	NN	O	O
and	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
different	NN	O	O
treatments	NN	O	O
on	NN	O	O
airway	NN	O	O
inflammation	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
,	NN	O	O
parallel	NN	O	O
group	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
salmeterol	NN	O	B-INT
plus	NN	O	O
fluticasone	NN	O	B-INT
propionate	NN	O	I-INT
(	NN	O	I-INT
FP	NN	O	I-INT
)	NN	O	I-INT
(	NN	O	I-INT
Seretide	NN	O	I-INT
;	NN	O	I-INT
SFC	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
FP	NN	O	B-INT
plus	NN	O	O
montelukast	NN	O	B-INT
(	NN	O	I-INT
FP/M	NN	O	I-INT
)	NN	O	I-INT
on	NN	O	O
sputum	NN	O	B-OUT
inflammatory	NN	O	I-OUT
markers	NN	O	I-OUT
,	NN	O	I-OUT
airway	NN	O	I-OUT
responsiveness	NN	O	I-OUT
,	NN	O	I-OUT
lung	NN	O	I-OUT
function	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
symptoms	NN	O	B-OUT
in	NN	O	O
adult	NN	O	B-PAR
asthmatics	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Sixty-six	NN	O	B-PAR
subjects	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
SFC	NN	O	B-INT
or	NN	O	O
FP/M	NN	O	B-INT
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
changes	NN	O	B-OUT
in	NN	O	I-OUT
neutrophil	NN	O	I-OUT
,	NN	O	I-OUT
eosinophil	NN	O	I-OUT
,	NN	O	I-OUT
macrophage	NN	O	I-OUT
,	NN	O	I-OUT
lymphocyte	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
epithelial	NN	O	I-OUT
cell	NN	O	I-OUT
levels	NN	O	I-OUT
in	NN	O	I-OUT
induced	NN	O	I-OUT
sputum	NN	O	I-OUT
.	NN	O	O

Additional	NN	O	O
outcomes	NN	O	O
included	NN	O	O
the	NN	O	O
change	NN	O	B-OUT
in	NN	O	I-OUT
other	NN	O	I-OUT
sputum	NN	O	I-OUT
markers	NN	O	I-OUT
of	NN	O	I-OUT
airway	NN	O	I-OUT
inflammation	NN	O	I-OUT
,	NN	O	I-OUT
airway	NN	O	I-OUT
responsiveness	NN	O	I-OUT
,	NN	O	I-OUT
symptom	NN	O	I-OUT
control	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
lung	NN	O	I-OUT
function	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
Both	NN	O	O
treatments	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
induced	NN	O	O
sputum	NN	O	B-OUT
inflammatory	NN	O	I-OUT
cells	NN	O	O
,	NN	O	O
although	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
trend	NN	O	O
for	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
sputum	NN	O	B-OUT
eosinophils	NN	O	I-OUT
.	NN	O	O

Both	NN	O	O
treatments	NN	O	O
significantly	NN	O	O
improved	NN	O	O
airway	NN	O	B-OUT
responsiveness	NN	O	I-OUT
,	NN	O	O
whereas	NN	O	O
SFC	NN	O	B-INT
generally	NN	O	O
led	NN	O	O
to	NN	O	O
greater	NN	O	O
improvements	NN	O	O
in	NN	O	O
symptom	NN	O	B-OUT
control	NN	O	I-OUT
and	NN	O	I-OUT
lung	NN	O	I-OUT
function	NN	O	I-OUT
than	NN	O	O
FP/M	NN	O	B-INT
.	NN	O	O

FP/M	NN	O	B-INT
led	NN	O	O
to	NN	O	O
significantly	NN	O	O
greater	NN	O	O
reductions	NN	O	O
in	NN	O	O
sputum	NN	O	B-OUT
cysteinyl	NN	O	I-OUT
leukotrienes	NN	O	I-OUT
than	NN	O	O
SFC	NN	O	B-INT
(	NN	O	O
treatment	NN	O	O
ratio	NN	O	O
1.80	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1.09	NN	O	O
,	NN	O	O
2.94	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Both	NN	O	O
treatments	NN	O	O
led	NN	O	O
to	NN	O	O
similar	NN	O	O
control	NN	O	O
of	NN	O	O
eosinophilic	NN	O	B-OUT
airway	NN	O	I-OUT
inflammation	NN	O	I-OUT
,	NN	O	O
although	NN	O	O
PEF	NN	O	O
and	NN	O	O
symptom	NN	O	O
control	NN	O	O
were	NN	O	O
better	NN	O	O
with	NN	O	O
SFC	NN	O	B-INT
.	NN	O	O

STUDY	NN	O	O
NUMBER	NN	O	O
:	NN	O	O
SAM40030	NN	O	O
(	NN	O	O
SOLTA	NN	O	O
)	NN	O	O
.	NN	O	O



--DOCSTART-- (18077611)

A	NN	O	O
double-blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
multicenter	NN	O	O
safety	NN	O	O
and	NN	O	O
immunogenicity	NN	O	O
study	NN	O	O
of	NN	O	O
a	NN	O	O
refrigerator-stable	NN	O	O
formulation	NN	O	O
of	NN	O	O
Zostavax	NN	O	B-INT
.	NN	O	O

The	NN	O	O
vaccine	NN	O	O
Zostavax	NN	O	B-INT
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
prevent	NN	O	O
herpes	NN	O	O
zoster	NN	O	O
(	NN	O	O
HZ	NN	O	O
)	NN	O	O
and	NN	O	O
postherpetic	NN	O	O
neuralgia	NN	O	O
and	NN	O	O
is	NN	O	O
recommended	NN	O	O
for	NN	O	O
individuals	NN	O	O
>	NN	O	O
or	NN	O	O
=60	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
compared	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
the	NN	O	O
immunogenicity	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
refrigerator-stable	NN	O	O
formulation	NN	O	O
(	NN	O	O
Zostavax	NN	O	B-INT
refrigerated	NN	O	O
)	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
current	NN	O	O
formulation	NN	O	O
(	NN	O	O
Zostavax	NN	O	B-INT
frozen	NN	O	O
)	NN	O	O
in	NN	O	O
subjects	NN	O	B-PAR
>	NN	O	I-PAR
or	NN	O	I-PAR
=50	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	B-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
negative	NN	O	I-PAR
history	NN	O	I-PAR
for	NN	O	I-PAR
HZ	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
1:1	NN	O	O
to	NN	O	O
receive	NN	O	O
one	NN	O	O
dose	NN	O	O
of	NN	O	O
either	NN	O	O
formulation	NN	O	O
.	NN	O	O

Enrollment	NN	O	B-PAR
was	NN	O	I-PAR
stratified	NN	O	I-PAR
1:2	NN	O	I-PAR
by	NN	O	I-PAR
age	NN	O	I-PAR
(	NN	O	I-PAR
50	NN	O	I-PAR
to	NN	O	I-PAR
59	NN	O	I-PAR
years	NN	O	I-PAR
and	NN	O	I-PAR
>	NN	O	I-PAR
or	NN	O	I-PAR
=60	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	O
.	NN	O	O

Safety	NN	O	B-OUT
was	NN	O	O
evaluated	NN	O	O
for	NN	O	O
28	NN	O	O
days	NN	O	O
postvaccination	NN	O	O
.	NN	O	O

Varicella-zoster	NN	O	B-OUT
virus	NN	O	I-OUT
(	NN	O	I-OUT
VZV	NN	O	I-OUT
)	NN	O	I-OUT
antibody	NN	O	I-OUT
responses	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
by	NN	O	O
a	NN	O	O
glycoprotein	NN	O	O
enzyme-linked	NN	O	O
immunosorbent	NN	O	O
assay	NN	O	O
(	NN	O	O
gpELISA	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
endpoints	NN	O	O
were	NN	O	O
the	NN	O	O
VZV	NN	O	B-OUT
antibody	NN	O	I-OUT
geometric	NN	O	I-OUT
mean	NN	O	I-OUT
titer	NN	O	I-OUT
(	NN	O	I-OUT
GMT	NN	O	I-OUT
;	NN	O	O
day	NN	O	O
28	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
VZV	NN	O	B-OUT
antibody	NN	O	I-OUT
geometric	NN	O	I-OUT
mean	NN	O	I-OUT
rise	NN	O	I-OUT
(	NN	O	I-OUT
GMR	NN	O	I-OUT
;	NN	O	O
days	NN	O	O
1	NN	O	O
to	NN	O	O
28	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
vaccine-related	NN	O	I-OUT
serious	NN	O	I-OUT
adverse	NN	O	I-OUT
experiences	NN	O	I-OUT
(	NN	O	I-OUT
AEs	NN	O	I-OUT
)	NN	O	I-OUT
over	NN	O	O
28	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
refrigerated	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
182	NN	O	O
)	NN	O	O
and	NN	O	O
frozen	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
185	NN	O	O
)	NN	O	O
formulations	NN	O	O
induced	NN	O	O
similar	NN	O	O
GMTs	NN	O	B-OUT
(	NN	O	O
727.4	NN	O	O
and	NN	O	O
834.4	NN	O	O
gpELISA	NN	O	O
units/ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
estimated	NN	O	O
GMT	NN	O	B-OUT
ratio	NN	O	O
(	NN	O	O
refrigerated	NN	O	O
formulation/frozen	NN	O	O
formulation	NN	O	O
)	NN	O	O
was	NN	O	O
0.87	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0.71	NN	O	O
to	NN	O	O
1.07	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
GMRs	NN	O	B-OUT
were	NN	O	O
2.6-	NN	O	O
and	NN	O	O
2.9-fold	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

No	NN	O	O
vaccine-related	NN	O	B-OUT
serious	NN	O	I-OUT
AEs	NN	O	I-OUT
were	NN	O	O
reported	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
profiles	NN	O	O
of	NN	O	O
the	NN	O	O
formulations	NN	O	O
were	NN	O	O
generally	NN	O	O
similar	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
of	NN	O	O
injection-site	NN	O	B-OUT
AEs	NN	O	I-OUT
during	NN	O	O
follow-up	NN	O	O
were	NN	O	O
35.6	NN	O	O
%	NN	O	O
and	NN	O	O
46.4	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
refrigerated	NN	O	O
and	NN	O	O
the	NN	O	O
frozen	NN	O	O
formulation	NN	O	O
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
generally	NN	O	O
mild	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
of	NN	O	O
systemic	NN	O	B-OUT
AEs	NN	O	I-OUT
were	NN	O	O
similar	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
,	NN	O	O
and	NN	O	O
those	NN	O	O
of	NN	O	O
vaccine-related	NN	O	B-OUT
AEs	NN	O	I-OUT
were	NN	O	O
approximately	NN	O	O
6	NN	O	O
%	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
refrigerator-stable	NN	O	O
formulation	NN	O	O
of	NN	O	O
Zostavax	NN	O	B-INT
has	NN	O	O
an	NN	O	O
acceptable	NN	O	O
safety	NN	O	B-OUT
profile	NN	O	O
and	NN	O	O
is	NN	O	O
as	NN	O	O
immunogenic	NN	O	B-OUT
as	NN	O	O
the	NN	O	O
frozen	NN	O	O
formulation	NN	O	O
;	NN	O	O
thus	NN	O	O
,	NN	O	O
the	NN	O	O
vaccine	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
clinical	NN	O	O
settings	NN	O	O
where	NN	O	O
freezer	NN	O	O
availability	NN	O	O
is	NN	O	O
limited	NN	O	O
.	NN	O	O



--DOCSTART-- (18189160)

Feasibility	NN	O	O
of	NN	O	O
two	NN	O	O
dose-dense	NN	O	O
FEC	NN	O	B-INT
regimens	NN	O	O
with	NN	O	O
growth	NN	O	O
factor	NN	O	O
support	NN	O	O
for	NN	O	O
adjuvant	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
early	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
:	NN	O	O
results	NN	O	O
from	NN	O	O
a	NN	O	O
randomised	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
Central	NN	O	O
European	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
(	NN	O	O
CECOG	NN	O	O
)	NN	O	O
.	NN	O	O

Addition	NN	O	O
of	NN	O	O
epirubicin	NN	O	B-INT
to	NN	O	O
adjuvant	NN	O	O
chemotherapy	NN	O	O
can	NN	O	O
provide	NN	O	O
important	NN	O	O
benefits	NN	O	O
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
early	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
,	NN	O	O
but	NN	O	O
the	NN	O	O
optimal	NN	O	O
dose	NN	O	O
remains	NN	O	O
unclear	NN	O	O
.	NN	O	O

Further	NN	O	O
improvements	NN	O	O
can	NN	O	O
be	NN	O	O
achieved	NN	O	O
with	NN	O	O
dose-dense	NN	O	O
regimens	NN	O	O
,	NN	O	O
but	NN	O	O
densification	NN	O	O
of	NN	O	O
fluorouracil/epirubicin/cyclophosphamide	NN	O	B-INT
(	NN	O	I-INT
FEC	NN	O	I-INT
)	NN	O	I-INT
has	NN	O	O
proved	NN	O	O
difficult	NN	O	O
,	NN	O	O
with	NN	O	O
FEC	NN	O	O
(	NN	O	O
60	NN	O	O
)	NN	O	O
providing	NN	O	O
little	NN	O	O
benefit	NN	O	O
over	NN	O	O
standard	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
100	NN	O	O
)	NN	O	O
associated	NN	O	O
with	NN	O	O
toxicity	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
feasibility	NN	O	O
of	NN	O	O
two	NN	O	O
intermediate	NN	O	O
dose-dense	NN	O	O
FEC	NN	O	B-INT
regimens	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
six	NN	O	O
cycles	NN	O	O
of	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
75	NN	O	O
)	NN	O	O
or	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
all	NN	O	O
three	NN	O	O
drugs	NN	O	O
given	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
of	NN	O	O
each	NN	O	O
14-day	NN	O	O
cycle	NN	O	O
.	NN	O	O

Patients	NN	O	O
also	NN	O	O
received	NN	O	O
pegfilgrastim	NN	O	B-INT
6	NN	O	O
mg	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
on	NN	O	O
day	NN	O	O
2	NN	O	O
of	NN	O	O
each	NN	O	O
cycle	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
efficacy	NN	O	O
endpoint	NN	O	O
was	NN	O	O
the	NN	O	O
proportion	NN	O	B-OUT
of	NN	O	I-OUT
subjects	NN	O	I-OUT
receiving	NN	O	I-OUT
>	NN	O	I-OUT
or	NN	O	I-OUT
=85	NN	O	I-OUT
%	NN	O	I-OUT
relative	NN	O	I-OUT
dose	NN	O	I-OUT
intensity	NN	O	I-OUT
and	NN	O	O
was	NN	O	O
achieved	NN	O	O
by	NN	O	O
96	NN	O	O
%	NN	O	O
and	NN	O	O
88	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
FEC	NN	O	O
(	NN	O	O
75	NN	O	O
)	NN	O	O
and	NN	O	O
FEC	NN	O	O
(	NN	O	O
90	NN	O	O
)	NN	O	O
arms	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Of	NN	O	O
147	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
75	NN	O	O
)	NN	O	O
infusions	NN	O	O
,	NN	O	O
4.1	NN	O	O
%	NN	O	O
were	NN	O	O
delayed	NN	O	O
,	NN	O	O
while	NN	O	O
9.8	NN	O	O
%	NN	O	O
of	NN	O	O
143	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
infusions	NN	O	O
were	NN	O	O
delayed	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
reasons	NN	O	O
for	NN	O	O
delay	NN	O	O
were	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
and	NN	O	O
personal/logistical	NN	O	O
reasons	NN	O	O
.	NN	O	O

One	NN	O	O
dose	NN	O	O
reduction	NN	O	O
occurred	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
related	NN	O	O
to	NN	O	O
diarrhoea	NN	O	B-OUT
.	NN	O	O

Grade	NN	O	O
3-4	NN	O	O
haematological	NN	O	B-OUT
toxicities	NN	O	I-OUT
were	NN	O	O
reported	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
arm	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
incidences	NN	O	O
of	NN	O	O
febrile	NN	O	B-OUT
neutropenia	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
increases	NN	O	O
in	NN	O	O
liver	NN	O	B-OUT
enzymes	NN	O	I-OUT
and	NN	O	I-OUT
gastrointestinal	NN	O	I-OUT
events	NN	O	I-OUT
;	NN	O	O
no	NN	O	O
event	NN	O	O
resulted	NN	O	O
in	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

Only	NN	O	O
one	NN	O	O
patient	NN	O	O
(	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
)	NN	O	O
experienced	NN	O	O
serious	NN	O	B-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
(	NN	O	I-OUT
vomiting	NN	O	I-OUT
and	NN	O	I-OUT
throat	NN	O	I-OUT
oedema	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
dose-dense	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
75	NN	O	O
)	NN	O	O
and	NN	O	O
FEC	NN	O	B-INT
(	NN	O	O
90	NN	O	O
)	NN	O	O
are	NN	O	O
feasible	NN	O	O
with	NN	O	O
pegfilgrastim	NN	O	O
support	NN	O	O
.	NN	O	O

These	NN	O	O
regimens	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
very	NN	O	O
low	NN	O	O
risk	NN	O	O
of	NN	O	O
Grade	NN	O	O
3-4	NN	O	O
toxicity	NN	O	O
.	NN	O	O



--DOCSTART-- (18229990)

Language	NN	O	B-OUT
outcome	NN	O	I-OUT
in	NN	O	O
autism	NN	O	B-PAR
:	NN	O	O
randomized	NN	O	O
comparison	NN	O	O
of	NN	O	O
joint	NN	O	B-INT
attention	NN	O	I-INT
and	NN	O	O
play	NN	O	B-INT
interventions	NN	O	I-INT
.	NN	O	O

This	NN	O	O
study	NN	O	O
reports	NN	O	O
results	NN	O	O
of	NN	O	O
a	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
aimed	NN	O	O
at	NN	O	O
joint	NN	O	B-INT
attention	NN	O	I-INT
(	NN	O	I-INT
JA	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
symbolic	NN	O	B-INT
play	NN	O	I-INT
(	NN	O	I-INT
SP	NN	O	I-INT
)	NN	O	I-INT
in	NN	O	O
preschool	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
,	NN	O	O
with	NN	O	O
prediction	NN	O	O
to	NN	O	O
language	NN	O	B-OUT
outcome	NN	O	I-OUT
12	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

Participants	NN	O	B-PAR
were	NN	O	I-PAR
58	NN	O	I-PAR
children	NN	O	I-PAR
(	NN	O	I-PAR
46	NN	O	I-PAR
boys	NN	O	I-PAR
)	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
between	NN	O	I-PAR
3	NN	O	I-PAR
and	NN	O	I-PAR
4	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
.	NN	O	I-PAR
Children	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
a	NN	O	O
JA	NN	O	B-INT
intervention	NN	O	O
,	NN	O	O
an	NN	O	O
SP	NN	O	B-INT
intervention	NN	O	O
,	NN	O	O
or	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Interventions	NN	O	O
were	NN	O	O
conducted	NN	O	O
30	NN	O	O
min	NN	O	O
daily	NN	O	O
for	NN	O	O
5-6	NN	O	O
weeks	NN	O	O
.	NN	O	O

Assessments	NN	O	O
of	NN	O	O
JA	NN	O	B-OUT
skills	NN	O	I-OUT
,	NN	O	I-OUT
SP	NN	O	I-OUT
skills	NN	O	I-OUT
,	NN	O	I-OUT
mother-child	NN	O	I-OUT
interactions	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
language	NN	O	I-OUT
development	NN	O	I-OUT
were	NN	O	O
collected	NN	O	O
at	NN	O	O
4	NN	O	O
time	NN	O	O
points	NN	O	O
:	NN	O	O
pre-	NN	O	O
and	NN	O	O
postintervention	NN	O	O
and	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
postintervention	NN	O	O
by	NN	O	O
independent	NN	O	O
testers	NN	O	O
.	NN	O	O

Results	NN	O	O
indicate	NN	O	O
that	NN	O	O
expressive	NN	O	B-OUT
language	NN	O	I-OUT
gains	NN	O	I-OUT
were	NN	O	O
greater	NN	O	O
for	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
results	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
explained	NN	O	O
by	NN	O	O
differences	NN	O	O
in	NN	O	O
other	NN	O	O
interventions	NN	O	O
in	NN	O	O
which	NN	O	O
children	NN	O	O
participated	NN	O	O
.	NN	O	O

For	NN	O	O
children	NN	O	O
beginning	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
lowest	NN	O	O
language	NN	O	O
levels	NN	O	O
,	NN	O	O
the	NN	O	O
JA	NN	O	B-INT
intervention	NN	O	O
improved	NN	O	O
language	NN	O	B-OUT
outcome	NN	O	I-OUT
significantly	NN	O	O
more	NN	O	O
than	NN	O	O
did	NN	O	O
the	NN	O	O
SP	NN	O	B-INT
or	NN	O	O
control	NN	O	O
interventions	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
clinically	NN	O	O
significant	NN	O	O
benefits	NN	O	O
of	NN	O	O
actively	NN	O	O
treating	NN	O	O
JA	NN	O	B-INT
and	NN	O	O
SP	NN	O	B-INT
skills	NN	O	O
in	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (18337284)

Once-daily	NN	O	O
amoxicillin	NN	O	B-INT
versus	NN	O	O
twice-daily	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	I-INT
in	NN	O	O
group	NN	O	O
A	NN	O	O
beta-haemolytic	NN	O	B-PAR
streptococcal	NN	O	I-PAR
pharyngitis	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Rheumatic	NN	O	O
fever	NN	O	O
is	NN	O	O
a	NN	O	O
preventable	NN	O	O
chronic	NN	O	O
disease	NN	O	O
preceded	NN	O	O
by	NN	O	O
group	NN	O	B-PAR
A	NN	O	I-PAR
beta-haemolytic	NN	O	I-PAR
streptococcal	NN	O	I-PAR
(	NN	O	I-PAR
GABHS	NN	O	I-PAR
)	NN	O	I-PAR
pharyngitis	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
test	NN	O	O
the	NN	O	O
non-inferiority	NN	O	B-OUT
of	NN	O	O
once-daily	NN	O	O
(	NN	O	O
QD	NN	O	O
)	NN	O	O
oral	NN	O	O
amoxicillin	NN	O	B-INT
to	NN	O	O
the	NN	O	O
recommended	NN	O	O
twice-daily	NN	O	O
(	NN	O	O
BID	NN	O	O
)	NN	O	O
oral	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	I-INT
in	NN	O	O
GABHS	NN	O	O
pharyngitis	NN	O	O
.	NN	O	O

METHODS	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
randomised	NN	O	O
non-inferiority	NN	O	B-OUT
trial	NN	O	O
carried	NN	O	O
out	NN	O	O
in	NN	O	O
a	NN	O	O
school-based	NN	O	B-PAR
clinic	NN	O	I-PAR
in	NN	O	I-PAR
New	NN	O	I-PAR
Zealand	NN	O	I-PAR
.	NN	O	O

Children	NN	O	B-PAR
presenting	NN	O	I-PAR
with	NN	O	I-PAR
GABHS	NN	O	I-PAR
pharyngitis	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
oral	NN	O	O
amoxicillin	NN	O	B-INT
1500	NN	O	O
mg	NN	O	O
QD	NN	O	O
(	NN	O	O
or	NN	O	O
750	NN	O	O
mg	NN	O	O
if	NN	O	O
bodyweight	NN	O	O
was	NN	O	O
<	NN	O	O
or=30	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
to	NN	O	O
oral	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	O
500	NN	O	O
mg	NN	O	O
BID	NN	O	O
(	NN	O	O
or	NN	O	O
250	NN	O	O
mg	NN	O	O
if	NN	O	O
bodyweight	NN	O	O
was	NN	O	O
<	NN	O	O
or=20	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

Observed	NN	O	O
medication	NN	O	O
and	NN	O	O
weekend	NN	O	O
diary	NN	O	O
cards	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
monitor	NN	O	O
adherence	NN	O	O
.	NN	O	O

OUTCOME	NN	O	O
Eradication	NN	O	B-OUT
of	NN	O	I-OUT
GABHS	NN	O	I-OUT
,	NN	O	O
determined	NN	O	O
with	NN	O	O
follow-up	NN	O	O
throat	NN	O	O
cultures	NN	O	O
on	NN	O	O
days	NN	O	O
3-6	NN	O	O
,	NN	O	O
12-16	NN	O	O
and	NN	O	O
26-36	NN	O	O
.	NN	O	O

GABHS	NN	O	O
isolates	NN	O	O
were	NN	O	O
serotyped	NN	O	O
to	NN	O	O
distinguish	NN	O	O
bacteriological	NN	O	B-OUT
treatment	NN	O	I-OUT
failures	NN	O	I-OUT
(	NN	O	O
and	NN	O	O
relapses	NN	O	B-OUT
)	NN	O	O
from	NN	O	O
new	NN	O	O
acquisitions	NN	O	O
.	NN	O	O

Non-inferiority	NN	O	B-OUT
was	NN	O	O
defined	NN	O	O
as	NN	O	O
an	NN	O	O
upper	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
limit	NN	O	O
(	NN	O	O
CL	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
difference	NN	O	O
in	NN	O	O
success	NN	O	O
of	NN	O	O
eradication	NN	O	O
in	NN	O	O
the	NN	O	O
amoxicillin	NN	O	B-INT
and	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	O
treatment	NN	O	O
groups	NN	O	O
of	NN	O	O
<	NN	O	O
or=10	NN	O	O
%	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
353	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
positive	NN	O	I-PAR
throat	NN	O	I-PAR
swabs	NN	O	I-PAR
for	NN	O	I-PAR
GABHS	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
amoxicillin	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
177	NN	O	O
)	NN	O	O
or	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
176	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
upper	NN	O	O
95	NN	O	O
%	NN	O	O
CL	NN	O	O
for	NN	O	O
the	NN	O	O
differences	NN	O	O
in	NN	O	O
positive	NN	O	O
cultures	NN	O	O
between	NN	O	O
the	NN	O	O
antibiotics	NN	O	O
was	NN	O	O
4.9	NN	O	O
%	NN	O	O
at	NN	O	O
days	NN	O	O
3-6	NN	O	O
,	NN	O	O
6.5	NN	O	O
%	NN	O	O
at	NN	O	O
days	NN	O	O
12-16	NN	O	O
and	NN	O	O
8.5	NN	O	O
%	NN	O	O
at	NN	O	O
days	NN	O	O
26-36	NN	O	O
.	NN	O	O

Treatment	NN	O	B-OUT
failures	NN	O	I-OUT
(	NN	O	O
including	NN	O	O
relapses	NN	O	B-OUT
)	NN	O	O
occurred	NN	O	O
at	NN	O	O
each	NN	O	O
visit	NN	O	O
in	NN	O	O
5.8	NN	O	O
%	NN	O	O
,	NN	O	O
12.7	NN	O	O
%	NN	O	O
and	NN	O	O
10.7	NN	O	O
%	NN	O	O
of	NN	O	O
amoxicillin	NN	O	B-INT
recipients	NN	O	O
and	NN	O	O
6.2	NN	O	O
%	NN	O	O
,	NN	O	O
11.9	NN	O	O
%	NN	O	O
and	NN	O	O
11.3	NN	O	O
%	NN	O	O
of	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	O
recipients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
resolution	NN	O	B-OUT
of	NN	O	I-OUT
symptoms	NN	O	I-OUT
were	NN	O	O
noted	NN	O	O
between	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

One	NN	O	O
case	NN	O	O
of	NN	O	O
unsubstantiated	NN	O	O
acute	NN	O	O
rheumatic	NN	O	O
fever	NN	O	O
occurred	NN	O	O
after	NN	O	O
7	NN	O	O
days	NN	O	O
of	NN	O	O
amoxicillin	NN	O	B-INT
.	NN	O	O

CONCLUSION	NN	O	O
In	NN	O	O
this	NN	O	O
adequately	NN	O	O
powered	NN	O	O
study	NN	O	O
,	NN	O	O
once-daily	NN	O	O
oral	NN	O	O
amoxicillin	NN	O	B-INT
is	NN	O	O
not	NN	O	O
inferior	NN	O	O
to	NN	O	O
twice-daily	NN	O	O
penicillin	NN	O	B-INT
V	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
eradication	NN	O	O
of	NN	O	O
GABHS	NN	O	B-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
pharyngitis	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (18503531)

A	NN	O	O
multi-component	NN	O	B-INT
social	NN	O	I-INT
skills	NN	O	I-INT
intervention	NN	O	I-INT
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
Asperger	NN	O	I-PAR
syndrome	NN	O	I-PAR
:	NN	O	O
the	NN	O	O
Junior	NN	O	B-INT
Detective	NN	O	I-INT
Training	NN	O	I-INT
Program	NN	O	I-INT
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effectiveness	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
new	NN	O	O
multi-component	NN	O	B-INT
social	NN	O	I-INT
skills	NN	O	I-INT
intervention	NN	O	I-INT
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
Asperger	NN	O	I-PAR
syndrome	NN	O	I-PAR
(	NN	O	I-PAR
AS	NN	O	I-PAR
)	NN	O	I-PAR
:	NN	O	O
The	NN	O	O
Junior	NN	O	O
Detective	NN	O	O
Training	NN	O	O
Program	NN	O	O
.	NN	O	O

This	NN	O	O
7-week	NN	O	O
program	NN	O	O
included	NN	O	O
a	NN	O	O
computer	NN	O	O
game	NN	O	O
,	NN	O	O
small	NN	O	O
group	NN	O	O
sessions	NN	O	O
,	NN	O	O
parent	NN	O	O
training	NN	O	O
sessions	NN	O	O
and	NN	O	O
teacher	NN	O	O
handouts	NN	O	O
.	NN	O	O

METHOD	NN	O	O
Forty-nine	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
AS	NN	O	I-PAR
were	NN	O	O
recruited	NN	O	O
to	NN	O	O
participate	NN	O	O
and	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
intervention	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
26	NN	O	O
)	NN	O	O
or	NN	O	O
wait-list	NN	O	O
control	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
23	NN	O	O
)	NN	O	O
conditions	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Relative	NN	O	O
to	NN	O	O
children	NN	O	O
in	NN	O	O
the	NN	O	O
wait-list	NN	O	O
group	NN	O	O
,	NN	O	O
program	NN	O	O
participants	NN	O	O
showed	NN	O	O
greater	NN	O	O
improvements	NN	O	B-OUT
in	NN	O	I-OUT
social	NN	O	I-OUT
skills	NN	O	I-OUT
over	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
intervention	NN	O	O
,	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
parent-report	NN	O	O
measures	NN	O	O
.	NN	O	O

Teacher-report	NN	O	O
data	NN	O	O
also	NN	O	O
confirmed	NN	O	O
that	NN	O	O
children	NN	O	O
receiving	NN	O	O
the	NN	O	O
intervention	NN	O	O
made	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
social	NN	O	B-OUT
functioning	NN	O	I-OUT
from	NN	O	O
pre-	NN	O	O
to	NN	O	O
post-treatment	NN	O	O
.	NN	O	O

Treatment	NN	O	O
group	NN	O	O
participants	NN	O	O
were	NN	O	O
better	NN	O	O
able	NN	O	O
to	NN	O	O
suggest	NN	O	O
appropriate	NN	O	O
emotion-management	NN	O	B-OUT
strategies	NN	O	I-OUT
for	NN	O	O
story	NN	O	O
characters	NN	O	O
at	NN	O	O
post-intervention	NN	O	O
than	NN	O	O
at	NN	O	O
pre-intervention	NN	O	O
,	NN	O	O
whereas	NN	O	O
control	NN	O	O
participants	NN	O	O
were	NN	O	O
not	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
improvements	NN	O	O
made	NN	O	O
by	NN	O	O
children	NN	O	O
in	NN	O	O
the	NN	O	O
intervention	NN	O	O
and	NN	O	O
control	NN	O	O
conditions	NN	O	O
on	NN	O	O
facial	NN	O	B-OUT
expression	NN	O	I-OUT
and	NN	O	I-OUT
body-posture	NN	O	I-OUT
recognition	NN	O	I-OUT
measures	NN	O	I-OUT
.	NN	O	O

Follow-up	NN	O	O
data	NN	O	O
suggested	NN	O	O
that	NN	O	O
treatment	NN	O	O
gains	NN	O	O
were	NN	O	O
maintained	NN	O	O
by	NN	O	O
children	NN	O	O
at	NN	O	O
5-months	NN	O	O
post-intervention	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
Junior	NN	O	B-INT
Detective	NN	O	I-INT
Training	NN	O	I-INT
Program	NN	O	I-INT
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
enhancing	NN	O	O
the	NN	O	O
social	NN	O	B-OUT
skills	NN	O	I-OUT
and	NN	O	I-OUT
emotional	NN	O	I-OUT
understanding	NN	O	I-OUT
of	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
AS	NN	O	I-PAR
.	NN	O	O

Limitations	NN	O	O
and	NN	O	O
suggestions	NN	O	O
for	NN	O	O
future	NN	O	O
research	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O



--DOCSTART-- (18544974)

In	NN	O	O
school-aged	NN	O	B-PAR
children	NN	O	I-PAR
a	NN	O	O
combination	NN	O	O
of	NN	O	O
galacto-oligosaccharides	NN	O	B-INT
and	NN	O	I-INT
Lactobacillus	NN	O	I-INT
GG	NN	O	I-INT
increases	NN	O	O
bifidobacteria	NN	O	O
more	NN	O	O
than	NN	O	O
Lactobacillus	NN	O	B-INT
GG	NN	O	I-INT
on	NN	O	O
its	NN	O	O
own	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
Lactobacillus	NN	O	B-INT
GG	NN	O	I-INT
(	NN	O	I-INT
LGG	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	I-INT
galacto-oligosaccharides	NN	O	I-INT
(	NN	O	I-INT
GOS	NN	O	I-INT
)	NN	O	I-INT
with	NN	O	O
LGG	NN	O	B-INT
on	NN	O	O
its	NN	O	O
own	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
intestinal	NN	O	O
microbiota	NN	O	O
in	NN	O	O
school-aged	NN	O	B-PAR
children	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blinded	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
comprised	NN	O	O
30	NN	O	B-PAR
healthy	NN	O	I-PAR
children	NN	O	I-PAR
.	NN	O	O

There	NN	O	O
were	NN	O	O
two	NN	O	O
3-week	NN	O	O
study	NN	O	O
periods	NN	O	O
with	NN	O	O
a	NN	O	O
4-week	NN	O	O
wash-out	NN	O	O
period	NN	O	O
in	NN	O	O
between	NN	O	O
.	NN	O	O

The	NN	O	O
children	NN	O	O
ingested	NN	O	O
daily	NN	O	O
65	NN	O	O
ml	NN	O	O
of	NN	O	O
milk-based	NN	O	O
fruit	NN	O	O
juice	NN	O	O
containing	NN	O	O
either	NN	O	O
LGG	NN	O	B-INT
alone	NN	O	O
(	NN	O	O
6.5	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
CFU	NN	O	O
)	NN	O	O
or	NN	O	O
LGG	NN	O	B-INT
plus	NN	O	O
2	NN	O	O
g	NN	O	O
of	NN	O	O
GOS	NN	O	B-INT
.	NN	O	O

Symptom	NN	O	O
diaries	NN	O	O
were	NN	O	O
filled	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
periods	NN	O	O
.	NN	O	O

Fecal	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
at	NN	O	O
the	NN	O	O
beginning	NN	O	O
and	NN	O	O
end	NN	O	O
of	NN	O	O
both	NN	O	O
study	NN	O	O
periods	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
both	NN	O	O
study	NN	O	O
periods	NN	O	O
,	NN	O	O
the	NN	O	O
amount	NN	O	B-OUT
of	NN	O	I-OUT
bifidobacteria	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
greater	NN	O	O
after	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
LGG	NN	O	B-INT
+	NN	O	I-INT
GOS	NN	O	I-INT
compared	NN	O	O
with	NN	O	O
LGG	NN	O	B-INT
alone	NN	O	O
(	NN	O	O
geometric	NN	O	O
mean	NN	O	O
9.33	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
vs.	NN	O	O
4.28	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
CFU/g	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
lactobacilli	NN	O	B-OUT
or	NN	O	O
LGG	NN	O	B-INT
,	NN	O	O
nor	NN	O	O
did	NN	O	O
gastrointestinal	NN	O	B-OUT
symptoms	NN	O	I-OUT
,	NN	O	I-OUT
defecation	NN	O	I-OUT
frequency	NN	O	I-OUT
,	NN	O	I-OUT
consistency	NN	O	I-OUT
of	NN	O	I-OUT
stools	NN	O	I-OUT
or	NN	O	I-OUT
ease	NN	O	I-OUT
of	NN	O	I-OUT
defecation	NN	O	I-OUT
differ	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
study	NN	O	O
periods	NN	O	O
.	NN	O	O

Ingestion	NN	O	O
of	NN	O	O
LGG	NN	O	B-INT
combined	NN	O	O
with	NN	O	O
2	NN	O	O
g	NN	O	O
of	NN	O	O
GOS	NN	O	B-INT
increased	NN	O	O
the	NN	O	O
bifidobacteria	NN	O	B-OUT
more	NN	O	O
than	NN	O	O
LGG	NN	O	B-INT
on	NN	O	O
its	NN	O	O
own	NN	O	O
and	NN	O	O
thus	NN	O	O
GOS	NN	O	B-INT
clearly	NN	O	O
has	NN	O	O
a	NN	O	O
prebiotic	NN	O	O
effect	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
.	NN	O	O

The	NN	O	O
children	NN	O	B-PAR
tolerated	NN	O	O
well	NN	O	O
a	NN	O	O
daily	NN	O	O
intake	NN	O	O
of	NN	O	O
2	NN	O	O
g	NN	O	O
of	NN	O	O
GOS	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (18773733)

Vibrotactile	NN	O	O
--	NN	O	O
auditory	NN	O	O
interactions	NN	O	O
are	NN	O	O
post-perceptual	NN	O	O
.	NN	O	O

Vibrotactile	NN	O	B-INT
stimuli	NN	O	I-INT
can	NN	O	O
elicit	NN	O	O
compelling	NN	O	O
auditory	NN	O	O
sensations	NN	O	O
,	NN	O	O
even	NN	O	O
when	NN	O	O
sound	NN	O	O
energy	NN	O	O
levels	NN	O	O
are	NN	O	O
minimal	NN	O	O
and	NN	O	O
undetectable	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
previously	NN	O	O
been	NN	O	O
shown	NN	O	O
that	NN	O	O
subjects	NN	O	O
judge	NN	O	O
auditory	NN	O	O
tones	NN	O	O
embedded	NN	O	O
in	NN	O	O
white	NN	O	O
noise	NN	O	O
to	NN	O	O
be	NN	O	O
louder	NN	O	O
when	NN	O	O
they	NN	O	O
are	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
vibrotactile	NN	O	B-INT
stimulus	NN	O	I-INT
of	NN	O	O
the	NN	O	O
same	NN	O	O
frequency	NN	O	O
.	NN	O	O

A	NN	O	O
first	NN	O	O
experiment	NN	O	O
replicated	NN	O	O
this	NN	O	O
result	NN	O	O
at	NN	O	O
four	NN	O	O
different	NN	O	O
levels	NN	O	O
of	NN	O	O
auditory	NN	O	O
stimulation	NN	O	O
(	NN	O	O
no	NN	O	O
tone	NN	O	O
,	NN	O	O
tone	NN	O	O
at	NN	O	O
detection	NN	O	O
threshold	NN	O	O
,	NN	O	O
tone	NN	O	O
at	NN	O	O
5	NN	O	O
dB	NN	O	O
above	NN	O	O
threshold	NN	O	O
,	NN	O	O
and	NN	O	O
tone	NN	O	O
at	NN	O	O
10	NN	O	O
dB	NN	O	O
above	NN	O	O
threshold	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
vibrotactile	NN	O	B-INT
stimulus	NN	O	I-INT
induced	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
perceived	NN	O	O
loudness	NN	O	O
of	NN	O	O
auditory	NN	O	B-OUT
tones	NN	O	I-OUT
at	NN	O	O
three	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
values	NN	O	O
in	NN	O	O
this	NN	O	O
range	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
further	NN	O	O
experiments	NN	O	O
,	NN	O	O
a	NN	O	O
2-interval	NN	O	O
forced-choice	NN	O	O
procedure	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
this	NN	O	O
cross-modal	NN	O	O
interaction	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
biased	NN	O	O
when	NN	O	O
vibrotaction	NN	O	B-INT
was	NN	O	O
applied	NN	O	O
in	NN	O	O
one	NN	O	O
interval	NN	O	O
,	NN	O	O
but	NN	O	O
applying	NN	O	O
vibrotaction	NN	O	B-INT
in	NN	O	O
both	NN	O	O
intervals	NN	O	O
produced	NN	O	O
performance	NN	O	O
comparable	NN	O	O
to	NN	O	O
conditions	NN	O	O
without	NN	O	O
vibrotactile	NN	O	B-INT
stimuli	NN	O	I-INT
.	NN	O	O

This	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
vibrotaction	NN	O	B-INT
is	NN	O	O
sometimes	NN	O	O
ignored	NN	O	O
when	NN	O	O
judging	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
an	NN	O	O
auditory	NN	O	O
tone	NN	O	O
.	NN	O	O

Hence	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
vibrotaction	NN	O	B-INT
and	NN	O	O
audition	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
occur	NN	O	O
at	NN	O	O
an	NN	O	O
early	NN	O	O
perceptual	NN	O	O
level	NN	O	O
.	NN	O	O



--DOCSTART-- (18783504)

Psychological	NN	O	O
mediators	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
sustained-release	NN	O	I-INT
treatment	NN	O	O
for	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
.	NN	O	O

AIM	NN	O	O
The	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
test	NN	O	O
simultaneously	NN	O	O
our	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
sustained-release	NN	O	I-INT
(	NN	O	I-INT
SR	NN	O	I-INT
)	NN	O	I-INT
treatment	NN	O	O
on	NN	O	O
putative	NN	O	O
mediators	NN	O	O
and	NN	O	O
our	NN	O	O
understanding	NN	O	O
of	NN	O	O
determinants	NN	O	O
of	NN	O	O
post-quit	NN	O	O
abstinence	NN	O	O
,	NN	O	O
including	NN	O	O
withdrawal	NN	O	O
distress	NN	O	O
,	NN	O	O
cigarette	NN	O	O
craving	NN	O	O
,	NN	O	O
positive	NN	O	O
affect	NN	O	O
and	NN	O	O
subjective	NN	O	O
reactions	NN	O	O
to	NN	O	O
cigarettes	NN	O	O
smoked	NN	O	O
during	NN	O	O
a	NN	O	O
lapse	NN	O	O
.	NN	O	O

The	NN	O	O
specificity	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
SR	NN	O	I-INT
effects	NN	O	O
was	NN	O	O
also	NN	O	O
tested	NN	O	O
in	NN	O	O
exploratory	NN	O	O
analyses	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
Data	NN	O	O
from	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
SR	NN	O	I-INT
were	NN	O	O
submitted	NN	O	O
to	NN	O	O
mediation	NN	O	O
analyses	NN	O	O
.	NN	O	O

SETTING	NN	O	O
Center	NN	O	O
for	NN	O	O
Tobacco	NN	O	O
Research	NN	O	O
and	NN	O	O
Intervention	NN	O	O
,	NN	O	O
Madison	NN	O	B-PAR
,	NN	O	I-PAR
WI	NN	O	I-PAR
,	NN	O	I-PAR
USA	NN	O	I-PAR
.	NN	O	O

PARTICIPANTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
403	NN	O	I-PAR
adult	NN	O	I-PAR
,	NN	O	I-PAR
daily	NN	O	I-PAR
smokers	NN	O	I-PAR
without	NN	O	I-PAR
contraindications	NN	O	I-PAR
to	NN	O	I-PAR
bupropion	NN	O	I-INT
SR	NN	O	I-INT
use	NN	O	I-PAR
.	NN	O	O

INTERVENTION	NN	O	O
Participants	NN	O	O
were	NN	O	O
assigned	NN	O	O
randomly	NN	O	O
to	NN	O	O
receive	NN	O	O
a	NN	O	O
9-week	NN	O	O
course	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
SR	NN	O	I-INT
or	NN	O	O
placebo	NN	O	B-INT
pill	NN	O	O
and	NN	O	O
to	NN	O	O
receive	NN	O	O
eight	NN	O	O
brief	NN	O	O
individual	NN	O	O
counseling	NN	O	O
sessions	NN	O	O
or	NN	O	O
no	NN	O	O
counseling	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
Ecological	NN	O	B-OUT
momentary	NN	O	I-OUT
assessment	NN	O	I-OUT
ratings	NN	O	I-OUT
of	NN	O	I-OUT
smoking	NN	O	I-OUT
behavior	NN	O	I-OUT
and	NN	O	I-OUT
putative	NN	O	I-OUT
mediators	NN	O	I-OUT
were	NN	O	O
collected	NN	O	O
pre-	NN	O	O
and	NN	O	O
post-quit	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
Results	NN	O	O
of	NN	O	O
structural	NN	O	O
equation	NN	O	O
and	NN	O	O
hierarchical	NN	O	O
linear	NN	O	O
models	NN	O	O
did	NN	O	O
not	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
bupropion	NN	O	O
SR	NN	O	O
treatment	NN	O	O
improves	NN	O	O
short-term	NN	O	B-OUT
abstinence	NN	O	I-OUT
by	NN	O	O
reducing	NN	O	O
withdrawal	NN	O	O
distress	NN	O	O
or	NN	O	O
affecting	NN	O	O
the	NN	O	O
subjective	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
lapse	NN	O	O
cigarette	NN	O	O
,	NN	O	O
but	NN	O	O
provided	NN	O	O
partial	NN	O	O
support	NN	O	O
for	NN	O	O
mediation	NN	O	O
by	NN	O	O
cigarette	NN	O	B-OUT
craving	NN	O	I-OUT
reduction	NN	O	I-OUT
and	NN	O	O
enhanced	NN	O	O
positive	NN	O	B-OUT
affect	NN	O	I-OUT
.	NN	O	O

Bupropion	NN	O	B-INT
SR	NN	O	I-INT
effects	NN	O	O
on	NN	O	O
point-prevalence	NN	O	O
abstinence	NN	O	B-OUT
at	NN	O	O
1	NN	O	O
month	NN	O	O
post-quit	NN	O	O
were	NN	O	O
also	NN	O	O
mediated	NN	O	O
partially	NN	O	O
by	NN	O	O
enhanced	NN	O	O
motivation	NN	O	O
to	NN	O	O
quit	NN	O	O
and	NN	O	O
self-efficacy	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Results	NN	O	O
provided	NN	O	O
some	NN	O	O
support	NN	O	O
for	NN	O	O
models	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
SR	NN	O	I-INT
treatment	NN	O	O
and	NN	O	O
relapse	NN	O	O
and	NN	O	O
suggested	NN	O	O
that	NN	O	O
motivational	NN	O	O
processes	NN	O	O
may	NN	O	O
partially	NN	O	O
account	NN	O	O
for	NN	O	O
bupropion	NN	O	O
SR	NN	O	O
efficacy	NN	O	O
.	NN	O	O



--DOCSTART-- (18845996)

Identifying	NN	O	O
patients	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
for	NN	O	O
neutropenic	NN	O	B-OUT
complications	NN	O	I-OUT
during	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
metastatic	NN	O	B-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
with	NN	O	O
doxorubicin	NN	O	B-INT
or	NN	O	O
pegylated	NN	O	B-INT
liposomal	NN	O	I-INT
doxorubicin	NN	O	I-INT
:	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
a	NN	O	O
prediction	NN	O	O
model	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
develop	NN	O	O
a	NN	O	O
cycle-based	NN	O	O
risk	NN	O	O
prediction	NN	O	O
model	NN	O	O
for	NN	O	O
neutropenic	NN	O	B-OUT
complications	NN	O	I-OUT
(	NN	O	I-OUT
NC	NN	O	I-OUT
)	NN	O	I-OUT
during	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
doxorubicin	NN	O	B-INT
(	NN	O	I-INT
DOX	NN	O	I-INT
)	NN	O	I-INT
or	NN	O	O
a	NN	O	O
pegylated	NN	O	B-INT
liposomal	NN	O	I-INT
formulation	NN	O	I-INT
(	NN	O	I-INT
PLD	NN	O	I-INT
)	NN	O	I-INT
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
metastatic	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
(	NN	O	I-PAR
MBC	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Data	NN	O	O
analyzed	NN	O	O
was	NN	O	O
from	NN	O	O
a	NN	O	O
phase	NN	O	O
III	NN	O	O
,	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
DOX	NN	O	B-INT
(	NN	O	O
60	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
)	NN	O	O
or	NN	O	O
PLD	NN	O	B-INT
(	NN	O	O
50	NN	O	O
mg/m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
every	NN	O	O
4	NN	O	O
weeks	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
line	NN	O	O
therapy	NN	O	O
for	NN	O	O
MBC	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
509	NN	O	O
)	NN	O	O
(	NN	O	O
O'Brien	NN	O	O
et	NN	O	O
al	NN	O	O
,	NN	O	O
Ann	NN	O	O
Oncol	NN	O	O
.	NN	O	O

2004	NN	O	O
;	NN	O	O
15:440-449	NN	O	O
)	NN	O	O
.	NN	O	O

NC	NN	O	B-OUT
were	NN	O	O
defined	NN	O	O
as	NN	O	O
an	NN	O	O
absolute	NN	O	B-OUT
neutrophil	NN	O	I-OUT
count	NN	O	I-OUT
<	NN	O	I-OUT
or	NN	O	I-OUT
=1.5	NN	O	I-OUT
x	NN	O	I-OUT
10	NN	O	I-OUT
(	NN	O	I-OUT
9	NN	O	I-OUT
)	NN	O	I-OUT
cells/L	NN	O	I-OUT
(	NN	O	O
ie	NN	O	O
,	NN	O	O
>	NN	O	O
or	NN	O	O
=grade	NN	O	O
II	NN	O	O
)	NN	O	O
before	NN	O	O
the	NN	O	O
next	NN	O	O
cycle	NN	O	O
,	NN	O	O
febrile	NN	O	B-OUT
neutropenia	NN	O	I-OUT
or	NN	O	I-OUT
neutropenia	NN	O	I-OUT
with	NN	O	I-OUT
a	NN	O	I-OUT
documented	NN	O	I-OUT
infection	NN	O	I-OUT
.	NN	O	O

Patient	NN	O	O
and	NN	O	O
hematologic	NN	O	O
factors	NN	O	O
potentially	NN	O	O
associated	NN	O	O
with	NN	O	O
NC	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Factors	NN	O	O
with	NN	O	O
a	NN	O	O
P	NN	O	O
value	NN	O	O
of	NN	O	O
<	NN	O	O
or	NN	O	O
=0.25	NN	O	O
within	NN	O	O
a	NN	O	O
cycle	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
a	NN	O	O
generalized	NN	O	O
estimating	NN	O	O
equations	NN	O	O
regression	NN	O	O
model	NN	O	O
.	NN	O	O

Using	NN	O	O
backward	NN	O	O
elimination	NN	O	O
,	NN	O	O
we	NN	O	O
derived	NN	O	O
a	NN	O	O
risk	NN	O	O
scoring	NN	O	O
algorithm	NN	O	O
(	NN	O	O
range	NN	O	O
0-63	NN	O	O
)	NN	O	O
from	NN	O	O
the	NN	O	O
final	NN	O	O
reduced	NN	O	O
model	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Risk	NN	O	O
factors	NN	O	O
retained	NN	O	O
in	NN	O	O
the	NN	O	O
model	NN	O	O
included	NN	O	O
poor	NN	O	B-OUT
performance	NN	O	I-OUT
status	NN	O	I-OUT
,	NN	O	I-OUT
absolute	NN	O	I-OUT
neutrophil	NN	O	I-OUT
count	NN	O	I-OUT
<	NN	O	I-OUT
or	NN	O	I-OUT
=2.0	NN	O	I-OUT
x	NN	O	I-OUT
10	NN	O	I-OUT
(	NN	O	I-OUT
9	NN	O	I-OUT
)	NN	O	I-OUT
cells/L	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
previous	NN	O	O
cycle	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
cycle	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
DOX	NN	O	B-INT
versus	NN	O	O
PLD	NN	O	B-INT
and	NN	O	O
advanced	NN	O	O
age	NN	O	B-OUT
.	NN	O	O

A	NN	O	O
precycle	NN	O	B-OUT
risk	NN	O	I-OUT
score	NN	O	I-OUT
from	NN	O	O
>	NN	O	O
or	NN	O	O
=25	NN	O	O
to	NN	O	O
<	NN	O	O
40	NN	O	O
for	NN	O	O
a	NN	O	O
given	NN	O	O
patient	NN	O	O
was	NN	O	O
identified	NN	O	O
as	NN	O	O
being	NN	O	O
the	NN	O	O
optimal	NN	O	O
threshold	NN	O	O
for	NN	O	O
sensitivity	NN	O	O
(	NN	O	O
58.0	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
specificity	NN	O	O
(	NN	O	O
78.7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
a	NN	O	O
score	NN	O	O
at	NN	O	O
or	NN	O	O
beyond	NN	O	O
this	NN	O	O
threshold	NN	O	O
would	NN	O	O
be	NN	O	O
considered	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	B-OUT
for	NN	O	O
developing	NN	O	O
NC	NN	O	O
in	NN	O	O
later	NN	O	O
cycles	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
model	NN	O	O
may	NN	O	O
enhance	NN	O	O
patient	NN	O	O
care	NN	O	O
by	NN	O	O
targeting	NN	O	O
preventative	NN	O	O
therapies	NN	O	O
(	NN	O	O
eg	NN	O	O
,	NN	O	O
granulocyte	NN	O	O
colony	NN	O	O
stimulating	NN	O	O
factor	NN	O	O
or	NN	O	O
PLD	NN	O	O
)	NN	O	O
to	NN	O	O
those	NN	O	O
MBC	NN	O	O
patients	NN	O	B-PAR
most	NN	O	O
likely	NN	O	O
to	NN	O	O
experience	NN	O	O
NC	NN	O	B-OUT
during	NN	O	O
anthracycline-based	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O



--DOCSTART-- (18958161)

Neural	NN	O	O
basis	NN	O	O
of	NN	O	O
self	NN	O	O
and	NN	O	O
other	NN	O	O
representation	NN	O	O
in	NN	O	O
autism	NN	O	B-PAR
:	NN	O	O
an	NN	O	O
FMRI	NN	O	O
study	NN	O	O
of	NN	O	O
self-face	NN	O	B-OUT
recognition	NN	O	I-OUT
.	NN	O	O

BACKGROUND	NN	O	O
Autism	NN	O	O
is	NN	O	O
a	NN	O	O
developmental	NN	O	O
disorder	NN	O	O
characterized	NN	O	O
by	NN	O	O
decreased	NN	O	O
interest	NN	O	O
and	NN	O	O
engagement	NN	O	O
in	NN	O	O
social	NN	O	O
interactions	NN	O	O
and	NN	O	O
by	NN	O	O
enhanced	NN	O	O
self-focus	NN	O	O
.	NN	O	O

While	NN	O	O
previous	NN	O	O
theoretical	NN	O	O
approaches	NN	O	O
to	NN	O	O
understanding	NN	O	O
autism	NN	O	O
have	NN	O	O
emphasized	NN	O	O
social	NN	O	O
impairments	NN	O	O
and	NN	O	O
altered	NN	O	O
interpersonal	NN	O	O
interactions	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
recent	NN	O	O
shift	NN	O	O
towards	NN	O	O
understanding	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
the	NN	O	O
representation	NN	O	O
of	NN	O	O
the	NN	O	O
self	NN	O	O
in	NN	O	O
individuals	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Still	NN	O	O
,	NN	O	O
the	NN	O	O
neural	NN	O	O
mechanisms	NN	O	O
subserving	NN	O	O
self-representations	NN	O	O
in	NN	O	O
ASD	NN	O	O
are	NN	O	O
relatively	NN	O	O
unexplored	NN	O	O
.	NN	O	O

METHODOLOGY/PRINCIPAL	NN	O	O
FINDINGS	NN	O	O
We	NN	O	O
used	NN	O	O
event-related	NN	O	O
fMRI	NN	O	O
to	NN	O	O
investigate	NN	O	O
brain	NN	O	B-OUT
responsiveness	NN	O	I-OUT
to	NN	O	O
images	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
'	NN	O	O
own	NN	O	O
face	NN	O	O
and	NN	O	O
to	NN	O	O
faces	NN	O	O
of	NN	O	O
others	NN	O	O
.	NN	O	O

Children	NN	O	B-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	I-PAR
typically	NN	O	I-PAR
developing	NN	O	I-PAR
(	NN	O	I-PAR
TD	NN	O	I-PAR
)	NN	O	I-PAR
children	NN	O	I-PAR
viewed	NN	O	O
randomly	NN	O	O
presented	NN	O	O
digital	NN	O	O
morphs	NN	O	O
between	NN	O	O
their	NN	O	O
own	NN	O	O
face	NN	O	O
and	NN	O	O
a	NN	O	O
gender-matched	NN	O	O
other	NN	O	O
face	NN	O	O
,	NN	O	O
and	NN	O	O
made	NN	O	O
self/other	NN	O	O
judgments	NN	O	O
.	NN	O	O

Both	NN	O	O
groups	NN	O	O
of	NN	O	O
children	NN	O	O
activated	NN	O	O
a	NN	O	O
right	NN	O	B-OUT
premotor/prefrontal	NN	O	I-OUT
system	NN	O	I-OUT
when	NN	O	O
identifying	NN	O	O
images	NN	O	O
containing	NN	O	O
a	NN	O	O
greater	NN	O	O
percentage	NN	O	O
of	NN	O	O
the	NN	O	O
self	NN	O	O
face	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
while	NN	O	O
TD	NN	O	O
children	NN	O	O
showed	NN	O	O
activation	NN	O	O
of	NN	O	O
this	NN	O	O
system	NN	O	O
during	NN	O	O
both	NN	O	O
self-	NN	O	O
and	NN	O	O
other-processing	NN	O	O
,	NN	O	O
children	NN	O	O
with	NN	O	O
ASD	NN	O	O
only	NN	O	O
recruited	NN	O	O
this	NN	O	O
system	NN	O	O
while	NN	O	O
viewing	NN	O	O
images	NN	O	O
containing	NN	O	O
mostly	NN	O	O
their	NN	O	O
own	NN	O	O
face	NN	O	O
.	NN	O	O

CONCLUSIONS/SIGNIFICANCE	NN	O	O
This	NN	O	O
functional	NN	O	O
dissociation	NN	O	O
between	NN	O	O
the	NN	O	O
representation	NN	O	O
of	NN	O	O
self	NN	O	O
versus	NN	O	O
others	NN	O	O
points	NN	O	O
to	NN	O	O
a	NN	O	O
potential	NN	O	O
neural	NN	O	O
substrate	NN	O	O
for	NN	O	O
the	NN	O	O
characteristic	NN	O	O
self-focus	NN	O	O
and	NN	O	O
decreased	NN	O	O
social	NN	O	O
understanding	NN	O	O
exhibited	NN	O	O
by	NN	O	O
these	NN	O	O
individuals	NN	O	O
,	NN	O	O
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
individuals	NN	O	O
with	NN	O	O
ASD	NN	O	O
lack	NN	O	O
the	NN	O	O
shared	NN	O	O
neural	NN	O	O
representations	NN	O	O
for	NN	O	O
self	NN	O	O
and	NN	O	O
others	NN	O	O
that	NN	O	O
TD	NN	O	O
children	NN	O	O
and	NN	O	O
adults	NN	O	O
possess	NN	O	O
and	NN	O	O
may	NN	O	O
use	NN	O	O
to	NN	O	O
understand	NN	O	O
others	NN	O	O
.	NN	O	O



--DOCSTART-- (18975051)

Bolus	NN	O	O
injection	NN	O	O
of	NN	O	O
contrast	NN	O	O
agents	NN	O	O
with	NN	O	O
various	NN	O	O
iodine	NN	O	O
concentrations	NN	O	O
and	NN	O	O
delivery	NN	O	O
rates	NN	O	O
for	NN	O	O
intracranial	NN	O	O
three-dimensional	NN	O	O
CT	NN	O	O
angiography	NN	O	O
:	NN	O	O
evaluation	NN	O	O
of	NN	O	O
intracranial	NN	O	B-OUT
arteriovenous	NN	O	I-OUT
contrast	NN	O	I-OUT
using	NN	O	O
a	NN	O	O
multidetector-row	NN	O	O
CT	NN	O	O
scanner	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
difference	NN	O	B-OUT
in	NN	O	O
computed	NN	O	O
tomography	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
attenuation	NN	O	O
values	NN	O	O
of	NN	O	O
the	NN	O	O
intracranial	NN	O	O
arterial	NN	O	O
and	NN	O	O
venous	NN	O	O
systems	NN	O	O
among	NN	O	O
the	NN	O	O
various	NN	O	O
contrast	NN	O	O
injection	NN	O	O
protocols	NN	O	O
(	NN	O	O
higher	NN	O	O
iodine	NN	O	O
delivery	NN	O	O
rate	NN	O	O
or	NN	O	O
higher	NN	O	O
concentration	NN	O	O
of	NN	O	O
the	NN	O	O
agent	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
source	NN	O	O
images	NN	O	O
of	NN	O	O
intracranial	NN	O	O
three-dimensional	NN	O	O
CT	NN	O	O
angiography	NN	O	O
(	NN	O	O
3D-CTA	NN	O	O
)	NN	O	O
using	NN	O	O
a	NN	O	O
multidetector-row	NN	O	O
CT	NN	O	O
(	NN	O	O
MDCT	NN	O	O
)	NN	O	O
scanner	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
We	NN	O	O
used	NN	O	O
100	NN	O	O
ml	NN	O	O
of	NN	O	O
iopamidol	NN	O	B-INT
300	NN	O	O
at	NN	O	O
an	NN	O	O
injection	NN	O	O
rate	NN	O	O
of	NN	O	O
3.0	NN	O	O
ml/s	NN	O	O
,	NN	O	O
100	NN	O	O
ml	NN	O	O
of	NN	O	O
iopamidol	NN	O	B-INT
300	NN	O	O
at	NN	O	O
an	NN	O	O
injection	NN	O	O
rate	NN	O	O
of	NN	O	O
3.7	NN	O	O
ml/s	NN	O	O
,	NN	O	O
and	NN	O	O
80	NN	O	O
ml	NN	O	O
of	NN	O	O
iopamidol	NN	O	B-INT
370	NN	O	O
at	NN	O	O
an	NN	O	O
injection	NN	O	O
rate	NN	O	O
of	NN	O	O
3.0	NN	O	O
ml/s	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
10	NN	O	B-PAR
patients	NN	O	I-PAR
in	NN	O	I-PAR
each	NN	O	I-PAR
group	NN	O	I-PAR
.	NN	O	O

Attenuation	NN	O	B-OUT
values	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
bilateral	NN	O	I-OUT
internal	NN	O	I-OUT
carotid	NN	O	I-OUT
arteries	NN	O	I-OUT
(	NN	O	I-OUT
ICAs	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
basilar	NN	O	I-OUT
artery	NN	O	I-OUT
trunk	NN	O	I-OUT
,	NN	O	I-OUT
bilateral	NN	O	I-OUT
cavernous	NN	O	I-OUT
sinuses	NN	O	I-OUT
(	NN	O	I-OUT
CSs	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
Galenic	NN	O	I-OUT
vein	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
quantitatively	NN	O	O
on	NN	O	O
the	NN	O	O
axial	NN	O	O
CT	NN	O	O
angiographic	NN	O	O
source	NN	O	O
images	NN	O	O
obtained	NN	O	O
by	NN	O	O
four-channel	NN	O	O
MDCT	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Injection	NN	O	O
of	NN	O	O
the	NN	O	O
high-concentration	NN	O	O
contrast	NN	O	O
with	NN	O	O
a	NN	O	O
higher	NN	O	O
iodine-delivery	NN	O	O
rate	NN	O	O
achieved	NN	O	O
good	NN	O	O
arteriovenous	NN	O	B-OUT
contrast	NN	O	I-OUT
at	NN	O	O
the	NN	O	O
cavernous	NN	O	O
portion	NN	O	O
.	NN	O	O

With	NN	O	O
the	NN	O	O
same	NN	O	O
rate	NN	O	O
of	NN	O	O
iodine	NN	O	O
delivery	NN	O	O
,	NN	O	O
injection	NN	O	O
of	NN	O	O
the	NN	O	O
intermediate	NN	O	O
concentrate	NN	O	O
agent	NN	O	O
increased	NN	O	O
the	NN	O	O
CT	NN	O	B-OUT
value	NN	O	I-OUT
of	NN	O	O
not	NN	O	O
only	NN	O	O
the	NN	O	O
ICAs	NN	O	O
but	NN	O	O
also	NN	O	O
the	NN	O	O
CSs	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
High-concentration	NN	O	O
contrast	NN	O	O
could	NN	O	O
increase	NN	O	O
ICA	NN	O	B-OUT
attenuation	NN	O	I-OUT
without	NN	O	O
intracavernous	NN	O	B-OUT
attenuation	NN	O	I-OUT
gain	NN	O	O
during	NN	O	O
the	NN	O	O
first-pass	NN	O	O
phase	NN	O	O
.	NN	O	O



--DOCSTART-- (19096921)

Trial	NN	O	O
design	NN	O	O
challenges	NN	O	O
when	NN	O	O
combining	NN	O	O
medication	NN	O	B-INT
and	NN	O	O
parent	NN	O	B-INT
training	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
pervasive	NN	O	I-PAR
developmental	NN	O	I-PAR
disorders	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
paper	NN	O	O
presents	NN	O	O
the	NN	O	O
rationale	NN	O	O
for	NN	O	O
a	NN	O	O
24-week	NN	O	O
,	NN	O	O
randomized	NN	O	O
trial	NN	O	O
designed	NN	O	O
to	NN	O	O
test	NN	O	O
whether	NN	O	O
risperidone	NN	O	B-INT
plus	NN	O	O
structured	NN	O	B-INT
parent	NN	O	I-INT
training	NN	O	I-INT
would	NN	O	O
be	NN	O	O
superior	NN	O	O
to	NN	O	O
risperidone	NN	O	B-INT
only	NN	O	O
on	NN	O	O
measures	NN	O	O
of	NN	O	O
noncompliance	NN	O	B-OUT
,	NN	O	I-OUT
irritability	NN	O	I-OUT
and	NN	O	I-OUT
adaptive	NN	O	I-OUT
functioning	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
this	NN	O	O
model	NN	O	O
,	NN	O	O
medication	NN	O	O
reduces	NN	O	O
tantrums	NN	O	B-OUT
,	NN	O	I-OUT
aggression	NN	O	I-OUT
and	NN	O	I-OUT
self-injury	NN	O	I-OUT
;	NN	O	O
parent	NN	O	O
training	NN	O	O
promotes	NN	O	O
improvement	NN	O	O
in	NN	O	O
noncompliance	NN	O	B-OUT
and	NN	O	I-OUT
adaptive	NN	O	I-OUT
functioning	NN	O	I-OUT
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
medication	NN	O	O
and	NN	O	O
parent	NN	O	O
training	NN	O	O
target	NN	O	O
related	NN	O	O
,	NN	O	O
but	NN	O	O
separate	NN	O	O
,	NN	O	O
outcomes	NN	O	O
.	NN	O	O

At	NN	O	O
week	NN	O	O
24	NN	O	O
,	NN	O	O
the	NN	O	O
medication	NN	O	O
was	NN	O	O
gradually	NN	O	O
withdrawn	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
subjects	NN	O	O
in	NN	O	O
the	NN	O	O
combined	NN	O	O
treatment	NN	O	O
group	NN	O	O
could	NN	O	O
be	NN	O	O
managed	NN	O	O
on	NN	O	O
a	NN	O	O
lower	NN	O	O
dose	NN	O	O
or	NN	O	O
off	NN	O	O
medication	NN	O	O
without	NN	O	O
relapse	NN	O	O
.	NN	O	O

Both	NN	O	O
symptom	NN	O	B-OUT
reduction	NN	O	O
and	NN	O	O
functional	NN	O	B-OUT
improvement	NN	O	O
are	NN	O	O
important	NN	O	O
clinical	NN	O	O
treatment	NN	O	O
targets	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
experimental	NN	O	O
evidence	NN	O	O
on	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
combining	NN	O	O
pharmacotherapy	NN	O	O
and	NN	O	O
exportable	NN	O	O
behavioral	NN	O	O
interventions	NN	O	O
is	NN	O	O
needed	NN	O	O
to	NN	O	O
guide	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O



--DOCSTART-- (19108790)

Comparison	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
,	NN	O	O
droperidol	NN	O	B-INT
,	NN	O	O
and	NN	O	O
metoclopramide	NN	O	B-INT
for	NN	O	O
prophylaxis	NN	O	O
of	NN	O	O
postoperative	NN	O	B-OUT
nausea	NN	O	I-OUT
and	NN	O	I-OUT
vomiting	NN	O	I-OUT
after	NN	O	O
breast	NN	O	B-PAR
cancer	NN	O	I-PAR
surgery	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
in	NN	O	O
Japanese	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Breast	NN	O	O
cancer	NN	O	O
surgery	NN	O	O
performed	NN	O	O
with	NN	O	O
the	NN	O	O
patient	NN	O	B-PAR
under	NN	O	I-PAR
general	NN	O	I-PAR
anesthesia	NN	O	I-PAR
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
relatively	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	B-OUT
nausea	NN	O	I-OUT
and	NN	O	I-OUT
vomiting	NN	O	I-OUT
(	NN	O	I-OUT
PONV	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Between	NN	O	O
60	NN	O	O
%	NN	O	O
and	NN	O	O
80	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
undergo	NN	O	O
mastectomy	NN	O	O
(	NN	O	O
with	NN	O	O
axillary	NN	O	O
dissection	NN	O	O
)	NN	O	O
experience	NN	O	O
PONV	NN	O	B-OUT
.	NN	O	O

We	NN	O	O
previously	NN	O	O
reported	NN	O	O
that	NN	O	O
propofol	NN	O	B-INT
at	NN	O	O
a	NN	O	O
subhypnotic	NN	O	O
dose	NN	O	O
of	NN	O	O
0.5	NN	O	O
mg/kg	NN	O	O
was	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
preventing	NN	O	O
PONV	NN	O	B-OUT
in	NN	O	O
women	NN	O	O
who	NN	O	O
undergo	NN	O	O
mastectomy	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
subhypnotic	NN	O	O
dose	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
with	NN	O	O
the	NN	O	O
conventional	NN	O	O
antiemetics	NN	O	O
droperidol	NN	O	B-INT
and	NN	O	O
metoclopramide	NN	O	B-INT
for	NN	O	O
the	NN	O	O
prophylaxis	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
after	NN	O	O
breast	NN	O	B-PAR
cancer	NN	O	I-PAR
surgery	NN	O	I-PAR
in	NN	O	I-PAR
Japanese	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
this	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
,	NN	O	O
Japanese	NN	O	B-PAR
women	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
1	NN	O	O
of	NN	O	O
4	NN	O	O
groups	NN	O	O
to	NN	O	O
receive	NN	O	O
IV	NN	O	O
administration	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
0.5	NN	O	O
mg/kg	NN	O	O
,	NN	O	O
droperidol	NN	O	B-INT
20	NN	O	O
microg/kg	NN	O	O
,	NN	O	O
metoclopramide	NN	O	B-INT
0.2	NN	O	O
mg/kg	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
(	NN	O	I-INT
isotonic	NN	O	I-INT
saline	NN	O	I-INT
)	NN	O	I-INT
immediately	NN	O	O
after	NN	O	O
skin	NN	O	O
suture	NN	O	O
.	NN	O	O

A	NN	O	O
standard	NN	O	O
general	NN	O	O
anesthetic	NN	O	O
technique	NN	O	O
,	NN	O	O
including	NN	O	O
sevoflurane	NN	O	O
and	NN	O	O
air	NN	O	O
in	NN	O	O
oxygen	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

All	NN	O	O
episodes	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
during	NN	O	O
the	NN	O	O
first	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
anesthesia	NN	O	O
administration	NN	O	O
were	NN	O	O
recorded	NN	O	O
by	NN	O	O
an	NN	O	O
investigator	NN	O	O
who	NN	O	O
was	NN	O	O
blinded	NN	O	O
to	NN	O	O
treatment	NN	O	O
assignment	NN	O	O
.	NN	O	O

The	NN	O	O
investigator	NN	O	O
questioned	NN	O	O
the	NN	O	O
patients	NN	O	O
as	NN	O	O
to	NN	O	O
whether	NN	O	O
they	NN	O	O
experienced	NN	O	O
extrapyramidal	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

To	NN	O	O
maintain	NN	O	O
the	NN	O	O
integrity	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
results	NN	O	O
,	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
received	NN	O	O
preanesthetic	NN	O	O
medication	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
100	NN	O	I-PAR
women	NN	O	I-PAR
(	NN	O	I-PAR
mean	NN	O	I-PAR
[	NN	O	I-PAR
SD	NN	O	I-PAR
]	NN	O	I-PAR
age	NN	O	I-PAR
,	NN	O	I-PAR
52	NN	O	I-PAR
[	NN	O	I-PAR
7	NN	O	I-PAR
]	NN	O	I-PAR
years	NN	O	I-PAR
;	NN	O	I-PAR
height	NN	O	I-PAR
,	NN	O	I-PAR
154	NN	O	I-PAR
[	NN	O	I-PAR
6	NN	O	I-PAR
]	NN	O	I-PAR
cm	NN	O	I-PAR
;	NN	O	I-PAR
weight	NN	O	I-PAR
,	NN	O	I-PAR
54	NN	O	I-PAR
[	NN	O	I-PAR
7	NN	O	I-PAR
]	NN	O	I-PAR
kg	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Each	NN	O	O
study	NN	O	O
group	NN	O	O
comprised	NN	O	O
25	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
treatment	NN	O	O
groups	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
patient	NN	O	O
demographics	NN	O	O
,	NN	O	O
surgery	NN	O	O
type	NN	O	O
,	NN	O	O
or	NN	O	O
awakening	NN	O	O
time	NN	O	O
.	NN	O	O

The	NN	O	O
prevalences	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
0	NN	O	O
to	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
anesthesia	NN	O	O
were	NN	O	O
28	NN	O	O
%	NN	O	O
with	NN	O	O
propofol	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.005	NN	O	O
)	NN	O	O
,	NN	O	O
32	NN	O	O
%	NN	O	O
with	NN	O	O
droperidol	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.011	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
60	NN	O	O
%	NN	O	O
with	NN	O	O
metoclopramide	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=	NN	O	O
NS	NN	O	O
)	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
68	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
was	NN	O	O
found	NN	O	O
between	NN	O	O
patients	NN	O	O
receiving	NN	O	O
propofol	NN	O	B-INT
and	NN	O	O
those	NN	O	O
receiving	NN	O	O
droperidol	NN	O	B-INT
,	NN	O	O
and	NN	O	O
propofol	NN	O	B-INT
and	NN	O	O
droperidol	NN	O	B-INT
were	NN	O	O
associated	NN	O	O
with	NN	O	O
significantly	NN	O	O
lower	NN	O	O
prevalences	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
compared	NN	O	O
with	NN	O	O
metoclopramide	NN	O	B-INT
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.022	NN	O	O
and	NN	O	O
P	NN	O	O
=	NN	O	O
0.043	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	B-OUT
symptoms	NN	O	I-OUT
were	NN	O	O
not	NN	O	O
reported	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
prevalences	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
propofol	NN	O	B-INT
0.5	NN	O	O
mg/kg	NN	O	O
and	NN	O	O
droperidol	NN	O	B-INT
20	NN	O	O
microg/kg	NN	O	O
0	NN	O	O
to	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
anesthesia	NN	O	O
in	NN	O	O
this	NN	O	O
small	NN	O	O
,	NN	O	O
select	NN	O	O
group	NN	O	O
of	NN	O	O
Japanese	NN	O	O
women	NN	O	O
who	NN	O	O
underwent	NN	O	O
breast	NN	O	O
cancer	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
prevalences	NN	O	O
of	NN	O	O
PONV	NN	O	B-OUT
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
with	NN	O	O
propofol	NN	O	B-INT
and	NN	O	O
droperidol	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
metoclopramide	NN	O	B-INT
0.2	NN	O	O
mg/kg	NN	O	O
and	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (19159999)

To	NN	O	O
compare	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
nifedipine	NN	O	B-INT
sustained	NN	O	I-INT
release	NN	O	I-INT
with	NN	O	O
Ginkgo	NN	O	B-INT
biloba	NN	O	I-INT
extract	NN	O	I-INT
to	NN	O	O
treat	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
Raynaud	NN	O	I-PAR
's	NN	O	I-PAR
phenomenon	NN	O	I-PAR
in	NN	O	I-PAR
South	NN	O	I-PAR
Korea	NN	O	I-PAR
;	NN	O	O
Korean	NN	O	O
Raynaud	NN	O	O
study	NN	O	O
(	NN	O	O
KOARA	NN	O	O
study	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
of	NN	O	O
nifedipine	NN	O	B-INT
sustained	NN	O	I-INT
release	NN	O	I-INT
(	NN	O	O
nifedipine	NN	O	B-INT
SR	NN	O	I-INT
)	NN	O	O
compared	NN	O	O
with	NN	O	O
Ginkgo	NN	O	B-INT
biloba	NN	O	I-INT
extract	NN	O	I-INT
as	NN	O	O
treatment	NN	O	O
for	NN	O	O
primary	NN	O	O
Raynaud	NN	O	O
's	NN	O	O
phenomenon	NN	O	O
(	NN	O	O
RP	NN	O	O
)	NN	O	O
in	NN	O	O
Korea	NN	O	O
.	NN	O	O

Primary	NN	O	O
RP	NN	O	O
were	NN	O	O
screened	NN	O	O
and	NN	O	O
assigned	NN	O	O
to	NN	O	O
either	NN	O	O
the	NN	O	O
nifedipine	NN	O	B-INT
SR	NN	O	I-INT
group	NN	O	O
(	NN	O	O
Group	NN	O	O
N	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
Ginkgo	NN	O	B-INT
biloba	NN	O	I-INT
extract	NN	O	I-INT
group	NN	O	O
(	NN	O	O
Group	NN	O	O
G	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
ratio	NN	O	O
of	NN	O	O
2:1	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
run-in	NN	O	O
period	NN	O	O
of	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
patients	NN	O	O
received	NN	O	O
treatment	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
the	NN	O	O
percent	NN	O	B-OUT
improvement	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
RP	NN	O	I-OUT
attack	NN	O	I-OUT
rate	NN	O	I-OUT
between	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
8-week	NN	O	O
treatment	NN	O	O
.	NN	O	O

Ninety-three	NN	O	B-PAR
subjects	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
.	NN	O	O

The	NN	O	O
percent	NN	O	O
improvement	NN	O	O
in	NN	O	O
Group	NN	O	O
N	NN	O	O
was	NN	O	O
50.1	NN	O	O
%	NN	O	O
at	NN	O	O
8	NN	O	O
weeks	NN	O	O
after	NN	O	O
treatment	NN	O	O
,	NN	O	O
while	NN	O	O
it	NN	O	O
was	NN	O	O
31.0	NN	O	O
%	NN	O	O
in	NN	O	O
Group	NN	O	O
G	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
serious	NN	O	B-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
occurred	NN	O	O
,	NN	O	O
and	NN	O	O
almost	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
were	NN	O	O
mild	NN	O	O
and	NN	O	O
improved	NN	O	O
without	NN	O	O
specific	NN	O	O
treatment	NN	O	O
.	NN	O	O

nifedipine	NN	O	B-INT
SR	NN	O	I-INT
was	NN	O	O
more	NN	O	O
effective	NN	O	B-OUT
than	NN	O	O
Ginkgo	NN	O	B-INT
biloba	NN	O	I-INT
extract	NN	O	I-INT
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
primary	NN	O	O
RP	NN	O	O
in	NN	O	O
Korean	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

Both	NN	O	O
drugs	NN	O	O
were	NN	O	O
tolerable	NN	O	B-OUT
with	NN	O	O
primary	NN	O	O
RP	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (19301724)

A	NN	O	O
comparison	NN	O	O
of	NN	O	O
continuous	NN	O	B-INT
femoral	NN	O	I-INT
nerve	NN	O	I-INT
block	NN	O	I-INT
(	NN	O	I-INT
CFNB	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
continuous	NN	O	B-INT
epidural	NN	O	I-INT
infusion	NN	O	I-INT
(	NN	O	I-INT
CEI	NN	O	I-INT
)	NN	O	I-INT
in	NN	O	O
postoperative	NN	O	O
analgesia	NN	O	O
and	NN	O	O
knee	NN	O	O
rehabilitation	NN	O	O
after	NN	O	O
total	NN	O	B-PAR
knee	NN	O	I-PAR
arthroplasty	NN	O	I-PAR
(	NN	O	I-PAR
TKA	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Postoperative	NN	O	O
epidural	NN	O	O
analgesia	NN	O	O
(	NN	O	O
EA	NN	O	O
)	NN	O	O
and	NN	O	O
femoral	NN	O	B-INT
nerve	NN	O	I-INT
block	NN	O	I-INT
(	NN	O	I-INT
FNB	NN	O	I-INT
)	NN	O	I-INT
provided	NN	O	O
effective	NN	O	O
pain	NN	O	O
relief	NN	O	O
However	NN	O	O
,	NN	O	O
EA	NN	O	O
has	NN	O	O
common	NN	O	O
side	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
nausea	NN	O	O
,	NN	O	O
vomiting	NN	O	O
,	NN	O	O
pruritus	NN	O	O
,	NN	O	O
dizziness	NN	O	O
,	NN	O	O
and	NN	O	O
hypotension	NN	O	O
.	NN	O	O

Some	NN	O	O
investigations	NN	O	O
found	NN	O	O
that	NN	O	O
those	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
less	NN	O	O
in	NN	O	O
FNB	NN	O	O
than	NN	O	O
in	NN	O	O
EA	NN	O	O
.	NN	O	O

However	NN	O	O
the	NN	O	O
analgesic	NN	O	O
equivalent	NN	O	O
of	NN	O	O
both	NN	O	O
techniques	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
confirmed	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
authors	NN	O	O
compared	NN	O	O
continuous	NN	O	B-INT
epidural	NN	O	I-INT
infusion	NN	O	I-INT
(	NN	O	I-INT
CEI	NN	O	I-INT
)	NN	O	I-INT
with	NN	O	O
continuous	NN	O	B-INT
femoral	NN	O	I-INT
nerve	NN	O	I-INT
block	NN	O	I-INT
(	NN	O	I-INT
CFNB	NN	O	I-INT
)	NN	O	I-INT
regarding	NN	O	O
the	NN	O	O
postoperative	NN	O	B-OUT
analgesic	NN	O	I-OUT
efficacy	NN	O	I-OUT
,	NN	O	I-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
,	NN	O	I-OUT
postoperative	NN	O	I-OUT
knee	NN	O	I-OUT
rehabilitation	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
hospital	NN	O	I-OUT
length	NN	O	I-OUT
of	NN	O	I-OUT
stay	NN	O	I-OUT
(	NN	O	I-OUT
LOS	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHOD	NN	O	O
In	NN	O	O
this	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
study	NN	O	O
,	NN	O	O
61	NN	O	B-PAR
ASA	NN	O	I-PAR
physical	NN	O	I-PAR
status	NN	O	I-PAR
I-III	NN	O	I-PAR
patients	NN	O	I-PAR
scheduled	NN	O	I-PAR
for	NN	O	I-PAR
elective	NN	O	I-PAR
unilateral	NN	O	I-PAR
total	NN	O	I-PAR
knee	NN	O	I-PAR
arthroplasty	NN	O	I-PAR
(	NN	O	I-PAR
TKA	NN	O	I-PAR
)	NN	O	I-PAR
under	NN	O	I-PAR
spinal	NN	O	I-PAR
anesthesia	NN	O	I-PAR
(	NN	O	I-PAR
SA	NN	O	I-PAR
)	NN	O	I-PAR
participated	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
allocated	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
ward	NN	O	O
,	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
I	NN	O	O
(	NN	O	O
CEI	NN	O	B-INT
)	NN	O	O
were	NN	O	O
maintained	NN	O	O
by	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
0.125	NN	O	O
%	NN	O	O
levobupivacaine	NN	O	B-INT
with	NN	O	O
morphine	NN	O	B-INT
0.0125	NN	O	O
mg/ml	NN	O	O
(	NN	O	O
4	NN	O	O
ml/hr	NN	O	O
)	NN	O	O
,	NN	O	O
Group	NN	O	O
II	NN	O	O
(	NN	O	O
CFNB	NN	O	B-INT
)	NN	O	O
were	NN	O	O
maintained	NN	O	O
by	NN	O	O
0.125	NN	O	O
%	NN	O	O
levobupivacaine	NN	O	B-INT
(	NN	O	O
8	NN	O	O
ml/hr	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Patients	NN	O	O
in	NN	O	O
the	NN	O	O
CFNB	NN	O	B-INT
group	NN	O	O
,	NN	O	O
the	NN	O	O
VAS	NN	O	B-OUT
scores	NN	O	I-OUT
at	NN	O	O
PO6-12	NN	O	O
hr	NN	O	O
and	NN	O	O
tramadol	NN	O	B-OUT
IV	NN	O	I-OUT
requirement	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
than	NN	O	O
the	NN	O	O
CEI	NN	O	B-INT
group	NN	O	O
(	NN	O	O
VAS	NN	O	O
:	NN	O	O
PO6	NN	O	O
hr	NN	O	O
p-value	NN	O	O
=	NN	O	O
0.001	NN	O	O
,	NN	O	O
PO12	NN	O	O
hr	NN	O	O
p-value	NN	O	O
=	NN	O	O
0.004	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
CEI	NN	O	B-INT
group	NN	O	O
experienced	NN	O	O
dizziness	NN	O	B-OUT
,	NN	O	I-OUT
pruritus	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
PONV	NN	O	I-OUT
more	NN	O	O
than	NN	O	O
the	NN	O	O
CFNB	NN	O	B-INT
group	NN	O	O
significantly	NN	O	O
.	NN	O	O

Patient	NN	O	B-OUT
satisfaction	NN	O	I-OUT
was	NN	O	O
greater	NN	O	O
with	NN	O	O
the	NN	O	O
CFNB	NN	O	B-INT
group	NN	O	O
although	NN	O	O
postoperative	NN	O	B-OUT
knee	NN	O	I-OUT
rehabilitation	NN	O	I-OUT
and	NN	O	O
the	NN	O	O
hospital	NN	O	B-OUT
LOS	NN	O	I-OUT
were	NN	O	O
not	NN	O	O
different	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
CFNB	NN	O	B-INT
represents	NN	O	O
the	NN	O	O
optimal	NN	O	O
analgesia	NN	O	O
with	NN	O	O
fewer	NN	O	O
side	NN	O	B-OUT
effects	NN	O	I-OUT
and	NN	O	O
greater	NN	O	O
patient	NN	O	B-OUT
,	NN	O	I-OUT
satisfaction	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
rehabilitation	NN	O	B-OUT
indices	NN	O	I-OUT
and	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
hospital	NN	O	I-OUT
stay	NN	O	I-OUT
are	NN	O	O
comparable	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O



--DOCSTART-- (19376304)

Rationale	NN	O	O
and	NN	O	O
design	NN	O	O
of	NN	O	O
RE-LY	NN	O	O
:	NN	O	O
randomized	NN	O	O
evaluation	NN	O	O
of	NN	O	O
long-term	NN	O	O
anticoagulant	NN	O	O
therapy	NN	O	O
,	NN	O	O
warfarin	NN	O	B-INT
,	NN	O	O
compared	NN	O	O
with	NN	O	O
dabigatran	NN	O	B-INT
.	NN	O	O

Vitamin	NN	O	O
K	NN	O	O
antagonists	NN	O	O
(	NN	O	O
VKAs	NN	O	O
)	NN	O	O
are	NN	O	O
effective	NN	O	O
for	NN	O	O
stroke	NN	O	O
prevention	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
atrial	NN	O	I-PAR
fibrillation	NN	O	I-PAR
(	NN	O	I-PAR
AF	NN	O	I-PAR
)	NN	O	I-PAR
but	NN	O	O
are	NN	O	O
difficult	NN	O	O
to	NN	O	O
use	NN	O	O
.	NN	O	O

Dabigatran	NN	O	B-INT
etexilate	NN	O	I-INT
is	NN	O	O
a	NN	O	O
prodrug	NN	O	O
that	NN	O	O
is	NN	O	O
rapidly	NN	O	O
converted	NN	O	O
to	NN	O	O
the	NN	O	O
active	NN	O	O
direct	NN	O	O
thrombin	NN	O	O
inhibitor	NN	O	O
dabigatran	NN	O	B-INT
.	NN	O	O

It	NN	O	O
is	NN	O	O
administered	NN	O	O
in	NN	O	O
a	NN	O	O
fixed	NN	O	O
dose	NN	O	O
without	NN	O	O
laboratory	NN	O	O
monitoring	NN	O	O
and	NN	O	O
is	NN	O	O
being	NN	O	O
compared	NN	O	O
with	NN	O	O
warfarin	NN	O	B-INT
(	NN	O	O
international	NN	O	O
normalized	NN	O	O
ratio	NN	O	O
2-3	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
RE-LY	NN	O	O
trial	NN	O	O
.	NN	O	O

Two	NN	O	O
doses	NN	O	O
of	NN	O	O
dabigatran	NN	O	B-INT
(	NN	O	O
110	NN	O	O
and	NN	O	O
150	NN	O	O
mg	NN	O	O
BID	NN	O	O
)	NN	O	O
are	NN	O	O
being	NN	O	O
evaluated	NN	O	O
.	NN	O	O

RE-LY	NN	O	O
is	NN	O	O
a	NN	O	O
phase	NN	O	O
3	NN	O	O
,	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
open-label	NN	O	O
multinational	NN	O	O
(	NN	O	O
44	NN	O	O
countries	NN	O	O
)	NN	O	O
trial	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
nonvalvular	NN	O	I-PAR
AF	NN	O	I-PAR
and	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
1	NN	O	I-PAR
risk	NN	O	I-PAR
factor	NN	O	I-PAR
for	NN	O	I-PAR
stroke	NN	O	I-PAR
.	NN	O	O

Recruitment	NN	O	O
concluded	NN	O	O
with	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
18,113	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

Patients	NN	O	B-PAR
who	NN	O	I-PAR
were	NN	O	I-PAR
VKA-naive	NN	O	I-PAR
and	NN	O	I-PAR
experienced	NN	O	I-PAR
are	NN	O	I-PAR
included	NN	O	I-PAR
in	NN	O	I-PAR
balanced	NN	O	I-PAR
proportions	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
is	NN	O	O
stroke	NN	O	B-OUT
(	NN	O	I-OUT
including	NN	O	I-OUT
hemorrhagic	NN	O	I-OUT
)	NN	O	I-OUT
or	NN	O	O
systemic	NN	O	B-OUT
embolism	NN	O	I-OUT
.	NN	O	O

Safety	NN	O	O
outcomes	NN	O	O
are	NN	O	O
bleeding	NN	O	B-OUT
,	NN	O	I-OUT
liver	NN	O	I-OUT
function	NN	O	I-OUT
abnormalities	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
other	NN	O	I-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
.	NN	O	O

Adjudication	NN	O	O
of	NN	O	O
end	NN	O	O
points	NN	O	O
is	NN	O	O
blinded	NN	O	O
to	NN	O	O
drug	NN	O	O
assignment	NN	O	O
.	NN	O	O

The	NN	O	O
trial	NN	O	O
is	NN	O	O
expected	NN	O	O
to	NN	O	O
accrue	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
450	NN	O	O
events	NN	O	O
with	NN	O	O
a	NN	O	O
minimum	NN	O	O
1-year	NN	O	O
of	NN	O	O
follow-up	NN	O	O
.	NN	O	O

RE-LY	NN	O	O
is	NN	O	O
the	NN	O	O
largest	NN	O	O
AF	NN	O	O
stroke	NN	O	O
prevention	NN	O	O
trial	NN	O	O
yet	NN	O	O
undertaken	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
unique	NN	O	O
because	NN	O	O
it	NN	O	O
includes	NN	O	O
equal	NN	O	O
numbers	NN	O	O
of	NN	O	O
VKA-experienced	NN	O	O
and	NN	O	O
naive	NN	O	O
patients	NN	O	O
and	NN	O	O
evaluates	NN	O	O
2	NN	O	O
different	NN	O	O
dosages	NN	O	O
of	NN	O	O
dabigatran	NN	O	B-INT
,	NN	O	O
which	NN	O	O
may	NN	O	O
allow	NN	O	O
tailoring	NN	O	O
of	NN	O	O
dosing	NN	O	O
to	NN	O	O
individual	NN	O	O
patient	NN	O	O
needs	NN	O	O
.	NN	O	O

The	NN	O	O
worldwide	NN	O	O
site	NN	O	O
distribution	NN	O	O
and	NN	O	O
broad	NN	O	O
range	NN	O	O
of	NN	O	O
stroke	NN	O	O
risk	NN	O	O
further	NN	O	O
increase	NN	O	O
the	NN	O	O
general	NN	O	O
applicability	NN	O	O
of	NN	O	O
the	NN	O	O
trial	NN	O	O
.	NN	O	O

Results	NN	O	O
are	NN	O	O
expected	NN	O	O
in	NN	O	O
2009	NN	O	O
.	NN	O	O



--DOCSTART-- (1963383)

[	NN	O	O
Effect	NN	O	O
of	NN	O	O
liu	NN	O	B-INT
wei	NN	O	I-INT
di	NN	O	I-INT
huang	NN	O	I-INT
or	NN	O	O
jin	NN	O	B-INT
gui	NN	O	I-INT
shen	NN	O	I-INT
qi	NN	O	I-INT
decoction	NN	O	O
as	NN	O	O
on	NN	O	O
adjuvant	NN	O	O
treatment	NN	O	O
in	NN	O	O
small	NN	O	B-PAR
cell	NN	O	I-PAR
lung	NN	O	I-PAR
cancer	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

Eighty-three	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
small	NN	O	I-PAR
cell	NN	O	I-PAR
lung	NN	O	I-PAR
cancer	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
using	NN	O	O
a	NN	O	O
traditional	NN	O	O
Chinese	NN	O	O
Kidney-tonifying	NN	O	B-INT
decoction	NN	O	I-INT
(	NN	O	O
Liu	NN	O	B-INT
Wei	NN	O	I-INT
Di	NN	O	I-INT
Huang	NN	O	I-INT
or	NN	O	O
Jin	NN	O	B-INT
Gui	NN	O	I-INT
Shen	NN	O	I-INT
Qi	NN	O	I-INT
medicinal	NN	O	O
decoction	NN	O	O
)	NN	O	O
in	NN	O	O
chemotherapy	NN	O	O
or	NN	O	O
radiotherapy	NN	O	O
courses	NN	O	O
.	NN	O	O

74	NN	O	B-PAR
patients	NN	O	I-PAR
were	NN	O	O
availble	NN	O	O
to	NN	O	O
be	NN	O	O
analysis	NN	O	O
.	NN	O	O

The	NN	O	O
two	NN	O	O
treatment	NN	O	O
groups	NN	O	O
were	NN	O	O
well-matched	NN	O	O
in	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
stage	NN	O	O
and	NN	O	O
performance	NN	O	O
status	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
response	NN	O	B-OUT
rate	NN	O	I-OUT
and	NN	O	I-OUT
the	NN	O	I-OUT
median	NN	O	I-OUT
survival	NN	O	I-OUT
between	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	B-OUT
response	NN	O	I-OUT
rate	NN	O	I-OUT
(	NN	O	O
CR+PR	NN	O	O
)	NN	O	O
was	NN	O	O
91.5	NN	O	O
%	NN	O	O
for	NN	O	O
Chinese	NN	O	B-INT
herb	NN	O	I-INT
group	NN	O	O
and	NN	O	O
46.9	NN	O	O
%	NN	O	O
for	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	B-OUT
survival	NN	O	I-OUT
was	NN	O	O
16	NN	O	O
months	NN	O	O
for	NN	O	O
the	NN	O	O
traditional	NN	O	O
Chinese	NN	O	O
Kidney-tonifying	NN	O	B-INT
decoction	NN	O	I-INT
group	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
months	NN	O	O
for	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Survival	NN	O	B-OUT
curve	NN	O	I-OUT
(	NN	O	I-OUT
Kaplan-meire	NN	O	I-OUT
's	NN	O	I-OUT
)	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
Chinese	NN	O	O
herb	NN	O	O
group	NN	O	O
was	NN	O	O
better	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

10	NN	O	O
patients	NN	O	O
of	NN	O	O
Chinese	NN	O	B-INT
herb	NN	O	I-INT
group	NN	O	O
was	NN	O	O
alive	NN	O	O
beyond	NN	O	O
more	NN	O	O
than	NN	O	O
2	NN	O	O
years	NN	O	O
.	NN	O	O

Until	NN	O	O
now	NN	O	O
,	NN	O	O
4	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
Chinese	NN	O	B-INT
herb	NN	O	I-INT
group	NN	O	O
,	NN	O	O
one	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
are	NN	O	O
still	NN	O	O
enjoying	NN	O	O
their	NN	O	O
disease-free	NN	O	B-OUT
life	NN	O	I-OUT
for	NN	O	O
more	NN	O	O
than	NN	O	O
7	NN	O	O
years	NN	O	O
.	NN	O	O

Hematologic	NN	O	B-OUT
toxicities	NN	O	I-OUT
were	NN	O	O
observed	NN	O	O
much	NN	O	O
frequently	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.005	NN	O	O
and	NN	O	O
0.01/WBC	NN	O	O
and	NN	O	O
BPC	NN	O	O
)	NN	O	O
.	NN	O	O

Results	NN	O	O
of	NN	O	O
animal	NN	O	O
experiments	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
traditional	NN	O	O
medicinal	NN	O	O
decoctions	NN	O	O
as	NN	O	O
used	NN	O	O
in	NN	O	O
clinic	NN	O	O
have	NN	O	O
showed	NN	O	O
immuno-enhancement	NN	O	B-OUT
activities	NN	O	I-OUT
.	NN	O	O

These	NN	O	O
results	NN	O	O
have	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
traditional	NN	O	O
Chinese	NN	O	B-INT
Kidney-tonifying	NN	O	I-INT
decoction	NN	O	I-INT
may	NN	O	O
enhance	NN	O	O
non-specific	NN	O	O
immunology	NN	O	O
activities	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
much	NN	O	O
useful	NN	O	O
for	NN	O	O
solid	NN	O	B-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
as	NN	O	O
an	NN	O	O
adjuvant	NN	O	O
treatment	NN	O	O
.	NN	O	O



--DOCSTART-- (1968178)

Effects	NN	O	O
of	NN	O	O
cuff	NN	O	O
inflation	NN	O	O
on	NN	O	O
self-recorded	NN	O	B-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
continuously	NN	O	O
recorded	NN	O	O
'Finapres	NN	O	B-OUT
'	NN	O	I-OUT
finger	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
in	NN	O	O
ten	NN	O	B-PAR
normotensive	NN	O	I-PAR
and	NN	O	I-PAR
seven	NN	O	I-PAR
hypertensive	NN	O	I-PAR
subjects	NN	O	I-PAR
induced	NN	O	O
by	NN	O	O
self-inflation	NN	O	B-INT
of	NN	O	I-INT
the	NN	O	I-INT
cuff	NN	O	I-INT
or	NN	O	O
just	NN	O	B-INT
wearing	NN	O	I-INT
the	NN	O	I-INT
inflated	NN	O	I-INT
cuff	NN	O	I-INT
were	NN	O	O
studied	NN	O	O
.	NN	O	O

Inflating	NN	O	B-INT
the	NN	O	I-INT
cuff	NN	O	I-INT
caused	NN	O	O
an	NN	O	O
instantaneous	NN	O	O
rise	NN	O	O
in	NN	O	O
systolic	NN	O	B-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
of	NN	O	O
13	NN	O	O
and	NN	O	O
12	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
hypertensive	NN	O	O
and	NN	O	O
normotensive	NN	O	O
subjects	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Wearing	NN	O	O
the	NN	O	O
inflated	NN	O	B-INT
cuff	NN	O	I-INT
did	NN	O	O
not	NN	O	O
change	NN	O	O
blood	NN	O	B-OUT
pressure	NN	O	I-OUT
.	NN	O	O

Thus	NN	O	O
the	NN	O	O
rise	NN	O	O
in	NN	O	O
pressure	NN	O	B-OUT
was	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
muscular	NN	O	O
activity	NN	O	O
required	NN	O	O
for	NN	O	O
cuff	NN	O	B-INT
inflation	NN	O	I-INT
.	NN	O	O

Systolic	NN	O	B-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
took	NN	O	O
on	NN	O	O
average	NN	O	O
7	NN	O	O
s	NN	O	O
and	NN	O	O
at	NN	O	O
most	NN	O	O
21	NN	O	O
s	NN	O	O
to	NN	O	O
return	NN	O	O
to	NN	O	O
baseline	NN	O	O
level	NN	O	O
after	NN	O	O
stopping	NN	O	O
cuff	NN	O	O
inflation	NN	O	O
.	NN	O	O

Since	NN	O	O
first	NN	O	O
Korotkoff	NN	O	O
sounds	NN	O	O
may	NN	O	O
already	NN	O	O
be	NN	O	O
heard	NN	O	O
after	NN	O	O
10-15	NN	O	O
s	NN	O	O
when	NN	O	O
following	NN	O	O
recommended	NN	O	O
procedures	NN	O	O
,	NN	O	O
self-recorded	NN	O	B-OUT
systolic	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
may	NN	O	O
be	NN	O	O
recorded	NN	O	O
as	NN	O	O
too	NN	O	O
high	NN	O	O
when	NN	O	O
subjects	NN	O	O
inflate	NN	O	O
their	NN	O	O
cuff	NN	O	O
at	NN	O	O
too	NN	O	O
low	NN	O	O
a	NN	O	O
pressure	NN	O	O
or	NN	O	O
deflate	NN	O	O
it	NN	O	O
too	NN	O	O
fast	NN	O	O
.	NN	O	O



--DOCSTART-- (19708562)

[	NN	O	O
Effect	NN	O	O
of	NN	O	O
transcranial	NN	O	B-INT
electrostimulation	NN	O	I-INT
on	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
characteristics	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
gastric	NN	O	I-PAR
ulcer	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
included	NN	O	O
100	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
gastric	NN	O	I-PAR
ulcer	NN	O	I-PAR
aged	NN	O	I-PAR
from	NN	O	I-PAR
16	NN	O	I-PAR
to	NN	O	I-PAR
60	NN	O	I-PAR
years	NN	O	I-PAR
.	NN	O	O

In	NN	O	O
58	NN	O	O
patients	NN	O	O
,	NN	O	O
traditional	NN	O	B-INT
treatment	NN	O	I-INT
was	NN	O	O
supplemented	NN	O	O
by	NN	O	O
transcranial	NN	O	B-INT
electrotherapy	NN	O	I-INT
using	NN	O	O
a	NN	O	O
TRANSAIR-02	NN	O	O
apparatus	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
studies	NN	O	O
included	NN	O	O
measurements	NN	O	O
of	NN	O	O
lactoferrin	NN	O	B-OUT
(	NN	O	I-OUT
LF	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
tumour	NN	O	B-OUT
necrosis	NN	O	I-OUT
factor-alpha	NN	O	I-OUT
(	NN	O	I-OUT
TNF-alpha	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
besides	NN	O	O
standard	NN	O	O
analyses	NN	O	O
.	NN	O	O

Combined	NN	O	O
treatment	NN	O	O
(	NN	O	B-INT
traditional	NN	O	I-INT
therapy	NN	O	I-INT
plus	NN	O	I-INT
electrostimulation	NN	O	I-INT
)	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
main	NN	O	I-OUT
symptoms	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
gastric	NN	O	B-PAR
ulcer	NN	O	I-PAR
depending	NN	O	O
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
ulceration	NN	O	O
process	NN	O	O
,	NN	O	O
patients	NN	O	O
'	NN	O	O
age	NN	O	O
and	NN	O	O
sex	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
it	NN	O	O
facilitated	NN	O	O
ulcer	NN	O	B-OUT
scarring	NN	O	I-OUT
and	NN	O	O
had	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
on	NN	O	O
dynamics	NN	O	O
of	NN	O	O
serum	NN	O	B-OUT
LF	NN	O	I-OUT
and	NN	O	I-OUT
TNF-alpha	NN	O	I-OUT
levels	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (19727232)

[	NN	O	O
Effects	NN	O	O
of	NN	O	O
auditory	NN	O	B-INT
integrative	NN	O	I-INT
training	NN	O	I-INT
on	NN	O	O
autistic	NN	O	B-PAR
children	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
explore	NN	O	O
the	NN	O	O
short-term	NN	O	O
treatment	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
auditory	NN	O	B-INT
integrative	NN	O	I-INT
training	NN	O	I-INT
on	NN	O	O
autistic	NN	O	B-PAR
children	NN	O	I-PAR
and	NN	O	O
provide	NN	O	O
them	NN	O	O
with	NN	O	O
clinical	NN	O	O
support	NN	O	O
for	NN	O	O
rehabilitative	NN	O	O
treatment	NN	O	O
.	NN	O	O

METHODS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
81	NN	O	I-PAR
cases	NN	O	I-PAR
of	NN	O	I-PAR
autistic	NN	O	I-PAR
children	NN	O	I-PAR
were	NN	O	O
selected	NN	O	O
through	NN	O	O
the	NN	O	O
standard	NN	O	O
of	NN	O	O
DSM-4	NN	O	O
and	NN	O	O
clinical	NN	O	O
case	NN	O	O
study	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
divided	NN	O	O
randomly	NN	O	O
into	NN	O	O
experimental	NN	O	O
group	NN	O	O
and	NN	O	O
control	NN	O	O
one	NN	O	O
,	NN	O	O
and	NN	O	O
respectively	NN	O	O
received	NN	O	O
auditory	NN	O	B-INT
integrative	NN	O	I-INT
training	NN	O	I-INT
and	NN	O	O
no	NN	O	O
training	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
multiple	NN	O	O
therapies	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
investigated	NN	O	O
using	NN	O	O
clinical	NN	O	B-OUT
manifestation	NN	O	I-OUT
and	NN	O	O
Autism	NN	O	B-OUT
Behavior	NN	O	I-OUT
Checklist	NN	O	I-OUT
(	NN	O	I-OUT
ABC	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
intelligence	NN	O	B-OUT
quotient	NN	O	I-OUT
(	NN	O	I-OUT
IQ	NN	O	I-OUT
)	NN	O	I-OUT
before	NN	O	O
and	NN	O	O
after	NN	O	O
six	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
was	NN	O	O
evaluated	NN	O	O
through	NN	O	O
the	NN	O	O
changes	NN	O	B-OUT
of	NN	O	I-OUT
clinical	NN	O	I-OUT
manifestations	NN	O	I-OUT
and	NN	O	O
scores	NN	O	O
of	NN	O	O
ABC	NN	O	B-OUT
and	NN	O	O
IQ	NN	O	B-OUT
.	NN	O	O

The	NN	O	O
changes	NN	O	O
of	NN	O	O
scores	NN	O	O
of	NN	O	O
IQ	NN	O	B-OUT
were	NN	O	O
determined	NN	O	O
with	NN	O	O
Gesell	NN	O	O
and	NN	O	O
WPPSI	NN	O	O
or	NN	O	O
WISC-R	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Compared	NN	O	O
with	NN	O	O
40	NN	O	O
patients	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
after	NN	O	O
the	NN	O	O
six	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
auditory	NN	O	B-INT
integrative	NN	O	I-INT
training	NN	O	I-INT
,	NN	O	O
41	NN	O	O
of	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
had	NN	O	O
greatly	NN	O	O
improved	NN	O	O
in	NN	O	O
many	NN	O	O
aspects	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
disorders	NN	O	B-OUT
of	NN	O	I-OUT
their	NN	O	I-OUT
language	NN	O	I-OUT
,	NN	O	I-OUT
social	NN	O	I-OUT
interactions	NN	O	I-OUT
and	NN	O	I-OUT
typical	NN	O	I-OUT
behavior	NN	O	I-OUT
symptoms	NN	O	I-OUT
while	NN	O	O
they	NN	O	O
had	NN	O	O
not	NN	O	O
changed	NN	O	O
in	NN	O	O
their	NN	O	O
abnormal	NN	O	B-OUT
behaviors	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
scores	NN	O	B-OUT
of	NN	O	I-OUT
IQ	NN	O	I-OUT
or	NN	O	I-OUT
DQ	NN	O	I-OUT
had	NN	O	O
increased	NN	O	O
and	NN	O	O
scores	NN	O	O
of	NN	O	O
ABC	NN	O	B-OUT
had	NN	O	O
dropped	NN	O	O
.	NN	O	O

The	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
greatly	NN	O	O
significant	NN	O	O
in	NN	O	O
statistics	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
decreasing	NN	O	O
level	NN	O	O
of	NN	O	O
both	NN	O	O
ABC	NN	O	B-OUT
scores	NN	O	I-OUT
and	NN	O	O
the	NN	O	O
increasing	NN	O	O
level	NN	O	O
of	NN	O	O
the	NN	O	O
IQ	NN	O	B-OUT
scores	NN	O	I-OUT
were	NN	O	O
negatively	NN	O	O
correlated	NN	O	O
with	NN	O	O
age	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
decreasing	NN	O	O
level	NN	O	O
of	NN	O	O
ABC	NN	O	B-OUT
scores	NN	O	I-OUT
was	NN	O	O
in	NN	O	O
line	NN	O	O
regression	NN	O	O
(	NN	O	O
positive	NN	O	O
correlation	NN	O	O
)	NN	O	O
with	NN	O	O
base	NN	O	O
IQ	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
treatment	NN	O	O
of	NN	O	O
auditory	NN	O	B-INT
integrative	NN	O	I-INT
training	NN	O	I-INT
(	NN	O	I-INT
AIT	NN	O	I-INT
)	NN	O	I-INT
could	NN	O	O
greatly	NN	O	O
improve	NN	O	O
on	NN	O	O
language	NN	O	B-OUT
disorders	NN	O	I-OUT
,	NN	O	O
the	NN	O	O
difficulties	NN	O	B-OUT
of	NN	O	I-OUT
social	NN	O	I-OUT
interactions	NN	O	I-OUT
,	NN	O	I-OUT
typical	NN	O	I-OUT
behavior	NN	O	I-OUT
symptoms	NN	O	I-OUT
and	NN	O	O
developmental	NN	O	B-OUT
levels	NN	O	I-OUT
,	NN	O	O
therefore	NN	O	O
it	NN	O	O
is	NN	O	O
positive	NN	O	O
to	NN	O	O
the	NN	O	O
autistic	NN	O	B-PAR
children	NN	O	I-PAR
in	NN	O	O
its	NN	O	O
short-term	NN	O	O
treatment	NN	O	O
effect	NN	O	O
.	NN	O	O



--DOCSTART-- (19802506)

The	NN	O	O
effect	NN	O	O
of	NN	O	O
weight	NN	O	B-INT
training	NN	O	I-INT
on	NN	O	O
bone	NN	O	B-OUT
mineral	NN	O	I-OUT
density	NN	O	I-OUT
and	NN	O	O
bone	NN	O	B-OUT
turnover	NN	O	I-OUT
in	NN	O	O
postmenopausal	NN	O	B-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
survivors	NN	O	I-PAR
with	NN	O	I-PAR
bone	NN	O	I-PAR
loss	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
24-month	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

SUMMARY	NN	O	O
This	NN	O	O
study	NN	O	O
examined	NN	O	O
whether	NN	O	O
24	NN	O	O
months	NN	O	O
of	NN	O	O
weight	NN	O	B-INT
training	NN	O	I-INT
exercises	NN	O	I-INT
enhanced	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
risedronate	NN	O	O
,	NN	O	O
calcium	NN	O	O
,	NN	O	O
and	NN	O	O
vitamin	NN	O	O
D	NN	O	O
in	NN	O	O
maintaining	NN	O	O
or	NN	O	O
improving	NN	O	O
bone	NN	O	B-OUT
mineral	NN	O	I-OUT
density	NN	O	I-OUT
(	NN	O	I-OUT
BMD	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
223	NN	O	B-PAR
postmenopausal	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
survivors	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	O
who	NN	O	O
were	NN	O	O
>	NN	O	O
or	NN	O	O
=50	NN	O	O
%	NN	O	O
adherent	NN	O	O
to	NN	O	O
exercise	NN	O	O
had	NN	O	O
no	NN	O	O
improvement	NN	O	O
in	NN	O	O
BMD	NN	O	B-OUT
but	NN	O	O
were	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
lose	NN	O	O
BMD	NN	O	B-OUT
.	NN	O	O

INTRODUCTION	NN	O	O
This	NN	O	O
study	NN	O	O
examined	NN	O	O
whether	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
postmenopausal	NN	O	B-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
survivors	NN	O	I-PAR
(	NN	O	I-PAR
BCS	NN	O	I-PAR
)	NN	O	I-PAR
with	NN	O	I-PAR
bone	NN	O	I-PAR
loss	NN	O	I-PAR
taking	NN	O	O
24	NN	O	O
months	NN	O	O
of	NN	O	O
risedronate	NN	O	B-INT
,	NN	O	O
calcium	NN	O	B-INT
,	NN	O	O
and	NN	O	O
vitamin	NN	O	B-INT
D	NN	O	I-INT
had	NN	O	O
increased	NN	O	O
bone	NN	O	B-OUT
mineral	NN	O	I-OUT
density	NN	O	I-OUT
(	NN	O	I-OUT
BMD	NN	O	I-OUT
)	NN	O	I-OUT
at	NN	O	O
the	NN	O	O
total	NN	O	O
hip	NN	O	O
,	NN	O	O
femoral	NN	O	O
neck	NN	O	O
,	NN	O	O
L1-L4	NN	O	O
spine	NN	O	O
,	NN	O	O
total	NN	O	O
radius	NN	O	O
and	NN	O	O
33	NN	O	O
%	NN	O	O
radius	NN	O	O
,	NN	O	O
and	NN	O	O
decreased	NN	O	O
bone	NN	O	B-OUT
turnover	NN	O	I-OUT
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
subjects	NN	O	O
who	NN	O	O
also	NN	O	O
participated	NN	O	O
in	NN	O	O
strength/weight	NN	O	B-INT
training	NN	O	I-INT
(	NN	O	I-INT
ST	NN	O	I-INT
)	NN	O	I-INT
exercises	NN	O	I-INT
had	NN	O	O
greater	NN	O	O
increases	NN	O	O
in	NN	O	O
BMD	NN	O	B-OUT
and	NN	O	O
greater	NN	O	O
decreases	NN	O	O
in	NN	O	O
bone	NN	O	B-OUT
turnover	NN	O	I-OUT
;	NN	O	O
and	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
subjects	NN	O	O
who	NN	O	O
also	NN	O	O
exercised	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
preserve	NN	O	O
(	NN	O	O
at	NN	O	O
least	NN	O	O
maintain	NN	O	O
)	NN	O	O
BMD	NN	O	B-OUT
.	NN	O	O

METHODS	NN	O	O
Postmenopausal	NN	O	B-PAR
BCS	NN	O	I-PAR
(	NN	O	I-PAR
223	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
exercise	NN	O	B-INT
plus	NN	O	I-INT
medication	NN	O	I-INT
or	NN	O	O
medication	NN	O	B-INT
only	NN	O	O
groups	NN	O	O
.	NN	O	O

Both	NN	O	O
groups	NN	O	O
received	NN	O	O
24	NN	O	O
months	NN	O	O
of	NN	O	O
1,200	NN	O	O
mg	NN	O	O
of	NN	O	O
calcium	NN	O	B-INT
and	NN	O	O
400	NN	O	O
IU	NN	O	O
of	NN	O	O
vitamin	NN	O	B-INT
D	NN	O	I-INT
daily	NN	O	O
and	NN	O	O
35	NN	O	O
mg	NN	O	O
of	NN	O	O
risedronate	NN	O	B-INT
weekly	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
exercise	NN	O	B-INT
group	NN	O	O
additionally	NN	O	O
had	NN	O	O
ST	NN	O	B-INT
exercises	NN	O	I-INT
twice	NN	O	O
weekly	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
After	NN	O	O
24	NN	O	O
months	NN	O	O
,	NN	O	O
women	NN	O	O
who	NN	O	O
took	NN	O	O
medications	NN	O	B-INT
without	NN	O	O
exercising	NN	O	B-INT
had	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
BMD	NN	O	B-OUT
at	NN	O	O
the	NN	O	O
total	NN	O	O
hip	NN	O	O
(	NN	O	O
+1.81	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
spine	NN	O	O
(	NN	O	O
+2.85	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
significant	NN	O	O
decreases	NN	O	O
in	NN	O	O
Alkphase	NN	O	B-OUT
B	NN	O	I-OUT
(	NN	O	O
-8.7	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
serum	NN	O	B-OUT
NTx	NN	O	I-OUT
(	NN	O	O
-16.7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
also	NN	O	O
exercised	NN	O	B-INT
had	NN	O	O
additional	NN	O	O
increases	NN	O	O
in	NN	O	O
BMD	NN	O	B-OUT
at	NN	O	O
the	NN	O	O
femoral	NN	O	O
neck	NN	O	O
(	NN	O	O
+0.29	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
hip	NN	O	O
(	NN	O	O
+0.34	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
spine	NN	O	O
(	NN	O	O
+0.23	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
radius	NN	O	O
(	NN	O	O
+0.30	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
additional	NN	O	O
decreases	NN	O	O
in	NN	O	O
Alkphase	NN	O	B-OUT
B	NN	O	I-OUT
(	NN	O	O
-2.4	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
Serum	NN	O	B-OUT
NTx	NN	O	I-OUT
(	NN	O	O
-6.5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Additional	NN	O	O
changes	NN	O	O
in	NN	O	O
BMD	NN	O	B-OUT
and	NN	O	I-OUT
bone	NN	O	I-OUT
turnover	NN	O	I-OUT
with	NN	O	O
exercise	NN	O	O
were	NN	O	O
not	NN	O	O
significant	NN	O	O
.	NN	O	O

Subjects	NN	O	O
who	NN	O	O
were	NN	O	O
>	NN	O	O
or	NN	O	O
=50	NN	O	O
%	NN	O	O
adherent	NN	O	O
to	NN	O	O
exercise	NN	O	B-INT
were	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
lose	NN	O	O
BMD	NN	O	B-OUT
at	NN	O	O
the	NN	O	O
total	NN	O	O
hip	NN	O	O
(	NN	O	O
chi-square	NN	O	O
[	NN	O	O
1	NN	O	O
]	NN	O	O
=	NN	O	O
4.66	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
and	NN	O	O
femoral	NN	O	O
neck	NN	O	O
(	NN	O	O
chi-square	NN	O	O
[	NN	O	O
1	NN	O	O
]	NN	O	O
=	NN	O	O
4.63	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Strength/weight	NN	O	B-INT
training	NN	O	I-INT
exercises	NN	O	I-INT
may	NN	O	O
prevent	NN	O	O
loss	NN	O	O
of	NN	O	O
BMD	NN	O	B-OUT
in	NN	O	O
postmenopausal	NN	O	O
BCS	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
bone	NN	O	O
loss	NN	O	O
.	NN	O	O



--DOCSTART-- (20147856)

Randomized	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
two	NN	O	O
different	NN	O	O
schedules	NN	O	O
of	NN	O	O
gemcitabine	NN	O	B-INT
and	NN	O	O
oral	NN	O	O
S-1	NN	O	B-INT
in	NN	O	O
chemo-na?ve	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
advanced	NN	O	I-PAR
non-small	NN	O	I-PAR
cell	NN	O	I-PAR
lung	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O

INTRODUCTION	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
to	NN	O	O
compare	NN	O	O
dosing	NN	O	O
schedules	NN	O	O
of	NN	O	O
gemcitabine	NN	O	B-INT
combined	NN	O	O
with	NN	O	O
S-1	NN	O	B-INT
in	NN	O	O
chemo-na?ve	NN	O	B-PAR
non-small	NN	O	I-PAR
cell	NN	O	I-PAR
lung	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Patients	NN	O	B-PAR
with	NN	O	I-PAR
chemo-na?ve	NN	O	I-PAR
stage	NN	O	I-PAR
IIIB/IV	NN	O	I-PAR
non-small	NN	O	I-PAR
cell	NN	O	I-PAR
lung	NN	O	I-PAR
cancer	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
into	NN	O	O
two	NN	O	O
treatment	NN	O	O
arms	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
given	NN	O	O
oral	NN	O	O
S-1	NN	O	B-INT
(	NN	O	O
60	NN	O	O
mg/m/d	NN	O	O
,	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
)	NN	O	O
from	NN	O	O
days	NN	O	O
1	NN	O	O
to	NN	O	O
14	NN	O	O
with	NN	O	O
gemcitabine	NN	O	B-INT
(	NN	O	O
1000	NN	O	O
mg/m/d	NN	O	O
)	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
and	NN	O	O
8	NN	O	O
(	NN	O	O
arm	NN	O	O
A	NN	O	O
)	NN	O	O
or	NN	O	O
on	NN	O	O
days	NN	O	O
8	NN	O	O
and	NN	O	O
15	NN	O	O
(	NN	O	O
arm	NN	O	O
B	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
cycle	NN	O	O
was	NN	O	O
repeated	NN	O	O
every	NN	O	O
21	NN	O	O
days	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
80	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	I-PAR
entered	NN	O	I-PAR
in	NN	O	I-PAR
this	NN	O	I-PAR
trial	NN	O	I-PAR
.	NN	O	I-PAR
The	NN	O	O
primary	NN	O	O
end	NN	O	O
point	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
response	NN	O	B-OUT
rate	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
response	NN	O	B-OUT
rates	NN	O	I-OUT
of	NN	O	O
arm	NN	O	O
A	NN	O	O
and	NN	O	O
arm	NN	O	O
B	NN	O	O
were	NN	O	O
22.0	NN	O	O
and	NN	O	O
28.9	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.606	NN	O	O
)	NN	O	O
.	NN	O	O

Median	NN	O	O
time	NN	O	B-OUT
to	NN	O	I-OUT
treatment	NN	O	I-OUT
failure	NN	O	I-OUT
in	NN	O	O
arm	NN	O	O
A	NN	O	O
was	NN	O	O
3.6	NN	O	O
months	NN	O	O
and	NN	O	O
4.8	NN	O	O
months	NN	O	O
in	NN	O	O
arm	NN	O	O
B	NN	O	O
.	NN	O	O

Median	NN	O	O
time	NN	O	B-OUT
to	NN	O	I-OUT
progression	NN	O	I-OUT
in	NN	O	O
arm	NN	O	O
A	NN	O	O
was	NN	O	O
4.1	NN	O	O
months	NN	O	O
and	NN	O	O
5.5	NN	O	O
months	NN	O	O
in	NN	O	O
arm	NN	O	O
B	NN	O	O
.	NN	O	O

Median	NN	O	O
survival	NN	O	B-OUT
time	NN	O	I-OUT
in	NN	O	O
arm	NN	O	O
A	NN	O	O
and	NN	O	O
arm	NN	O	O
B	NN	O	O
was	NN	O	O
15.5	NN	O	O
months	NN	O	O
and	NN	O	O
18.8	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
toxicity	NN	O	B-OUT
profile	NN	O	I-OUT
was	NN	O	O
relatively	NN	O	O
mild	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
very	NN	O	O
much	NN	O	O
between	NN	O	O
two	NN	O	O
arms	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
gemcitabine	NN	O	B-INT
and	NN	O	O
S-1	NN	O	B-INT
was	NN	O	O
determined	NN	O	O
to	NN	O	O
be	NN	O	O
feasible	NN	O	B-OUT
and	NN	O	O
effective	NN	O	B-OUT
for	NN	O	O
advanced	NN	O	O
non-small	NN	O	O
cell	NN	O	O
lung	NN	O	O
cancer	NN	O	O
.	NN	O	O

We	NN	O	O
selected	NN	O	O
arm	NN	O	O
B	NN	O	O
for	NN	O	O
further	NN	O	O
studies	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
higher	NN	O	O
response	NN	O	B-OUT
rate	NN	O	I-OUT
and	NN	O	I-OUT
survival	NN	O	I-OUT
data	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (20189026)

Remote	NN	O	B-INT
ischaemic	NN	O	I-INT
conditioning	NN	O	I-INT
before	NN	O	O
hospital	NN	O	O
admission	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
complement	NN	O	O
to	NN	O	O
angioplasty	NN	O	O
,	NN	O	O
and	NN	O	O
effect	NN	O	O
on	NN	O	O
myocardial	NN	O	B-OUT
salvage	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
acute	NN	O	I-PAR
myocardial	NN	O	I-PAR
infarction	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Remote	NN	O	B-INT
ischaemic	NN	O	I-INT
preconditioning	NN	O	I-INT
attenuates	NN	O	O
cardiac	NN	O	O
injury	NN	O	O
at	NN	O	O
elective	NN	O	O
surgery	NN	O	O
and	NN	O	O
angioplasty	NN	O	O
.	NN	O	O

We	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
remote	NN	O	B-INT
ischaemic	NN	O	I-INT
conditioning	NN	O	I-INT
during	NN	O	O
evolving	NN	O	O
ST-elevation	NN	O	O
myocardial	NN	O	O
infarction	NN	O	O
,	NN	O	O
and	NN	O	O
done	NN	O	O
before	NN	O	O
primary	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
,	NN	O	O
increases	NN	O	O
myocardial	NN	O	B-OUT
salvage	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
333	NN	O	B-PAR
consecutive	NN	O	I-PAR
adult	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
suspected	NN	O	I-PAR
first	NN	O	I-PAR
acute	NN	O	I-PAR
myocardial	NN	O	I-PAR
infarction	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
in	NN	O	O
a	NN	O	O
1:1	NN	O	O
ratio	NN	O	O
by	NN	O	O
computerised	NN	O	O
block	NN	O	O
randomisation	NN	O	O
to	NN	O	O
receive	NN	O	O
primary	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
with	NN	O	O
(	NN	O	O
n=166	NN	O	O
patients	NN	O	O
)	NN	O	O
versus	NN	O	O
without	NN	O	O
(	NN	O	O
n=167	NN	O	O
)	NN	O	O
remote	NN	O	B-INT
conditioning	NN	O	I-INT
(	NN	O	O
intermittent	NN	O	O
arm	NN	O	O
ischaemia	NN	O	O
through	NN	O	O
four	NN	O	O
cycles	NN	O	O
of	NN	O	O
5-min	NN	O	O
inflation	NN	O	O
and	NN	O	O
5-min	NN	O	O
deflation	NN	O	O
of	NN	O	O
a	NN	O	O
blood-pressure	NN	O	O
cuff	NN	O	O
)	NN	O	O
.	NN	O	O

Allocation	NN	O	O
was	NN	O	O
concealed	NN	O	O
with	NN	O	O
opaque	NN	O	O
sealed	NN	O	O
envelopes	NN	O	O
.	NN	O	O

Patients	NN	O	O
received	NN	O	O
remote	NN	O	B-INT
conditioning	NN	O	I-INT
during	NN	O	O
transport	NN	O	O
to	NN	O	O
hospital	NN	O	O
,	NN	O	O
and	NN	O	O
primary	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
in	NN	O	O
hospital	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
endpoint	NN	O	O
was	NN	O	O
myocardial	NN	O	B-OUT
salvage	NN	O	I-OUT
index	NN	O	I-OUT
at	NN	O	I-OUT
30	NN	O	I-OUT
days	NN	O	I-OUT
after	NN	O	I-OUT
primary	NN	O	I-OUT
percutaneous	NN	O	I-OUT
coronary	NN	O	I-OUT
intervention	NN	O	I-OUT
,	NN	O	O
measured	NN	O	O
by	NN	O	O
myocardial	NN	O	B-OUT
perfusion	NN	O	I-OUT
imaging	NN	O	I-OUT
as	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
the	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
salvaged	NN	O	O
by	NN	O	O
treatment	NN	O	O
;	NN	O	O
analysis	NN	O	O
was	NN	O	O
per	NN	O	O
protocol	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
is	NN	O	O
registered	NN	O	O
with	NN	O	O
ClinicalTrials.gov	NN	O	O
,	NN	O	O
number	NN	O	O
NCT00435266	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
82	NN	O	B-PAR
patients	NN	O	I-PAR
were	NN	O	I-PAR
excluded	NN	O	I-PAR
on	NN	O	I-PAR
arrival	NN	O	I-PAR
at	NN	O	I-PAR
hospital	NN	O	I-PAR
because	NN	O	I-PAR
they	NN	O	I-PAR
did	NN	O	I-PAR
not	NN	O	I-PAR
meet	NN	O	I-PAR
inclusion	NN	O	I-PAR
criteria	NN	O	I-PAR
,	NN	O	I-PAR
32	NN	O	I-PAR
were	NN	O	I-PAR
lost	NN	O	I-PAR
to	NN	O	I-PAR
follow-up	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
77	NN	O	I-PAR
did	NN	O	I-PAR
not	NN	O	I-PAR
complete	NN	O	I-PAR
the	NN	O	I-PAR
follow-up	NN	O	I-PAR
with	NN	O	O
data	NN	O	O
for	NN	O	O
salvage	NN	O	O
index	NN	O	O
.	NN	O	O

Median	NN	O	B-OUT
salvage	NN	O	I-OUT
index	NN	O	I-OUT
was	NN	O	O
0.75	NN	O	O
(	NN	O	O
IQR	NN	O	O
0.50-0.93	NN	O	O
,	NN	O	O
n=73	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
remote	NN	O	B-INT
conditioning	NN	O	I-INT
group	NN	O	O
versus	NN	O	O
0.55	NN	O	O
(	NN	O	O
0.35-0.88	NN	O	O
,	NN	O	O
n=69	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
with	NN	O	O
median	NN	O	O
difference	NN	O	O
of	NN	O	O
0.10	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0.01-0.22	NN	O	O
;	NN	O	O
p=0.0333	NN	O	O
)	NN	O	O
;	NN	O	O
mean	NN	O	B-OUT
salvage	NN	O	I-OUT
index	NN	O	I-OUT
was	NN	O	O
0.69	NN	O	O
(	NN	O	O
SD	NN	O	O
0.27	NN	O	O
)	NN	O	O
versus	NN	O	O
0.57	NN	O	O
(	NN	O	O
0.26	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
mean	NN	O	O
difference	NN	O	O
of	NN	O	O
0.12	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0.01-0.21	NN	O	O
;	NN	O	O
p=0.0333	NN	O	O
)	NN	O	O
.	NN	O	O

Major	NN	O	B-OUT
adverse	NN	O	I-OUT
coronary	NN	O	I-OUT
events	NN	O	I-OUT
were	NN	O	O
death	NN	O	B-OUT
(	NN	O	O
n=3	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
reinfarction	NN	O	B-OUT
(	NN	O	O
n=1	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
heart	NN	O	B-OUT
failure	NN	O	I-OUT
(	NN	O	O
n=3	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
Remote	NN	O	B-INT
ischaemic	NN	O	I-INT
conditioning	NN	O	I-INT
before	NN	O	O
hospital	NN	O	O
admission	NN	O	O
increases	NN	O	O
myocardial	NN	O	B-OUT
salvage	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
has	NN	O	O
a	NN	O	O
favourable	NN	O	O
safety	NN	O	B-OUT
profile	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
merit	NN	O	O
a	NN	O	O
larger	NN	O	O
trial	NN	O	O
to	NN	O	O
establish	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
remote	NN	O	B-INT
conditioning	NN	O	I-INT
on	NN	O	O
clinical	NN	O	O
outcomes	NN	O	O
.	NN	O	O

FUNDING	NN	O	O
Fondation	NN	O	O
Leducq	NN	O	O
.	NN	O	O



--DOCSTART-- (20226474)

Cryoprobe	NN	O	B-INT
biopsy	NN	O	I-INT
increases	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
yield	NN	O	O
in	NN	O	O
endobronchial	NN	O	B-PAR
tumor	NN	O	I-PAR
lesions	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
Forceps	NN	O	O
biopsy	NN	O	O
is	NN	O	O
the	NN	O	O
standard	NN	O	O
method	NN	O	O
to	NN	O	O
obtain	NN	O	O
specimens	NN	O	O
in	NN	O	O
endoscopically	NN	O	O
visible	NN	O	O
lesions	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
common	NN	O	O
to	NN	O	O
combine	NN	O	O
forceps	NN	O	O
biopsy	NN	O	O
with	NN	O	O
cytology	NN	O	O
methods	NN	O	O
to	NN	O	O
increase	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
yield	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
flexible	NN	O	O
cryoprobe	NN	O	B-INT
has	NN	O	O
been	NN	O	O
established	NN	O	O
for	NN	O	O
bronchoscopic	NN	O	O
interventions	NN	O	O
in	NN	O	O
malignant	NN	O	O
stenosis	NN	O	O
,	NN	O	O
the	NN	O	O
obtained	NN	O	O
biopsies	NN	O	O
,	NN	O	O
called	NN	O	O
cryobiopsies	NN	O	O
,	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
investigated	NN	O	O
in	NN	O	O
a	NN	O	O
large	NN	O	O
cohort	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
feasibility	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
prospectively	NN	O	O
evaluate	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
yield	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
cryobiopsy	NN	O	B-INT
and	NN	O	O
forceps	NN	O	B-INT
biopsy	NN	O	I-INT
.	NN	O	O

METHODS	NN	O	O
During	NN	O	O
a	NN	O	O
6-year	NN	O	O
period	NN	O	O
,	NN	O	O
296	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
visible	NN	O	I-PAR
endoluminal	NN	O	I-PAR
tumor	NN	O	I-PAR
lesions	NN	O	I-PAR
were	NN	O	I-PAR
included	NN	O	I-PAR
in	NN	O	O
the	NN	O	O
study	NN	O	O
at	NN	O	O
the	NN	O	O
bronchoscopy	NN	O	O
unit	NN	O	O
of	NN	O	O
a	NN	O	O
university	NN	O	O
hospital	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
consecutively	NN	O	O
conducted	NN	O	O
55	NN	O	O
cases	NN	O	O
,	NN	O	O
both	NN	O	O
techniques	NN	O	O
,	NN	O	O
forceps	NN	O	B-INT
biopsy	NN	O	I-INT
and	NN	O	I-INT
cryobiopsy	NN	O	I-INT
,	NN	O	O
were	NN	O	O
applied	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

Pathologic	NN	O	O
and	NN	O	O
quantitative	NN	O	O
image	NN	O	O
analyses	NN	O	O
were	NN	O	O
performed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
size	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
the	NN	O	O
obtained	NN	O	O
specimens	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
diagnostic	NN	O	B-OUT
yield	NN	O	I-OUT
to	NN	O	O
describe	NN	O	O
the	NN	O	O
feasibility	NN	O	O
of	NN	O	O
cryobiopsy	NN	O	B-INT
.	NN	O	O

RESULTS	NN	O	O
Comparative	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
conducted	NN	O	O
and	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
55	NN	O	O
cases	NN	O	O
revealed	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
diagnostic	NN	O	B-OUT
yield	NN	O	I-OUT
for	NN	O	O
cryobiopsy	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
forceps	NN	O	B-INT
biopsy	NN	O	I-INT
(	NN	O	O
89.1	NN	O	O
%	NN	O	O
vs	NN	O	O
65.5	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
cohort	NN	O	O
,	NN	O	O
quantitative	NN	O	O
image	NN	O	O
analysis	NN	O	O
showed	NN	O	O
significantly	NN	O	O
larger	NN	O	O
biopsies	NN	O	O
regarding	NN	O	O
size	NN	O	B-OUT
and	NN	O	O
artifact-free	NN	O	O
tissue	NN	O	O
sections	NN	O	O
for	NN	O	O
cryobiopsy	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
forceps	NN	O	B-INT
biopsy	NN	O	I-INT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.0001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
diagnostic	NN	O	B-OUT
yield	NN	O	I-OUT
of	NN	O	O
cryobiopsy	NN	O	B-INT
was	NN	O	O
89.5	NN	O	O
%	NN	O	O
.	NN	O	O

Mild	NN	O	O
bleeding	NN	O	B-OUT
occurred	NN	O	O
in	NN	O	O
11	NN	O	O
cases	NN	O	O
(	NN	O	O
3.7	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
moderate	NN	O	O
bleeding	NN	O	B-OUT
occurred	NN	O	O
in	NN	O	O
3	NN	O	O
cases	NN	O	O
(	NN	O	O
1.0	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
severe	NN	O	O
bleeding	NN	O	B-OUT
occurred	NN	O	O
in	NN	O	O
1	NN	O	O
case	NN	O	O
(	NN	O	O
0.3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Cryobiopsy	NN	O	B-INT
is	NN	O	O
safe	NN	O	B-OUT
and	NN	O	O
increases	NN	O	O
the	NN	O	O
diagnostic	NN	O	B-OUT
yield	NN	O	I-OUT
in	NN	O	O
endobronchial	NN	O	O
tumor	NN	O	O
lesions	NN	O	O
.	NN	O	O

The	NN	O	O
method	NN	O	O
also	NN	O	O
is	NN	O	O
feasible	NN	O	B-OUT
under	NN	O	O
routine	NN	O	O
conditions	NN	O	O
.	NN	O	O



--DOCSTART-- (20509069)

Virtual	NN	O	B-INT
reality	NN	O	I-INT
hypnosis	NN	O	I-INT
for	NN	O	O
pain	NN	O	O
associated	NN	O	O
with	NN	O	O
recovery	NN	O	O
from	NN	O	O
physical	NN	O	B-PAR
trauma	NN	O	I-PAR
.	NN	O	O

Pain	NN	O	O
following	NN	O	O
traumatic	NN	O	B-PAR
injuries	NN	O	I-PAR
is	NN	O	O
common	NN	O	O
,	NN	O	O
can	NN	O	O
impair	NN	O	O
injury	NN	O	O
recovery	NN	O	O
and	NN	O	O
is	NN	O	O
often	NN	O	O
inadequately	NN	O	O
treated	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
,	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
adjunctive	NN	O	O
nonpharmacologic	NN	O	O
analgesic	NN	O	O
techniques	NN	O	O
is	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
21	NN	O	B-PAR
hospitalized	NN	O	I-PAR
trauma	NN	O	I-PAR
patients	NN	O	I-PAR
to	NN	O	O
assess	NN	O	O
the	NN	O	O
analgesic	NN	O	O
efficacy	NN	O	O
of	NN	O	O
virtual	NN	O	B-INT
reality	NN	O	I-INT
hypnosis	NN	O	I-INT
(	NN	O	I-INT
VRH	NN	O	I-INT
)	NN	O	I-INT
-hypnotic	NN	O	I-INT
induction	NN	O	I-INT
and	NN	O	O
analgesic	NN	O	O
suggestion	NN	O	O
delivered	NN	O	O
by	NN	O	O
customized	NN	O	O
virtual	NN	O	O
reality	NN	O	O
(	NN	O	O
VR	NN	O	O
)	NN	O	O
hardware/software	NN	O	O
.	NN	O	O

Subjective	NN	O	B-OUT
pain	NN	O	I-OUT
ratings	NN	O	I-OUT
were	NN	O	O
obtained	NN	O	O
immediately	NN	O	O
and	NN	O	O
8	NN	O	O
hours	NN	O	O
after	NN	O	O
VRH	NN	O	O
(	NN	O	O
used	NN	O	O
as	NN	O	O
an	NN	O	O
adjunct	NN	O	O
to	NN	O	O
standard	NN	O	O
analgesic	NN	O	O
care	NN	O	O
)	NN	O	O
and	NN	O	O
compared	NN	O	O
to	NN	O	O
both	NN	O	O
adjunctive	NN	O	O
VR	NN	O	O
without	NN	O	O
hypnosis	NN	O	O
and	NN	O	O
standard	NN	O	O
care	NN	O	O
alone	NN	O	O
.	NN	O	O

VRH	NN	O	O
patients	NN	O	O
reported	NN	O	O
less	NN	O	O
pain	NN	O	B-OUT
intensity	NN	O	I-OUT
and	NN	O	O
less	NN	O	O
pain	NN	O	B-OUT
unpleasantness	NN	O	I-OUT
compared	NN	O	O
to	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
preliminary	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
VRH	NN	O	B-INT
analgesia	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
technology	NN	O	O
worthy	NN	O	O
of	NN	O	O
further	NN	O	O
study	NN	O	O
,	NN	O	O
both	NN	O	O
to	NN	O	O
improve	NN	O	O
pain	NN	O	B-OUT
management	NN	O	I-OUT
and	NN	O	O
to	NN	O	O
increase	NN	O	O
availability	NN	O	O
of	NN	O	O
hypnotic	NN	O	O
analgesia	NN	O	O
to	NN	O	O
populations	NN	O	O
without	NN	O	O
access	NN	O	O
to	NN	O	O
therapist-provided	NN	O	O
hypnosis	NN	O	O
and	NN	O	O
suggestion	NN	O	O
.	NN	O	O



--DOCSTART-- (20560622)

Influence	NN	O	O
of	NN	O	O
diets	NN	O	O
rich	NN	O	O
in	NN	O	O
Maillard	NN	O	B-INT
reaction	NN	O	I-INT
products	NN	O	I-INT
on	NN	O	O
calcium	NN	O	B-OUT
bioavailability	NN	O	I-OUT
.	NN	O	O

Assays	NN	O	O
in	NN	O	O
male	NN	O	B-PAR
adolescents	NN	O	I-PAR
and	NN	O	O
in	NN	O	O
Caco-2	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
high	NN	O	O
intake	NN	O	O
of	NN	O	O
Maillard	NN	O	B-INT
reaction	NN	O	I-INT
products	NN	O	I-INT
(	NN	O	I-INT
MRP	NN	O	I-INT
)	NN	O	I-INT
on	NN	O	O
calcium	NN	O	B-OUT
availability	NN	O	I-OUT
in	NN	O	O
adolescents	NN	O	B-PAR
and	NN	O	O
across	NN	O	O
Caco-2	NN	O	O
cell	NN	O	O
monolayers	NN	O	O
were	NN	O	O
examined	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
2	NN	O	O
week	NN	O	O
randomized	NN	O	O
two-period	NN	O	O
crossover	NN	O	O
trial	NN	O	O
,	NN	O	O
18	NN	O	B-PAR
male	NN	O	I-PAR
adolescents	NN	O	I-PAR
consumed	NN	O	O
two	NN	O	O
diets	NN	O	O
,	NN	O	O
named	NN	O	O
white	NN	O	B-INT
diet	NN	O	I-INT
(	NN	O	I-INT
WD	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
brown	NN	O	B-INT
diet	NN	O	I-INT
(	NN	O	I-INT
BD	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
which	NN	O	O
were	NN	O	O
poor	NN	O	O
and	NN	O	O
rich	NN	O	O
in	NN	O	O
MRP	NN	O	B-INT
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

A	NN	O	O
3	NN	O	O
day	NN	O	O
balance	NN	O	O
was	NN	O	O
performed	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
each	NN	O	O
period	NN	O	O
,	NN	O	O
and	NN	O	O
fasting	NN	O	B-OUT
blood	NN	O	I-OUT
samples	NN	O	I-OUT
were	NN	O	O
collected	NN	O	O
.	NN	O	O

Calcium	NN	O	B-OUT
solubility	NN	O	I-OUT
and	NN	O	I-OUT
absorption	NN	O	I-OUT
across	NN	O	I-OUT
Caco-2	NN	O	I-OUT
cells	NN	O	I-OUT
were	NN	O	O
studied	NN	O	O
after	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
digestion	NN	O	O
of	NN	O	O
the	NN	O	O
diets	NN	O	O
.	NN	O	O

The	NN	O	O
in	NN	O	O
vitro	NN	O	O
assay	NN	O	O
showed	NN	O	O
similar	NN	O	O
solubility	NN	O	B-OUT
after	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
digestion	NN	O	O
and	NN	O	O
similar	NN	O	O
transport	NN	O	O
across	NN	O	O
Caco-2	NN	O	O
cells	NN	O	O
.	NN	O	O

In	NN	O	O
accordance	NN	O	O
,	NN	O	O
calcium	NN	O	B-OUT
bioavailability	NN	O	I-OUT
in	NN	O	O
adolescents	NN	O	O
did	NN	O	O
not	NN	O	O
vary	NN	O	O
between	NN	O	O
the	NN	O	O
diets	NN	O	O
(	NN	O	O
%	NN	O	O
WD	NN	O	O
=	NN	O	O
40.4	NN	O	O
+/-	NN	O	O
5.1	NN	O	O
,	NN	O	O
%	NN	O	O
BD	NN	O	O
=	NN	O	O
38.2	NN	O	O
+/-	NN	O	O
3.6	NN	O	O
)	NN	O	O
.	NN	O	O

Serum	NN	O	B-OUT
and	NN	O	I-OUT
urine	NN	O	I-OUT
biochemical	NN	O	I-OUT
parameters	NN	O	I-OUT
related	NN	O	I-OUT
to	NN	O	I-OUT
calcium	NN	O	I-OUT
status	NN	O	I-OUT
and	NN	O	I-OUT
bone	NN	O	I-OUT
metabolism	NN	O	I-OUT
remained	NN	O	O
unaltered	NN	O	O
.	NN	O	O

Only	NN	O	O
deoxypyridinoline	NN	O	B-OUT
values	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
after	NN	O	O
consumption	NN	O	O
of	NN	O	O
the	NN	O	O
BD	NN	O	O
(	NN	O	O
13.0	NN	O	O
+/-	NN	O	O
1.1	NN	O	O
compared	NN	O	O
to	NN	O	O
18.3	NN	O	O
+/-	NN	O	O
2.1	NN	O	O
nM/Mm	NN	O	O
Cr	NN	O	O
in	NN	O	O
the	NN	O	O
WD	NN	O	O
)	NN	O	O
,	NN	O	O
possibly	NN	O	O
indicative	NN	O	O
of	NN	O	O
less	NN	O	O
efficient	NN	O	O
bone	NN	O	B-OUT
turnover	NN	O	I-OUT
during	NN	O	O
this	NN	O	O
period	NN	O	O
.	NN	O	O

As	NN	O	O
calcium	NN	O	O
acquired	NN	O	O
during	NN	O	O
adolescence	NN	O	O
is	NN	O	O
essential	NN	O	O
to	NN	O	O
maximize	NN	O	O
peak	NN	O	O
bone	NN	O	O
mass	NN	O	O
and	NN	O	O
to	NN	O	O
prevent	NN	O	O
osteoporosis	NN	O	O
,	NN	O	O
possible	NN	O	O
long-term	NN	O	O
effects	NN	O	O
of	NN	O	O
excessive	NN	O	O
MRP	NN	O	B-INT
intake	NN	O	O
during	NN	O	O
this	NN	O	O
period	NN	O	O
warrant	NN	O	O
attention	NN	O	O
.	NN	O	O



--DOCSTART-- (20618920)

Effectiveness	NN	O	B-OUT
of	NN	O	O
hygienic-dietary	NN	O	B-INT
recommendations	NN	O	I-INT
as	NN	O	O
enhancers	NN	O	O
of	NN	O	O
antidepressant	NN	O	O
treatment	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
depression	NN	O	I-PAR
:	NN	O	O
study	NN	O	O
protocol	NN	O	O
of	NN	O	O
a	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
In	NN	O	O
recent	NN	O	O
years	NN	O	O
some	NN	O	O
studies	NN	O	O
have	NN	O	O
been	NN	O	O
published	NN	O	O
supporting	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
light	NN	O	O
exposure	NN	O	O
,	NN	O	O
physical	NN	O	O
activity	NN	O	O
,	NN	O	O
sleep	NN	O	O
control	NN	O	O
and	NN	O	O
a	NN	O	O
Mediterranean	NN	O	O
diet	NN	O	O
pattern	NN	O	O
on	NN	O	O
the	NN	O	O
improvement	NN	O	O
or	NN	O	O
prevention	NN	O	O
of	NN	O	O
depression	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
to	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
no	NN	O	O
studies	NN	O	O
using	NN	O	O
all	NN	O	O
these	NN	O	O
measures	NN	O	O
together	NN	O	O
as	NN	O	O
an	NN	O	O
adjuvant	NN	O	O
antidepressant	NN	O	O
strategy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
two	NN	O	O
arm-parallel	NN	O	O
,	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

Eighty	NN	O	B-PAR
depressed	NN	O	I-PAR
patients	NN	O	I-PAR
undergoing	NN	O	I-PAR
standard	NN	O	I-PAR
antidepressant	NN	O	I-PAR
treatment	NN	O	I-PAR
will	NN	O	O
be	NN	O	O
advised	NN	O	O
to	NN	O	O
follow	NN	O	O
four	NN	O	O
additional	NN	O	O
hygienic-dietary	NN	O	B-INT
recommendations	NN	O	I-INT
about	NN	O	O
exercise	NN	O	O
,	NN	O	O
diet	NN	O	O
,	NN	O	O
sunlight	NN	O	O
exposure	NN	O	O
and	NN	O	O
sleep	NN	O	O
.	NN	O	O

Outcome	NN	O	O
measures	NN	O	O
will	NN	O	O
be	NN	O	O
assessed	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
6	NN	O	O
month	NN	O	O
intervention	NN	O	O
period	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
We	NN	O	O
expect	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
active	NN	O	O
recommendations	NN	O	O
group	NN	O	O
to	NN	O	O
experience	NN	O	O
a	NN	O	O
greater	NN	O	O
improvement	NN	O	O
in	NN	O	O
their	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

If	NN	O	O
so	NN	O	O
,	NN	O	O
this	NN	O	O
would	NN	O	O
be	NN	O	O
a	NN	O	O
great	NN	O	O
support	NN	O	O
for	NN	O	O
doctors	NN	O	O
who	NN	O	O
might	NN	O	O
systematically	NN	O	O
recommend	NN	O	O
these	NN	O	O
simple	NN	O	O
and	NN	O	O
costless	NN	O	O
measures	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
primary	NN	O	O
care	NN	O	O
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
ISRCTN59506583	NN	O	O
.	NN	O	O



--DOCSTART-- (2066441)

Therapeutic	NN	O	O
effects	NN	O	O
of	NN	O	O
combined	NN	O	O
treatment	NN	O	O
using	NN	O	O
tetracycline-immobilized	NN	O	B-INT
collagen	NN	O	I-INT
film	NN	O	I-INT
and	NN	O	I-INT
root	NN	O	I-INT
planing	NN	O	I-INT
in	NN	O	O
periodontal	NN	O	B-PAR
furcation	NN	O	I-PAR
pockets	NN	O	I-PAR
.	NN	O	O

46	NN	O	B-PAR
upper	NN	O	I-PAR
and	NN	O	I-PAR
lower	NN	O	I-PAR
molars	NN	O	I-PAR
with	NN	O	I-PAR
furcation	NN	O	I-PAR
grade	NN	O	I-PAR
II	NN	O	I-PAR
involvement	NN	O	I-PAR
were	NN	O	O
selected	NN	O	O
from	NN	O	O
16	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
periodontal	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
teeth	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
the	NN	O	O
following	NN	O	O
groups	NN	O	O
according	NN	O	O
to	NN	O	O
treatment	NN	O	O
;	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
4	NN	O	O
consecutive	NN	O	O
administrations	NN	O	O
of	NN	O	O
tetracycline-immobilized	NN	O	B-INT
cross-linked	NN	O	I-INT
collagen	NN	O	I-INT
film	NN	O	I-INT
(	NN	O	I-INT
TC	NN	O	I-INT
film	NN	O	I-INT
)	NN	O	I-INT
at	NN	O	O
intervals	NN	O	O
of	NN	O	O
1	NN	O	O
week	NN	O	O
(	NN	O	O
TC	NN	O	O
group	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
1	NN	O	O
root	NN	O	B-INT
planing	NN	O	I-INT
treatment	NN	O	I-INT
(	NN	O	I-INT
RP	NN	O	I-INT
group	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
combination	NN	O	O
treatment	NN	O	O
(	NN	O	O
TC	NN	O	B-INT
+	NN	O	I-INT
RP	NN	O	I-INT
group	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
no	NN	O	O
treatment	NN	O	O
(	NN	O	O
control	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
therapeutic	NN	O	O
effects	NN	O	O
of	NN	O	O
each	NN	O	O
treatment	NN	O	O
were	NN	O	O
compared	NN	O	O
both	NN	O	O
clinically	NN	O	O
and	NN	O	O
microbiologically	NN	O	O
.	NN	O	O

Records	NN	O	O
of	NN	O	O
plaque	NN	O	B-OUT
index	NN	O	I-OUT
,	NN	O	I-OUT
gingival	NN	O	I-OUT
index	NN	O	I-OUT
,	NN	O	I-OUT
bleeding	NN	O	I-OUT
on	NN	O	I-OUT
probing	NN	O	I-OUT
,	NN	O	I-OUT
probing	NN	O	I-OUT
depth	NN	O	I-OUT
,	NN	O	I-OUT
probing	NN	O	I-OUT
attachment	NN	O	I-OUT
level	NN	O	I-OUT
and	NN	O	I-OUT
microscopic	NN	O	I-OUT
counts	NN	O	I-OUT
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
0	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
6	NN	O	O
and	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
marked	NN	O	O
decreases	NN	O	O
in	NN	O	O
probing	NN	O	B-OUT
depth	NN	O	I-OUT
and	NN	O	I-OUT
density	NN	O	I-OUT
of	NN	O	I-OUT
micro-organisms	NN	O	I-OUT
in	NN	O	O
both	NN	O	O
the	NN	O	O
RP	NN	O	B-INT
and	NN	O	O
TC	NN	O	B-INT
+	NN	O	I-INT
RP	NN	O	I-INT
groups	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
,	NN	O	O
the	NN	O	O
TC	NN	O	B-INT
+	NN	O	I-INT
RP	NN	O	I-INT
group	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
decreased	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
bleeding	NN	O	I-OUT
on	NN	O	I-OUT
pocket	NN	O	I-OUT
probing	NN	O	I-OUT
and	NN	O	O
an	NN	O	O
increased	NN	O	O
probing	NN	O	B-OUT
attachment	NN	O	I-OUT
gain	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
above	NN	O	O
findings	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
root	NN	O	O
planning	NN	O	O
is	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
furcation	NN	O	O
involvement	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
are	NN	O	O
enhanced	NN	O	O
by	NN	O	O
the	NN	O	O
local	NN	O	O
administration	NN	O	O
of	NN	O	O
TC	NN	O	B-INT
films	NN	O	O
.	NN	O	O



--DOCSTART-- (20739054)

Eltrombopag	NN	O	B-INT
for	NN	O	O
management	NN	O	O
of	NN	O	O
chronic	NN	O	B-PAR
immune	NN	O	I-PAR
thrombocytopenia	NN	O	I-PAR
(	NN	O	O
RAISE	NN	O	O
)	NN	O	O
:	NN	O	O
a	NN	O	O
6-month	NN	O	O
,	NN	O	O
randomised	NN	O	O
,	NN	O	O
phase	NN	O	O
3	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Eltrombopag	NN	O	B-INT
is	NN	O	O
an	NN	O	O
oral	NN	O	O
thrombopoietin	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
thrombocytopenia	NN	O	O
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
response	NN	O	B-OUT
to	NN	O	O
once	NN	O	O
daily	NN	O	O
eltrombopag	NN	O	B-INT
versus	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
chronic	NN	O	I-PAR
immune	NN	O	I-PAR
thrombocytopenia	NN	O	I-PAR
during	NN	O	O
a	NN	O	O
6-month	NN	O	O
period	NN	O	O
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
undertook	NN	O	O
a	NN	O	O
phase	NN	O	O
3	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
in	NN	O	O
adults	NN	O	B-PAR
with	NN	O	I-PAR
previously	NN	O	I-PAR
treated	NN	O	I-PAR
immune	NN	O	I-PAR
thrombocytopenia	NN	O	I-PAR
of	NN	O	I-PAR
more	NN	O	I-PAR
than	NN	O	I-PAR
6	NN	O	I-PAR
months	NN	O	I-PAR
'	NN	O	I-PAR
duration	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
baseline	NN	O	I-PAR
platelet	NN	O	I-PAR
counts	NN	O	I-PAR
lower	NN	O	I-PAR
than	NN	O	I-PAR
30,000	NN	O	I-PAR
per	NN	O	I-PAR
?L	NN	O	I-PAR
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
(	NN	O	O
in	NN	O	O
a	NN	O	O
2:1	NN	O	O
ratio	NN	O	O
)	NN	O	O
treatment	NN	O	O
with	NN	O	O
local	NN	O	O
standard	NN	O	O
of	NN	O	O
care	NN	O	O
plus	NN	O	O
50	NN	O	O
mg	NN	O	O
eltrombopag	NN	O	B-INT
or	NN	O	O
matching	NN	O	O
placebo	NN	O	B-INT
once	NN	O	O
daily	NN	O	O
for	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

Randomisation	NN	O	O
was	NN	O	O
done	NN	O	O
centrally	NN	O	O
with	NN	O	O
a	NN	O	O
computer-generated	NN	O	O
randomisation	NN	O	O
schedule	NN	O	O
and	NN	O	O
was	NN	O	O
stratified	NN	O	O
by	NN	O	O
baseline	NN	O	O
platelet	NN	O	O
count	NN	O	O
(	NN	O	O
?	NN	O	O
15,000	NN	O	O
per	NN	O	O
?L	NN	O	O
)	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
treatment	NN	O	O
for	NN	O	O
immune	NN	O	O
thrombocytopenia	NN	O	O
,	NN	O	O
and	NN	O	O
splenectomy	NN	O	O
status	NN	O	O
.	NN	O	O

Patients	NN	O	O
,	NN	O	O
investigators	NN	O	O
,	NN	O	O
and	NN	O	O
those	NN	O	O
assessing	NN	O	O
data	NN	O	O
were	NN	O	O
masked	NN	O	O
to	NN	O	O
allocation	NN	O	O
.	NN	O	O

Dose	NN	O	O
modifications	NN	O	O
were	NN	O	O
made	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
platelet	NN	O	O
response	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
response	NN	O	B-OUT
to	NN	O	I-OUT
treatment	NN	O	I-OUT
(	NN	O	I-OUT
defined	NN	O	I-OUT
as	NN	O	I-OUT
a	NN	O	I-OUT
platelet	NN	O	I-OUT
count	NN	O	I-OUT
of	NN	O	I-OUT
50,000-400,000	NN	O	O
per	NN	O	O
?L	NN	O	O
)	NN	O	O
weekly	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
6	NN	O	O
weeks	NN	O	O
and	NN	O	O
at	NN	O	O
least	NN	O	O
once	NN	O	O
every	NN	O	O
4	NN	O	O
weeks	NN	O	O
thereafter	NN	O	O
;	NN	O	O
the	NN	O	O
primary	NN	O	O
endpoint	NN	O	O
was	NN	O	O
the	NN	O	O
odds	NN	O	B-OUT
of	NN	O	I-OUT
response	NN	O	I-OUT
to	NN	O	O
eltrombopag	NN	O	B-INT
versus	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

Analysis	NN	O	O
was	NN	O	O
by	NN	O	O
intention	NN	O	O
to	NN	O	O
treat	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
is	NN	O	O
registered	NN	O	O
at	NN	O	O
ClinicalTrials.gov	NN	O	O
,	NN	O	O
number	NN	O	O
NCT00370331	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
Between	NN	O	B-PAR
Nov	NN	O	I-PAR
22	NN	O	I-PAR
,	NN	O	I-PAR
2006	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
July	NN	O	I-PAR
31	NN	O	I-PAR
,	NN	O	I-PAR
2007	NN	O	I-PAR
,	NN	O	I-PAR
197	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
treatment	NN	O	O
groups	NN	O	O
and	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
intention-to-treat	NN	O	O
analysis	NN	O	O
(	NN	O	O
135	NN	O	O
eltrombopag	NN	O	B-INT
,	NN	O	O
62	NN	O	O
placebo	NN	O	B-INT
)	NN	O	O
.	NN	O	O

106	NN	O	O
(	NN	O	O
79	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
eltrombopag	NN	O	B-INT
group	NN	O	O
responded	NN	O	B-OUT
to	NN	O	O
treatment	NN	O	O
at	NN	O	O
least	NN	O	O
once	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
17	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
odds	NN	O	O
of	NN	O	B-OUT
responding	NN	O	I-OUT
were	NN	O	O
greater	NN	O	O
in	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
eltrombopag	NN	O	B-INT
group	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
throughout	NN	O	O
the	NN	O	O
6-month	NN	O	O
treatment	NN	O	O
period	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
8?2	NN	O	O
,	NN	O	O
99	NN	O	O
%	NN	O	O
CI	NN	O	O
3?59-18?73	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0?0001	NN	O	O
)	NN	O	O
.	NN	O	O

37	NN	O	O
(	NN	O	O
59	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
receiving	NN	O	O
eltrombopag	NN	O	B-INT
reduced	NN	O	O
concomitant	NN	O	B-OUT
treatment	NN	O	I-OUT
versus	NN	O	O
ten	NN	O	O
(	NN	O	O
32	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
receiving	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
p=0?016	NN	O	O
)	NN	O	O
.	NN	O	O

24	NN	O	O
(	NN	O	O
18	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
receiving	NN	O	O
eltrombopag	NN	O	B-INT
needed	NN	O	O
rescue	NN	O	B-OUT
treatment	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
25	NN	O	O
(	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
receiving	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
p=0?001	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
(	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
receiving	NN	O	O
eltrombopag	NN	O	B-INT
had	NN	O	O
thromboembolic	NN	O	B-OUT
events	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
none	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

Nine	NN	O	O
(	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
eltrombopag-treated	NN	O	O
patients	NN	O	O
and	NN	O	O
two	NN	O	O
(	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
had	NN	O	O
mild	NN	O	O
increases	NN	O	O
in	NN	O	O
alanine	NN	O	B-OUT
aminotransferase	NN	O	I-OUT
concentration	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
five	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
eltrombopag-treated	NN	O	B-INT
patients	NN	O	O
(	NN	O	O
vs	NN	O	O
none	NN	O	O
allocated	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
)	NN	O	O
had	NN	O	O
increases	NN	O	O
in	NN	O	O
total	NN	O	B-OUT
bilirubin	NN	O	I-OUT
.	NN	O	O

Four	NN	O	O
(	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
taking	NN	O	O
placebo	NN	O	B-INT
had	NN	O	O
serious	NN	O	B-OUT
bleeding	NN	O	I-OUT
events	NN	O	I-OUT
,	NN	O	O
compared	NN	O	O
with	NN	O	O
one	NN	O	O
(	NN	O	O
<	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
eltrombopag	NN	O	B-INT
.	NN	O	O

INTERPRETATION	NN	O	O
Eltrombopag	NN	O	B-INT
is	NN	O	O
effective	NN	O	O
for	NN	O	O
management	NN	O	O
of	NN	O	O
chronic	NN	O	O
immune	NN	O	O
thrombocytopenia	NN	O	O
,	NN	O	O
and	NN	O	O
could	NN	O	O
be	NN	O	O
particularly	NN	O	O
beneficial	NN	O	O
for	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
not	NN	O	O
responded	NN	O	O
to	NN	O	O
splenectomy	NN	O	O
or	NN	O	O
previous	NN	O	O
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
benefits	NN	O	O
should	NN	O	O
be	NN	O	O
balanced	NN	O	O
with	NN	O	O
the	NN	O	O
potential	NN	O	O
risks	NN	O	O
associated	NN	O	O
with	NN	O	O
eltrombopag	NN	O	B-INT
treatment	NN	O	O
.	NN	O	O

FUNDING	NN	O	O
GlaxoSmithKline	NN	O	O
.	NN	O	O



--DOCSTART-- (20804366)

Randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
acupuncture	NN	O	B-INT
versus	NN	O	O
sham	NN	O	B-INT
acupuncture	NN	O	I-INT
in	NN	O	O
autism	NN	O	B-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
We	NN	O	O
aim	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
acupuncture	NN	O	B-INT
versus	NN	O	O
sham	NN	O	B-INT
acupuncture	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
single-blind	NN	O	O
randomized	NN	O	O
control	NN	O	O
trial	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
50	NN	O	B-PAR
children	NN	O	I-PAR
.	NN	O	O

These	NN	O	O
children	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
treatment	NN	O	O
group	NN	O	O
with	NN	O	O
tongue	NN	O	B-INT
acupuncture	NN	O	I-INT
(	NN	O	O
40	NN	O	O
sessions	NN	O	O
over	NN	O	O
8	NN	O	O
weeks	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
sham	NN	O	B-INT
tongue	NN	O	I-INT
acupuncture	NN	O	I-INT
to	NN	O	O
nonacupoints	NN	O	O
in	NN	O	O
the	NN	O	O
tongue	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
There	NN	O	O
was	NN	O	O
improvement	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
control	NN	O	O
groups	NN	O	O
in	NN	O	O
all	NN	O	O
assessed	NN	O	O
measures	NN	O	O
but	NN	O	O
more	NN	O	O
so	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
eye-hand	NN	O	B-OUT
coordination	NN	O	I-OUT
,	NN	O	I-OUT
performance	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
practical	NN	O	I-OUT
reasoning	NN	O	I-OUT
of	NN	O	I-OUT
Griffiths	NN	O	I-OUT
Mental	NN	O	I-OUT
Developmental	NN	O	I-OUT
Scale	NN	O	I-OUT
;	NN	O	I-OUT
(	NN	O	I-OUT
2	NN	O	I-OUT
)	NN	O	I-OUT
sensory-motor	NN	O	I-OUT
,	NN	O	I-OUT
social	NN	O	I-OUT
,	NN	O	I-OUT
affectual	NN	O	I-OUT
,	NN	O	I-OUT
language	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
score	NN	O	I-OUT
of	NN	O	I-OUT
Ritvo-Freeman	NN	O	I-OUT
Real	NN	O	I-OUT
Life	NN	O	I-OUT
Scale	NN	O	I-OUT
;	NN	O	I-OUT
(	NN	O	I-OUT
3	NN	O	I-OUT
)	NN	O	I-OUT
Comprehension	NN	O	I-OUT
Language	NN	O	I-OUT
age	NN	O	I-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
Reynell	NN	O	I-OUT
Language	NN	O	I-OUT
Developmental	NN	O	I-OUT
Scale	NN	O	I-OUT
;	NN	O	I-OUT
and	NN	O	I-OUT
(	NN	O	I-OUT
4	NN	O	I-OUT
)	NN	O	I-OUT
Total	NN	O	I-OUT
Score	NN	O	I-OUT
and	NN	O	I-OUT
Mental	NN	O	I-OUT
Age	NN	O	I-OUT
in	NN	O	I-OUT
Symbolic	NN	O	I-OUT
Play	NN	O	I-OUT
Test	NN	O	I-OUT
.	NN	O	I-OUT
The	NN	O	O
only	NN	O	O
statistically	NN	O	O
significant	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
self-care	NN	O	B-OUT
and	NN	O	I-OUT
cognition	NN	O	I-OUT
domains	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
Functional	NN	O	I-OUT
Independence	NN	O	I-OUT
Measure	NN	O	I-OUT
for	NN	O	I-OUT
children	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
We	NN	O	O
had	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
a	NN	O	O
short	NN	O	O
course	NN	O	O
of	NN	O	O
acupuncture	NN	O	B-INT
had	NN	O	O
efficacy	NN	O	O
in	NN	O	O
improving	NN	O	O
various	NN	O	O
developmental	NN	O	O
and	NN	O	O
behavioral	NN	O	O
aspects	NN	O	O
of	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
long-term	NN	O	O
efficacy	NN	O	O
in	NN	O	O
functional	NN	O	O
gain	NN	O	O
needs	NN	O	O
to	NN	O	O
be	NN	O	O
further	NN	O	O
explored	NN	O	O
.	NN	O	O



--DOCSTART-- (2088233)

The	NN	O	O
immediate	NN	O	B-OUT
efficacy	NN	O	I-OUT
of	NN	O	O
adjunctive	NN	O	O
doxycycline	NN	O	B-INT
in	NN	O	O
treatment	NN	O	O
of	NN	O	O
localized	NN	O	B-PAR
juvenile	NN	O	I-PAR
periodontitis	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
immediate	NN	O	B-OUT
clinical	NN	O	I-OUT
and	NN	O	I-OUT
microbiological	NN	O	I-OUT
efficacy	NN	O	I-OUT
of	NN	O	O
doxycycline	NN	O	B-INT
(	NN	O	O
100	NN	O	O
mg	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
)	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
benefit	NN	O	O
of	NN	O	O
adjunctive	NN	O	O
medication	NN	O	O
in	NN	O	O
16	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
localized	NN	O	I-PAR
juvenile	NN	O	I-PAR
periodontitis	NN	O	I-PAR
.	NN	O	O

Measurements	NN	O	O
of	NN	O	O
gingival	NN	O	B-OUT
fluid	NN	O	I-OUT
flow	NN	O	I-OUT
,	NN	O	I-OUT
probing	NN	O	I-OUT
depths	NN	O	I-OUT
,	NN	O	I-OUT
bleeding	NN	O	I-OUT
on	NN	O	I-OUT
probing	NN	O	I-OUT
and	NN	O	I-OUT
suppuration	NN	O	I-OUT
were	NN	O	O
determined	NN	O	O
at	NN	O	O
2	NN	O	O
periodontal	NN	O	O
sites	NN	O	O
with	NN	O	O
and	NN	O	O
2	NN	O	O
without	NN	O	O
radiographic	NN	O	O
attachment	NN	O	O
loss	NN	O	O
,	NN	O	O
at	NN	O	O
weeks	NN	O	O
0	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O

Subgingival	NN	O	B-OUT
bacterial	NN	O	I-OUT
samples	NN	O	I-OUT
were	NN	O	O
taken	NN	O	O
with	NN	O	O
curettes	NN	O	O
from	NN	O	O
the	NN	O	O
same	NN	O	O
sites	NN	O	O
.	NN	O	O

Spirochaetes	NN	O	B-OUT
were	NN	O	O
searched	NN	O	O
for	NN	O	O
by	NN	O	O
dark-field	NN	O	B-OUT
microscopy	NN	O	I-OUT
.	NN	O	O

Actinobacillus	NN	O	O
actinomycetemcomitans	NN	O	O
,	NN	O	O
pigmented	NN	O	O
and	NN	O	O
non-pigmented	NN	O	O
Bacteroides	NN	O	O
spp.	NN	O	O
,	NN	O	O
Capnocytophaga	NN	O	O
,	NN	O	O
Fusobacterium	NN	O	O
and	NN	O	O
Actinomyces	NN	O	O
spp	NN	O	O
.	NN	O	O

were	NN	O	O
cultured	NN	O	O
on	NN	O	O
various	NN	O	O
selective	NN	O	O
and	NN	O	O
non-selective	NN	O	O
media	NN	O	O
.	NN	O	O

Bacterial	NN	O	O
species	NN	O	O
found	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
and	NN	O	O
comprising	NN	O	O
on	NN	O	O
average	NN	O	O
5	NN	O	O
%	NN	O	O
or	NN	O	O
more	NN	O	O
of	NN	O	O
the	NN	O	O
cultivable	NN	O	O
flora	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
.	NN	O	O

Neither	NN	O	O
short-term	NN	O	B-OUT
clinical	NN	O	I-OUT
nor	NN	O	I-OUT
microbiological	NN	O	I-OUT
efficacy	NN	O	I-OUT
beyond	NN	O	O
that	NN	O	O
of	NN	O	O
a	NN	O	O
course	NN	O	O
of	NN	O	O
mechanical	NN	O	O
debridement	NN	O	O
alone	NN	O	O
was	NN	O	O
found	NN	O	O
by	NN	O	O
using	NN	O	O
systemic	NN	O	O
medication	NN	O	O
with	NN	O	O
doxycycline	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
localized	NN	O	I-PAR
juvenile	NN	O	I-PAR
periodontitis	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (20943715)

Visual	NN	O	B-INT
and	NN	O	I-INT
kinesthetic	NN	O	I-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
integrated	NN	O	O
with	NN	O	O
auditory	NN	O	B-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
for	NN	O	O
walking	NN	O	O
performance	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
chronic	NN	O	I-PAR
stroke	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
visual	NN	O	B-INT
and	NN	O	I-INT
kinesthetic	NN	O	I-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
on	NN	O	O
walking	NN	O	B-OUT
performance	NN	O	I-OUT
and	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
clinical	NN	O	O
feasibility	NN	O	O
of	NN	O	O
incorporating	NN	O	O
auditory	NN	O	B-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
into	NN	O	O
the	NN	O	O
training	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
Randomized	NN	O	O
crossover	NN	O	O
trial	NN	O	O
.	NN	O	O

SETTING	NN	O	O
Laboratory	NN	O	O
of	NN	O	O
a	NN	O	O
Department	NN	O	O
of	NN	O	O
Physical	NN	O	O
Therapy	NN	O	O
.	NN	O	O

SUBJECTS	NN	O	O
Fifteen	NN	O	B-PAR
subjects	NN	O	I-PAR
with	NN	O	I-PAR
post-stroke	NN	O	I-PAR
hemiparesis	NN	O	I-PAR
.	NN	O	O

INTERVENTION	NN	O	O
Four	NN	O	O
locomotor	NN	O	B-INT
imagery	NN	O	I-INT
trainings	NN	O	I-INT
on	NN	O	O
walking	NN	O	O
performance	NN	O	O
:	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
,	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
,	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
with	NN	O	I-INT
auditory	NN	O	I-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
and	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
with	NN	O	I-INT
auditory	NN	O	I-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURES	NN	O	O
The	NN	O	B-OUT
timed	NN	O	I-OUT
up-and-go	NN	O	I-OUT
test	NN	O	I-OUT
and	NN	O	I-OUT
electromyographic	NN	O	I-OUT
and	NN	O	I-OUT
kinematic	NN	O	I-OUT
analyses	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
affected	NN	O	I-OUT
lower	NN	O	I-OUT
limb	NN	O	I-OUT
during	NN	O	O
one	NN	O	O
gait	NN	O	O
cycle	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
After	NN	O	O
the	NN	O	O
interventions	NN	O	O
,	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
timed	NN	O	B-OUT
up-and-go	NN	O	I-OUT
test	NN	O	I-OUT
results	NN	O	O
between	NN	O	O
the	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
(	NN	O	O
25.69	NN	O	O
?	NN	O	O
16.16	NN	O	O
to	NN	O	O
23.97	NN	O	O
?	NN	O	O
14.30	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
with	NN	O	I-INT
auditory	NN	O	I-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
(	NN	O	O
22.68	NN	O	O
?	NN	O	O
12.35	NN	O	O
to	NN	O	O
15.77	NN	O	O
?	NN	O	O
8.58	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
swing	NN	O	O
and	NN	O	O
stance	NN	O	O
phases	NN	O	O
,	NN	O	O
the	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
exhibited	NN	O	O
significantly	NN	O	O
increased	NN	O	O
activation	NN	O	O
in	NN	O	O
a	NN	O	O
greater	NN	O	O
number	NN	O	O
of	NN	O	O
muscles	NN	O	O
and	NN	O	O
increased	NN	O	O
angular	NN	O	B-OUT
displacement	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
knee	NN	O	I-OUT
and	NN	O	I-OUT
ankle	NN	O	I-OUT
joints	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
the	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
,	NN	O	O
and	NN	O	O
these	NN	O	O
effects	NN	O	O
were	NN	O	O
more	NN	O	O
prominent	NN	O	O
when	NN	O	O
auditory	NN	O	B-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
was	NN	O	O
integrated	NN	O	O
into	NN	O	O
each	NN	O	O
form	NN	O	O
of	NN	O	O
locomotor	NN	O	B-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
.	NN	O	O

The	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
hamstring	NN	O	O
during	NN	O	O
the	NN	O	O
swing	NN	O	O
phase	NN	O	O
and	NN	O	O
the	NN	O	O
gastrocnemius	NN	O	O
during	NN	O	O
the	NN	O	O
stance	NN	O	O
phase	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
kinematic	NN	O	O
data	NN	O	O
of	NN	O	O
the	NN	O	O
knee	NN	O	O
joint	NN	O	O
,	NN	O	O
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
for	NN	O	O
posttest	NN	O	O
values	NN	O	O
between	NN	O	O
the	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
and	NN	O	O
the	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
with	NN	O	I-INT
auditory	NN	O	I-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
therapeutic	NN	O	O
effect	NN	O	O
may	NN	O	O
be	NN	O	O
further	NN	O	O
enhanced	NN	O	O
in	NN	O	O
the	NN	O	O
kinesthetic	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
than	NN	O	O
in	NN	O	O
the	NN	O	O
visual	NN	O	B-INT
locomotor	NN	O	I-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
.	NN	O	O

The	NN	O	O
auditory	NN	O	B-INT
step	NN	O	I-INT
rhythm	NN	O	I-INT
together	NN	O	O
with	NN	O	O
the	NN	O	O
locomotor	NN	O	B-INT
imagery	NN	O	I-INT
training	NN	O	I-INT
produces	NN	O	O
a	NN	O	O
greater	NN	O	O
positive	NN	O	O
effect	NN	O	O
in	NN	O	O
improving	NN	O	O
the	NN	O	O
walking	NN	O	B-OUT
performance	NN	O	I-OUT
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
post-stroke	NN	O	I-PAR
hemiparesis	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (21029638)

[	NN	O	O
Efficacy	NN	O	O
of	NN	O	O
paliperidone	NN	O	B-INT
extended-release	NN	O	O
tablets	NN	O	O
in	NN	O	O
the	NN	O	O
improvement	NN	O	O
of	NN	O	O
social	NN	O	B-OUT
functions	NN	O	I-OUT
in	NN	O	O
schizophrenics	NN	O	B-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
and	NN	O	O
controlled	NN	O	O
study	NN	O	O
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
explore	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
paliperidone	NN	O	B-INT
extended-release	NN	O	O
tablets	NN	O	O
in	NN	O	O
the	NN	O	O
improvement	NN	O	O
of	NN	O	O
social	NN	O	B-OUT
functions	NN	O	I-OUT
in	NN	O	O
schizophrenics	NN	O	B-PAR
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
81	NN	O	B-PAR
schizophrenics	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
study	NN	O	O
group	NN	O	O
with	NN	O	O
paliperidone	NN	O	B-INT
extended-release	NN	O	O
tablets	NN	O	O
and	NN	O	O
control	NN	O	O
group	NN	O	O
with	NN	O	O
risperidone	NN	O	B-INT
for	NN	O	O
a	NN	O	O
12-week	NN	O	O
treatment	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
assessed	NN	O	O
and	NN	O	O
analyzed	NN	O	O
by	NN	O	O
positive	NN	O	B-OUT
and	NN	O	I-OUT
negative	NN	O	I-OUT
symptoms	NN	O	I-OUT
scales	NN	O	I-OUT
(	NN	O	I-OUT
PANSS	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
social	NN	O	I-OUT
disability	NN	O	I-OUT
screening	NN	O	I-OUT
schedule	NN	O	I-OUT
(	NN	O	I-OUT
SDSS	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
treatment	NN	O	B-OUT
emergent	NN	O	I-OUT
symptom	NN	O	I-OUT
scale	NN	O	I-OUT
(	NN	O	I-OUT
TESS	NN	O	I-OUT
)	NN	O	I-OUT
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
6	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
and	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
In	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
factors	NN	O	B-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
scores	NN	O	I-OUT
of	NN	O	I-OUT
PANSS	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
[	NN	O	O
(	NN	O	O
12.0	NN	O	O
?	NN	O	O
2.8	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
12.1	NN	O	O
?	NN	O	O
3.6	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
26.2	NN	O	O
?	NN	O	O
5.0	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
50.2	NN	O	O
?	NN	O	O
8.7	NN	O	O
)	NN	O	O
]	NN	O	O
were	NN	O	O
all	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
at	NN	O	O
baseline	NN	O	O
[	NN	O	O
(	NN	O	O
24.7	NN	O	O
?	NN	O	O
5.3	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
23.8	NN	O	O
?	NN	O	O
3.6	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
45.0	NN	O	O
?	NN	O	O
2.9	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
93.5	NN	O	O
?	NN	O	O
6.8	NN	O	O
)	NN	O	O
]	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
9.60-16.78	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
positive	NN	O	B-OUT
factor	NN	O	I-OUT
,	NN	O	I-OUT
negative	NN	O	I-OUT
factor	NN	O	I-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
scores	NN	O	I-OUT
of	NN	O	I-OUT
PANSS	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
[	NN	O	O
(	NN	O	O
12.0	NN	O	O
?	NN	O	O
2.8	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
12.1	NN	O	O
?	NN	O	O
3.6	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
50.2	NN	O	O
?	NN	O	O
8.7	NN	O	O
)	NN	O	O
]	NN	O	O
were	NN	O	O
all	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
6	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
[	NN	O	O
(	NN	O	O
14.2	NN	O	O
?	NN	O	O
1.8	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
14.6	NN	O	O
?	NN	O	O
2.4	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
56.5	NN	O	O
?	NN	O	O
6.4	NN	O	O
)	NN	O	O
]	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
2.58-4.26	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
factors	NN	O	B-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
scores	NN	O	I-OUT
of	NN	O	I-OUT
PANSS	NN	O	I-OUT
in	NN	O	O
study	NN	O	O
group	NN	O	O
[	NN	O	O
(	NN	O	O
12.0	NN	O	O
?	NN	O	O
2.8	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
12.1	NN	O	O
?	NN	O	O
3.6	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
26.2	NN	O	O
?	NN	O	O
5.0	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
50.2	NN	O	O
?	NN	O	O
8.7	NN	O	O
)	NN	O	O
]	NN	O	O
were	NN	O	O
all	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
control	NN	O	O
group	NN	O	O
[	NN	O	O
(	NN	O	O
16.9	NN	O	O
?	NN	O	O
4.9	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
18.7	NN	O	O
?	NN	O	O
5.3	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
32.5	NN	O	O
?	NN	O	O
5.1	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	O
68.1	NN	O	O
?	NN	O	O
13.0	NN	O	O
)	NN	O	O
]	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
-4.28	NN	O	O
--	NN	O	O
5.67	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
total	NN	O	O
scores	NN	O	B-OUT
of	NN	O	I-OUT
SDSS	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
5.93	NN	O	O
?	NN	O	O
2.78	NN	O	O
)	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
at	NN	O	O
baseline	NN	O	O
(	NN	O	O
13.9	NN	O	O
?	NN	O	O
3.4	NN	O	O
)	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
10.83	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
total	NN	O	O
scores	NN	O	B-OUT
of	NN	O	I-OUT
SDSS	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
5.9	NN	O	O
?	NN	O	O
2.8	NN	O	O
)	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
6	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
7.6	NN	O	O
?	NN	O	O
2.9	NN	O	O
)	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
5.21	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

But	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
improvement	NN	O	O
in	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
1.88	NN	O	O
,	NN	O	O
P	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
12	NN	O	O
(	NN	O	O
th	NN	O	O
)	NN	O	O
weekend	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
total	NN	O	O
scores	NN	O	B-OUT
of	NN	O	I-OUT
SDSS	NN	O	I-OUT
in	NN	O	O
study	NN	O	O
group	NN	O	O
(	NN	O	O
5.9	NN	O	O
?	NN	O	O
2.8	NN	O	O
)	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
8.8	NN	O	O
?	NN	O	O
2.9	NN	O	O
)	NN	O	O
(	NN	O	O
t	NN	O	O
=	NN	O	O
-4.49	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
severe	NN	O	B-OUT
adverse	NN	O	I-OUT
effect	NN	O	I-OUT
was	NN	O	O
reported	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Paliperidone	NN	O	B-INT
extended-release	NN	O	O
tablets	NN	O	O
are	NN	O	O
effective	NN	O	O
to	NN	O	O
improve	NN	O	O
social	NN	O	B-OUT
functions	NN	O	I-OUT
and	NN	O	O
psychiatric	NN	O	B-OUT
symptoms	NN	O	I-OUT
of	NN	O	O
schizophrenics	NN	O	B-PAR
.	NN	O	O



--DOCSTART-- (21106663)

Time-varying	NN	O	O
smoking	NN	O	O
abstinence	NN	O	O
predicts	NN	O	O
lower	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
following	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
treatment	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
The	NN	O	O
question	NN	O	O
of	NN	O	O
whether	NN	O	O
abstinence	NN	O	O
during	NN	O	O
the	NN	O	O
months	NN	O	O
following	NN	O	O
a	NN	O	O
planned	NN	O	O
quit	NN	O	O
attempt	NN	O	O
exacerbates	NN	O	O
or	NN	O	O
improves	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
is	NN	O	O
an	NN	O	O
important	NN	O	O
clinical	NN	O	O
issue	NN	O	O
.	NN	O	O

Extant	NN	O	O
research	NN	O	O
has	NN	O	O
primarily	NN	O	O
modeled	NN	O	O
between-person	NN	O	O
covariation	NN	O	O
between	NN	O	O
postquit	NN	O	O
abstinence	NN	O	O
and	NN	O	O
depressive	NN	O	O
symptom	NN	O	O
trajectories	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
approach	NN	O	O
can	NN	O	O
not	NN	O	O
account	NN	O	O
for	NN	O	O
potential	NN	O	O
third	NN	O	O
variables	NN	O	O
between	NN	O	O
participants	NN	O	O
that	NN	O	O
may	NN	O	O
affect	NN	O	O
both	NN	O	O
smoking	NN	O	O
and	NN	O	O
depression	NN	O	O
.	NN	O	O

Accordingly	NN	O	O
,	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
examined	NN	O	O
within-person	NN	O	O
covariation	NN	O	O
between	NN	O	O
time-varying	NN	O	O
abstinence	NN	O	O
and	NN	O	O
depressive	NN	O	B-OUT
symptom	NN	O	I-OUT
in	NN	O	O
a	NN	O	O
multilevel	NN	O	O
model	NN	O	O
(	NN	O	O
MLM	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
allowed	NN	O	O
for	NN	O	O
transitions	NN	O	O
between	NN	O	O
smoking	NN	O	O
statuses	NN	O	O
within	NN	O	O
a	NN	O	O
participant	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Participants	NN	O	B-PAR
were	NN	O	I-PAR
236	NN	O	I-PAR
heavy	NN	O	I-PAR
drinking	NN	O	I-PAR
smokers	NN	O	I-PAR
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trial	NN	O	O
testing	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
incorporating	NN	O	O
brief	NN	O	O
alcohol	NN	O	B-INT
intervention	NN	O	I-INT
into	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
treatment	NN	O	O
.	NN	O	O

Depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
and	NN	O	O
biochemically	NN	O	B-OUT
verified	NN	O	I-OUT
abstinence	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
1	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
and	NN	O	O
2	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
16	NN	O	O
,	NN	O	O
and	NN	O	O
26	NN	O	O
weeks	NN	O	O
after	NN	O	O
quit	NN	O	O
date	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
MLMs	NN	O	O
indicated	NN	O	O
a	NN	O	O
slight	NN	O	O
increase	NN	O	O
in	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
over	NN	O	O
time	NN	O	O
in	NN	O	O
the	NN	O	O
sample	NN	O	O
as	NN	O	O
a	NN	O	O
whole	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
an	NN	O	O
inverse	NN	O	O
relation	NN	O	O
between	NN	O	O
time-varying	NN	O	O
abstinence	NN	O	O
(	NN	O	O
vs.	NN	O	O
smoking	NN	O	O
)	NN	O	O
and	NN	O	O
concurrent	NN	O	O
level	NN	O	B-OUT
of	NN	O	I-OUT
depressive	NN	O	I-OUT
symptoms	NN	O	I-OUT
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
transitions	NN	O	O
from	NN	O	O
smoking	NN	O	O
to	NN	O	O
abstinence	NN	O	O
within	NN	O	O
individuals	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
reductions	NN	O	O
in	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
During	NN	O	O
the	NN	O	O
first	NN	O	O
6	NN	O	O
months	NN	O	O
following	NN	O	O
a	NN	O	O
planned	NN	O	O
quit	NN	O	O
attempt	NN	O	O
,	NN	O	O
being	NN	O	O
abstinent	NN	O	O
in	NN	O	O
a	NN	O	O
particular	NN	O	O
week	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
lower	NN	O	O
levels	NN	O	O
of	NN	O	O
concurrent	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
not	NN	O	O
concordant	NN	O	O
with	NN	O	O
the	NN	O	O
view	NN	O	O
that	NN	O	O
intentional	NN	O	O
smoking	NN	O	O
abstinence	NN	O	O
exacerbates	NN	O	O
depressive	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

Efforts	NN	O	O
to	NN	O	O
promote	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
should	NN	O	O
highlight	NN	O	O
that	NN	O	O
individuals	NN	O	O
are	NN	O	O
likely	NN	O	O
to	NN	O	O
feel	NN	O	O
more	NN	O	O
rather	NN	O	O
than	NN	O	O
less	NN	O	O
psychologically	NN	O	O
healthy	NN	O	O
when	NN	O	O
they	NN	O	O
successfully	NN	O	O
quit	NN	O	O
smoking	NN	O	O
.	NN	O	O



--DOCSTART-- (21170734)

Serum	NN	O	O
biochemical	NN	O	O
characteristics	NN	O	O
of	NN	O	O
Beluga	NN	O	B-PAR
,	NN	O	I-PAR
Huso	NN	O	I-PAR
huso	NN	O	I-PAR
(	NN	O	I-PAR
L.	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
blood	NN	O	O
sampling	NN	O	O
after	NN	O	O
clove	NN	O	O
powder	NN	O	O
solution	NN	O	O
exposure	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
on	NN	O	O
serum	NN	O	O
parameters	NN	O	O
,	NN	O	O
Beluga	NN	O	B-PAR
,	NN	O	I-PAR
Huso	NN	O	I-PAR
huso	NN	O	I-PAR
(	NN	O	I-PAR
L.	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
blood-sampled	NN	O	O
immediately	NN	O	O
without	NN	O	O
anesthesia	NN	O	B-INT
(	NN	O	O
control	NN	O	O
)	NN	O	O
or	NN	O	O
subjected	NN	O	O
to	NN	O	O
following	NN	O	O
anesthesia	NN	O	B-INT
procedure	NN	O	O
:	NN	O	O
40	NN	O	O
,	NN	O	O
120	NN	O	O
,	NN	O	O
and	NN	O	O
240	NN	O	O
s	NN	O	O
exposure	NN	O	O
to	NN	O	O
3,000	NN	O	O
,	NN	O	O
700	NN	O	O
,	NN	O	O
and	NN	O	O
500	NN	O	O
mg	NN	O	O
l??	NN	O	O
clove	NN	O	B-INT
solution	NN	O	I-INT
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
after	NN	O	O
these	NN	O	O
periods	NN	O	O
,	NN	O	O
when	NN	O	O
fish	NN	O	B-PAR
were	NN	O	O
immobile	NN	O	O
and	NN	O	O
reached	NN	O	O
stage	NN	O	O
4	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Results	NN	O	O
showed	NN	O	O
that	NN	O	O
cortisol	NN	O	B-OUT
and	NN	O	I-OUT
glucose	NN	O	I-OUT
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
high	NN	O	O
in	NN	O	O
700	NN	O	O
and	NN	O	O
500	NN	O	O
but	NN	O	O
not	NN	O	O
3,000	NN	O	O
mg	NN	O	O
l??	NN	O	O
group	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
.	NN	O	O

Serum	NN	O	B-OUT
lactate	NN	O	I-OUT
levels	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
high	NN	O	O
in	NN	O	O
500	NN	O	O
mg	NN	O	O
l??	NN	O	O
group	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Lactate	NN	O	B-OUT
levels	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
differed	NN	O	O
between	NN	O	O
control	NN	O	O
,	NN	O	O
3,000	NN	O	O
,	NN	O	O
and	NN	O	O
700	NN	O	O
mg	NN	O	O
l??	NN	O	O
groups	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
serum	NN	O	B-OUT
levels	NN	O	I-OUT
of	NN	O	I-OUT
cholesterol	NN	O	I-OUT
,	NN	O	I-OUT
total	NN	O	I-OUT
protein	NN	O	I-OUT
,	NN	O	I-OUT
lactate	NN	O	I-OUT
dehydrogenase	NN	O	I-OUT
,	NN	O	I-OUT
aspartate	NN	O	I-OUT
aminotransferase	NN	O	I-OUT
,	NN	O	I-OUT
alanine	NN	O	I-OUT
aminotransferase	NN	O	I-OUT
,	NN	O	I-OUT
Na?	NN	O	I-OUT
,	NN	O	I-OUT
Cl?	NN	O	I-OUT
,	NN	O	I-OUT
K?	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
Ca??	NN	O	I-OUT
.	NN	O	O

Results	NN	O	O
suggest	NN	O	O
that	NN	O	O
rapid	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
higher	NN	O	O
dose	NN	O	O
is	NN	O	O
better	NN	O	O
than	NN	O	O
slow	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
lower	NN	O	O
dose	NN	O	O
for	NN	O	O
blood	NN	O	O
sampling	NN	O	O
in	NN	O	O
Beluga	NN	O	B-PAR
.	NN	O	O



--DOCSTART-- (21211686)

Lowering	NN	O	O
the	NN	O	O
triglyceride/high-density	NN	O	B-OUT
lipoprotein	NN	O	I-OUT
cholesterol	NN	O	I-OUT
ratio	NN	O	I-OUT
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
beneficial	NN	O	O
impact	NN	O	O
of	NN	O	O
pioglitazone	NN	O	B-INT
on	NN	O	O
progression	NN	O	O
of	NN	O	O
coronary	NN	O	B-OUT
atherosclerosis	NN	O	I-OUT
in	NN	O	O
diabetic	NN	O	B-PAR
patients	NN	O	I-PAR
:	NN	O	O
insights	NN	O	O
from	NN	O	O
the	NN	O	O
PERISCOPE	NN	O	O
(	NN	O	O
Pioglitazone	NN	O	O
Effect	NN	O	O
on	NN	O	O
Regression	NN	O	O
of	NN	O	O
Intravascular	NN	O	O
Sonographic	NN	O	O
Coronary	NN	O	O
Obstruction	NN	O	O
Prospective	NN	O	O
Evaluation	NN	O	O
)	NN	O	O
study	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
favorable	NN	O	O
effect	NN	O	O
of	NN	O	O
pioglitazone	NN	O	B-INT
on	NN	O	O
atheroma	NN	O	O
progression	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Diabetes	NN	O	O
mellitus	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
accelerated	NN	O	O
coronary	NN	O	O
atheroma	NN	O	O
progression	NN	O	O
.	NN	O	O

Pioglitazone	NN	O	B-INT
slowed	NN	O	O
progression	NN	O	O
compared	NN	O	O
with	NN	O	O
glimepiride	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
all	NN	O	O
,	NN	O	O
360	NN	O	B-PAR
diabetic	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
coronary	NN	O	I-PAR
artery	NN	O	I-PAR
disease	NN	O	I-PAR
were	NN	O	O
treated	NN	O	O
with	NN	O	O
pioglitazone	NN	O	B-INT
or	NN	O	O
glimepiride	NN	O	B-INT
for	NN	O	O
18	NN	O	O
months	NN	O	O
in	NN	O	O
the	NN	O	O
PERISCOPE	NN	O	O
(	NN	O	O
Pioglitazone	NN	O	O
Effect	NN	O	O
on	NN	O	O
Regression	NN	O	O
of	NN	O	O
Intravascular	NN	O	O
Sonographic	NN	O	O
Coronary	NN	O	O
Obstruction	NN	O	O
Prospective	NN	O	O
Evaluation	NN	O	O
)	NN	O	O
study	NN	O	O
.	NN	O	O

Coronary	NN	O	B-OUT
atheroma	NN	O	I-OUT
progression	NN	O	I-OUT
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
serial	NN	O	O
intravascular	NN	O	O
ultrasound	NN	O	O
.	NN	O	O

The	NN	O	O
relationship	NN	O	O
between	NN	O	O
changes	NN	O	B-OUT
in	NN	O	I-OUT
biochemical	NN	O	I-OUT
parameters	NN	O	I-OUT
,	NN	O	I-OUT
percent	NN	O	I-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Pioglitazone-treated	NN	O	B-INT
patients	NN	O	O
demonstrated	NN	O	O
greater	NN	O	O
increases	NN	O	O
in	NN	O	O
high-density	NN	O	B-OUT
lipoprotein	NN	O	I-OUT
cholesterol	NN	O	I-OUT
(	NN	O	I-OUT
HDL-C	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
reductions	NN	O	O
in	NN	O	O
glycated	NN	O	B-OUT
hemoglobin	NN	O	I-OUT
,	NN	O	I-OUT
triglycerides	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
C-reactive	NN	O	I-OUT
protein	NN	O	I-OUT
.	NN	O	O

Significant	NN	O	O
correlations	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
changes	NN	O	O
in	NN	O	O
percent	NN	O	B-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
and	NN	O	I-OUT
triglycerides	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.15	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
,	NN	O	O
triglyceride/HDL-C	NN	O	B-OUT
ratio	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.16	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
glycated	NN	O	B-OUT
hemoglobin	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.16	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
with	NN	O	O
pioglitazone	NN	O	B-INT
,	NN	O	O
and	NN	O	O
changes	NN	O	O
in	NN	O	O
low-density	NN	O	B-OUT
lipoprotein	NN	O	I-OUT
cholesterol	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
-0.15	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
apolipoprotein	NN	O	B-OUT
B	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
-0.16	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
apolipoprotein	NN	O	B-OUT
A-I	NN	O	I-OUT
(	NN	O	O
r	NN	O	O
=	NN	O	O
-0.20	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
with	NN	O	O
glimepiride	NN	O	B-INT
.	NN	O	O

Substantial	NN	O	O
atheroma	NN	O	O
regression	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
progression	NN	O	O
,	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
greater	NN	O	O
relative	NN	O	O
increases	NN	O	O
in	NN	O	O
HDL-C	NN	O	B-OUT
(	NN	O	O
14.2	NN	O	O
%	NN	O	O
vs.	NN	O	O
7.8	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
,	NN	O	O
relative	NN	O	O
decreases	NN	O	O
in	NN	O	O
triglycerides	NN	O	B-OUT
(	NN	O	O
-13.3	NN	O	O
%	NN	O	O
vs.	NN	O	O
-1.9	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.045	NN	O	O
)	NN	O	O
,	NN	O	O
triglyceride/HDL-C	NN	O	B-OUT
ratio	NN	O	I-OUT
(	NN	O	O
-22.5	NN	O	O
vs.	NN	O	O
-9.9	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
decrease	NN	O	O
in	NN	O	O
glycated	NN	O	B-OUT
hemoglobin	NN	O	I-OUT
(	NN	O	O
-0.6	NN	O	O
%	NN	O	O
vs.	NN	O	O
-0.3	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

Multivariable	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
pioglitazone-induced	NN	O	B-INT
effects	NN	O	O
on	NN	O	O
triglyceride/HDL-C	NN	O	B-OUT
were	NN	O	O
associated	NN	O	O
with	NN	O	O
changes	NN	O	O
in	NN	O	O
percent	NN	O	B-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
and	NN	O	O
total	NN	O	B-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Favorable	NN	O	O
effects	NN	O	O
of	NN	O	O
pioglitazone	NN	O	B-INT
on	NN	O	O
the	NN	O	O
triglyceride/HDL-C	NN	O	B-OUT
ratio	NN	O	I-OUT
correlated	NN	O	O
with	NN	O	O
delayed	NN	O	O
atheroma	NN	O	B-OUT
progression	NN	O	I-OUT
in	NN	O	O
diabetic	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
finding	NN	O	O
highlights	NN	O	O
the	NN	O	O
potential	NN	O	O
importance	NN	O	O
of	NN	O	O
targeting	NN	O	O
atherogenic	NN	O	O
dyslipidemia	NN	O	O
in	NN	O	O
diabetic	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
coronary	NN	O	I-PAR
artery	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (21393467)

Distinct	NN	O	O
fast	NN	O	O
and	NN	O	O
slow	NN	O	O
processes	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
selection	NN	O	O
of	NN	O	O
preferred	NN	O	O
step	NN	O	O
frequency	NN	O	O
during	NN	O	O
human	NN	O	B-PAR
walking	NN	O	O
.	NN	O	O

Humans	NN	O	O
spontaneously	NN	O	O
select	NN	O	O
a	NN	O	O
step	NN	O	O
frequency	NN	O	O
that	NN	O	O
minimizes	NN	O	O
the	NN	O	O
energy	NN	O	O
expenditure	NN	O	O
of	NN	O	O
walking	NN	O	O
.	NN	O	O

This	NN	O	O
selection	NN	O	O
might	NN	O	O
be	NN	O	O
embedded	NN	O	O
within	NN	O	O
the	NN	O	O
neural	NN	O	O
circuits	NN	O	O
that	NN	O	O
generate	NN	O	O
gait	NN	O	O
so	NN	O	O
that	NN	O	O
the	NN	O	O
optimum	NN	O	O
is	NN	O	O
pre-programmed	NN	O	O
for	NN	O	O
a	NN	O	O
given	NN	O	O
walking	NN	O	O
speed	NN	O	O
.	NN	O	O

Or	NN	O	O
perhaps	NN	O	O
step	NN	O	O
frequency	NN	O	O
is	NN	O	O
directly	NN	O	O
optimized	NN	O	O
,	NN	O	O
based	NN	O	O
on	NN	O	O
sensed	NN	O	O
feedback	NN	O	O
of	NN	O	O
energy	NN	O	O
expenditure	NN	O	O
.	NN	O	O

Direct	NN	O	O
optimization	NN	O	O
is	NN	O	O
expected	NN	O	O
to	NN	O	O
be	NN	O	O
slow	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
compounded	NN	O	O
effect	NN	O	O
of	NN	O	O
delays	NN	O	O
and	NN	O	O
iteration	NN	O	O
,	NN	O	O
whereas	NN	O	O
a	NN	O	O
pre-programmed	NN	O	O
mechanism	NN	O	O
presumably	NN	O	O
allows	NN	O	O
for	NN	O	O
faster	NN	O	O
step	NN	O	O
frequency	NN	O	O
selection	NN	O	O
,	NN	O	O
albeit	NN	O	O
dependent	NN	O	O
on	NN	O	O
prior	NN	O	O
experience	NN	O	O
.	NN	O	O

To	NN	O	O
test	NN	O	O
for	NN	O	O
both	NN	O	O
pre-programmed	NN	O	O
selection	NN	O	O
and	NN	O	O
direct	NN	O	O
optimization	NN	O	O
,	NN	O	O
we	NN	O	O
applied	NN	O	O
perturbations	NN	O	B-INT
to	NN	O	I-INT
treadmill	NN	O	I-INT
walking	NN	O	I-INT
to	NN	O	O
elicit	NN	O	O
transient	NN	O	O
changes	NN	O	O
in	NN	O	O
step	NN	O	O
frequency	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
human	NN	O	B-OUT
step	NN	O	I-OUT
frequency	NN	O	I-OUT
adjustments	NN	O	I-OUT
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
occurred	NN	O	O
with	NN	O	O
two	NN	O	O
components	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
dominating	NN	O	O
the	NN	O	O
response	NN	O	O
(	NN	O	O
66	NN	O	O
?	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
total	NN	O	O
amplitude	NN	O	O
change	NN	O	O
;	NN	O	O
mean	NN	O	O
?	NN	O	O
SD	NN	O	O
)	NN	O	O
and	NN	O	O
occurring	NN	O	O
quite	NN	O	O
quickly	NN	O	O
(	NN	O	O
1.44	NN	O	O
?	NN	O	O
1.14	NN	O	O
s	NN	O	O
to	NN	O	O
complete	NN	O	O
95	NN	O	O
%	NN	O	O
of	NN	O	O
total	NN	O	O
change	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
component	NN	O	O
was	NN	O	O
of	NN	O	O
smaller	NN	O	O
amplitude	NN	O	B-OUT
(	NN	O	O
35	NN	O	O
?	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
total	NN	O	O
change	NN	O	O
)	NN	O	O
and	NN	O	O
took	NN	O	O
tens	NN	O	O
of	NN	O	O
seconds	NN	O	O
(	NN	O	O
27.56	NN	O	O
?	NN	O	O
16.18	NN	O	O
s	NN	O	O
for	NN	O	O
95	NN	O	O
%	NN	O	O
completion	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
fast	NN	O	O
process	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
too	NN	O	O
fast	NN	O	O
for	NN	O	O
direct	NN	O	O
optimization	NN	O	O
and	NN	O	O
more	NN	O	O
indicative	NN	O	O
of	NN	O	O
a	NN	O	O
pre-programmed	NN	O	O
response	NN	O	O
.	NN	O	O

It	NN	O	O
also	NN	O	O
persisted	NN	O	O
even	NN	O	O
with	NN	O	O
unusual	NN	O	O
closed-loop	NN	O	O
perturbations	NN	O	O
that	NN	O	O
conflicted	NN	O	O
with	NN	O	O
prior	NN	O	O
experience	NN	O	O
and	NN	O	O
rendered	NN	O	O
the	NN	O	O
response	NN	O	O
energetically	NN	O	O
suboptimal	NN	O	O
.	NN	O	O

The	NN	O	O
slow	NN	O	O
process	NN	O	O
was	NN	O	O
more	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
timing	NN	O	O
expected	NN	O	O
for	NN	O	O
direct	NN	O	O
optimization	NN	O	O
.	NN	O	O

Our	NN	O	O
interpretation	NN	O	O
of	NN	O	O
these	NN	O	O
results	NN	O	O
is	NN	O	O
that	NN	O	O
humans	NN	O	B-PAR
may	NN	O	O
rely	NN	O	O
heavily	NN	O	O
on	NN	O	O
pre-programmed	NN	O	O
gaits	NN	O	O
to	NN	O	O
rapidly	NN	O	O
select	NN	O	O
their	NN	O	O
preferred	NN	O	O
step	NN	O	O
frequency	NN	O	O
and	NN	O	O
then	NN	O	O
gradually	NN	O	O
fine-tune	NN	O	O
that	NN	O	O
selection	NN	O	O
with	NN	O	O
direct	NN	O	O
optimization	NN	O	O
.	NN	O	O



--DOCSTART-- (21491990)

A	NN	O	O
novel	NN	O	O
approach	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
subgingival	NN	O	O
controlled-release	NN	O	O
chlorhexidine	NN	O	B-INT
delivery	NN	O	O
in	NN	O	O
chronic	NN	O	B-PAR
periodontitis	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
We	NN	O	O
aimed	NN	O	O
to	NN	O	O
analyze	NN	O	O
clinical	NN	O	B-OUT
,	NN	O	I-OUT
microbiologic	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
serologic	NN	O	I-OUT
effects	NN	O	I-OUT
of	NN	O	O
chlorhexidine	NN	O	B-INT
(	NN	O	I-INT
CHX	NN	O	I-INT
)	NN	O	I-INT
chips	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
subgingival	NN	O	O
controlled-release	NN	O	O
delivery	NN	O	O
device	NN	O	O
before	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
scaling	NN	O	O
and	NN	O	O
root	NN	O	O
planing	NN	O	O
(	NN	O	O
SRP	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Twenty-four	NN	O	B-PAR
patients	NN	O	I-PAR
presenting	NN	O	I-PAR
with	NN	O	I-PAR
?12	NN	O	I-PAR
teeth	NN	O	I-PAR
with	NN	O	I-PAR
probing	NN	O	I-PAR
depth	NN	O	I-PAR
(	NN	O	I-PAR
PD	NN	O	I-PAR
)	NN	O	I-PAR
?5	NN	O	I-PAR
mm	NN	O	I-PAR
and	NN	O	I-PAR
bleeding	NN	O	I-PAR
on	NN	O	I-PAR
probing	NN	O	I-PAR
were	NN	O	O
assigned	NN	O	O
in	NN	O	O
test	NN	O	O
or	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

After	NN	O	O
prophylaxis	NN	O	O
,	NN	O	O
CHX	NN	O	B-INT
chips	NN	O	I-INT
(	NN	O	O
test	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
chips	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
were	NN	O	O
placed	NN	O	O
in	NN	O	O
pockets	NN	O	O
with	NN	O	O
PD	NN	O	O
?5	NN	O	O
mm	NN	O	O
.	NN	O	O

Ten	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
SRP	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
all	NN	O	O
teeth	NN	O	O
with	NN	O	O
PD	NN	O	O
?4	NN	O	O
mm	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
appointment	NN	O	O
.	NN	O	O

Immediately	NN	O	O
after	NN	O	O
SRP	NN	O	O
,	NN	O	O
new	NN	O	O
chips	NN	O	O
were	NN	O	O
inserted	NN	O	O
in	NN	O	O
all	NN	O	O
pockets	NN	O	O
with	NN	O	O
PD	NN	O	O
?5	NN	O	O
mm	NN	O	O
.	NN	O	O

Parameters	NN	O	O
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
baseline	NN	O	O
;	NN	O	O
beginning	NN	O	O
of	NN	O	O
SRP	NN	O	O
;	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

Subgingival	NN	O	O
samples	NN	O	B-OUT
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
baseline	NN	O	O
;	NN	O	O
beginning	NN	O	O
of	NN	O	O
SRP	NN	O	O
;	NN	O	O
and	NN	O	O
at	NN	O	O
1	NN	O	O
month	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

Periodontal	NN	O	O
pathogens	NN	O	B-OUT
Aggregatibacter	NN	O	I-OUT
actinomycetemcomitans	NN	O	I-OUT
,	NN	O	I-OUT
Porphyromonas	NN	O	I-OUT
gingivalis	NN	O	I-OUT
,	NN	O	I-OUT
Prevotella	NN	O	I-OUT
intermedia	NN	O	I-OUT
,	NN	O	I-OUT
Tannerella	NN	O	I-OUT
forsythia	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
Treponema	NN	O	I-OUT
denticola	NN	O	I-OUT
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Serum	NN	O	B-OUT
levels	NN	O	O
of	NN	O	B-OUT
high	NN	O	I-OUT
sensitive	NN	O	I-OUT
C-reactive	NN	O	I-OUT
and	NN	O	I-OUT
lipopolysaccharide-binding	NN	O	I-OUT
proteins	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
.	NN	O	O

The	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
parameters	NN	O	O
between	NN	O	O
and	NN	O	O
within	NN	O	O
the	NN	O	O
groups	NN	O	O
were	NN	O	O
tested	NN	O	O
by	NN	O	O
Mann-Whitney	NN	O	B-OUT
U	NN	O	I-OUT
test	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
All	NN	O	O
clinical	NN	O	O
and	NN	O	O
serologic	NN	O	O
parameters	NN	O	O
improved	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
over	NN	O	O
time	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
clinical	NN	O	B-OUT
attachment	NN	O	I-OUT
level	NN	O	I-OUT
(	NN	O	I-OUT
CAL	NN	O	I-OUT
)	NN	O	I-OUT
gain	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
between	NN	O	O
groups	NN	O	O
(	NN	O	O
1.17	NN	O	O
mm	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
versus	NN	O	O
0.79	NN	O	O
mm	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
with	NN	O	O
CHX	NN	O	B-INT
chips	NN	O	I-INT
showed	NN	O	O
a	NN	O	O
greater	NN	O	O
reduction	NN	O	O
of	NN	O	B-OUT
the	NN	O	I-OUT
microorganisms	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
red	NN	O	I-OUT
complex	NN	O	I-OUT
after	NN	O	O
1	NN	O	O
month	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
use	NN	O	O
of	NN	O	O
CHX	NN	O	B-INT
chips	NN	O	I-INT
before	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
SRP	NN	O	O
improved	NN	O	O
CAL	NN	O	B-OUT
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
subgingival	NN	O	B-OUT
microorganisms	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
red	NN	O	I-OUT
complex	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	O
periodontitis	NN	O	O
.	NN	O	O



--DOCSTART-- (21669557)

Intervention	NN	O	O
to	NN	O	O
lower	NN	O	O
household	NN	O	O
wood	NN	O	O
smoke	NN	O	O
exposure	NN	O	O
in	NN	O	O
Guatemala	NN	O	O
reduces	NN	O	O
ST-segment	NN	O	B-OUT
depression	NN	O	I-OUT
on	NN	O	O
electrocardiograms	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
A	NN	O	O
large	NN	O	O
body	NN	O	O
of	NN	O	O
evidence	NN	O	O
suggests	NN	O	O
that	NN	O	O
fine	NN	O	O
particulate	NN	O	O
matter	NN	O	O
(	NN	O	O
PM	NN	O	O
)	NN	O	O
air	NN	O	O
pollution	NN	O	O
is	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
disease	NN	O	O
,	NN	O	O
but	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
in	NN	O	O
particular	NN	O	O
about	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
indoor	NN	O	O
air	NN	O	O
pollution	NN	O	O
from	NN	O	O
household	NN	O	O
use	NN	O	O
of	NN	O	O
solid	NN	O	O
fuels	NN	O	O
in	NN	O	O
developing	NN	O	O
countries	NN	O	O
.	NN	O	O

RESPIRE	NN	O	O
(	NN	O	O
Randomized	NN	O	O
Exposure	NN	O	O
Study	NN	O	O
of	NN	O	O
Pollution	NN	O	O
Indoors	NN	O	O
and	NN	O	O
Respiratory	NN	O	O
Effects	NN	O	O
)	NN	O	O
was	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
a	NN	O	O
chimney	NN	O	B-INT
woodstove	NN	O	I-INT
that	NN	O	O
reduces	NN	O	O
wood	NN	O	O
smoke	NN	O	O
exposure	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
We	NN	O	O
tested	NN	O	O
the	NN	O	O
hypotheses	NN	O	O
that	NN	O	O
the	NN	O	O
stove	NN	O	B-INT
intervention	NN	O	I-INT
,	NN	O	O
compared	NN	O	O
with	NN	O	O
open	NN	O	B-INT
fire	NN	O	I-INT
use	NN	O	O
,	NN	O	O
would	NN	O	O
reduce	NN	O	O
ST-segment	NN	O	B-OUT
depression	NN	O	I-OUT
and	NN	O	O
increase	NN	O	O
heart	NN	O	B-OUT
rate	NN	O	I-OUT
variability	NN	O	I-OUT
(	NN	O	I-OUT
HRV	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
used	NN	O	O
two	NN	O	O
complementary	NN	O	O
study	NN	O	O
designs	NN	O	O
:	NN	O	O
a	NN	O	O
)	NN	O	O
between-groups	NN	O	O
comparisons	NN	O	O
based	NN	O	O
on	NN	O	O
randomized	NN	O	O
stove	NN	O	B-INT
assignment	NN	O	O
,	NN	O	O
and	NN	O	O
b	NN	O	O
)	NN	O	O
before-and-after	NN	O	O
comparisons	NN	O	O
within	NN	O	O
control	NN	O	O
subjects	NN	O	O
who	NN	O	O
used	NN	O	O
open	NN	O	B-INT
fires	NN	O	I-INT
during	NN	O	O
the	NN	O	O
trial	NN	O	O
and	NN	O	O
received	NN	O	O
chimney	NN	O	B-INT
stoves	NN	O	I-INT
after	NN	O	O
the	NN	O	O
trial	NN	O	O
.	NN	O	O

Electrocardiogram	NN	O	O
sessions	NN	O	O
that	NN	O	O
lasted	NN	O	O
20	NN	O	O
hr	NN	O	O
were	NN	O	O
repeated	NN	O	O
up	NN	O	O
to	NN	O	O
three	NN	O	O
times	NN	O	O
among	NN	O	O
49	NN	O	B-PAR
intervention	NN	O	I-PAR
and	NN	O	I-PAR
70	NN	O	I-PAR
control	NN	O	I-PAR
women	NN	O	I-PAR
38-84	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
55	NN	O	I-PAR
control	NN	O	I-PAR
subjects	NN	O	I-PAR
were	NN	O	O
also	NN	O	O
assessed	NN	O	O
after	NN	O	O
receiving	NN	O	O
stoves	NN	O	B-INT
.	NN	O	O

HRV	NN	O	B-OUT
and	NN	O	I-OUT
ST-segment	NN	O	I-OUT
values	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
each	NN	O	O
30-min	NN	O	O
period	NN	O	O
.	NN	O	O

ST-segment	NN	O	B-OUT
depression	NN	O	I-OUT
was	NN	O	O
defined	NN	O	O
as	NN	O	O
an	NN	O	O
average	NN	O	O
value	NN	O	O
below	NN	O	O
-1.00	NN	O	O
mm	NN	O	O
.	NN	O	O

Personal	NN	O	B-OUT
fine	NN	O	I-OUT
PM	NN	O	I-OUT
[	NN	O	O
aerodynamic	NN	O	O
diameter	NN	O	O
?	NN	O	O
2.5	NN	O	O
?m	NN	O	O
(	NN	O	O
PM?.?	NN	O	O
]	NN	O	B-OUT
exposures	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
for	NN	O	O
24	NN	O	O
hr	NN	O	O
before	NN	O	O
each	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
PM?.?	NN	O	B-OUT
exposure	NN	O	I-OUT
means	NN	O	O
were	NN	O	O
266	NN	O	O
and	NN	O	O
102	NN	O	O
?g/m?	NN	O	O
during	NN	O	O
the	NN	O	O
trial	NN	O	O
period	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
intervention	NN	O	O
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
trial	NN	O	O
,	NN	O	O
the	NN	O	O
stove	NN	O	B-INT
intervention	NN	O	I-INT
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
odds	NN	O	O
ratio	NN	O	O
of	NN	O	O
0.26	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0.08-0.90	NN	O	O
)	NN	O	O
for	NN	O	O
ST-segment	NN	O	B-OUT
depression	NN	O	I-OUT
.	NN	O	O

We	NN	O	O
found	NN	O	O
similar	NN	O	O
associations	NN	O	O
with	NN	O	O
the	NN	O	O
before-and-after	NN	O	O
comparison	NN	O	O
.	NN	O	O

The	NN	O	O
intervention	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
HRV	NN	O	B-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
stove	NN	O	B-INT
intervention	NN	O	I-INT
was	NN	O	O
associated	NN	O	O
with	NN	O	O
reduced	NN	O	O
occurrence	NN	O	O
of	NN	O	O
nonspecific	NN	O	O
ST-segment	NN	O	B-OUT
depression	NN	O	I-OUT
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
household	NN	O	O
wood	NN	O	O
smoke	NN	O	O
exposures	NN	O	O
affect	NN	O	O
ventricular	NN	O	O
repolarization	NN	O	O
and	NN	O	O
potentially	NN	O	O
cardiovascular	NN	O	O
health	NN	O	O
.	NN	O	O



--DOCSTART-- (21718094)

Insulin	NN	O	B-INT
pump	NN	O	I-INT
therapy	NN	O	O
started	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
:	NN	O	O
effects	NN	O	O
on	NN	O	O
glycemic	NN	O	B-OUT
control	NN	O	I-OUT
and	NN	O	O
pancreatic	NN	O	B-OUT
?-cell	NN	O	I-OUT
function	NN	O	I-OUT
in	NN	O	O
type	NN	O	B-PAR
1	NN	O	I-PAR
diabetes	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
In	NN	O	O
the	NN	O	O
interest	NN	O	O
of	NN	O	O
preserving	NN	O	O
residual	NN	O	O
insulin	NN	O	O
secretory	NN	O	O
capacity	NN	O	O
present	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
with	NN	O	O
type	NN	O	B-PAR
1	NN	O	I-PAR
diabetes	NN	O	I-PAR
(	NN	O	I-PAR
T1D	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	O
we	NN	O	O
compared	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
starting	NN	O	O
insulin	NN	O	B-INT
pump	NN	O	I-INT
therapy	NN	O	O
at	NN	O	O
diagnosis	NN	O	O
with	NN	O	O
standard	NN	O	O
multiple	NN	O	O
daily	NN	O	O
insulin	NN	O	B-INT
injections	NN	O	O
(	NN	O	O
MDIs	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
pilot	NN	O	O
trial	NN	O	O
comparing	NN	O	O
MDI	NN	O	B-INT
therapy	NN	O	O
with	NN	O	O
continuous	NN	O	O
subcutaneous	NN	O	O
insulin	NN	O	B-INT
therapy	NN	O	I-INT
(	NN	O	O
pump	NN	O	B-INT
therapy	NN	O	I-INT
)	NN	O	O
in	NN	O	O
24	NN	O	B-PAR
patients	NN	O	I-PAR
,	NN	O	I-PAR
8-18	NN	O	I-PAR
years	NN	O	I-PAR
old	NN	O	I-PAR
,	NN	O	I-PAR
with	NN	O	I-PAR
newly	NN	O	I-PAR
diagnosed	NN	O	I-PAR
T1D	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
evaluated	NN	O	O
at	NN	O	O
enrollment	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
9	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
after	NN	O	O
initial	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
T1D	NN	O	O
.	NN	O	O

Preservation	NN	O	O
of	NN	O	B-OUT
insulin	NN	O	I-OUT
secretion	NN	O	I-OUT
,	NN	O	I-OUT
measured	NN	O	O
by	NN	O	O
mixed-meal-stimulated	NN	O	B-OUT
C-peptide	NN	O	I-OUT
secretion	NN	O	I-OUT
,	NN	O	O
was	NN	O	O
compared	NN	O	O
after	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Between-group	NN	O	O
differences	NN	O	O
in	NN	O	O
glycosylated	NN	O	B-OUT
hemoglobin	NN	O	I-OUT
(	NN	O	I-OUT
HbA1c	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
continuous	NN	O	I-OUT
glucose	NN	O	I-OUT
sensor	NN	O	I-OUT
data	NN	O	I-OUT
,	NN	O	I-OUT
insulin	NN	O	I-OUT
utilization	NN	O	I-OUT
,	NN	O	I-OUT
anthropometric	NN	O	I-OUT
measures	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
patient	NN	O	I-OUT
satisfaction	NN	O	I-OUT
with	NN	O	O
therapy	NN	O	O
were	NN	O	O
also	NN	O	O
compared	NN	O	O
at	NN	O	O
multiple	NN	O	O
time	NN	O	O
points	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Initiation	NN	O	O
of	NN	O	O
pump	NN	O	B-INT
therapy	NN	O	I-INT
within	NN	O	O
1	NN	O	O
month	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
resulted	NN	O	O
in	NN	O	O
consistently	NN	O	O
higher	NN	O	O
mixed-meal	NN	O	B-OUT
tolerance	NN	O	I-OUT
test-stimulated	NN	O	I-OUT
C-peptide	NN	O	I-OUT
values	NN	O	I-OUT
at	NN	O	O
all	NN	O	O
time	NN	O	O
points	NN	O	O
,	NN	O	O
although	NN	O	O
these	NN	O	O
differences	NN	O	O
were	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

Nonetheless	NN	O	O
,	NN	O	O
improved	NN	O	O
glycemic	NN	O	B-OUT
control	NN	O	I-OUT
was	NN	O	O
observed	NN	O	O
in	NN	O	O
insulin	NN	O	B-INT
pump-treated	NN	O	O
subjects	NN	O	O
(	NN	O	O
more	NN	O	O
time	NN	O	O
spent	NN	O	O
with	NN	O	O
normoglycemia	NN	O	O
,	NN	O	O
better	NN	O	O
mean	NN	O	O
HbA1c	NN	O	B-OUT
)	NN	O	O
,	NN	O	O
and	NN	O	O
pump-treated	NN	O	O
subjects	NN	O	O
reported	NN	O	O
comparatively	NN	O	O
greater	NN	O	O
satisfaction	NN	O	B-OUT
with	NN	O	O
route	NN	O	O
of	NN	O	O
treatment	NN	O	O
administration	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Initiation	NN	O	O
of	NN	O	O
insulin	NN	O	B-INT
pump	NN	O	I-INT
therapy	NN	O	I-INT
at	NN	O	O
diagnosis	NN	O	O
improved	NN	O	O
glycemic	NN	O	B-OUT
control	NN	O	I-OUT
,	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
and	NN	O	O
contributed	NN	O	O
to	NN	O	O
improved	NN	O	O
patient	NN	O	B-OUT
satisfaction	NN	O	I-OUT
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
also	NN	O	O
suggests	NN	O	O
that	NN	O	O
earlier	NN	O	O
use	NN	O	O
of	NN	O	O
pump	NN	O	O
therapy	NN	O	O
might	NN	O	O
help	NN	O	O
to	NN	O	O
preserve	NN	O	O
residual	NN	O	B-OUT
?-cell	NN	O	I-OUT
function	NN	O	I-OUT
,	NN	O	O
although	NN	O	O
a	NN	O	O
larger	NN	O	O
clinical	NN	O	O
trial	NN	O	O
would	NN	O	O
be	NN	O	O
required	NN	O	O
to	NN	O	O
confirm	NN	O	O
this	NN	O	O
.	NN	O	O



--DOCSTART-- (21866656)

[	NN	O	O
Clinical	NN	O	O
study	NN	O	O
on	NN	O	O
treatment	NN	O	O
of	NN	O	O
endometriosis-related	NN	O	B-PAR
infertility	NN	O	I-PAR
patients	NN	O	I-PAR
by	NN	O	O
laparoscopic	NN	O	B-INT
surgery	NN	O	I-INT
in	NN	O	O
combination	NN	O	O
of	NN	O	O
quyu	NN	O	B-INT
jiedu	NN	O	I-INT
recipe	NN	O	I-INT
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
clinical	NN	O	B-OUT
efficacy	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
laparoscopic	NN	O	B-INT
surgery	NN	O	I-INT
in	NN	O	O
combination	NN	O	O
of	NN	O	O
Quyu	NN	O	B-INT
Jiedu	NN	O	I-INT
Recipe	NN	O	I-INT
(	NN	O	I-INT
QYJDR	NN	O	I-INT
)	NN	O	I-INT
on	NN	O	O
endometriosis	NN	O	B-PAR
(	NN	O	I-PAR
EMs	NN	O	I-PAR
)	NN	O	I-PAR
-related	NN	O	I-PAR
infertility	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
130	NN	O	B-PAR
EMs-related	NN	O	I-PAR
infertility	NN	O	I-PAR
patients	NN	O	I-PAR
of	NN	O	I-PAR
blood	NN	O	I-PAR
stasis	NN	O	I-PAR
and	NN	O	I-PAR
toxin	NN	O	I-PAR
accumulation	NN	O	I-PAR
syndrome	NN	O	I-PAR
diagnosed	NN	O	I-PAR
and	NN	O	I-PAR
treated	NN	O	I-PAR
by	NN	O	I-PAR
laparoscopic	NN	O	I-PAR
surgery	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
,	NN	O	O
i.e.	NN	O	O
,	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
(	NN	O	O
75	NN	O	O
cases	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
55	NN	O	O
cases	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
routine	NN	O	O
progesterone	NN	O	B-INT
treatment	NN	O	O
after	NN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
.	NN	O	O

QYJDR	NN	O	B-INT
was	NN	O	O
given	NN	O	O
to	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
after	NN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
,	NN	O	O
lasting	NN	O	O
for	NN	O	O
twelve	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
pregnancy	NN	O	B-OUT
rate	NN	O	I-OUT
within	NN	O	O
one	NN	O	O
year	NN	O	O
after	NN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
were	NN	O	O
compared	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
Chinese	NN	O	B-OUT
medicine	NN	O	I-OUT
syndrome	NN	O	I-OUT
integrals	NN	O	I-OUT
,	NN	O	I-OUT
serum	NN	O	I-OUT
endometrium	NN	O	I-OUT
antibody	NN	O	I-OUT
(	NN	O	I-OUT
EMAb	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	I-OUT
cancer	NN	O	I-OUT
antigen	NN	O	I-OUT
125	NN	O	I-OUT
(	NN	O	I-OUT
CA125	NN	O	I-OUT
)	NN	O	I-OUT
levels	NN	O	I-OUT
were	NN	O	O
compared	NN	O	O
between	NN	O	O
before	NN	O	O
drug	NN	O	O
therapy	NN	O	O
and	NN	O	O
three	NN	O	O
months	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
pregnancy	NN	O	B-OUT
rate	NN	O	I-OUT
within	NN	O	O
one	NN	O	O
year	NN	O	O
after	NN	O	O
laparoscopic	NN	O	O
surgery	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
[	NN	O	O
61.33	NN	O	O
%	NN	O	O
(	NN	O	O
46/75	NN	O	O
)	NN	O	O
vs	NN	O	O
45.45	NN	O	O
%	NN	O	O
(	NN	O	O
25/55	NN	O	O
)	NN	O	O
]	NN	O	O
,	NN	O	O
showing	NN	O	O
significant	NN	O	O
difference	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
Chinese	NN	O	B-OUT
medicine	NN	O	I-OUT
syndrome	NN	O	I-OUT
integral	NN	O	I-OUT
was	NN	O	O
(	NN	O	O
16.07	NN	O	O
+/-	NN	O	O
6.77	NN	O	O
)	NN	O	O
score	NN	O	O
and	NN	O	O
(	NN	O	O
7.25	NN	O	O
+/-	NN	O	O
3.27	NN	O	O
)	NN	O	O
score	NN	O	O
before	NN	O	O
and	NN	O	O
3	NN	O	O
months	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
,	NN	O	O
while	NN	O	O
it	NN	O	O
was	NN	O	O
(	NN	O	O
15.92	NN	O	O
+/-	NN	O	O
7.51	NN	O	O
)	NN	O	O
score	NN	O	O
and	NN	O	O
(	NN	O	O
12.73	NN	O	O
+/-	NN	O	O
6.12	NN	O	O
)	NN	O	O
score	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
Chinese	NN	O	B-OUT
medicine	NN	O	I-OUT
syndrome	NN	O	I-OUT
integral	NN	O	I-OUT
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
before	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
group	NN	O	O
.	NN	O	O

Besides	NN	O	O
,	NN	O	O
the	NN	O	O
integral	NN	O	O
difference	NN	O	O
between	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
[	NN	O	O
(	NN	O	O
9.12	NN	O	O
+/-	NN	O	O
6.16	NN	O	O
)	NN	O	O
score	NN	O	O
vs	NN	O	O
(	NN	O	O
3.48	NN	O	O
+/-	NN	O	O
2.06	NN	O	O
)	NN	O	O
score	NN	O	O
)	NN	O	O
]	NN	O	O
,	NN	O	O
showing	NN	O	O
statistical	NN	O	O
difference	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
three-month	NN	O	O
drug	NN	O	O
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
serum	NN	O	B-OUT
EMAb	NN	O	I-OUT
negative	NN	O	O
conversion	NN	O	O
rate	NN	O	O
was	NN	O	O
obviously	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
44.44	NN	O	O
%	NN	O	O
vs	NN	O	O
15.62	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
showing	NN	O	O
statistical	NN	O	O
difference	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	B-OUT
CA125	NN	O	I-OUT
level	NN	O	I-OUT
was	NN	O	O
(	NN	O	O
31.88	NN	O	O
+/-	NN	O	O
15.78	NN	O	O
)	NN	O	O
U/mL	NN	O	O
before	NN	O	O
drug	NN	O	O
therapy	NN	O	O
and	NN	O	O
(	NN	O	O
18.82	NN	O	O
+/-	NN	O	O
10.08	NN	O	O
)	NN	O	O
U/mL	NN	O	O
three	NN	O	O
months	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
test	NN	O	O
group	NN	O	O
,	NN	O	O
while	NN	O	O
it	NN	O	O
was	NN	O	O
(	NN	O	O
30.63	NN	O	O
+/-	NN	O	O
19.28	NN	O	O
)	NN	O	O
U/mL	NN	O	O
and	NN	O	O
(	NN	O	O
18.05	NN	O	O
+/-	NN	O	O
11.20	NN	O	O
)	NN	O	O
U/mL	NN	O	O
respectively	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
lowered	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
with	NN	O	O
statistical	NN	O	O
difference	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
statistical	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
after	NN	O	O
drug	NN	O	O
therapy	NN	O	O
(	NN	O	O
P	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
laparoscopic	NN	O	B-INT
surgery	NN	O	I-INT
in	NN	O	O
combination	NN	O	O
of	NN	O	O
QYJDR	NN	O	B-INT
could	NN	O	O
effectively	NN	O	O
improve	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
of	NN	O	O
EMs	NN	O	O
patients	NN	O	O
of	NN	O	O
blood	NN	O	B-OUT
stasis	NN	O	I-OUT
and	NN	O	O
toxin	NN	O	B-OUT
accumulation	NN	O	I-OUT
syndrome	NN	O	I-OUT
,	NN	O	O
promote	NN	O	O
negative	NN	O	B-OUT
conversion	NN	O	I-OUT
of	NN	O	I-OUT
EMAb	NN	O	I-OUT
,	NN	O	O
lower	NN	O	O
serum	NN	O	B-OUT
CA125	NN	O	I-OUT
levels	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
elevate	NN	O	O
the	NN	O	O
clinical	NN	O	B-OUT
pregnancy	NN	O	I-OUT
rate	NN	O	I-OUT
.	NN	O	O

QYJDR	NN	O	B-INT
is	NN	O	O
an	NN	O	O
effective	NN	O	O
formula	NN	O	O
in	NN	O	O
treatment	NN	O	O
of	NN	O	O
EMs-related	NN	O	O
infertility	NN	O	O
.	NN	O	O



--DOCSTART-- (2188766)

Chronic	NN	O	O
vasodilator	NN	O	O
therapy	NN	O	O
with	NN	O	O
flosequinan	NN	O	B-INT
in	NN	O	O
congestive	NN	O	B-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
long-term	NN	O	B-OUT
effect	NN	O	I-OUT
of	NN	O	O
flosequinan	NN	O	B-INT
,	NN	O	O
a	NN	O	O
new	NN	O	O
orally	NN	O	O
administered	NN	O	O
arterial	NN	O	O
and	NN	O	O
venous	NN	O	O
dilator	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
clinical	NN	O	O
course	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
moderate	NN	O	I-PAR
to	NN	O	I-PAR
severe	NN	O	I-PAR
congestive	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
.	NN	O	O

Seventeen	NN	O	B-PAR
patients	NN	O	I-PAR
on	NN	O	I-PAR
chronic	NN	O	I-PAR
digitalis	NN	O	I-PAR
and	NN	O	I-PAR
diuretic	NN	O	I-PAR
therapy	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
flosequinan	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
fashion	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
symptomatology	NN	O	B-OUT
,	NN	O	I-OUT
exercise	NN	O	I-OUT
performance	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
left	NN	O	B-OUT
ventricular	NN	O	I-OUT
function	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
serially	NN	O	O
during	NN	O	O
the	NN	O	O
two-month	NN	O	O
treatment	NN	O	O
period	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
a	NN	O	O
modest	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
symptom	NN	O	B-OUT
scores	NN	O	I-OUT
and	NN	O	O
functional	NN	O	B-OUT
classification	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
flosequinan-treated	NN	O	O
patients	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Flosequinan	NN	O	B-INT
evoked	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
maximal	NN	O	B-OUT
exercise	NN	O	I-OUT
capacity	NN	O	I-OUT
.	NN	O	O

While	NN	O	O
long-term	NN	O	O
flosequinan	NN	O	B-INT
administration	NN	O	O
also	NN	O	O
effected	NN	O	O
a	NN	O	O
progressive	NN	O	O
increase	NN	O	O
in	NN	O	O
resting	NN	O	B-OUT
heart	NN	O	I-OUT
rate	NN	O	I-OUT
,	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
consistently	NN	O	O
improve	NN	O	O
indices	NN	O	O
of	NN	O	O
left	NN	O	B-OUT
ventricular	NN	O	I-OUT
systolic	NN	O	I-OUT
function	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
addition	NN	O	O
of	NN	O	O
chronic	NN	O	O
vasodilator	NN	O	O
therapy	NN	O	O
with	NN	O	O
flosequinan	NN	O	B-INT
to	NN	O	O
standard	NN	O	O
digitalis-diuretic	NN	O	O
regimens	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
inducing	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
moderate	NN	O	I-PAR
to	NN	O	I-PAR
severe	NN	O	I-PAR
chronic	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
.	NN	O	O

Trials	NN	O	O
involving	NN	O	O
larger	NN	O	O
patient	NN	O	O
populations	NN	O	O
will	NN	O	O
be	NN	O	O
necessary	NN	O	O
to	NN	O	O
confirm	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
preliminary	NN	O	O
study	NN	O	O
and	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
,	NN	O	O
subpopulations	NN	O	O
benefited	NN	O	O
,	NN	O	O
role	NN	O	O
in	NN	O	O
heart	NN	O	O
failure	NN	O	O
therapeutics	NN	O	O
,	NN	O	O
and	NN	O	O
so	NN	O	O
forth	NN	O	O
.	NN	O	O



--DOCSTART-- (21896676)

A	NN	O	O
physiotherapy	NN	O	B-INT
service	NN	O	I-INT
to	NN	O	O
an	NN	O	O
emergency	NN	O	O
extended	NN	O	O
care	NN	O	O
unit	NN	O	O
does	NN	O	O
not	NN	O	O
decrease	NN	O	O
admission	NN	O	B-OUT
rates	NN	O	I-OUT
to	NN	O	I-OUT
hospital	NN	O	I-OUT
:	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
One	NN	O	O
of	NN	O	O
the	NN	O	O
reasons	NN	O	O
physiotherapy	NN	O	B-INT
services	NN	O	O
are	NN	O	O
provided	NN	O	O
to	NN	O	O
emergency	NN	O	O
departments	NN	O	O
(	NN	O	O
EDs	NN	O	O
)	NN	O	O
and	NN	O	O
emergency	NN	O	O
extended	NN	O	O
care	NN	O	O
units	NN	O	O
(	NN	O	O
EECUs	NN	O	O
)	NN	O	O
is	NN	O	O
to	NN	O	O
review	NN	O	O
patients	NN	O	O
'	NN	O	O
mobility	NN	O	O
to	NN	O	O
ensure	NN	O	O
they	NN	O	O
are	NN	O	O
safe	NN	O	O
to	NN	O	O
be	NN	O	O
discharged	NN	O	O
home	NN	O	O
.	NN	O	O

AIM	NN	O	O
To	NN	O	O
investigate	NN	O	O
whether	NN	O	O
a	NN	O	O
physiotherapy	NN	O	B-INT
service	NN	O	I-INT
to	NN	O	O
an	NN	O	O
EECU	NN	O	O
altered	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
hospital	NN	O	I-OUT
admission	NN	O	I-OUT
,	NN	O	I-OUT
rate	NN	O	I-OUT
of	NN	O	I-OUT
re-presentation	NN	O	I-OUT
to	NN	O	I-OUT
the	NN	O	I-OUT
ED	NN	O	I-OUT
,	NN	O	I-OUT
visits	NN	O	I-OUT
to	NN	O	I-OUT
community	NN	O	I-OUT
healthcare	NN	O	I-OUT
practitioners	NN	O	I-OUT
,	NN	O	I-OUT
return	NN	O	I-OUT
to	NN	O	I-OUT
usual	NN	O	I-OUT
work/home/leisure	NN	O	I-OUT
activities	NN	O	I-OUT
and	NN	O	O
patient	NN	O	B-OUT
satisfaction	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
randomised	NN	O	O
trial	NN	O	O
with	NN	O	O
concealed	NN	O	O
allocation	NN	O	O
,	NN	O	O
assessor	NN	O	O
blinding	NN	O	O
and	NN	O	O
intention-to-treat	NN	O	O
analysis	NN	O	O
was	NN	O	O
undertaken	NN	O	O
in	NN	O	O
an	NN	O	O
EECU	NN	O	O
.	NN	O	O

The	NN	O	O
sample	NN	O	O
comprised	NN	O	O
186	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
mean	NN	O	I-PAR
age	NN	O	I-PAR
70	NN	O	I-PAR
years	NN	O	I-PAR
,	NN	O	I-PAR
123	NN	O	I-PAR
(	NN	O	I-PAR
66	NN	O	I-PAR
%	NN	O	I-PAR
)	NN	O	I-PAR
female	NN	O	I-PAR
patients	NN	O	I-PAR
,	NN	O	I-PAR
130	NN	O	I-PAR
(	NN	O	I-PAR
70	NN	O	I-PAR
%	NN	O	I-PAR
)	NN	O	I-PAR
trauma	NN	O	I-PAR
)	NN	O	I-PAR
who	NN	O	I-PAR
were	NN	O	I-PAR
referred	NN	O	I-PAR
for	NN	O	I-PAR
physiotherapy	NN	O	I-INT
assessment/intervention	NN	O	I-INT
.	NN	O	O

Referral	NN	O	O
occurred	NN	O	O
at	NN	O	O
any	NN	O	O
stage	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
EECU	NN	O	O
admission	NN	O	O
.	NN	O	O

All	NN	O	O
participants	NN	O	O
received	NN	O	O
medical/nursing	NN	O	O
care	NN	O	O
as	NN	O	O
required	NN	O	O
.	NN	O	O

The	NN	O	O
physiotherapy	NN	O	B-INT
group	NN	O	O
also	NN	O	O
received	NN	O	O
physiotherapy	NN	O	B-INT
assessment/intervention	NN	O	I-INT
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
physiotherapy	NN	O	B-INT
group	NN	O	O
had	NN	O	O
a	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
-18	NN	O	O
%	NN	O	O
to	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
lower	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
admission	NN	O	I-OUT
to	NN	O	I-OUT
hospital	NN	O	I-OUT
than	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
and	NN	O	O
a	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
-6	NN	O	O
%	NN	O	O
to	NN	O	O
13	NN	O	O
%	NN	O	O
)	NN	O	O
higher	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
re-presentation	NN	O	I-OUT
to	NN	O	I-OUT
the	NN	O	I-OUT
ED	NN	O	I-OUT
,	NN	O	O
which	NN	O	O
were	NN	O	O
statistically	NN	O	O
non-significant	NN	O	O
(	NN	O	O
p?0.45	NN	O	O
)	NN	O	O
.	NN	O	O

Differences	NN	O	O
between	NN	O	O
groups	NN	O	O
for	NN	O	O
use	NN	O	B-OUT
of	NN	O	I-OUT
community	NN	O	I-OUT
healthcare	NN	O	I-OUT
resources	NN	O	I-OUT
,	NN	O	I-OUT
return	NN	O	I-OUT
to	NN	O	I-OUT
usual	NN	O	I-OUT
work/home/leisure	NN	O	I-OUT
activities	NN	O	I-OUT
and	NN	O	I-OUT
satisfaction	NN	O	I-OUT
with	NN	O	I-OUT
their	NN	O	I-OUT
EECU	NN	O	I-OUT
care	NN	O	I-OUT
were	NN	O	O
small	NN	O	O
and	NN	O	O
not	NN	O	O
significant	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
A	NN	O	O
physiotherapy	NN	O	B-INT
service	NN	O	I-INT
for	NN	O	O
EECU	NN	O	O
patients	NN	O	O
,	NN	O	O
as	NN	O	O
provided	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
reduce	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
hospital	NN	O	I-OUT
admission	NN	O	I-OUT
,	NN	O	I-OUT
rate	NN	O	I-OUT
of	NN	O	I-OUT
re-presentation	NN	O	I-OUT
to	NN	O	I-OUT
the	NN	O	I-OUT
ED	NN	O	I-OUT
,	NN	O	I-OUT
use	NN	O	I-OUT
of	NN	O	I-OUT
community	NN	O	I-OUT
healthcare	NN	O	I-OUT
resources	NN	O	I-OUT
,	NN	O	O
or	NN	O	O
improve	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
return	NN	O	I-OUT
to	NN	O	I-OUT
usual	NN	O	I-OUT
work/home/leisure	NN	O	I-OUT
activities	NN	O	I-OUT
or	NN	O	I-OUT
patient	NN	O	I-OUT
satisfaction	NN	O	I-OUT
.	NN	O	O

Trial	NN	O	O
registration	NN	O	O
number	NN	O	O
ANZCTRN12609000106235	NN	O	O
.	NN	O	O



--DOCSTART-- (21914768)

Cancer	NN	O	O
information	NN	O	O
and	NN	O	O
anxiety	NN	O	B-OUT
:	NN	O	O
applying	NN	O	O
the	NN	O	O
extended	NN	O	O
parallel	NN	O	O
process	NN	O	O
model	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
concern	NN	O	O
that	NN	O	O
public	NN	O	O
education	NN	O	O
about	NN	O	O
testicular	NN	O	O
cancer	NN	O	O
(	NN	O	O
TC	NN	O	O
)	NN	O	O
may	NN	O	O
cause	NN	O	O
unnecessary	NN	O	O
anxiety	NN	O	O
.	NN	O	O

Psychological	NN	O	O
theory	NN	O	O
suggests	NN	O	O
that	NN	O	O
if	NN	O	O
threat	NN	O	O
(	NN	O	O
eg	NN	O	O
,	NN	O	O
TC	NN	O	O
)	NN	O	O
information	NN	O	O
is	NN	O	O
accompanied	NN	O	O
with	NN	O	O
threat	NN	O	O
control	NN	O	O
strategies	NN	O	O
(	NN	O	O
eg	NN	O	O
,	NN	O	O
testicular	NN	O	B-INT
self-examination	NN	O	I-INT
;	NN	O	I-INT
TSE	NN	O	O
)	NN	O	O
anxiety	NN	O	O
is	NN	O	O
less	NN	O	O
likely	NN	O	O
.	NN	O	O

Male	NN	O	B-PAR
students	NN	O	I-PAR
(	NN	O	I-PAR
N=443	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
either	NN	O	O
a	NN	O	O
TC	NN	O	B-INT
or	NN	O	O
TC	NN	O	B-INT
+TSE	NN	O	I-INT
information	NN	O	O
group	NN	O	O
or	NN	O	O
a	NN	O	O
no	NN	O	O
information	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
assessed	NN	O	O
at	NN	O	O
three	NN	O	O
time	NN	O	O
points	NN	O	O
.	NN	O	O

Anxiety	NN	O	B-OUT
levels	NN	O	I-OUT
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
and	NN	O	O
exposure	NN	O	O
to	NN	O	O
TC+TSE	NN	O	O
resulted	NN	O	O
in	NN	O	O
greater	NN	O	O
perceived	NN	O	B-OUT
message	NN	O	I-OUT
benefit	NN	O	I-OUT
,	NN	O	O
increased	NN	O	O
intention	NN	O	B-OUT
to	NN	O	I-OUT
self-examine	NN	O	I-OUT
and	NN	O	O
lower	NN	O	O
message	NN	O	B-OUT
denigration	NN	O	I-OUT
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
TC	NN	O	B-INT
information	NN	O	O
is	NN	O	O
not	NN	O	O
anxiogenic	NN	O	O
,	NN	O	O
but	NN	O	O
inclusion	NN	O	O
of	NN	O	O
TSE	NN	O	O
information	NN	O	O
may	NN	O	O
improve	NN	O	O
acceptance	NN	O	O
of	NN	O	O
disease	NN	O	O
awareness	NN	O	O
information	NN	O	O
.	NN	O	O



--DOCSTART-- (21924760)

Quality	NN	O	O
of	NN	O	O
individual	NN	O	O
INR	NN	O	O
control	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
stroke	NN	O	O
and	NN	O	O
bleeding	NN	O	O
events	NN	O	O
in	NN	O	O
atrial	NN	O	B-PAR
fibrillation	NN	O	I-PAR
patients	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
nested	NN	O	O
case	NN	O	O
control	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
ACTIVE	NN	O	O
W	NN	O	O
study	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
Time	NN	O	B-OUT
in	NN	O	I-OUT
therapeutic	NN	O	I-OUT
range	NN	O	I-OUT
(	NN	O	I-OUT
TTR	NN	O	I-OUT
)	NN	O	I-OUT
for	NN	O	O
international	NN	O	O
normalized	NN	O	O
ratio	NN	O	O
(	NN	O	O
INR	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
accepted	NN	O	O
quality	NN	O	O
measure	NN	O	O
of	NN	O	O
anticoagulation	NN	O	O
control	NN	O	O
in	NN	O	O
patient	NN	O	O
populations	NN	O	O
,	NN	O	O
but	NN	O	O
its	NN	O	O
usefulness	NN	O	O
for	NN	O	O
predicting	NN	O	O
stroke	NN	O	O
and	NN	O	O
bleeding	NN	O	O
in	NN	O	O
individuals	NN	O	O
is	NN	O	O
not	NN	O	O
well	NN	O	O
understood	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
In	NN	O	O
a	NN	O	O
nested	NN	O	O
case	NN	O	O
control	NN	O	O
analysis	NN	O	O
among	NN	O	O
ACTIVE	NN	O	B-PAR
W	NN	O	I-PAR
study	NN	O	I-PAR
patients	NN	O	I-PAR
,	NN	O	O
cases	NN	O	B-PAR
with	NN	O	I-PAR
stroke	NN	O	I-PAR
and	NN	O	I-PAR
cases	NN	O	I-PAR
with	NN	O	I-PAR
bleeding	NN	O	I-PAR
were	NN	O	I-PAR
separately	NN	O	I-PAR
matched	NN	O	I-PAR
with	NN	O	I-PAR
controls	NN	O	I-PAR
.	NN	O	O

Several	NN	O	O
anticoagulation	NN	O	O
quality	NN	O	O
measures	NN	O	O
were	NN	O	O
compared	NN	O	O
,	NN	O	O
overall	NN	O	O
and	NN	O	O
in	NN	O	O
a	NN	O	O
time-dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
32	NN	O	B-PAR
cases	NN	O	I-PAR
with	NN	O	I-PAR
ischemic	NN	O	I-PAR
stroke	NN	O	I-PAR
and	NN	O	I-PAR
234	NN	O	I-PAR
cases	NN	O	I-PAR
with	NN	O	I-PAR
bleeding	NN	O	I-PAR
in	NN	O	I-PAR
the	NN	O	I-PAR
analysis	NN	O	I-PAR
were	NN	O	O
matched	NN	O	O
in	NN	O	O
a	NN	O	O
4:1	NN	O	O
ratio	NN	O	O
to	NN	O	O
122	NN	O	O
and	NN	O	O
865	NN	O	O
controls	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Follow-up	NN	O	O
duration	NN	O	O
was	NN	O	O
257?154days	NN	O	O
for	NN	O	O
the	NN	O	O
stroke	NN	O	O
analysis	NN	O	O
and	NN	O	O
222?146days	NN	O	O
for	NN	O	O
the	NN	O	O
bleeding	NN	O	O
analysis	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
their	NN	O	O
respective	NN	O	O
controls	NN	O	O
,	NN	O	O
the	NN	O	O
study	NN	O	O
mean	NN	O	O
TTR	NN	O	B-OUT
of	NN	O	O
both	NN	O	O
stroke	NN	O	O
cases	NN	O	O
(	NN	O	O
53.9	NN	O	O
%	NN	O	O
?25.1	NN	O	O
vs	NN	O	O
63.4	NN	O	O
%	NN	O	O
?24.8	NN	O	O
;	NN	O	O
p=0.055	NN	O	O
)	NN	O	O
and	NN	O	O
bleeding	NN	O	O
cases	NN	O	O
(	NN	O	O
56.2	NN	O	O
%	NN	O	O
?25.4	NN	O	O
vs	NN	O	O
63.4	NN	O	O
%	NN	O	O
?26.8	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
was	NN	O	O
lower	NN	O	O
.	NN	O	O

Time	NN	O	B-OUT
below	NN	O	O
range	NN	O	O
for	NN	O	O
stroke	NN	O	O
and	NN	O	O
time	NN	O	B-OUT
above	NN	O	O
range	NN	O	O
for	NN	O	O
bleeding	NN	O	O
were	NN	O	O
only	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
month	NN	O	O
leading	NN	O	O
up	NN	O	O
to	NN	O	O
the	NN	O	O
event	NN	O	O
,	NN	O	O
not	NN	O	O
over	NN	O	O
the	NN	O	O
entire	NN	O	O
study	NN	O	O
period	NN	O	O
.	NN	O	O

Rather	NN	O	O
,	NN	O	O
over	NN	O	O
the	NN	O	O
entire	NN	O	O
study	NN	O	O
period	NN	O	O
bleeding	NN	O	O
cases	NN	O	O
spent	NN	O	O
more	NN	O	O
time	NN	O	O
below	NN	O	O
range	NN	O	O
than	NN	O	O
controls	NN	O	O
(	NN	O	O
26.8	NN	O	O
%	NN	O	O
?25.9	NN	O	O
vs	NN	O	O
20.8	NN	O	O
%	NN	O	O
?24.0	NN	O	O
;	NN	O	O
p=0.001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
TTR	NN	O	B-OUT
was	NN	O	O
lower	NN	O	O
in	NN	O	O
individual	NN	O	B-PAR
AF	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	O
stroke	NN	O	O
or	NN	O	O
bleeding	NN	O	O
compared	NN	O	O
with	NN	O	O
matched	NN	O	O
controls	NN	O	O
in	NN	O	O
ACTIVE	NN	O	O
W.	NN	O	O
Maintaining	NN	O	O
a	NN	O	O
high	NN	O	O
TTR	NN	O	O
,	NN	O	O
with	NN	O	O
equal	NN	O	O
importance	NN	O	O
to	NN	O	O
avoid	NN	O	O
low	NN	O	O
and	NN	O	O
high	NN	O	O
INRs	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
relevant	NN	O	O
goal	NN	O	O
of	NN	O	O
individual	NN	O	O
patient	NN	O	O
treatment	NN	O	O
to	NN	O	O
prevent	NN	O	O
stroke	NN	O	O
and	NN	O	O
bleeding	NN	O	O
.	NN	O	O



--DOCSTART-- (21975269)

Use	NN	O	O
of	NN	O	O
hormonal	NN	O	B-INT
contraceptives	NN	O	I-INT
and	NN	O	O
risk	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
transmission	NN	O	O
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
cohort	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Hormonal	NN	O	B-INT
contraceptives	NN	O	I-INT
are	NN	O	O
used	NN	O	O
widely	NN	O	O
but	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
HIV-1	NN	O	O
risk	NN	O	O
are	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
hormonal	NN	O	B-INT
contraceptive	NN	O	I-INT
use	NN	O	O
and	NN	O	O
risk	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
acquisition	NN	O	O
by	NN	O	O
women	NN	O	O
and	NN	O	O
HIV-1	NN	O	O
transmission	NN	O	O
from	NN	O	O
HIV-1-infected	NN	O	O
women	NN	O	O
to	NN	O	O
their	NN	O	O
male	NN	O	O
partners	NN	O	O
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
this	NN	O	O
prospective	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
followed	NN	O	O
up	NN	O	O
3790	NN	O	B-PAR
heterosexual	NN	O	I-PAR
HIV-1-serodiscordant	NN	O	I-PAR
couples	NN	O	I-PAR
participating	NN	O	I-PAR
in	NN	O	I-PAR
two	NN	O	I-PAR
longitudinal	NN	O	I-PAR
studies	NN	O	I-PAR
of	NN	O	I-PAR
HIV-1	NN	O	I-PAR
incidence	NN	O	I-PAR
in	NN	O	I-PAR
seven	NN	O	I-PAR
African	NN	O	I-PAR
countries	NN	O	I-PAR
.	NN	O	O

Among	NN	O	O
injectable	NN	O	O
and	NN	O	O
oral	NN	O	O
hormonal	NN	O	B-INT
contraceptive	NN	O	I-INT
users	NN	O	O
and	NN	O	O
non-users	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
rates	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
acquisition	NN	O	O
by	NN	O	O
women	NN	O	O
and	NN	O	O
HIV-1	NN	O	O
transmission	NN	O	O
from	NN	O	O
women	NN	O	O
to	NN	O	O
men	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
measure	NN	O	O
was	NN	O	O
HIV-1	NN	O	O
seroconversion	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
Cox	NN	O	O
proportional	NN	O	O
hazards	NN	O	O
regression	NN	O	O
and	NN	O	O
marginal	NN	O	O
structural	NN	O	O
modelling	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
contraceptive	NN	O	O
use	NN	O	O
on	NN	O	O
HIV-1	NN	O	O
risk	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
Among	NN	O	O
1314	NN	O	B-PAR
couples	NN	O	I-PAR
in	NN	O	I-PAR
which	NN	O	I-PAR
the	NN	O	I-PAR
HIV-1-seronegative	NN	O	I-PAR
partner	NN	O	I-PAR
was	NN	O	I-PAR
female	NN	O	I-PAR
(	NN	O	O
median	NN	O	O
follow-up	NN	O	O
18?0	NN	O	O
[	NN	O	O
IQR	NN	O	O
12?6-24?2	NN	O	O
]	NN	O	O
months	NN	O	O
)	NN	O	O
,	NN	O	O
rates	NN	O	O
of	NN	O	O
HIV-1	NN	O	B-OUT
acquisition	NN	O	I-OUT
were	NN	O	O
6?61	NN	O	O
per	NN	O	O
100	NN	O	O
person-years	NN	O	O
in	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
hormonal	NN	O	B-INT
contraception	NN	O	I-INT
and	NN	O	O
3?78	NN	O	O
per	NN	O	O
100	NN	O	O
person-years	NN	O	O
in	NN	O	O
those	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
(	NN	O	O
adjusted	NN	O	O
hazard	NN	O	O
ratio	NN	O	O
1?98	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1?06-3?68	NN	O	O
,	NN	O	O
p=0?03	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
2476	NN	O	O
couples	NN	O	B-PAR
in	NN	O	I-PAR
which	NN	O	I-PAR
the	NN	O	I-PAR
HIV-1-seronegative	NN	O	I-PAR
partner	NN	O	I-PAR
was	NN	O	I-PAR
male	NN	O	I-PAR
(	NN	O	O
median	NN	O	O
follow-up	NN	O	O
18?7	NN	O	O
[	NN	O	O
IQR	NN	O	O
12?8-24?2	NN	O	O
]	NN	O	O
months	NN	O	O
)	NN	O	O
,	NN	O	O
rates	NN	O	O
of	NN	O	O
HIV-1	NN	O	B-OUT
transmission	NN	O	I-OUT
from	NN	O	O
women	NN	O	O
to	NN	O	O
men	NN	O	O
were	NN	O	O
2?61	NN	O	O
per	NN	O	O
100	NN	O	O
person-years	NN	O	O
in	NN	O	O
couples	NN	O	O
in	NN	O	O
which	NN	O	O
women	NN	O	O
used	NN	O	O
hormonal	NN	O	B-INT
contraception	NN	O	I-INT
and	NN	O	O
1?51	NN	O	O
per	NN	O	O
100	NN	O	O
person-years	NN	O	O
in	NN	O	O
couples	NN	O	O
in	NN	O	O
which	NN	O	O
women	NN	O	O
did	NN	O	O
not	NN	O	O
use	NN	O	O
hormonal	NN	O	B-INT
contraception	NN	O	I-INT
(	NN	O	O
adjusted	NN	O	O
hazard	NN	O	O
ratio	NN	O	O
1?97	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1?12-3?45	NN	O	O
,	NN	O	O
p=0?02	NN	O	O
)	NN	O	O
.	NN	O	O

Marginal	NN	O	O
structural	NN	O	O
model	NN	O	O
analyses	NN	O	O
generated	NN	O	O
much	NN	O	O
the	NN	O	O
same	NN	O	O
results	NN	O	O
to	NN	O	O
the	NN	O	O
Cox	NN	O	O
proportional	NN	O	O
hazards	NN	O	O
regression	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
Women	NN	O	O
should	NN	O	O
be	NN	O	O
counselled	NN	O	O
about	NN	O	O
potentially	NN	O	O
increased	NN	O	O
risk	NN	O	B-OUT
of	NN	O	I-OUT
HIV-1	NN	O	I-OUT
acquisition	NN	O	I-OUT
and	NN	O	I-OUT
transmission	NN	O	I-OUT
with	NN	O	O
hormonal	NN	O	B-INT
contraception	NN	O	I-INT
,	NN	O	O
especially	NN	O	O
injectable	NN	O	O
methods	NN	O	O
,	NN	O	O
and	NN	O	O
about	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
dual	NN	O	O
protection	NN	O	O
with	NN	O	O
condoms	NN	O	O
to	NN	O	O
decrease	NN	O	O
HIV-1	NN	O	O
risk	NN	O	O
.	NN	O	O

Non-hormonal	NN	O	O
or	NN	O	O
low-dose	NN	O	O
hormonal	NN	O	B-INT
contraceptive	NN	O	I-INT
methods	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
for	NN	O	O
women	NN	O	O
with	NN	O	O
or	NN	O	O
at-risk	NN	O	O
for	NN	O	O
HIV-1	NN	O	O
.	NN	O	O

FUNDING	NN	O	O
US	NN	O	O
National	NN	O	O
Institutes	NN	O	O
of	NN	O	O
Health	NN	O	O
and	NN	O	O
the	NN	O	O
Bill	NN	O	O
&	NN	O	O
Melinda	NN	O	O
Gates	NN	O	O
Foundation	NN	O	O
.	NN	O	O



--DOCSTART-- (21982657)

A	NN	O	O
double-blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
multicenter	NN	O	O
study	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
cardiovascular	NN	O	B-OUT
effects	NN	O	I-OUT
of	NN	O	O
skeletal	NN	O	B-INT
myoblast	NN	O	I-INT
implantation	NN	O	I-INT
by	NN	O	O
catheter	NN	O	O
delivery	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
chronic	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
after	NN	O	I-PAR
myocardial	NN	O	I-PAR
infarction	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
We	NN	O	O
sought	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
preliminary	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
transcatheter	NN	O	O
intramyocardial	NN	O	O
administration	NN	O	O
of	NN	O	O
myoblasts	NN	O	B-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
(	NN	O	I-PAR
HF	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
MARVEL	NN	O	O
is	NN	O	O
a	NN	O	O
randomized	NN	O	O
placebo-controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
image-guided	NN	O	O
,	NN	O	O
catheter-based	NN	O	O
intramyocardial	NN	O	O
injection	NN	O	O
of	NN	O	O
placebo	NN	O	B-INT
or	NN	O	O
myoblasts	NN	O	B-INT
(	NN	O	O
400	NN	O	O
or	NN	O	O
800	NN	O	O
million	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
class	NN	O	I-PAR
II	NN	O	I-PAR
to	NN	O	I-PAR
IV	NN	O	I-PAR
HF	NN	O	I-PAR
and	NN	O	I-PAR
ejection	NN	O	I-PAR
fraction	NN	O	I-PAR
<	NN	O	I-PAR
35	NN	O	I-PAR
%	NN	O	I-PAR
.	NN	O	O

Primary	NN	O	O
end	NN	O	O
points	NN	O	O
were	NN	O	O
frequency	NN	O	B-OUT
of	NN	O	I-OUT
serious	NN	O	I-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
(	NN	O	I-OUT
safety	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
changes	NN	O	B-OUT
in	NN	O	I-OUT
6-minute	NN	O	I-OUT
walk	NN	O	I-OUT
test	NN	O	I-OUT
and	NN	O	O
Minnesota	NN	O	B-OUT
Living	NN	O	I-OUT
With	NN	O	I-OUT
HF	NN	O	I-OUT
score	NN	O	I-OUT
(	NN	O	I-OUT
efficacy	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Of	NN	O	B-PAR
330	NN	O	I-PAR
patients	NN	O	I-PAR
intended	NN	O	I-PAR
for	NN	O	I-PAR
enrollment	NN	O	I-PAR
,	NN	O	I-PAR
23	NN	O	I-PAR
were	NN	O	I-PAR
randomized	NN	O	I-PAR
(	NN	O	I-PAR
MARVEL-1	NN	O	I-PAR
)	NN	O	I-PAR
before	NN	O	I-PAR
stopping	NN	O	I-PAR
the	NN	O	I-PAR
study	NN	O	I-PAR
for	NN	O	I-PAR
financial	NN	O	I-PAR
reasons	NN	O	I-PAR
.	NN	O	O

RESULTS	NN	O	O
At	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
similar	NN	O	O
numbers	NN	O	O
of	NN	O	O
events	NN	O	O
occurred	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
:	NN	O	O
8	NN	O	O
(	NN	O	O
placebo	NN	O	B-INT
)	NN	O	O
,	NN	O	O
7	NN	O	O
(	NN	O	O
low	NN	O	O
dose	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
8	NN	O	O
(	NN	O	O
high	NN	O	O
dose	NN	O	O
)	NN	O	O
,	NN	O	O
without	NN	O	O
deaths	NN	O	O
.	NN	O	O

Ventricular	NN	O	B-OUT
tachycardia	NN	O	I-OUT
responsive	NN	O	I-OUT
to	NN	O	O
amiodarone	NN	O	O
was	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
myoblast-treated	NN	O	B-INT
patients	NN	O	O
:	NN	O	O
1	NN	O	O
(	NN	O	O
placebo	NN	O	B-INT
)	NN	O	O
,	NN	O	O
3	NN	O	O
(	NN	O	O
low	NN	O	O
dose	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
(	NN	O	O
high	NN	O	O
dose	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
trend	NN	O	O
toward	NN	O	O
improvement	NN	O	O
in	NN	O	O
functional	NN	O	B-OUT
capacity	NN	O	I-OUT
was	NN	O	O
noted	NN	O	O
in	NN	O	O
myoblast-treated	NN	O	B-INT
groups	NN	O	O
(	NN	O	O
?6-minute	NN	O	O
walk	NN	O	O
test	NN	O	O
of	NN	O	O
-3.6	NN	O	O
vs	NN	O	O
+95.6	NN	O	O
vs	NN	O	O
+85.5	NN	O	O
m	NN	O	O
[	NN	O	O
placebo	NN	O	O
vs	NN	O	O
low	NN	O	O
dose	NN	O	O
vs	NN	O	O
high	NN	O	O
dose	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.50	NN	O	O
]	NN	O	O
)	NN	O	O
without	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
Minnesota	NN	O	B-OUT
Living	NN	O	I-OUT
With	NN	O	I-OUT
HF	NN	O	I-OUT
scores	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
In	NN	O	O
HF	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
chronic	NN	O	I-PAR
postinfarction	NN	O	I-PAR
cardiomyopathy	NN	O	I-PAR
,	NN	O	O
transcatheter	NN	O	O
administration	NN	O	O
of	NN	O	O
myoblasts	NN	O	B-INT
in	NN	O	O
doses	NN	O	O
of	NN	O	O
400	NN	O	O
to	NN	O	O
800	NN	O	O
million	NN	O	O
cells	NN	O	O
is	NN	O	O
feasible	NN	O	O
and	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
important	NN	O	O
clinical	NN	O	O
benefits	NN	O	O
.	NN	O	O

Ventricular	NN	O	O
tachycardia	NN	O	O
may	NN	O	O
be	NN	O	O
provoked	NN	O	O
by	NN	O	O
myoblast	NN	O	B-INT
injection	NN	O	O
but	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
transient	NN	O	O
and	NN	O	O
treatable	NN	O	O
problem	NN	O	O
.	NN	O	O

A	NN	O	O
large-scale	NN	O	O
outcome	NN	O	O
trial	NN	O	O
of	NN	O	O
myoblast	NN	O	B-INT
administration	NN	O	O
in	NN	O	O
HF	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
postinfarction	NN	O	I-PAR
cardiomyopathy	NN	O	I-PAR
is	NN	O	O
feasible	NN	O	O
and	NN	O	O
warranted	NN	O	O
.	NN	O	O



--DOCSTART-- (22154769)

Safety	NN	O	B-OUT
,	NN	O	I-OUT
tolerability	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
immunogenicity	NN	O	I-OUT
after	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
doses	NN	O	O
of	NN	O	O
zoster	NN	O	B-INT
vaccine	NN	O	I-INT
in	NN	O	O
healthy	NN	O	B-PAR
adults	NN	O	I-PAR
?60	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
herpes	NN	O	O
zoster	NN	O	O
(	NN	O	O
HZ	NN	O	O
)	NN	O	O
and	NN	O	O
postherpetic	NN	O	O
neuralgia	NN	O	O
increase	NN	O	O
with	NN	O	O
age	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
age-related	NN	O	O
decrease	NN	O	O
in	NN	O	O
immunity	NN	O	O
to	NN	O	O
varicella-zoster	NN	O	O
virus	NN	O	O
(	NN	O	O
VZV	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
dose	NN	O	O
of	NN	O	O
zoster	NN	O	B-INT
vaccine	NN	O	I-INT
(	NN	O	I-INT
ZV	NN	O	I-INT
)	NN	O	I-INT
has	NN	O	O
demonstrated	NN	O	O
substantial	NN	O	O
protection	NN	O	O
against	NN	O	O
HZ	NN	O	O
;	NN	O	O
this	NN	O	O
study	NN	O	O
examined	NN	O	O
impact	NN	O	O
of	NN	O	O
a	NN	O	O
second	NN	O	O
dose	NN	O	O
of	NN	O	O
ZV	NN	O	B-INT
.	NN	O	O

METHODS	NN	O	O
Randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
multicenter	NN	O	O
study	NN	O	O
with	NN	O	O
210	NN	O	B-PAR
subjects	NN	O	I-PAR
?60	NN	O	I-PAR
years	NN	O	I-PAR
old	NN	O	I-PAR
compared	NN	O	O
immunity	NN	O	B-OUT
and	NN	O	I-OUT
safety	NN	O	I-OUT
profiles	NN	O	I-OUT
after	NN	O	O
one	NN	O	O
and	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
ZV	NN	O	B-INT
,	NN	O	O
separated	NN	O	O
by	NN	O	O
6	NN	O	O
weeks	NN	O	O
,	NN	O	O
vs.	NN	O	O
placebo	NN	O	O
.	NN	O	O

Immunogenicity	NN	O	O
was	NN	O	B-OUT
evaluated	NN	O	O
using	NN	O	O
VZV	NN	O	B-OUT
interferon-gamma	NN	O	I-OUT
(	NN	O	I-OUT
IFN-?	NN	O	I-OUT
)	NN	O	I-OUT
enzyme-linked	NN	O	I-OUT
immunospot	NN	O	I-OUT
(	NN	O	I-OUT
ELISPOT	NN	O	I-OUT
)	NN	O	I-OUT
assay	NN	O	I-OUT
and	NN	O	I-OUT
VZV	NN	O	I-OUT
glycoprotein	NN	O	I-OUT
enzyme-linked	NN	O	I-OUT
immunosorbent	NN	O	I-OUT
antibody	NN	O	I-OUT
(	NN	O	I-OUT
gpELISA	NN	O	I-OUT
)	NN	O	I-OUT
assay	NN	O	I-OUT
.	NN	O	O

Adverse	NN	O	O
experiences	NN	O	B-OUT
(	NN	O	I-OUT
AEs	NN	O	I-OUT
)	NN	O	I-OUT
were	NN	O	O
recorded	NN	O	O
on	NN	O	O
a	NN	O	O
standardized	NN	O	O
Vaccination	NN	O	O
Report	NN	O	O
Card	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
No	NN	O	O
serious	NN	O	O
vaccine-related	NN	O	B-OUT
AEs	NN	O	I-OUT
occurred	NN	O	O
.	NN	O	O

VZV	NN	O	B-OUT
IFN-?	NN	O	O
ELISPOT	NN	O	B-OUT
geometric	NN	O	I-OUT
mean	NN	O	I-OUT
count	NN	O	I-OUT
(	NN	O	I-OUT
GMC	NN	O	I-OUT
)	NN	O	I-OUT
of	NN	O	I-OUT
spot-forming	NN	O	I-OUT
cells	NN	O	I-OUT
per	NN	O	I-OUT
10	NN	O	I-OUT
(	NN	O	I-OUT
6	NN	O	I-OUT
)	NN	O	I-OUT
peripheral	NN	O	I-OUT
blood	NN	O	I-OUT
mononuclear	NN	O	I-OUT
cells	NN	O	I-OUT
increased	NN	O	O
in	NN	O	O
the	NN	O	O
ZV	NN	O	B-INT
group	NN	O	O
from	NN	O	O
16.9	NN	O	O
prevaccination	NN	O	O
to	NN	O	O
49.5	NN	O	O
and	NN	O	O
32.8	NN	O	O
at	NN	O	O
2	NN	O	O
and	NN	O	O
6	NN	O	O
weeks	NN	O	O
postdose	NN	O	O
1	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Two	NN	O	O
weeks	NN	O	O
,	NN	O	O
6	NN	O	O
weeks	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
postdose	NN	O	O
2	NN	O	O
,	NN	O	O
GMC	NN	O	O
was	NN	O	O
44.3	NN	O	O
,	NN	O	O
42.9	NN	O	O
,	NN	O	O
and	NN	O	O
36.5	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

GMC	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
peak	NN	O	O
ELISPOT	NN	O	B-OUT
response	NN	O	I-OUT
occurred	NN	O	O
?2	NN	O	O
weeks	NN	O	O
after	NN	O	O
each	NN	O	O
ZV	NN	O	B-INT
dose	NN	O	O
.	NN	O	O

The	NN	O	O
gpELISA	NN	O	O
geometric	NN	O	B-OUT
mean	NN	O	I-OUT
titers	NN	O	I-OUT
(	NN	O	I-OUT
GMTs	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
ZV	NN	O	B-INT
group	NN	O	O
were	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
at	NN	O	O
6	NN	O	O
weeks	NN	O	O
after	NN	O	O
each	NN	O	O
dose	NN	O	O
.	NN	O	O

Correlation	NN	O	O
between	NN	O	O
the	NN	O	O
IFN-?	NN	O	B-OUT
ELISPOT	NN	O	I-OUT
and	NN	O	I-OUT
gpELISA	NN	O	I-OUT
assays	NN	O	I-OUT
was	NN	O	O
poor	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
ZV	NN	O	B-INT
was	NN	O	O
generally	NN	O	O
well-tolerated	NN	O	O
and	NN	O	O
immunogenic	NN	O	O
in	NN	O	O
adults	NN	O	O
?60	NN	O	O
years	NN	O	O
old	NN	O	O
.	NN	O	O

A	NN	O	O
second	NN	O	O
dose	NN	O	O
of	NN	O	O
ZV	NN	O	B-INT
was	NN	O	O
generally	NN	O	O
safe	NN	O	B-OUT
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
boost	NN	O	O
VZV-specific	NN	O	O
immunity	NN	O	B-OUT
beyond	NN	O	O
levels	NN	O	O
achieved	NN	O	O
postdose	NN	O	O
1	NN	O	O
.	NN	O	O



--DOCSTART-- (2223363)

Effect	NN	O	O
of	NN	O	O
different	NN	O	O
rates	NN	O	O
of	NN	O	O
infusion	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
for	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
in	NN	O	O
elderly	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
changing	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
infusion	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
for	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
60	NN	O	B-PAR
elderly	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

Propofol	NN	O	B-INT
was	NN	O	O
administered	NN	O	O
at	NN	O	O
300	NN	O	O
,	NN	O	O
600	NN	O	O
or	NN	O	O
1200	NN	O	O
ml	NN	O	O
h-1	NN	O	O
until	NN	O	O
loss	NN	O	B-OUT
of	NN	O	I-OUT
consciousness	NN	O	I-OUT
(	NN	O	O
as	NN	O	O
judged	NN	O	O
by	NN	O	O
loss	NN	O	B-OUT
of	NN	O	I-OUT
verbal	NN	O	I-OUT
contact	NN	O	I-OUT
with	NN	O	I-OUT
the	NN	O	I-OUT
patient	NN	O	I-OUT
)	NN	O	I-OUT
had	NN	O	O
been	NN	O	O
achieved	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
induction	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
longer	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
slower	NN	O	O
infusion	NN	O	O
rates	NN	O	O
(	NN	O	O
104	NN	O	O
,	NN	O	O
68	NN	O	O
and	NN	O	O
51	NN	O	O
s	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
total	NN	O	B-OUT
dose	NN	O	I-OUT
used	NN	O	O
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
(	NN	O	O
1.2	NN	O	O
,	NN	O	O
1.6	NN	O	O
and	NN	O	O
2.5	NN	O	O
mg	NN	O	O
kg-1	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
systolic	NN	O	B-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
arterial	NN	O	I-OUT
pressure	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
300-ml	NN	O	O
h-1	NN	O	O
group	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
induction	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
induction	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
apnoea	NN	O	I-OUT
was	NN	O	O
also	NN	O	O
significantly	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
slower	NN	O	O
infusion	NN	O	O
group	NN	O	O
.	NN	O	O



--DOCSTART-- (2224060)

Randomized	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
chemoimmunotherapy	NN	O	O
with	NN	O	O
bestatin	NN	O	B-INT
of	NN	O	O
acute	NN	O	B-PAR
nonlymphocytic	NN	O	I-PAR
leukemia	NN	O	I-PAR
in	NN	O	I-PAR
adults	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
new	NN	O	O
immunomodulating	NN	O	O
agent	NN	O	O
,	NN	O	O
bestatin	NN	O	B-INT
(	NN	O	O
INN	NN	O	O
:	NN	O	O
Ubenimex	NN	O	O
has	NN	O	O
low	NN	O	O
toxicity	NN	O	O
even	NN	O	O
after	NN	O	O
long-term	NN	O	O
oral	NN	O	O
administration	NN	O	O
and	NN	O	O
has	NN	O	O
significant	NN	O	O
modifications	NN	O	O
in	NN	O	O
immunological	NN	O	O
response	NN	O	O
.	NN	O	O

A	NN	O	O
cooperative	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
bestatin	NN	O	B-INT
immunotherapy	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
remission	NN	O	O
maintenance	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
adult	NN	O	B-PAR
acute	NN	O	I-PAR
nonlymphocytic	NN	O	I-PAR
leukemia	NN	O	I-PAR
(	NN	O	I-PAR
ANLL	NN	O	I-PAR
)	NN	O	I-PAR
was	NN	O	O
performed	NN	O	O
.	NN	O	O

After	NN	O	O
induction	NN	O	O
of	NN	O	O
complete	NN	O	O
remission	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
the	NN	O	O
bestatin	NN	O	B-INT
group	NN	O	O
(	NN	O	O
30	NN	O	O
mg/bw	NN	O	O
per	NN	O	O
os	NN	O	O
(	NN	O	O
po	NN	O	O
)	NN	O	O
daily	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
101	NN	O	B-PAR
eligible	NN	O	I-PAR
cases	NN	O	I-PAR
(	NN	O	I-PAR
bestatin	NN	O	I-INT
:	NN	O	I-PAR
48	NN	O	I-PAR
,	NN	O	I-PAR
control	NN	O	I-PAR
:	NN	O	I-PAR
53	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
analyzed	NN	O	O
;	NN	O	O
the	NN	O	O
bestatin	NN	O	B-INT
group	NN	O	O
achieved	NN	O	O
longer	NN	O	O
remission	NN	O	B-OUT
than	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
and	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
longer	NN	O	O
survival	NN	O	B-OUT
.	NN	O	O

Though	NN	O	O
this	NN	O	O
prolongation	NN	O	B-OUT
of	NN	O	I-OUT
remission	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
significant	NN	O	O
in	NN	O	O
the	NN	O	O
bestatin	NN	O	B-INT
group	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
in	NN	O	O
the	NN	O	O
15-49	NN	O	O
yr	NN	O	O
age	NN	O	O
group	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
50-65	NN	O	O
yr	NN	O	O
age	NN	O	O
group	NN	O	O
it	NN	O	O
was	NN	O	O
significantly	NN	O	O
longer	NN	O	O
.	NN	O	O

Bestatin	NN	O	B-INT
is	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
clinically	NN	O	O
useful	NN	O	O
drug	NN	O	O
for	NN	O	O
immunotherapy	NN	O	O
of	NN	O	O
adult	NN	O	O
ANLL	NN	O	O
,	NN	O	O
since	NN	O	O
it	NN	O	O
has	NN	O	O
prolonged	NN	O	O
survival	NN	O	B-OUT
and	NN	O	I-OUT
remission	NN	O	I-OUT
especially	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
few	NN	O	O
side-effects	NN	O	B-OUT
.	NN	O	O



--DOCSTART-- (22271197)

Goal	NN	O	B-OUT
attainment	NN	O	I-OUT
scaling	NN	O	I-OUT
as	NN	O	O
an	NN	O	O
outcome	NN	O	O
measure	NN	O	O
in	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trials	NN	O	O
of	NN	O	O
psychosocial	NN	O	B-INT
interventions	NN	O	I-INT
in	NN	O	O
autism	NN	O	B-PAR
.	NN	O	O

Goal	NN	O	B-OUT
attainment	NN	O	I-OUT
scaling	NN	O	I-OUT
(	NN	O	I-OUT
GAS	NN	O	I-OUT
)	NN	O	I-OUT
holds	NN	O	O
promise	NN	O	O
as	NN	O	O
an	NN	O	O
idiographic	NN	O	O
approach	NN	O	O
for	NN	O	O
measuring	NN	O	O
outcomes	NN	O	O
of	NN	O	O
psychosocial	NN	O	B-INT
interventions	NN	O	I-INT
in	NN	O	O
community	NN	O	O
settings	NN	O	O
.	NN	O	O

GAS	NN	O	O
has	NN	O	O
been	NN	O	O
criticized	NN	O	O
for	NN	O	O
untested	NN	O	O
assumptions	NN	O	O
of	NN	O	O
scaling	NN	O	O
level	NN	O	O
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
interval	NN	O	O
or	NN	O	O
ordinal	NN	O	O
)	NN	O	O
,	NN	O	O
inter-individual	NN	O	O
equivalence	NN	O	O
and	NN	O	O
comparability	NN	O	O
,	NN	O	O
and	NN	O	O
reliability	NN	O	O
of	NN	O	O
coding	NN	O	O
across	NN	O	O
different	NN	O	O
behavioral	NN	O	O
observation	NN	O	O
methods	NN	O	O
.	NN	O	O

We	NN	O	O
tested	NN	O	O
assumptions	NN	O	O
of	NN	O	O
equality	NN	O	O
between	NN	O	O
GAS	NN	O	O
descriptions	NN	O	O
for	NN	O	O
outcome	NN	O	O
measurement	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
measurability	NN	O	O
,	NN	O	O
equidistance	NN	O	O
,	NN	O	O
level	NN	O	O
of	NN	O	O
difficulty	NN	O	O
,	NN	O	O
comparability	NN	O	O
of	NN	O	O
behavior	NN	O	O
samples	NN	O	O
collected	NN	O	O
from	NN	O	O
teachers	NN	O	O
vs.	NN	O	O
researchers	NN	O	O
and	NN	O	O
live	NN	O	O
vs.	NN	O	O
videotape	NN	O	O
)	NN	O	O
.	NN	O	O

Results	NN	O	O
suggest	NN	O	O
GAS	NN	O	O
descriptions	NN	O	O
can	NN	O	O
be	NN	O	O
evaluated	NN	O	O
for	NN	O	O
equivalency	NN	O	O
,	NN	O	O
that	NN	O	O
teacher	NN	O	O
collected	NN	O	O
behavior	NN	O	O
samples	NN	O	O
are	NN	O	O
representative	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
varied	NN	O	O
sources	NN	O	O
of	NN	O	O
behavior	NN	O	O
samples	NN	O	O
can	NN	O	O
be	NN	O	O
reliably	NN	O	O
coded	NN	O	O
.	NN	O	O

GAS	NN	O	O
is	NN	O	O
a	NN	O	O
promising	NN	O	O
measurement	NN	O	O
approach	NN	O	O
.	NN	O	O

Recommendations	NN	O	O
are	NN	O	O
provided	NN	O	O
to	NN	O	O
ensure	NN	O	O
methodological	NN	O	O
quality	NN	O	O
.	NN	O	O



--DOCSTART-- (22341427)

Intermediate-term	NN	O	O
mortality	NN	O	O
and	NN	O	O
cardiac	NN	O	B-INT
transplantation	NN	O	I-INT
in	NN	O	O
infants	NN	O	B-PAR
with	NN	O	I-PAR
single-ventricle	NN	O	I-PAR
lesions	NN	O	I-PAR
:	NN	O	O
risk	NN	O	O
factors	NN	O	O
and	NN	O	O
their	NN	O	O
interaction	NN	O	O
with	NN	O	O
shunt	NN	O	O
type	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
study	NN	O	O
objective	NN	O	O
was	NN	O	O
to	NN	O	O
identify	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
death	NN	O	O
and	NN	O	O
cardiac	NN	O	B-INT
transplantation	NN	O	I-INT
in	NN	O	O
infants	NN	O	B-PAR
undergoing	NN	O	I-PAR
the	NN	O	I-PAR
Norwood	NN	O	I-PAR
procedure	NN	O	I-PAR
and	NN	O	O
to	NN	O	O
determine	NN	O	O
differences	NN	O	O
in	NN	O	O
associations	NN	O	O
that	NN	O	O
might	NN	O	O
favor	NN	O	O
the	NN	O	O
modified	NN	O	O
Blalock-Taussig	NN	O	O
shunt	NN	O	O
or	NN	O	O
a	NN	O	O
right	NN	O	O
ventricle-to-pulmonary	NN	O	O
artery	NN	O	O
shunt	NN	O	O
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
used	NN	O	O
competing	NN	O	O
risks	NN	O	O
methodology	NN	O	O
to	NN	O	O
analyze	NN	O	O
death	NN	O	O
without	NN	O	O
transplantation	NN	O	O
,	NN	O	O
cardiac	NN	O	O
transplantation	NN	O	O
,	NN	O	O
and	NN	O	O
survival	NN	O	O
without	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Parametric	NN	O	O
time-to-event	NN	O	O
modeling	NN	O	O
and	NN	O	O
bootstrapping	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
identify	NN	O	O
independent	NN	O	O
predictors	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Data	NN	O	O
from	NN	O	O
549	NN	O	B-PAR
subjects	NN	O	I-PAR
(	NN	O	I-PAR
follow-up	NN	O	I-PAR
,	NN	O	I-PAR
2.7	NN	O	I-PAR
?	NN	O	I-PAR
0.9	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Mortality	NN	O	O
risk	NN	O	B-OUT
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
early	NN	O	O
and	NN	O	O
constant	NN	O	O
phases	NN	O	O
;	NN	O	O
transplant	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
only	NN	O	O
a	NN	O	O
constant	NN	O	O
phase	NN	O	O
.	NN	O	O

Early	NN	O	O
phase	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
death	NN	O	B-OUT
included	NN	O	O
lower	NN	O	O
socioeconomic	NN	O	O
status	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.01	NN	O	O
)	NN	O	O
,	NN	O	O
obstructed	NN	O	O
pulmonary	NN	O	O
venous	NN	O	O
return	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
,	NN	O	O
smaller	NN	O	O
ascending	NN	O	O
aorta	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.02	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
anatomic	NN	O	O
subtype	NN	O	O
.	NN	O	O

Constant	NN	O	O
phase	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
death	NN	O	B-OUT
included	NN	O	O
genetic	NN	O	O
syndrome	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
and	NN	O	O
lower	NN	O	O
gestational	NN	O	O
age	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
right	NN	O	O
ventricle-to-pulmonary	NN	O	O
artery	NN	O	O
shunt	NN	O	O
demonstrated	NN	O	O
better	NN	O	O
survival	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
51	NN	O	O
%	NN	O	O
of	NN	O	O
subjects	NN	O	O
who	NN	O	O
were	NN	O	O
full	NN	O	O
term	NN	O	O
with	NN	O	O
aortic	NN	O	O
atresia	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
modified	NN	O	O
Blalock-Taussig	NN	O	O
shunt	NN	O	O
was	NN	O	O
better	NN	O	O
among	NN	O	O
the	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
subjects	NN	O	O
who	NN	O	O
were	NN	O	O
preterm	NN	O	O
with	NN	O	O
a	NN	O	O
patent	NN	O	O
aortic	NN	O	O
valve	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.003	NN	O	O
)	NN	O	O
.	NN	O	O

Lower	NN	O	O
pre-Norwood	NN	O	O
right	NN	O	O
ventricular	NN	O	O
fractional	NN	O	O
area	NN	O	O
change	NN	O	O
,	NN	O	O
pre-Norwood	NN	O	O
surgery	NN	O	O
,	NN	O	O
and	NN	O	O
anatomy	NN	O	O
other	NN	O	O
than	NN	O	O
hypoplastic	NN	O	O
left	NN	O	O
heart	NN	O	O
syndrome	NN	O	O
were	NN	O	O
independently	NN	O	O
associated	NN	O	O
with	NN	O	O
transplantation	NN	O	O
(	NN	O	O
all	NN	O	O
P	NN	O	O
<	NN	O	O
.03	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
shunt	NN	O	O
type	NN	O	O
was	NN	O	O
not	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.43	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Independent	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
intermediate-term	NN	O	O
mortality	NN	O	O
include	NN	O	O
lower	NN	O	O
socioeconomic	NN	O	O
status	NN	O	O
,	NN	O	O
anatomy	NN	O	O
,	NN	O	O
genetic	NN	O	O
syndrome	NN	O	O
,	NN	O	O
and	NN	O	O
lower	NN	O	O
gestational	NN	O	O
age	NN	O	O
.	NN	O	O

Term	NN	O	O
infants	NN	O	B-PAR
with	NN	O	O
aortic	NN	O	O
atresia	NN	O	O
benefited	NN	O	O
from	NN	O	O
a	NN	O	O
right	NN	O	O
ventricle-to-pulmonary	NN	O	O
artery	NN	O	O
shunt	NN	O	O
,	NN	O	O
and	NN	O	O
preterm	NN	O	O
infants	NN	O	B-PAR
with	NN	O	O
a	NN	O	O
patent	NN	O	O
aortic	NN	O	O
valve	NN	O	O
benefited	NN	O	O
from	NN	O	O
a	NN	O	O
modified	NN	O	O
Blalock-Taussig	NN	O	O
shunt	NN	O	O
.	NN	O	O

Right	NN	O	O
ventricular	NN	O	O
function	NN	O	O
and	NN	O	O
anatomy	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
shunt	NN	O	O
type	NN	O	O
,	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
transplantation	NN	O	O
.	NN	O	O



--DOCSTART-- (22416755)

Preschoolers	NN	O	B-PAR
acquire	NN	O	O
general	NN	O	O
knowledge	NN	O	O
by	NN	O	O
sharing	NN	O	O
in	NN	O	O
pretense	NN	O	B-INT
.	NN	O	O

Children	NN	O	O
acquire	NN	O	O
general	NN	O	O
knowledge	NN	O	O
about	NN	O	O
many	NN	O	O
kinds	NN	O	O
of	NN	O	O
things	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
are	NN	O	O
few	NN	O	O
known	NN	O	O
means	NN	O	O
by	NN	O	O
which	NN	O	O
this	NN	O	O
knowledge	NN	O	O
is	NN	O	O
acquired	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
article	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
proposed	NN	O	O
that	NN	O	O
children	NN	O	O
acquire	NN	O	O
generic	NN	O	O
knowledge	NN	O	O
by	NN	O	O
sharing	NN	O	O
in	NN	O	O
pretend	NN	O	B-INT
play	NN	O	I-INT
.	NN	O	O

In	NN	O	O
Experiment	NN	O	O
1	NN	O	O
,	NN	O	O
twenty-two	NN	O	B-PAR
3-	NN	O	I-PAR
to	NN	O	I-PAR
4-year-olds	NN	O	I-PAR
watched	NN	O	O
pretense	NN	O	B-INT
in	NN	O	O
which	NN	O	O
a	NN	O	O
puppet	NN	O	O
represented	NN	O	O
a	NN	O	O
nerp	NN	O	O
(	NN	O	O
an	NN	O	O
unfamiliar	NN	O	O
kind	NN	O	O
of	NN	O	O
animal	NN	O	O
)	NN	O	O
.	NN	O	O

For	NN	O	O
instance	NN	O	O
,	NN	O	O
in	NN	O	O
one	NN	O	O
scenario	NN	O	O
,	NN	O	O
the	NN	O	O
nerp	NN	O	O
ate	NN	O	O
and	NN	O	O
disliked	NN	O	O
a	NN	O	O
carrot	NN	O	O
.	NN	O	O

When	NN	O	O
subsequently	NN	O	O
asked	NN	O	O
generic	NN	O	O
questions	NN	O	O
about	NN	O	O
real	NN	O	O
nerps	NN	O	O
,	NN	O	O
children	NN	O	B-PAR
's	NN	O	O
responses	NN	O	B-OUT
suggested	NN	O	O
that	NN	O	O
they	NN	O	O
had	NN	O	O
learned	NN	O	O
general	NN	O	O
facts	NN	O	O
(	NN	O	O
e.g.	NN	O	O
,	NN	O	O
nerps	NN	O	O
dislike	NN	O	O
carrots	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
Experiment	NN	O	O
2	NN	O	O
,	NN	O	O
thirty-two	NN	O	B-PAR
4-	NN	O	I-PAR
to	NN	O	I-PAR
5-year-olds	NN	O	I-PAR
learned	NN	O	O
from	NN	O	O
scenarios	NN	O	B-INT
lacking	NN	O	I-INT
pretend	NN	O	I-INT
speech	NN	O	I-INT
or	NN	O	I-INT
sound	NN	O	I-INT
effects	NN	O	I-INT
.	NN	O	O

The	NN	O	O
findings	NN	O	O
reveal	NN	O	O
a	NN	O	O
long	NN	O	O
overlooked	NN	O	O
means	NN	O	O
by	NN	O	O
which	NN	O	O
children	NN	O	B-PAR
can	NN	O	O
acquire	NN	O	O
generic	NN	O	O
knowledge	NN	O	O
.	NN	O	O



--DOCSTART-- (22420121)

Training	NN	O	O
referential	NN	O	B-INT
communicative	NN	O	I-INT
skills	NN	O	I-INT
to	NN	O	O
individuals	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
reports	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
referential	NN	O	B-INT
communication	NN	O	I-INT
training	NN	O	I-INT
in	NN	O	O
individuals	NN	O	B-PAR
formally	NN	O	I-PAR
diagnosed	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
20	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
(	NN	O	I-PAR
M	NN	O	I-PAR
age	NN	O	I-PAR
=	NN	O	I-PAR
14.3	NN	O	I-PAR
yr.	NN	O	I-PAR
,	NN	O	O
SD	NN	O	B-PAR
=	NN	O	I-PAR
4.2	NN	O	I-PAR
;	NN	O	I-PAR
6	NN	O	I-PAR
girls	NN	O	I-PAR
,	NN	O	I-PAR
14	NN	O	I-PAR
boys	NN	O	I-PAR
)	NN	O	I-PAR
in	NN	O	I-PAR
the	NN	O	I-PAR
role	NN	O	I-PAR
of	NN	O	I-PAR
speakers	NN	O	I-PAR
and	NN	O	I-PAR
20	NN	O	I-PAR
control	NN	O	I-PAR
children	NN	O	I-PAR
,	NN	O	I-PAR
who	NN	O	I-PAR
acted	NN	O	I-PAR
as	NN	O	I-PAR
listeners	NN	O	I-PAR
.	NN	O	O

They	NN	O	O
were	NN	O	O
all	NN	O	O
enrolled	NN	O	O
in	NN	O	O
mainstream	NN	O	O
compulsory	NN	O	O
education	NN	O	O
.	NN	O	O

Inclusion/exclusion	NN	O	O
criteria	NN	O	O
were	NN	O	O
defined	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
clinical	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
ASD	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
additional	NN	O	O
or	NN	O	O
associated	NN	O	O
disability	NN	O	O
,	NN	O	O
previous	NN	O	O
training	NN	O	O
in	NN	O	O
referential	NN	O	O
communication	NN	O	O
,	NN	O	O
and	NN	O	O
any	NN	O	O
drug	NN	O	O
treatment	NN	O	O
.	NN	O	O

Speakers	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
two	NN	O	O
groups	NN	O	O
(	NN	O	O
trained	NN	O	O
vs	NN	O	O
untrained	NN	O	O
)	NN	O	O
.	NN	O	O

Linguistic	NN	O	B-OUT
age	NN	O	I-OUT
,	NN	O	I-OUT
cognitive	NN	O	I-OUT
level	NN	O	I-OUT
and	NN	O	I-OUT
autistic	NN	O	I-OUT
symptoms	NN	O	I-OUT
were	NN	O	O
analyzed	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
Peabody	NN	O	B-OUT
Picture	NN	O	I-OUT
Vocabulary	NN	O	I-OUT
Test	NN	O	I-OUT
(	NN	O	I-OUT
PPVT	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
the	NN	O	I-OUT
Wechsler	NN	O	I-OUT
Intelligence	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
WISC-R	NN	O	I-OUT
or	NN	O	I-OUT
WAIS-III	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
the	NN	O	I-OUT
Autistic	NN	O	I-OUT
Behavior	NN	O	I-OUT
Checklist	NN	O	I-OUT
(	NN	O	I-OUT
ABC	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Communicative	NN	O	B-OUT
abilities	NN	O	I-OUT
were	NN	O	O
analyzed	NN	O	O
through	NN	O	O
two	NN	O	O
indexes	NN	O	O
related	NN	O	O
to	NN	O	O
message	NN	O	O
complexity	NN	O	O
and	NN	O	O
self-regulation	NN	O	O
.	NN	O	O

The	NN	O	O
trained	NN	O	O
group	NN	O	O
was	NN	O	O
trained	NN	O	O
in	NN	O	O
referential	NN	O	B-INT
communication	NN	O	I-INT
tasks	NN	O	I-INT
(	NN	O	O
task	NN	O	B-INT
analysis	NN	O	I-INT
,	NN	O	O
role	NN	O	B-INT
taking	NN	O	I-INT
,	NN	O	O
and	NN	O	O
task	NN	O	B-INT
evaluation	NN	O	I-INT
)	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
untrained	NN	O	O
group	NN	O	O
took	NN	O	O
part	NN	O	O
in	NN	O	O
a	NN	O	O
communicative	NN	O	B-INT
game	NN	O	I-INT
but	NN	O	O
without	NN	O	O
any	NN	O	O
specific	NN	O	O
communicative	NN	O	O
training	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
complexity	NN	O	B-OUT
of	NN	O	I-OUT
emitted	NN	O	I-OUT
messages	NN	O	I-OUT
had	NN	O	O
improved	NN	O	O
statistically	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
trained	NN	O	O
group	NN	O	O
as	NN	O	O
an	NN	O	O
effect	NN	O	O
of	NN	O	O
training	NN	O	O
.	NN	O	O

Ecological	NN	O	O
referential	NN	O	B-INT
communication	NN	O	I-INT
is	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
appropriate	NN	O	O
paradigm	NN	O	O
for	NN	O	O
studying	NN	O	O
the	NN	O	O
communicative	NN	O	O
process	NN	O	O
and	NN	O	O
its	NN	O	O
products	NN	O	O
and	NN	O	O
could	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
develop	NN	O	O
and	NN	O	O
implement	NN	O	O
a	NN	O	O
training	NN	O	O
program	NN	O	O
focused	NN	O	O
on	NN	O	O
those	NN	O	O
skills	NN	O	O
in	NN	O	O
which	NN	O	O
individuals	NN	O	B-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
are	NN	O	O
most	NN	O	O
deficient	NN	O	O
.	NN	O	O



--DOCSTART-- (22435114)

Group	NN	O	B-INT
cognitive	NN	O	I-INT
behavior	NN	O	I-INT
therapy	NN	O	I-INT
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
high-functioning	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
and	NN	O	I-PAR
anxiety	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Children	NN	O	B-PAR
with	NN	O	O
high-functioning	NN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NN	O	O
(	NN	O	O
ASD	NN	O	O
)	NN	O	O
are	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
for	NN	O	O
developing	NN	O	O
significant	NN	O	O
anxiety	NN	O	O
.	NN	O	O

Anxiety	NN	O	O
can	NN	O	O
adversely	NN	O	O
impact	NN	O	O
functioning	NN	O	O
across	NN	O	O
school	NN	O	O
,	NN	O	O
home	NN	O	O
and	NN	O	O
community	NN	O	O
environments	NN	O	O
.	NN	O	O

Cognitive	NN	O	B-INT
behavioral	NN	O	I-INT
therapies	NN	O	I-INT
(	NN	O	I-INT
CBT	NN	O	I-INT
)	NN	O	I-INT
are	NN	O	O
frequently	NN	O	O
used	NN	O	O
with	NN	O	O
success	NN	O	O
for	NN	O	O
children	NN	O	O
with	NN	O	O
anxiety	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

Modified	NN	O	O
CBT	NN	O	B-INT
interventions	NN	O	O
for	NN	O	O
anxiety	NN	O	B-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
have	NN	O	O
also	NN	O	O
yielded	NN	O	O
promising	NN	O	O
results	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Fifty	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
high-functioning	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	I-PAR
anxiety	NN	O	I-PAR
were	NN	O	O
randomizedto	NN	O	O
group	NN	O	O
CBT	NN	O	B-INT
or	NN	O	O
treatment-as-usual	NN	O	B-INT
(	NN	O	I-INT
TAU	NN	O	I-INT
)	NN	O	I-INT
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Independent	NN	O	O
clinical	NN	O	O
evaluators	NN	O	O
,	NN	O	O
blind	NN	O	O
to	NN	O	O
condition	NN	O	O
,	NN	O	O
completed	NN	O	O
structured	NN	O	O
interviews	NN	O	O
(	NN	O	B-OUT
Anxiety	NN	O	I-OUT
Disorders	NN	O	I-OUT
Interview	NN	O	I-OUT
Schedule	NN	O	I-OUT
?	NN	O	I-OUT
Parent	NN	O	I-OUT
Version	NN	O	I-OUT
;	NN	O	I-OUT
ADIS-P	NN	O	I-OUT
)	NN	O	I-OUT
pre-	NN	O	O
and	NN	O	O
post-intervention	NN	O	O
condition	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Forty-seven	NN	O	B-PAR
children	NN	O	I-PAR
completed	NN	O	O
either	NN	O	O
the	NN	O	O
CBT	NN	O	B-INT
or	NN	O	O
TAU	NN	O	B-INT
condition	NN	O	O
.	NN	O	O

Results	NN	O	O
indicated	NN	O	O
markedly	NN	O	O
better	NN	O	O
outcomes	NN	O	O
for	NN	O	O
the	NN	O	O
CBT	NN	O	B-INT
group	NN	O	O
.	NN	O	O

Significant	NN	O	O
differences	NN	O	O
by	NN	O	O
group	NN	O	O
were	NN	O	O
noted	NN	O	O
in	NN	O	O
Clinician	NN	O	B-OUT
Severity	NN	O	I-OUT
Ratings	NN	O	I-OUT
,	NN	O	I-OUT
diagnostic	NN	O	I-OUT
status	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
clinician	NN	O	I-OUT
ratings	NN	O	I-OUT
of	NN	O	I-OUT
global	NN	O	I-OUT
improvement	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
the	NN	O	O
intent-to-treat	NN	O	O
sample	NN	O	O
,	NN	O	O
10	NN	O	O
of	NN	O	O
20	NN	O	O
children	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
CBT	NN	O	B-INT
group	NN	O	O
had	NN	O	O
a	NN	O	O
clinically	NN	O	O
meaningful	NN	O	O
positive	NN	O	O
treatment	NN	O	O
response	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
2	NN	O	O
of	NN	O	O
23	NN	O	O
children	NN	O	O
(	NN	O	O
8.7	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
TAU	NN	O	B-INT
group	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Initial	NN	O	O
results	NN	O	O
from	NN	O	O
this	NN	O	O
randomized	NN	O	O
,	NN	O	O
designed	NN	O	O
treatment	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
agroup	NN	O	O
CBT	NN	O	B-INT
intervention	NN	O	O
specifically	NN	O	O
developed	NN	O	O
for	NN	O	O
children	NN	O	O
with	NN	O	O
ASD	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
decreasing	NN	O	O
anxiety	NN	O	O
.	NN	O	O

Limitations	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
include	NN	O	O
small	NN	O	O
sample	NN	O	O
size	NN	O	O
,	NN	O	O
lack	NN	O	O
of	NN	O	O
an	NN	O	O
attention	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
use	NN	O	O
of	NN	O	O
outcome	NN	O	O
measures	NN	O	O
normed	NN	O	O
with	NN	O	O
typically	NN	O	O
developing	NN	O	O
children	NN	O	O


--DOCSTART-- (22538329)

Spotty	NN	O	O
calcification	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
accelerated	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
coronary	NN	O	I-OUT
atherosclerosis	NN	O	I-OUT
:	NN	O	O
insights	NN	O	O
from	NN	O	O
serial	NN	O	O
intravascular	NN	O	O
ultrasound	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
atheroma	NN	O	B-OUT
progression	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
spotty	NN	O	I-PAR
calcification	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Although	NN	O	O
extensively	NN	O	O
calcified	NN	O	O
atherosclerotic	NN	O	O
lesions	NN	O	O
have	NN	O	O
been	NN	O	O
proposed	NN	O	O
to	NN	O	O
be	NN	O	O
clinically	NN	O	O
quiescent	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
within	NN	O	O
plaque	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
ischemic	NN	O	O
cardiovascular	NN	O	O
events	NN	O	O
.	NN	O	O

The	NN	O	O
relationship	NN	O	O
between	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
and	NN	O	O
disease	NN	O	B-OUT
progression	NN	O	I-OUT
has	NN	O	O
not	NN	O	O
been	NN	O	O
investigated	NN	O	O
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
total	NN	O	B-PAR
of	NN	O	I-PAR
1,347	NN	O	I-PAR
stable	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
angiographic	NN	O	I-PAR
coronary	NN	O	I-PAR
artery	NN	O	I-PAR
disease	NN	O	I-PAR
underwent	NN	O	O
serial	NN	O	O
evaluation	NN	O	O
of	NN	O	O
atheroma	NN	O	B-OUT
burden	NN	O	I-OUT
with	NN	O	O
intravascular	NN	O	O
ultrasound	NN	O	O
imaging	NN	O	O
.	NN	O	O

Patients	NN	O	B-PAR
with	NN	O	I-PAR
spotty	NN	O	I-PAR
calcification	NN	O	I-PAR
were	NN	O	I-PAR
identified	NN	O	I-PAR
based	NN	O	I-PAR
on	NN	O	I-PAR
the	NN	O	I-PAR
presence	NN	O	I-PAR
of	NN	O	I-PAR
lesions	NN	O	I-PAR
(	NN	O	I-PAR
1	NN	O	I-PAR
to	NN	O	I-PAR
4	NN	O	I-PAR
mm	NN	O	I-PAR
in	NN	O	I-PAR
length	NN	O	I-PAR
)	NN	O	I-PAR
containing	NN	O	I-PAR
an	NN	O	I-PAR
arc	NN	O	I-PAR
of	NN	O	I-PAR
calcification	NN	O	I-PAR
of	NN	O	I-PAR
<	NN	O	I-PAR
90?	NN	O	I-PAR
.	NN	O	O

Clinical	NN	O	O
characteristics	NN	O	B-OUT
and	NN	O	I-OUT
disease	NN	O	I-OUT
progression	NN	O	I-OUT
were	NN	O	O
compared	NN	O	O
between	NN	O	O
patients	NN	O	O
with	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
922	NN	O	O
)	NN	O	O
and	NN	O	O
those	NN	O	O
with	NN	O	O
no	NN	O	O
calcification	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
425	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Patients	NN	O	B-PAR
with	NN	O	I-PAR
spotty	NN	O	I-PAR
calcification	NN	O	I-PAR
were	NN	O	I-PAR
older	NN	O	I-PAR
(	NN	O	I-PAR
age	NN	O	I-PAR
56	NN	O	I-PAR
years	NN	O	I-PAR
vs.	NN	O	I-PAR
54	NN	O	O
years	NN	O	B-PAR
;	NN	O	I-PAR
p	NN	O	I-PAR
=	NN	O	I-PAR
0.001	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	I-PAR
more	NN	O	I-PAR
likely	NN	O	I-PAR
to	NN	O	I-PAR
be	NN	O	I-PAR
male	NN	O	I-PAR
(	NN	O	I-PAR
68	NN	O	I-PAR
%	NN	O	I-PAR
vs.	NN	O	I-PAR
54	NN	O	O
%	NN	O	B-PAR
;	NN	O	I-PAR
p	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
have	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
diabetes	NN	O	O
mellitus	NN	O	O
(	NN	O	O
30	NN	O	O
%	NN	O	O
vs.	NN	O	O
24	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
myocardial	NN	O	O
infarction	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
vs.	NN	O	O
20	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.004	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
have	NN	O	O
lower	NN	O	O
on-treatment	NN	O	O
high-density	NN	O	B-OUT
lipoprotein	NN	O	I-OUT
cholesterol	NN	O	I-OUT
levels	NN	O	I-OUT
(	NN	O	O
48	NN	O	O
?	NN	O	O
16	NN	O	O
mg/dl	NN	O	O
vs.	NN	O	O
51	NN	O	O
?	NN	O	O
17	NN	O	O
mg/dl	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
greater	NN	O	O
percent	NN	O	B-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
(	NN	O	I-OUT
PAV	NN	O	I-OUT
)	NN	O	I-OUT
(	NN	O	O
36.0	NN	O	O
?	NN	O	O
7.6	NN	O	O
%	NN	O	O
vs.	NN	O	O
29.0	NN	O	O
?	NN	O	O
8.5	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
and	NN	O	O
total	NN	O	B-OUT
atheroma	NN	O	I-OUT
volume	NN	O	I-OUT
(	NN	O	O
174.6	NN	O	O
?	NN	O	O
71.9	NN	O	O
mm	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
vs.	NN	O	O
133.9	NN	O	O
?	NN	O	O
64.9	NN	O	O
mm	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
serial	NN	O	O
evaluation	NN	O	O
,	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
greater	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
PAV	NN	O	I-OUT
(	NN	O	O
+0.43	NN	O	O
?	NN	O	O
0.07	NN	O	O
%	NN	O	O
vs.	NN	O	O
+0.02	NN	O	O
?	NN	O	O
0.11	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
intensive	NN	O	O
low-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
and	NN	O	O
blood	NN	O	O
pressure	NN	O	O
lowering	NN	O	O
therapy	NN	O	O
slowed	NN	O	O
disease	NN	O	O
progression	NN	O	O
,	NN	O	O
these	NN	O	O
efficacies	NN	O	O
were	NN	O	O
attenuated	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
spotty	NN	O	I-PAR
calcification	NN	O	I-PAR
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
presence	NN	O	O
of	NN	O	O
spotty	NN	O	O
calcification	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
more	NN	O	O
extensive	NN	O	O
and	NN	O	O
diffuse	NN	O	O
coronary	NN	O	B-OUT
atherosclerosis	NN	O	I-OUT
and	NN	O	O
accelerated	NN	O	O
disease	NN	O	O
progression	NN	O	O
despite	NN	O	O
use	NN	O	O
of	NN	O	O
medical	NN	O	O
therapies	NN	O	O
.	NN	O	O



--DOCSTART-- (22646975)

Effects	NN	O	O
of	NN	O	O
guided	NN	O	O
imagery	NN	O	O
with	NN	O	O
relaxation	NN	O	B-INT
training	NN	O	I-INT
on	NN	O	O
anxiety	NN	O	B-OUT
and	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
among	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
inflammatory	NN	O	I-PAR
bowel	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Inflammatory	NN	O	O
Bowel	NN	O	O
Disease	NN	O	O
(	NN	O	O
IBD	NN	O	O
)	NN	O	O
impacts	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
(	NN	O	I-OUT
QoL	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Psychological	NN	O	O
factors	NN	O	O
influence	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
and	NN	O	O
should	NN	O	O
be	NN	O	O
targeted	NN	O	O
for	NN	O	O
intervention	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Our	NN	O	O
study	NN	O	O
was	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomised	NN	O	O
control	NN	O	O
trial	NN	O	O
.	NN	O	O

Fifty-six	NN	O	B-PAR
outpatients	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
chosen	NN	O	O
and	NN	O	O
allocated	NN	O	O
to	NN	O	O
a	NN	O	O
treatment	NN	O	O
group	NN	O	O
or	NN	O	O
a	NN	O	O
waiting-list	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Treatment	NN	O	O
group	NN	O	O
patients	NN	O	O
attended	NN	O	O
three	NN	O	O
relaxation-training	NN	O	B-INT
sessions	NN	O	I-INT
and	NN	O	O
received	NN	O	O
an	NN	O	O
audio	NN	O	O
disc	NN	O	O
for	NN	O	O
home	NN	O	O
practice	NN	O	O
.	NN	O	O

Evaluations	NN	O	O
performed	NN	O	O
pre	NN	O	O
and	NN	O	O
post-treatment	NN	O	O
:	NN	O	O
state	NN	O	B-OUT
anxiety	NN	O	I-OUT
was	NN	O	O
assessed	NN	O	O
with	NN	O	O
the	NN	O	O
State-Trait	NN	O	B-OUT
Anxiety	NN	O	I-OUT
Inventory	NN	O	I-OUT
,	NN	O	I-OUT
QoL	NN	O	I-OUT
with	NN	O	I-OUT
the	NN	O	I-OUT
IBD	NN	O	I-OUT
Questionnaire	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
Visual	NN	O	B-OUT
Analogue	NN	O	I-OUT
Scale	NN	O	I-OUT
assessed	NN	O	O
pain	NN	O	B-OUT
,	NN	O	I-OUT
depression	NN	O	I-OUT
,	NN	O	I-OUT
stress	NN	O	I-OUT
and	NN	O	O
mood	NN	O	B-OUT
.	NN	O	O

Patients	NN	O	O
completed	NN	O	O
a	NN	O	O
symptom	NN	O	O
monitoring	NN	O	O
diary	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
's	NN	O	O
symptoms	NN	O	O
were	NN	O	O
monitored	NN	O	O
without	NN	O	O
study-related	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Thirty-nine	NN	O	B-PAR
subjects	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
study	NN	O	I-PAR
and	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
data	NN	O	O
analysis	NN	O	O
.	NN	O	O

Following	NN	O	O
the	NN	O	O
relaxation-training	NN	O	B-INT
intervention	NN	O	O
,	NN	O	O
the	NN	O	O
treatment	NN	O	O
group	NN	O	O
's	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
18	NN	O	O
)	NN	O	O
measured	NN	O	O
results	NN	O	O
showed	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
improvement	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
21	NN	O	O
)	NN	O	O
(	NN	O	O
time	NN	O	O
by	NN	O	O
treatment	NN	O	O
interaction	NN	O	O
)	NN	O	O
:	NN	O	O
anxiety	NN	O	B-OUT
levels	NN	O	I-OUT
decreased	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
,	NN	O	O
QoL	NN	O	B-OUT
and	NN	O	I-OUT
mood	NN	O	I-OUT
improved	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
levels	NN	O	O
of	NN	O	O
pain	NN	O	B-OUT
and	NN	O	I-OUT
stress	NN	O	I-OUT
decreased	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Findings	NN	O	O
indicate	NN	O	O
IBD	NN	O	B-PAR
patients	NN	O	I-PAR
may	NN	O	O
benefit	NN	O	O
from	NN	O	O
relaxation	NN	O	B-INT
training	NN	O	I-INT
in	NN	O	O
their	NN	O	O
holistic	NN	O	O
care	NN	O	O
.	NN	O	O

New	NN	O	O
studies	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
further	NN	O	O
investigation	NN	O	O
of	NN	O	O
the	NN	O	O
subject	NN	O	O
are	NN	O	O
warranted	NN	O	O
.	NN	O	O



--DOCSTART-- (22744141)

Parent-implemented	NN	O	O
enhanced	NN	O	B-INT
milieu	NN	O	I-INT
teaching	NN	O	I-INT
with	NN	O	O
preschool	NN	O	B-PAR
children	NN	O	I-PAR
who	NN	O	I-PAR
have	NN	O	I-PAR
intellectual	NN	O	I-PAR
disabilities	NN	O	I-PAR
.	NN	O	O

PURPOSE	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
enhanced	NN	O	B-INT
milieu	NN	O	I-INT
teaching	NN	O	I-INT
(	NN	O	I-INT
EMT	NN	O	I-INT
)	NN	O	I-INT
implemented	NN	O	O
by	NN	O	O
parents	NN	O	O
and	NN	O	O
therapists	NN	O	O
versus	NN	O	O
therapists	NN	O	O
only	NN	O	O
on	NN	O	O
the	NN	O	O
language	NN	O	O
skills	NN	O	O
of	NN	O	O
preschool	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
intellectual	NN	O	I-PAR
disabilities	NN	O	I-PAR
(	NN	O	I-PAR
IDs	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	I-PAR
including	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
Down	NN	O	I-PAR
syndrome	NN	O	I-PAR
and	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
.	NN	O	O

METHOD	NN	O	O
Seventy-seven	NN	O	B-PAR
children	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
2	NN	O	O
treatments	NN	O	O
(	NN	O	O
parent	NN	O	B-INT
+	NN	O	I-INT
therapist	NN	O	I-INT
EMT	NN	O	I-INT
or	NN	O	O
therapist-only	NN	O	B-INT
EMT	NN	O	I-INT
)	NN	O	O
and	NN	O	O
received	NN	O	O
36	NN	O	O
intervention	NN	O	O
sessions	NN	O	O
.	NN	O	O

Children	NN	O	O
were	NN	O	O
assessed	NN	O	O
before	NN	O	O
,	NN	O	O
immediately	NN	O	O
after	NN	O	O
,	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
after	NN	O	O
intervention	NN	O	O
.	NN	O	O

Separate	NN	O	O
linear	NN	O	O
regressions	NN	O	O
were	NN	O	O
conducted	NN	O	O
for	NN	O	O
each	NN	O	O
standardized	NN	O	O
and	NN	O	O
observational	NN	O	O
measure	NN	O	O
at	NN	O	O
each	NN	O	O
time	NN	O	O
point	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Parents	NN	O	O
in	NN	O	O
the	NN	O	O
parent	NN	O	O
+	NN	O	O
therapist	NN	O	O
group	NN	O	O
demonstrated	NN	O	O
greater	NN	O	O
use	NN	O	O
of	NN	O	O
EMT	NN	O	B-OUT
strategies	NN	O	I-OUT
at	NN	O	O
home	NN	O	O
than	NN	O	O
untrained	NN	O	O
parents	NN	O	O
in	NN	O	O
the	NN	O	O
therapist-only	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
these	NN	O	O
effects	NN	O	O
maintained	NN	O	O
over	NN	O	O
time	NN	O	O
.	NN	O	O

Effect	NN	O	O
sizes	NN	O	O
for	NN	O	O
observational	NN	O	B-OUT
measures	NN	O	I-OUT
ranged	NN	O	O
from	NN	O	O
d	NN	O	O
=	NN	O	O
0.10	NN	O	O
to	NN	O	O
d	NN	O	O
=	NN	O	O
1.32	NN	O	O
favoring	NN	O	O
the	NN	O	O
parent	NN	O	O
+	NN	O	O
therapist	NN	O	O
group	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
largest	NN	O	O
effect	NN	O	O
sizes	NN	O	O
found	NN	O	O
12	NN	O	O
months	NN	O	O
after	NN	O	O
intervention	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Findings	NN	O	O
from	NN	O	O
this	NN	O	O
study	NN	O	O
indicate	NN	O	O
generally	NN	O	O
that	NN	O	O
there	NN	O	O
are	NN	O	O
benefits	NN	O	O
to	NN	O	O
training	NN	O	O
parents	NN	O	O
to	NN	O	O
implement	NN	O	O
naturalistic	NN	O	O
language	NN	O	O
intervention	NN	O	O
strategies	NN	O	O
with	NN	O	O
preschool	NN	O	B-PAR
children	NN	O	I-PAR
who	NN	O	I-PAR
have	NN	O	I-PAR
ID	NN	O	I-PAR
and	NN	O	I-PAR
significant	NN	O	I-PAR
language	NN	O	I-PAR
impairments	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (22865017)

RESPECT-PTSD	NN	O	O
:	NN	O	O
re-engineering	NN	O	O
systems	NN	O	O
for	NN	O	O
the	NN	O	O
primary	NN	O	O
care	NN	O	O
treatment	NN	O	O
of	NN	O	O
PTSD	NN	O	B-PAR
,	NN	O	O
a	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Although	NN	O	O
collaborative	NN	O	O
care	NN	O	O
is	NN	O	O
effective	NN	O	O
for	NN	O	O
treating	NN	O	O
depression	NN	O	O
and	NN	O	O
other	NN	O	O
mental	NN	O	O
disorders	NN	O	O
in	NN	O	O
primary	NN	O	O
care	NN	O	O
,	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
no	NN	O	O
randomized	NN	O	O
trials	NN	O	O
of	NN	O	O
collaborative	NN	O	O
care	NN	O	O
specifically	NN	O	O
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
Posttraumatic	NN	O	I-PAR
stress	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
PTSD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
compare	NN	O	O
a	NN	O	O
collaborative	NN	O	O
approach	NN	O	O
,	NN	O	O
the	NN	O	O
Three	NN	O	B-INT
Component	NN	O	I-INT
Model	NN	O	I-INT
(	NN	O	I-INT
3CM	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
with	NN	O	O
usual	NN	O	B-INT
care	NN	O	I-INT
for	NN	O	O
treating	NN	O	O
PTSD	NN	O	O
in	NN	O	O
primary	NN	O	O
care	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
The	NN	O	O
study	NN	O	O
was	NN	O	O
a	NN	O	O
two-arm	NN	O	O
,	NN	O	O
parallel	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

PTSD	NN	O	B-PAR
patients	NN	O	I-PAR
were	NN	O	I-PAR
recruited	NN	O	I-PAR
from	NN	O	I-PAR
five	NN	O	I-PAR
primary	NN	O	I-PAR
care	NN	O	I-PAR
clinics	NN	O	I-PAR
at	NN	O	I-PAR
four	NN	O	I-PAR
Veterans	NN	O	I-PAR
Affairs	NN	O	I-PAR
healthcare	NN	O	I-PAR
facilities	NN	O	I-PAR
and	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
usual	NN	O	B-INT
care	NN	O	I-INT
or	NN	O	O
usual	NN	O	B-INT
care	NN	O	I-INT
plus	NN	O	I-INT
3CM	NN	O	I-INT
.	NN	O	O

Blinded	NN	O	O
assessors	NN	O	O
collected	NN	O	O
data	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
3-month	NN	O	O
and	NN	O	O
6-month	NN	O	O
follow-up	NN	O	O
.	NN	O	O

PARTICIPANTS	NN	O	O
Participants	NN	O	B-PAR
were	NN	O	I-PAR
195	NN	O	I-PAR
Veterans	NN	O	I-PAR
.	NN	O	O

Their	NN	O	B-PAR
average	NN	O	I-PAR
age	NN	O	I-PAR
was	NN	O	I-PAR
45	NN	O	I-PAR
years	NN	O	I-PAR
,	NN	O	I-PAR
91	NN	O	I-PAR
%	NN	O	I-PAR
were	NN	O	I-PAR
male	NN	O	I-PAR
,	NN	O	I-PAR
58	NN	O	I-PAR
%	NN	O	I-PAR
were	NN	O	I-PAR
white	NN	O	I-PAR
,	NN	O	I-PAR
40	NN	O	I-PAR
%	NN	O	I-PAR
served	NN	O	I-PAR
in	NN	O	I-PAR
Iraq	NN	O	I-PAR
or	NN	O	I-PAR
Afghanistan	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
42	NN	O	I-PAR
%	NN	O	I-PAR
served	NN	O	I-PAR
in	NN	O	I-PAR
Vietnam	NN	O	I-PAR
.	NN	O	O

INTERVENTION	NN	O	O
All	NN	O	O
participants	NN	O	O
received	NN	O	O
usual	NN	O	O
care	NN	O	O
.	NN	O	O

Participants	NN	O	O
assigned	NN	O	O
to	NN	O	O
3CM	NN	O	B-INT
also	NN	O	O
received	NN	O	O
telephone	NN	O	B-INT
care	NN	O	I-INT
management	NN	O	I-INT
.	NN	O	O

Care	NN	O	O
managers	NN	O	O
received	NN	O	O
supervision	NN	O	O
from	NN	O	O
a	NN	O	O
psychiatrist	NN	O	O
.	NN	O	O

MAIN	NN	O	O
MEASURES	NN	O	O
PTSD	NN	O	B-OUT
symptom	NN	O	I-OUT
severity	NN	O	I-OUT
was	NN	O	O
the	NN	O	O
primary	NN	O	O
outcome	NN	O	O
.	NN	O	O

Depression	NN	O	B-OUT
,	NN	O	I-OUT
functioning	NN	O	I-OUT
,	NN	O	I-OUT
perceived	NN	O	I-OUT
quality	NN	O	I-OUT
of	NN	O	I-OUT
care	NN	O	I-OUT
,	NN	O	I-OUT
utilization	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
costs	NN	O	I-OUT
were	NN	O	O
secondary	NN	O	O
outcomes	NN	O	O
.	NN	O	O

KEY	NN	O	O
RESULTS	NN	O	O
There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
between	NN	O	O
3CM	NN	O	O
and	NN	O	O
usual	NN	O	O
care	NN	O	O
in	NN	O	O
symptoms	NN	O	B-OUT
or	NN	O	O
functioning	NN	O	B-OUT
.	NN	O	O

Participants	NN	O	O
assigned	NN	O	O
to	NN	O	O
3CM	NN	O	B-INT
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
mental	NN	O	B-OUT
health	NN	O	I-OUT
visit	NN	O	I-OUT
,	NN	O	I-OUT
fill	NN	O	I-OUT
an	NN	O	I-OUT
antidepressant	NN	O	I-OUT
prescription	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
have	NN	O	O
adequate	NN	O	B-OUT
antidepressant	NN	O	I-OUT
refills	NN	O	I-OUT
.	NN	O	O

3CM	NN	O	B-INT
participants	NN	O	O
also	NN	O	O
had	NN	O	O
more	NN	O	O
mental	NN	O	B-OUT
health	NN	O	I-OUT
visits	NN	O	I-OUT
and	NN	O	O
higher	NN	O	O
outpatient	NN	O	B-OUT
pharmacy	NN	O	I-OUT
costs	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
Results	NN	O	O
suggest	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
careful	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
way	NN	O	O
that	NN	O	O
collaborative	NN	O	O
care	NN	O	O
models	NN	O	O
are	NN	O	O
implemented	NN	O	O
for	NN	O	O
treating	NN	O	O
PTSD	NN	O	O
,	NN	O	O
and	NN	O	O
for	NN	O	O
additional	NN	O	O
supports	NN	O	O
to	NN	O	O
encourage	NN	O	O
primary	NN	O	O
care	NN	O	O
providers	NN	O	O
to	NN	O	O
manage	NN	O	O
PTSD	NN	O	O
.	NN	O	O



--DOCSTART-- (22881991)

Teaching	NN	O	O
emotion	NN	O	B-INT
recognition	NN	O	I-INT
skills	NN	O	O
to	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
an	NN	O	O
emotion	NN	O	B-INT
training	NN	O	I-INT
programme	NN	O	I-INT
.	NN	O	O

BACKGROUND	NN	O	O
Children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
have	NN	O	O
difficulties	NN	O	O
in	NN	O	O
emotion	NN	O	O
recognition	NN	O	O
and	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
interventions	NN	O	O
have	NN	O	O
been	NN	O	O
designed	NN	O	O
to	NN	O	O
target	NN	O	O
these	NN	O	O
problems	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
few	NN	O	O
emotion	NN	O	B-INT
training	NN	O	I-INT
interventions	NN	O	O
have	NN	O	O
been	NN	O	O
trialled	NN	O	O
with	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
and	NN	O	I-PAR
co-morbid	NN	O	I-PAR
ID	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
an	NN	O	O
emotion	NN	O	B-INT
training	NN	O	I-INT
programme	NN	O	I-INT
for	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
range	NN	O	I-PAR
of	NN	O	I-PAR
intellectual	NN	O	I-PAR
ability	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Participants	NN	O	B-PAR
were	NN	O	I-PAR
55	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
,	NN	O	I-PAR
aged	NN	O	I-PAR
4-7	NN	O	I-PAR
years	NN	O	I-PAR
(	NN	O	I-PAR
FSIQ	NN	O	I-PAR
42-107	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Children	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
an	NN	O	O
intervention	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
28	NN	O	O
)	NN	O	O
or	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
27	NN	O	O
)	NN	O	O
.	NN	O	O

Participants	NN	O	O
in	NN	O	O
the	NN	O	O
intervention	NN	O	O
group	NN	O	O
watched	NN	O	O
a	NN	O	O
DVD	NN	O	O
designed	NN	O	O
to	NN	O	O
teach	NN	O	O
emotion	NN	O	B-INT
recognition	NN	O	I-INT
skills	NN	O	I-INT
to	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	O
(	NN	O	O
the	NN	O	B-INT
Transporters	NN	O	I-INT
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
watched	NN	O	O
a	NN	O	O
DVD	NN	O	O
of	NN	O	O
Thomas	NN	O	B-INT
the	NN	O	I-INT
Tank	NN	O	I-INT
Engine	NN	O	I-INT
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
assessed	NN	O	O
on	NN	O	O
their	NN	O	O
ability	NN	O	O
to	NN	O	O
complete	NN	O	O
basic	NN	O	B-OUT
emotion	NN	O	I-OUT
recognition	NN	O	I-OUT
tasks	NN	O	I-OUT
,	NN	O	I-OUT
mindreading	NN	O	I-OUT
and	NN	O	I-OUT
theory	NN	O	I-OUT
of	NN	O	I-OUT
mind	NN	O	I-OUT
(	NN	O	I-OUT
TOM	NN	O	I-OUT
)	NN	O	I-OUT
tasks	NN	O	I-OUT
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
4-week	NN	O	O
intervention	NN	O	O
period	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
3-month	NN	O	O
follow-up	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Analyses	NN	O	O
controlled	NN	O	O
for	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronological	NN	O	O
age	NN	O	O
,	NN	O	O
verbal	NN	O	O
intelligence	NN	O	O
,	NN	O	O
gender	NN	O	O
and	NN	O	O
DVD	NN	O	O
viewing	NN	O	O
time	NN	O	O
on	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Children	NN	O	O
in	NN	O	O
the	NN	O	O
intervention	NN	O	O
group	NN	O	O
showed	NN	O	O
improved	NN	O	O
performance	NN	O	O
in	NN	O	O
the	NN	O	O
recognition	NN	O	B-OUT
of	NN	O	I-OUT
anger	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
with	NN	O	O
few	NN	O	O
improvements	NN	O	O
maintained	NN	O	O
at	NN	O	O
3-month	NN	O	O
follow-up	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
generalisation	NN	O	O
of	NN	O	O
skills	NN	O	O
to	NN	O	O
TOM	NN	O	B-OUT
or	NN	O	O
social	NN	O	B-OUT
skills	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	B-INT
Transporters	NN	O	I-INT
programme	NN	O	O
showed	NN	O	O
limited	NN	O	O
efficacy	NN	O	B-OUT
in	NN	O	O
teaching	NN	O	O
basic	NN	O	O
emotion	NN	O	O
recognition	NN	O	O
skills	NN	O	O
to	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
with	NN	O	O
a	NN	O	O
lower	NN	O	O
range	NN	O	O
of	NN	O	O
cognitive	NN	O	O
ability	NN	O	O
.	NN	O	O

Improvements	NN	O	O
were	NN	O	O
limited	NN	O	O
to	NN	O	O
the	NN	O	O
recognition	NN	O	O
of	NN	O	O
expressions	NN	O	O
of	NN	O	O
anger	NN	O	O
,	NN	O	O
with	NN	O	O
poor	NN	O	O
maintenance	NN	O	O
of	NN	O	O
these	NN	O	O
skills	NN	O	O
at	NN	O	O
follow-up	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
provide	NN	O	O
limited	NN	O	O
support	NN	O	O
for	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
Transporters	NN	O	B-INT
programme	NN	O	O
for	NN	O	O
young	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
of	NN	O	O
a	NN	O	O
lower	NN	O	O
cognitive	NN	O	O
range	NN	O	O
.	NN	O	O



--DOCSTART-- (22897461)

Effect	NN	O	O
of	NN	O	O
rosuvastatin	NN	O	B-INT
monotherapy	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
fenofibrate	NN	O	B-INT
or	NN	O	O
?-3	NN	O	B-INT
fatty	NN	O	I-INT
acids	NN	O	I-INT
on	NN	O	O
lipoprotein	NN	O	B-OUT
subfraction	NN	O	I-OUT
profile	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
mixed	NN	O	I-PAR
dyslipidaemia	NN	O	I-PAR
and	NN	O	I-PAR
metabolic	NN	O	I-PAR
syndrome	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Raised	NN	O	O
triglycerides	NN	O	O
(	NN	O	O
TG	NN	O	O
)	NN	O	O
,	NN	O	O
decreased	NN	O	O
high-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
(	NN	O	O
HDL-C	NN	O	O
)	NN	O	O
levels	NN	O	O
and	NN	O	O
a	NN	O	O
predominance	NN	O	O
of	NN	O	O
small	NN	O	O
dense	NN	O	O
low	NN	O	O
density	NN	O	O
lipoproteins	NN	O	O
(	NN	O	O
sdLDL	NN	O	O
)	NN	O	O
are	NN	O	O
characteristics	NN	O	O
of	NN	O	O
the	NN	O	O
metabolic	NN	O	B-PAR
syndrome	NN	O	I-PAR
(	NN	O	I-PAR
MetS	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
high-dose	NN	O	O
rosuvastatin	NN	O	B-INT
monotherapy	NN	O	O
with	NN	O	O
moderate	NN	O	O
dosing	NN	O	O
combined	NN	O	O
with	NN	O	O
fenofibrate	NN	O	B-INT
or	NN	O	O
?-3	NN	O	B-INT
fatty	NN	O	I-INT
acids	NN	O	I-INT
on	NN	O	O
the	NN	O	O
lipoprotein	NN	O	B-OUT
subfraction	NN	O	I-OUT
profile	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
mixed	NN	O	I-PAR
dyslipidaemia	NN	O	I-PAR
and	NN	O	I-PAR
MetS	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
previously	NN	O	O
randomised	NN	O	O
patients	NN	O	O
with	NN	O	O
low-density	NN	O	O
lipoprotein	NN	O	O
cholesterol	NN	O	O
(	NN	O	O
LDL-C	NN	O	O
)	NN	O	O
>	NN	O	O
160	NN	O	O
and	NN	O	O
TG	NN	O	O
>	NN	O	O
200	NN	O	O
mg/dl	NN	O	O
to	NN	O	O
rosuvastatin	NN	O	B-INT
monotherapy	NN	O	O
40	NN	O	O
mg/day	NN	O	O
(	NN	O	O
R	NN	O	O
group	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
30	NN	O	O
)	NN	O	O
or	NN	O	O
rosuvastatin	NN	O	B-INT
10	NN	O	O
mg/day	NN	O	O
combined	NN	O	O
with	NN	O	O
fenofibrate	NN	O	B-INT
200	NN	O	O
mg/day	NN	O	O
(	NN	O	O
RF	NN	O	O
group	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
30	NN	O	O
)	NN	O	O
or	NN	O	O
?-3	NN	O	B-INT
fatty	NN	O	I-INT
acids	NN	O	I-INT
2	NN	O	O
g/day	NN	O	O
(	NN	O	O
R?	NN	O	O
group	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
30	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
only	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
MetS	NN	O	I-PAR
were	NN	O	I-PAR
included	NN	O	I-PAR
(	NN	O	O
24	NN	O	O
,	NN	O	O
23	NN	O	O
and	NN	O	O
24	NN	O	O
in	NN	O	O
the	NN	O	O
R	NN	O	O
,	NN	O	O
RF	NN	O	O
and	NN	O	O
R?	NN	O	O
groups	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
lipoprotein	NN	O	B-OUT
subfraction	NN	O	I-OUT
profile	NN	O	I-OUT
was	NN	O	O
determined	NN	O	O
by	NN	O	O
polyacrylamide	NN	O	O
3	NN	O	O
%	NN	O	O
gel	NN	O	O
electrophoresis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
mean	NN	O	B-OUT
LDL	NN	O	I-OUT
size	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
.	NN	O	O

This	NN	O	O
change	NN	O	O
was	NN	O	O
more	NN	O	O
prominent	NN	O	O
with	NN	O	O
RF	NN	O	B-INT
than	NN	O	O
with	NN	O	O
other	NN	O	O
treatments	NN	O	O
in	NN	O	O
parallel	NN	O	O
with	NN	O	O
its	NN	O	O
greater	NN	O	O
hypotriglyceridemic	NN	O	B-OUT
capacity	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
compared	NN	O	O
with	NN	O	O
R	NN	O	O
and	NN	O	O
R?	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
decrease	NN	O	O
in	NN	O	O
insulin	NN	O	B-OUT
resistance	NN	O	I-OUT
by	NN	O	O
RF	NN	O	O
was	NN	O	O
also	NN	O	O
noted	NN	O	O
.	NN	O	O

Only	NN	O	O
RF	NN	O	B-INT
significantly	NN	O	O
raised	NN	O	O
HDL-C	NN	O	B-OUT
levels	NN	O	I-OUT
(	NN	O	O
by	NN	O	O
7.7	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
cholesterol	NN	O	O
of	NN	O	O
small	NN	O	O
HDL	NN	O	O
particles	NN	O	O
.	NN	O	O

The	NN	O	O
cholesterol	NN	O	O
of	NN	O	B-OUT
larger	NN	O	I-OUT
HDL	NN	O	I-OUT
subclasses	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
by	NN	O	O
R	NN	O	B-INT
and	NN	O	O
R?	NN	O	B-INT
.	NN	O	O

CONCLUSIONS	NN	O	O
All	NN	O	O
regimens	NN	O	O
increased	NN	O	O
mean	NN	O	O
LDL	NN	O	B-OUT
size	NN	O	I-OUT
;	NN	O	O
RF	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
.	NN	O	O

A	NN	O	O
differential	NN	O	O
effect	NN	O	O
of	NN	O	O
treatments	NN	O	O
was	NN	O	O
noted	NN	O	O
on	NN	O	O
the	NN	O	O
HDL	NN	O	O
subfraction	NN	O	O
profile	NN	O	O
.	NN	O	O



--DOCSTART-- (22956006)

A	NN	O	O
randomized	NN	O	O
double-blind	NN	O	O
placebo-controlled	NN	O	O
cross-over	NN	O	O
trial	NN	O	O
of	NN	O	O
the	NN	O	O
impact	NN	O	O
on	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
of	NN	O	O
continuing	NN	O	O
dexamethasone	NN	O	B-INT
beyond	NN	O	O
24	NN	O	O
h	NN	O	O
following	NN	O	O
adjuvant	NN	O	B-PAR
chemotherapy	NN	O	I-PAR
for	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O

Uncertainty	NN	O	O
remains	NN	O	O
about	NN	O	O
the	NN	O	O
optimal	NN	O	O
anti-emetic	NN	O	O
regimen	NN	O	O
for	NN	O	O
control	NN	O	O
of	NN	O	O
delayed	NN	O	O
nausea	NN	O	O
and	NN	O	O
vomiting	NN	O	O
after	NN	O	O
adjuvant	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

Many	NN	O	O
patients	NN	O	O
receive	NN	O	O
dexamethasone	NN	O	B-INT
but	NN	O	O
complain	NN	O	O
of	NN	O	O
insomnia	NN	O	O
,	NN	O	O
anxiety/agitation	NN	O	O
,	NN	O	O
and	NN	O	O
indigestion	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
patients	NN	O	O
receiving	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
breast	NN	O	B-PAR
cancer	NN	O	I-PAR
prefer	NN	O	O
treatment	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
for	NN	O	O
prophylaxis	NN	O	O
against	NN	O	O
delayed	NN	O	O
nausea	NN	O	O
and	NN	O	O
vomiting	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
compare	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
(	NN	O	I-OUT
QOL	NN	O	I-OUT
)	NN	O	I-OUT
between	NN	O	O
the	NN	O	O
two	NN	O	O
treatments	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
cross-over	NN	O	O
trial	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
oral	NN	O	O
dexamethasone	NN	O	B-INT
(	NN	O	O
4	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
days	NN	O	O
)	NN	O	O
versus	NN	O	O
placebo	NN	O	B-INT
for	NN	O	O
chemotherapy-na?ve	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
intravenous	NN	O	O
granisetron	NN	O	B-INT
and	NN	O	O
dexamethasone	NN	O	B-INT
pre-chemotherapy	NN	O	O
and	NN	O	O
oral	NN	O	O
granisetron	NN	O	B-INT
on	NN	O	O
day	NN	O	O
2	NN	O	O
.	NN	O	O

Primary	NN	O	O
endpoints	NN	O	O
were	NN	O	O
:	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
patient	NN	O	B-OUT
preference	NN	O	I-OUT
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
difference	NN	O	O
between	NN	O	O
cycles	NN	O	O
in	NN	O	O
change	NN	O	B-OUT
of	NN	O	I-OUT
QOL	NN	O	I-OUT
from	NN	O	O
days	NN	O	O
1	NN	O	O
to	NN	O	O
8	NN	O	O
.	NN	O	O

Median	NN	O	O
age	NN	O	B-PAR
of	NN	O	I-PAR
the	NN	O	I-PAR
94	NN	O	I-PAR
women	NN	O	I-PAR
was	NN	O	I-PAR
51	NN	O	I-PAR
years	NN	O	I-PAR
(	NN	O	I-PAR
range	NN	O	I-PAR
27-76	NN	O	I-PAR
)	NN	O	I-PAR
:	NN	O	O
79	NN	O	O
received	NN	O	O
fluorouracil/epirubicin/cyclophosphamide	NN	O	B-INT
and	NN	O	O
15	NN	O	O
received	NN	O	O
doxorubicin/cyclophosphamide	NN	O	B-INT
.	NN	O	O

Thirteen	NN	O	O
withdrew	NN	O	O
pre-cycle	NN	O	O
2	NN	O	O
with	NN	O	O
no	NN	O	O
differences	NN	O	O
between	NN	O	O
arms	NN	O	O
.	NN	O	O

Of	NN	O	O
80	NN	O	O
patients	NN	O	O
stating	NN	O	O
a	NN	O	O
preference	NN	O	O
,	NN	O	O
31	NN	O	O
preferred	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
39	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
28-50	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
37	NN	O	O
(	NN	O	O
46	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
35-58	NN	O	O
%	NN	O	O
)	NN	O	O
preferred	NN	O	O
dexamethasone	NN	O	B-INT
;	NN	O	O
12	NN	O	O
had	NN	O	O
no	NN	O	O
preference	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
intensity	NN	O	B-OUT
of	NN	O	I-OUT
vomiting	NN	O	I-OUT
,	NN	O	I-OUT
nausea	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
onset	NN	O	I-OUT
of	NN	O	I-OUT
vomiting	NN	O	I-OUT
.	NN	O	O

There	NN	O	O
was	NN	O	O
greater	NN	O	O
decrease	NN	O	O
in	NN	O	O
global	NN	O	B-OUT
QOL	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.06	NN	O	O
)	NN	O	O
when	NN	O	O
patients	NN	O	O
received	NN	O	O
dexamethasone	NN	O	B-INT
.	NN	O	O

No	NN	O	O
other	NN	O	B-OUT
symptom/QOL	NN	O	O
domains	NN	O	O
differed	NN	O	O
significantly	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
patient	NN	O	B-OUT
preference	NN	O	I-OUT
,	NN	O	I-OUT
QOL	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
symptoms	NN	O	I-OUT
regardless	NN	O	O
of	NN	O	O
whether	NN	O	O
dexamethasone	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
was	NN	O	O
used	NN	O	O
after	NN	O	O
adjuvant	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O



--DOCSTART-- (23021296)

Adherence	NN	O	B-OUT
to	NN	O	O
lifestyle	NN	O	B-INT
recommendations	NN	O	O
by	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
depression	NN	O	I-PAR
.	NN	O	O

INTRODUCTION	NN	O	O
There	NN	O	O
is	NN	O	O
an	NN	O	O
increasing	NN	O	O
amount	NN	O	O
of	NN	O	O
evidence	NN	O	O
showing	NN	O	O
that	NN	O	O
physical	NN	O	O
activity	NN	O	O
and	NN	O	O
sun	NN	O	O
exposure	NN	O	O
are	NN	O	O
effective	NN	O	O
coadjuvant	NN	O	O
treatments	NN	O	O
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
mild	NN	O	I-PAR
to	NN	O	I-PAR
moderate	NN	O	I-PAR
depression	NN	O	I-PAR
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
lack	NN	O	O
of	NN	O	O
information	NN	O	O
regarding	NN	O	O
patient	NN	O	O
's	NN	O	O
adherence	NN	O	B-OUT
to	NN	O	O
these	NN	O	O
recommendations	NN	O	O
in	NN	O	O
daily	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
study	NN	O	O
including	NN	O	O
15	NN	O	B-PAR
depressive	NN	O	I-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
been	NN	O	I-PAR
under	NN	O	I-PAR
antidepressant	NN	O	I-PAR
treatment	NN	O	I-PAR
for	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
one	NN	O	I-PAR
month	NN	O	I-PAR
.	NN	O	O

They	NN	O	O
wore	NN	O	O
a	NN	O	O
wrist-watch-like	NN	O	O
actimetry	NN	O	O
sensor	NN	O	O
to	NN	O	O
measure	NN	O	O
physical	NN	O	B-OUT
activity	NN	O	I-OUT
and	NN	O	I-OUT
sun	NN	O	I-OUT
exposure	NN	O	I-OUT
24	NN	O	O
hours	NN	O	O
a	NN	O	O
day	NN	O	O
.	NN	O	O

After	NN	O	O
one	NN	O	O
week	NN	O	O
of	NN	O	O
baseline	NN	O	O
assessment	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
randomised	NN	O	O
into	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
arms	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
received	NN	O	O
a	NN	O	O
brief	NN	O	O
note	NN	O	O
in	NN	O	O
which	NN	O	O
they	NN	O	O
were	NN	O	O
explicitly	NN	O	O
asked	NN	O	O
to	NN	O	O
increase	NN	O	O
both	NN	O	O
their	NN	O	O
physical	NN	O	B-OUT
activity	NN	O	I-OUT
level	NN	O	I-OUT
and	NN	O	O
time	NN	O	B-OUT
of	NN	O	I-OUT
sun	NN	O	I-OUT
exposure	NN	O	I-OUT
,	NN	O	O
while	NN	O	O
control	NN	O	B-INT
group	NN	O	O
patients	NN	O	O
did	NN	O	O
not	NN	O	B-INT
receive	NN	O	I-INT
these	NN	O	I-INT
explicit	NN	O	I-INT
recommendations	NN	O	I-INT
.	NN	O	O

RESULTS	NN	O	O
One	NN	O	O
week	NN	O	O
after	NN	O	O
recommendations	NN	O	O
were	NN	O	O
delivered	NN	O	O
,	NN	O	O
only	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
had	NN	O	O
increased	NN	O	O
time	NN	O	B-OUT
of	NN	O	I-OUT
sun	NN	O	I-OUT
exposure	NN	O	I-OUT
and	NN	O	I-OUT
physical	NN	O	I-OUT
activity	NN	O	I-OUT
(	NN	O	O
25.8	NN	O	O
%	NN	O	O
and	NN	O	O
14.3	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Depressive	NN	O	B-PAR
patients	NN	O	I-PAR
are	NN	O	O
able	NN	O	O
to	NN	O	O
follow	NN	O	O
prescribed	NN	O	O
lifestyle	NN	O	O
recommendations	NN	O	O
in	NN	O	O
the	NN	O	O
short-term	NN	O	O
.	NN	O	O



--DOCSTART-- (23103798)

Role	NN	O	O
of	NN	O	O
posterior	NN	O	B-INT
tibial	NN	O	I-INT
nerve	NN	O	I-INT
stimulation	NN	O	I-INT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
refractory	NN	O	O
monosymptomatic	NN	O	O
nocturnal	NN	O	O
enuresis	NN	O	O
:	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
early	NN	O	O
clinical	NN	O	O
and	NN	O	O
urodynamic	NN	O	O
results	NN	O	O
of	NN	O	O
posterior	NN	O	B-INT
tibial	NN	O	I-INT
nerve	NN	O	I-INT
stimulation	NN	O	I-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
refractory	NN	O	I-PAR
monosymptomatic	NN	O	I-PAR
nocturnal	NN	O	I-PAR
enuresis	NN	O	I-PAR
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
We	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
28	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
refractory	NN	O	I-PAR
monosymptomatic	NN	O	I-PAR
nocturnal	NN	O	I-PAR
enuresis	NN	O	I-PAR
to	NN	O	O
2	NN	O	O
equal	NN	O	O
groups	NN	O	O
.	NN	O	O

Group	NN	O	O
1	NN	O	O
received	NN	O	O
a	NN	O	O
weekly	NN	O	O
session	NN	O	O
of	NN	O	O
posterior	NN	O	B-INT
tibial	NN	O	I-INT
nerve	NN	O	I-INT
stimulation	NN	O	I-INT
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
and	NN	O	O
group	NN	O	O
2	NN	O	O
was	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
posterior	NN	O	O
tibial	NN	O	O
nerve	NN	O	O
stimulation	NN	O	O
to	NN	O	O
compare	NN	O	O
clinical	NN	O	O
and	NN	O	O
urodynamic	NN	O	O
findings	NN	O	O
.	NN	O	O

Another	NN	O	O
clinical	NN	O	O
assessment	NN	O	O
was	NN	O	O
done	NN	O	O
3	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
followup	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
2	NN	O	O
groups	NN	O	O
were	NN	O	O
comparable	NN	O	O
in	NN	O	O
baseline	NN	O	O
clinical	NN	O	O
and	NN	O	O
urodynamic	NN	O	O
data	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
13	NN	O	O
patients	NN	O	O
(	NN	O	O
46.4	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
detrusor	NN	O	B-OUT
overactivity	NN	O	I-OUT
and	NN	O	O
14	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
decreased	NN	O	O
bladder	NN	O	B-OUT
capacity	NN	O	I-OUT
.	NN	O	O

After	NN	O	O
treatment	NN	O	O
11	NN	O	O
group	NN	O	O
1	NN	O	O
patients	NN	O	O
(	NN	O	O
78.6	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
partial	NN	O	O
or	NN	O	O
full	NN	O	O
response	NN	O	B-OUT
to	NN	O	O
posterior	NN	O	O
tibial	NN	O	O
nerve	NN	O	O
stimulation	NN	O	O
but	NN	O	O
only	NN	O	O
2	NN	O	O
(	NN	O	O
14.3	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
2	NN	O	O
had	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	B-OUT
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
the	NN	O	O
average	NN	O	O
number	NN	O	B-OUT
of	NN	O	I-OUT
wet	NN	O	I-OUT
nights	NN	O	I-OUT
in	NN	O	O
group	NN	O	O
1	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
at	NN	O	O
baseline	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
urodynamic	NN	O	B-OUT
parameters	NN	O	I-OUT
significantly	NN	O	O
improved	NN	O	O
in	NN	O	O
group	NN	O	O
1	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
wet	NN	O	B-OUT
nights	NN	O	I-OUT
and	NN	O	I-OUT
urodynamic	NN	O	I-OUT
parameters	NN	O	I-OUT
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
in	NN	O	O
group	NN	O	O
2	NN	O	O
.	NN	O	O

At	NN	O	O
3-month	NN	O	O
followup	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
partial	NN	O	O
or	NN	O	O
full	NN	O	O
response	NN	O	B-OUT
in	NN	O	O
group	NN	O	O
1	NN	O	O
had	NN	O	O
decreased	NN	O	O
from	NN	O	O
11	NN	O	O
(	NN	O	O
78.6	NN	O	O
%	NN	O	O
)	NN	O	O
to	NN	O	O
6	NN	O	O
(	NN	O	O
42.9	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
change	NN	O	O
was	NN	O	O
evident	NN	O	O
in	NN	O	O
group	NN	O	O
2	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Posterior	NN	O	B-INT
tibial	NN	O	I-INT
nerve	NN	O	I-INT
stimulation	NN	O	I-INT
can	NN	O	O
be	NN	O	O
a	NN	O	O
viable	NN	O	O
treatment	NN	O	O
option	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
refractory	NN	O	I-PAR
monosymptomatic	NN	O	I-PAR
nocturnal	NN	O	I-PAR
enuresis	NN	O	I-PAR
.	NN	O	O

However	NN	O	O
,	NN	O	O
deterioration	NN	O	O
in	NN	O	O
some	NN	O	O
responders	NN	O	O
with	NN	O	O
time	NN	O	O
suggests	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
maintenance	NN	O	O
protocols	NN	O	O
.	NN	O	O



--DOCSTART-- (23114870)

Custom-fit	NN	O	O
minimally	NN	O	O
invasive	NN	O	O
total	NN	O	B-INT
knee	NN	O	I-INT
arthroplasty	NN	O	I-INT
:	NN	O	O
effect	NN	O	O
on	NN	O	O
blood	NN	O	B-OUT
loss	NN	O	I-OUT
and	NN	O	O
early	NN	O	B-OUT
clinical	NN	O	I-OUT
outcomes	NN	O	I-OUT
.	NN	O	O

PURPOSE	NN	O	O
Recently	NN	O	O
,	NN	O	O
new	NN	O	O
custom-fit	NN	O	O
pin	NN	O	O
guides	NN	O	O
in	NN	O	O
total	NN	O	B-INT
knee	NN	O	I-INT
arthroplasty	NN	O	I-INT
(	NN	O	I-PAR
TKA	NN	O	I-INT
)	NN	O	I-PAR
have	NN	O	O
been	NN	O	O
introduced	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
these	NN	O	O
guides	NN	O	O
may	NN	O	O
reduce	NN	O	O
operating	NN	O	O
time	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
the	NN	O	O
guides	NN	O	O
combined	NN	O	O
with	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
intramedullary	NN	O	O
alignment	NN	O	O
jigs	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
reduced	NN	O	O
blood	NN	O	B-OUT
loss	NN	O	I-OUT
and	NN	O	O
improved	NN	O	O
early	NN	O	B-OUT
outcomes	NN	O	I-OUT
.	NN	O	O

Our	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
blood	NN	O	B-OUT
loss	NN	O	I-OUT
and	NN	O	O
early	NN	O	B-OUT
clinical	NN	O	I-OUT
outcomes	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
undergoing	NN	O	I-PAR
minimally	NN	O	I-PAR
invasive	NN	O	I-PAR
TKA	NN	O	I-PAR
using	NN	O	O
custom-fit	NN	O	B-INT
magnetic	NN	O	I-INT
resonance	NN	O	I-INT
imaging	NN	O	I-INT
(	NN	O	I-INT
MRI	NN	O	I-INT
)	NN	O	I-INT
-based	NN	O	I-INT
pin	NN	O	I-INT
guides	NN	O	I-INT
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
prospective	NN	O	O
study	NN	O	O
in	NN	O	O
80	NN	O	B-PAR
patients	NN	O	I-PAR
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
divided	NN	O	O
randomly	NN	O	O
into	NN	O	O
2	NN	O	O
equal	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
group	NN	O	O
,	NN	O	O
intramedullary	NN	O	B-INT
alignment	NN	O	I-INT
jigs	NN	O	I-INT
were	NN	O	O
used	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
second	NN	O	O
group	NN	O	O
,	NN	O	O
custom-fit	NN	O	B-INT
MRI-based	NN	O	I-INT
pin	NN	O	I-INT
guides	NN	O	I-INT
were	NN	O	O
used	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
the	NN	O	O
same	NN	O	O
cemented	NN	O	B-INT
posterior-stabilized	NN	O	I-INT
implant	NN	O	I-INT
through	NN	O	O
a	NN	O	O
mini-midvastus	NN	O	O
approach	NN	O	O
.	NN	O	O

The	NN	O	O
volume	NN	O	O
in	NN	O	O
the	NN	O	O
drain	NN	O	O
bottles	NN	O	O
was	NN	O	O
recorded	NN	O	O
after	NN	O	O
48	NN	O	O
h.	NN	O	O
Hb	NN	O	B-OUT
loss	NN	O	I-OUT
was	NN	O	O
estimated	NN	O	O
by	NN	O	O
subtracting	NN	O	O
the	NN	O	O
postoperative	NN	O	O
from	NN	O	O
the	NN	O	O
preoperative	NN	O	O
Hb	NN	O	O
level	NN	O	O
.	NN	O	O

Transfusion	NN	O	B-OUT
requirements	NN	O	I-OUT
and	NN	O	O
surgical	NN	O	B-OUT
time	NN	O	I-OUT
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Outcome	NN	O	O
measures	NN	O	O
were	NN	O	O
Knee	NN	O	B-OUT
Society	NN	O	I-OUT
Scores	NN	O	I-OUT
(	NN	O	I-OUT
KSS	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	I-OUT
knee	NN	O	I-OUT
flexion	NN	O	I-OUT
,	NN	O	I-OUT
knee	NN	O	I-OUT
swelling	NN	O	I-OUT
and	NN	O	I-OUT
pain	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
There	NN	O	O
was	NN	O	O
lower	NN	O	O
mean	NN	O	O
drainage	NN	O	B-OUT
of	NN	O	I-OUT
blood	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
custom-fit	NN	O	B-INT
group	NN	O	O
(	NN	O	O
391	NN	O	O
ml	NN	O	O
vs.	NN	O	O
603	NN	O	O
ml	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.0001	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
estimated	NN	O	O
loss	NN	O	B-OUT
of	NN	O	I-OUT
Hb	NN	O	I-OUT
(	NN	O	O
3.6	NN	O	O
g/dl	NN	O	O
vs.	NN	O	O
4.1	NN	O	O
g/dl	NN	O	O
;	NN	O	O
n.s	NN	O	O
.	NN	O	O

)	NN	O	O
and	NN	O	O
in	NN	O	O
transfusion	NN	O	O
requirements	NN	O	O
(	NN	O	O
7.5	NN	O	O
%	NN	O	O
vs.	NN	O	O
10	NN	O	O
%	NN	O	O
;	NN	O	O
n.s.	NN	O	O
)	NN	O	O
.	NN	O	O

Surgical	NN	O	B-OUT
time	NN	O	I-OUT
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
custom-fit	NN	O	B-INT
group	NN	O	O
(	NN	O	O
12	NN	O	O
min	NN	O	O
less	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

KSS	NN	O	B-OUT
measured	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
,	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

Knee	NN	O	B-OUT
flexion	NN	O	I-OUT
measured	NN	O	O
on	NN	O	O
days	NN	O	O
7	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
at	NN	O	O
week	NN	O	O
6	NN	O	O
,	NN	O	O
12	NN	O	O
and	NN	O	O
knee	NN	O	B-OUT
swelling	NN	O	I-OUT
and	NN	O	O
pain	NN	O	B-OUT
measured	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
at	NN	O	O
week	NN	O	O
6	NN	O	O
,	NN	O	O
12	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Using	NN	O	O
custom-fit	NN	O	B-INT
pin	NN	O	I-INT
guides	NN	O	I-INT
reduces	NN	O	O
blood	NN	O	B-OUT
drainage	NN	O	I-OUT
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
estimated	NN	O	O
Hb	NN	O	B-OUT
loss	NN	O	I-OUT
in	NN	O	O
minimally	NN	O	O
invasive	NN	O	O
TKA	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
affect	NN	O	O
transfusion	NN	O	B-OUT
rate	NN	O	I-OUT
.	NN	O	O

Surgical	NN	O	B-OUT
time	NN	O	I-OUT
is	NN	O	O
reduced	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
early	NN	O	B-OUT
clinical	NN	O	I-OUT
outcomes	NN	O	I-OUT
.	NN	O	O

LEVEL	NN	O	O
OF	NN	O	O
EVIDENCE	NN	O	O
Therapeutic	NN	O	O
study	NN	O	O
,	NN	O	O
Level	NN	O	O
I	NN	O	O
.	NN	O	O



--DOCSTART-- (23356250)

Influence	NN	O	O
of	NN	O	O
lime	NN	O	B-INT
juice	NN	O	I-INT
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
sickle	NN	O	B-PAR
cell	NN	O	I-PAR
anemia	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
OBJECTIVES	NN	O	O
The	NN	O	O
pain	NN	O	O
in	NN	O	O
sickle	NN	O	O
cell	NN	O	O
anemia	NN	O	O
(	NN	O	O
SCA	NN	O	O
)	NN	O	O
is	NN	O	O
often	NN	O	O
triggered	NN	O	O
by	NN	O	O
dehydration	NN	O	O
,	NN	O	O
acidosis	NN	O	O
,	NN	O	O
and	NN	O	O
fever	NN	O	O
that	NN	O	O
are	NN	O	O
usually	NN	O	O
due	NN	O	O
to	NN	O	O
malaria	NN	O	O
.	NN	O	O

Intake	NN	O	O
of	NN	O	O
lime	NN	O	B-INT
juice	NN	O	I-INT
was	NN	O	O
recently	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
facilitate	NN	O	O
clearance	NN	O	O
of	NN	O	O
the	NN	O	O
malaria	NN	O	O
parasite	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
therefore	NN	O	O
sought	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
regular	NN	O	O
intake	NN	O	O
of	NN	O	O
lime	NN	O	B-INT
juice	NN	O	I-INT
will	NN	O	O
ameliorate	NN	O	O
crisis	NN	O	O
,	NN	O	O
especially	NN	O	O
recurrent	NN	O	B-OUT
bone	NN	O	I-OUT
pain	NN	O	I-OUT
.	NN	O	O

DESIGN	NN	O	O
In	NN	O	O
this	NN	O	O
preliminary	NN	O	O
,	NN	O	O
open-labeled	NN	O	O
,	NN	O	O
randomized	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
lime	NN	O	B-INT
juice	NN	O	I-INT
on	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
some	NN	O	O
laboratory	NN	O	O
characteristics	NN	O	O
of	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
SCA	NN	O	I-PAR
were	NN	O	O
tested	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Among	NN	O	O
the	NN	O	O
113	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
SCA	NN	O	I-PAR
studied	NN	O	I-PAR
in	NN	O	I-PAR
two	NN	O	I-PAR
hospitals	NN	O	I-PAR
,	NN	O	O
the	NN	O	O
58	NN	O	O
receiving	NN	O	O
lime	NN	O	O
treatment	NN	O	O
had	NN	O	O
lower	NN	O	O
rates	NN	O	O
of	NN	O	O
significant	NN	O	B-OUT
painful	NN	O	I-OUT
episodes	NN	O	I-OUT
than	NN	O	O
the	NN	O	O
55	NN	O	O
without	NN	O	B-INT
lime	NN	O	I-INT
(	NN	O	O
37	NN	O	O
versus	NN	O	O
83	NN	O	O
crises	NN	O	O
in	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
0.64?0.11	NN	O	O
versus	NN	O	O
1.51?0.34	NN	O	O
average	NN	O	O
rates	NN	O	O
per	NN	O	O
child	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
fewer	NN	O	O
subjects	NN	O	O
than	NN	O	O
the	NN	O	O
controls	NN	O	O
had	NN	O	O
significant	NN	O	O
painful	NN	O	B-OUT
episodes	NN	O	I-OUT
(	NN	O	O
50.0	NN	O	O
%	NN	O	O
versus	NN	O	O
92.7	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
febrile	NN	O	B-OUT
illness	NN	O	I-OUT
(	NN	O	O
46.6	NN	O	O
%	NN	O	O
versus	NN	O	O
87.3	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
admission	NN	O	B-OUT
rate	NN	O	I-OUT
(	NN	O	O
3.4	NN	O	O
%	NN	O	O
versus	NN	O	O
34.5	NN	O	O
%	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	B-OUT
hematocrit	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
(	NN	O	O
26.23?2.03	NN	O	O
%	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
also	NN	O	O
higher	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
transfusion	NN	O	B-OUT
rate	NN	O	I-OUT
,	NN	O	I-OUT
presence	NN	O	I-OUT
of	NN	O	I-OUT
hepatomegaly	NN	O	I-OUT
,	NN	O	I-OUT
splenomegaly	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
jaundice	NN	O	I-OUT
was	NN	O	O
similar	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
lime	NN	O	B-INT
did	NN	O	O
not	NN	O	O
cause	NN	O	O
any	NN	O	O
significant	NN	O	B-OUT
side-effect	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
Regular	NN	O	O
intake	NN	O	O
of	NN	O	O
lime	NN	O	B-INT
juice	NN	O	I-INT
may	NN	O	O
be	NN	O	O
of	NN	O	O
great	NN	O	O
therapeutic	NN	O	O
and	NN	O	O
nutritional	NN	O	O
relevance	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
SCA	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (23357440)

The	NN	O	O
effect	NN	O	O
of	NN	O	O
cognitive-behavioral	NN	O	B-INT
therapy	NN	O	I-INT
versus	NN	O	O
treatment	NN	O	B-INT
as	NN	O	I-INT
usual	NN	O	I-INT
for	NN	O	O
anxiety	NN	O	B-PAR
in	NN	O	I-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
examine	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
of	NN	O	O
a	NN	O	O
modular	NN	O	O
cognitive-behavioral	NN	O	B-INT
therapy	NN	O	I-INT
(	NN	O	I-INT
CBT	NN	O	I-INT
)	NN	O	I-INT
protocol	NN	O	O
relative	NN	O	O
to	NN	O	O
treatment	NN	O	B-INT
as	NN	O	I-INT
usual	NN	O	I-INT
(	NN	O	I-INT
TAU	NN	O	I-INT
)	NN	O	I-INT
among	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
high-functioning	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
and	NN	O	I-PAR
clinically	NN	O	I-PAR
significant	NN	O	I-PAR
anxiety	NN	O	I-PAR
.	NN	O	O

METHOD	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
45	NN	O	I-PAR
children	NN	O	I-PAR
(	NN	O	I-PAR
7-11	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
)	NN	O	I-PAR
with	NN	O	I-PAR
high-functioning	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	I-PAR
clinically	NN	O	I-PAR
significant	NN	O	I-PAR
anxiety	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
16	NN	O	O
sessions	NN	O	O
of	NN	O	O
weekly	NN	O	O
CBT	NN	O	B-INT
or	NN	O	O
TAU	NN	O	B-INT
for	NN	O	O
an	NN	O	O
equivalent	NN	O	O
duration	NN	O	O
.	NN	O	O

After	NN	O	O
screening	NN	O	O
,	NN	O	O
assessments	NN	O	O
were	NN	O	O
conducted	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
post-treatment	NN	O	O
,	NN	O	O
and	NN	O	O
3-month	NN	O	O
follow-up	NN	O	O
.	NN	O	O

Raters	NN	O	O
were	NN	O	O
blind	NN	O	O
to	NN	O	O
treatment	NN	O	O
condition	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Youth	NN	O	O
receiving	NN	O	O
CBT	NN	O	B-INT
showed	NN	O	O
substantial	NN	O	O
improvement	NN	O	O
relative	NN	O	O
to	NN	O	O
TAU	NN	O	B-INT
on	NN	O	O
primary	NN	O	B-OUT
anxiety	NN	O	I-OUT
outcomes	NN	O	I-OUT
.	NN	O	O

Of	NN	O	O
24	NN	O	O
children	NN	O	O
randomized	NN	O	O
to	NN	O	O
the	NN	O	O
CBT	NN	O	B-INT
arm	NN	O	O
,	NN	O	O
18	NN	O	O
(	NN	O	O
75	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
treatment	NN	O	O
responders	NN	O	O
,	NN	O	O
versus	NN	O	O
only	NN	O	O
3	NN	O	O
of	NN	O	O
21	NN	O	O
children	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
TAU	NN	O	B-INT
arm	NN	O	O
.	NN	O	O

Gains	NN	O	O
were	NN	O	O
generally	NN	O	O
maintained	NN	O	O
at	NN	O	O
3-month	NN	O	O
follow-up	NN	O	O
for	NN	O	O
CBT	NN	O	B-INT
responders	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Relative	NN	O	O
to	NN	O	O
usual	NN	O	O
care	NN	O	O
,	NN	O	O
CBT	NN	O	B-INT
adapted	NN	O	O
for	NN	O	O
anxious	NN	O	O
youth	NN	O	O
with	NN	O	O
high-functioning	NN	O	O
ASD	NN	O	O
demonstrates	NN	O	O
large	NN	O	O
effects	NN	O	O
in	NN	O	O
reducing	NN	O	O
anxiety	NN	O	B-OUT
symptoms	NN	O	I-OUT
.	NN	O	O

This	NN	O	O
study	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
growing	NN	O	O
literature	NN	O	O
supporting	NN	O	O
adapted	NN	O	O
CBT	NN	O	B-INT
approaches	NN	O	O
for	NN	O	O
treating	NN	O	O
anxiety	NN	O	O
in	NN	O	O
youth	NN	O	O
with	NN	O	O
ASD	NN	O	O
.	NN	O	O



--DOCSTART-- (23392542)

Plasma	NN	O	B-OUT
AGE-peptides	NN	O	I-OUT
and	NN	O	I-OUT
C-peptide	NN	O	I-OUT
in	NN	O	O
early-stage	NN	O	B-PAR
diabetic	NN	O	I-PAR
nephropathy	NN	O	I-PAR
patients	NN	O	I-PAR
on	NN	O	O
thiamine	NN	O	O
and	NN	O	O
pyridoxine	NN	O	O
therapy	NN	O	O
.	NN	O	O

AIM	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
circulatory	NN	O	B-OUT
AGE-peptide	NN	O	I-OUT
levels	NN	O	I-OUT
in	NN	O	O
diabetic	NN	O	O
nephropathy	NN	O	O
and	NN	O	O
to	NN	O	O
observe	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
thiamine	NN	O	B-INT
(	NN	O	I-INT
vitamin	NN	O	I-INT
B1	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
pyridoxine	NN	O	B-INT
(	NN	O	I-INT
vitamin	NN	O	I-INT
B6	NN	O	I-INT
)	NN	O	I-INT
therapy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Type	NN	O	B-PAR
2	NN	O	I-PAR
diabetic	NN	O	I-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
N.=57	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
divided	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
as	NN	O	O
with	NN	O	O
nephropathy	NN	O	O
(	NN	O	O
N.=27	NN	O	O
)	NN	O	O
and	NN	O	O
without	NN	O	O
nephropathy	NN	O	O
(	NN	O	O
N.=30	NN	O	O
)	NN	O	O
.	NN	O	O

Diabetic	NN	O	B-PAR
nephropathy	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	O
treated	NN	O	O
with	NN	O	O
either	NN	O	O
B6	NN	O	B-INT
(	NN	O	O
N.=12	NN	O	O
)	NN	O	O
(	NN	O	O
250	NN	O	O
mg/day	NN	O	O
)	NN	O	O
or	NN	O	O
B1+B6	NN	O	B-INT
(	NN	O	O
N.=15	NN	O	O
)	NN	O	O
(	NN	O	O
250	NN	O	O
mg/day	NN	O	O
,	NN	O	O
each	NN	O	O
)	NN	O	O
for	NN	O	O
five	NN	O	O
months	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
beginning	NN	O	O
and	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
experimentation	NN	O	O
period	NN	O	O
,	NN	O	O
glucose	NN	O	B-OUT
,	NN	O	I-OUT
HbA1c	NN	O	I-OUT
,	NN	O	I-OUT
triglyceride	NN	O	I-OUT
,	NN	O	I-OUT
cholesterol	NN	O	I-OUT
,	NN	O	I-OUT
insulin	NN	O	I-OUT
,	NN	O	I-OUT
C-peptide	NN	O	I-OUT
,	NN	O	I-OUT
thiamine	NN	O	I-OUT
pyrophosphate	NN	O	I-OUT
,	NN	O	I-OUT
pyridoxal	NN	O	I-OUT
phosphate	NN	O	I-OUT
and	NN	O	I-OUT
AGE-	NN	O	I-OUT
peptides	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
AGE-peptides	NN	O	B-OUT
were	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
diabetic	NN	O	B-PAR
group	NN	O	O
with	NN	O	O
nephropathy	NN	O	O
than	NN	O	O
without	NN	O	O
nephropathy	NN	O	O
(	NN	O	O
P=0.005	NN	O	O
)	NN	O	O
.	NN	O	O

Within	NN	O	O
five	NN	O	O
months	NN	O	O
AGE-peptides	NN	O	B-OUT
increased	NN	O	O
in	NN	O	O
the	NN	O	O
diabetic	NN	O	B-PAR
group	NN	O	O
without	NN	O	O
nephropathy	NN	O	O
(	NN	O	O
P=0.042	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
with	NN	O	O
nephropathy	NN	O	O
treated	NN	O	O
either	NN	O	O
with	NN	O	O
B1+B6	NN	O	B-INT
or	NN	O	O
B6	NN	O	B-INT
.	NN	O	O

In	NN	O	O
B6	NN	O	B-INT
treated	NN	O	O
group	NN	O	O
a	NN	O	O
substantial	NN	O	O
decrease	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
HbA1c	NN	O	B-OUT
(	NN	O	O
P=0.033	NN	O	O
)	NN	O	O
.	NN	O	O

B1+B6	NN	O	B-INT
or	NN	O	O
B6	NN	O	B-INT
treatment	NN	O	O
both	NN	O	O
caused	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
C-peptide	NN	O	B-OUT
(	NN	O	O
P=0.006	NN	O	O
,	NN	O	O
P=0.004	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Among	NN	O	O
the	NN	O	O
parameters	NN	O	O
measured	NN	O	O
,	NN	O	O
plasma	NN	O	B-OUT
AGE-peptides	NN	O	I-OUT
was	NN	O	O
the	NN	O	O
only	NN	O	O
parameter	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
higher	NN	O	O
in	NN	O	O
type	NN	O	B-PAR
2	NN	O	I-PAR
diabetes	NN	O	I-PAR
mellitus	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	O
nephropathy	NN	O	O
than	NN	O	O
without	NN	O	O
nephropathy	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
patients	NN	O	B-PAR
with	NN	O	O
nephropathy	NN	O	O
treated	NN	O	O
with	NN	O	O
B1+B6	NN	O	B-INT
or	NN	O	O
B6	NN	O	B-INT
did	NN	O	O
not	NN	O	O
display	NN	O	O
any	NN	O	O
further	NN	O	O
increase	NN	O	O
in	NN	O	O
AGE-peptides	NN	O	B-OUT
within	NN	O	O
five	NN	O	O
months	NN	O	O
.	NN	O	O

Both	NN	O	O
of	NN	O	O
the	NN	O	O
treatments	NN	O	O
caused	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
C-peptide	NN	O	B-OUT
.	NN	O	O



--DOCSTART-- (23417625)

Social	NN	O	O
skills	NN	O	O
improvement	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
high-functioning	NN	O	I-PAR
autism	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
pilot	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

High-functioning	NN	O	O
autism	NN	O	O
(	NN	O	O
HFA	NN	O	O
)	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
persistent	NN	O	O
impairment	NN	O	O
in	NN	O	O
social	NN	O	O
interaction	NN	O	O
despite	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
mental	NN	O	O
retardation	NN	O	O
.	NN	O	O

Although	NN	O	O
an	NN	O	O
increasing	NN	O	O
number	NN	O	O
of	NN	O	O
group-based	NN	O	O
programs	NN	O	O
for	NN	O	O
the	NN	O	O
improvement	NN	O	O
of	NN	O	O
social	NN	O	O
skills	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
,	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trials	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
their	NN	O	O
efficacy	NN	O	O
.	NN	O	O

To	NN	O	O
compare	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
Social	NN	O	B-INT
Skills	NN	O	I-INT
Training	NN	O	I-INT
Group-based	NN	O	I-INT
Program	NN	O	I-INT
(	NN	O	I-INT
SST-GP	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
a	NN	O	O
Leisure	NN	O	B-INT
Activities	NN	O	I-INT
Group-based	NN	O	I-INT
Program	NN	O	I-INT
(	NN	O	I-INT
LA-GP	NN	O	I-INT
)	NN	O	I-INT
on	NN	O	O
the	NN	O	O
perception	NN	O	O
of	NN	O	O
facial	NN	O	O
emotions	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
(	NN	O	O
QoL	NN	O	O
)	NN	O	O
in	NN	O	O
young	NN	O	O
people	NN	O	O
with	NN	O	O
HFA	NN	O	O
.	NN	O	O

Eligible	NN	O	O
patients	NN	O	O
were	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
adolescents	NN	O	I-PAR
with	NN	O	I-PAR
HFA	NN	O	I-PAR
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
the	NN	O	O
SST	NN	O	B-INT
or	NN	O	O
LA	NN	O	B-INT
group	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
an	NN	O	O
improvement	NN	O	O
of	NN	O	O
2	NN	O	O
points	NN	O	O
in	NN	O	O
error	NN	O	B-OUT
rates	NN	O	I-OUT
for	NN	O	I-OUT
facial	NN	O	I-OUT
emotion	NN	O	I-OUT
labeling	NN	O	I-OUT
(	NN	O	I-OUT
DANVA2	NN	O	I-OUT
)	NN	O	I-OUT
from	NN	O	O
baseline	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
6-month	NN	O	O
training	NN	O	O
period	NN	O	O
,	NN	O	O
the	NN	O	O
SST	NN	O	B-INT
Group	NN	O	O
made	NN	O	O
fewer	NN	O	O
errors	NN	O	O
in	NN	O	O
labeling	NN	O	O
anger	NN	O	O
on	NN	O	O
adult	NN	O	O
faces	NN	O	O
,	NN	O	O
whereas	NN	O	O
error	NN	O	O
rates	NN	O	O
in	NN	O	O
the	NN	O	O
LA	NN	O	B-INT
Group	NN	O	O
remained	NN	O	O
stable	NN	O	O
.	NN	O	O

Progress	NN	O	O
in	NN	O	O
the	NN	O	O
ability	NN	O	B-OUT
to	NN	O	I-OUT
recognize	NN	O	I-OUT
anger	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
SST	NN	O	B-INT
Group	NN	O	O
was	NN	O	O
due	NN	O	O
to	NN	O	O
better	NN	O	O
recognition	NN	O	O
of	NN	O	O
low	NN	O	O
intensity	NN	O	O
stimuli	NN	O	O
on	NN	O	O
adult	NN	O	O
faces	NN	O	O
.	NN	O	O

QoL	NN	O	B-OUT
increased	NN	O	O
in	NN	O	O
the	NN	O	O
SST	NN	O	B-INT
Group	NN	O	O
in	NN	O	O
the	NN	O	O
dimension	NN	O	O
of	NN	O	O
school	NN	O	O
environment	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
the	NN	O	O
transfer	NN	O	O
of	NN	O	O
skills	NN	O	O
acquired	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
setting	NN	O	O
to	NN	O	O
their	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
community	NN	O	O
.	NN	O	O

The	NN	O	O
SST-GP	NN	O	B-INT
had	NN	O	O
higher	NN	O	O
efficacy	NN	O	B-OUT
than	NN	O	O
the	NN	O	O
LA-GP	NN	O	B-INT
.	NN	O	O

Data	NN	O	O
justify	NN	O	O
replication	NN	O	O
using	NN	O	O
larger	NN	O	O
samples	NN	O	O
.	NN	O	O



--DOCSTART-- (23549581)

Effect	NN	O	O
of	NN	O	O
duloxetine	NN	O	B-INT
on	NN	O	O
pain	NN	O	B-OUT
,	NN	O	I-OUT
function	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
quality	NN	O	I-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
among	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
chemotherapy-induced	NN	O	I-PAR
painful	NN	O	I-PAR
peripheral	NN	O	I-PAR
neuropathy	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

IMPORTANCE	NN	O	O
There	NN	O	O
are	NN	O	O
no	NN	O	O
known	NN	O	O
effective	NN	O	O
treatments	NN	O	O
for	NN	O	O
painful	NN	O	O
chemotherapy-induced	NN	O	O
peripheral	NN	O	O
neuropathy	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
duloxetine	NN	O	B-INT
,	NN	O	O
60	NN	O	O
mg	NN	O	O
daily	NN	O	O
,	NN	O	O
on	NN	O	O
average	NN	O	B-OUT
pain	NN	O	I-OUT
severity	NN	O	I-OUT
.	NN	O	O

DESIGN	NN	O	O
,	NN	O	O
SETTING	NN	O	O
,	NN	O	O
AND	NN	O	O
PATIENTS	NN	O	O
Randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
crossover	NN	O	O
trial	NN	O	O
at	NN	O	O
8	NN	O	O
National	NN	O	O
Cancer	NN	O	O
Institute	NN	O	O
(	NN	O	O
NCI	NN	O	O
)	NN	O	O
-funded	NN	O	O
cooperative	NN	O	O
research	NN	O	O
networks	NN	O	O
that	NN	O	O
enrolled	NN	O	O
231	NN	O	B-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
were	NN	O	I-PAR
25	NN	O	I-PAR
years	NN	O	I-PAR
or	NN	O	I-PAR
older	NN	O	I-PAR
being	NN	O	I-PAR
treated	NN	O	I-PAR
at	NN	O	I-PAR
community	NN	O	I-PAR
and	NN	O	I-PAR
academic	NN	O	I-PAR
settings	NN	O	I-PAR
between	NN	O	I-PAR
April	NN	O	I-PAR
2008	NN	O	I-PAR
and	NN	O	I-PAR
March	NN	O	I-PAR
2011	NN	O	I-PAR
.	NN	O	O

Study	NN	O	O
follow-up	NN	O	O
was	NN	O	O
completed	NN	O	O
July	NN	O	O
2012	NN	O	O
.	NN	O	O

Stratified	NN	O	O
by	NN	O	O
chemotherapeutic	NN	O	O
drug	NN	O	O
and	NN	O	O
comorbid	NN	O	O
pain	NN	O	O
risk	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
duloxetine	NN	O	B-INT
followed	NN	O	O
by	NN	O	O
placebo	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
followed	NN	O	O
by	NN	O	O
duloxetine	NN	O	B-INT
.	NN	O	O

Eligibility	NN	O	B-PAR
required	NN	O	I-PAR
that	NN	O	I-PAR
patients	NN	O	I-PAR
have	NN	O	I-PAR
grade	NN	O	I-PAR
1	NN	O	I-PAR
or	NN	O	I-PAR
higher	NN	O	I-PAR
sensory	NN	O	I-PAR
neuropathy	NN	O	I-PAR
according	NN	O	I-PAR
to	NN	O	I-PAR
the	NN	O	I-PAR
NCI	NN	O	I-PAR
Common	NN	O	I-PAR
Terminology	NN	O	I-PAR
Criteria	NN	O	I-PAR
for	NN	O	I-PAR
Adverse	NN	O	I-PAR
Events	NN	O	I-PAR
and	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
4	NN	O	I-PAR
on	NN	O	I-PAR
a	NN	O	I-PAR
scale	NN	O	I-PAR
of	NN	O	I-PAR
0	NN	O	I-PAR
to	NN	O	I-PAR
10	NN	O	I-PAR
,	NN	O	I-PAR
representing	NN	O	I-PAR
average	NN	O	I-PAR
chemotherapy-induced	NN	O	I-PAR
pain	NN	O	I-PAR
,	NN	O	I-PAR
after	NN	O	I-PAR
paclitaxel	NN	O	I-PAR
,	NN	O	I-PAR
other	NN	O	I-PAR
taxane	NN	O	I-PAR
,	NN	O	I-PAR
or	NN	O	I-PAR
oxaliplatin	NN	O	I-PAR
treatment	NN	O	I-PAR
.	NN	O	O

INTERVENTIONS	NN	O	O
The	NN	O	O
initial	NN	O	O
treatment	NN	O	O
consisted	NN	O	O
of	NN	O	O
taking	NN	O	O
1	NN	O	O
capsule	NN	O	O
daily	NN	O	O
of	NN	O	O
either	NN	O	O
30	NN	O	O
mg	NN	O	O
of	NN	O	O
duloxetine	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
for	NN	O	O
the	NN	O	O
first	NN	O	O
week	NN	O	O
and	NN	O	O
2	NN	O	O
capsules	NN	O	O
of	NN	O	O
either	NN	O	O
30	NN	O	O
mg	NN	O	O
of	NN	O	O
duloxetine	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
daily	NN	O	O
for	NN	O	O
4	NN	O	O
additional	NN	O	O
weeks	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURES	NN	O	O
The	NN	O	O
primary	NN	O	O
hypothesis	NN	O	O
was	NN	O	O
that	NN	O	O
duloxetine	NN	O	B-INT
would	NN	O	O
be	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
decreasing	NN	O	O
chemotherapy-induced	NN	O	B-OUT
peripheral	NN	O	I-OUT
neuropathic	NN	O	I-OUT
pain	NN	O	I-OUT
.	NN	O	O

Pain	NN	O	B-OUT
severity	NN	O	I-OUT
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
the	NN	O	O
Brief	NN	O	B-OUT
Pain	NN	O	I-OUT
Inventory-Short	NN	O	I-OUT
Form	NN	O	I-OUT
average	NN	O	I-OUT
pain	NN	O	I-OUT
item	NN	O	I-OUT
with	NN	O	O
0	NN	O	O
representing	NN	O	O
no	NN	O	O
pain	NN	O	B-OUT
and	NN	O	O
10	NN	O	O
representing	NN	O	O
as	NN	O	O
bad	NN	O	O
as	NN	O	O
can	NN	O	O
be	NN	O	O
imagined	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Individuals	NN	O	O
receiving	NN	O	O
duloxetine	NN	O	O
as	NN	O	O
their	NN	O	O
initial	NN	O	O
5-week	NN	O	O
treatment	NN	O	O
reported	NN	O	O
a	NN	O	O
mean	NN	O	O
decrease	NN	O	O
in	NN	O	O
average	NN	O	B-OUT
pain	NN	O	I-OUT
of	NN	O	O
1.06	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0.72-1.40	NN	O	O
)	NN	O	O
vs	NN	O	O
0.34	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0.01-0.66	NN	O	O
)	NN	O	O
among	NN	O	O
those	NN	O	O
who	NN	O	O
received	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.003	NN	O	O
;	NN	O	O
effect	NN	O	O
size	NN	O	O
,	NN	O	O
0.513	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
observed	NN	O	O
mean	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
average	NN	O	B-OUT
pain	NN	O	I-OUT
score	NN	O	I-OUT
between	NN	O	O
duloxetine	NN	O	B-INT
and	NN	O	O
placebo	NN	O	B-INT
was	NN	O	O
0.73	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0.26-1.20	NN	O	O
)	NN	O	O
.	NN	O	O

Fifty-nine	NN	O	O
percent	NN	O	O
of	NN	O	O
those	NN	O	O
initially	NN	O	O
receiving	NN	O	O
duloxetine	NN	O	B-INT
vs	NN	O	O
38	NN	O	O
%	NN	O	O
of	NN	O	O
those	NN	O	O
initially	NN	O	O
receiving	NN	O	O
placebo	NN	O	O
reported	NN	O	O
decreased	NN	O	O
pain	NN	O	B-OUT
of	NN	O	O
any	NN	O	O
amount	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
AND	NN	O	O
RELEVANCE	NN	O	O
Among	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
painful	NN	O	I-PAR
chemotherapy-induced	NN	O	I-PAR
peripheral	NN	O	I-PAR
neuropathy	NN	O	I-PAR
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
duloxetine	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
placebo	NN	O	B-INT
for	NN	O	O
5	NN	O	O
weeks	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
greater	NN	O	O
reduction	NN	O	O
in	NN	O	O
pain	NN	O	B-OUT
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
clinicaltrials.gov	NN	O	O
Identifier	NN	O	O
:	NN	O	O
NCT00489411	NN	O	O
.	NN	O	O



--DOCSTART-- (23838728)

Teacher	NN	O	O
and	NN	O	O
child	NN	O	O
predictors	NN	O	O
of	NN	O	O
achieving	NN	O	O
IEP	NN	O	O
goals	NN	O	O
of	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O

It	NN	O	O
is	NN	O	O
encouraging	NN	O	O
that	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
show	NN	O	O
a	NN	O	O
strong	NN	O	O
response	NN	O	O
to	NN	O	O
early	NN	O	O
intervention	NN	O	O
,	NN	O	O
yet	NN	O	O
more	NN	O	O
research	NN	O	O
is	NN	O	O
needed	NN	O	O
for	NN	O	O
understanding	NN	O	O
the	NN	O	O
variability	NN	O	O
in	NN	O	O
responsiveness	NN	O	O
to	NN	O	O
specialized	NN	O	O
programs	NN	O	O
.	NN	O	O

Treatment	NN	O	O
predictor	NN	O	O
variables	NN	O	O
from	NN	O	O
47	NN	O	B-PAR
teachers	NN	O	I-PAR
and	NN	O	I-PAR
children	NN	O	I-PAR
who	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
the	NN	O	O
COMPASS	NN	O	B-INT
intervention	NN	O	I-INT
(	NN	O	O
Ruble	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O

in	NN	O	O
The	NN	O	O
collaborative	NN	O	O
model	NN	O	O
for	NN	O	O
promoting	NN	O	O
competence	NN	O	O
and	NN	O	O
success	NN	O	O
for	NN	O	O
students	NN	O	O
with	NN	O	O
ASD	NN	O	O
.	NN	O	O

Springer	NN	O	O
,	NN	O	O
New	NN	O	O
York	NN	O	O
,	NN	O	O
2012a	NN	O	O
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Predictors	NN	O	O
evaluated	NN	O	O
against	NN	O	O
child	NN	O	O
IEP	NN	O	O
goal	NN	O	O
attainment	NN	O	O
included	NN	O	O
child	NN	O	O
,	NN	O	O
teacher	NN	O	O
,	NN	O	O
intervention	NN	O	O
practice	NN	O	O
,	NN	O	O
and	NN	O	O
implementation	NN	O	O
practice	NN	O	O
variables	NN	O	O
based	NN	O	O
on	NN	O	O
an	NN	O	O
implementation	NN	O	O
science	NN	O	O
framework	NN	O	O
(	NN	O	O
Dunst	NN	O	O
and	NN	O	O
Trivette	NN	O	O
in	NN	O	O
J	NN	O	O
Soc	NN	O	O
Sci	NN	O	O
8:143-148	NN	O	O
,	NN	O	O
2012	NN	O	O
)	NN	O	O
.	NN	O	O

Findings	NN	O	O
revealed	NN	O	O
one	NN	O	O
child	NN	O	O
(	NN	O	O
engagement	NN	O	O
)	NN	O	O
,	NN	O	O
one	NN	O	O
teacher	NN	O	O
(	NN	O	O
exhaustion	NN	O	O
)	NN	O	O
,	NN	O	O
two	NN	O	O
intervention	NN	O	O
quality	NN	O	O
(	NN	O	O
IEP	NN	O	O
quality	NN	O	O
for	NN	O	O
targeted	NN	O	O
and	NN	O	O
not	NN	O	O
targeted	NN	O	O
elements	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
implementation	NN	O	O
quality	NN	O	O
variables	NN	O	O
accounted	NN	O	O
for	NN	O	O
variance	NN	O	O
in	NN	O	O
child	NN	O	O
outcomes	NN	O	O
when	NN	O	O
analyzed	NN	O	O
separately	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
four	NN	O	O
significant	NN	O	O
variables	NN	O	O
were	NN	O	O
compared	NN	O	O
against	NN	O	O
each	NN	O	O
other	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
regression	NN	O	O
analysis	NN	O	O
,	NN	O	O
IEP	NN	O	O
quality	NN	O	O
accounted	NN	O	O
for	NN	O	O
one	NN	O	O
quarter	NN	O	O
of	NN	O	O
the	NN	O	O
variance	NN	O	O
in	NN	O	O
child	NN	O	O
outcomes	NN	O	O
.	NN	O	O



--DOCSTART-- (23849147)

Bayesian	NN	O	B-INT
adaptive	NN	O	I-INT
trials	NN	O	O
offer	NN	O	O
advantages	NN	O	O
in	NN	O	O
comparative	NN	O	O
effectiveness	NN	O	O
trials	NN	O	O
:	NN	O	O
an	NN	O	O
example	NN	O	O
in	NN	O	O
status	NN	O	B-PAR
epilepticus	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
We	NN	O	O
present	NN	O	O
a	NN	O	O
novel	NN	O	O
Bayesian	NN	O	B-INT
adaptive	NN	O	I-INT
comparative	NN	O	O
effectiveness	NN	O	O
trial	NN	O	O
comparing	NN	O	O
three	NN	O	O
treatments	NN	O	O
for	NN	O	O
status	NN	O	O
epilepticus	NN	O	O
that	NN	O	O
uses	NN	O	O
adaptive	NN	O	O
randomization	NN	O	O
with	NN	O	O
potential	NN	O	O
early	NN	O	O
stopping	NN	O	O
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
AND	NN	O	O
SETTING	NN	O	O
The	NN	O	O
trial	NN	O	O
will	NN	O	O
enroll	NN	O	O
720	NN	O	B-PAR
unique	NN	O	I-PAR
patients	NN	O	I-PAR
in	NN	O	I-PAR
emergency	NN	O	I-PAR
departments	NN	O	I-PAR
and	NN	O	I-PAR
uses	NN	O	I-PAR
a	NN	O	I-PAR
Bayesian	NN	O	I-INT
adaptive	NN	O	I-INT
design	NN	O	I-INT
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
trial	NN	O	O
design	NN	O	O
is	NN	O	O
compared	NN	O	O
to	NN	O	O
a	NN	O	O
trial	NN	O	O
without	NN	O	O
adaptive	NN	O	O
randomization	NN	O	O
and	NN	O	O
produces	NN	O	O
an	NN	O	O
efficient	NN	O	O
trial	NN	O	O
in	NN	O	O
which	NN	O	O
a	NN	O	O
higher	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
are	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
randomized	NN	O	O
to	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
treatment	NN	O	O
arm	NN	O	O
while	NN	O	O
generally	NN	O	O
using	NN	O	O
fewer	NN	O	O
total	NN	O	O
patients	NN	O	O
and	NN	O	O
offers	NN	O	O
higher	NN	O	O
power	NN	O	O
than	NN	O	O
an	NN	O	O
analogous	NN	O	O
trial	NN	O	O
with	NN	O	O
fixed	NN	O	O
randomization	NN	O	O
when	NN	O	O
identifying	NN	O	O
a	NN	O	O
superior	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
When	NN	O	O
one	NN	O	O
treatment	NN	O	O
is	NN	O	O
superior	NN	O	O
to	NN	O	O
the	NN	O	O
other	NN	O	O
two	NN	O	O
,	NN	O	O
the	NN	O	O
trial	NN	O	O
design	NN	O	O
provides	NN	O	O
better	NN	O	O
patient	NN	O	B-OUT
care	NN	O	I-OUT
,	NN	O	O
higher	NN	O	O
power	NN	O	B-OUT
,	NN	O	O
and	NN	O	O
a	NN	O	O
lower	NN	O	O
expected	NN	O	B-OUT
sample	NN	O	I-OUT
size	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (23985254)

[	NN	O	O
Impact	NN	O	O
of	NN	O	O
CCND1	NN	O	O
A870G	NN	O	O
polymorphism	NN	O	O
on	NN	O	O
acute	NN	O	B-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
in	NN	O	O
postoperative	NN	O	B-PAR
rectal	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
treated	NN	O	I-PAR
with	NN	O	I-PAR
adjuvant	NN	O	I-PAR
concurrent	NN	O	I-PAR
chemoradiotherapy	NN	O	I-INT
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
single	NN	O	O
nucleotide	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
SNP	NN	O	O
)	NN	O	O
of	NN	O	O
CCND1	NN	O	O
A870G	NN	O	O
and	NN	O	O
acute	NN	O	B-OUT
adverse	NN	O	I-OUT
events	NN	O	I-OUT
(	NN	O	I-OUT
AEs	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
postoperative	NN	O	B-PAR
rectal	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
received	NN	O	I-PAR
capecitabine-based	NN	O	I-INT
postoperative	NN	O	I-PAR
chemoradiotherapy	NN	O	I-INT
(	NN	O	I-PAR
CRT	NN	O	I-INT
)	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Four	NN	O	B-PAR
hundred	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
stage	NN	O	I-PAR
II	NN	O	I-PAR
and	NN	O	I-PAR
III	NN	O	I-PAR
rectal	NN	O	I-PAR
cancer	NN	O	I-PAR
received	NN	O	I-PAR
postoperative	NN	O	I-PAR
CRT	NN	O	I-PAR
of	NN	O	I-PAR
capecitabine	NN	O	I-INT
with	NN	O	O
or	NN	O	O
without	NN	O	O
oxaliplatin	NN	O	B-INT
were	NN	O	O
accumulated	NN	O	O
and	NN	O	O
prostectively	NN	O	O
studied	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Two	NN	O	O
hundred	NN	O	O
and	NN	O	O
twenty-eight	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
concurrent	NN	O	O
capecitabine	NN	O	B-INT
and	NN	O	I-INT
radiotherapy	NN	O	I-INT
(	NN	O	I-INT
Cap-CRT	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
and	NN	O	O
172	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
capecitabine	NN	O	B-INT
and	NN	O	I-INT
oxaliplatin	NN	O	I-INT
plus	NN	O	I-INT
radiotherapy	NN	O	I-INT
(	NN	O	I-INT
Cap-Oxa-CRT	NN	O	I-INT
)	NN	O	I-INT
.	NN	O	O

Adverse	NN	O	B-OUT
events	NN	O	I-OUT
were	NN	O	O
graded	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
Common	NN	O	B-OUT
Terminology	NN	O	I-OUT
Criteria	NN	O	I-OUT
for	NN	O	I-OUT
Adverse	NN	O	I-OUT
Events	NN	O	I-OUT
,	NN	O	I-OUT
v.	NN	O	I-OUT
3.0	NN	O	I-OUT
(	NN	O	I-OUT
CTCAE	NN	O	I-OUT
v3.0	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
genotype	NN	O	O
of	NN	O	O
CCND1	NN	O	O
A870G	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
was	NN	O	O
detected	NN	O	O
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction-based	NN	O	O
restriction	NN	O	O
fragment	NN	O	O
length	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
PCR-RFLP	NN	O	O
)	NN	O	O
analysis	NN	O	O
.	NN	O	O

The	NN	O	O
associations	NN	O	O
between	NN	O	O
the	NN	O	O
SNP	NN	O	O
and	NN	O	O
acute	NN	O	B-OUT
AEs	NN	O	I-OUT
were	NN	O	O
indicated	NN	O	O
by	NN	O	O
odds	NN	O	O
ratios	NN	O	O
(	NN	O	O
ORs	NN	O	O
)	NN	O	O
and	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NN	O	O
(	NN	O	O
CIs	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
computed	NN	O	O
with	NN	O	O
logistic	NN	O	O
regression	NN	O	O
model	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
136	NN	O	O
patients	NN	O	O
presented	NN	O	O
severe	NN	O	O
AEs	NN	O	B-OUT
.	NN	O	O

Among	NN	O	O
them	NN	O	O
the	NN	O	O
frequencies	NN	O	O
of	NN	O	O
the	NN	O	O
three	NN	O	O
genotypes	NN	O	O
GG	NN	O	O
,	NN	O	O
GA	NN	O	O
and	NN	O	O
AA	NN	O	O
were	NN	O	O
16.9	NN	O	O
%	NN	O	O
,	NN	O	O
50.7	NN	O	O
%	NN	O	O
and	NN	O	O
32.4	NN	O	O
%	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
24.6	NN	O	O
%	NN	O	O
,	NN	O	O
48.1	NN	O	O
%	NN	O	O
and	NN	O	O
27.3	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
among	NN	O	O
the	NN	O	O
patients	NN	O	O
without	NN	O	O
severe	NN	O	O
AEs	NN	O	B-OUT
.	NN	O	O

Diarrhea	NN	O	B-OUT
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
AE	NN	O	B-OUT
,	NN	O	O
and	NN	O	O
severe	NN	O	B-OUT
diarrhea	NN	O	I-OUT
occurred	NN	O	O
in	NN	O	O
109	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
of	NN	O	O
the	NN	O	O
three	NN	O	O
genotypes	NN	O	O
GG	NN	O	O
,	NN	O	O
GA	NN	O	O
and	NN	O	O
AA	NN	O	O
were	NN	O	O
15.6	NN	O	O
%	NN	O	O
,	NN	O	O
47.7	NN	O	O
%	NN	O	O
and	NN	O	O
36.7	NN	O	O
%	NN	O	O
among	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
24.4	NN	O	O
%	NN	O	O
,	NN	O	O
49.5	NN	O	O
%	NN	O	O
and	NN	O	O
26.1	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
among	NN	O	O
patients	NN	O	O
without	NN	O	O
severe	NN	O	B-OUT
diarrhea	NN	O	I-OUT
.	NN	O	O

Multivariate	NN	O	O
logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
showed	NN	O	O
a	NN	O	O
1.66-fold	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
severe	NN	O	B-OUT
diarrhea	NN	O	I-OUT
in	NN	O	O
patients	NN	O	O
with	NN	O	O
AA	NN	O	O
genotype	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1.03	NN	O	O
-	NN	O	O
2.67	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0.038	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
cases	NN	O	O
with	NN	O	O
GG	NN	O	O
or	NN	O	O
GA	NN	O	O
genotypes	NN	O	O
.	NN	O	O

Stratified	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
Cap-Oxa-CRT	NN	O	B-INT
group	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
AA	NN	O	O
genotype	NN	O	O
showed	NN	O	O
a	NN	O	O
2.34-fold	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
severe	NN	O	B-OUT
diarrhea	NN	O	I-OUT
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1.16	NN	O	O
-	NN	O	O
4.76	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0.018	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
with	NN	O	O
GG	NN	O	O
or	NN	O	O
GA	NN	O	O
genotypes	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
the	NN	O	O
Cap-CRT	NN	O	B-INT
group	NN	O	O
,	NN	O	O
the	NN	O	O
SNP	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
severe	NN	O	B-OUT
diarrhea	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
genetic	NN	O	O
polymorphism	NN	O	O
of	NN	O	O
CCND1	NN	O	O
A870G	NN	O	O
might	NN	O	O
be	NN	O	O
a	NN	O	O
potential	NN	O	O
biomarker	NN	O	O
for	NN	O	O
predicting	NN	O	O
acute	NN	O	B-OUT
AEs	NN	O	I-OUT
in	NN	O	O
postoperative	NN	O	B-PAR
stage	NN	O	I-PAR
II	NN	O	I-PAR
and	NN	O	I-PAR
III	NN	O	I-PAR
rectal	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
treated	NN	O	O
with	NN	O	O
adjuvant	NN	O	O
concurrent	NN	O	O
chemoradiotherapy	NN	O	B-INT
of	NN	O	O
capecitabine	NN	O	B-INT
and	NN	O	O
oxaliplatin	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (24075141)

Data	NN	O	O
mining	NN	O	O
the	NN	O	O
ScanBrit	NN	O	O
study	NN	O	O
of	NN	O	O
a	NN	O	O
gluten-	NN	O	B-INT
and	NN	O	I-INT
casein-free	NN	O	I-INT
dietary	NN	O	I-INT
intervention	NN	O	I-INT
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
:	NN	O	O
behavioural	NN	O	B-OUT
and	NN	O	I-OUT
psychometric	NN	O	I-OUT
measures	NN	O	I-OUT
of	NN	O	O
dietary	NN	O	O
response	NN	O	O
.	NN	O	O

We	NN	O	O
previously	NN	O	O
reported	NN	O	O
results	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
examination	NN	O	O
of	NN	O	O
a	NN	O	O
gluten-	NN	O	B-INT
and	NN	O	I-INT
casein-free	NN	O	I-INT
diet	NN	O	I-INT
as	NN	O	O
an	NN	O	O
intervention	NN	O	O
for	NN	O	O
children	NN	O	B-PAR
diagnosed	NN	O	I-PAR
with	NN	O	I-PAR
an	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
as	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
ScanBrit	NN	O	O
collaboration	NN	O	O
.	NN	O	O

Analysis	NN	O	O
based	NN	O	O
on	NN	O	O
grouped	NN	O	O
results	NN	O	O
indicated	NN	O	O
several	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
dietary	NN	O	O
and	NN	O	O
non-dietary	NN	O	O
participants	NN	O	O
across	NN	O	O
various	NN	O	O
core	NN	O	O
and	NN	O	O
peripheral	NN	O	O
areas	NN	O	O
of	NN	O	O
functioning	NN	O	O
.	NN	O	O

Results	NN	O	O
also	NN	O	O
indicated	NN	O	O
some	NN	O	O
disparity	NN	O	O
in	NN	O	O
individual	NN	O	O
responses	NN	O	O
to	NN	O	O
dietary	NN	O	O
modification	NN	O	O
potentially	NN	O	O
indicative	NN	O	O
of	NN	O	O
responder	NN	O	O
and	NN	O	O
non-responder	NN	O	O
differences	NN	O	O
.	NN	O	O

Further	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
behavioural	NN	O	O
and	NN	O	O
psychometric	NN	O	O
data	NN	O	O
garnered	NN	O	O
from	NN	O	O
participants	NN	O	O
was	NN	O	O
undertaken	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
view	NN	O	O
to	NN	O	O
determining	NN	O	O
potential	NN	O	O
factors	NN	O	O
pertinent	NN	O	O
to	NN	O	O
response	NN	O	O
to	NN	O	O
dietary	NN	O	B-INT
intervention	NN	O	I-INT
.	NN	O	O

Participants	NN	O	O
with	NN	O	O
clinically	NN	O	O
significant	NN	O	O
scores	NN	O	O
indicative	NN	O	O
of	NN	O	O
inattention	NN	O	B-OUT
and	NN	O	I-OUT
hyperactivity	NN	O	I-OUT
behaviours	NN	O	I-OUT
and	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
positive	NN	O	O
changes	NN	O	O
to	NN	O	O
said	NN	O	O
scores	NN	O	O
were	NN	O	O
defined	NN	O	O
as	NN	O	O
responders	NN	O	O
to	NN	O	O
the	NN	O	O
dietary	NN	O	B-INT
intervention	NN	O	I-INT
.	NN	O	O

Analyses	NN	O	O
indicated	NN	O	O
several	NN	O	O
factors	NN	O	O
to	NN	O	O
be	NN	O	O
potentially	NN	O	O
pertinent	NN	O	O
to	NN	O	O
a	NN	O	O
positive	NN	O	O
response	NN	O	B-OUT
to	NN	O	O
dietary	NN	O	B-INT
intervention	NN	O	I-INT
in	NN	O	O
terms	NN	O	O
of	NN	O	O
symptom	NN	O	O
presentation	NN	O	O
.	NN	O	O

Chronological	NN	O	O
age	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
strongest	NN	O	O
predictor	NN	O	O
of	NN	O	O
response	NN	O	O
,	NN	O	O
where	NN	O	O
those	NN	O	O
participants	NN	O	O
aged	NN	O	O
between	NN	O	O
7	NN	O	O
and	NN	O	O
9	NN	O	O
years	NN	O	O
seemed	NN	O	O
to	NN	O	O
derive	NN	O	O
most	NN	O	O
benefit	NN	O	O
from	NN	O	O
dietary	NN	O	B-INT
intervention	NN	O	I-INT
.	NN	O	O

Further	NN	O	O
analysis	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
criteria	NN	O	O
for	NN	O	O
original	NN	O	O
study	NN	O	O
inclusion	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
urine	NN	O	O
compound	NN	O	O
,	NN	O	O
trans-indolyl-3-acryloylglycine	NN	O	O
may	NN	O	O
also	NN	O	O
merit	NN	O	O
further	NN	O	O
investigation	NN	O	O
.	NN	O	O

These	NN	O	O
preliminary	NN	O	O
observations	NN	O	O
on	NN	O	O
potential	NN	O	O
best	NN	O	O
responder	NN	O	O
characteristics	NN	O	O
to	NN	O	O
a	NN	O	O
gluten-	NN	O	B-INT
and	NN	O	I-INT
casein-free	NN	O	I-INT
diet	NN	O	I-INT
for	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	O
require	NN	O	O
independent	NN	O	O
replication	NN	O	O
.	NN	O	O



--DOCSTART-- (24080592)

Effect	NN	O	O
of	NN	O	O
simvastatin	NN	O	B-INT
on	NN	O	O
hemostasis	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
isolated	NN	O	I-PAR
hypertriglyceridemia	NN	O	I-PAR
.	NN	O	O

BACKGROUNDS/AIMS	NN	O	O
Elevated	NN	O	O
triglyceride	NN	O	O
levels	NN	O	O
seem	NN	O	O
to	NN	O	O
predispose	NN	O	O
to	NN	O	O
the	NN	O	O
earlier	NN	O	O
development	NN	O	O
and	NN	O	O
accelerated	NN	O	O
progression	NN	O	O
of	NN	O	O
coronary	NN	O	O
artery	NN	O	O
disease	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
assessed	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
whether	NN	O	O
simvastatin	NN	O	B-INT
treatment	NN	O	O
affects	NN	O	O
coagulation	NN	O	B-OUT
and	NN	O	I-OUT
fibrinolysis	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
isolated	NN	O	I-PAR
hypertriglyceridemia	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
The	NN	O	O
study	NN	O	O
included	NN	O	O
39	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
elevated	NN	O	I-PAR
triglyceride	NN	O	I-PAR
levels	NN	O	I-PAR
and	NN	O	I-PAR
peripheral	NN	O	I-PAR
artery	NN	O	I-PAR
sclerosis	NN	O	I-PAR
,	NN	O	O
treated	NN	O	O
for	NN	O	O
90	NN	O	O
days	NN	O	O
with	NN	O	O
either	NN	O	O
simvastatin	NN	O	B-INT
(	NN	O	O
40	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

Plasma	NN	O	B-OUT
lipids	NN	O	I-OUT
,	NN	O	I-OUT
glucose	NN	O	I-OUT
homeostasis	NN	O	I-OUT
markers	NN	O	I-OUT
and	NN	O	O
hemostasic	NN	O	B-OUT
variables	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Simvastatin	NN	O	B-INT
,	NN	O	O
but	NN	O	O
not	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
administered	NN	O	O
to	NN	O	O
these	NN	O	O
patients	NN	O	O
reduced	NN	O	O
plasma	NN	O	B-OUT
levels/activity	NN	O	I-OUT
of	NN	O	I-OUT
fibrinogen	NN	O	I-OUT
(	NN	O	O
from	NN	O	O
3.5	NN	O	O
?	NN	O	O
0.4	NN	O	O
to	NN	O	O
2.8	NN	O	O
?	NN	O	O
0.3	NN	O	O
g/l	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
,	NN	O	O
factor	NN	O	B-OUT
VII	NN	O	I-OUT
(	NN	O	O
from	NN	O	O
144.2	NN	O	O
?	NN	O	O
16.9	NN	O	O
to	NN	O	O
112.5	NN	O	O
?	NN	O	O
14.0	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
plasminogen	NN	O	B-OUT
activator	NN	O	I-OUT
inhibitor-1	NN	O	I-OUT
(	NN	O	O
from	NN	O	O
76.9	NN	O	O
?	NN	O	O
13.5	NN	O	O
to	NN	O	O
50.2	NN	O	O
?	NN	O	O
9.2	NN	O	O
ng/ml	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
without	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
von	NN	O	B-OUT
Willebrand	NN	O	I-OUT
factor	NN	O	I-OUT
levels	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
tended	NN	O	O
to	NN	O	O
prolong	NN	O	O
the	NN	O	O
prothrombin	NN	O	B-OUT
and	NN	O	I-OUT
partial	NN	O	I-OUT
thromboplastin	NN	O	I-OUT
times	NN	O	I-OUT
.	NN	O	O

CONCLUSION	NN	O	O
Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
statin	NN	O	B-INT
treatment	NN	O	O
produces	NN	O	O
a	NN	O	O
multidirectional	NN	O	O
effect	NN	O	O
on	NN	O	O
coagulation	NN	O	B-OUT
and	NN	O	I-OUT
fibrinolysis	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
isolated	NN	O	I-PAR
hypertriglyceridemia	NN	O	I-PAR
and	NN	O	O
that	NN	O	O
this	NN	O	O
treatment	NN	O	O
may	NN	O	O
bring	NN	O	O
some	NN	O	O
benefits	NN	O	O
to	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
elevated	NN	O	I-PAR
triglyceride	NN	O	I-PAR
levels	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (24317958)

The	NN	O	O
effect	NN	O	O
of	NN	O	O
four	NN	O	O
different	NN	O	O
irrigation	NN	O	O
systems	NN	O	O
in	NN	O	O
the	NN	O	O
removal	NN	O	O
of	NN	O	O
a	NN	O	O
root	NN	O	O
canal	NN	O	O
sealer	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
efficiency	NN	O	B-OUT
of	NN	O	O
sonic	NN	O	B-INT
,	NN	O	I-INT
ultrasonic	NN	O	I-INT
,	NN	O	I-INT
and	NN	O	I-INT
hydrodynamic	NN	O	I-INT
devices	NN	O	I-INT
in	NN	O	O
the	NN	O	O
removal	NN	O	O
of	NN	O	O
a	NN	O	O
root	NN	O	O
canal	NN	O	O
sealer	NN	O	O
from	NN	O	O
the	NN	O	O
surface	NN	O	O
and	NN	O	O
from	NN	O	O
simulated	NN	O	O
irregularities	NN	O	O
of	NN	O	O
root	NN	O	O
canals	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
Fifty-three	NN	O	O
root	NN	O	O
canals	NN	O	O
with	NN	O	O
two	NN	O	O
standardized	NN	O	O
grooves	NN	O	O
in	NN	O	O
the	NN	O	O
apical	NN	O	O
and	NN	O	O
coronal	NN	O	O
parts	NN	O	O
of	NN	O	O
longitudinally	NN	O	O
split	NN	O	O
roots	NN	O	O
were	NN	O	O
covered	NN	O	O
with	NN	O	O
AH	NN	O	O
Plus	NN	O	O
root	NN	O	O
canal	NN	O	O
sealer	NN	O	O
.	NN	O	O

Compared	NN	O	O
were	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
syringe	NN	O	B-INT
irrigation	NN	O	I-INT
,	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
CanalBrush	NN	O	B-INT
,	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
passive	NN	O	B-INT
ultrasonic	NN	O	I-INT
irrigation	NN	O	I-INT
,	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
EndoActivator	NN	O	B-INT
,	NN	O	O
and	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
RinsEndo	NN	O	B-INT
on	NN	O	O
the	NN	O	O
removal	NN	O	O
of	NN	O	O
the	NN	O	O
sealer	NN	O	O
.	NN	O	O

The	NN	O	O
specimens	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
four	NN	O	O
groups	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
and	NN	O	O
one	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
via	NN	O	O
randomization	NN	O	O
.	NN	O	O

The	NN	O	O
amount	NN	O	O
of	NN	O	B-OUT
remaining	NN	O	I-OUT
sealer	NN	O	I-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
irregularities	NN	O	I-OUT
was	NN	O	I-OUT
evaluated	NN	O	O
under	NN	O	O
a	NN	O	O
microscope	NN	O	O
using	NN	O	O
a	NN	O	O
4-grade	NN	O	O
scoring	NN	O	O
system	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
remaining	NN	O	B-OUT
sealer	NN	O	I-OUT
on	NN	O	I-OUT
the	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
surface	NN	O	I-OUT
was	NN	O	O
evaluated	NN	O	O
with	NN	O	B-OUT
a	NN	O	I-OUT
7-grade	NN	O	I-OUT
scoring	NN	O	I-OUT
system	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
Passive	NN	O	B-INT
ultrasonic	NN	O	I-INT
irrigation	NN	O	I-INT
is	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
the	NN	O	O
other	NN	O	O
tested	NN	O	O
irrigation	NN	O	B-INT
systems	NN	O	I-INT
or	NN	O	O
syringe	NN	O	B-INT
irrigation	NN	O	I-INT
in	NN	O	O
removing	NN	O	B-OUT
sealer	NN	O	I-OUT
from	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
walls	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
techniques	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
cleaning	NN	O	B-OUT
the	NN	O	I-OUT
lateral	NN	O	I-OUT
grooves	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
Within	NN	O	O
the	NN	O	O
limitations	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
protocol	NN	O	O
ultrasonic	NN	O	B-INT
irrigation	NN	O	I-INT
shows	NN	O	O
a	NN	O	O
superior	NN	O	O
effect	NN	O	O
on	NN	O	O
sealer	NN	O	B-OUT
removal	NN	O	I-OUT
from	NN	O	I-OUT
the	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
surface	NN	O	I-OUT
during	NN	O	O
endodontic	NN	O	O
retreatment	NN	O	O
.	NN	O	O

Cleaning	NN	O	O
of	NN	O	O
lateral	NN	O	O
grooves	NN	O	O
seems	NN	O	O
not	NN	O	O
to	NN	O	O
be	NN	O	O
possible	NN	O	O
with	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
techniques	NN	O	O
investigated	NN	O	O
.	NN	O	O

CLINICAL	NN	O	O
RELEVANCE	NN	O	O
Incomplete	NN	O	O
removal	NN	O	B-OUT
of	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
sealer	NN	O	I-OUT
during	NN	O	O
re-treatment	NN	O	O
may	NN	O	O
cause	NN	O	O
treatment	NN	O	O
failure	NN	O	O
.	NN	O	O

Passive	NN	O	B-INT
Ultrasonic	NN	O	O
irrigation	NN	O	B-INT
seems	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
system	NN	O	O
to	NN	O	O
remove	NN	O	B-OUT
sealer	NN	O	I-OUT
from	NN	O	I-OUT
a	NN	O	I-OUT
root	NN	O	I-OUT
canal	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (24350813)

An	NN	O	O
open-label	NN	O	O
extension	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
risperidone	NN	O	B-INT
in	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
adolescents	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
long-term	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
risperidone	NN	O	B-INT
in	NN	O	O
treating	NN	O	O
irritability	NN	O	O
and	NN	O	O
related	NN	O	O
behaviors	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
adolescents	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorders	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
this	NN	O	O
6	NN	O	O
month	NN	O	O
(	NN	O	O
26	NN	O	O
week	NN	O	O
)	NN	O	O
open-label	NN	O	O
extension	NN	O	O
(	NN	O	O
OLE	NN	O	O
)	NN	O	O
study	NN	O	O
,	NN	O	O
patients	NN	O	B-PAR
(	NN	O	I-PAR
5-17	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
,	NN	O	I-PAR
who	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
previous	NN	O	I-PAR
fixed-dose	NN	O	I-PAR
,	NN	O	I-PAR
6	NN	O	I-PAR
week	NN	O	I-PAR
,	NN	O	I-PAR
double-blind	NN	O	I-PAR
[	NN	O	I-PAR
DB	NN	O	I-PAR
]	NN	O	I-PAR
phase	NN	O	I-PAR
)	NN	O	O
were	NN	O	O
flexibly	NN	O	O
dosed	NN	O	O
with	NN	O	O
risperidone	NN	O	B-INT
based	NN	O	O
on	NN	O	O
body	NN	O	O
weight	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
allowed	NN	O	O
dose	NN	O	O
was	NN	O	O
1.25	NN	O	O
mg/day	NN	O	O
for	NN	O	O
those	NN	O	O
weighing	NN	O	O
20	NN	O	O
to	NN	O	O
<	NN	O	O
45	NN	O	O
kg	NN	O	O
,	NN	O	O
and	NN	O	O
1.75	NN	O	O
mg/day	NN	O	O
for	NN	O	O
those	NN	O	O
weighing	NN	O	O
?	NN	O	O
45	NN	O	O
kg	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
primarily	NN	O	O
assessed	NN	O	O
risperidone	NN	O	B-INT
's	NN	O	O
safety	NN	O	B-OUT
;	NN	O	O
efficacy	NN	O	B-OUT
was	NN	O	O
assessed	NN	O	O
as	NN	O	O
a	NN	O	O
secondary	NN	O	O
end-point	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Fifty-six	NN	O	B-PAR
(	NN	O	I-PAR
71	NN	O	I-PAR
%	NN	O	I-PAR
)	NN	O	I-PAR
out	NN	O	I-PAR
of	NN	O	I-PAR
79	NN	O	I-PAR
enrolled	NN	O	I-PAR
patients	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
OLE	NN	O	I-PAR
;	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
discontinuations	NN	O	O
were	NN	O	O
for	NN	O	O
insufficient	NN	O	O
response	NN	O	O
(	NN	O	O
7	NN	O	O
[	NN	O	O
9	NN	O	O
%	NN	O	O
]	NN	O	O
)	NN	O	O
or	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
(	NN	O	I-OUT
AE	NN	O	O
)	NN	O	O
(	NN	O	O
5	NN	O	O
[	NN	O	O
6	NN	O	O
%	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
(	NN	O	O
?	NN	O	O
5	NN	O	O
%	NN	O	O
frequency	NN	O	O
in	NN	O	O
the	NN	O	O
total	NN	O	O
group	NN	O	O
)	NN	O	O
AEs	NN	O	O
were	NN	O	O
increased	NN	O	O
appetite	NN	O	B-OUT
(	NN	O	O
11	NN	O	O
%	NN	O	O
[	NN	O	O
n=9	NN	O	O
]	NN	O	O
)	NN	O	O
;	NN	O	O
increased	NN	O	O
weight	NN	O	B-OUT
and	NN	O	I-OUT
vomiting	NN	O	I-OUT
(	NN	O	O
9	NN	O	O
%	NN	O	O
[	NN	O	O
n=7	NN	O	O
]	NN	O	O
each	NN	O	O
)	NN	O	O
;	NN	O	O
sedation	NN	O	B-OUT
,	NN	O	I-OUT
pyrexia	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
upper	NN	O	I-OUT
respiratory	NN	O	I-OUT
tract	NN	O	I-OUT
infection	NN	O	I-OUT
(	NN	O	O
8	NN	O	O
%	NN	O	O
[	NN	O	O
n=6	NN	O	O
]	NN	O	O
each	NN	O	O
)	NN	O	O
;	NN	O	O
nasopharyngitis	NN	O	B-OUT
(	NN	O	O
6	NN	O	O
%	NN	O	O
[	NN	O	O
n=5	NN	O	O
]	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
somnolence	NN	O	B-OUT
and	NN	O	I-OUT
fatigue	NN	O	I-OUT
(	NN	O	O
5	NN	O	O
%	NN	O	O
[	NN	O	O
n=4	NN	O	O
]	NN	O	O
each	NN	O	O
)	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	O
AEs	NN	O	B-OUT
were	NN	O	O
reported	NN	O	O
in	NN	O	O
6	NN	O	O
(	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

Increase	NN	O	O
in	NN	O	B-OUT
mean	NN	O	I-OUT
weight	NN	O	I-OUT
(	NN	O	O
11-15	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
body	NN	O	B-OUT
mass	NN	O	I-OUT
index	NN	O	I-OUT
(	NN	O	O
5-10	NN	O	O
%	NN	O	O
)	NN	O	O
occurred	NN	O	O
;	NN	O	O
one	NN	O	O
patient	NN	O	O
discontinued	NN	O	O
because	NN	O	O
of	NN	O	O
weight	NN	O	B-OUT
increase	NN	O	O
.	NN	O	O

One	NN	O	O
potentially	NN	O	O
prolactin-related	NN	O	B-OUT
AE	NN	O	I-OUT
(	NN	O	I-OUT
irregular	NN	O	I-OUT
menstruation	NN	O	I-OUT
)	NN	O	I-OUT
was	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
risperidone	NN	O	B-INT
high-dose	NN	O	O
group	NN	O	O
had	NN	O	O
the	NN	O	O
greatest	NN	O	O
mean	NN	O	O
improvement	NN	O	O
in	NN	O	B-OUT
sleep	NN	O	I-OUT
visual	NN	O	I-OUT
analog	NN	O	I-OUT
scale	NN	O	I-OUT
(	NN	O	O
24.6	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
groups	NN	O	O
showed	NN	O	O
additional	NN	O	O
improvement	NN	O	O
in	NN	O	O
efficacy	NN	O	B-OUT
scale	NN	O	I-OUT
scores	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
OLE	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
During	NN	O	O
this	NN	O	O
OLE	NN	O	O
,	NN	O	O
safety	NN	O	O
findings	NN	O	O
with	NN	O	O
risperidone	NN	O	B-INT
treatment	NN	O	O
(	NN	O	O
maximum	NN	O	O
weight-based	NN	O	O
dose	NN	O	O
of	NN	O	O
1.25	NN	O	O
mg/day	NN	O	O
or	NN	O	O
1.75	NN	O	O
mg/day	NN	O	O
)	NN	O	O
were	NN	O	O
consistent	NN	O	O
with	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
DB	NN	O	O
phase	NN	O	O
,	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
current	NN	O	O
safety	NN	O	O
information	NN	O	O
for	NN	O	O
risperidone	NN	O	B-INT
in	NN	O	O
autistic	NN	O	O
,	NN	O	O
psychiatric	NN	O	O
,	NN	O	O
and	NN	O	O
behavioral	NN	O	O
disorders	NN	O	O
.	NN	O	O

Patients	NN	O	O
experienced	NN	O	O
some	NN	O	O
additional	NN	O	O
improvement	NN	O	O
in	NN	O	O
irritability	NN	O	B-OUT
and	NN	O	I-OUT
related	NN	O	I-OUT
behaviors	NN	O	I-OUT
.	NN	O	O

CLINICAL	NN	O	O
TRIALS	NN	O	O
REGISTRY	NN	O	O
This	NN	O	O
phase-4	NN	O	O
study	NN	O	O
is	NN	O	O
registered	NN	O	O
at	NN	O	O
ClinicalTrials.gov	NN	O	O
(	NN	O	O
NCT00576732	NN	O	O
)	NN	O	O
.	NN	O	O



--DOCSTART-- (24451919)

Inverse	NN	O	O
Effect	NN	O	O
of	NN	O	O
Fluoxetine	NN	O	B-INT
on	NN	O	O
Medial	NN	O	O
Prefrontal	NN	O	O
Cortex	NN	O	O
Activation	NN	O	O
During	NN	O	O
Reward	NN	O	O
Reversal	NN	O	O
in	NN	O	O
ADHD	NN	O	B-PAR
and	NN	O	I-PAR
Autism	NN	O	I-PAR
.	NN	O	O

Attention	NN	O	B-PAR
deficit	NN	O	I-PAR
hyperactivity	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ADHD	NN	O	I-PAR
)	NN	O	I-PAR
and	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
share	NN	O	O
brain	NN	O	O
function	NN	O	O
abnormalities	NN	O	O
during	NN	O	O
cognitive	NN	O	O
flexibility	NN	O	O
.	NN	O	O

Serotonin	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
both	NN	O	O
disorders	NN	O	O
,	NN	O	O
and	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
SSRIs	NN	O	O
)	NN	O	O
can	NN	O	O
modulate	NN	O	O
cognitive	NN	O	O
flexibility	NN	O	O
and	NN	O	O
improve	NN	O	O
behavior	NN	O	O
in	NN	O	O
both	NN	O	O
disorders	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
investigates	NN	O	O
shared	NN	O	O
and	NN	O	O
disorder-specific	NN	O	O
brain	NN	O	O
dysfunctions	NN	O	O
in	NN	O	O
these	NN	O	O
2	NN	O	O
disorders	NN	O	O
during	NN	O	O
reward	NN	O	O
reversal	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
acute	NN	O	O
effects	NN	O	O
of	NN	O	O
an	NN	O	O
SSRI	NN	O	O
on	NN	O	O
these	NN	O	O
.	NN	O	O

Age-matched	NN	O	B-PAR
boys	NN	O	I-PAR
with	NN	O	I-PAR
ADHD	NN	O	I-PAR
(	NN	O	I-PAR
15	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	I-PAR
ASD	NN	O	I-PAR
(	NN	O	I-PAR
18	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	I-PAR
and	NN	O	I-PAR
controls	NN	O	I-PAR
(	NN	O	I-PAR
21	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
compared	NN	O	O
with	NN	O	O
functional	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
fMRI	NN	O	O
)	NN	O	O
during	NN	O	O
a	NN	O	O
reversal	NN	O	O
task	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
scanned	NN	O	O
twice	NN	O	O
,	NN	O	O
under	NN	O	O
either	NN	O	O
an	NN	O	O
acute	NN	O	O
dose	NN	O	O
of	NN	O	O
Fluoxetine	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
randomized	NN	O	O
design	NN	O	O
.	NN	O	O

Repeated-measures	NN	O	O
analyses	NN	O	O
within	NN	O	O
patients	NN	O	O
assessed	NN	O	O
drug	NN	O	O
effects	NN	O	O
.	NN	O	O

Patients	NN	O	O
under	NN	O	O
each	NN	O	O
drug	NN	O	O
condition	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
to	NN	O	O
assess	NN	O	O
normalization	NN	O	O
effects	NN	O	O
.	NN	O	O

fMRI	NN	O	O
data	NN	O	O
showed	NN	O	O
that	NN	O	O
,	NN	O	O
under	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
ASD	NN	O	O
boys	NN	O	O
underactivated	NN	O	O
medial	NN	O	B-OUT
prefrontal	NN	O	I-OUT
cortex	NN	O	I-OUT
(	NN	O	I-OUT
mPFC	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
and	NN	O	O
ADHD	NN	O	O
boys	NN	O	O
.	NN	O	O

Both	NN	O	O
patient	NN	O	O
groups	NN	O	O
shared	NN	O	O
decreased	NN	O	O
precuneus	NN	O	B-OUT
activation	NN	O	I-OUT
.	NN	O	O

Under	NN	O	O
Fluoxetine	NN	O	B-INT
,	NN	O	O
mPFC	NN	O	B-OUT
activation	NN	O	I-OUT
was	NN	O	O
up-regulated	NN	O	O
and	NN	O	O
normalized	NN	O	O
in	NN	O	O
ASD	NN	O	O
boys	NN	O	O
relative	NN	O	O
to	NN	O	O
controls	NN	O	O
,	NN	O	O
but	NN	O	O
down-regulated	NN	O	O
in	NN	O	O
ADHD	NN	O	O
boys	NN	O	O
relative	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
which	NN	O	O
was	NN	O	O
concomitant	NN	O	O
with	NN	O	O
worse	NN	O	O
task	NN	O	B-OUT
performance	NN	O	I-OUT
in	NN	O	O
ADHD	NN	O	O
.	NN	O	O

Fluoxetine	NN	O	B-INT
therefore	NN	O	O
has	NN	O	O
inverse	NN	O	O
effects	NN	O	O
on	NN	O	O
mPFC	NN	O	B-OUT
activation	NN	O	I-OUT
in	NN	O	O
ASD	NN	O	O
and	NN	O	O
ADHD	NN	O	O
during	NN	O	O
reversal	NN	O	O
learning	NN	O	O
,	NN	O	O
suggesting	NN	O	O
dissociated	NN	O	O
underlying	NN	O	O
serotonin	NN	O	O
abnormalities	NN	O	O
.	NN	O	O



--DOCSTART-- (24515505)

Economic	NN	O	O
burden	NN	O	O
of	NN	O	O
childhood	NN	O	B-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
estimate	NN	O	O
the	NN	O	O
associations	NN	O	O
between	NN	O	O
autism	NN	O	B-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
diagnoses	NN	O	O
and	NN	O	O
service	NN	O	B-OUT
use	NN	O	I-OUT
,	NN	O	I-OUT
caregiver	NN	O	I-OUT
time	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
cost	NN	O	I-OUT
outcomes	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
We	NN	O	O
used	NN	O	O
national	NN	O	O
data	NN	O	O
from	NN	O	O
the	NN	O	O
Medical	NN	O	O
Expenditure	NN	O	O
Panel	NN	O	O
Survey	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
National	NN	O	O
Health	NN	O	O
Interview	NN	O	O
Survey	NN	O	O
and	NN	O	O
a	NN	O	O
study-specific	NN	O	O
survey	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
annual	NN	O	B-OUT
utilization	NN	O	I-OUT
and	NN	O	I-OUT
costs	NN	O	I-OUT
for	NN	O	O
health	NN	O	B-OUT
care	NN	O	I-OUT
,	NN	O	I-OUT
school	NN	O	I-OUT
,	NN	O	I-OUT
ASD-related	NN	O	I-OUT
therapy	NN	O	I-OUT
,	NN	O	I-OUT
family-coordinated	NN	O	I-OUT
services	NN	O	I-OUT
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
caregiver	NN	O	B-OUT
time	NN	O	I-OUT
in	NN	O	O
children	NN	O	B-PAR
aged	NN	O	I-PAR
3	NN	O	I-PAR
to	NN	O	I-PAR
17	NN	O	I-PAR
years	NN	O	I-PAR
,	NN	O	I-PAR
with	NN	O	I-PAR
and	NN	O	I-PAR
without	NN	O	I-PAR
parent-reported	NN	O	I-PAR
ASD	NN	O	I-PAR
.	NN	O	I-PAR
Regression	NN	O	O
analyses	NN	O	O
estimated	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
ASD	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
cost	NN	O	B-OUT
,	NN	O	O
controlling	NN	O	O
for	NN	O	O
child	NN	O	O
gender	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
race/ethnicity	NN	O	O
,	NN	O	O
insurance	NN	O	O
status	NN	O	O
,	NN	O	O
household	NN	O	O
income	NN	O	O
,	NN	O	O
country	NN	O	O
region	NN	O	O
and	NN	O	O
urban/rural	NN	O	O
classification	NN	O	O
,	NN	O	O
and	NN	O	O
non-ASD-related	NN	O	O
illnesses	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Children	NN	O	B-PAR
with	NN	O	I-PAR
parent-reported	NN	O	I-PAR
ASD	NN	O	I-PAR
had	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
health	NN	O	B-OUT
care	NN	O	I-OUT
office	NN	O	I-OUT
visits	NN	O	I-OUT
and	NN	O	O
prescription	NN	O	B-OUT
drug	NN	O	I-OUT
use	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
children	NN	O	O
without	NN	O	O
ASD	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
greater	NN	O	O
proportion	NN	O	O
of	NN	O	O
children	NN	O	O
in	NN	O	O
the	NN	O	O
ASD	NN	O	O
group	NN	O	O
used	NN	O	O
special	NN	O	B-OUT
educational	NN	O	I-OUT
services	NN	O	I-OUT
(	NN	O	O
76	NN	O	O
%	NN	O	O
vs.	NN	O	O
7	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
adjusting	NN	O	O
for	NN	O	O
child	NN	O	O
demographic	NN	O	O
characteristics	NN	O	O
and	NN	O	O
non-ASD-associated	NN	O	O
illnesses	NN	O	O
,	NN	O	O
ASD	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
$	NN	O	O
3020	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
:	NN	O	O
$	NN	O	O
1017-	NN	O	O
$	NN	O	O
4259	NN	O	O
)	NN	O	O
higher	NN	O	O
health	NN	O	B-OUT
care	NN	O	I-OUT
costs	NN	O	I-OUT
and	NN	O	O
$	NN	O	O
14,061	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
$	NN	O	O
4390-	NN	O	O
$	NN	O	O
24,302	NN	O	O
)	NN	O	O
higher	NN	O	O
aggregate	NN	O	O
non-health	NN	O	B-OUT
care	NN	O	I-OUT
costs	NN	O	I-OUT
,	NN	O	O
including	NN	O	O
$	NN	O	O
8610	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
$	NN	O	O
6595-	NN	O	O
$	NN	O	O
10,421	NN	O	O
)	NN	O	O
higher	NN	O	B-OUT
school	NN	O	I-OUT
costs	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
adjusted	NN	O	O
analyses	NN	O	O
,	NN	O	O
parents	NN	O	O
who	NN	O	O
reported	NN	O	O
that	NN	O	O
their	NN	O	O
child	NN	O	O
had	NN	O	O
ASD	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
significantly	NN	O	O
higher	NN	O	O
out-of-pocket	NN	O	B-OUT
costs	NN	O	I-OUT
or	NN	O	O
spend	NN	O	O
more	NN	O	O
time	NN	O	B-OUT
on	NN	O	I-OUT
caregiving	NN	O	I-OUT
activities	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
control	NN	O	O
parents	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
economic	NN	O	O
burden	NN	O	O
associated	NN	O	O
with	NN	O	O
ASD	NN	O	O
is	NN	O	O
substantial	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
measured	NN	O	O
across	NN	O	O
multiple	NN	O	O
sectors	NN	O	O
of	NN	O	O
our	NN	O	O
society	NN	O	O
.	NN	O	O

Previous	NN	O	O
analyses	NN	O	O
that	NN	O	O
focused	NN	O	O
on	NN	O	O
health	NN	O	O
care	NN	O	O
underestimated	NN	O	O
this	NN	O	O
economic	NN	O	O
burden	NN	O	O
,	NN	O	O
particularly	NN	O	O
for	NN	O	O
school	NN	O	O
systems	NN	O	O
.	NN	O	O



--DOCSTART-- (24660757)

Compensation	NN	O	B-OUT
in	NN	O	O
intergroup	NN	O	O
relations	NN	O	O
:	NN	O	O
an	NN	O	O
investigation	NN	O	O
of	NN	O	O
its	NN	O	O
structural	NN	O	O
and	NN	O	O
strategic	NN	O	O
foundations	NN	O	O
.	NN	O	O

Recent	NN	O	O
work	NN	O	O
in	NN	O	O
intergroup	NN	O	O
relations	NN	O	O
stresses	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
two	NN	O	O
fundamental	NN	O	O
dimensions	NN	O	O
,	NN	O	O
competence	NN	O	O
and	NN	O	O
warmth	NN	O	O
,	NN	O	O
which	NN	O	O
organize	NN	O	O
the	NN	O	O
perception	NN	O	O
of	NN	O	O
social	NN	O	O
groups	NN	O	O
.	NN	O	O

A	NN	O	O
pattern	NN	O	O
often	NN	O	O
encountered	NN	O	O
in	NN	O	O
people	NN	O	O
's	NN	O	O
ratings	NN	O	O
is	NN	O	O
one	NN	O	O
of	NN	O	O
compensation	NN	O	O
in	NN	O	O
that	NN	O	O
a	NN	O	O
group	NN	O	O
that	NN	O	O
is	NN	O	O
evaluated	NN	O	O
higher	NN	O	O
than	NN	O	O
another	NN	O	O
group	NN	O	O
on	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
fundamental	NN	O	O
dimensions	NN	O	O
is	NN	O	O
also	NN	O	O
judged	NN	O	O
lower	NN	O	O
on	NN	O	O
the	NN	O	O
other	NN	O	O
fundamental	NN	O	O
dimension	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
Social	NN	O	O
Identity	NN	O	O
Theory	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
work	NN	O	O
extends	NN	O	O
previous	NN	O	O
research	NN	O	O
on	NN	O	O
compensation	NN	O	O
by	NN	O	O
examining	NN	O	O
boundary	NN	O	B-OUT
conditions	NN	O	I-OUT
as	NN	O	O
well	NN	O	O
as	NN	O	O
underlying	NN	O	B-OUT
psychological	NN	O	I-OUT
processes	NN	O	I-OUT
.	NN	O	O

Two	NN	O	O
studies	NN	O	O
involving	NN	O	O
experimental	NN	O	O
and	NN	O	O
correlational	NN	O	O
evidence	NN	O	O
,	NN	O	O
minimal	NN	O	O
and	NN	O	O
real	NN	O	O
groups	NN	O	O
,	NN	O	O
and	NN	O	O
different	NN	O	O
kinds	NN	O	O
of	NN	O	O
conflict	NN	O	O
,	NN	O	O
reveal	NN	O	O
that	NN	O	O
compensation	NN	O	O
is	NN	O	O
more	NN	O	O
likely	NN	O	O
when	NN	O	O
the	NN	O	O
groups	NN	O	O
are	NN	O	O
in	NN	O	O
asymmetrical	NN	O	O
relation	NN	O	O
and	NN	O	O
share	NN	O	O
a	NN	O	O
cooperative	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
intergroup	NN	O	O
setting	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
,	NN	O	O
among	NN	O	O
members	NN	O	O
of	NN	O	O
low	NN	O	O
status	NN	O	O
groups	NN	O	O
,	NN	O	O
compensation	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
social	NN	O	B-OUT
creativity	NN	O	I-OUT
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
line	NN	O	O
with	NN	O	O
the	NN	O	O
'noblesse	NN	O	O
oblige	NN	O	O
'	NN	O	O
effect	NN	O	O
,	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
high	NN	O	O
status	NN	O	O
group	NN	O	O
would	NN	O	O
seem	NN	O	O
to	NN	O	O
rely	NN	O	O
on	NN	O	O
compensation	NN	O	O
as	NN	O	O
a	NN	O	O
means	NN	O	O
to	NN	O	O
appear	NN	O	O
non-discriminatory	NN	O	O
.	NN	O	O



--DOCSTART-- (24726342)

Assessment	NN	O	O
of	NN	O	O
acute	NN	O	O
bronchodilator	NN	O	O
effects	NN	O	O
from	NN	O	O
specific	NN	O	O
airway	NN	O	O
resistance	NN	O	O
changes	NN	O	O
in	NN	O	O
stable	NN	O	B-PAR
COPD	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
In	NN	O	O
COPD	NN	O	B-PAR
patients	NN	O	I-PAR
,	NN	O	O
reversibility	NN	O	O
is	NN	O	O
currently	NN	O	O
evaluated	NN	O	O
from	NN	O	O
the	NN	O	O
changes	NN	O	O
of	NN	O	O
forced	NN	O	O
expiratory	NN	O	O
volume	NN	O	O
at	NN	O	O
1s	NN	O	O
(	NN	O	O
?FEV1	NN	O	O
)	NN	O	O
and	NN	O	O
forced	NN	O	O
vital	NN	O	O
capacity	NN	O	O
(	NN	O	O
?FVC	NN	O	O
)	NN	O	O
.	NN	O	O

By	NN	O	O
lowering	NN	O	O
peripheral	NN	O	O
airway	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
tone	NN	O	O
,	NN	O	O
bronchodilators	NN	O	O
should	NN	O	O
decrease	NN	O	O
dynamic	NN	O	O
hyperinflation	NN	O	O
,	NN	O	O
gas	NN	O	O
trapping	NN	O	O
,	NN	O	O
and	NN	O	O
possibly	NN	O	O
dyspnea	NN	O	O
at	NN	O	O
rest	NN	O	O
.	NN	O	O

Hence	NN	O	O
,	NN	O	O
we	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
specific	NN	O	B-OUT
airway	NN	O	I-OUT
resistance	NN	O	I-OUT
changes	NN	O	I-OUT
(	NN	O	I-OUT
?sRAW	NN	O	I-OUT
)	NN	O	I-OUT
should	NN	O	O
better	NN	O	O
characterize	NN	O	O
the	NN	O	O
acute	NN	O	O
response	NN	O	O
to	NN	O	O
bronchodilators	NN	O	O
.	NN	O	O

METHODS	NN	O	O
On	NN	O	O
two	NN	O	O
days	NN	O	O
,	NN	O	O
60	NN	O	B-PAR
COPD	NN	O	I-PAR
patients	NN	O	I-PAR
underwent	NN	O	O
dyspnea	NN	O	B-OUT
evaluation	NN	O	I-OUT
(	NN	O	I-OUT
VAS	NN	O	I-OUT
score	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
pulmonary	NN	O	B-OUT
function	NN	O	I-OUT
testing	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
one	NN	O	O
hour	NN	O	O
after	NN	O	O
placebo	NN	O	B-INT
or	NN	O	O
300?g	NN	O	O
indacaterol	NN	O	B-INT
administration	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Spirographic	NN	O	B-OUT
and	NN	O	I-OUT
?sRAW-based	NN	O	I-OUT
criteria	NN	O	I-OUT
identified	NN	O	O
as	NN	O	O
responders	NN	O	O
24	NN	O	O
and	NN	O	O
45	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

?sRAW	NN	O	O
correlated	NN	O	O
with	NN	O	O
changes	NN	O	O
of	NN	O	O
intrathoracic	NN	O	B-OUT
gas	NN	O	I-OUT
volume	NN	O	I-OUT
(	NN	O	I-OUT
?ITGV	NN	O	I-OUT
)	NN	O	I-OUT
(	NN	O	O
r=0.61	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
residual	NN	O	B-OUT
volume	NN	O	I-OUT
(	NN	O	I-OUT
?RV	NN	O	I-OUT
)	NN	O	I-OUT
(	NN	O	O
r=0.60	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
?FVC	NN	O	B-OUT
(	NN	O	O
r=0.44	NN	O	O
;	NN	O	O
p=0.001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
?VAS	NN	O	O
(	NN	O	O
r=0.73	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
?FEV1	NN	O	B-OUT
correlated	NN	O	O
only	NN	O	O
with	NN	O	O
?FVC	NN	O	B-OUT
(	NN	O	O
r=0.34	NN	O	O
;	NN	O	O
p=0.008	NN	O	O
)	NN	O	O
.	NN	O	O

Significant	NN	O	O
differences	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
?ITGV	NN	O	B-OUT
(	NN	O	O
p=0.002	NN	O	O
)	NN	O	O
,	NN	O	O
?RV	NN	O	B-OUT
(	NN	O	O
p=0.023	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
?VAS	NN	O	B-OUT
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
occurred	NN	O	O
only	NN	O	O
if	NN	O	O
patients	NN	O	O
were	NN	O	O
stratified	NN	O	O
according	NN	O	O
to	NN	O	O
?sRAW	NN	O	B-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
In	NN	O	O
assessing	NN	O	O
the	NN	O	O
acute	NN	O	O
functional	NN	O	O
effect	NN	O	O
of	NN	O	O
bronchodilators	NN	O	O
,	NN	O	O
?sRAW-based	NN	O	O
criterion	NN	O	O
is	NN	O	O
preferable	NN	O	O
to	NN	O	O
FEV1-FVC-based	NN	O	O
criteria	NN	O	O
,	NN	O	O
being	NN	O	O
more	NN	O	O
closely	NN	O	O
related	NN	O	O
to	NN	O	O
bronchodilator-induced	NN	O	O
improvements	NN	O	B-OUT
of	NN	O	I-OUT
lung	NN	O	O
mechanics	NN	O	O
and	NN	O	O
dyspnea	NN	O	O
at	NN	O	O
rest	NN	O	O
.	NN	O	O



--DOCSTART-- (24803369)

Youth	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
comprehend	NN	O	O
lexicalized	NN	O	B-INT
and	NN	O	O
novel	NN	O	O
primary	NN	O	B-INT
conceptual	NN	O	I-INT
metaphors	NN	O	I-INT
.	NN	O	O

Individuals	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
have	NN	O	O
difficulty	NN	O	O
comprehending	NN	O	B-OUT
metaphors	NN	O	I-OUT
.	NN	O	O

However	NN	O	O
,	NN	O	O
no	NN	O	O
study	NN	O	O
to	NN	O	O
date	NN	O	O
has	NN	O	O
examined	NN	O	O
whether	NN	O	O
or	NN	O	O
not	NN	O	O
they	NN	O	O
understand	NN	O	O
conceptual	NN	O	B-OUT
metaphors	NN	O	I-OUT
(	NN	O	O
i.e	NN	O	O
.	NN	O	O

mappings	NN	O	O
between	NN	O	O
conceptual	NN	O	O
structures	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
could	NN	O	O
be	NN	O	O
the	NN	O	O
building	NN	O	O
blocks	NN	O	O
of	NN	O	O
metaphoric	NN	O	O
thinking	NN	O	O
and	NN	O	O
understanding	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
whether	NN	O	O
13	NN	O	B-PAR
participants	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
(	NN	O	I-PAR
age	NN	O	I-PAR
7	NN	O	I-PAR
;	NN	O	I-PAR
03-22	NN	O	I-PAR
;	NN	O	I-PAR
03	NN	O	I-PAR
)	NN	O	I-PAR
and	NN	O	I-PAR
13	NN	O	I-PAR
age-matched	NN	O	I-PAR
typically	NN	O	I-PAR
developing	NN	O	I-PAR
(	NN	O	I-PAR
TD	NN	O	I-PAR
)	NN	O	I-PAR
controls	NN	O	I-PAR
could	NN	O	O
comprehend	NN	O	O
lexicalized	NN	O	B-OUT
conceptual	NN	O	I-OUT
metaphors	NN	O	I-OUT
(	NN	O	O
e.g.	NN	O	O
,	NN	O	O
Susan	NN	O	O
is	NN	O	O
a	NN	O	O
warm	NN	O	O
person	NN	O	O
)	NN	O	O
and	NN	O	O
novel	NN	O	B-OUT
ones	NN	O	I-OUT
(	NN	O	O
e.g.	NN	O	O
,	NN	O	O
Susan	NN	O	O
is	NN	O	O
a	NN	O	O
toasty	NN	O	O
person	NN	O	O
)	NN	O	O
.	NN	O	O

Individuals	NN	O	B-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
performed	NN	O	O
at	NN	O	O
greater	NN	O	O
than	NN	O	O
chance	NN	O	O
levels	NN	O	O
on	NN	O	O
both	NN	O	O
metaphor	NN	O	B-OUT
types	NN	O	O
,	NN	O	O
although	NN	O	O
their	NN	O	O
performance	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
TD	NN	O	O
participants	NN	O	O
.	NN	O	O

We	NN	O	O
discuss	NN	O	O
the	NN	O	O
theoretical	NN	O	O
relevance	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
and	NN	O	O
educational	NN	O	O
implications	NN	O	O
.	NN	O	O



--DOCSTART-- (24960665)

Paternal	NN	O	O
RHD	NN	O	O
zygosity	NN	O	O
determination	NN	O	O
in	NN	O	O
Tunisians	NN	O	B-PAR
:	NN	O	O
evaluation	NN	O	O
of	NN	O	O
three	NN	O	O
molecular	NN	O	O
tests	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
choice	NN	O	O
of	NN	O	O
a	NN	O	O
molecular	NN	O	O
test	NN	O	O
for	NN	O	O
first	NN	O	O
intention	NN	O	O
determination	NN	O	O
of	NN	O	O
paternal	NN	O	O
RHD	NN	O	O
zygosity	NN	O	O
,	NN	O	O
before	NN	O	O
entering	NN	O	O
into	NN	O	O
invasive	NN	O	O
diagnostics	NN	O	O
,	NN	O	O
is	NN	O	O
important	NN	O	O
for	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
pregnancies	NN	O	O
at	NN	O	O
risk	NN	O	O
of	NN	O	O
haemolytic	NN	O	O
disease	NN	O	O
of	NN	O	O
the	NN	O	O
foetus	NN	O	O
and	NN	O	O
newborn	NN	O	O
related	NN	O	O
to	NN	O	O
anti-RhD	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
RHD	NN	O	O
zygosity	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
370	NN	O	B-PAR
RH:1	NN	O	I-PAR
Tunisian	NN	O	I-PAR
donors	NN	O	I-PAR
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
-	NN	O	O
sequence-specific	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
PCR-SSP	NN	O	O
)	NN	O	O
analysis	NN	O	O
and	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
-	NN	O	O
restriction	NN	O	O
fragment	NN	O	O
length	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
PCR-RFLP	NN	O	O
)	NN	O	O
amplification	NN	O	O
of	NN	O	O
hybrid	NN	O	O
Rhesus	NN	O	O
box	NN	O	O
and	NN	O	O
by	NN	O	O
real	NN	O	O
time	NN	O	O
quantitative	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	NN	O	O
RQ-PCR	NN	O	O
)	NN	O	O
specific	NN	O	O
for	NN	O	O
RHD	NN	O	O
exon	NN	O	O
5	NN	O	O
.	NN	O	O

To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
accuracy	NN	O	O
of	NN	O	O
molecular	NN	O	O
tests	NN	O	O
in	NN	O	O
the	NN	O	O
cases	NN	O	O
of	NN	O	O
discordant	NN	O	O
results	NN	O	O
,	NN	O	O
the	NN	O	O
ten	NN	O	O
exons	NN	O	O
of	NN	O	O
RHD	NN	O	O
and	NN	O	O
Rhesus	NN	O	O
boxes	NN	O	O
were	NN	O	O
amplified	NN	O	O
by	NN	O	O
PCR	NN	O	O
and	NN	O	O
sequenced	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Molecular	NN	O	O
investigations	NN	O	O
revealed	NN	O	O
that	NN	O	O
our	NN	O	O
370	NN	O	B-PAR
donors	NN	O	I-PAR
comprise	NN	O	O
193	NN	O	O
dizygous	NN	O	O
and	NN	O	O
145	NN	O	O
hemizygous	NN	O	O
individuals	NN	O	O
and	NN	O	O
32	NN	O	O
subjects	NN	O	O
whose	NN	O	O
zygosity	NN	O	O
remains	NN	O	O
unknown	NN	O	O
.	NN	O	O

Positive	NN	O	B-OUT
predictive	NN	O	I-OUT
values	NN	O	I-OUT
were	NN	O	O
higher	NN	O	O
than	NN	O	O
99	NN	O	O
%	NN	O	O
for	NN	O	O
all	NN	O	O
the	NN	O	O
methods	NN	O	O
,	NN	O	O
reaching	NN	O	O
100	NN	O	O
%	NN	O	O
for	NN	O	O
RQ-PCR	NN	O	O
.	NN	O	O

Negative	NN	O	B-OUT
predictive	NN	O	I-OUT
values	NN	O	I-OUT
were	NN	O	O
83.24	NN	O	O
%	NN	O	O
,	NN	O	O
87.27	NN	O	O
%	NN	O	O
and	NN	O	O
98	NN	O	O
%	NN	O	O
for	NN	O	O
PCR-SSP	NN	O	O
,	NN	O	O
PCR-RFLP	NN	O	O
and	NN	O	O
RQ-PCR	NN	O	O
respectively	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
also	NN	O	O
revealed	NN	O	O
19	NN	O	O
novel	NN	O	O
Rhesus	NN	O	B-OUT
box	NN	O	I-OUT
polymorphisms	NN	O	I-OUT
and	NN	O	O
three	NN	O	O
novel	NN	O	O
RHD	NN	O	B-OUT
alleles	NN	O	I-OUT
:	NN	O	O
RHD	NN	O	O
(	NN	O	O
Trp185Stop	NN	O	O
)	NN	O	O
,	NN	O	O
RHD	NN	O	O
(	NN	O	O
Ala176Thr	NN	O	O
)	NN	O	O
and	NN	O	O
RHD	NN	O	O
(	NN	O	O
Ile342Ile	NN	O	O
)	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
RQ-PCR	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
convenient	NN	O	O
method	NN	O	O
for	NN	O	O
first	NN	O	O
intention	NN	O	O
determination	NN	O	O
of	NN	O	O
paternal	NN	O	O
RHD	NN	O	O
zygosity	NN	O	O
in	NN	O	O
Tunisians	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
taking	NN	O	O
into	NN	O	O
account	NN	O	O
positive	NN	O	O
and	NN	O	O
negative	NN	O	O
predictive	NN	O	O
values	NN	O	O
,	NN	O	O
PCR-RFLP	NN	O	O
could	NN	O	O
be	NN	O	O
an	NN	O	O
alternative	NN	O	O
despite	NN	O	O
the	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
Rhesus	NN	O	O
boxes	NN	O	O
and	NN	O	O
the	NN	O	O
complexity	NN	O	O
of	NN	O	O
RHD	NN	O	O
.	NN	O	O



--DOCSTART-- (24989854)

A	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
a	NN	O	O
social	NN	O	B-INT
skills	NN	O	I-INT
training	NN	O	I-INT
for	NN	O	O
preadolescent	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
:	NN	O	O
generalization	NN	O	O
of	NN	O	O
skills	NN	O	O
by	NN	O	O
training	NN	O	O
parents	NN	O	O
and	NN	O	O
teachers	NN	O	O
?	NN	O	O
BACKGROUND	NN	O	O
Social	NN	O	B-INT
skills	NN	O	I-INT
training	NN	O	I-INT
(	NN	O	I-INT
SST	NN	O	I-INT
)	NN	O	I-INT
is	NN	O	O
a	NN	O	O
common	NN	O	O
intervention	NN	O	O
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
(	NN	O	I-PAR
ASDs	NN	O	I-PAR
)	NN	O	I-PAR
to	NN	O	O
improve	NN	O	O
their	NN	O	O
social	NN	O	O
and	NN	O	O
communication	NN	O	O
skills	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
SSTs	NN	O	B-INT
are	NN	O	O
often	NN	O	O
applied	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
,	NN	O	O
the	NN	O	O
evidence	NN	O	O
for	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
these	NN	O	O
trainings	NN	O	O
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
is	NN	O	O
inconclusive	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
long	NN	O	O
term	NN	O	O
outcome	NN	O	O
and	NN	O	O
generalization	NN	O	O
of	NN	O	O
learned	NN	O	O
skills	NN	O	O
are	NN	O	O
little	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
research	NN	O	O
on	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
involvement	NN	O	O
of	NN	O	O
parents	NN	O	O
and	NN	O	O
teachers	NN	O	O
on	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
SST	NN	O	B-INT
and	NN	O	O
on	NN	O	O
the	NN	O	O
generalization	NN	O	O
of	NN	O	O
learned	NN	O	O
social	NN	O	O
skills	NN	O	O
to	NN	O	O
daily	NN	O	O
life	NN	O	O
.	NN	O	O

We	NN	O	O
expect	NN	O	O
parent	NN	O	O
and	NN	O	O
teacher	NN	O	O
involvement	NN	O	O
in	NN	O	O
SST	NN	O	B-INT
to	NN	O	O
enhance	NN	O	O
treatment	NN	O	O
efficacy	NN	O	O
and	NN	O	O
to	NN	O	O
facilitate	NN	O	O
generalization	NN	O	O
of	NN	O	O
learned	NN	O	O
skills	NN	O	O
to	NN	O	O
daily	NN	O	O
life	NN	O	O
.	NN	O	O

METHOD/DESIGN	NN	O	O
In	NN	O	O
a	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
(	NN	O	O
RCT	NN	O	O
)	NN	O	O
with	NN	O	O
three	NN	O	O
conditions	NN	O	O
,	NN	O	O
120	NN	O	B-PAR
participants	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
at	NN	O	I-PAR
the	NN	O	I-PAR
end	NN	O	I-PAR
of	NN	O	I-PAR
primary	NN	O	I-PAR
school	NN	O	I-PAR
(	NN	O	I-PAR
10-12	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
calendar	NN	O	I-PAR
age	NN	O	I-PAR
)	NN	O	I-PAR
have	NN	O	O
been	NN	O	O
randomized	NN	O	O
to	NN	O	O
SST	NN	O	B-INT
,	NN	O	O
SST-PTI	NN	O	B-INT
(	NN	O	I-INT
SST	NN	O	I-INT
with	NN	O	I-INT
Parent	NN	O	I-INT
&	NN	O	I-INT
Teacher	NN	O	I-INT
Involvement	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
or	NN	O	O
care-as-usual	NN	O	B-INT
.	NN	O	O

The	NN	O	O
SST	NN	O	B-INT
consists	NN	O	O
of	NN	O	O
18	NN	O	O
group	NN	O	O
sessions	NN	O	O
of	NN	O	O
1.5	NN	O	O
hours	NN	O	O
for	NN	O	O
the	NN	O	O
children	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
SST-PTI	NN	O	B-INT
condition	NN	O	O
,	NN	O	O
parents	NN	O	O
additionally	NN	O	O
participate	NN	O	O
in	NN	O	O
8	NN	O	O
parent	NN	O	O
sessions	NN	O	O
and	NN	O	O
parents	NN	O	O
and	NN	O	O
teachers	NN	O	O
are	NN	O	O
actively	NN	O	O
involved	NN	O	O
in	NN	O	O
homework	NN	O	O
assignments	NN	O	O
.	NN	O	O

Assessment	NN	O	O
takes	NN	O	O
place	NN	O	O
at	NN	O	O
three	NN	O	O
moments	NN	O	O
:	NN	O	O
before	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
the	NN	O	O
intervention	NN	O	O
period	NN	O	O
and	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
follow-up	NN	O	O
.	NN	O	O

Primary	NN	O	O
outcome	NN	O	O
is	NN	O	O
socialization	NN	O	B-OUT
,	NN	O	O
as	NN	O	O
an	NN	O	O
aspect	NN	O	O
of	NN	O	O
adaptive	NN	O	O
functioning	NN	O	O
.	NN	O	O

Secondary	NN	O	O
outcomes	NN	O	O
focus	NN	O	O
on	NN	O	O
specific	NN	O	B-OUT
social	NN	O	I-OUT
skills	NN	O	I-OUT
children	NN	O	O
learn	NN	O	O
during	NN	O	O
SST	NN	O	B-INT
and	NN	O	O
on	NN	O	O
more	NN	O	O
general	NN	O	B-OUT
social	NN	O	I-OUT
skills	NN	O	I-OUT
pertaining	NN	O	O
to	NN	O	O
home	NN	O	O
and	NN	O	O
community	NN	O	O
settings	NN	O	O
from	NN	O	O
a	NN	O	O
multi-informant	NN	O	O
perspective	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
possible	NN	O	O
predictors	NN	O	O
of	NN	O	O
treatment	NN	O	O
outcome	NN	O	O
will	NN	O	O
be	NN	O	O
assessed	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
The	NN	O	O
current	NN	O	O
study	NN	O	O
is	NN	O	O
an	NN	O	O
RCT	NN	O	O
study	NN	O	O
evaluating	NN	O	O
SST	NN	O	B-INT
in	NN	O	O
a	NN	O	O
large	NN	O	O
sample	NN	O	O
of	NN	O	O
Dutch	NN	O	B-PAR
children	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
in	NN	O	I-PAR
a	NN	O	I-PAR
specific	NN	O	I-PAR
age	NN	O	I-PAR
range	NN	O	I-PAR
(	NN	O	I-PAR
10-12	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Strengths	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
are	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
one	NN	O	O
manualized	NN	O	O
protocol	NN	O	O
,	NN	O	O
application	NN	O	O
of	NN	O	O
standardized	NN	O	O
and	NN	O	O
internationally	NN	O	O
used	NN	O	O
rating	NN	O	O
instruments	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
multiple	NN	O	O
raters	NN	O	O
,	NN	O	O
investigation	NN	O	O
of	NN	O	O
generalization	NN	O	O
of	NN	O	O
learned	NN	O	O
skills	NN	O	O
to	NN	O	O
daily	NN	O	O
life	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
efficacy	NN	O	O
in	NN	O	O
the	NN	O	O
longer	NN	O	O
term	NN	O	O
by	NN	O	O
follow-up	NN	O	O
measures	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
training	NN	O	O
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
NTR2405	NN	O	O
.	NN	O	O



--DOCSTART-- (25068497)

Safety	NN	O	B-OUT
and	NN	O	O
preliminary	NN	O	B-OUT
immunogenicity	NN	O	I-OUT
of	NN	O	O
Cuban	NN	O	B-INT
pneumococcal	NN	O	I-INT
conjugate	NN	O	I-INT
vaccine	NN	O	I-INT
candidate	NN	O	O
in	NN	O	O
healthy	NN	O	B-PAR
children	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
phase	NN	O	O
I	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
heptavalent	NN	O	B-INT
conjugate	NN	O	I-INT
vaccine	NN	O	I-INT
(	NN	O	I-INT
PCV7-TT	NN	O	I-INT
)	NN	O	I-INT
is	NN	O	O
under	NN	O	O
development	NN	O	O
in	NN	O	O
Cuba	NN	O	O
.	NN	O	O

PCV7-TT	NN	O	B-INT
contains	NN	O	O
2	NN	O	O
?g	NN	O	O
of	NN	O	O
serotypes	NN	O	O
1	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
18C	NN	O	O
,	NN	O	O
19F	NN	O	O
,	NN	O	O
23F	NN	O	O
and	NN	O	O
4	NN	O	O
?g	NN	O	O
of	NN	O	O
6B	NN	O	O
,	NN	O	O
each	NN	O	O
one	NN	O	O
conjugated	NN	O	O
to	NN	O	O
tetanus	NN	O	O
toxoid	NN	O	O
(	NN	O	O
TT	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
vaccine	NN	O	O
was	NN	O	O
designed	NN	O	O
with	NN	O	O
the	NN	O	O
serotypes	NN	O	O
that	NN	O	O
cause	NN	O	O
most	NN	O	O
invasive	NN	O	O
pneumococcal	NN	O	O
diseases	NN	O	O
(	NN	O	O
IPD	NN	O	O
)	NN	O	O
worldwide	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
explored	NN	O	O
the	NN	O	O
immunogenicity	NN	O	B-OUT
of	NN	O	O
PCV7-TT	NN	O	B-INT
during	NN	O	O
a	NN	O	O
controlled	NN	O	O
,	NN	O	O
randomized	NN	O	O
and	NN	O	O
double	NN	O	O
blind	NN	O	O
clinical	NN	O	O
trial	NN	O	O
phase	NN	O	O
I	NN	O	O
in	NN	O	O
4-5-year-old	NN	O	B-PAR
children	NN	O	I-PAR
.	NN	O	O

PCV7-TT	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	B-OUT
and	NN	O	O
as	NN	O	O
safe	NN	O	B-OUT
as	NN	O	O
Synflorix	NN	O	B-INT
used	NN	O	O
as	NN	O	O
control	NN	O	O
vaccine	NN	O	O
.	NN	O	O

Following	NN	O	O
a	NN	O	O
single-dose	NN	O	O
vaccination	NN	O	O
,	NN	O	O
all	NN	O	O
individual	NN	O	O
serotypes	NN	O	O
included	NN	O	O
in	NN	O	O
PCV7-TT	NN	O	B-INT
induced	NN	O	O
statistically	NN	O	O
significant	NN	O	O
increase	NN	O	O
of	NN	O	O
IgG	NN	O	B-OUT
GMC	NN	O	I-OUT
and	NN	O	O
OPA	NN	O	B-OUT
GMT	NN	O	I-OUT
.	NN	O	O

These	NN	O	O
are	NN	O	O
the	NN	O	O
first	NN	O	O
clinical	NN	O	O
results	NN	O	O
of	NN	O	O
PCV7-TT	NN	O	B-INT
in	NN	O	O
children	NN	O	O
and	NN	O	O
they	NN	O	O
pave	NN	O	O
the	NN	O	O
way	NN	O	O
toward	NN	O	O
next	NN	O	O
clinical	NN	O	O
trials	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
infants	NN	O	O
.	NN	O	O

This	NN	O	O
clinical	NN	O	O
trial	NN	O	O
was	NN	O	O
published	NN	O	O
in	NN	O	O
the	NN	O	O
Cuban	NN	O	O
Public	NN	O	O
Register	NN	O	O
of	NN	O	O
Clinical	NN	O	O
Trials	NN	O	O
with	NN	O	O
code	NN	O	O
RPCEC00000173	NN	O	O
.	NN	O	O



--DOCSTART-- (25369243)

Atomoxetine	NN	O	B-INT
in	NN	O	O
autism	NN	O	B-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
:	NN	O	O
no	NN	O	O
effects	NN	O	O
on	NN	O	O
social	NN	O	B-OUT
functioning	NN	O	I-OUT
;	NN	O	O
some	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
on	NN	O	O
stereotyped	NN	O	B-OUT
behaviors	NN	O	I-OUT
,	NN	O	I-OUT
inappropriate	NN	O	I-OUT
speech	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
fear	NN	O	B-OUT
of	NN	O	I-OUT
change	NN	O	I-OUT
.	NN	O	O

UNLABELLED	NN	O	O
Abstract	NN	O	O
Objective	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
short-term	NN	O	O
treatment	NN	O	O
effects	NN	O	O
of	NN	O	O
atomoxetine	NN	O	B-INT
on	NN	O	O
autism	NN	O	B-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
symptoms	NN	O	O
in	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
adolescents	NN	O	I-PAR
with	NN	O	I-PAR
both	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	I-PAR
attention-deficit/hyperactivity	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ADHD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
97	NN	O	B-PAR
patients	NN	O	I-PAR
6-17	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
,	NN	O	I-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
and	NN	O	I-PAR
ADHD	NN	O	I-PAR
,	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
1.2	NN	O	O
mg/kg/day	NN	O	O
of	NN	O	O
atomoxetine	NN	O	B-INT
during	NN	O	O
an	NN	O	O
8	NN	O	O
week	NN	O	O
double-blind	NN	O	O
placebo-controlled	NN	O	B-INT
period	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
effects	NN	O	O
on	NN	O	O
two	NN	O	O
parent-based	NN	O	O
secondary	NN	O	O
outcome	NN	O	O
measures	NN	O	O
,	NN	O	O
the	NN	O	O
Aberrant	NN	O	B-OUT
Behavior	NN	O	I-OUT
Checklist	NN	O	I-OUT
(	NN	O	I-OUT
ABC	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
the	NN	O	O
Children	NN	O	B-OUT
's	NN	O	I-OUT
Social	NN	O	I-OUT
Behavior	NN	O	I-OUT
Questionnaire	NN	O	I-OUT
(	NN	O	I-OUT
CSBQ	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

RESULTS	NN	O	O
After	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
double-blind	NN	O	O
treatment	NN	O	O
,	NN	O	O
atomoxetine	NN	O	B-INT
administration	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
treatment	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
ABC	NN	O	B-OUT
subscales	NN	O	I-OUT
Hyperactivity	NN	O	I-OUT
,	NN	O	I-OUT
Inappropriate	NN	O	I-OUT
Speech	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
Stereotypic	NN	O	I-OUT
Behavior	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
CSBQ	NN	O	B-OUT
subscale	NN	O	I-OUT
Fear	NN	O	I-OUT
for	NN	O	I-OUT
Changes	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
Our	NN	O	O
study	NN	O	O
results	NN	O	O
indicate	NN	O	O
no	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
atomoxetine	NN	O	O
on	NN	O	O
social	NN	O	O
functioning	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
atomoxetine	NN	O	B-INT
may	NN	O	O
ameliorate	NN	O	O
restricted	NN	O	O
and	NN	O	O
stereotyped	NN	O	B-OUT
behaviors	NN	O	I-OUT
and	NN	O	I-OUT
communication	NN	O	I-OUT
.	NN	O	O

This	NN	O	O
study	NN	O	O
has	NN	O	O
been	NN	O	O
registered	NN	O	O
in	NN	O	O
ClinicalTrials.gov	NN	O	O
(	NN	O	O
www.clinicaltrials.gov	NN	O	O
)	NN	O	O
under	NN	O	O
registration	NN	O	O
number	NN	O	O
NCT00380692	NN	O	O
.	NN	O	O



--DOCSTART-- (25479285)

Randomised	NN	O	O
trial	NN	O	O
of	NN	O	O
text	NN	O	O
messaging	NN	O	O
on	NN	O	O
adherence	NN	O	B-OUT
to	NN	O	O
cardiovascular	NN	O	O
preventive	NN	O	O
treatment	NN	O	O
(	NN	O	O
INTERACT	NN	O	O
trial	NN	O	O
)	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
About	NN	O	O
one	NN	O	O
third	NN	O	O
of	NN	O	O
patients	NN	O	B-PAR
prescribed	NN	O	I-PAR
blood	NN	O	I-PAR
pressure	NN	O	I-PAR
or	NN	O	I-PAR
lipid-lowering	NN	O	I-PAR
drugs	NN	O	I-PAR
for	NN	O	I-PAR
the	NN	O	I-PAR
prevention	NN	O	I-PAR
of	NN	O	I-PAR
coronary	NN	O	I-PAR
heart	NN	O	I-PAR
disease	NN	O	I-PAR
and	NN	O	I-PAR
stroke	NN	O	I-PAR
do	NN	O	O
not	NN	O	O
take	NN	O	O
their	NN	O	O
medication	NN	O	O
as	NN	O	O
prescribed	NN	O	O
.	NN	O	O

We	NN	O	O
conducted	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
to	NN	O	O
evaluate	NN	O	O
text	NN	O	B-INT
messaging	NN	O	I-INT
as	NN	O	O
a	NN	O	O
means	NN	O	O
of	NN	O	O
improving	NN	O	O
adherence	NN	O	B-OUT
to	NN	O	O
cardiovascular	NN	O	O
disease	NN	O	O
preventive	NN	O	O
treatment	NN	O	O
.	NN	O	O

METHODS	NN	O	O
303	NN	O	B-PAR
patients	NN	O	I-PAR
taking	NN	O	I-PAR
blood	NN	O	I-PAR
pressure	NN	O	I-PAR
and/or	NN	O	I-PAR
lipid-lowering	NN	O	I-PAR
medications	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
being	NN	O	O
sent	NN	O	O
text	NN	O	B-INT
messages	NN	O	I-INT
(	NN	O	O
Text	NN	O	B-INT
group	NN	O	O
,	NN	O	O
151	NN	O	O
)	NN	O	O
or	NN	O	O
not	NN	O	B-INT
being	NN	O	I-INT
sent	NN	O	I-INT
them	NN	O	I-INT
(	NN	O	O
No	NN	O	O
text	NN	O	O
group	NN	O	O
,	NN	O	O
152	NN	O	O
)	NN	O	O
.	NN	O	O

Texts	NN	O	O
were	NN	O	O
sent	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
alternate	NN	O	O
days	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
and	NN	O	O
weekly	NN	O	O
thereafter	NN	O	O
for	NN	O	O
22	NN	O	O
weeks	NN	O	O
(	NN	O	O
6	NN	O	O
months	NN	O	O
overall	NN	O	O
)	NN	O	O
,	NN	O	O
using	NN	O	O
an	NN	O	O
automated	NN	O	O
computer	NN	O	O
programme	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
asked	NN	O	O
to	NN	O	O
respond	NN	O	O
on	NN	O	O
whether	NN	O	O
they	NN	O	O
had	NN	O	O
taken	NN	O	O
their	NN	O	O
medication	NN	O	O
,	NN	O	O
whether	NN	O	O
the	NN	O	O
text	NN	O	O
reminded	NN	O	O
them	NN	O	O
to	NN	O	O
do	NN	O	O
so	NN	O	O
if	NN	O	O
they	NN	O	O
had	NN	O	O
forgotten	NN	O	O
,	NN	O	O
and	NN	O	O
if	NN	O	O
they	NN	O	O
had	NN	O	O
not	NN	O	O
taken	NN	O	O
their	NN	O	O
medication	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
reason	NN	O	O
for	NN	O	O
not	NN	O	O
doing	NN	O	O
so	NN	O	O
.	NN	O	O

At	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
medication	NN	O	O
was	NN	O	O
assessed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Two	NN	O	O
patients	NN	O	O
were	NN	O	O
lost	NN	O	O
to	NN	O	O
follow-up	NN	O	O
,	NN	O	O
providing	NN	O	O
data	NN	O	O
on	NN	O	O
301	NN	O	O
for	NN	O	O
analysis	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
No	NN	O	O
text	NN	O	O
group	NN	O	O
38/151	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
took	NN	O	O
less	NN	O	O
than	NN	O	O
80	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
prescribed	NN	O	O
regimen	NN	O	O
(	NN	O	O
ie	NN	O	O
.	NN	O	O

stopped	NN	O	O
medication	NN	O	O
completely	NN	O	O
or	NN	O	O
took	NN	O	O
it	NN	O	O
on	NN	O	O
fewer	NN	O	O
than	NN	O	O
22	NN	O	O
of	NN	O	O
the	NN	O	O
last	NN	O	O
28	NN	O	O
days	NN	O	O
of	NN	O	O
follow-up	NN	O	O
)	NN	O	O
compared	NN	O	O
to	NN	O	O
14/150	NN	O	O
patients	NN	O	O
(	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
Text	NN	O	B-INT
group	NN	O	O
-	NN	O	O
an	NN	O	O
improvement	NN	O	O
in	NN	O	O
adherence	NN	O	B-OUT
affecting	NN	O	O
16	NN	O	O
per	NN	O	O
100	NN	O	O
patients	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
7	NN	O	O
to	NN	O	O
24	NN	O	O
)	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
.	NN	O	O

The	NN	O	O
texts	NN	O	O
reminded	NN	O	O
98/151	NN	O	O
patients	NN	O	O
(	NN	O	O
65	NN	O	O
%	NN	O	O
)	NN	O	O
to	NN	O	O
take	NN	O	O
medication	NN	O	O
on	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
occasion	NN	O	O
and	NN	O	O
lead	NN	O	O
to	NN	O	O
20/151	NN	O	O
(	NN	O	O
13	NN	O	O
%	NN	O	O
)	NN	O	O
who	NN	O	O
stopped	NN	O	O
taking	NN	O	O
medication	NN	O	O
because	NN	O	O
of	NN	O	O
concern	NN	O	O
over	NN	O	O
efficacy	NN	O	O
or	NN	O	O
side-effects	NN	O	O
,	NN	O	O
resuming	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
In	NN	O	O
patients	NN	O	B-PAR
taking	NN	O	I-PAR
blood	NN	O	I-PAR
pressure	NN	O	I-PAR
or	NN	O	I-PAR
lipid-lowering	NN	O	I-PAR
treatment	NN	O	I-PAR
for	NN	O	I-PAR
the	NN	O	I-PAR
prevention	NN	O	I-PAR
of	NN	O	I-PAR
cardiovascular	NN	O	I-PAR
disease	NN	O	I-PAR
,	NN	O	O
text	NN	O	B-INT
messaging	NN	O	I-INT
improved	NN	O	O
medication	NN	O	B-OUT
adherence	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
no	NN	O	B-INT
text	NN	O	I-INT
messaging	NN	O	I-INT
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
Controlled-Trials.com	NN	O	O
ISRCTN74757601	NN	O	O
.	NN	O	O



--DOCSTART-- (25784723)

Regional	NN	O	O
ventricular	NN	O	O
performance	NN	O	O
and	NN	O	O
exercise	NN	O	B-INT
training	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
young	NN	O	I-PAR
adults	NN	O	I-PAR
after	NN	O	I-PAR
repair	NN	O	I-PAR
of	NN	O	I-PAR
tetralogy	NN	O	I-PAR
of	NN	O	I-PAR
Fallot	NN	O	I-PAR
:	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Public-health	NN	O	O
guidelines	NN	O	O
recommend	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
congenital	NN	O	I-PAR
heart	NN	O	I-PAR
disease	NN	O	I-PAR
to	NN	O	O
exercise	NN	O	O
.	NN	O	O

Studies	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
patients	NN	O	O
with	NN	O	O
congenital	NN	O	O
heart	NN	O	O
disease	NN	O	O
can	NN	O	O
improve	NN	O	O
physical	NN	O	O
exercise	NN	O	O
capacity	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
training	NN	O	B-INT
on	NN	O	O
regional	NN	O	O
ventricular	NN	O	O
performance	NN	O	O
has	NN	O	O
hardly	NN	O	O
been	NN	O	O
studied	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
to	NN	O	O
assess	NN	O	O
whether	NN	O	O
an	NN	O	O
exercise	NN	O	B-INT
training	NN	O	I-INT
program	NN	O	I-INT
would	NN	O	O
result	NN	O	O
in	NN	O	O
adverse	NN	O	O
changes	NN	O	O
of	NN	O	O
regional	NN	O	O
ventricular	NN	O	O
performance	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
corrected	NN	O	I-PAR
tetralogy	NN	O	I-PAR
of	NN	O	I-PAR
Fallot	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
Multicenter	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
pilot	NN	O	O
study	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
tetralogy	NN	O	I-PAR
of	NN	O	I-PAR
Fallot	NN	O	I-PAR
aged	NN	O	I-PAR
10	NN	O	I-PAR
to	NN	O	I-PAR
25	NN	O	I-PAR
years	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
12-week	NN	O	O
standardized	NN	O	O
aerobic	NN	O	O
dynamic	NN	O	O
exercise	NN	O	B-INT
training	NN	O	I-INT
program	NN	O	I-INT
(	NN	O	O
3	NN	O	O
one-hour	NN	O	O
sessions	NN	O	O
per	NN	O	O
week	NN	O	O
)	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

Pre-	NN	O	O
and	NN	O	O
post-training	NN	O	O
cardiopulmonary	NN	O	B-OUT
exercise	NN	O	I-OUT
tests	NN	O	I-OUT
,	NN	O	I-OUT
MRI	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
echocardiography	NN	O	I-OUT
,	NN	O	I-OUT
including	NN	O	I-OUT
tissue-Doppler	NN	O	I-OUT
imaging	NN	O	I-OUT
,	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
the	NN	O	O
exercise	NN	O	B-INT
group	NN	O	O
(	NN	O	O
n=28	NN	O	O
)	NN	O	O
or	NN	O	O
control	NN	O	B-INT
group	NN	O	O
(	NN	O	O
n=20	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
in	NN	O	O
the	NN	O	O
exercise	NN	O	B-INT
group	NN	O	O
dropped	NN	O	O
out	NN	O	O
.	NN	O	O

Change	NN	O	B-OUT
in	NN	O	I-OUT
tissue-Doppler	NN	O	I-OUT
imaging	NN	O	I-OUT
parameters	NN	O	I-OUT
was	NN	O	O
similar	NN	O	O
in	NN	O	O
the	NN	O	O
exercise	NN	O	B-INT
group	NN	O	O
and	NN	O	O
control	NN	O	B-INT
group	NN	O	O
(	NN	O	O
change	NN	O	O
in	NN	O	O
right	NN	O	O
ventricle	NN	O	O
free	NN	O	O
wall	NN	O	O
peak	NN	O	O
velocity	NN	O	O
E	NN	O	O
'	NN	O	O
exercise	NN	O	O
group	NN	O	O
,	NN	O	O
0.8?2.6	NN	O	O
cm/s	NN	O	O
;	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
0.9?4.1	NN	O	O
;	NN	O	O
peak	NN	O	O
velocity	NN	O	O
A	NN	O	O
'	NN	O	O
exercise	NN	O	O
group	NN	O	O
,	NN	O	O
0.4?2.4	NN	O	O
m/s	NN	O	O
;	NN	O	O
control	NN	O	O
group	NN	O	O
4.6?18.1	NN	O	O
cm/s	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
This	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
pilot	NN	O	O
study	NN	O	O
provides	NN	O	O
preliminary	NN	O	O
data	NN	O	O
suggesting	NN	O	O
that	NN	O	O
regional	NN	O	O
ventricular	NN	O	O
performance	NN	O	O
is	NN	O	O
well	NN	O	O
maintained	NN	O	O
during	NN	O	O
3-month	NN	O	O
aerobic	NN	O	O
dynamic	NN	O	O
exercise	NN	O	B-INT
training	NN	O	I-INT
in	NN	O	O
children	NN	O	B-PAR
and	NN	O	I-PAR
young	NN	O	I-PAR
adults	NN	O	I-PAR
with	NN	O	I-PAR
repaired	NN	O	I-PAR
tetralogy	NN	O	I-PAR
of	NN	O	I-PAR
Fallot	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
information	NN	O	O
might	NN	O	O
help	NN	O	O
patients	NN	O	O
adhere	NN	O	O
to	NN	O	O
current	NN	O	O
public-health	NN	O	O
guidelines	NN	O	O
.	NN	O	O

CLINICAL	NN	O	O
TRIAL	NN	O	O
REGISTRATION	NN	O	O
URL	NN	O	O
:	NN	O	O
http//	NN	O	O
:	NN	O	O
www.trialregister.nl	NN	O	O
.	NN	O	O

Unique	NN	O	O
identifier	NN	O	O
:	NN	O	O
NTR2731	NN	O	O
.	NN	O	O



--DOCSTART-- (25885649)

Subjective	NN	O	O
and	NN	O	O
objective	NN	O	O
levels	NN	O	O
of	NN	O	O
physical	NN	O	O
activity	NN	O	O
and	NN	O	O
their	NN	O	O
association	NN	O	O
with	NN	O	O
cardiorespiratory	NN	O	O
fitness	NN	O	O
in	NN	O	O
rheumatoid	NN	O	B-PAR
arthritis	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

INTRODUCTION	NN	O	O
The	NN	O	O
aims	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
were	NN	O	O
:	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
agreement	NN	O	O
between	NN	O	O
subjective	NN	O	O
(	NN	O	O
assessed	NN	O	O
via	NN	O	O
the	NN	O	O
International	NN	O	B-OUT
Physical	NN	O	I-OUT
Activity	NN	O	I-OUT
Questionnaire	NN	O	I-OUT
;	NN	O	I-OUT
IPAQ	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
objective	NN	O	O
(	NN	O	O
accelerometry	NN	O	O
;	NN	O	O
GT3X	NN	O	B-OUT
)	NN	O	I-OUT
physical	NN	O	I-OUT
activity	NN	O	I-OUT
(	NN	O	I-OUT
PA	NN	O	I-OUT
)	NN	O	I-OUT
levels	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
rheumatoid	NN	O	I-PAR
arthritis	NN	O	I-PAR
(	NN	O	I-PAR
RA	NN	O	I-PAR
)	NN	O	I-PAR
,	NN	O	O
and	NN	O	O
(	NN	O	O
b	NN	O	O
)	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
associations	NN	O	O
of	NN	O	O
RA	NN	O	O
patients	NN	O	O
'	NN	O	O
subjective	NN	O	O
and	NN	O	O
objective	NN	O	O
PA	NN	O	O
to	NN	O	O
their	NN	O	O
scores	NN	O	O
on	NN	O	O
the	NN	O	O
maximal	NN	O	B-OUT
oxygen	NN	O	I-OUT
uptake	NN	O	I-OUT
test	NN	O	I-OUT
(	NN	O	I-OUT
VO2max	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
The	NN	O	O
participants	NN	O	O
wore	NN	O	O
the	NN	O	O
GT3X	NN	O	O
for	NN	O	O
seven	NN	O	O
days	NN	O	O
before	NN	O	O
completing	NN	O	O
the	NN	O	O
IPAQ	NN	O	B-OUT
and	NN	O	O
VO2max	NN	O	B-OUT
test	NN	O	O
.	NN	O	O

The	NN	O	O
Bland-Altman	NN	O	O
plot	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
illustrate	NN	O	O
the	NN	O	O
agreement	NN	O	O
between	NN	O	O
the	NN	O	O
objective	NN	O	O
and	NN	O	O
subjective	NN	O	O
PA	NN	O	O
data	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
Wilcoxon	NN	O	O
test	NN	O	O
was	NN	O	O
employed	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
differences	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
PA	NN	O	B-OUT
measurement	NN	O	I-OUT
and	NN	O	O
VO2max	NN	O	B-OUT
test	NN	O	O
was	NN	O	O
examined	NN	O	O
via	NN	O	O
the	NN	O	O
correlations	NN	O	O
and	NN	O	O
the	NN	O	O
magnitude	NN	O	O
was	NN	O	O
presented	NN	O	O
by	NN	O	O
the	NN	O	O
Steiger	NN	O	O
's	NN	O	O
Z	NN	O	O
value	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Sixty-eight	NN	O	B-PAR
RA	NN	O	I-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
age=55?13	NN	O	I-PAR
years	NN	O	I-PAR
,	NN	O	I-PAR
body	NN	O	I-PAR
mass	NN	O	I-PAR
index	NN	O	I-PAR
:	NN	O	I-PAR
27.8?5.4	NN	O	I-PAR
kg/m2	NN	O	I-PAR
,	NN	O	I-PAR
median	NN	O	I-PAR
of	NN	O	I-PAR
disease	NN	O	I-PAR
duration=5	NN	O	I-PAR
(	NN	O	I-PAR
2-8	NN	O	I-PAR
)	NN	O	I-PAR
yrs	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
recruited	NN	O	O
.	NN	O	O

Smaller	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
subjective	NN	O	O
and	NN	O	O
objective	NN	O	O
measures	NN	O	O
were	NN	O	O
found	NN	O	O
when	NN	O	O
PA	NN	O	O
was	NN	O	O
assessed	NN	O	O
at	NN	O	O
the	NN	O	O
moderate	NN	O	O
level	NN	O	O
.	NN	O	O

Wilcoxon	NN	O	O
tests	NN	O	O
revealed	NN	O	O
that	NN	O	O
patients	NN	O	O
reported	NN	O	O
less	NN	O	O
time	NN	O	O
spent	NN	O	O
engaged	NN	O	O
in	NN	O	O
sedentary	NN	O	B-OUT
behaviours	NN	O	I-OUT
(	NN	O	O
Z=-6.80	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
light	NN	O	B-OUT
PA	NN	O	I-OUT
(	NN	O	O
Z=-6.89	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
more	NN	O	O
moderate	NN	O	O
PA	NN	O	O
(	NN	O	O
Z=-6.26	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
than	NN	O	O
was	NN	O	O
objectively	NN	O	O
indicated	NN	O	O
.	NN	O	O

Significant	NN	O	O
positive	NN	O	O
correlations	NN	O	O
were	NN	O	O
revealed	NN	O	O
between	NN	O	O
VO2max	NN	O	B-OUT
with	NN	O	O
all	NN	O	O
PA	NN	O	O
levels	NN	O	O
derived	NN	O	O
from	NN	O	O
accelerometry	NN	O	O
(	NN	O	O
light	NN	O	O
PA	NN	O	O
rho=.35	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.01	NN	O	O
;	NN	O	O
moderate	NN	O	O
PA	NN	O	O
rho=.34	NN	O	O
,	NN	O	O
P=.01	NN	O	O
;	NN	O	O
moderate	NN	O	O
and	NN	O	O
vigorous	NN	O	O
PA	NN	O	O
,	NN	O	O
(	NN	O	O
MVPA	NN	O	O
)	NN	O	O
rho=.33	NN	O	O
,	NN	O	O
P=.01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
negative	NN	O	O
association	NN	O	O
to	NN	O	O
sedentary	NN	O	B-OUT
time	NN	O	I-OUT
(	NN	O	I-OUT
ST	NN	O	O
)	NN	O	O
emerged	NN	O	O
(	NN	O	O
rho=-.27	NN	O	O
,	NN	O	O
P=.04	NN	O	O
)	NN	O	O
.	NN	O	O

IPAQ-reported	NN	O	O
moderate	NN	O	B-OUT
PA	NN	O	I-OUT
and	NN	O	I-OUT
MVPA	NN	O	I-OUT
positively	NN	O	O
correlated	NN	O	O
with	NN	O	O
maxV02	NN	O	B-OUT
(	NN	O	O
rho=.25	NN	O	O
,	NN	O	O
P=.01	NN	O	O
,	NN	O	O
rho=.27	NN	O	O
,	NN	O	O
P=.01	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Differences	NN	O	O
between	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
correlations	NN	O	O
between	NN	O	O
the	NN	O	O
IPAQ-VO2	NN	O	B-OUT
max	NN	O	I-OUT
and	NN	O	I-OUT
GT3X-VO2	NN	O	I-OUT
max	NN	O	I-OUT
were	NN	O	O
only	NN	O	O
significant	NN	O	O
for	NN	O	O
ST	NN	O	O
(	NN	O	O
Z=3.43	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Via	NN	O	O
responses	NN	O	O
to	NN	O	O
the	NN	O	O
IPAQ	NN	O	B-OUT
,	NN	O	O
RA	NN	O	O
patients	NN	O	O
reported	NN	O	O
that	NN	O	O
they	NN	O	O
were	NN	O	O
less	NN	O	O
sedentary	NN	O	B-OUT
and	NN	O	O
engaged	NN	O	O
in	NN	O	O
more	NN	O	O
higher	NN	O	O
intensity	NN	O	O
PA	NN	O	B-OUT
than	NN	O	O
what	NN	O	O
was	NN	O	O
objectively	NN	O	O
assessed	NN	O	O
.	NN	O	O

Accelerometry	NN	O	O
data	NN	O	O
correlated	NN	O	O
with	NN	O	O
VO2max	NN	O	B-OUT
at	NN	O	O
all	NN	O	O
PA	NN	O	O
levels	NN	O	O
.	NN	O	O

Only	NN	O	O
subjective	NN	O	O
moderate	NN	O	O
and	NN	O	O
MPVA	NN	O	B-OUT
correlated	NN	O	O
with	NN	O	O
VO2max	NN	O	B-OUT
.	NN	O	O

Findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
self-reported	NN	O	O
PA	NN	O	B-OUT
and	NN	O	O
ST	NN	O	B-OUT
should	NN	O	O
be	NN	O	O
interpreted	NN	O	O
with	NN	O	O
caution	NN	O	O
in	NN	O	O
people	NN	O	O
with	NN	O	O
RA	NN	O	O
and	NN	O	O
complemented	NN	O	O
with	NN	O	O
accelerometry	NN	O	O
when	NN	O	O
possible	NN	O	O
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
Trial	NN	O	O
registration	NN	O	O
:	NN	O	O
ClinicalTrials.gov	NN	O	O
ISRCTN04121489	NN	O	O
.	NN	O	O

Registered	NN	O	O
5	NN	O	O
September	NN	O	O
2012	NN	O	O
.	NN	O	O



--DOCSTART-- (25886492)

A	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
personalised	NN	O	B-INT
decision	NN	O	I-INT
support	NN	O	I-INT
delivered	NN	O	O
via	NN	O	O
the	NN	O	O
internet	NN	O	O
for	NN	O	O
bowel	NN	O	O
cancer	NN	O	O
screening	NN	O	O
with	NN	O	O
a	NN	O	O
faecal	NN	O	O
occult	NN	O	O
blood	NN	O	O
test	NN	O	O
:	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
tailoring	NN	O	O
of	NN	O	O
messages	NN	O	O
according	NN	O	O
to	NN	O	O
social	NN	O	O
cognitive	NN	O	O
variables	NN	O	O
on	NN	O	O
participation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
In	NN	O	O
Australia	NN	O	B-PAR
,	NN	O	O
bowel	NN	O	O
cancer	NN	O	O
screening	NN	O	O
participation	NN	O	O
using	NN	O	O
faecal	NN	O	O
occult	NN	O	O
blood	NN	O	O
testing	NN	O	O
(	NN	O	O
FOBT	NN	O	O
)	NN	O	O
is	NN	O	O
low	NN	O	O
.	NN	O	O

Decision	NN	O	O
support	NN	O	O
tailored	NN	O	O
to	NN	O	O
psychological	NN	O	O
predictors	NN	O	O
of	NN	O	O
participation	NN	O	O
may	NN	O	O
increase	NN	O	O
screening	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
compared	NN	O	O
tailored	NN	O	B-INT
computerised	NN	O	I-INT
decision	NN	O	I-INT
support	NN	O	I-INT
to	NN	O	O
non-tailored	NN	O	O
computer	NN	O	O
or	NN	O	O
paper	NN	O	O
information	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
FOBT	NN	O	B-OUT
return	NN	O	I-OUT
within	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Additional	NN	O	O
analyses	NN	O	O
were	NN	O	O
conducted	NN	O	O
on	NN	O	O
movement	NN	O	B-OUT
in	NN	O	I-OUT
decision	NN	O	I-OUT
to	NN	O	I-OUT
screen	NN	O	I-OUT
and	NN	O	O
change	NN	O	O
on	NN	O	O
psychological	NN	O	B-OUT
variables	NN	O	I-OUT
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
parallel	NN	O	O
,	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
,	NN	O	O
trial	NN	O	O
invited	NN	O	B-PAR
25,511	NN	O	I-PAR
people	NN	O	I-PAR
aged	NN	O	I-PAR
50-74	NN	O	I-PAR
years	NN	O	I-PAR
to	NN	O	O
complete	NN	O	O
an	NN	O	O
eligibility	NN	O	O
questionnaire	NN	O	O
.	NN	O	O

Eligible	NN	O	O
respondents	NN	O	O
(	NN	O	O
n	NN	O	B-PAR
=	NN	O	I-PAR
3,408	NN	O	I-PAR
)	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
Tailored	NN	O	B-INT
Personalised	NN	O	I-INT
Decision	NN	O	I-INT
Support	NN	O	I-INT
(	NN	O	I-INT
TPDS	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
Non-Tailored	NN	O	B-INT
PDS	NN	O	I-INT
(	NN	O	I-INT
NTPDS	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
or	NN	O	O
Control	NN	O	B-INT
(	NN	O	O
CG	NN	O	O
)	NN	O	O
(	NN	O	O
intention-to-treat	NN	O	O
,	NN	O	O
ITT	NN	O	O
sample	NN	O	O
)	NN	O	O
.	NN	O	O

TPDS	NN	O	B-INT
and	NN	O	O
NTPDS	NN	O	B-INT
groups	NN	O	O
completed	NN	O	O
an	NN	O	O
on-line	NN	O	O
baseline	NN	O	O
survey	NN	O	O
(	NN	O	O
BS	NN	O	O
)	NN	O	O
and	NN	O	O
accessed	NN	O	O
generic	NN	O	O
information	NN	O	O
.	NN	O	O

The	NN	O	O
TPDS	NN	O	O
group	NN	O	O
additionally	NN	O	O
received	NN	O	O
a	NN	O	O
tailored	NN	O	O
intervention	NN	O	O
.	NN	O	O

CG	NN	O	O
participants	NN	O	O
completed	NN	O	O
a	NN	O	O
paper	NN	O	O
BS	NN	O	O
only	NN	O	O
.	NN	O	O

Those	NN	O	O
completing	NN	O	O
the	NN	O	O
BS	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2270	NN	O	O
)	NN	O	O
were	NN	O	O
mailed	NN	O	O
an	NN	O	O
FOBT	NN	O	O
and	NN	O	O
requested	NN	O	O
to	NN	O	O
complete	NN	O	O
an	NN	O	O
endpoint	NN	O	O
survey	NN	O	O
(	NN	O	O
ES	NN	O	O
)	NN	O	O
that	NN	O	O
re-measured	NN	O	O
BS	NN	O	O
variables	NN	O	O
(	NN	O	O
per-protocol	NN	O	O
,	NN	O	O
PP	NN	O	O
sample	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
FOBT	NN	O	O
return	NN	O	B-OUT
:	NN	O	O
In	NN	O	O
the	NN	O	O
ITT	NN	O	O
sample	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
any	NN	O	O
group	NN	O	O
(	NN	O	O
?	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
2.57	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
.26	NN	O	O
;	NN	O	O
TPDS	NN	O	O
,	NN	O	O
32.5	NN	O	O
%	NN	O	O
;	NN	O	O
NTPDS	NN	O	O
,	NN	O	O
33	NN	O	O
%	NN	O	O
;	NN	O	O
and	NN	O	O
CG	NN	O	O
,	NN	O	O
34.5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
PP	NN	O	O
sample	NN	O	O
,	NN	O	O
FOBT	NN	O	B-OUT
return	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
internet	NN	O	O
groups	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
paper	NN	O	O
group	NN	O	O
(	NN	O	O
?	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
17.01	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
.001	NN	O	O
;	NN	O	O
TPDS	NN	O	O
,	NN	O	O
80	NN	O	O
%	NN	O	O
;	NN	O	O
NTPDS	NN	O	O
,	NN	O	O
83	NN	O	O
%	NN	O	O
;	NN	O	O
and	NN	O	O
CG	NN	O	O
,	NN	O	O
74	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

FOBT	NN	O	B-OUT
completion	NN	O	O
by	NN	O	O
TPDS	NN	O	B-INT
and	NN	O	O
NTPDS	NN	O	B-INT
did	NN	O	O
not	NN	O	O
differ	NN	O	O
(	NN	O	O
?	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
=	NN	O	O
2.23	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
.13	NN	O	O
)	NN	O	O
.	NN	O	O

Age	NN	O	O
was	NN	O	O
positively	NN	O	O
associated	NN	O	O
with	NN	O	O
kit	NN	O	O
return	NN	O	O
.	NN	O	O

Decision	NN	O	O
to	NN	O	O
screen	NN	O	O
:	NN	O	O
2227/2270	NN	O	O
of	NN	O	O
the	NN	O	O
PP	NN	O	O
sample	NN	O	O
provided	NN	O	O
complete	NN	O	O
BS	NN	O	O
data	NN	O	O
.	NN	O	O

Participants	NN	O	O
not	NN	O	O
wanting	NN	O	O
to	NN	O	O
screen	NN	O	O
at	NN	O	O
baseline	NN	O	O
(	NN	O	O
1083/2227	NN	O	O
)	NN	O	O
and	NN	O	O
allocated	NN	O	O
to	NN	O	O
TPDS	NN	O	O
and	NN	O	O
NTPDS	NN	O	O
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
decide	NN	O	O
to	NN	O	O
screen	NN	O	O
and	NN	O	O
return	NN	O	B-OUT
an	NN	O	I-OUT
FOBT	NN	O	I-OUT
than	NN	O	O
those	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
CG	NN	O	O
.	NN	O	O

FOBT	NN	O	B-OUT
return	NN	O	I-OUT
by	NN	O	O
TPDS	NN	O	B-INT
and	NN	O	O
NTPDS	NN	O	B-INT
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
one	NN	O	O
another	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
1.16	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
.42	NN	O	O
)	NN	O	O
.	NN	O	O

Change	NN	O	O
on	NN	O	O
psychosocial	NN	O	B-OUT
predictors	NN	O	I-OUT
:	NN	O	O
Analysis	NN	O	O
of	NN	O	O
change	NN	O	O
indicated	NN	O	O
that	NN	O	O
salience	NN	O	B-OUT
and	NN	O	I-OUT
coherence	NN	O	I-OUT
of	NN	O	I-OUT
screening	NN	O	I-OUT
and	NN	O	O
self-efficacy	NN	O	B-OUT
were	NN	O	O
improved	NN	O	O
and	NN	O	O
faecal	NN	O	O
aversion	NN	O	O
decreased	NN	O	O
by	NN	O	O
tailored	NN	O	O
messaging	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Online	NN	O	O
information	NN	O	O
resources	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
encouraging	NN	O	O
internet-enabled	NN	O	O
people	NN	O	O
who	NN	O	O
are	NN	O	O
uncommitted	NN	O	O
to	NN	O	O
screening	NN	O	O
to	NN	O	O
change	NN	O	O
their	NN	O	O
attitudes	NN	O	O
,	NN	O	O
perceptions	NN	O	O
and	NN	O	O
behaviour	NN	O	O
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
Australian	NN	O	O
New	NN	O	O
Zealand	NN	O	O
Clinical	NN	O	O
Trials	NN	O	O
Registry	NN	O	O
ACTRN12610000095066	NN	O	O
.	NN	O	O



--DOCSTART-- (25898782)

Sedation	NN	O	O
during	NN	O	B-PAR
endoscopic	NN	O	I-PAR
retrograde	NN	O	I-PAR
cholangiopancreatography	NN	O	I-PAR
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
patient-controlled	NN	O	O
propofol	NN	O	B-INT
sedation	NN	O	O
and	NN	O	O
that	NN	O	O
given	NN	O	O
by	NN	O	O
a	NN	O	O
nurse	NN	O	O
anesthetist	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
Different	NN	O	O
regimens	NN	O	O
are	NN	O	O
used	NN	O	O
for	NN	O	O
sedation	NN	O	O
during	NN	O	O
endoscopic	NN	O	O
retrograde	NN	O	O
cholangiopancreatography	NN	O	O
(	NN	O	O
ERCP	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
objectives	NN	O	O
were	NN	O	O
to	NN	O	O
compare	NN	O	O
safety	NN	O	B-OUT
,	NN	O	I-OUT
ease	NN	O	I-OUT
of	NN	O	I-OUT
treatment	NN	O	I-OUT
,	NN	O	I-OUT
recovery	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
patients	NN	O	B-OUT
'	NN	O	I-OUT
experiences	NN	O	I-OUT
using	NN	O	O
patient-controlled	NN	O	B-INT
sedation	NN	O	I-INT
(	NN	O	O
PCS	NN	O	O
)	NN	O	O
with	NN	O	O
propofol	NN	O	B-INT
,	NN	O	O
nurse	NN	O	O
anesthetist-controlled	NN	O	B-INT
sedation	NN	O	I-INT
(	NN	O	O
ACS	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
the	NN	O	O
department	NN	O	O
's	NN	O	O
standard	NN	O	B-INT
of	NN	O	I-INT
care	NN	O	I-INT
,	NN	O	O
midazolam	NN	O	B-INT
given	NN	O	O
by	NN	O	O
the	NN	O	O
procedure	NN	O	O
team	NN	O	O
(	NN	O	O
control	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
The	NN	O	O
study	NN	O	B-PAR
included	NN	O	I-PAR
281	NN	O	I-PAR
adults	NN	O	I-PAR
in	NN	O	I-PAR
301	NN	O	I-PAR
procedures	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
PCS	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
101	NN	O	O
)	NN	O	O
delivered	NN	O	O
bolus	NN	O	O
doses	NN	O	O
of	NN	O	O
5	NN	O	O
mg	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
according	NN	O	O
to	NN	O	O
their	NN	O	O
need	NN	O	O
for	NN	O	O
sedation	NN	O	O
.	NN	O	O

The	NN	O	O
ACS	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
100	NN	O	O
)	NN	O	O
had	NN	O	O
2-8	NN	O	O
mg/kg/h	NN	O	O
of	NN	O	O
propofol	NN	O	B-INT
infused	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
target	NN	O	O
for	NN	O	O
sedation	NN	O	O
being	NN	O	O
level	NN	O	O
3	NN	O	O
of	NN	O	O
the	NN	O	O
Observer	NN	O	O
's	NN	O	O
Assessment	NN	O	O
of	NN	O	O
Alertness/Sedation	NN	O	O
(	NN	O	O
OAA/S	NN	O	O
)	NN	O	O
scale	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
was	NN	O	O
given	NN	O	O
2-3	NN	O	O
mg	NN	O	O
of	NN	O	O
midazolam	NN	O	B-INT
for	NN	O	O
induction	NN	O	O
and	NN	O	O
additional	NN	O	O
1	NN	O	O
mg	NN	O	O
if	NN	O	O
required	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
PCS	NN	O	O
and	NN	O	O
ACS	NN	O	O
increased	NN	O	O
the	NN	O	O
ease	NN	O	B-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
procedure	NN	O	I-OUT
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
number	NN	O	B-OUT
of	NN	O	I-OUT
sedation	NN	O	I-OUT
failures	NN	O	I-OUT
compared	NN	O	O
to	NN	O	O
midazolam	NN	O	B-INT
sedation	NN	O	O
(	NN	O	O
ACS	NN	O	O
n	NN	O	O
=	NN	O	O
0	NN	O	O
;	NN	O	O
PCS	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
;	NN	O	O
midazolam	NN	O	B-INT
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ACS	NN	O	O
group	NN	O	O
had	NN	O	O
more	NN	O	O
deeply	NN	O	O
sedated	NN	O	O
patients	NN	O	O
(	NN	O	O
OAA/S	NN	O	O
level	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
desaturation	NN	O	O
,	NN	O	O
and	NN	O	O
obstructed	NN	O	O
airways	NN	O	O
than	NN	O	O
the	NN	O	O
PCS	NN	O	O
and	NN	O	O
midazolam	NN	O	B-INT
groups	NN	O	O
.	NN	O	O

Time	NN	O	B-OUT
to	NN	O	I-OUT
full	NN	O	I-OUT
recovery	NN	O	I-OUT
(	NN	O	I-OUT
Aldrete	NN	O	I-OUT
score	NN	O	I-OUT
?9	NN	O	O
)	NN	O	O
was	NN	O	O
shortest	NN	O	O
following	NN	O	O
PCS	NN	O	O
.	NN	O	O

PCS	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
least	NN	O	O
fatigue	NN	O	B-OUT
and	NN	O	I-OUT
pain	NN	O	I-OUT
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
.	NN	O	O

Patients	NN	O	O
'	NN	O	B-OUT
preference	NN	O	I-OUT
for	NN	O	O
PCS	NN	O	O
and	NN	O	O
ACS	NN	O	O
was	NN	O	O
the	NN	O	O
same	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
PCS	NN	O	O
with	NN	O	O
propofol	NN	O	B-INT
is	NN	O	O
superior	NN	O	O
to	NN	O	O
midazolam	NN	O	B-INT
and	NN	O	O
comparable	NN	O	O
to	NN	O	O
ACS	NN	O	O
.	NN	O	O

PCS	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
rapid	NN	O	O
recovery	NN	O	B-OUT
,	NN	O	O
fewer	NN	O	O
respiratory	NN	O	B-OUT
events	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
was	NN	O	O
almost	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
ACS	NN	O	O
in	NN	O	O
ensuring	NN	O	O
a	NN	O	O
successful	NN	O	O
examination	NN	O	O
.	NN	O	O



--DOCSTART-- (25931290)

Sensory	NN	O	B-INT
Adapted	NN	O	I-INT
Dental	NN	O	I-INT
Environments	NN	O	I-INT
to	NN	O	O
Enhance	NN	O	O
Oral	NN	O	O
Care	NN	O	O
for	NN	O	O
Children	NN	O	B-PAR
with	NN	O	I-PAR
Autism	NN	O	I-PAR
Spectrum	NN	O	I-PAR
Disorders	NN	O	I-PAR
:	NN	O	O
A	NN	O	O
Randomized	NN	O	O
Controlled	NN	O	O
Pilot	NN	O	O
Study	NN	O	O
.	NN	O	O

This	NN	O	O
pilot	NN	O	O
and	NN	O	O
feasibility	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
a	NN	O	O
sensory	NN	O	B-INT
adapted	NN	O	I-INT
dental	NN	O	I-INT
environment	NN	O	I-INT
(	NN	O	I-INT
SADE	NN	O	I-INT
)	NN	O	I-INT
to	NN	O	O
reduce	NN	O	O
distress	NN	O	B-OUT
,	NN	O	I-OUT
sensory	NN	O	I-OUT
discomfort	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
perception	NN	O	I-OUT
of	NN	O	I-OUT
pain	NN	O	I-OUT
during	NN	O	O
oral	NN	O	O
prophylaxis	NN	O	O
for	NN	O	O
children	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
spectrum	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Participants	NN	O	B-PAR
were	NN	O	I-PAR
44	NN	O	I-PAR
children	NN	O	I-PAR
ages	NN	O	I-PAR
6-12	NN	O	I-PAR
(	NN	O	I-PAR
n	NN	O	I-PAR
=	NN	O	I-PAR
22	NN	O	I-PAR
typical	NN	O	I-PAR
,	NN	O	I-PAR
n	NN	O	I-PAR
=	NN	O	I-PAR
22	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

In	NN	O	O
an	NN	O	O
experimental	NN	O	O
crossover	NN	O	O
design	NN	O	O
,	NN	O	O
each	NN	O	O
participant	NN	O	O
underwent	NN	O	O
two	NN	O	O
professional	NN	O	O
dental	NN	O	O
cleanings	NN	O	O
,	NN	O	O
one	NN	O	O
in	NN	O	O
a	NN	O	O
regular	NN	O	B-INT
dental	NN	O	I-INT
environment	NN	O	I-INT
(	NN	O	I-INT
RDE	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
one	NN	O	O
in	NN	O	O
a	NN	O	O
SADE	NN	O	B-INT
,	NN	O	O
administered	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
and	NN	O	O
counterbalanced	NN	O	O
order	NN	O	O
3-4	NN	O	O
months	NN	O	O
apart	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
included	NN	O	O
measures	NN	O	O
of	NN	O	O
physiological	NN	O	B-OUT
anxiety	NN	O	I-OUT
,	NN	O	I-OUT
behavioral	NN	O	I-OUT
distress	NN	O	I-OUT
,	NN	O	I-OUT
pain	NN	O	I-OUT
intensity	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
sensory	NN	O	I-OUT
discomfort	NN	O	I-OUT
.	NN	O	O

Both	NN	O	O
groups	NN	O	O
exhibited	NN	O	O
decreased	NN	O	O
physiological	NN	O	B-OUT
anxiety	NN	O	I-OUT
and	NN	O	O
reported	NN	O	O
lower	NN	O	O
pain	NN	O	B-OUT
and	NN	O	I-OUT
sensory	NN	O	I-OUT
discomfort	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
SADE	NN	O	B-INT
condition	NN	O	O
compared	NN	O	O
to	NN	O	O
RDE	NN	O	B-INT
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
SADE	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (25950425)

The	NN	O	O
effects	NN	O	O
of	NN	O	O
preoperative	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
and	NN	O	O
perioperative	NN	O	O
intravenous	NN	O	O
lidocaine	NN	O	B-INT
infusion	NN	O	O
on	NN	O	O
postoperative	NN	O	B-OUT
morphine	NN	O	I-OUT
requirement	NN	O	I-OUT
in	NN	O	O
patients	NN	O	B-PAR
undergoing	NN	O	I-PAR
laparatomy	NN	O	I-PAR
.	NN	O	O

OBJECTIVES	NN	O	O
To	NN	O	O
evaluate	NN	O	O
and	NN	O	O
compare	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
preoperative	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
and	NN	O	O
perioperative	NN	O	O
intravenous	NN	O	O
lidocaine	NN	O	B-INT
infusion	NN	O	O
on	NN	O	O
postoperative	NN	O	B-OUT
morphine	NN	O	I-OUT
requirement	NN	O	I-OUT
,	NN	O	I-OUT
adverse	NN	O	I-OUT
effects	NN	O	I-OUT
,	NN	O	I-OUT
patients	NN	O	I-OUT
'	NN	O	I-OUT
satisfaction	NN	O	I-OUT
,	NN	O	I-OUT
mobilization	NN	O	I-OUT
,	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
first	NN	O	I-OUT
defecation	NN	O	I-OUT
and	NN	O	O
time	NN	O	B-OUT
to	NN	O	I-OUT
discharge	NN	O	I-OUT
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
laparotomy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Eighty	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
18	NN	O	I-PAR
to	NN	O	I-PAR
65	NN	O	I-PAR
years	NN	O	I-PAR
of	NN	O	I-PAR
age	NN	O	I-PAR
)	NN	O	I-PAR
undergoing	NN	O	I-PAR
elective	NN	O	I-PAR
laparotomy	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
four	NN	O	O
groups	NN	O	O
(	NN	O	O
n=20	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
)	NN	O	O
:	NN	O	O
group	NN	O	O
C	NN	O	O
,	NN	O	O
placebo	NN	O	B-INT
capsules	NN	O	O
and	NN	O	O
normal	NN	O	B-INT
saline	NN	O	I-INT
infusion	NN	O	I-INT
perioperatively	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
;	NN	O	O
group	NN	O	O
L	NN	O	O
,	NN	O	O
placebo	NN	O	B-INT
capsules	NN	O	O
and	NN	O	O
lidocaine	NN	O	B-INT
1	NN	O	O
mg?kg	NN	O	O
intravenous	NN	O	O
bolus	NN	O	O
dose	NN	O	O
followed	NN	O	O
by	NN	O	O
2	NN	O	O
mg?kg?h	NN	O	O
infusion	NN	O	O
until	NN	O	O
skin	NN	O	O
closure	NN	O	O
;	NN	O	O
group	NN	O	O
P	NN	O	O
,	NN	O	O
150	NN	O	O
mg	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
and	NN	O	O
normal	NN	O	B-INT
saline	NN	O	I-INT
infusion	NN	O	I-INT
perioperatively	NN	O	O
;	NN	O	O
and	NN	O	O
group	NN	O	O
PL	NN	O	O
,	NN	O	O
150	NN	O	O
&	NN	O	O
nbsp	NN	O	O
;	NN	O	O
mg	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
and	NN	O	O
lidocaine	NN	O	B-INT
2	NN	O	O
mg?kg?h	NN	O	O
infusion	NN	O	O
until	NN	O	O
skin	NN	O	O
closure	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
parameters	NN	O	B-OUT
,	NN	O	I-OUT
visual	NN	O	I-OUT
analogue	NN	O	I-OUT
scale	NN	O	I-OUT
(	NN	O	I-OUT
VAS	NN	O	I-OUT
)	NN	O	I-OUT
scores	NN	O	I-OUT
,	NN	O	I-OUT
analgesic	NN	O	I-OUT
consumption	NN	O	I-OUT
,	NN	O	I-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
,	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
mobilization	NN	O	I-OUT
,	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
first	NN	O	I-OUT
defecation	NN	O	I-OUT
,	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
discharge	NN	O	I-OUT
and	NN	O	I-OUT
patients	NN	O	I-OUT
'	NN	O	I-OUT
satisfaction	NN	O	I-OUT
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
VAS	NN	O	O
scores	NN	O	B-OUT
of	NN	O	O
group	NN	O	O
L	NN	O	O
,	NN	O	O
group	NN	O	O
P	NN	O	O
and	NN	O	O
group	NN	O	O
PL	NN	O	O
were	NN	O	O
lower	NN	O	O
than	NN	O	O
group	NN	O	O
C	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Morphine	NN	O	B-OUT
consumption	NN	O	O
of	NN	O	O
group	NN	O	O
P	NN	O	O
and	NN	O	O
group	NN	O	O
PL	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
group	NN	O	O
C	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Incidence	NN	O	B-OUT
of	NN	O	I-OUT
nausea	NN	O	I-OUT
in	NN	O	O
group	NN	O	O
C	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
group	NN	O	O
L	NN	O	O
and	NN	O	O
group	NN	O	O
PL	NN	O	O
.	NN	O	O

Time	NN	O	B-OUT
to	NN	O	I-OUT
first	NN	O	O
defecation	NN	O	B-OUT
and	NN	O	I-OUT
mobilization	NN	O	I-OUT
were	NN	O	O
shorter	NN	O	O
in	NN	O	O
group	NN	O	O
L	NN	O	O
and	NN	O	O
group	NN	O	O
PL	NN	O	O
compared	NN	O	O
with	NN	O	O
group	NN	O	O
C	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Preoperative	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
and	NN	O	O
perioperative	NN	O	O
intravenous	NN	O	O
lidocaine	NN	O	B-INT
infusion	NN	O	O
decreased	NN	O	O
postoperative	NN	O	B-OUT
VAS	NN	O	I-OUT
scores	NN	O	I-OUT
.	NN	O	O

Preoperative	NN	O	O
oral	NN	O	O
pregabalin	NN	O	B-INT
decreased	NN	O	O
morphine	NN	O	B-OUT
requirement	NN	O	I-OUT
and	NN	O	O
perioperative	NN	O	O
intravenous	NN	O	O
lidocaine	NN	O	B-INT
infusion	NN	O	O
hastened	NN	O	O
gastrointestinal	NN	O	O
motility	NN	O	O
and	NN	O	O
mobilization	NN	O	O
,	NN	O	O
and	NN	O	O
decreased	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
nausea	NN	O	I-OUT
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
laparotomy	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
preoperative	NN	O	O
pregabalin	NN	O	B-INT
with	NN	O	O
or	NN	O	O
without	NN	O	O
lidocaine	NN	O	B-INT
provides	NN	O	O
superior	NN	O	O
pain	NN	O	O
relief	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
laparatomy	NN	O	O
.	NN	O	O



--DOCSTART-- (26210844)

A	NN	O	O
New	NN	O	O
Interactive	NN	O	B-INT
Screening	NN	O	I-INT
Test	NN	O	I-INT
for	NN	O	O
Autism	NN	O	B-PAR
Spectrum	NN	O	I-PAR
Disorders	NN	O	I-PAR
in	NN	O	I-PAR
Toddlers	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
develop	NN	O	O
a	NN	O	O
clinically	NN	O	O
valid	NN	O	O
interactive	NN	O	O
level	NN	O	O
2	NN	O	O
screening	NN	O	O
assessment	NN	O	O
for	NN	O	O
autism	NN	O	B-PAR
spectrum	NN	O	I-PAR
disorders	NN	O	I-PAR
(	NN	O	I-PAR
ASD	NN	O	I-PAR
)	NN	O	I-PAR
in	NN	O	I-PAR
toddlers	NN	O	I-PAR
that	NN	O	O
is	NN	O	O
brief	NN	O	O
,	NN	O	O
easily	NN	O	O
administered	NN	O	O
,	NN	O	O
and	NN	O	O
scored	NN	O	O
by	NN	O	O
clinicians	NN	O	O
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
We	NN	O	O
describe	NN	O	O
the	NN	O	O
development	NN	O	O
,	NN	O	O
training	NN	O	O
,	NN	O	O
standardization	NN	O	O
,	NN	O	O
and	NN	O	O
validation	NN	O	O
of	NN	O	O
the	NN	O	O
Rapid	NN	O	B-INT
Interactive	NN	O	I-INT
Screening	NN	O	I-INT
Test	NN	O	I-INT
for	NN	O	O
Autism	NN	O	O
in	NN	O	O
Toddlers	NN	O	B-PAR
(	NN	O	O
RITA-T	NN	O	O
)	NN	O	O
with	NN	O	O
ASD-specific	NN	O	O
diagnostic	NN	O	O
instruments	NN	O	O
.	NN	O	O

The	NN	O	O
RITA-T	NN	O	B-INT
can	NN	O	O
be	NN	O	O
administered	NN	O	O
and	NN	O	O
scored	NN	O	O
in	NN	O	O
10	NN	O	O
minutes	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
validity	NN	O	O
of	NN	O	O
the	NN	O	O
RITA-T	NN	O	B-INT
to	NN	O	O
distinguish	NN	O	O
between	NN	O	O
toddlers	NN	O	B-PAR
with	NN	O	I-PAR
ASD	NN	O	I-PAR
from	NN	O	I-PAR
toddlers	NN	O	I-PAR
with	NN	O	I-PAR
developmental	NN	O	I-PAR
delay	NN	O	I-PAR
(	NN	O	I-PAR
DD	NN	O	I-PAR
)	NN	O	I-PAR
/non-ASD	NN	O	I-PAR
in	NN	O	I-PAR
an	NN	O	I-PAR
early	NN	O	I-PAR
childhood	NN	O	I-PAR
clinic	NN	O	I-PAR
.	NN	O	O

We	NN	O	O
also	NN	O	O
evaluated	NN	O	O
the	NN	O	O
test	NN	O	O
's	NN	O	O
performance	NN	O	O
in	NN	O	O
toddlers	NN	O	B-PAR
with	NN	O	I-PAR
no	NN	O	I-PAR
developmental	NN	O	I-PAR
concerns	NN	O	I-PAR
.	NN	O	O

We	NN	O	O
identified	NN	O	O
a	NN	O	O
cutoff	NN	O	B-OUT
score	NN	O	I-OUT
based	NN	O	O
on	NN	O	O
sensitivity	NN	O	B-OUT
,	NN	O	I-OUT
specificity	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
positive	NN	O	I-OUT
predictive	NN	O	I-OUT
value	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
RITA-T	NN	O	B-OUT
that	NN	O	O
best	NN	O	O
differentiates	NN	O	O
between	NN	O	O
ASD	NN	O	O
and	NN	O	O
DD/non-ASD	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
A	NN	O	B-PAR
total	NN	O	I-PAR
of	NN	O	I-PAR
61	NN	O	I-PAR
toddlers	NN	O	I-PAR
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

RITA-T	NN	O	B-OUT
scores	NN	O	I-OUT
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
ASD-specific	NN	O	O
diagnostic	NN	O	O
tools	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.79	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.01	NN	O	O
)	NN	O	O
and	NN	O	O
ASD	NN	O	O
clinical	NN	O	O
diagnoses	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.77	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.01	NN	O	O
)	NN	O	O
.	NN	O	O

Mean	NN	O	O
scores	NN	O	B-OUT
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
in	NN	O	O
subjects	NN	O	O
with	NN	O	O
ASD	NN	O	O
,	NN	O	O
those	NN	O	O
with	NN	O	O
DD/non-ASD	NN	O	O
,	NN	O	O
and	NN	O	O
those	NN	O	O
with	NN	O	O
no	NN	O	O
developmental	NN	O	O
concerns	NN	O	O
(	NN	O	O
20.8	NN	O	O
vs	NN	O	O
13	NN	O	O
vs	NN	O	O
10.6	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.0001	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
a	NN	O	O
cutoff	NN	O	O
score	NN	O	O
of	NN	O	O
>	NN	O	O
14	NN	O	O
,	NN	O	O
the	NN	O	O
RITA-T	NN	O	B-INT
had	NN	O	O
a	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
1.00	NN	O	O
,	NN	O	O
specificity	NN	O	O
of	NN	O	O
0.84	NN	O	O
,	NN	O	O
and	NN	O	O
positive	NN	O	O
predictive	NN	O	O
value	NN	O	O
of	NN	O	O
0.88	NN	O	O
for	NN	O	O
identifying	NN	O	O
ASD	NN	O	O
risk	NN	O	O
in	NN	O	O
a	NN	O	O
high-risk	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
The	NN	O	O
RITA-T	NN	O	B-INT
is	NN	O	O
a	NN	O	O
promising	NN	O	O
new	NN	O	O
level	NN	O	O
2	NN	O	O
interactive	NN	O	O
screening	NN	O	O
tool	NN	O	O
for	NN	O	O
improving	NN	O	O
the	NN	O	O
early	NN	O	O
identification	NN	O	O
of	NN	O	O
ASD	NN	O	B-PAR
in	NN	O	I-PAR
toddlers	NN	O	I-PAR
in	NN	O	O
general	NN	O	O
pediatric	NN	O	O
and	NN	O	O
early	NN	O	O
intervention	NN	O	O
settings	NN	O	O
and	NN	O	O
allowing	NN	O	O
access	NN	O	O
to	NN	O	O
treatment	NN	O	O
.	NN	O	O



--DOCSTART-- (26278470)

Inference-Based	NN	O	B-INT
Approach	NN	O	I-INT
versus	NN	O	O
Cognitive	NN	O	B-INT
Behavioral	NN	O	I-INT
Therapy	NN	O	I-INT
in	NN	O	O
the	NN	O	O
Treatment	NN	O	O
of	NN	O	O
Obsessive-Compulsive	NN	O	B-PAR
Disorder	NN	O	I-PAR
with	NN	O	I-PAR
Poor	NN	O	I-PAR
Insight	NN	O	I-PAR
:	NN	O	O
A	NN	O	O
24-Session	NN	O	O
Randomized	NN	O	O
Controlled	NN	O	O
Trial	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
Obsessive-compulsive	NN	O	O
disorder	NN	O	O
(	NN	O	O
OCD	NN	O	O
)	NN	O	O
with	NN	O	O
poor	NN	O	O
insight	NN	O	O
has	NN	O	O
severe	NN	O	O
consequences	NN	O	O
for	NN	O	O
patients	NN	O	O
;	NN	O	O
nonetheless	NN	O	O
,	NN	O	O
no	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
has	NN	O	O
ever	NN	O	O
been	NN	O	O
performed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
any	NN	O	O
treatment	NN	O	O
specifically	NN	O	O
for	NN	O	O
poor-insight	NN	O	O
OCD	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
psychotherapy	NN	O	O
for	NN	O	O
OCD	NN	O	O
,	NN	O	O
the	NN	O	O
inference-based	NN	O	B-INT
approach	NN	O	I-INT
(	NN	O	I-INT
IBA	NN	O	I-INT
)	NN	O	I-INT
,	NN	O	O
targets	NN	O	O
insight	NN	O	O
in	NN	O	O
OCD	NN	O	O
by	NN	O	O
strengthening	NN	O	O
normal	NN	O	O
sensory-driven	NN	O	O
reality	NN	O	O
testing	NN	O	O
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
this	NN	O	O
new	NN	O	O
treatment	NN	O	O
to	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
cognitive	NN	O	B-INT
behavior	NN	O	I-INT
therapy	NN	O	I-INT
(	NN	O	I-INT
CBT	NN	O	I-INT
)	NN	O	I-INT
for	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
OCD	NN	O	I-PAR
with	NN	O	I-PAR
poor	NN	O	I-PAR
insight	NN	O	I-PAR
.	NN	O	O

METHOD	NN	O	O
A	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
was	NN	O	O
conducted	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
90	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
OCD	NN	O	I-PAR
with	NN	O	I-PAR
poor	NN	O	I-PAR
insight	NN	O	I-PAR
received	NN	O	O
either	NN	O	O
24	NN	O	O
CBT	NN	O	B-INT
sessions	NN	O	O
or	NN	O	O
24	NN	O	O
IBA	NN	O	B-INT
sessions	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
measure	NN	O	O
was	NN	O	O
the	NN	O	O
Yale-Brown	NN	O	B-OUT
Obsessive	NN	O	I-OUT
Compulsive	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
YBOCS	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Secondary	NN	O	O
outcome	NN	O	O
measures	NN	O	O
were	NN	O	O
level	NN	O	B-OUT
of	NN	O	I-OUT
insight	NN	O	I-OUT
,	NN	O	I-OUT
anxiety	NN	O	I-OUT
and	NN	O	I-OUT
depressive	NN	O	I-OUT
symptoms	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
quality	NN	O	I-OUT
of	NN	O	I-OUT
life	NN	O	I-OUT
.	NN	O	O

Mixed-effects	NN	O	O
models	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
treatment	NN	O	O
effect	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
In	NN	O	O
both	NN	O	O
conditions	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
OCD	NN	O	B-OUT
symptom	NN	O	I-OUT
reduction	NN	O	I-OUT
was	NN	O	O
reached	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
condition	NN	O	O
effects	NN	O	O
were	NN	O	O
established	NN	O	O
.	NN	O	O

Post	NN	O	O
hoc	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
small	NN	O	O
subgroup	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
worst	NN	O	O
insight	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
23	NN	O	O
)	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
IBA	NN	O	B-INT
reached	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
OCD	NN	O	B-OUT
symptom	NN	O	I-OUT
reduction	NN	O	I-OUT
than	NN	O	O
the	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
CBT	NN	O	B-INT
[	NN	O	O
estimated	NN	O	O
marginal	NN	O	O
mean	NN	O	O
=	NN	O	O
-7.77	NN	O	O
,	NN	O	O
t	NN	O	O
(	NN	O	O
219.45	NN	O	O
)	NN	O	O
=	NN	O	O
-2.4	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.017	NN	O	O
]	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Patients	NN	O	B-PAR
with	NN	O	I-PAR
OCD	NN	O	I-PAR
with	NN	O	I-PAR
poor	NN	O	I-PAR
insight	NN	O	I-PAR
improve	NN	O	O
significantly	NN	O	O
after	NN	O	O
psychological	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
both	NN	O	O
CBT	NN	O	B-INT
and	NN	O	O
the	NN	O	O
IBA	NN	O	B-INT
are	NN	O	O
effective	NN	O	O
treatments	NN	O	O
for	NN	O	O
OCD	NN	O	O
with	NN	O	O
poor	NN	O	O
insight	NN	O	O
.	NN	O	O

The	NN	O	O
IBA	NN	O	B-INT
might	NN	O	O
be	NN	O	O
more	NN	O	O
promising	NN	O	O
than	NN	O	O
CBT	NN	O	B-INT
for	NN	O	O
patients	NN	O	O
with	NN	O	O
more	NN	O	O
extreme	NN	O	O
poor	NN	O	O
insight	NN	O	O
.	NN	O	O



--DOCSTART-- (2678230)

[	NN	O	O
The	NN	O	O
effect	NN	O	O
of	NN	O	O
ionic	NN	O	B-INT
and	NN	O	O
nonionic	NN	O	B-INT
x-ray	NN	O	I-INT
contrast	NN	O	I-INT
media	NN	O	O
on	NN	O	O
myocardial	NN	O	O
perfusion	NN	O	O
and	NN	O	O
myocardial	NN	O	B-OUT
function	NN	O	O
]	NN	O	O
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
injections	NN	O	O
of	NN	O	O
Amidotrizoate	NN	O	B-INT
and	NN	O	O
Iopromide	NN	O	B-INT
into	NN	O	O
the	NN	O	O
left	NN	O	O
coronary	NN	O	O
artery	NN	O	O
on	NN	O	O
global	NN	O	B-OUT
myocardial	NN	O	I-OUT
perfusion	NN	O	I-OUT
and	NN	O	I-OUT
function	NN	O	I-OUT
(	NN	O	O
pressures	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
ventricle	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
excitation	NN	O	O
formation	NN	O	O
and	NN	O	O
transmission	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
16	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
ischaemic	NN	O	I-PAR
heart	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O

No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
myocardial	NN	O	B-OUT
perfusion	NN	O	I-OUT
measured	NN	O	O
were	NN	O	O
found	NN	O	O
with	NN	O	O
xenon-133	NN	O	O
in	NN	O	O
this	NN	O	O
small	NN	O	O
group	NN	O	O
between	NN	O	O
rest	NN	O	O
and	NN	O	O
dipyridamole	NN	O	O
load	NN	O	O
for	NN	O	O
ionic	NN	O	O
and	NN	O	O
non-ionic	NN	O	O
contrast	NN	O	O
media	NN	O	O
.	NN	O	O



--DOCSTART-- (2803397)

[	NN	O	O
The	NN	O	O
sympatho-adrenergic	NN	O	O
stress	NN	O	O
reaction	NN	O	O
in	NN	O	O
ear	NN	O	B-PAR
surgery	NN	O	I-PAR
using	NN	O	O
various	NN	O	O
anesthesia	NN	O	O
technics	NN	O	O
]	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
various	NN	O	O
anaesthetic	NN	O	O
procedures	NN	O	O
on	NN	O	O
the	NN	O	O
endocrine	NN	O	O
stress	NN	O	O
responses	NN	O	O
during	NN	O	O
ear	NN	O	B-PAR
microsurgical	NN	O	I-PAR
operations	NN	O	I-PAR
.	NN	O	O

Simple	NN	O	B-PAR
mastoidectomies	NN	O	I-PAR
,	NN	O	I-PAR
radical	NN	O	I-PAR
mastoidectomies	NN	O	I-PAR
and	NN	O	I-PAR
tympano	NN	O	I-PAR
plastics	NN	O	I-PAR
were	NN	O	I-PAR
carried	NN	O	I-PAR
out	NN	O	I-PAR
in	NN	O	I-PAR
49	NN	O	I-PAR
patients	NN	O	I-PAR
under	NN	O	O
the	NN	O	O
following	NN	O	O
randomised	NN	O	O
anaesthetic	NN	O	O
procedures	NN	O	O
:	NN	O	O
Group	NN	O	O
1	NN	O	O
halothane	NN	O	B-INT
anaesthesia	NN	O	O
and	NN	O	O
retroauricular	NN	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
lidocaine	NN	O	B-INT
and	NN	O	O
ornipressin	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
14	NN	O	O
)	NN	O	O
,	NN	O	O
Group	NN	O	O
2	NN	O	O
fentanyl	NN	O	B-INT
anaesthesia	NN	O	O
and	NN	O	O
retroauricular	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
lidocaine	NN	O	B-INT
and	NN	O	O
ornipressin	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
Group	NN	O	O
3	NN	O	O
fentanyl	NN	O	B-INT
anaesthesia	NN	O	O
and	NN	O	O
retroauricular	NN	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
lidocaine	NN	O	B-INT
and	NN	O	O
epinephrine	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
14	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Group	NN	O	O
4	NN	O	O
retroauricular	NN	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
prilocaine	NN	O	B-INT
and	NN	O	O
epinephrine	NN	O	B-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
14	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	B-OUT
levels	NN	O	I-OUT
of	NN	O	I-OUT
epinephrine	NN	O	I-OUT
,	NN	O	I-OUT
norepinephrine	NN	O	I-OUT
,	NN	O	I-OUT
glucose	NN	O	I-OUT
,	NN	O	I-OUT
lactate	NN	O	I-OUT
and	NN	O	O
free	NN	O	O
glycerol	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
immediately	NN	O	O
before	NN	O	O
anaesthesia	NN	O	O
,	NN	O	O
10	NN	O	O
minutes	NN	O	O
after	NN	O	O
skin	NN	O	O
incision	NN	O	O
,	NN	O	O
10	NN	O	O
minutes	NN	O	O
after	NN	O	O
having	NN	O	O
started	NN	O	O
bone	NN	O	O
drilling	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
operation	NN	O	O
and	NN	O	O
3	NN	O	O
hours	NN	O	O
after	NN	O	O
operation	NN	O	O
.	NN	O	O

All	NN	O	O
data	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
covariance	NN	O	O
analysis	NN	O	O
including	NN	O	O
the	NN	O	O
age	NN	O	O
factor	NN	O	O
.	NN	O	O

Plasma	NN	O	B-OUT
catecholamine	NN	O	I-OUT
concentrations	NN	O	I-OUT
remained	NN	O	O
within	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
during	NN	O	O
the	NN	O	O
investigation	NN	O	O
in	NN	O	O
patients	NN	O	O
subjected	NN	O	O
to	NN	O	O
general	NN	O	O
anaesthesia	NN	O	O
(	NN	O	O
Groups	NN	O	O
1-3	NN	O	O
)	NN	O	O
.	NN	O	O

Plasma	NN	O	B-OUT
catecholamines	NN	O	I-OUT
(	NN	O	I-OUT
epinephrine	NN	O	I-OUT
and	NN	O	I-OUT
norepinephrine	NN	O	I-OUT
)	NN	O	I-OUT
increased	NN	O	O
significantly	NN	O	O
in	NN	O	O
Group	NN	O	O
4	NN	O	O
(	NN	O	O
retroauricular	NN	O	O
infiltration	NN	O	O
anaesthesia	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
group	NN	O	O
variabilities	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
MAP	NN	O	B-OUT
and	NN	O	O
HR	NN	O	B-OUT
.	NN	O	O

The	NN	O	O
plasma	NN	O	B-OUT
levels	NN	O	I-OUT
of	NN	O	I-OUT
epinephrine	NN	O	I-OUT
and	NN	O	I-OUT
norepinephrine	NN	O	I-OUT
demonstrate	NN	O	O
a	NN	O	O
direct	NN	O	O
response	NN	O	O
to	NN	O	O
stress	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
secondary	NN	O	O
change	NN	O	O
in	NN	O	O
glucose	NN	O	B-OUT
,	NN	O	I-OUT
lactate	NN	O	I-OUT
and	NN	O	I-OUT
free	NN	O	I-OUT
glycerol	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
general	NN	O	O
anaesthesia	NN	O	O
is	NN	O	O
documented	NN	O	O
by	NN	O	O
normal	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
and	NN	O	O
norepinephrine	NN	O	O
throughout	NN	O	O
the	NN	O	O
operation	NN	O	O
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O


--DOCSTART-- (2908133)

Low	NN	O	O
doses	NN	O	O
of	NN	O	O
ketazolam	NN	O	B-INT
in	NN	O	O
anxiety	NN	O	B-PAR
:	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
multicenter	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
between-patient	NN	O	O
trial	NN	O	O
comparing	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
ketazolam	NN	O	B-INT
(	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
)	NN	O	O
with	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
each	NN	O	O
given	NN	O	O
once	NN	O	O
daily	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
evening	NN	O	O
,	NN	O	O
to	NN	O	O
92	NN	O	B-PAR
outpatients	NN	O	I-PAR
affected	NN	O	I-PAR
by	NN	O	I-PAR
generalized	NN	O	I-PAR
anxiety	NN	O	I-PAR
disorders	NN	O	I-PAR
for	NN	O	I-PAR
at	NN	O	I-PAR
least	NN	O	I-PAR
1	NN	O	I-PAR
month	NN	O	I-PAR
,	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

After	NN	O	O
1-week	NN	O	O
washout	NN	O	O
period	NN	O	O
47	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
ketazolam	NN	O	B-INT
15	NN	O	O
mg	NN	O	O
,	NN	O	O
and	NN	O	O
45	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
for	NN	O	O
15	NN	O	O
days	NN	O	O
(	NN	O	O
first	NN	O	O
period	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
this	NN	O	O
period	NN	O	O
,	NN	O	O
if	NN	O	O
the	NN	O	O
patient	NN	O	O
experienced	NN	O	O
a	NN	O	O
decrease	NN	O	O
on	NN	O	O
the	NN	O	O
total	NN	O	B-OUT
Hamilton	NN	O	I-OUT
Anxiety	NN	O	I-OUT
Rating	NN	O	I-OUT
Scale	NN	O	I-OUT
(	NN	O	I-OUT
HAM-A	NN	O	I-OUT
)	NN	O	I-OUT
of	NN	O	O
at	NN	O	O
least	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
basal	NN	O	O
value	NN	O	O
,	NN	O	O
the	NN	O	O
treatment	NN	O	O
was	NN	O	O
kept	NN	O	O
unchanged	NN	O	O
for	NN	O	O
a	NN	O	O
further	NN	O	O
15	NN	O	O
days	NN	O	O
,	NN	O	O
otherwise	NN	O	O
15	NN	O	O
mg	NN	O	O
of	NN	O	O
ketazolam	NN	O	B-INT
were	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
previous	NN	O	O
treatment	NN	O	O
(	NN	O	O
second	NN	O	O
period	NN	O	O
)	NN	O	O
.	NN	O	O

Anxiety	NN	O	O
was	NN	O	O
rated	NN	O	O
after	NN	O	O
2	NN	O	O
and	NN	O	O
4	NN	O	O
weeks	NN	O	O
with	NN	O	O
the	NN	O	O
Italian	NN	O	B-OUT
HAM-A	NN	O	I-OUT
scale	NN	O	I-OUT
and	NN	O	O
with	NN	O	O
a	NN	O	O
4-point	NN	O	B-OUT
scale	NN	O	I-OUT
(	NN	O	I-OUT
patient	NN	O	I-OUT
's	NN	O	I-OUT
assessment	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Seventy-eight	NN	O	B-PAR
patients	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
first	NN	O	I-PAR
period	NN	O	I-PAR
and	NN	O	I-PAR
75	NN	O	I-PAR
the	NN	O	I-PAR
whole	NN	O	I-PAR
study	NN	O	I-PAR
.	NN	O	O

During	NN	O	O
the	NN	O	O
first	NN	O	O
period	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
responders	NN	O	O
was	NN	O	O
almost	NN	O	O
identical	NN	O	O
in	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
during	NN	O	O
the	NN	O	O
second	NN	O	O
period	NN	O	O
a	NN	O	O
further	NN	O	O
slight	NN	O	O
improvement	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
placebo	NN	O	B-INT
responders	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
HAM-A	NN	O	B-OUT
score	NN	O	I-OUT
of	NN	O	O
patients	NN	O	O
on	NN	O	O
ketazolam	NN	O	B-INT
continued	NN	O	O
to	NN	O	O
improve	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Likewise	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
difference	NN	O	O
between	NN	O	O
treatments	NN	O	O
was	NN	O	O
observed	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
4-point	NN	O	B-OUT
scale	NN	O	I-OUT
,	NN	O	O
in	NN	O	O
the	NN	O	O
population	NN	O	O
as	NN	O	O
a	NN	O	O
whole	NN	O	O
(	NN	O	O
end	NN	O	O
of	NN	O	O
first	NN	O	O
period	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
responder	NN	O	O
patients	NN	O	O
(	NN	O	O
end	NN	O	O
second	NN	O	O
period	NN	O	O
)	NN	O	O
.	NN	O	O

Tolerability	NN	O	O
was	NN	O	O
good	NN	O	O
,	NN	O	O
except	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
on	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
who	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
because	NN	O	O
of	NN	O	O
severe	NN	O	B-OUT
headache	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (3067745)

Levobunolol	NN	O	B-INT
compared	NN	O	O
with	NN	O	O
timolol	NN	O	B-INT
:	NN	O	O
a	NN	O	O
four-year	NN	O	O
study	NN	O	O
.	NN	O	O

Fifty-one	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
raised	NN	O	I-PAR
intraocular	NN	O	I-PAR
pressure	NN	O	I-PAR
(	NN	O	I-PAR
IOP	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
treated	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
four	NN	O	O
years	NN	O	O
with	NN	O	O
one	NN	O	O
of	NN	O	O
three	NN	O	O
ophthalmic	NN	O	O
solutions	NN	O	O
:	NN	O	O
0.5	NN	O	O
%	NN	O	O
levobunolol	NN	O	B-INT
,	NN	O	O
1	NN	O	O
%	NN	O	O
levobunolol	NN	O	B-INT
,	NN	O	O
or	NN	O	O
0.5	NN	O	O
%	NN	O	O
timolol	NN	O	B-INT
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
as	NN	O	O
a	NN	O	O
double-masked	NN	O	O
,	NN	O	O
randomised	NN	O	O
trial	NN	O	O
in	NN	O	O
which	NN	O	O
medications	NN	O	O
were	NN	O	O
administered	NN	O	O
twice	NN	O	O
daily	NN	O	O
to	NN	O	O
both	NN	O	O
eyes	NN	O	O
.	NN	O	O

Levobunolol	NN	O	B-INT
and	NN	O	O
timolol	NN	O	B-INT
were	NN	O	O
equally	NN	O	O
effective	NN	O	O
in	NN	O	O
reducing	NN	O	O
overall	NN	O	B-OUT
mean	NN	O	I-OUT
IOP	NN	O	I-OUT
;	NN	O	O
reductions	NN	O	O
were	NN	O	O
greater	NN	O	O
than	NN	O	O
8.8	NN	O	O
mmHg	NN	O	O
in	NN	O	O
all	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
showed	NN	O	O
levobunolol	NN	O	B-INT
to	NN	O	O
be	NN	O	O
as	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
as	NN	O	O
timolol	NN	O	B-INT
in	NN	O	O
the	NN	O	O
long-term	NN	O	O
control	NN	O	O
of	NN	O	O
raised	NN	O	O
IOP	NN	O	O
.	NN	O	O



--DOCSTART-- (3074300)

Role	NN	O	O
of	NN	O	O
angiotensin-converting	NN	O	B-INT
enzyme	NN	O	I-INT
inhibitors	NN	O	I-INT
in	NN	O	O
early	NN	O	O
antihypertensive	NN	O	O
treatment	NN	O	O
in	NN	O	O
non-insulin	NN	O	B-PAR
dependent	NN	O	I-PAR
diabetes	NN	O	I-PAR
mellitus	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
captopril	NN	O	B-INT
monotherapy	NN	O	O
on	NN	O	O
blood	NN	O	B-OUT
pressure	NN	O	I-OUT
and	NN	O	O
metabolism	NN	O	B-OUT
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
a	NN	O	O
placebo-controlled	NN	O	B-INT
study	NN	O	O
in	NN	O	O
30	NN	O	B-PAR
non-insulin	NN	O	I-PAR
dependent	NN	O	I-PAR
(	NN	O	I-PAR
Type	NN	O	I-PAR
II	NN	O	I-PAR
)	NN	O	I-PAR
diabetic	NN	O	I-PAR
subjects	NN	O	I-PAR
during	NN	O	O
a	NN	O	O
3-week	NN	O	O
observation	NN	O	O
period	NN	O	O
(	NN	O	O
run-in/drug	NN	O	O
;	NN	O	O
placebo/wash-out	NN	O	O
)	NN	O	O
on	NN	O	O
a	NN	O	O
metabolic	NN	O	O
ward	NN	O	O
.	NN	O	O

Captopril	NN	O	B-INT
significantly	NN	O	O
reduced	NN	O	O
both	NN	O	O
systolic	NN	O	B-OUT
and	NN	O	I-OUT
diastolic	NN	O	I-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
(	NN	O	O
154/90	NN	O	O
+/-	NN	O	O
5/2	NN	O	O
vs.	NN	O	O
144/86	NN	O	O
+/-	NN	O	O
4/3	NN	O	O
mmHg	NN	O	O
)	NN	O	O
without	NN	O	O
major	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Mean	NN	O	O
run-in	NN	O	O
postprandial	NN	O	B-OUT
blood	NN	O	I-OUT
glucose	NN	O	I-OUT
concentrations	NN	O	I-OUT
were	NN	O	O
also	NN	O	O
reduced	NN	O	O
upon	NN	O	O
ACE-inhibition	NN	O	O
(	NN	O	O
9	NN	O	O
a.m.	NN	O	O
:	NN	O	O
12.7	NN	O	O
+/-	NN	O	O
0.4	NN	O	O
vs.	NN	O	O
11.1	NN	O	O
+/-	NN	O	O
0.4	NN	O	O
mmol/l	NN	O	O
;	NN	O	O
1	NN	O	O
p.m.	NN	O	O
:	NN	O	O
11.0	NN	O	O
+/-	NN	O	O
0.3	NN	O	O
vs.	NN	O	O
8.9	NN	O	O
+/-	NN	O	O
0.3	NN	O	O
mmol/l	NN	O	O
;	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
blood	NN	O	B-OUT
kinin	NN	O	I-OUT
concentrations	NN	O	I-OUT
(	NN	O	O
40.0	NN	O	O
+/-	NN	O	O
2.5	NN	O	O
pmol/l	NN	O	O
)	NN	O	O
were	NN	O	O
approximately	NN	O	O
doubled	NN	O	O
(	NN	O	O
108.8	NN	O	O
+/-	NN	O	O
23.5	NN	O	O
pmol/l	NN	O	O
;	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Body	NN	O	B-OUT
mass	NN	O	I-OUT
index	NN	O	I-OUT
,	NN	O	I-OUT
fasting	NN	O	I-OUT
plasma	NN	O	I-OUT
insulin	NN	O	I-OUT
,	NN	O	I-OUT
serum	NN	O	I-OUT
electrolyte	NN	O	I-OUT
pattern	NN	O	I-OUT
,	NN	O	I-OUT
uric	NN	O	I-OUT
acid	NN	O	I-OUT
,	NN	O	I-OUT
white	NN	O	I-OUT
blood	NN	O	I-OUT
count	NN	O	I-OUT
,	NN	O	I-OUT
lipid	NN	O	I-OUT
profile	NN	O	I-OUT
as	NN	O	O
well	NN	O	O
as	NN	O	O
hepatic	NN	O	B-OUT
and	NN	O	I-OUT
renal	NN	O	I-OUT
function	NN	O	I-OUT
parameters	NN	O	O
remained	NN	O	O
unaltered	NN	O	O
throughout	NN	O	O
the	NN	O	O
observation	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
are	NN	O	O
in	NN	O	O
line	NN	O	O
with	NN	O	O
recent	NN	O	O
experimental	NN	O	O
studies	NN	O	O
showing	NN	O	O
a	NN	O	O
beneficial	NN	O	O
metabolic	NN	O	O
effect	NN	O	O
of	NN	O	O
captopril	NN	O	B-INT
in	NN	O	O
Type	NN	O	O
II	NN	O	O
diabetes	NN	O	O
.	NN	O	O

ACE	NN	O	B-INT
inhibitors	NN	O	I-INT
might	NN	O	O
therefore	NN	O	O
become	NN	O	O
first-line	NN	O	O
drugs	NN	O	O
in	NN	O	O
early	NN	O	O
antihypertensive	NN	O	O
intervention	NN	O	O
in	NN	O	O
Type	NN	O	B-PAR
II	NN	O	I-PAR
diabetic	NN	O	I-PAR
patients	NN	O	O
.	NN	O	O



--DOCSTART-- (3081600)

Double-blind	NN	O	O
comparison	NN	O	O
of	NN	O	O
doxepin	NN	O	B-INT
versus	NN	O	O
bupropion	NN	O	B-INT
in	NN	O	O
outpatients	NN	O	B-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
major	NN	O	I-PAR
depressive	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
double-blind	NN	O	O
controlled	NN	O	O
study	NN	O	O
comparing	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
bupropion	NN	O	B-INT
to	NN	O	O
doxepin	NN	O	B-INT
in	NN	O	O
outpatients	NN	O	B-PAR
with	NN	O	I-PAR
primary	NN	O	I-PAR
depression	NN	O	I-PAR
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
evaluate	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
safety	NN	O	B-OUT
differences	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
drugs	NN	O	O
.	NN	O	O

Following	NN	O	O
a	NN	O	O
7-day	NN	O	O
placebo	NN	O	B-INT
washout	NN	O	O
period	NN	O	O
,	NN	O	O
patients	NN	O	O
could	NN	O	O
be	NN	O	O
treated	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
13	NN	O	O
weeks	NN	O	O
on	NN	O	O
either	NN	O	O
treatment	NN	O	O
.	NN	O	O

Antidepressant	NN	O	B-OUT
response	NN	O	I-OUT
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
the	NN	O	O
Hamilton	NN	O	B-OUT
Depression	NN	O	I-OUT
and	NN	O	I-OUT
Anxiety	NN	O	I-OUT
Scales	NN	O	I-OUT
,	NN	O	I-OUT
Clinical	NN	O	I-OUT
Global	NN	O	I-OUT
Severity	NN	O	I-OUT
and	NN	O	I-OUT
Improvement	NN	O	I-OUT
Ratings	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
the	NN	O	O
Zung	NN	O	B-OUT
Self-Rating	NN	O	I-OUT
Depression	NN	O	I-OUT
Scale	NN	O	I-OUT
.	NN	O	O

Comparable	NN	O	O
efficacy	NN	O	B-OUT
between	NN	O	O
the	NN	O	O
compounds	NN	O	O
was	NN	O	O
found	NN	O	O
across	NN	O	O
the	NN	O	O
13-week	NN	O	O
study	NN	O	O
.	NN	O	O

Doxepin	NN	O	B-INT
differed	NN	O	O
from	NN	O	O
bupropion	NN	O	B-INT
mainly	NN	O	O
on	NN	O	O
the	NN	O	O
sleep	NN	O	B-OUT
factor	NN	O	O
of	NN	O	O
the	NN	O	O
Hamilton	NN	O	B-OUT
Depression	NN	O	I-OUT
Scale	NN	O	I-OUT
,	NN	O	O
with	NN	O	O
doxepin	NN	O	B-INT
improving	NN	O	O
sleep	NN	O	B-OUT
to	NN	O	O
a	NN	O	O
greater	NN	O	O
extent	NN	O	O
than	NN	O	O
bupropion	NN	O	B-INT
.	NN	O	O

Doxepin	NN	O	B-INT
produced	NN	O	O
a	NN	O	O
greater	NN	O	O
incidence	NN	O	O
of	NN	O	O
anticholinergic	NN	O	B-OUT
side	NN	O	I-OUT
effects	NN	O	I-OUT
,	NN	O	O
including	NN	O	O
dry	NN	O	B-OUT
mouth	NN	O	I-OUT
,	NN	O	I-OUT
constipation	NN	O	I-OUT
,	NN	O	I-OUT
sleepiness	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
tiredness	NN	O	I-OUT
,	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
bupropion	NN	O	B-INT
.	NN	O	O

Also	NN	O	O
,	NN	O	O
increased	NN	O	O
appetite	NN	O	B-OUT
and	NN	O	I-OUT
weight	NN	O	I-OUT
gain	NN	O	I-OUT
were	NN	O	O
consistent	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
doxepin	NN	O	B-INT
relative	NN	O	O
to	NN	O	O
bupropion	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (3534803)

Review	NN	O	O
of	NN	O	O
the	NN	O	O
Multicenter	NN	O	O
Trial	NN	O	O
Committee	NN	O	O
report	NN	O	O
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
prophylaxis	NN	O	O
of	NN	O	O
postoperative	NN	O	O
deep	NN	O	O
venous	NN	O	O
thrombosis	NN	O	O
.	NN	O	O

The	NN	O	O
etiology	NN	O	O
of	NN	O	O
postoperative	NN	O	O
deep	NN	O	O
venous	NN	O	O
thrombosis	NN	O	O
(	NN	O	O
DVT	NN	O	O
)	NN	O	O
is	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
factors	NN	O	O
including	NN	O	O
stasis	NN	O	O
,	NN	O	O
a	NN	O	O
hypercoagulable	NN	O	O
state	NN	O	O
and	NN	O	O
venous	NN	O	O
endothelial	NN	O	O
damage	NN	O	O
.	NN	O	O

Methods	NN	O	O
of	NN	O	O
prophylaxis	NN	O	O
are	NN	O	O
directed	NN	O	O
toward	NN	O	O
correcting	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
of	NN	O	O
these	NN	O	O
pathologic	NN	O	O
events	NN	O	O
.	NN	O	O

Methods	NN	O	O
counteracting	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
factors	NN	O	O
can	NN	O	O
be	NN	O	O
expected	NN	O	O
to	NN	O	O
be	NN	O	O
even	NN	O	O
more	NN	O	O
effective	NN	O	O
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
dihydroergotamine	NN	O	B-INT
(	NN	O	I-INT
DHE	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
heparin	NN	O	B-INT
was	NN	O	O
anticipated	NN	O	O
to	NN	O	O
minimize	NN	O	O
stasis	NN	O	O
and	NN	O	O
the	NN	O	O
hypercoagulable	NN	O	O
state	NN	O	O
respectively	NN	O	O
.	NN	O	O

Based	NN	O	O
upon	NN	O	O
current	NN	O	O
experimental	NN	O	O
evidence	NN	O	O
and	NN	O	O
current	NN	O	O
theory	NN	O	O
,	NN	O	O
an	NN	O	O
additional	NN	O	O
benefit	NN	O	O
might	NN	O	O
include	NN	O	O
minimizing	NN	O	O
venous	NN	O	O
endothelial	NN	O	O
injury	NN	O	O
by	NN	O	O
controlling	NN	O	O
venomotor	NN	O	O
tone	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
multicenter	NN	O	O
trial	NN	O	O
was	NN	O	O
designed	NN	O	O
and	NN	O	O
performed	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	B-PAR
States	NN	O	I-PAR
evaluating	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
efficacy	NN	O	O
of	NN	O	O
DHE	NN	O	B-INT
0.5	NN	O	O
mg	NN	O	O
plus	NN	O	O
heparin	NN	O	B-INT
5000	NN	O	O
U	NN	O	O
,	NN	O	O
DHE	NN	O	B-INT
0.5	NN	O	O
mg	NN	O	O
plus	NN	O	O
heparin	NN	O	B-INT
2500	NN	O	O
U	NN	O	O
,	NN	O	O
heparin	NN	O	B-INT
5000	NN	O	O
U	NN	O	O
,	NN	O	O
and	NN	O	O
DHE	NN	O	B-INT
0.5	NN	O	O
mg	NN	O	O
versus	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

General	NN	O	B-PAR
surgical	NN	O	I-PAR
patients	NN	O	I-PAR
including	NN	O	I-PAR
those	NN	O	I-PAR
undergoing	NN	O	I-PAR
noncardiac	NN	O	I-PAR
thoracic	NN	O	I-PAR
and	NN	O	I-PAR
pelvic	NN	O	I-PAR
operations	NN	O	I-PAR
who	NN	O	I-PAR
were	NN	O	I-PAR
identified	NN	O	I-PAR
at	NN	O	I-PAR
moderate	NN	O	I-PAR
to	NN	O	I-PAR
high	NN	O	I-PAR
risk	NN	O	I-PAR
for	NN	O	I-PAR
postop	NN	O	I-PAR
DVT	NN	O	I-PAR
were	NN	O	I-PAR
included	NN	O	I-PAR
.	NN	O	O

Study	NN	O	O
medications	NN	O	O
were	NN	O	O
injected	NN	O	O
subcutaneously	NN	O	O
two	NN	O	O
hours	NN	O	O
preoperatively	NN	O	O
and	NN	O	O
every	NN	O	O
12	NN	O	O
hours	NN	O	O
postoperatively	NN	O	O
for	NN	O	O
5-7	NN	O	O
days	NN	O	O
or	NN	O	O
until	NN	O	O
the	NN	O	O
125I-fibrinogen-uptake	NN	O	O
test	NN	O	O
(	NN	O	O
RFUT	NN	O	O
)	NN	O	O
became	NN	O	O
positive	NN	O	O
.	NN	O	O

Eight	NN	O	B-PAR
hundred	NN	O	I-PAR
and	NN	O	I-PAR
eighty	NN	O	I-PAR
eight	NN	O	I-PAR
patients	NN	O	I-PAR
were	NN	O	I-PAR
entered	NN	O	I-PAR
into	NN	O	I-PAR
this	NN	O	I-PAR
trial	NN	O	I-PAR
and	NN	O	I-PAR
744	NN	O	I-PAR
(	NN	O	I-PAR
85	NN	O	I-PAR
%	NN	O	I-PAR
)	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
study	NN	O	I-PAR
.	NN	O	I-PAR
Results	NN	O	O
showed	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
benefit	NN	O	O
from	NN	O	O
DHE/Hep	NN	O	B-INT
5000	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
compared	NN	O	O
to	NN	O	O
other	NN	O	O
active	NN	O	O
agents	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
active	NN	O	O
agents	NN	O	O
showed	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
prophylactic	NN	O	O
benefit	NN	O	O
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O


--DOCSTART-- (361799)

[	NN	O	O
The	NN	O	O
chemotherapy	NN	O	B-INT
of	NN	O	O
advanced	NN	O	B-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
.	NN	O	O

A	NN	O	O
report	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
600	NN	O	B-PAR
cases	NN	O	I-PAR
in	NN	O	O
a	NN	O	O
cooperative	NN	O	O
programme	NN	O	O
to	NN	O	O
carry	NN	O	O
out	NN	O	O
a	NN	O	O
systematic	NN	O	O
study	NN	O	O
(	NN	O	O
1974-1977	NN	O	O
)	NN	O	O
(	NN	O	O
author	NN	O	O
's	NN	O	O
transl	NN	O	O
)	NN	O	O
]	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
explain	NN	O	O
the	NN	O	O
objectives	NN	O	O
and	NN	O	O
the	NN	O	O
structure	NN	O	O
of	NN	O	O
a	NN	O	O
programme	NN	O	O
evolved	NN	O	O
for	NN	O	O
the	NN	O	O
methodic	NN	O	O
study	NN	O	O
of	NN	O	O
advanced	NN	O	B-PAR
breast	NN	O	I-PAR
cancers	NN	O	I-PAR
which	NN	O	O
they	NN	O	O
have	NN	O	O
worked	NN	O	O
out	NN	O	O
and	NN	O	O
carried	NN	O	O
out	NN	O	O
in	NN	O	O
cooperation	NN	O	O
with	NN	O	O
the	NN	O	O
departments	NN	O	O
of	NN	O	O
medicine	NN	O	O
in	NN	O	O
eight	NN	O	O
French	NN	O	B-PAR
anticancer	NN	O	O
centres	NN	O	O
.	NN	O	O

They	NN	O	O
analyse	NN	O	O
the	NN	O	O
initial	NN	O	O
phases	NN	O	O
,	NN	O	O
which	NN	O	O
correspond	NN	O	O
to	NN	O	O
the	NN	O	O
three	NN	O	O
first	NN	O	O
years	NN	O	O
of	NN	O	O
work	NN	O	O
.	NN	O	O

They	NN	O	O
give	NN	O	O
the	NN	O	O
state	NN	O	O
of	NN	O	O
the	NN	O	O
results	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
obtained	NN	O	O
in	NN	O	O
603	NN	O	B-PAR
patients	NN	O	I-PAR
using	NN	O	O
three	NN	O	O
protocols	NN	O	O
for	NN	O	O
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
consisted	NN	O	O
of	NN	O	O
the	NN	O	O
administration	NN	O	O
in	NN	O	O
interrupted	NN	O	O
doses	NN	O	O
of	NN	O	O
chemotherapy	NN	O	B-INT
which	NN	O	O
consisted	NN	O	O
of	NN	O	O
vincristine	NN	O	B-INT
associated	NN	O	O
for	NN	O	O
the	NN	O	O
one	NN	O	O
part	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-INT
and	NN	O	O
5-fluoro-uracil	NN	O	B-INT
and	NN	O	O
on	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
with	NN	O	O
doxorubicine	NN	O	B-INT
or/and	NN	O	O
with	NN	O	O
methotrexate	NN	O	B-INT
.	NN	O	O

From	NN	O	O
this	NN	O	O
study	NN	O	O
there	NN	O	O
emerged	NN	O	O
the	NN	O	O
value	NN	O	O
of	NN	O	O
combined	NN	O	O
therapy	NN	O	O
using	NN	O	O
doxorubicine	NN	O	B-INT
as	NN	O	O
much	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
frequency	NN	O	O
with	NN	O	O
which	NN	O	O
results	NN	O	B-OUT
better	NN	O	O
than	NN	O	O
50	NN	O	O
%	NN	O	O
were	NN	O	O
obtained	NN	O	O
(	NN	O	O
in	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
)	NN	O	O
as	NN	O	O
by	NN	O	O
their	NN	O	O
quality	NN	O	B-OUT
,	NN	O	O
which	NN	O	O
was	NN	O	O
made	NN	O	O
clear	NN	O	O
in	NN	O	O
an	NN	O	O
important	NN	O	O
series	NN	O	O
of	NN	O	O
240	NN	O	O
cases	NN	O	O
.	NN	O	O

They	NN	O	O
point	NN	O	O
out	NN	O	O
the	NN	O	O
conditions	NN	O	O
required	NN	O	O
to	NN	O	O
initiate	NN	O	O
the	NN	O	O
place	NN	O	O
of	NN	O	O
such	NN	O	O
a	NN	O	O
scheme	NN	O	O
in	NN	O	O
all	NN	O	O
complex	NN	O	O
therapy	NN	O	O
which	NN	O	O
aims	NN	O	O
as	NN	O	O
much	NN	O	O
at	NN	O	O
palliation	NN	O	O
as	NN	O	O
at	NN	O	O
cure	NN	O	O
,	NN	O	O
and	NN	O	O
point	NN	O	O
out	NN	O	O
how	NN	O	O
important	NN	O	O
it	NN	O	O
is	NN	O	O
to	NN	O	O
be	NN	O	O
methodical	NN	O	O
in	NN	O	O
the	NN	O	O
application	NN	O	O
of	NN	O	O
chemotherapy	NN	O	B-INT
in	NN	O	O
order	NN	O	O
to	NN	O	O
ensure	NN	O	O
its	NN	O	O
development	NN	O	O
as	NN	O	O
an	NN	O	O
anticancer	NN	O	O
therapy	NN	O	O
.	NN	O	O



--DOCSTART-- (384815)

Ascaris	NN	O	O
and	NN	O	O
growth	NN	O	O
rates	NN	O	O
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Three	NN	O	B-PAR
hundred	NN	O	I-PAR
forty-one	NN	O	I-PAR
Tanzanian	NN	O	I-PAR
preschool	NN	O	I-PAR
children	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
levamisole	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
treatment	NN	O	O
given	NN	O	O
at	NN	O	O
three-month	NN	O	O
intervals	NN	O	O
.	NN	O	O

Weights	NN	O	B-OUT
and	NN	O	I-OUT
heights	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
at	NN	O	O
the	NN	O	O
tri-monthly	NN	O	O
treatment	NN	O	O
visits	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
273	NN	O	O
children	NN	O	O
who	NN	O	O
were	NN	O	O
seen	NN	O	O
and	NN	O	O
weighed	NN	O	O
at	NN	O	O
the	NN	O	O
one-year	NN	O	O
follow-up	NN	O	O
visit	NN	O	O
,	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
weight	NN	O	I-OUT
gain	NN	O	I-OUT
was	NN	O	O
8	NN	O	O
per	NN	O	O
cent	NN	O	O
greater	NN	O	O
for	NN	O	O
those	NN	O	O
receiving	NN	O	O
levamisole	NN	O	B-INT
than	NN	O	O
for	NN	O	O
placebo-treated	NN	O	B-INT
controls	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
.06	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
78	NN	O	O
children	NN	O	B-PAR
known	NN	O	O
to	NN	O	O
be	NN	O	O
infected	NN	O	O
with	NN	O	O
Ascaris	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
weight	NN	O	I-OUT
gain	NN	O	I-OUT
was	NN	O	O
21	NN	O	O
per	NN	O	O
cent	NN	O	O
greater	NN	O	O
in	NN	O	O
children	NN	O	O
treated	NN	O	O
with	NN	O	O
levamisole	NN	O	B-INT
than	NN	O	O
in	NN	O	O
those	NN	O	O
receiving	NN	O	O
placebo	NN	O	B-INT
(	NN	O	O
p	NN	O	O
=	NN	O	O
.03	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
height	NN	O	I-OUT
gain	NN	O	I-OUT
was	NN	O	O
no	NN	O	O
different	NN	O	O
for	NN	O	O
treatment	NN	O	O
and	NN	O	O
placebo	NN	O	B-INT
groups	NN	O	O
.	NN	O	O



--DOCSTART-- (3919804)

Rapid	NN	O	O
tightening	NN	O	O
of	NN	O	O
blood	NN	O	O
glucose	NN	O	O
control	NN	O	O
leads	NN	O	O
to	NN	O	O
transient	NN	O	O
deterioration	NN	O	O
of	NN	O	O
retinopathy	NN	O	B-OUT
in	NN	O	O
insulin	NN	O	B-PAR
dependent	NN	O	I-PAR
diabetes	NN	O	I-PAR
mellitus	NN	O	I-PAR
:	NN	O	O
the	NN	O	O
Oslo	NN	O	O
study	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
retinopathy	NN	O	O
during	NN	O	O
one	NN	O	O
year	NN	O	O
of	NN	O	O
tight	NN	O	O
blood	NN	O	O
glucose	NN	O	O
control	NN	O	O
45	NN	O	B-PAR
type	NN	O	I-PAR
I	NN	O	I-PAR
(	NN	O	I-PAR
insulin	NN	O	I-PAR
dependent	NN	O	I-PAR
)	NN	O	I-PAR
diabetics	NN	O	I-PAR
without	NN	O	I-PAR
proliferative	NN	O	I-PAR
retinopathy	NN	O	I-PAR
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
continuous	NN	O	O
subcutaneous	NN	O	O
insulin	NN	O	B-INT
infusion	NN	O	I-INT
,	NN	O	O
multiple	NN	O	O
insulin	NN	O	B-INT
injections	NN	O	I-INT
,	NN	O	O
or	NN	O	O
conventional	NN	O	O
insulin	NN	O	B-INT
treatment	NN	O	I-INT
(	NN	O	O
controls	NN	O	O
)	NN	O	O
.	NN	O	O

Near	NN	O	O
normoglycaemia	NN	O	O
was	NN	O	O
achieved	NN	O	O
with	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
and	NN	O	O
multiple	NN	O	O
injections	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
conventional	NN	O	O
treatment	NN	O	O
.	NN	O	O

Blind	NN	O	O
evaluation	NN	O	O
of	NN	O	O
fluorescein	NN	O	B-OUT
angiograms	NN	O	I-OUT
performed	NN	O	O
three	NN	O	O
monthly	NN	O	O
showed	NN	O	O
progression	NN	O	B-OUT
of	NN	O	I-OUT
retinopathy	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
transient	NN	O	O
deterioration	NN	O	O
in	NN	O	O
the	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
multiple	NN	O	O
injection	NN	O	O
group	NN	O	O
.	NN	O	O

Half	NN	O	O
the	NN	O	O
patients	NN	O	O
receiving	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
and	NN	O	O
multiple	NN	O	O
injections	NN	O	O
developed	NN	O	O
retinal	NN	O	O
cotton	NN	O	O
wool	NN	O	O
spots	NN	O	O
after	NN	O	O
three	NN	O	O
to	NN	O	O
six	NN	O	O
months	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
regressed	NN	O	O
in	NN	O	O
all	NN	O	O
but	NN	O	O
four	NN	O	O
patients	NN	O	O
after	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

Control	NN	O	O
patients	NN	O	O
did	NN	O	O
not	NN	O	O
develop	NN	O	O
cotton	NN	O	B-OUT
wool	NN	O	I-OUT
spots	NN	O	I-OUT
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
developed	NN	O	O
cotton	NN	O	O
wool	NN	O	O
spots	NN	O	O
are	NN	O	O
characterised	NN	O	O
by	NN	O	O
a	NN	O	O
larger	NN	O	O
decrement	NN	O	O
in	NN	O	O
glycosylated	NN	O	B-OUT
haemoglobin	NN	O	I-OUT
and	NN	O	I-OUT
blood	NN	O	I-OUT
glucose	NN	O	I-OUT
values	NN	O	I-OUT
,	NN	O	O
more	NN	O	O
frequent	NN	O	O
episodes	NN	O	B-OUT
of	NN	O	I-OUT
hypoglycaemia	NN	O	I-OUT
,	NN	O	O
a	NN	O	O
longer	NN	O	O
duration	NN	O	B-OUT
of	NN	O	I-OUT
diabetes	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
more	NN	O	O
severe	NN	O	O
retinopathy	NN	O	B-OUT
at	NN	O	O
onset	NN	O	O
.	NN	O	O

A	NN	O	O
large	NN	O	O
and	NN	O	O
rapid	NN	O	O
fall	NN	O	O
in	NN	O	O
blood	NN	O	B-OUT
glucose	NN	O	I-OUT
concentration	NN	O	I-OUT
may	NN	O	O
promote	NN	O	O
transient	NN	O	O
deterioration	NN	O	O
of	NN	O	O
diabetic	NN	O	O
retinopathy	NN	O	O
.	NN	O	O



--DOCSTART-- (4919024)

Protection	NN	O	O
of	NN	O	O
man	NN	O	O
from	NN	O	O
natural	NN	O	O
infection	NN	O	O
with	NN	O	O
influenza	NN	O	O
A2	NN	O	O
Hong	NN	O	O
Kong	NN	O	O
virus	NN	O	O
by	NN	O	O
amantadine	NN	O	B-INT
:	NN	O	O
a	NN	O	O
controlled	NN	O	O
field	NN	O	O
trial	NN	O	O
.	NN	O	O

Prophylactic	NN	O	O
administration	NN	O	O
of	NN	O	O
amantadine	NN	O	B-INT
in	NN	O	O
doses	NN	O	O
of	NN	O	O
100	NN	O	O
mg.	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
offered	NN	O	O
statistically	NN	O	O
significant	NN	O	O
protection	NN	O	O
against	NN	O	O
influenza	NN	O	O
A2	NN	O	O
infection	NN	O	O
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
field	NN	O	O
trial	NN	O	O
involving	NN	O	O
391	NN	O	B-PAR
medical	NN	O	I-PAR
student	NN	O	I-PAR
volunteers	NN	O	I-PAR
during	NN	O	I-PAR
the	NN	O	I-PAR
influenza	NN	O	I-PAR
A2	NN	O	I-PAR
Hong	NN	O	I-PAR
Kong	NN	O	I-PAR
epidemic	NN	O	I-PAR
in	NN	O	I-PAR
Helsinki	NN	O	I-PAR
in	NN	O	I-PAR
the	NN	O	I-PAR
winter	NN	O	I-PAR
of	NN	O	I-PAR
1969	NN	O	I-PAR
.	NN	O	O

Serologically	NN	O	B-OUT
verified	NN	O	I-OUT
influenza	NN	O	I-OUT
,	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
complement	NN	O	B-OUT
fixation	NN	O	I-OUT
and/or	NN	O	I-OUT
haemagglutination	NN	O	I-OUT
inhibition	NN	O	I-OUT
,	NN	O	O
occurred	NN	O	O
in	NN	O	O
27	NN	O	O
out	NN	O	O
of	NN	O	O
192	NN	O	O
students	NN	O	O
in	NN	O	O
the	NN	O	O
amantadine	NN	O	B-INT
group	NN	O	O
against	NN	O	O
57	NN	O	O
out	NN	O	O
of	NN	O	O
199	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
,	NN	O	O
giving	NN	O	O
a	NN	O	O
protection	NN	O	O
rate	NN	O	O
of	NN	O	O
52	NN	O	O
%	NN	O	O
.	NN	O	O



--DOCSTART-- (6418441)

The	NN	O	O
treatment	NN	O	O
of	NN	O	O
asthma	NN	O	B-PAR
in	NN	O	I-PAR
adults	NN	O	I-PAR
using	NN	O	O
sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
pressurized	NN	O	O
aerosol	NN	O	O
:	NN	O	O
a	NN	O	O
double-blind	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

Sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
formulated	NN	O	O
as	NN	O	O
a	NN	O	O
pressurized	NN	O	O
aerosol	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
4-times	NN	O	O
daily	NN	O	O
)	NN	O	O
and	NN	O	O
placebo	NN	O	B-INT
were	NN	O	O
compared	NN	O	O
in	NN	O	O
31	NN	O	B-PAR
adult	NN	O	I-PAR
asthmatic	NN	O	I-PAR
patients	NN	O	I-PAR
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
crossover	NN	O	O
trial	NN	O	O
lasting	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
was	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
improving	NN	O	O
breathlessness	NN	O	B-OUT
at	NN	O	I-OUT
rest	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
breathlessness	NN	O	B-OUT
on	NN	O	I-OUT
exertion	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
quality	NN	O	B-OUT
of	NN	O	I-OUT
sleep	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
in	NN	O	O
improving	NN	O	O
the	NN	O	O
morning	NN	O	B-OUT
peak	NN	O	I-OUT
expiratory	NN	O	I-OUT
flow	NN	O	I-OUT
rate	NN	O	I-OUT
value	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
clinicians	NN	O	O
'	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
treatment	NN	O	O
opinions	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
treatment	NN	O	B-OUT
preferences	NN	O	I-OUT
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
favoured	NN	O	O
sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
usage	NN	O	O
of	NN	O	O
bronchodilators	NN	O	O
(	NN	O	O
theophylline	NN	O	O
and	NN	O	O
aerosol	NN	O	O
beta-stimulants	NN	O	O
combined	NN	O	O
)	NN	O	O
declined	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
during	NN	O	O
sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
treatment	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

No	NN	O	O
side-effects	NN	O	B-OUT
were	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
show	NN	O	O
that	NN	O	O
sodium	NN	O	B-INT
cromoglycate	NN	O	I-INT
delivered	NN	O	O
by	NN	O	O
pressurized	NN	O	O
aerosol	NN	O	O
was	NN	O	O
significantly	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
not	NN	O	O
only	NN	O	O
in	NN	O	O
improving	NN	O	O
asthmatic	NN	O	B-OUT
symptoms	NN	O	I-OUT
,	NN	O	O
but	NN	O	O
also	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
concomitant	NN	O	O
bronchodilator	NN	O	B-OUT
therapy	NN	O	I-OUT
required	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (6421395)

Effects	NN	O	O
of	NN	O	O
mild	NN	O	B-INT
physical	NN	O	I-INT
exercise	NN	O	I-INT
on	NN	O	O
serum	NN	O	B-OUT
lipoproteins	NN	O	I-OUT
and	NN	O	O
metabolites	NN	O	B-OUT
of	NN	O	I-OUT
arachidonic	NN	O	I-OUT
acid	NN	O	I-OUT
:	NN	O	O
a	NN	O	O
controlled	NN	O	O
randomised	NN	O	O
trial	NN	O	O
in	NN	O	O
middle	NN	O	B-PAR
aged	NN	O	I-PAR
men	NN	O	I-PAR
.	NN	O	O

To	NN	O	O
study	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
physical	NN	O	B-INT
exercise	NN	O	I-INT
on	NN	O	O
biochemical	NN	O	B-OUT
risk	NN	O	I-OUT
factors	NN	O	I-OUT
for	NN	O	I-OUT
ischaemic	NN	O	I-OUT
heart	NN	O	I-OUT
disease	NN	O	I-OUT
31	NN	O	I-PAR
healthy	NN	O	I-PAR
middle	NN	O	I-PAR
aged	NN	O	I-PAR
men	NN	O	I-PAR
undertook	NN	O	O
regular	NN	O	B-INT
physical	NN	O	I-INT
exercise	NN	O	I-INT
for	NN	O	O
two	NN	O	O
months	NN	O	O
and	NN	O	O
29	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
in	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
men	NN	O	O
taking	NN	O	O
regular	NN	O	O
exercise	NN	O	O
serum	NN	O	B-OUT
cholesterol	NN	O	I-OUT
concentrations	NN	O	I-OUT
increased	NN	O	O
26	NN	O	O
%	NN	O	O
more	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	B-OUT
density	NN	O	I-OUT
lipoprotein	NN	O	I-OUT
subfraction	NN	O	I-OUT
two	NN	O	I-OUT
(	NN	O	I-OUT
HDL2	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
decreased	NN	O	O
31	NN	O	O
%	NN	O	O
more	NN	O	O
in	NN	O	O
the	NN	O	O
subfraction	NN	O	B-OUT
three	NN	O	I-OUT
(	NN	O	I-OUT
HDL3	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
9	NN	O	O
%	NN	O	O
more	NN	O	O
in	NN	O	O
the	NN	O	O
low	NN	O	B-OUT
density	NN	O	I-OUT
lipoprotein	NN	O	I-OUT
fraction	NN	O	I-OUT
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

A	NN	O	O
tendency	NN	O	O
towards	NN	O	O
increased	NN	O	O
plasma	NN	O	B-OUT
6-keto-prostaglandin	NN	O	I-OUT
F1	NN	O	I-OUT
alpha	NN	O	I-OUT
concentration	NN	O	I-OUT
and	NN	O	O
decreased	NN	O	O
serum	NN	O	B-OUT
thromboxane	NN	O	I-OUT
B2	NN	O	I-OUT
concentration	NN	O	I-OUT
was	NN	O	O
found	NN	O	O
during	NN	O	O
the	NN	O	O
period	NN	O	O
of	NN	O	O
regular	NN	O	O
exercise	NN	O	B-INT
,	NN	O	O
but	NN	O	O
prostaglandin	NN	O	B-OUT
E2	NN	O	I-OUT
concentrations	NN	O	I-OUT
remained	NN	O	O
unchanged	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
in	NN	O	O
plasma	NN	O	B-OUT
6-keto-prostaglandin	NN	O	I-OUT
F1	NN	O	I-OUT
alpha	NN	O	I-OUT
concentration	NN	O	I-OUT
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	B-OUT
HDL2	NN	O	I-OUT
cholesterol	NN	O	I-OUT
concentration	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
group	NN	O	O
taking	NN	O	O
regular	NN	O	O
exercise	NN	O	B-INT
.	NN	O	O

Our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
mild	NN	O	B-INT
regular	NN	O	I-INT
physical	NN	O	I-INT
exercise	NN	O	I-INT
favourably	NN	O	O
influences	NN	O	O
cholesterol	NN	O	O
distribution	NN	O	O
in	NN	O	O
serum	NN	O	B-OUT
lipoproteins	NN	O	I-OUT
in	NN	O	O
healthy	NN	O	B-PAR
middle	NN	O	I-PAR
aged	NN	O	I-PAR
men	NN	O	I-PAR
and	NN	O	O
may	NN	O	O
have	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
on	NN	O	O
circulating	NN	O	B-OUT
metabolites	NN	O	I-OUT
of	NN	O	I-OUT
arachidonic	NN	O	I-OUT
acid	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (6920252)

Experimental	NN	O	O
hyaline	NN	O	O
membrane	NN	O	O
disease	NN	O	O
in	NN	O	O
the	NN	O	B-PAR
premature	NN	O	I-PAR
monkey	NN	O	I-PAR
:	NN	O	O
effects	NN	O	O
of	NN	O	O
antenatal	NN	O	O
dexamethasone	NN	O	B-INT
.	NN	O	O

A	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
antenatal	NN	O	O
glucocorticoid	NN	O	B-INT
treatment	NN	O	O
was	NN	O	O
conducted	NN	O	O
using	NN	O	O
the	NN	O	O
premature	NN	O	B-PAR
monkey	NN	O	I-PAR
(	NN	O	I-PAR
Macaca	NN	O	I-PAR
nemestrina	NN	O	I-PAR
)	NN	O	I-PAR
model	NN	O	I-PAR
of	NN	O	I-PAR
hyaline	NN	O	I-PAR
membrane	NN	O	I-PAR
disease	NN	O	I-PAR
(	NN	O	I-PAR
HMD	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Twelve	NN	O	B-PAR
dams	NN	O	I-PAR
received	NN	O	O
dexamethasone	NN	O	B-INT
(	NN	O	O
2	NN	O	O
mg/dose	NN	O	O
)	NN	O	O
72	NN	O	O
,	NN	O	O
48	NN	O	O
,	NN	O	O
and	NN	O	O
24	NN	O	O
h	NN	O	O
before	NN	O	O
abdominal	NN	O	O
delivery	NN	O	O
at	NN	O	O
135	NN	O	O
+/-	NN	O	O
1	NN	O	O
days	NN	O	O
of	NN	O	O
gestation	NN	O	O
.	NN	O	O

Twelve	NN	O	B-PAR
control	NN	O	I-PAR
animals	NN	O	I-PAR
received	NN	O	O
saline	NN	O	B-INT
.	NN	O	O

Infants	NN	O	O
of	NN	O	O
dexamethasone-treated	NN	O	B-INT
dams	NN	O	O
had	NN	O	O
significantly	NN	O	O
lower	NN	O	O
incidence	NN	O	B-OUT
and	NN	O	I-OUT
severity	NN	O	I-OUT
of	NN	O	I-OUT
HMD	NN	O	I-OUT
than	NN	O	O
did	NN	O	O
infants	NN	O	O
of	NN	O	O
control	NN	O	O
animals	NN	O	O
(	NN	O	O
50	NN	O	O
versus	NN	O	O
92	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Improvement	NN	O	O
with	NN	O	O
treatment	NN	O	O
was	NN	O	O
markedly	NN	O	O
greater	NN	O	O
for	NN	O	O
males	NN	O	O
than	NN	O	O
for	NN	O	O
females	NN	O	O
.	NN	O	O

Differences	NN	O	O
in	NN	O	O
volume-pressure	NN	O	B-OUT
behavior	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
excised	NN	O	O
lungs	NN	O	O
included	NN	O	O
greater	NN	O	O
distensibility	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
infants	NN	O	O
from	NN	O	O
dexamethasone-treated	NN	O	B-INT
dams	NN	O	O
(	NN	O	O
20.6	NN	O	O
+/-	NN	O	O
7.1	NN	O	O
ml/g	NN	O	O
dry	NN	O	O
lung	NN	O	O
versus	NN	O	O
14.7	NN	O	O
+/-	NN	O	O
6.1	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
enhanced	NN	O	O
deflation	NN	O	B-OUT
stability	NN	O	I-OUT
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

Accelerated	NN	O	O
production	NN	O	B-OUT
of	NN	O	I-OUT
surface	NN	O	I-OUT
active	NN	O	I-OUT
material	NN	O	I-OUT
(	NN	O	I-OUT
SAM	NN	O	I-OUT
)	NN	O	I-OUT
phospholipids	NN	O	I-OUT
in	NN	O	O
infants	NN	O	O
from	NN	O	O
dexamethasone-treated	NN	O	B-INT
dams	NN	O	O
was	NN	O	O
indicated	NN	O	O
by	NN	O	O
increases	NN	O	O
in	NN	O	O
total	NN	O	B-OUT
lung	NN	O	I-OUT
phospholipid	NN	O	I-OUT
(	NN	O	O
84.5	NN	O	O
+/-	NN	O	O
8.1	NN	O	O
mg/g	NN	O	O
dry	NN	O	O
lung	NN	O	O
versus	NN	O	O
75.1	NN	O	O
+/-	NN	O	O
9.9	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.025	NN	O	O
)	NN	O	O
,	NN	O	O
alveolar	NN	O	B-OUT
lavage	NN	O	I-OUT
fluid	NN	O	I-OUT
phospholipid	NN	O	I-OUT
(	NN	O	O
5.65	NN	O	O
+/-	NN	O	O
3.33	NN	O	O
mg/g	NN	O	O
dry	NN	O	O
lung	NN	O	O
versus	NN	O	O
3.01	NN	O	O
+/-	NN	O	O
1.84	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
alveolar	NN	O	B-OUT
lavage	NN	O	I-OUT
fluid	NN	O	I-OUT
disaturated	NN	O	I-OUT
phosphatidylcholine	NN	O	I-OUT
(	NN	O	O
DPC	NN	O	O
)	NN	O	O
(	NN	O	O
2.47	NN	O	O
+/-	NN	O	O
1.84	NN	O	O
mg/g	NN	O	O
dry	NN	O	O
lung	NN	O	O
versus	NN	O	O
1.06	NN	O	O
+/-	NN	O	O
1.05	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Incorporation	NN	O	O
of	NN	O	O
14C-palmitate	NN	O	B-OUT
into	NN	O	O
lung	NN	O	B-OUT
lipid	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
influenced	NN	O	O
by	NN	O	O
dexamethasone	NN	O	B-INT
,	NN	O	O
but	NN	O	O
a	NN	O	O
significantly	NN	O	O
greater	NN	O	O
portion	NN	O	O
of	NN	O	O
the	NN	O	O
label	NN	O	O
appeared	NN	O	O
in	NN	O	O
the	NN	O	O
DPC	NN	O	O
fraction	NN	O	O
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

Antenatal	NN	O	O
dexamethasone	NN	O	B-INT
treatment	NN	O	O
was	NN	O	O
successful	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
and	NN	O	I-OUT
severity	NN	O	I-OUT
of	NN	O	I-OUT
experimental	NN	O	I-OUT
HMD	NN	O	I-OUT
in	NN	O	O
this	NN	O	O
animal	NN	O	O
model	NN	O	O
;	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
treatment	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
accelerated	NN	O	O
maturation	NN	O	O
of	NN	O	O
fetal	NN	O	B-OUT
pulmonary	NN	O	I-OUT
functions	NN	O	I-OUT
,	NN	O	O
including	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
limited	NN	O	O
to	NN	O	O
,	NN	O	O
synthetic	NN	O	O
metabolism	NN	O	O
of	NN	O	O
SAM	NN	O	O
phospholipid	NN	O	O
.	NN	O	O



--DOCSTART-- (6938020)

EORTC	NN	O	O
protocols	NN	O	O
in	NN	O	O
prostatic	NN	O	B-PAR
cancer	NN	O	I-PAR
.	NN	O	O

An	NN	O	O
interim	NN	O	O
report	NN	O	O
.	NN	O	O

Two	NN	O	O
parallel	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
studies	NN	O	O
have	NN	O	O
been	NN	O	O
undertaken	NN	O	O
by	NN	O	O
the	NN	O	O
EORTC	NN	O	O
Urological	NN	O	O
Group	NN	O	O
in	NN	O	O
previously	NN	O	B-PAR
untreated	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
prostatic	NN	O	I-PAR
cancer	NN	O	I-PAR
in	NN	O	O
order	NN	O	O
to	NN	O	O
compare	NN	O	O
low	NN	O	O
dose	NN	O	O
Stilboestrol	NN	O	B-INT
versus	NN	O	O
Cyproterone	NN	O	B-INT
acetate	NN	O	I-INT
versus	NN	O	O
Medroxyprogesterone	NN	O	B-INT
acetate	NN	O	I-INT
in	NN	O	O
the	NN	O	O
first	NN	O	O
trial	NN	O	O
,	NN	O	O
and	NN	O	O
Stilboestrol	NN	O	B-INT
versus	NN	O	O
Estracyt	NN	O	B-INT
in	NN	O	O
the	NN	O	O
second	NN	O	O
trial	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
follow	NN	O	O
up	NN	O	O
is	NN	O	O
still	NN	O	O
short	NN	O	O
,	NN	O	O
no	NN	O	O
superiority	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
drugs	NN	O	O
over	NN	O	O
Stilboestrol	NN	O	B-INT
had	NN	O	O
appeared	NN	O	O
so	NN	O	O
far	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
either	NN	O	O
objective	NN	O	O
response	NN	O	O
or	NN	O	O
significant	NN	O	O
side	NN	O	B-OUT
effects	NN	O	I-OUT
apart	NN	O	O
from	NN	O	O
gynaecomastia	NN	O	B-OUT
.	NN	O	O

In	NN	O	O
the	NN	O	O
third	NN	O	O
trial	NN	O	O
,	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
advanced	NN	O	I-PAR
disease	NN	O	I-PAR
no	NN	O	I-PAR
longer	NN	O	I-PAR
responsive	NN	O	I-PAR
to	NN	O	I-PAR
hormonal	NN	O	I-PAR
treatment	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
either	NN	O	O
Adriamycin	NN	O	B-INT
or	NN	O	O
Procarbazine	NN	O	B-INT
.	NN	O	O

Toxicity	NN	O	B-OUT
and	NN	O	I-OUT
early	NN	O	I-OUT
death	NN	O	I-OUT
were	NN	O	O
particularly	NN	O	O
frequent	NN	O	O
in	NN	O	O
Procarbazine	NN	O	B-INT
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
whereas	NN	O	O
most	NN	O	O
patients	NN	O	O
progressed	NN	O	O
in	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O



--DOCSTART-- (6951573)

A	NN	O	O
controlled	NN	O	O
study	NN	O	O
of	NN	O	O
psychiatric	NN	O	B-INT
hospital	NN	O	I-INT
versus	NN	O	O
community	NN	O	B-INT
treatment	NN	O	I-INT
-	NN	O	O
the	NN	O	O
effect	NN	O	B-OUT
on	NN	O	I-OUT
relatives	NN	O	I-OUT
.	NN	O	O

One	NN	O	B-PAR
hundred	NN	O	I-PAR
and	NN	O	I-PAR
twenty	NN	O	I-PAR
patients	NN	O	I-PAR
presenting	NN	O	I-PAR
at	NN	O	I-PAR
Macquarie	NN	O	I-PAR
Hospital	NN	O	I-PAR
for	NN	O	I-PAR
admission	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
patients	NN	O	O
received	NN	O	O
standard	NN	O	B-INT
hospital	NN	O	I-INT
care	NN	O	I-INT
and	NN	O	I-INT
follow-up	NN	O	I-INT
.	NN	O	O

The	NN	O	O
project	NN	O	O
group	NN	O	O
patients	NN	O	O
were	NN	O	O
not	NN	O	O
admitted	NN	O	O
if	NN	O	O
this	NN	O	O
could	NN	O	O
be	NN	O	O
avoided	NN	O	O
;	NN	O	O
instead	NN	O	O
they	NN	O	O
were	NN	O	O
taken	NN	O	O
back	NN	O	B-INT
to	NN	O	I-INT
the	NN	O	I-INT
community	NN	O	I-INT
by	NN	O	O
the	NN	O	O
project	NN	O	O
team	NN	O	O
who	NN	O	O
provided	NN	O	O
them	NN	O	O
and	NN	O	O
their	NN	O	O
relatives	NN	O	O
with	NN	O	O
comprehensive	NN	O	O
,	NN	O	O
assertive	NN	O	O
and	NN	O	O
prolonged	NN	O	O
follow-up	NN	O	B-INT
treatment	NN	O	I-INT
backed	NN	O	O
by	NN	O	O
a	NN	O	O
24-hour	NN	O	O
crisis	NN	O	O
service	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
project	NN	O	O
group	NN	O	O
had	NN	O	O
no	NN	O	O
admission	NN	O	O
during	NN	O	O
the	NN	O	O
10	NN	O	O
month	NN	O	O
study	NN	O	O
period	NN	O	O
.	NN	O	O

Initially	NN	O	O
,	NN	O	O
the	NN	O	O
burden	NN	O	B-OUT
on	NN	O	I-OUT
the	NN	O	I-OUT
relatives	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
project	NN	O	O
group	NN	O	O
was	NN	O	O
higher	NN	O	O
,	NN	O	O
but	NN	O	O
by	NN	O	O
one	NN	O	O
month	NN	O	O
it	NN	O	O
was	NN	O	O
somewhat	NN	O	O
lower	NN	O	O
and	NN	O	O
by	NN	O	O
four	NN	O	O
months	NN	O	O
it	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
burden	NN	O	O
on	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
relatives	NN	O	O
.	NN	O	O

Relatives	NN	O	O
of	NN	O	O
the	NN	O	O
project	NN	O	O
group	NN	O	O
patients	NN	O	O
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
satisfied	NN	O	B-OUT
with	NN	O	O
the	NN	O	O
treatment	NN	O	O
than	NN	O	O
control	NN	O	O
group	NN	O	O
relatives	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
clearly	NN	O	O
feasible	NN	O	O
to	NN	O	O
treat	NN	O	O
most	NN	O	O
psychiatric	NN	O	B-PAR
patients	NN	O	I-PAR
in	NN	O	O
the	NN	O	O
community	NN	O	O
without	NN	O	O
increasing	NN	O	O
the	NN	O	O
burden	NN	O	B-OUT
on	NN	O	I-OUT
their	NN	O	I-OUT
relatives	NN	O	I-OUT
.	NN	O	O



--DOCSTART-- (6989377)

Changes	NN	O	O
in	NN	O	O
the	NN	O	O
fatty	NN	O	B-OUT
acid	NN	O	I-OUT
composition	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
plasma	NN	O	I-OUT
lipid	NN	O	I-OUT
esters	NN	O	I-OUT
during	NN	O	O
lipid-lowering	NN	O	O
treatment	NN	O	O
with	NN	O	O
diet	NN	O	B-INT
,	NN	O	O
clofibrate	NN	O	B-INT
and	NN	O	O
niceritrol	NN	O	B-INT
.	NN	O	O

Reduction	NN	O	O
of	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
linoleate	NN	O	B-OUT
by	NN	O	O
clofibrate	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
niceritrol	NN	O	O
.	NN	O	O

The	NN	O	O
fatty	NN	O	B-OUT
acid	NN	O	I-OUT
composition	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
plasma	NN	O	I-OUT
lipid	NN	O	I-OUT
esters	NN	O	I-OUT
has	NN	O	O
been	NN	O	O
studied	NN	O	O
during	NN	O	O
lipid-lowering	NN	O	O
treatment	NN	O	O
of	NN	O	O
95	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
atherosclerotic	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O

During	NN	O	O
the	NN	O	O
first	NN	O	O
two	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
trial	NN	O	O
only	NN	O	O
a	NN	O	O
diet	NN	O	O
was	NN	O	O
prescribed	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
ensuing	NN	O	O
two	NN	O	O
months	NN	O	O
either	NN	O	O
clofibrate	NN	O	B-INT
or	NN	O	O
niceritrol	NN	O	B-INT
,	NN	O	O
a	NN	O	O
nicotinic	NN	O	O
acid	NN	O	O
ester	NN	O	O
,	NN	O	O
was	NN	O	O
added	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
order	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
last	NN	O	O
two	NN	O	O
months	NN	O	O
the	NN	O	O
second	NN	O	O
drug	NN	O	O
was	NN	O	O
added	NN	O	O
.	NN	O	O

The	NN	O	O
combined	NN	O	O
treatment	NN	O	O
with	NN	O	O
diet	NN	O	B-INT
,	NN	O	O
clofibrate	NN	O	B-INT
and	NN	O	O
niceritrol	NN	O	B-INT
caused	NN	O	O
highly	NN	O	O
significant	NN	O	O
serum	NN	O	B-OUT
lipid	NN	O	I-OUT
reductions	NN	O	O
.	NN	O	O

The	NN	O	O
fatty	NN	O	B-OUT
acid	NN	O	I-OUT
composition	NN	O	I-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
plasma	NN	O	I-OUT
lipid	NN	O	I-OUT
esters	NN	O	I-OUT
was	NN	O	O
determined	NN	O	O
in	NN	O	O
samples	NN	O	O
from	NN	O	O
each	NN	O	O
trial	NN	O	O
period	NN	O	O
to	NN	O	O
measure	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
dietary	NN	O	O
adherence	NN	O	O
.	NN	O	O

During	NN	O	O
dietary	NN	O	O
treatment	NN	O	O
the	NN	O	O
relative	NN	O	O
content	NN	O	B-OUT
of	NN	O	I-OUT
saturated	NN	O	I-OUT
and	NN	O	I-OUT
monounsaturated	NN	O	I-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
secreased	NN	O	O
and	NN	O	O
the	NN	O	O
polyunsaturated	NN	O	B-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
increased	NN	O	O
with	NN	O	O
an	NN	O	O
increasing	NN	O	O
ratio	NN	O	B-OUT
between	NN	O	I-OUT
pulyunsaturated	NN	O	I-OUT
and	NN	O	I-OUT
saturated	NN	O	I-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
(	NN	O	I-OUT
P/S	NN	O	I-OUT
ratio	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
the	NN	O	O
cholesterol	NN	O	O
esters	NN	O	O
and	NN	O	O
triglycerides	NN	O	O
.	NN	O	O

Only	NN	O	O
minor	NN	O	O
changes	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
phospholipids	NN	O	B-OUT
.	NN	O	O

The	NN	O	O
changes	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
diet	NN	O	B-INT
were	NN	O	O
partly	NN	O	O
reversed	NN	O	O
by	NN	O	O
clofibrate	NN	O	B-INT
while	NN	O	O
niceritrol	NN	O	B-INT
did	NN	O	O
not	NN	O	O
cause	NN	O	O
any	NN	O	O
major	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
fatty	NN	O	B-OUT
acid	NN	O	I-OUT
composition	NN	O	I-OUT
.	NN	O	O

Clofibrate	NN	O	B-INT
treatment	NN	O	O
coincided	NN	O	O
with	NN	O	O
increasing	NN	O	O
amounts	NN	O	O
of	NN	O	O
monounsaturated	NN	O	B-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
,	NN	O	O
especially	NN	O	O
oleate	NN	O	B-OUT
(	NN	O	O
18	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
cholesterol	NN	O	O
esters	NN	O	O
,	NN	O	O
triglycerides	NN	O	B-OUT
and	NN	O	I-OUT
phospholipids	NN	O	I-OUT
while	NN	O	O
there	NN	O	O
were	NN	O	O
significant	NN	O	O
reductions	NN	O	O
of	NN	O	O
the	NN	O	O
content	NN	O	B-OUT
of	NN	O	I-OUT
linoleic	NN	O	I-OUT
(	NN	O	I-OUT
18	NN	O	I-OUT
:	NN	O	I-OUT
2	NN	O	I-OUT
)	NN	O	I-OUT
acid	NN	O	I-OUT
in	NN	O	O
both	NN	O	O
the	NN	O	O
cholesterol	NN	O	O
esters	NN	O	O
and	NN	O	O
triglycerides	NN	O	O
.	NN	O	O

The	NN	O	O
18	NN	O	O
:	NN	O	O
2/18	NN	O	O
:	NN	O	O
1	NN	O	O
ratio	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
lipid	NN	O	O
esters	NN	O	O
analyzed	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
P/S	NN	O	B-OUT
ratio	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
affected	NN	O	O
,	NN	O	O
partly	NN	O	O
because	NN	O	O
the	NN	O	O
relative	NN	O	O
content	NN	O	O
of	NN	O	O
saturated	NN	O	B-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
also	NN	O	O
tended	NN	O	O
to	NN	O	O
decrease	NN	O	O
during	NN	O	O
clofibrate	NN	O	O
treatment	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
addition	NN	O	O
of	NN	O	O
clofibrate	NN	O	O
treatment	NN	O	O
to	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
on	NN	O	O
a	NN	O	O
diet	NN	O	O
enriched	NN	O	O
with	NN	O	O
polyunsaturated	NN	O	O
fats	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
change	NN	O	O
from	NN	O	O
polyunsaturated	NN	O	B-OUT
to	NN	O	I-OUT
monounsaturated	NN	O	I-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
plasma	NN	O	I-OUT
lipid	NN	O	I-OUT
esters	NN	O	I-OUT
but	NN	O	O
does	NN	O	O
not	NN	O	O
significantly	NN	O	O
effect	NN	O	O
the	NN	O	O
ratio	NN	O	B-OUT
between	NN	O	I-OUT
polyunsaturated	NN	O	I-OUT
and	NN	O	I-OUT
saturated	NN	O	I-OUT
fatty	NN	O	I-OUT
acids	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
fatty	NN	O	O
acid	NN	O	B-OUT
changes	NN	O	I-OUT
caused	NN	O	O
by	NN	O	O
clofibrate	NN	O	B-INT
treatment	NN	O	O
and	NN	O	O
counteracted	NN	O	O
by	NN	O	O
an	NN	O	O
increased	NN	O	O
amount	NN	O	O
of	NN	O	O
polyunsaturated	NN	O	O
fat	NN	O	O
in	NN	O	O
the	NN	O	O
diet	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (7017018)

Bacteremia	NN	O	O
due	NN	O	O
to	NN	O	O
Bacteroides	NN	O	O
fragilis	NN	O	O
after	NN	O	O
elective	NN	O	B-PAR
appendectomy	NN	O	I-PAR
in	NN	O	I-PAR
renal	NN	O	I-PAR
transplant	NN	O	I-PAR
recipients	NN	O	I-PAR
.	NN	O	O

Bacteremia	NN	O	O
caused	NN	O	O
by	NN	O	O
Bacteroides	NN	O	O
fragilis	NN	O	O
occurred	NN	O	O
in	NN	O	O
four	NN	O	O
of	NN	O	O
75	NN	O	B-PAR
children	NN	O	I-PAR
after	NN	O	I-PAR
renal	NN	O	I-PAR
transplantation	NN	O	I-PAR
,	NN	O	O
and	NN	O	O
B.	NN	O	O
fragilis	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
postoperative	NN	O	O
bacteremia	NN	O	O
.	NN	O	O

Bacteroides	NN	O	O
bacteremia	NN	O	O
was	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
performance	NN	O	O
of	NN	O	O
elective	NN	O	O
appendectomy	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
transplantation	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
with	NN	O	O
profound	NN	O	O
lymphocytopenia	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
received	NN	O	O
antibiotics	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
surgery	NN	O	O
or	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
first	NN	O	O
positive	NN	O	O
blood	NN	O	O
culture	NN	O	O
,	NN	O	O
yet	NN	O	O
B.	NN	O	O
fragilis	NN	O	O
was	NN	O	O
the	NN	O	O
single	NN	O	O
organism	NN	O	O
isolated	NN	O	O
from	NN	O	O
blood	NN	O	O
and	NN	O	O
abscesses	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
role	NN	O	O
for	NN	O	O
lymphocytes	NN	O	O
in	NN	O	O
containment	NN	O	O
of	NN	O	O
B.	NN	O	O
fragilis	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
suggested	NN	O	O
previously	NN	O	O
,	NN	O	O
although	NN	O	O
unexplained	NN	O	O
occurrence	NN	O	B-OUT
of	NN	O	I-OUT
bacteroides	NN	O	I-OUT
bacteremia	NN	O	I-OUT
in	NN	O	O
immunocompromised	NN	O	O
patients	NN	O	O
has	NN	O	O
occasionally	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

Lymphocytes	NN	O	O
themselves	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
this	NN	O	O
host-bacterium	NN	O	O
interaction	NN	O	O
,	NN	O	O
or	NN	O	O
lymphocytopenia	NN	O	B-OUT
may	NN	O	O
be	NN	O	O
the	NN	O	O
marker	NN	O	O
for	NN	O	O
a	NN	O	O
more	NN	O	O
generalized	NN	O	O
deficiency	NN	O	O
in	NN	O	O
host	NN	O	O
defenses	NN	O	O
.	NN	O	O



--DOCSTART-- (7598243)

The	NN	O	O
efficacy	NN	O	O
of	NN	O	O
prophylactic	NN	O	O
ondansetron	NN	O	B-INT
,	NN	O	O
droperidol	NN	O	B-INT
,	NN	O	O
perphenazine	NN	O	B-INT
,	NN	O	O
and	NN	O	O
metoclopramide	NN	O	B-INT
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
nausea	NN	O	O
and	NN	O	O
vomiting	NN	O	O
after	NN	O	O
major	NN	O	O
gynecologic	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
prophylactic	NN	O	O
antiemetic	NN	O	O
efficacy	NN	O	O
of	NN	O	O
intravenous	NN	O	O
(	NN	O	O
i.v	NN	O	O
.	NN	O	O

)	NN	O	O
ondansetron	NN	O	B-INT
,	NN	O	O
droperidol	NN	O	B-INT
,	NN	O	O
perphenazine	NN	O	B-INT
,	NN	O	O
and	NN	O	O
metoclopramide	NN	O	B-INT
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
double-blind	NN	O	O
study	NN	O	O
of	NN	O	O
360	NN	O	B-PAR
ASA	NN	O	I-PAR
physical	NN	O	I-PAR
status	NN	O	I-PAR
I-III	NN	O	I-PAR
patients	NN	O	I-PAR
undergoing	NN	O	I-PAR
total	NN	O	I-PAR
abdominal	NN	O	I-PAR
hysterectomy	NN	O	I-PAR
(	NN	O	I-PAR
TAH	NN	O	I-PAR
)	NN	O	I-PAR
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
i.v.	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
ondansetron	NN	O	B-INT
4	NN	O	O
mg	NN	O	O
,	NN	O	O
droperidol	NN	O	B-INT
1.25	NN	O	O
mg	NN	O	O
,	NN	O	O
perphenazine	NN	O	B-INT
5	NN	O	O
mg	NN	O	O
,	NN	O	O
metoclopramide	NN	O	B-INT
10	NN	O	O
mg	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
prior	NN	O	O
to	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Hypotension	NN	O	B-OUT
immediately	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-INT
was	NN	O	O
observed	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
and	NN	O	O
four	NN	O	O
patients	NN	O	O
given	NN	O	O
ondansetron	NN	O	O
developed	NN	O	O
profound	NN	O	O
systolic	NN	O	O
hypotension	NN	O	O
at	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Twenty-two	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
droperidol	NN	O	O
became	NN	O	O
sedated	NN	O	O
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
patients	NN	O	O
developing	NN	O	O
severe	NN	O	B-OUT
nausea	NN	O	I-OUT
,	NN	O	I-OUT
retching	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
vomiting	NN	O	I-OUT
,	NN	O	O
defined	NN	O	O
as	NN	O	O
severe	NN	O	B-OUT
emetic	NN	O	I-OUT
sequelae	NN	O	I-OUT
(	NN	O	I-OUT
SES	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
were	NN	O	O
deemed	NN	O	O
to	NN	O	O
have	NN	O	O
failed	NN	O	O
antiemetic	NN	O	O
prophylaxis	NN	O	O
and	NN	O	O
received	NN	O	O
antiemetic	NN	O	O
rescue	NN	O	O
.	NN	O	O

A	NN	O	O
significantly	NN	O	O
larger	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
i.v	NN	O	O
.	NN	O	O

ondansetron	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
droperidol	NN	O	O
(	NN	O	O
76	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
perphenazine	NN	O	O
(	NN	O	O
70	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
free	NN	O	O
of	NN	O	O
SES	NN	O	B-OUT
when	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	O
(	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
.	NN	O	O

Metoclopramide	NN	O	O
was	NN	O	O
ineffective	NN	O	O
.	NN	O	O

Although	NN	O	O
ondansetron	NN	O	O
,	NN	O	O
droperidol	NN	O	O
,	NN	O	O
and	NN	O	O
perphenazine	NN	O	O
were	NN	O	O
effective	NN	O	B-OUT
in	NN	O	O
providing	NN	O	O
antiemetic	NN	O	O
prophylaxis	NN	O	O
,	NN	O	O
only	NN	O	O
i.v	NN	O	O
.	NN	O	O

perphenazine	NN	O	O
was	NN	O	O
free	NN	O	O
of	NN	O	O
side	NN	O	B-OUT
effects	NN	O	I-OUT
.	NN	O	O

Hence	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
perphenazine	NN	O	O
is	NN	O	O
the	NN	O	O
best	NN	O	O
choice	NN	O	O
for	NN	O	O
antiemetic	NN	O	O
prophylaxis	NN	O	O
after	NN	O	O
TAH	NN	O	O
.	NN	O	O



--DOCSTART-- (7707420)

Effects	NN	O	O
of	NN	O	O
individualized	NN	O	B-INT
breast	NN	O	I-INT
cancer	NN	O	I-INT
risk	NN	O	I-INT
counseling	NN	O	I-INT
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Studies	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
a	NN	O	O
majority	NN	O	O
of	NN	O	O
women	NN	O	B-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
family	NN	O	I-PAR
history	NN	O	I-PAR
of	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
have	NN	O	O
exaggerated	NN	O	O
perceptions	NN	O	O
of	NN	O	O
their	NN	O	O
own	NN	O	O
risk	NN	O	O
of	NN	O	O
this	NN	O	O
disease	NN	O	O
and	NN	O	O
experience	NN	O	O
excessive	NN	O	O
anxiety	NN	O	O
.	NN	O	O

In	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
need	NN	O	O
to	NN	O	O
communicate	NN	O	O
more	NN	O	O
accurate	NN	O	O
risk	NN	O	O
information	NN	O	O
to	NN	O	O
these	NN	O	O
women	NN	O	O
,	NN	O	O
specialized	NN	O	O
programs	NN	O	O
for	NN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
counseling	NN	O	O
have	NN	O	O
been	NN	O	O
initiated	NN	O	O
in	NN	O	O
medical	NN	O	O
centers	NN	O	O
across	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
Our	NN	O	O
purpose	NN	O	O
was	NN	O	O
1	NN	O	O
)	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
a	NN	O	O
standardized	NN	O	O
protocol	NN	O	O
for	NN	O	O
individualized	NN	O	B-INT
breast	NN	O	I-INT
cancer	NN	O	I-INT
risk	NN	O	I-INT
counseling	NN	O	I-INT
on	NN	O	O
comprehension	NN	O	O
of	NN	O	O
personal	NN	O	O
risk	NN	O	O
among	NN	O	O
first-degree	NN	O	B-PAR
relatives	NN	O	I-PAR
of	NN	O	I-PAR
index	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
and	NN	O	O
2	NN	O	O
)	NN	O	O
to	NN	O	O
identify	NN	O	O
women	NN	O	O
most	NN	O	O
and	NN	O	O
least	NN	O	O
likely	NN	O	O
to	NN	O	O
benefit	NN	O	O
from	NN	O	O
such	NN	O	O
counseling	NN	O	O
.	NN	O	O

METHODS	NN	O	O
This	NN	O	O
study	NN	O	O
is	NN	O	O
a	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
trial	NN	O	O
comparing	NN	O	O
individualized	NN	O	B-INT
breast	NN	O	I-INT
cancer	NN	O	I-INT
risk	NN	O	I-INT
counseling	NN	O	I-INT
to	NN	O	O
general	NN	O	B-INT
health	NN	O	I-INT
counseling	NN	O	I-INT
(	NN	O	I-INT
control	NN	O	I-INT
)	NN	O	I-INT
.	NN	O	O

We	NN	O	O
studied	NN	O	O
200	NN	O	B-PAR
women	NN	O	I-PAR
aged	NN	O	I-PAR
35	NN	O	I-PAR
years	NN	O	I-PAR
and	NN	O	I-PAR
older	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
a	NN	O	I-PAR
family	NN	O	I-PAR
history	NN	O	I-PAR
of	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
in	NN	O	I-PAR
a	NN	O	I-PAR
first-degree	NN	O	I-PAR
relative	NN	O	I-PAR
.	NN	O	O

Women	NN	O	B-PAR
with	NN	O	I-PAR
a	NN	O	I-PAR
personal	NN	O	I-PAR
history	NN	O	I-PAR
of	NN	O	I-PAR
cancer	NN	O	I-PAR
were	NN	O	I-PAR
excluded	NN	O	I-PAR
.	NN	O	O

Risk	NN	O	B-OUT
comprehension	NN	O	I-OUT
was	NN	O	O
assessed	NN	O	O
as	NN	O	O
the	NN	O	O
concordance	NN	O	O
between	NN	O	O
perceived	NN	O	O
subjective	NN	O	O
lifetime	NN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
and	NN	O	O
estimated	NN	O	O
objective	NN	O	O
lifetime	NN	O	O
risk	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
women	NN	O	O
who	NN	O	O
received	NN	O	O
risk	NN	O	B-INT
counseling	NN	O	I-INT
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
improve	NN	O	O
their	NN	O	O
risk	NN	O	B-OUT
comprehension	NN	O	I-OUT
,	NN	O	O
compared	NN	O	O
with	NN	O	O
women	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
condition	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
[	NN	O	O
OR	NN	O	O
]	NN	O	O
=	NN	O	O
3.5	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
=	NN	O	O
1.3-9.5	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.01	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
about	NN	O	O
two	NN	O	O
thirds	NN	O	O
of	NN	O	O
women	NN	O	O
continued	NN	O	O
to	NN	O	O
overestimate	NN	O	O
their	NN	O	O
lifetime	NN	O	B-OUT
risks	NN	O	I-OUT
substantially	NN	O	O
following	NN	O	O
counseling	NN	O	O
.	NN	O	O

Examination	NN	O	O
of	NN	O	O
subjects	NN	O	O
by	NN	O	O
treatment	NN	O	O
interaction	NN	O	O
effects	NN	O	O
indicated	NN	O	O
that	NN	O	O
risk	NN	O	B-INT
counseling	NN	O	I-INT
did	NN	O	O
not	NN	O	O
produce	NN	O	O
improved	NN	O	O
comprehension	NN	O	B-OUT
among	NN	O	O
the	NN	O	O
large	NN	O	O
proportion	NN	O	O
of	NN	O	O
women	NN	O	O
who	NN	O	O
had	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
anxious	NN	O	O
preoccupation	NN	O	O
with	NN	O	O
breast	NN	O	O
cancer	NN	O	O
at	NN	O	O
base	NN	O	O
line	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.02	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
white	NN	O	O
women	NN	O	O
were	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
benefit	NN	O	O
than	NN	O	O
African-American	NN	O	O
women	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
0.34	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
0.11-0.99	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
Efforts	NN	O	O
to	NN	O	O
counsel	NN	O	O
women	NN	O	O
about	NN	O	O
their	NN	O	O
breast	NN	O	O
cancer	NN	O	O
risks	NN	O	O
are	NN	O	O
not	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
unless	NN	O	O
their	NN	O	O
breast	NN	O	O
cancer	NN	O	O
anxieties	NN	O	O
are	NN	O	O
also	NN	O	O
addressed	NN	O	O
.	NN	O	O

IMPLICATIONS	NN	O	O
Attention	NN	O	O
to	NN	O	O
the	NN	O	O
psychological	NN	O	O
aspects	NN	O	O
of	NN	O	O
breast	NN	O	O
cancer	NN	O	O
risk	NN	O	O
will	NN	O	O
be	NN	O	O
critical	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
risk-counseling	NN	O	B-INT
programs	NN	O	I-INT
that	NN	O	O
incorporate	NN	O	O
testing	NN	O	O
for	NN	O	O
the	NN	O	O
recently	NN	O	O
cloned	NN	O	O
breast	NN	O	O
cancer	NN	O	O
susceptibility	NN	O	O
gene	NN	O	O
,	NN	O	O
BRCA1	NN	O	O
(	NN	O	O
and	NN	O	O
BRCA2	NN	O	O
when	NN	O	O
that	NN	O	O
gene	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
cloned	NN	O	O
)	NN	O	O
.	NN	O	O



--DOCSTART-- (7808649)

[	NN	O	O
Double-blind	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
effectiveness	NN	O	B-OUT
and	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
10	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
ketorolac	NN	O	B-INT
tromethamine	NN	O	I-INT
suppositories	NN	O	O
in	NN	O	O
post-cholecystectomy	NN	O	B-PAR
pain	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	B-OUT
and	NN	O	O
tolerability	NN	O	B-OUT
of	NN	O	O
ketorolac	NN	O	B-INT
tromethamine	NN	O	I-INT
10	NN	O	O
mg	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
suppositories	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
after	NN	O	O
single	NN	O	O
dose	NN	O	O
administration	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
suffering	NN	O	I-PAR
from	NN	O	I-PAR
post-operative	NN	O	I-PAR
pain	NN	O	I-PAR
after	NN	O	I-PAR
cholecystectomy	NN	O	I-PAR
.	NN	O	O

DESIGN	NN	O	O
Double-blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
Anaesthesia	NN	O	O
Service	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
99	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
severe	NN	O	I-PAR
pain	NN	O	I-PAR
following	NN	O	I-PAR
surgery	NN	O	I-PAR
.	NN	O	O

INTERVENTIONS	NN	O	O
Cholecystectomy	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
The	NN	O	O
analgesia	NN	O	O
activity	NN	O	O
of	NN	O	O
ketorolac	NN	O	B-INT
tromethamine	NN	O	I-INT
10	NN	O	O
mg	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
suppositories	NN	O	O
were	NN	O	O
evaluated	NN	O	O
after	NN	O	O
single	NN	O	O
dose	NN	O	O
administration	NN	O	O
by	NN	O	O
assessing	NN	O	O
pain	NN	O	B-OUT
intensity	NN	O	I-OUT
and	NN	O	I-OUT
pain	NN	O	I-OUT
relief	NN	O	I-OUT
using	NN	O	O
a	NN	O	O
4	NN	O	B-OUT
point	NN	O	I-OUT
scale	NN	O	I-OUT
(	NN	O	I-OUT
VRS	NN	O	I-OUT
)	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
period	NN	O	O
overall	NN	O	O
assessment	NN	O	O
of	NN	O	O
safety	NN	O	B-OUT
and	NN	O	O
efficacy	NN	O	B-OUT
were	NN	O	O
recorded	NN	O	O
by	NN	O	O
physician	NN	O	O
and	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
in	NN	O	O
both	NN	O	O
active	NN	O	O
groups	NN	O	O
after	NN	O	O
30	NN	O	O
'	NN	O	O
and	NN	O	O
until	NN	O	O
4	NN	O	O
hours	NN	O	O
,	NN	O	O
pain	NN	O	B-OUT
intensity	NN	O	I-OUT
decreased	NN	O	O
significantly	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
baseline	NN	O	O
.	NN	O	O

However	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
of	NN	O	O
p	NN	O	O
<	NN	O	O
0.02	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
and	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
favour	NN	O	O
of	NN	O	O
the	NN	O	O
30	NN	O	O
mg	NN	O	O
dose	NN	O	O
respectively	NN	O	O
at	NN	O	O
30	NN	O	O
'	NN	O	O
,	NN	O	O
6	NN	O	O
and	NN	O	O
8	NN	O	O
hours	NN	O	O
after	NN	O	O
administration	NN	O	O
.	NN	O	O

All	NN	O	O
the	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
placebo	NN	O	B-INT
suppositories	NN	O	O
required	NN	O	O
another	NN	O	O
rescue	NN	O	B-OUT
analgesic	NN	O	I-OUT
drug	NN	O	I-OUT
and	NN	O	O
withdrew	NN	O	O
from	NN	O	O
the	NN	O	O
trial	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
complained	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
not	NN	O	O
related	NN	O	O
to	NN	O	O
treatment	NN	O	O
:	NN	O	O
two	NN	O	O
on	NN	O	O
placebo	NN	O	O
and	NN	O	O
one	NN	O	O
on	NN	O	O
ketorolac	NN	O	O
10	NN	O	O
mg	NN	O	O
.	NN	O	O

The	NN	O	O
systemic	NN	O	B-OUT
and	NN	O	I-OUT
local	NN	O	I-OUT
tolerability	NN	O	I-OUT
of	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
good	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
ketorolac	NN	O	B-INT
30	NN	O	O
mg	NN	O	O
suppositories	NN	O	O
are	NN	O	O
effective	NN	O	O
in	NN	O	O
clinical	NN	O	O
conditions	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
after	NN	O	B-PAR
surgery	NN	O	I-PAR
,	NN	O	O
in	NN	O	O
which	NN	O	O
pain	NN	O	O
control	NN	O	O
must	NN	O	O
be	NN	O	O
achieved	NN	O	O
within	NN	O	O
the	NN	O	O
shortest	NN	O	O
time	NN	O	O
interval	NN	O	O
and	NN	O	O
maintained	NN	O	O
or	NN	O	O
improved	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
route	NN	O	O
of	NN	O	O
administration	NN	O	O
.	NN	O	O



--DOCSTART-- (7814711)

Efficacy	NN	O	O
of	NN	O	O
intramuscular	NN	O	O
oxytetracycline	NN	O	B-INT
as	NN	O	O
a	NN	O	O
dry	NN	O	O
cow	NN	O	O
treatment	NN	O	O
for	NN	O	O
Staphylococcus	NN	O	O
aureus	NN	O	O
mastitis	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
intramuscular	NN	O	O
oxytetracycline	NN	O	B-INT
as	NN	O	O
a	NN	O	O
supplemental	NN	O	O
dry	NN	O	O
cow	NN	O	O
treatment	NN	O	O
for	NN	O	O
Staphylococcus	NN	O	O
aureus	NN	O	O
mastitis	NN	O	O
,	NN	O	O
37	NN	O	B-PAR
Holstein	NN	O	I-PAR
cows	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
two	NN	O	O
treatment	NN	O	O
groups	NN	O	O
:	NN	O	O
intracisternal	NN	O	O
infusion	NN	O	O
with	NN	O	O
a	NN	O	O
commercial	NN	O	O
preparation	NN	O	O
of	NN	O	O
cephapirin	NN	O	B-INT
benzathine	NN	O	I-INT
at	NN	O	O
drying	NN	O	O
off	NN	O	O
(	NN	O	O
20	NN	O	O
cows	NN	O	O
)	NN	O	O
and	NN	O	O
infusion	NN	O	O
with	NN	O	O
cephapirin	NN	O	B-INT
benzathine	NN	O	I-INT
at	NN	O	O
drying	NN	O	O
off	NN	O	O
and	NN	O	O
intramuscular	NN	O	O
oxytetracycline	NN	O	B-INT
at	NN	O	O
11	NN	O	O
mg/kg	NN	O	O
once	NN	O	O
daily	NN	O	O
on	NN	O	O
d	NN	O	O
7	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
9	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
after	NN	O	O
drying	NN	O	O
off	NN	O	O
(	NN	O	O
17	NN	O	O
cows	NN	O	O
)	NN	O	O
.	NN	O	O

Milk	NN	O	O
samples	NN	O	O
collected	NN	O	O
7	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
and	NN	O	O
60	NN	O	O
d	NN	O	O
after	NN	O	O
calving	NN	O	O
were	NN	O	O
plated	NN	O	O
for	NN	O	O
bacterial	NN	O	O
isolation	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
collection	NN	O	O
and	NN	O	O
after	NN	O	O
24	NN	O	O
to	NN	O	O
72	NN	O	O
h	NN	O	O
of	NN	O	O
storage	NN	O	O
at	NN	O	O
-20	NN	O	O
degrees	NN	O	O
C.	NN	O	O
Quarters	NN	O	O
were	NN	O	O
defined	NN	O	O
as	NN	O	O
infected	NN	O	O
if	NN	O	O
S.	NN	O	O
aureus	NN	O	O
was	NN	O	O
isolated	NN	O	O
from	NN	O	O
the	NN	O	O
fresh	NN	O	O
and	NN	O	O
frozen	NN	O	O
cultures	NN	O	O
from	NN	O	O
any	NN	O	O
one	NN	O	O
sample	NN	O	O
collected	NN	O	O
before	NN	O	O
drying	NN	O	O
off	NN	O	O
.	NN	O	O

An	NN	O	O
infected	NN	O	O
quarter	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
cured	NN	O	O
if	NN	O	O
S.	NN	O	O
aureus	NN	O	O
was	NN	O	O
not	NN	O	O
isolated	NN	O	O
from	NN	O	O
the	NN	O	O
fresh	NN	O	O
or	NN	O	O
frozen	NN	O	O
culture	NN	O	O
from	NN	O	O
milk	NN	O	O
samples	NN	O	O
obtained	NN	O	O
following	NN	O	O
calving	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
cure	NN	O	I-OUT
by	NN	O	O
30	NN	O	O
d	NN	O	O
after	NN	O	O
calving	NN	O	O
for	NN	O	O
systemic	NN	O	O
oxytetracycline	NN	O	B-INT
(	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
cephapirin	NN	O	B-INT
treatment	NN	O	O
)	NN	O	O
was	NN	O	O
29.4	NN	O	O
%	NN	O	O
for	NN	O	O
infected	NN	O	O
quarters	NN	O	O
and	NN	O	O
29.4	NN	O	O
%	NN	O	O
for	NN	O	O
infected	NN	O	O
cows	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
27.5	NN	O	O
and	NN	O	O
25.0	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
for	NN	O	O
the	NN	O	O
cephapirin	NN	O	B-INT
treatment	NN	O	O
only	NN	O	O
.	NN	O	O

Results	NN	O	O
including	NN	O	O
the	NN	O	O
culture	NN	O	O
at	NN	O	O
60	NN	O	O
d	NN	O	O
after	NN	O	O
calving	NN	O	O
were	NN	O	O
21.2	NN	O	O
and	NN	O	O
22.5	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
for	NN	O	O
combination	NN	O	O
therapy	NN	O	O
and	NN	O	O
cephapirin	NN	O	B-INT
therapy	NN	O	O
only	NN	O	O
.	NN	O	O

Systemic	NN	O	O
oxytetracycline	NN	O	B-INT
,	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
intramammary	NN	O	O
dry	NN	O	O
cow	NN	O	O
treatment	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
cure	NN	O	I-OUT
for	NN	O	O
S.	NN	O	O
aureus	NN	O	O
mastitis	NN	O	O
.	NN	O	O



--DOCSTART-- (7827398)

Epidemiology	NN	O	O
of	NN	O	O
stroke	NN	O	O
.	NN	O	O

Importance	NN	O	O
of	NN	O	O
preventive	NN	O	O
pharmacological	NN	O	O
strategies	NN	O	O
in	NN	O	O
elderly	NN	O	B-PAR
patients	NN	O	I-PAR
and	NN	O	O
associated	NN	O	O
costs	NN	O	O
.	NN	O	O

Stroke	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
cause	NN	O	O
of	NN	O	O
death	NN	O	O
and	NN	O	O
disability	NN	O	O
in	NN	O	O
developed	NN	O	O
countries	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
stroke	NN	O	O
increases	NN	O	O
exponentially	NN	O	O
with	NN	O	O
age	NN	O	O
,	NN	O	O
yet	NN	O	O
,	NN	O	O
traditionally	NN	O	O
,	NN	O	O
many	NN	O	O
medical	NN	O	O
practitioners	NN	O	O
have	NN	O	O
been	NN	O	O
reluctant	NN	O	O
to	NN	O	O
treat	NN	O	O
hypertension	NN	O	O
in	NN	O	B-PAR
older	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

Since	NN	O	O
1991	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
3	NN	O	O
major	NN	O	O
trials	NN	O	O
--	NN	O	O
the	NN	O	O
British	NN	O	O
Medical	NN	O	O
Research	NN	O	O
Council	NN	O	O
(	NN	O	O
MRC	NN	O	O
)	NN	O	O
trial	NN	O	O
of	NN	O	O
treatment	NN	O	O
in	NN	O	O
older	NN	O	B-PAR
adults	NN	O	I-PAR
,	NN	O	O
the	NN	O	O
Swedish	NN	O	O
Trial	NN	O	O
in	NN	O	O
Old	NN	O	B-PAR
Patients	NN	O	I-PAR
with	NN	O	I-PAR
Hypertension	NN	O	I-PAR
(	NN	O	O
STOP-Hypertension	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
Systolic	NN	O	O
Hypertension	NN	O	O
in	NN	O	O
the	NN	O	O
Elderly	NN	O	O
Program	NN	O	O
(	NN	O	O
SHEP	NN	O	O
)	NN	O	O
--	NN	O	O
have	NN	O	O
conclusively	NN	O	O
established	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
treating	NN	O	O
older	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
>	NN	O	I-PAR
60	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	I-PAR
with	NN	O	I-PAR
both	NN	O	I-PAR
diastolic	NN	O	I-PAR
and	NN	O	I-PAR
isolated	NN	O	I-PAR
systolic	NN	O	I-PAR
hypertension	NN	O	I-PAR
.	NN	O	O

International	NN	O	O
guidelines	NN	O	O
for	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
hypertension	NN	O	O
--	NN	O	O
including	NN	O	O
the	NN	O	O
Fifth	NN	O	O
Report	NN	O	O
of	NN	O	O
the	NN	O	O
Joint	NN	O	O
National	NN	O	O
Committee	NN	O	O
,	NN	O	O
the	NN	O	O
1993	NN	O	O
report	NN	O	O
of	NN	O	O
the	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
and	NN	O	O
the	NN	O	O
International	NN	O	O
Society	NN	O	O
of	NN	O	O
Hypertension	NN	O	O
and	NN	O	O
the	NN	O	O
second	NN	O	O
report	NN	O	O
of	NN	O	O
the	NN	O	O
British	NN	O	O
Hypertension	NN	O	O
Society	NN	O	O
Working	NN	O	O
Party	NN	O	O
--	NN	O	O
have	NN	O	O
all	NN	O	O
been	NN	O	O
modified	NN	O	O
to	NN	O	O
reflect	NN	O	O
the	NN	O	O
emerging	NN	O	O
evidence	NN	O	O
concerning	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
treating	NN	O	O
older	NN	O	O
patients	NN	O	O
.	NN	O	O

Cost-effectiveness	NN	O	B-OUT
data	NN	O	I-OUT
are	NN	O	O
similarly	NN	O	O
in	NN	O	O
accord	NN	O	O
with	NN	O	O
giving	NN	O	O
high	NN	O	O
priority	NN	O	O
to	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
older	NN	O	B-PAR
individuals	NN	O	I-PAR
with	NN	O	I-PAR
hypertension	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (7831628)

Measurement	NN	O	O
of	NN	O	O
transfer	NN	O	O
factor	NN	O	O
during	NN	O	O
constant	NN	O	O
exhalation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Transfer	NN	O	B-OUT
factor	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
lung	NN	O	I-OUT
for	NN	O	I-OUT
carbon	NN	O	I-OUT
monoxide	NN	O	I-OUT
(	NN	O	I-OUT
TLCO	NN	O	I-OUT
)	NN	O	I-OUT
was	NN	O	O
measured	NN	O	O
by	NN	O	O
a	NN	O	O
new	NN	O	O
method	NN	O	O
based	NN	O	O
on	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
ratio	NN	O	O
of	NN	O	O
the	NN	O	O
concentrations	NN	O	O
of	NN	O	O
carbon	NN	O	O
monoxide	NN	O	O
to	NN	O	O
an	NN	O	O
inert	NN	O	O
gas	NN	O	O
(	NN	O	O
methane	NN	O	O
)	NN	O	O
relative	NN	O	O
to	NN	O	O
lung	NN	O	O
volume	NN	O	O
during	NN	O	O
a	NN	O	O
constant	NN	O	O
exhalation	NN	O	O
.	NN	O	O

Since	NN	O	O
this	NN	O	O
new	NN	O	O
technique	NN	O	O
is	NN	O	O
based	NN	O	O
solely	NN	O	O
upon	NN	O	O
exhalation	NN	O	O
,	NN	O	O
anomalies	NN	O	O
associated	NN	O	O
with	NN	O	O
inspiration	NN	O	O
and	NN	O	O
breath	NN	O	O
holding	NN	O	O
do	NN	O	O
not	NN	O	O
affect	NN	O	O
results	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
because	NN	O	O
prolonged	NN	O	O
breath	NN	O	O
holding	NN	O	O
is	NN	O	O
not	NN	O	O
required	NN	O	O
,	NN	O	O
measurements	NN	O	O
can	NN	O	O
readily	NN	O	O
be	NN	O	O
made	NN	O	O
in	NN	O	O
dyspnoeic	NN	O	B-PAR
patients	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Exhalation	NN	O	B-OUT
TLCO	NN	O	I-OUT
(	NN	O	I-OUT
TLCO	NN	O	I-OUT
,	NN	O	I-OUT
ex	NN	O	I-OUT
)	NN	O	I-OUT
was	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
standard	NN	O	B-OUT
(	NN	O	I-OUT
Jones	NN	O	I-OUT
and	NN	O	I-OUT
Meade	NN	O	I-OUT
)	NN	O	I-OUT
10	NN	O	I-OUT
second	NN	O	I-OUT
breath	NN	O	I-OUT
holding	NN	O	I-OUT
TLCO	NN	O	I-OUT
(	NN	O	I-OUT
TLCO	NN	O	I-OUT
,	NN	O	I-OUT
bh	NN	O	I-OUT
)	NN	O	I-OUT
in	NN	O	O
100	NN	O	B-PAR
consecutive	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

Patients	NN	O	O
did	NN	O	O
not	NN	O	O
practise	NN	O	O
the	NN	O	O
exhalation	NN	O	O
manoeuvre	NN	O	O
prior	NN	O	O
to	NN	O	O
testing	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
comparative	NN	O	O
results	NN	O	O
were	NN	O	O
very	NN	O	O
close	NN	O	O
;	NN	O	O
mean	NN	O	O
difference	NN	O	O
(	NN	O	O
bias	NN	O	O
)	NN	O	O
+/-	NN	O	O
standard	NN	O	O
deviation	NN	O	O
(	NN	O	O
precision	NN	O	O
)	NN	O	O
was	NN	O	O
0.05	NN	O	O
(	NN	O	O
0.84	NN	O	O
)	NN	O	O
mmol/min/kPa	NN	O	O
.	NN	O	O

The	NN	O	O
relation	NN	O	B-OUT
was	NN	O	O
equally	NN	O	O
strong	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
severe	NN	O	I-PAR
pulmonary	NN	O	I-PAR
disease	NN	O	I-PAR
;	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
FEV1	NN	O	O
<	NN	O	O
1.51	NN	O	O
the	NN	O	O
mean	NN	O	O
difference	NN	O	O
was	NN	O	O
0.21	NN	O	O
(	NN	O	O
0.80	NN	O	O
)	NN	O	O
mmol/min/kPa	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Since	NN	O	O
the	NN	O	O
results	NN	O	O
were	NN	O	O
essentially	NN	O	O
identical	NN	O	O
between	NN	O	O
the	NN	O	O
techniques	NN	O	O
,	NN	O	O
it	NN	O	O
seems	NN	O	O
that	NN	O	O
comparable	NN	O	O
pathophysiological	NN	O	O
factors	NN	O	O
affect	NN	O	O
TLCO	NN	O	O
during	NN	O	O
breath	NN	O	O
holding	NN	O	O
and	NN	O	O
constant	NN	O	O
exhalation	NN	O	O
.	NN	O	O

Constant	NN	O	O
exhalation	NN	O	O
may	NN	O	O
therefore	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
alternative	NN	O	O
to	NN	O	O
the	NN	O	O
breath	NN	O	O
holding	NN	O	O
technique	NN	O	O
for	NN	O	O
clinical	NN	O	O
measurement	NN	O	O
of	NN	O	O
TLCO	NN	O	O
.	NN	O	O



--DOCSTART-- (7844976)

The	NN	O	O
effect	NN	O	O
of	NN	O	O
two	NN	O	O
types	NN	O	O
of	NN	O	O
teacher	NN	O	B-INT
training	NN	O	I-INT
on	NN	O	O
implementation	NN	O	O
of	NN	O	O
Smart	NN	O	O
Choices	NN	O	O
:	NN	O	O
a	NN	O	O
tobacco	NN	O	O
prevention	NN	O	O
curriculum	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
implementation	NN	O	O
phase	NN	O	O
of	NN	O	O
a	NN	O	O
four-year	NN	O	O
research	NN	O	O
project	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
effectiveness	NN	O	B-OUT
of	NN	O	O
strategies	NN	O	O
to	NN	O	O
increase	NN	O	O
diffusion	NN	O	B-OUT
of	NN	O	I-OUT
Smart	NN	O	I-OUT
Choices	NN	O	I-OUT
,	NN	O	O
a	NN	O	O
school-based	NN	O	O
tobacco	NN	O	O
prevention	NN	O	O
program	NN	O	O
.	NN	O	O

The	NN	O	O
impact	NN	O	O
on	NN	O	O
curriculum	NN	O	O
implementation	NN	O	O
of	NN	O	O
two	NN	O	O
approaches	NN	O	O
to	NN	O	O
teacher	NN	O	B-PAR
training	NN	O	O
are	NN	O	O
compared	NN	O	O
.	NN	O	O

School	NN	O	O
districts	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
a	NN	O	O
live	NN	O	B-INT
workshop	NN	O	I-INT
training	NN	O	I-INT
or	NN	O	O
video	NN	O	B-INT
training	NN	O	I-INT
condition	NN	O	I-INT
.	NN	O	O

The	NN	O	O
outcome	NN	O	O
of	NN	O	O
the	NN	O	O
evaluation	NN	O	O
was	NN	O	O
teachers	NN	O	B-OUT
'	NN	O	I-OUT
implementation	NN	O	I-OUT
of	NN	O	I-OUT
Smart	NN	O	I-OUT
Choices	NN	O	I-OUT
.	NN	O	O

Results	NN	O	O
show	NN	O	O
a	NN	O	O
lower	NN	O	O
proportion	NN	O	O
of	NN	O	O
video-trained	NN	O	B-INT
teachers	NN	O	O
implemented	NN	O	O
the	NN	O	O
curriculum	NN	O	O
,	NN	O	O
but	NN	O	O
overall	NN	O	O
completeness	NN	O	B-OUT
and	NN	O	I-OUT
fidelity	NN	O	I-OUT
of	NN	O	I-OUT
implementation	NN	O	I-OUT
for	NN	O	O
those	NN	O	O
teachers	NN	O	B-PAR
who	NN	O	O
did	NN	O	O
teach	NN	O	O
the	NN	O	O
curriculum	NN	O	O
were	NN	O	O
comparable	NN	O	O
for	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Video-trained	NN	O	B-INT
teachers	NN	O	I-PAR
,	NN	O	O
however	NN	O	O
,	NN	O	O
were	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
use	NN	O	O
brainstorming	NN	O	O
and	NN	O	O
student	NN	O	O
presentations/role	NN	O	O
plays	NN	O	O
,	NN	O	O
two	NN	O	O
of	NN	O	O
the	NN	O	O
methods	NN	O	O
prescribed	NN	O	O
by	NN	O	O
the	NN	O	O
curriculum	NN	O	O
.	NN	O	O

Implications	NN	O	O
of	NN	O	O
the	NN	O	O
results	NN	O	O
for	NN	O	O
teacher	NN	O	B-PAR
training	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O



--DOCSTART-- (7853069)

Necessary	NN	O	O
but	NN	O	O
not	NN	O	O
sufficient	NN	O	O
:	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
screening	NN	O	O
and	NN	O	O
feedback	NN	O	O
on	NN	O	O
outcomes	NN	O	O
of	NN	O	O
primary	NN	O	B-PAR
care	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
untreated	NN	O	I-PAR
anxiety	NN	O	I-PAR
.	NN	O	O

OBJECTIVE	NN	O	O
To	NN	O	O
consider	NN	O	O
the	NN	O	O
impact	NN	O	O
on	NN	O	O
primary	NN	O	O
care	NN	O	O
patient	NN	O	O
outcomes	NN	O	O
of	NN	O	O
using	NN	O	O
both	NN	O	O
a	NN	O	O
screener	NN	O	O
to	NN	O	O
determine	NN	O	O
elevated	NN	O	O
anxiety	NN	O	O
levels	NN	O	O
among	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
previously	NN	O	I-PAR
undetected	NN	O	I-PAR
anxiety	NN	O	I-PAR
and	NN	O	O
a	NN	O	O
physician	NN	O	O
intervention	NN	O	O
to	NN	O	O
inform	NN	O	O
physicians	NN	O	O
of	NN	O	O
their	NN	O	O
patients	NN	O	O
'	NN	O	O
conditions	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
Participating	NN	O	O
physicians	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
either	NN	O	O
the	NN	O	O
demonstration	NN	O	B-INT
or	NN	O	O
the	NN	O	O
control	NN	O	O
arm	NN	O	O
,	NN	O	O
and	NN	O	O
patients	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
a	NN	O	O
study	NN	O	O
arm	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
randomization	NN	O	O
of	NN	O	O
their	NN	O	O
physicians	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
followed	NN	O	O
for	NN	O	O
change	NN	O	O
in	NN	O	O
outcome	NN	O	O
measures	NN	O	O
during	NN	O	O
the	NN	O	O
five-month	NN	O	O
study	NN	O	O
period	NN	O	O
.	NN	O	O

SETTING	NN	O	O
A	NN	O	O
mixed-model	NN	O	O
health	NN	O	O
maintenance	NN	O	O
organization	NN	O	O
serving	NN	O	O
approximately	NN	O	O
110,000	NN	O	O
enrollees	NN	O	O
in	NN	O	O
central	NN	O	O
Colorado	NN	O	O
.	NN	O	O

PATIENTS/PARTICIPANTS	NN	O	O
573	NN	O	B-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
unrecognized	NN	O	I-PAR
and	NN	O	I-PAR
untreated	NN	O	I-PAR
anxiety	NN	O	I-PAR
identified	NN	O	I-PAR
from	NN	O	I-PAR
the	NN	O	I-PAR
approximately	NN	O	I-PAR
8,000	NN	O	I-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
completed	NN	O	I-PAR
the	NN	O	I-PAR
waiting	NN	O	I-PAR
room	NN	O	I-PAR
screening	NN	O	I-PAR
questionnaire	NN	O	I-PAR
.	NN	O	O

INTERVENTIONS	NN	O	O
A	NN	O	O
physician	NN	O	B-INT
intervention	NN	O	I-INT
served	NN	O	O
the	NN	O	O
dual	NN	O	O
function	NN	O	O
of	NN	O	O
1	NN	O	O
)	NN	O	O
providing	NN	O	O
an	NN	O	O
educational	NN	O	O
demonstration	NN	O	O
of	NN	O	O
anxiety	NN	O	O
in	NN	O	O
the	NN	O	O
primary	NN	O	O
care	NN	O	O
setting	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
providing	NN	O	O
a	NN	O	O
reporting	NN	O	O
system	NN	O	O
for	NN	O	O
summarizing	NN	O	O
the	NN	O	O
anxiety	NN	O	O
symptom	NN	O	O
levels	NN	O	O
and	NN	O	O
functioning	NN	O	O
status	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
Patient	NN	O	O
outcomes	NN	O	O
were	NN	O	O
measured	NN	O	O
as	NN	O	O
changes	NN	O	O
in	NN	O	O
global	NN	O	B-OUT
anxiety	NN	O	I-OUT
scores	NN	O	I-OUT
,	NN	O	I-OUT
functioning	NN	O	I-OUT
and	NN	O	I-OUT
well-being	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	O
patients	NN	O	B-OUT
'	NN	O	I-OUT
reports	NN	O	I-OUT
of	NN	O	I-OUT
global	NN	O	I-OUT
improvements	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
this	NN	O	O
method	NN	O	O
of	NN	O	O
reporting	NN	O	O
symptoms	NN	O	O
and	NN	O	O
functioning	NN	O	O
status	NN	O	O
to	NN	O	O
primary	NN	O	O
care	NN	O	O
physicians	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
change	NN	O	O
patient	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Improvement	NN	O	O
in	NN	O	O
outcomes	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
more	NN	O	O
closely	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
patient	NN	O	O
's	NN	O	O
severity	NN	O	O
of	NN	O	O
psychological	NN	O	O
distress	NN	O	O
.	NN	O	O



--DOCSTART-- (8519720)

Double-blind	NN	O	O
randomized	NN	O	O
evaluation	NN	O	O
of	NN	O	O
intercostal	NN	O	B-INT
nerve	NN	O	I-INT
blocks	NN	O	I-INT
as	NN	O	O
an	NN	O	O
adjuvant	NN	O	O
to	NN	O	O
subarachnoid	NN	O	O
administered	NN	O	O
morphine	NN	O	B-INT
for	NN	O	O
post-thoracotomy	NN	O	B-PAR
analgesia	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
OBJECTIVES	NN	O	O
Thoracotomy	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
pain	NN	O	O
and	NN	O	O
compromised	NN	O	O
pulmonary	NN	O	O
function	NN	O	O
.	NN	O	O

Intercostal	NN	O	B-INT
nerve	NN	O	I-INT
blocks	NN	O	I-INT
(	NN	O	I-INT
INB	NN	O	I-INT
)	NN	O	I-INT
and	NN	O	O
subarachnoid	NN	O	B-INT
morphine	NN	O	I-INT
(	NN	O	I-INT
SM	NN	O	I-INT
)	NN	O	I-INT
act	NN	O	O
on	NN	O	O
different	NN	O	O
portions	NN	O	O
of	NN	O	O
the	NN	O	O
pain	NN	O	O
pathway	NN	O	O
.	NN	O	O

Each	NN	O	O
is	NN	O	O
effective	NN	O	O
for	NN	O	O
post-thoracotomy	NN	O	O
pain	NN	O	B-OUT
relief	NN	O	O
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
these	NN	O	O
two	NN	O	O
modalities	NN	O	O
in	NN	O	O
relieving	NN	O	O
post-thoracotomy	NN	O	B-OUT
pain	NN	O	I-OUT
and	NN	O	O
improving	NN	O	O
postoperative	NN	O	B-OUT
pulmonary	NN	O	I-OUT
function	NN	O	I-OUT
has	NN	O	O
not	NN	O	O
been	NN	O	O
investigated	NN	O	O
.	NN	O	O

METHODS	NN	O	O
In	NN	O	O
a	NN	O	O
double-blind	NN	O	O
study	NN	O	O
,	NN	O	O
20	NN	O	B-PAR
patients	NN	O	I-PAR
undergoing	NN	O	I-PAR
lateral	NN	O	I-PAR
thoracotomy	NN	O	I-PAR
for	NN	O	I-PAR
lung	NN	O	I-PAR
resection	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
0.5	NN	O	O
mg	NN	O	O
SM	NN	O	B-INT
preoperatively	NN	O	O
and	NN	O	O
INB	NN	O	B-INT
with	NN	O	O
bupivacaine	NN	O	B-INT
(	NN	O	O
INB+	NN	O	O
)	NN	O	O
prior	NN	O	O
to	NN	O	O
wound	NN	O	O
closure	NN	O	O
or	NN	O	O
0.5	NN	O	O
mg	NN	O	O
SM	NN	O	B-INT
with	NN	O	O
INB	NN	O	B-INT
using	NN	O	O
saline	NN	O	B-INT
(	NN	O	O
INB-	NN	O	B-INT
)	NN	O	O
.	NN	O	O

Visual	NN	O	B-OUT
analog	NN	O	I-OUT
scale	NN	O	I-OUT
pain	NN	O	I-OUT
scores	NN	O	I-OUT
at	NN	O	O
rest	NN	O	O
,	NN	O	O
with	NN	O	B-OUT
cough	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
with	NN	O	I-OUT
movement	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
ipsilateral	NN	O	I-OUT
arm	NN	O	I-OUT
,	NN	O	I-OUT
forced	NN	O	I-OUT
expiratory	NN	O	I-OUT
volume	NN	O	I-OUT
in	NN	O	I-OUT
1	NN	O	I-OUT
second	NN	O	I-OUT
(	NN	O	I-OUT
FEV1	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
forced	NN	O	B-OUT
vital	NN	O	I-OUT
capacity	NN	O	I-OUT
(	NN	O	I-OUT
FVC	NN	O	I-OUT
)	NN	O	I-OUT
were	NN	O	O
measured	NN	O	O
at	NN	O	O
4	NN	O	O
,	NN	O	O
24	NN	O	O
,	NN	O	O
48	NN	O	O
,	NN	O	O
and	NN	O	O
72	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
operation	NN	O	O
.	NN	O	O

Opioid	NN	O	B-OUT
use	NN	O	I-OUT
was	NN	O	O
measured	NN	O	O
during	NN	O	O
the	NN	O	O
initial	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
operation	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
At	NN	O	O
4	NN	O	O
hours	NN	O	O
,	NN	O	O
the	NN	O	O
INB+	NN	O	B-INT
group	NN	O	O
demonstrated	NN	O	O
better	NN	O	O
FEV1	NN	O	B-OUT
(	NN	O	O
56.6	NN	O	O
%	NN	O	O
vs.	NN	O	O
40.4	NN	O	O
%	NN	O	O
of	NN	O	O
baseline	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
and	NN	O	O
FVC	NN	O	B-OUT
values	NN	O	O
(	NN	O	O
54.6	NN	O	O
%	NN	O	O
vs.	NN	O	O
39.6	NN	O	O
%	NN	O	O
of	NN	O	O
baseline	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
and	NN	O	O
less	NN	O	O
resting	NN	O	O
and	NN	O	O
cough	NN	O	O
pain	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
FEV1	NN	O	B-OUT
continued	NN	O	O
to	NN	O	O
decline	NN	O	O
in	NN	O	O
the	NN	O	O
INB+	NN	O	B-INT
group	NN	O	O
at	NN	O	O
24	NN	O	O
hours	NN	O	O
to	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
INB-	NN	O	B-INT
group	NN	O	O
although	NN	O	O
pain	NN	O	B-OUT
scores	NN	O	I-OUT
were	NN	O	O
similar	NN	O	O
beyond	NN	O	O
4	NN	O	O
hours	NN	O	O
.	NN	O	O

Opioid	NN	O	B-OUT
usage	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
first	NN	O	O
24	NN	O	O
hours	NN	O	O
was	NN	O	O
similar	NN	O	O
(	NN	O	O
INB-	NN	O	B-INT
,	NN	O	O
16.7	NN	O	O
mg	NN	O	O
vs.	NN	O	O
INB+	NN	O	B-INT
,	NN	O	O
13.2	NN	O	O
mg	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.7	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Although	NN	O	O
postoperative	NN	O	O
INB	NN	O	B-INT
provided	NN	O	O
modest	NN	O	O
improvements	NN	O	O
in	NN	O	O
pain	NN	O	O
and	NN	O	O
pulmonary	NN	O	O
function	NN	O	O
when	NN	O	O
used	NN	O	O
as	NN	O	O
an	NN	O	O
adjuvant	NN	O	O
to	NN	O	O
0.5	NN	O	O
mg	NN	O	O
SM	NN	O	B-INT
for	NN	O	O
post-thoracotomy	NN	O	O
analgesia	NN	O	O
,	NN	O	O
the	NN	O	O
benefits	NN	O	O
were	NN	O	O
transient	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
do	NN	O	O
not	NN	O	O
recommend	NN	O	O
adding	NN	O	O
INB	NN	O	B-INT
for	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
lateral	NN	O	O
thoracotomy	NN	O	O
who	NN	O	O
receive	NN	O	O
0.5	NN	O	O
mg	NN	O	O
SM	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (8726604)

The	NN	O	O
effects	NN	O	O
of	NN	O	O
sevoflurane	NN	O	B-INT
and	NN	O	O
isoflurane	NN	O	B-INT
on	NN	O	O
recovery	NN	O	O
from	NN	O	O
outpatient	NN	O	B-PAR
surgery	NN	O	I-PAR
.	NN	O	O

This	NN	O	O
randomized	NN	O	O
,	NN	O	O
open-label	NN	O	O
study	NN	O	O
compared	NN	O	O
the	NN	O	O
investigational	NN	O	O
inhalational	NN	O	O
anesthetic	NN	O	O
sevoflurane	NN	O	B-INT
with	NN	O	O
isoflurane	NN	O	B-INT
in	NN	O	O
47	NN	O	B-PAR
healthy	NN	O	I-PAR
women	NN	O	I-PAR
undergoing	NN	O	I-PAR
elective	NN	O	I-PAR
ambulatory	NN	O	I-PAR
surgery	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
women	NN	O	B-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
sevoflurane	NN	O	B-INT
or	NN	O	O
isoflurane	NN	O	B-INT
in	NN	O	O
60	NN	O	O
%	NN	O	O
nitrous	NN	O	O
oxide-oxygen	NN	O	O
.	NN	O	O

Induction	NN	O	O
with	NN	O	O
thiopental	NN	O	B-INT
3-6	NN	O	O
mg/kg	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
vecuronium	NN	O	B-INT
0.1	NN	O	O
mg/kg	NN	O	O
and	NN	O	O
fentanyl	NN	O	B-INT
0-200	NN	O	O
micrograms	NN	O	O
.	NN	O	O

Duration	NN	O	B-OUT
of	NN	O	I-OUT
anesthesia	NN	O	I-OUT
,	NN	O	I-OUT
time	NN	O	I-OUT
to	NN	O	I-OUT
emergence	NN	O	I-OUT
,	NN	O	I-OUT
orientation	NN	O	I-OUT
,	NN	O	I-OUT
length	NN	O	I-OUT
of	NN	O	I-OUT
stay	NN	O	I-OUT
in	NN	O	I-OUT
the	NN	O	I-OUT
surgical	NN	O	I-OUT
unit	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
hospital	NN	O	I-OUT
discharge	NN	O	I-OUT
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

The	NN	O	O
emergence	NN	O	B-OUT
,	NN	O	I-OUT
length	NN	O	I-OUT
of	NN	O	I-OUT
stay	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
discharge	NN	O	I-OUT
times	NN	O	I-OUT
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
sevoflurane	NN	O	B-INT
were	NN	O	O
9.7	NN	O	O
+/-	NN	O	O
0.7	NN	O	O
,	NN	O	O
120.6	NN	O	O
+/-	NN	O	O
8.0	NN	O	O
,	NN	O	O
and	NN	O	O
244	NN	O	O
+/-	NN	O	O
15	NN	O	O
minutes	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
for	NN	O	O
isoflurane	NN	O	B-INT
were	NN	O	O
11.9	NN	O	O
+/-	NN	O	O
1.4	NN	O	O
,	NN	O	O
106.8	NN	O	O
+/-	NN	O	O
7.1	NN	O	O
,	NN	O	O
and	NN	O	O
282	NN	O	O
+/-	NN	O	O
24	NN	O	O
minutes	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
NS	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
isoflurane	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
frequency	NN	O	O
of	NN	O	O
postoperative	NN	O	B-OUT
cough	NN	O	I-OUT
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
surgery	NN	O	O
,	NN	O	O
the	NN	O	O
sevoflurane	NN	O	O
group	NN	O	O
received	NN	O	O
a	NN	O	O
deeper	NN	O	O
level	NN	O	O
of	NN	O	O
anesthesia	NN	O	B-OUT
(	NN	O	O
minimum	NN	O	O
alveolar	NN	O	O
concentration	NN	O	O
1.5	NN	O	O
vs	NN	O	O
1.3	NN	O	O
)	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
these	NN	O	O
patients	NN	O	O
were	NN	O	O
oriented	NN	O	O
earlier	NN	O	O
(	NN	O	O
13.6	NN	O	O
+/-	NN	O	O
1.1	NN	O	O
min	NN	O	O
vs	NN	O	O
17.0	NN	O	O
+/-	NN	O	O
1.5	NN	O	O
min	NN	O	O
isoflurane	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
although	NN	O	O
this	NN	O	O
difference	NN	O	O
is	NN	O	O
of	NN	O	O
little	NN	O	O
clinical	NN	O	O
significance	NN	O	O
.	NN	O	O



--DOCSTART-- (8771302)

Fluoroscopic	NN	O	O
functional	NN	O	O
evaluation	NN	O	O
of	NN	O	O
bileaflet	NN	O	B-INT
prostheses	NN	O	I-INT
:	NN	O	O
effect	NN	O	O
of	NN	O	O
different	NN	O	O
intraoperative	NN	O	O
valve	NN	O	O
orientation	NN	O	O
.	NN	O	O

Fluoroscopy	NN	O	O
is	NN	O	O
a	NN	O	O
reliable	NN	O	O
,	NN	O	O
easy	NN	O	O
,	NN	O	O
and	NN	O	O
readily	NN	O	O
available	NN	O	O
technique	NN	O	O
to	NN	O	O
follow-up	NN	O	O
prosthesis	NN	O	O
functioning	NN	O	O
after	NN	O	O
heart	NN	O	O
valve	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
different	NN	O	O
orientation	NN	O	O
given	NN	O	O
to	NN	O	O
the	NN	O	O
prosthesis	NN	O	O
may	NN	O	O
represent	NN	O	O
a	NN	O	O
limitation	NN	O	O
of	NN	O	O
the	NN	O	O
technique	NN	O	O
accounting	NN	O	O
for	NN	O	O
unsatisfactory	NN	O	O
results	NN	O	O
in	NN	O	O
10	NN	O	O
%	NN	O	O
to	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
whether	NN	O	O
and	NN	O	O
to	NN	O	O
what	NN	O	O
extent	NN	O	O
different	NN	O	O
intraoperative	NN	O	O
valve	NN	O	O
orientation	NN	O	O
influence	NN	O	O
feasibility	NN	O	B-OUT
and	NN	O	O
accuracy	NN	O	B-OUT
of	NN	O	O
postoperative	NN	O	O
fluoroscopic	NN	O	O
evaluation	NN	O	O
of	NN	O	O
bileaflet	NN	O	B-INT
prostheses	NN	O	I-INT
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
90	NN	O	B-PAR
patients	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
aortic	NN	O	I-PAR
,	NN	O	I-PAR
mitral	NN	O	I-PAR
,	NN	O	I-PAR
and/or	NN	O	I-PAR
tricuspid	NN	O	I-PAR
valve	NN	O	I-PAR
replacement	NN	O	I-PAR
with	NN	O	I-PAR
Sorin	NN	O	I-INT
Bicarbon	NN	O	I-INT
or	NN	O	I-INT
CarboMedics	NN	O	I-INT
bileaflet	NN	O	I-INT
prostheses	NN	O	I-INT
.	NN	O	O

Fifty	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
prostheses	NN	O	B-INT
oriented	NN	O	O
in	NN	O	O
a	NN	O	O
perpendicular	NN	O	O
or	NN	O	O
a	NN	O	O
parallel	NN	O	O
position	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
ventricular	NN	O	O
septum	NN	O	O
.	NN	O	O

Fluoroscopic	NN	O	O
evaluation	NN	O	O
was	NN	O	O
considered	NN	O	O
appropriate	NN	O	O
when	NN	O	O
the	NN	O	O
prosthesis	NN	O	O
'	NN	O	O
tilting	NN	O	O
disk	NN	O	O
projection	NN	O	O
was	NN	O	O
obtained	NN	O	O
.	NN	O	O

The	NN	O	O
valve	NN	O	O
's	NN	O	O
hemodynamic	NN	O	B-OUT
performance	NN	O	I-OUT
was	NN	O	O
investigated	NN	O	O
through	NN	O	O
Doppler	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
proper	NN	O	O
fluoroscopic	NN	O	B-OUT
evaluation	NN	O	I-OUT
was	NN	O	O
rapidly	NN	O	O
(	NN	O	O
15	NN	O	O
+/-	NN	O	O
5	NN	O	O
seconds	NN	O	O
)	NN	O	O
achieved	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
former	NN	O	O
orientation	NN	O	O
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
was	NN	O	O
impossible	NN	O	O
to	NN	O	O
obtain	NN	O	O
it	NN	O	O
in	NN	O	O
8	NN	O	O
of	NN	O	O
20	NN	O	O
(	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
19	NN	O	O
of	NN	O	O
20	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
of	NN	O	O
5	NN	O	O
(	NN	O	O
80	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
latter	NN	O	O
orientation	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
patients	NN	O	O
extremely	NN	O	O
angulated	NN	O	O
,	NN	O	O
uneasy	NN	O	O
projection	NN	O	O
was	NN	O	O
often	NN	O	O
required	NN	O	O
to	NN	O	O
get	NN	O	O
a	NN	O	O
correct	NN	O	O
fluoroscopic	NN	O	O
image	NN	O	O
.	NN	O	O

The	NN	O	O
Doppler	NN	O	O
study	NN	O	O
showed	NN	O	O
a	NN	O	O
similarly	NN	O	O
favorable	NN	O	O
hemodynamic	NN	O	B-OUT
performance	NN	O	I-OUT
regardless	NN	O	O
of	NN	O	O
valve	NN	O	O
orientation	NN	O	O
.	NN	O	O

Prosthesis	NN	O	B-INT
orientation	NN	O	O
crucially	NN	O	O
affects	NN	O	O
the	NN	O	O
rate	NN	O	B-OUT
of	NN	O	I-OUT
success	NN	O	I-OUT
of	NN	O	I-OUT
the	NN	O	I-OUT
fluoroscopic	NN	O	I-OUT
evaluation	NN	O	I-OUT
.	NN	O	O

The	NN	O	O
orientation	NN	O	O
perpendicular	NN	O	O
to	NN	O	O
the	NN	O	O
ventricular	NN	O	O
septum	NN	O	O
greatly	NN	O	O
facilitates	NN	O	O
the	NN	O	O
postoperative	NN	O	O
feasibility	NN	O	B-OUT
and	NN	O	I-OUT
accuracy	NN	O	I-OUT
of	NN	O	I-OUT
fluoroscopy	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
detrimental	NN	O	O
to	NN	O	O
the	NN	O	O
valve	NN	O	B-OUT
's	NN	O	I-OUT
hemodynamic	NN	O	I-OUT
performance	NN	O	I-OUT
.	NN	O	O

This	NN	O	O
valve	NN	O	O
orientation	NN	O	O
may	NN	O	O
provide	NN	O	O
a	NN	O	O
better	NN	O	O
fluoroscopic	NN	O	B-OUT
window	NN	O	O
whenever	NN	O	O
a	NN	O	O
valve	NN	O	O
dysfunction	NN	O	O
is	NN	O	O
suspected	NN	O	O
.	NN	O	O



--DOCSTART-- (8779382)

The	NN	O	O
effect	NN	O	O
of	NN	O	O
tunnelling	NN	O	B-INT
on	NN	O	O
epidural	NN	O	O
catheter	NN	O	O
migration	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomised	NN	O	O
study	NN	O	O
of	NN	O	O
82	NN	O	B-PAR
patients	NN	O	I-PAR
having	NN	O	I-PAR
postoperative	NN	O	I-PAR
epidural	NN	O	I-PAR
analgesia	NN	O	I-PAR
was	NN	O	O
performed	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
tunnelling	NN	O	B-INT
of	NN	O	O
an	NN	O	O
epidural	NN	O	O
catheter	NN	O	O
influences	NN	O	O
its	NN	O	O
migration	NN	O	B-OUT
.	NN	O	O

Tunnelling	NN	O	B-INT
of	NN	O	O
the	NN	O	O
catheter	NN	O	O
subcutaneously	NN	O	O
for	NN	O	O
a	NN	O	O
distance	NN	O	O
of	NN	O	O
5	NN	O	O
cm	NN	O	O
reduced	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
inward	NN	O	I-OUT
migration	NN	O	I-OUT
of	NN	O	O
1	NN	O	O
cm	NN	O	O
or	NN	O	O
more	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
compared	NN	O	O
to	NN	O	O
a	NN	O	O
standard	NN	O	O
method	NN	O	O
of	NN	O	O
fixation	NN	O	O
with	NN	O	O
a	NN	O	O
transparent	NN	O	O
adhesive	NN	O	O
dressing	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
more	NN	O	O
marked	NN	O	O
if	NN	O	O
the	NN	O	O
epidural	NN	O	O
catheter	NN	O	O
was	NN	O	O
sited	NN	O	O
in	NN	O	O
the	NN	O	O
thoracic	NN	O	O
rather	NN	O	O
than	NN	O	O
the	NN	O	O
lumbar	NN	O	O
area	NN	O	O
.	NN	O	O

Sixty	NN	O	O
two	NN	O	O
percent	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
26	NN	O	O
)	NN	O	O
of	NN	O	O
tunnelled	NN	O	B-INT
catheters	NN	O	I-INT
remained	NN	O	O
within	NN	O	O
0.5	NN	O	O
cm	NN	O	O
of	NN	O	O
their	NN	O	O
original	NN	O	O
position	NN	O	B-OUT
compared	NN	O	O
to	NN	O	O
38	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
16	NN	O	O
)	NN	O	O
of	NN	O	O
non-tunnelled	NN	O	B-INT
catheters	NN	O	I-INT
,	NN	O	O
although	NN	O	O
this	NN	O	O
difference	NN	O	O
was	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

Outward	NN	O	O
catheter	NN	O	B-OUT
migration	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
reduced	NN	O	O
by	NN	O	O
subcutaneous	NN	O	O
tunnelling	NN	O	B-INT
.	NN	O	O



--DOCSTART-- (8911222)

Effects	NN	O	O
of	NN	O	O
tryptophan	NN	O	O
depletion	NN	O	O
in	NN	O	O
drug-free	NN	O	B-PAR
adults	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
primary	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
behavioral	NN	O	O
and	NN	O	O
biochemical	NN	O	O
responses	NN	O	O
to	NN	O	O
acute	NN	O	O
tryptophan	NN	O	O
depletion	NN	O	O
in	NN	O	O
drug-free	NN	O	B-PAR
adult	NN	O	I-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

METHODS	NN	O	O
Twenty	NN	O	B-PAR
drug-free	NN	O	I-PAR
adults	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
(	NN	O	I-PAR
16	NN	O	I-PAR
men	NN	O	I-PAR
and	NN	O	I-PAR
4	NN	O	I-PAR
women	NN	O	I-PAR
)	NN	O	I-PAR
(	NN	O	I-PAR
mean	NN	O	I-PAR
[	NN	O	I-PAR
+/-	NN	O	I-PAR
SD	NN	O	I-PAR
]	NN	O	I-PAR
age	NN	O	I-PAR
,	NN	O	I-PAR
30.5	NN	O	I-PAR
+/-	NN	O	I-PAR
8.5	NN	O	I-PAR
years	NN	O	I-PAR
)	NN	O	I-PAR
underwent	NN	O	O
short-term	NN	O	O
tryptophan	NN	O	B-INT
depletion	NN	O	I-INT
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
,	NN	O	O
randomized	NN	O	O
crossover	NN	O	O
design	NN	O	O
.	NN	O	O

Patients	NN	O	O
received	NN	O	O
a	NN	O	O
24-hour	NN	O	O
,	NN	O	O
low-tryptophan	NN	O	B-INT
diet	NN	O	I-INT
followed	NN	O	O
the	NN	O	O
next	NN	O	O
morning	NN	O	O
by	NN	O	O
an	NN	O	O
amino	NN	O	B-INT
acid	NN	O	I-INT
drink	NN	O	I-INT
.	NN	O	O

Behavioral	NN	O	O
ratings	NN	O	O
were	NN	O	O
obtained	NN	O	O
on	NN	O	O
the	NN	O	O
morning	NN	O	O
of	NN	O	O
the	NN	O	O
amino	NN	O	B-INT
acid	NN	O	I-INT
drink	NN	O	I-INT
(	NN	O	O
baseline	NN	O	O
)	NN	O	O
and	NN	O	O
180	NN	O	O
,	NN	O	O
300	NN	O	O
,	NN	O	O
and	NN	O	O
420	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
drink	NN	O	O
.	NN	O	O

Plasma	NN	O	B-OUT
free	NN	O	I-OUT
and	NN	O	I-OUT
total	NN	O	I-OUT
tryptophan	NN	O	I-OUT
levels	NN	O	I-OUT
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
5	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
drink	NN	O	O
.	NN	O	O

The	NN	O	O
active	NN	O	O
and	NN	O	O
sham	NN	O	O
testing	NN	O	O
sessions	NN	O	O
were	NN	O	O
separated	NN	O	O
by	NN	O	O
7	NN	O	O
days	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Eleven	NN	O	O
(	NN	O	O
65	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
17	NN	O	O
patients	NN	O	O
who	NN	O	O
completed	NN	O	O
both	NN	O	O
test	NN	O	O
days	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
global	NN	O	O
worsening	NN	O	O
of	NN	O	O
behavioral	NN	O	O
symptoms	NN	O	O
with	NN	O	O
short-term	NN	O	O
tryptophan	NN	O	O
depletion	NN	O	O
,	NN	O	O
but	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
17	NN	O	O
patients	NN	O	O
showed	NN	O	O
any	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
clinical	NN	O	O
status	NN	O	O
from	NN	O	O
baseline	NN	O	O
after	NN	O	O
sham	NN	O	O
depletion	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.001	NN	O	O
)	NN	O	O
.	NN	O	O

Tryptophan	NN	O	O
depletion	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
behaviors	NN	O	O
such	NN	O	O
as	NN	O	O
whirling	NN	O	B-OUT
,	NN	O	I-OUT
flapping	NN	O	I-OUT
,	NN	O	I-OUT
pacing	NN	O	I-OUT
,	NN	O	I-OUT
banging	NN	O	I-OUT
and	NN	O	I-OUT
hitting	NN	O	I-OUT
self	NN	O	I-OUT
,	NN	O	I-OUT
rocking	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
toe	NN	O	I-OUT
walking	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
significantly	NN	O	O
less	NN	O	O
calm	NN	O	B-OUT
and	NN	O	I-OUT
happy	NN	O	I-OUT
and	NN	O	O
more	NN	O	O
anxious	NN	O	B-OUT
.	NN	O	O

No	NN	O	O
significant	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
social	NN	O	B-OUT
relatedness	NN	O	I-OUT
or	NN	O	I-OUT
repetitive	NN	O	I-OUT
thoughts	NN	O	I-OUT
and	NN	O	I-OUT
behavior	NN	O	I-OUT
.	NN	O	O

Plasma	NN	O	B-OUT
total	NN	O	I-OUT
and	NN	O	I-OUT
free	NN	O	I-OUT
tryptophan	NN	O	I-OUT
levels	NN	O	I-OUT
were	NN	O	O
reduced	NN	O	O
86	NN	O	O
%	NN	O	O
and	NN	O	O
69	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
5	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
tryptophan-deficient	NN	O	O
amino	NN	O	O
acid	NN	O	O
drink	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
global	NN	O	O
exacerbation	NN	O	O
of	NN	O	O
symptoms	NN	O	O
had	NN	O	O
significantly	NN	O	O
higher	NN	O	O
baseline	NN	O	O
plasma	NN	O	B-OUT
total	NN	O	I-OUT
tryptophan	NN	O	I-OUT
levels	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
and	NN	O	O
Autism	NN	O	B-OUT
Behavior	NN	O	I-OUT
Checklist	NN	O	I-OUT
scores	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
=	NN	O	O
.005	NN	O	O
)	NN	O	O
than	NN	O	O
did	NN	O	O
patients	NN	O	O
who	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
symptoms	NN	O	O
after	NN	O	O
tryptophan	NN	O	O
depletion	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
previous	NN	O	O
research	NN	O	O
that	NN	O	O
has	NN	O	O
implicated	NN	O	O
a	NN	O	O
dysregulation	NN	O	O
in	NN	O	O
serotonin	NN	O	O
function	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
autism	NN	O	I-PAR
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
short-term	NN	O	O
reduction	NN	O	O
of	NN	O	O
serotonin	NN	O	O
precursor	NN	O	O
availability	NN	O	O
may	NN	O	O
exacerbate	NN	O	O
some	NN	O	O
symptoms	NN	O	B-OUT
characteristic	NN	O	O
of	NN	O	O
autism	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
.	NN	O	O

Continued	NN	O	O
investigation	NN	O	O
into	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
serotonin	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
autistic	NN	O	B-PAR
disorder	NN	O	I-PAR
is	NN	O	O
warranted	NN	O	O
.	NN	O	O



--DOCSTART-- (8911223)

A	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	O
study	NN	O	O
of	NN	O	O
fluvoxamine	NN	O	B-INT
in	NN	O	O
adults	NN	O	B-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Autistic	NN	O	O
disorder	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
fundamental	NN	O	O
disturbance	NN	O	O
in	NN	O	O
social	NN	O	O
interaction	NN	O	O
,	NN	O	O
impairments	NN	O	O
in	NN	O	O
communication	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
markedly	NN	O	O
restricted	NN	O	O
repertoire	NN	O	O
of	NN	O	O
activities	NN	O	O
and	NN	O	O
interests	NN	O	O
.	NN	O	O

Abnormalities	NN	O	O
in	NN	O	O
the	NN	O	O
serotonin	NN	O	O
neurotransmitter	NN	O	O
system	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
some	NN	O	O
persons	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O

No	NN	O	O
consistently	NN	O	O
effective	NN	O	O
and	NN	O	O
safe	NN	O	O
drugs	NN	O	O
have	NN	O	O
been	NN	O	O
developed	NN	O	O
for	NN	O	O
treating	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
autism	NN	O	O
.	NN	O	O

METHODS	NN	O	O
Thirty	NN	O	B-PAR
adults	NN	O	I-PAR
with	NN	O	I-PAR
autistic	NN	O	I-PAR
disorder	NN	O	I-PAR
completed	NN	O	O
a	NN	O	O
12-week	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	B-INT
trial	NN	O	O
of	NN	O	O
the	NN	O	O
potent	NN	O	O
and	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
uptake	NN	O	O
inhibitor	NN	O	O
fluvoxamine	NN	O	B-INT
maleate	NN	O	I-INT
.	NN	O	O

Behavioral	NN	O	B-OUT
ratings	NN	O	I-OUT
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Eight	NN	O	O
(	NN	O	O
53	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
15	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
fluvoxamine-treated	NN	O	B-INT
group	NN	O	O
were	NN	O	O
categorized	NN	O	O
as	NN	O	O
responders	NN	O	O
compared	NN	O	O
with	NN	O	O
none	NN	O	O
of	NN	O	O
15	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.001	NN	O	O
)	NN	O	O
.	NN	O	O

Fluvoxamine	NN	O	B-INT
was	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
reducing	NN	O	O
repetitive	NN	O	B-OUT
thoughts	NN	O	I-OUT
and	NN	O	I-OUT
behavior	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
,	NN	O	O
maladaptive	NN	O	B-OUT
behavior	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
aggression	NN	O	B-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.03	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
improving	NN	O	O
some	NN	O	O
aspects	NN	O	O
of	NN	O	O
social	NN	O	B-OUT
relatedness	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.04	NN	O	O
)	NN	O	O
,	NN	O	O
especially	NN	O	O
language	NN	O	B-OUT
usage	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.008	NN	O	O
)	NN	O	O
.	NN	O	O

Treatment	NN	O	O
response	NN	O	O
was	NN	O	O
not	NN	O	O
correlated	NN	O	O
with	NN	O	O
age	NN	O	O
level	NN	O	O
of	NN	O	O
autistic	NN	O	O
behavior	NN	O	O
,	NN	O	O
or	NN	O	O
full-scale	NN	O	O
IQ	NN	O	O
.	NN	O	O

Other	NN	O	O
than	NN	O	O
mild	NN	O	B-OUT
sedation	NN	O	I-OUT
and	NN	O	I-OUT
nausea	NN	O	I-OUT
in	NN	O	O
a	NN	O	O
few	NN	O	O
patients	NN	O	O
,	NN	O	O
fluvoxamine	NN	O	B-INT
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

No	NN	O	O
dyskinesias	NN	O	B-OUT
,	NN	O	I-OUT
adverse	NN	O	I-OUT
cardiovascular	NN	O	I-OUT
events	NN	O	I-OUT
,	NN	O	I-OUT
or	NN	O	I-OUT
seizures	NN	O	I-OUT
occurred	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Fluvoxamine	NN	O	B-INT
is	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
the	NN	O	O
short-term	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
autistic	NN	O	O
disorder	NN	O	O
in	NN	O	O
adults	NN	O	O
.	NN	O	O

Controlled	NN	O	O
studies	NN	O	O
of	NN	O	O
fluvoxamine	NN	O	B-INT
and	NN	O	O
other	NN	O	O
potent	NN	O	O
and	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
uptake	NN	O	O
inhibitors	NN	O	O
seem	NN	O	O
warranted	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
adolescents	NN	O	O
with	NN	O	O
autism	NN	O	O
.	NN	O	O



--DOCSTART-- (8913901)

Methodology	NN	O	O
of	NN	O	O
serial	NN	O	O
ECG	NN	O	O
classification	NN	O	O
using	NN	O	O
an	NN	O	O
adaptation	NN	O	O
of	NN	O	O
the	NN	O	O
NOVACODE	NN	O	O
for	NN	O	O
Q	NN	O	O
wave	NN	O	O
myocardial	NN	O	O
infarction	NN	O	O
in	NN	O	O
the	NN	O	O
Bypass	NN	O	O
Angioplasty	NN	O	O
Revascularization	NN	O	O
Investigation	NN	O	O
(	NN	O	O
BARI	NN	O	O
)	NN	O	O
.	NN	O	O

Serial	NN	O	O
electrocardiographic	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
changes	NN	O	O
are	NN	O	O
a	NN	O	O
critical	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
algorithm	NN	O	O
for	NN	O	O
classification	NN	O	O
of	NN	O	O
myocardial	NN	O	O
ischemic	NN	O	O
events	NN	O	O
in	NN	O	O
large-scale	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
describes	NN	O	O
a	NN	O	O
computerized	NN	O	O
serial	NN	O	O
ECG	NN	O	O
classification	NN	O	O
program	NN	O	O
developed	NN	O	O
at	NN	O	O
the	NN	O	O
St.	NN	O	O
Louis	NN	O	O
University	NN	O	O
Core	NN	O	O
ECG	NN	O	O
Laboratory	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
Bypass	NN	O	O
Angioplasty	NN	O	O
Revascularization	NN	O	O
Investigation	NN	O	O
(	NN	O	O
BARI	NN	O	O
)	NN	O	O
trial	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
multivessel	NN	O	I-PAR
coronary	NN	O	I-PAR
artery	NN	O	I-PAR
disease	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
coronary	NN	O	B-INT
artery	NN	O	I-INT
bypass	NN	O	I-INT
grafting	NN	O	I-INT
or	NN	O	O
percutaneous	NN	O	B-INT
transluminal	NN	O	I-INT
coronary	NN	O	I-INT
angioplasty	NN	O	I-INT
.	NN	O	O

The	NN	O	O
St.	NN	O	O
Louis	NN	O	O
University	NN	O	O
program	NN	O	O
detects	NN	O	O
and	NN	O	O
codes	NN	O	O
serial	NN	O	B-OUT
changes	NN	O	I-OUT
in	NN	O	I-OUT
Q	NN	O	I-OUT
,	NN	O	I-OUT
ST	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
T	NN	O	I-OUT
wave	NN	O	I-OUT
items	NN	O	I-OUT
according	NN	O	O
to	NN	O	O
Minnesota	NN	O	O
code	NN	O	O
(	NN	O	O
MC	NN	O	O
)	NN	O	O
criteria	NN	O	O
using	NN	O	O
a	NN	O	O
modified	NN	O	O
NOVACODE	NN	O	O
hierarchical	NN	O	O
classification	NN	O	O
system	NN	O	O
.	NN	O	O

Measurements	NN	O	O
using	NN	O	O
a	NN	O	O
seven-power	NN	O	O
calibrated	NN	O	O
coding	NN	O	O
loupe	NN	O	O
are	NN	O	O
used	NN	O	O
to	NN	O	O
generate	NN	O	O
the	NN	O	O
MC	NN	O	O
from	NN	O	O
a	NN	O	O
customized	NN	O	O
software	NN	O	O
program	NN	O	O
.	NN	O	O

Significant	NN	O	O
minor	NN	O	O
or	NN	O	O
major	NN	O	O
changes	NN	O	O
are	NN	O	O
detected	NN	O	O
by	NN	O	O
the	NN	O	O
serial	NN	O	O
comparison	NN	O	O
program	NN	O	O
and	NN	O	O
referred	NN	O	O
to	NN	O	O
a	NN	O	O
physician	NN	O	O
coder	NN	O	O
for	NN	O	O
verification	NN	O	O
.	NN	O	O

Serial	NN	O	O
comparison	NN	O	O
coding	NN	O	O
rules	NN	O	O
are	NN	O	O
used	NN	O	O
to	NN	O	O
adjust	NN	O	O
for	NN	O	O
weaknesses	NN	O	O
in	NN	O	O
the	NN	O	O
standard	NN	O	O
MC	NN	O	O
classification	NN	O	O
system	NN	O	O
resulting	NN	O	O
from	NN	O	O
instability	NN	O	O
at	NN	O	O
decision	NN	O	O
boundaries	NN	O	O
.	NN	O	O

Of	NN	O	O
4,244	NN	O	B-PAR
BARI	NN	O	I-PAR
randomized	NN	O	I-PAR
and	NN	O	I-PAR
registry	NN	O	I-PAR
study	NN	O	I-PAR
participants	NN	O	I-PAR
with	NN	O	I-PAR
follow-up	NN	O	I-PAR
ECGs	NN	O	I-PAR
received	NN	O	I-PAR
at	NN	O	I-PAR
the	NN	O	I-PAR
Core	NN	O	I-PAR
ECG	NN	O	I-PAR
Laboratory	NN	O	I-PAR
as	NN	O	I-PAR
of	NN	O	I-PAR
March	NN	O	I-PAR
1995	NN	O	I-PAR
,	NN	O	O
a	NN	O	O
grade	NN	O	O
2	NN	O	O
MC	NN	O	O
Q	NN	O	O
wave	NN	O	O
progression	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
568	NN	O	O
participants	NN	O	O
(	NN	O	O
13.4	NN	O	O
%	NN	O	O
)	NN	O	O
using	NN	O	O
MC	NN	O	O
criteria	NN	O	O
alone	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
367	NN	O	O
(	NN	O	O
8.6	NN	O	O
%	NN	O	O
)	NN	O	O
after	NN	O	O
the	NN	O	O
St.	NN	O	O
Louis	NN	O	O
University	NN	O	O
coding	NN	O	O
rules	NN	O	O
were	NN	O	O
applied	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
grade	NN	O	O
1	NN	O	O
MC	NN	O	O
Q	NN	O	O
wave	NN	O	O
progressions	NN	O	O
was	NN	O	O
16.4	NN	O	O
%	NN	O	O
(	NN	O	O
697/4,244	NN	O	O
)	NN	O	O
versus	NN	O	O
6.1	NN	O	O
%	NN	O	O
(	NN	O	O
259/4,244	NN	O	O
)	NN	O	O
when	NN	O	O
the	NN	O	O
St.	NN	O	O
Louis	NN	O	O
University	NN	O	O
program	NN	O	O
was	NN	O	O
applied	NN	O	O
.	NN	O	O

Intraobserver	NN	O	O
variability	NN	O	O
for	NN	O	O
grade	NN	O	O
2	NN	O	O
Q	NN	O	O
wave	NN	O	O
progression	NN	O	O
codes	NN	O	O
determined	NN	O	O
from	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
812	NN	O	O
serial	NN	O	O
.	NN	O	O



--DOCSTART-- (8916620)

Analysis	NN	O	O
of	NN	O	O
prevention	NN	O	O
program	NN	O	O
effectiveness	NN	O	O
with	NN	O	O
clustered	NN	O	O
data	NN	O	O
using	NN	O	O
generalized	NN	O	O
estimating	NN	O	O
equations	NN	O	O
.	NN	O	O

Experimental	NN	O	O
studies	NN	O	O
of	NN	O	O
prevention	NN	O	O
programs	NN	O	O
often	NN	O	O
randomize	NN	O	O
clusters	NN	O	O
of	NN	O	O
individuals	NN	O	O
rather	NN	O	O
than	NN	O	O
individuals	NN	O	O
to	NN	O	O
treatment	NN	O	O
conditions	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
correlation	NN	O	O
among	NN	O	O
individuals	NN	O	O
within	NN	O	O
clusters	NN	O	O
is	NN	O	O
not	NN	O	O
accounted	NN	O	O
for	NN	O	O
in	NN	O	O
statistical	NN	O	O
analysis	NN	O	O
,	NN	O	O
the	NN	O	O
standard	NN	O	O
errors	NN	O	O
are	NN	O	O
biased	NN	O	O
,	NN	O	O
potentially	NN	O	O
resulting	NN	O	O
in	NN	O	O
misleading	NN	O	O
conclusions	NN	O	O
about	NN	O	O
the	NN	O	O
significance	NN	O	O
of	NN	O	O
treatment	NN	O	O
effects	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
the	NN	O	O
generalized	NN	O	B-INT
estimating	NN	O	I-INT
equations	NN	O	I-INT
(	NN	O	I-INT
GEE	NN	O	I-INT
)	NN	O	I-INT
method	NN	O	O
,	NN	O	O
focusing	NN	O	O
specifically	NN	O	O
on	NN	O	O
the	NN	O	O
GEE-independent	NN	O	B-INT
method	NN	O	O
,	NN	O	O
to	NN	O	O
control	NN	O	O
for	NN	O	O
within-cluster	NN	O	O
correlation	NN	O	O
in	NN	O	O
regression	NN	O	O
models	NN	O	O
with	NN	O	O
either	NN	O	O
continuous	NN	O	O
or	NN	O	O
binary	NN	O	O
outcomes	NN	O	O
.	NN	O	O

The	NN	O	O
GEE-independent	NN	O	B-INT
method	NN	O	O
yields	NN	O	O
consistent	NN	O	O
and	NN	O	O
robust	NN	O	O
variance	NN	O	O
estimates	NN	O	O
.	NN	O	O

Data	NN	O	O
from	NN	O	O
project	NN	O	O
DARE	NN	O	O
,	NN	O	O
a	NN	O	O
youth	NN	O	B-PAR
substance	NN	O	O
abuse	NN	O	O
prevention	NN	O	O
program	NN	O	O
,	NN	O	O
are	NN	O	O
used	NN	O	O
for	NN	O	O
illustration	NN	O	O
.	NN	O	O



--DOCSTART-- (8989009)

Prevention	NN	O	O
of	NN	O	O
spinal	NN	O	O
anesthesia-induced	NN	O	O
hypotension	NN	O	O
in	NN	O	O
the	NN	O	B-PAR
elderly	NN	O	I-PAR
:	NN	O	O
comparison	NN	O	O
between	NN	O	O
preanesthetic	NN	O	O
administration	NN	O	O
of	NN	O	O
crystalloids	NN	O	B-INT
,	NN	O	O
colloids	NN	O	B-INT
,	NN	O	O
and	NN	O	O
no	NN	O	B-INT
prehydration	NN	O	I-INT
.	NN	O	O

The	NN	O	O
practice	NN	O	O
of	NN	O	O
routinely	NN	O	O
prehydrating	NN	O	O
patients	NN	O	O
by	NN	O	O
infusing	NN	O	O
a	NN	O	O
crystalloid	NN	O	B-INT
or	NN	O	O
colloid	NN	O	B-INT
solution	NN	O	I-INT
(	NN	O	O
up	NN	O	O
to	NN	O	O
1.0	NN	O	O
L/70	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
prevention	NN	O	O
of	NN	O	O
spinal	NN	O	O
anesthesia-induced	NN	O	O
hypotension	NN	O	O
has	NN	O	O
been	NN	O	O
challenged	NN	O	O
recently	NN	O	O
,	NN	O	O
after	NN	O	O
several	NN	O	O
reports	NN	O	O
of	NN	O	O
failure	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
its	NN	O	O
efficacy	NN	O	O
in	NN	O	O
young	NN	O	O
women	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
and	NN	O	I-OUT
frequency	NN	O	I-OUT
of	NN	O	I-OUT
hypotension	NN	O	I-OUT
and	NN	O	I-OUT
vasopressor	NN	O	I-OUT
therapy	NN	O	I-OUT
after	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
and	NN	O	O
no	NN	O	B-INT
prehydration	NN	O	I-INT
with	NN	O	O
crystalloid	NN	O	B-INT
and	NN	O	O
colloid	NN	O	B-INT
prehydration	NN	O	I-INT
in	NN	O	I-PAR
elderly	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

Eighty-five	NN	O	B-PAR
ASA	NN	O	I-PAR
grade	NN	O	I-PAR
I	NN	O	I-PAR
or	NN	O	I-PAR
II	NN	O	I-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
aged	NN	O	I-PAR
60-89	NN	O	I-PAR
yr	NN	O	I-PAR
)	NN	O	I-PAR
for	NN	O	I-PAR
elective	NN	O	I-PAR
total	NN	O	I-PAR
hip	NN	O	I-PAR
replacement	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
500	NN	O	O
mL	NN	O	O
crystalloid	NN	O	B-INT
solution	NN	O	I-INT
(	NN	O	O
Hartmanns	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
29	NN	O	O
)	NN	O	O
,	NN	O	O
500	NN	O	O
mL	NN	O	O
colloid	NN	O	B-INT
(	NN	O	O
Haemaccel	NN	O	B-INT
,	NN	O	O
n	NN	O	O
=	NN	O	O
28	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
no	NN	O	B-INT
prehydration	NN	O	I-INT
(	NN	O	O
n	NN	O	O
=	NN	O	O
28	NN	O	O
)	NN	O	O
over	NN	O	O
10	NN	O	O
min	NN	O	O
prior	NN	O	O
to	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Hypotension	NN	O	B-OUT
was	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
30	NN	O	O
%	NN	O	O
decrease	NN	O	O
from	NN	O	O
baseline	NN	O	O
systolic	NN	O	B-OUT
blood	NN	O	I-OUT
pressure	NN	O	I-OUT
(	NN	O	O
BP	NN	O	O
)	NN	O	O
or	NN	O	O
systolic	NN	O	O
<	NN	O	O
90	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
ephedrine	NN	O	O
3-mg	NN	O	O
boluses	NN	O	O
.	NN	O	O

Although	NN	O	O
absolute	NN	O	B-OUT
systolic	NN	O	I-OUT
BP	NN	O	I-OUT
readings	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
colloid	NN	O	B-INT
group	NN	O	O
between	NN	O	O
6	NN	O	O
and	NN	O	O
30	NN	O	O
min	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
hypotension	NN	O	I-OUT
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	B-OUT
of	NN	O	I-OUT
ephedrine	NN	O	I-OUT
use	NN	O	I-OUT
,	NN	O	I-OUT
incidence	NN	O	I-OUT
of	NN	O	I-OUT
nausea/vomiting	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
median	NN	O	B-OUT
total	NN	O	I-OUT
dose	NN	O	I-OUT
of	NN	O	I-OUT
ephedrine	NN	O	I-OUT
were	NN	O	O
similar	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
elderly	NN	O	B-PAR
patients	NN	O	I-PAR
undergoing	NN	O	I-PAR
elective	NN	O	I-PAR
procedures	NN	O	I-PAR
,	NN	O	O
withholding	NN	O	O
prehydration	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
any	NN	O	O
greater	NN	O	O
degree	NN	O	O
of	NN	O	O
hypotension	NN	O	B-OUT
or	NN	O	O
need	NN	O	B-OUT
for	NN	O	I-OUT
vasopressor	NN	O	I-OUT
therapy	NN	O	I-OUT
compared	NN	O	O
with	NN	O	O
crystalloid	NN	O	B-INT
or	NN	O	O
colloid	NN	O	B-INT
prehydration	NN	O	I-INT
.	NN	O	O



--DOCSTART-- (9229602)

[	NN	O	O
Antazoline/tetryzoline	NN	O	B-INT
eyedrops	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
levocabastine	NN	O	B-INT
eyedrops	NN	O	O
in	NN	O	O
acute	NN	O	B-PAR
allergic	NN	O	I-PAR
conjunctivitis	NN	O	I-PAR
]	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
Allergic	NN	O	B-PAR
conjunctivitis	NN	O	I-PAR
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
allergic	NN	O	O
diseases	NN	O	O
of	NN	O	O
the	NN	O	O
anterior	NN	O	O
eye	NN	O	O
segment	NN	O	O
.	NN	O	O

METHODS	NN	O	O
This	NN	O	O
multicentre	NN	O	O
,	NN	O	O
clinical	NN	O	O
trial	NN	O	O
was	NN	O	O
an	NN	O	O
investigation	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
antiallergic	NN	O	O
efficacy	NN	O	O
,	NN	O	O
local	NN	O	O
tolerance	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
Antazolin/Tetryzolin	NN	O	B-INT
eye	NN	O	O
drops	NN	O	O
and	NN	O	O
Levocabastine	NN	O	B-INT
eye	NN	O	O
drops	NN	O	O
.	NN	O	O

69	NN	O	B-PAR
patients	NN	O	I-PAR
were	NN	O	O
treated	NN	O	O
over	NN	O	O
a	NN	O	O
2	NN	O	O
weeks	NN	O	O
course	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
subjective	NN	O	B-OUT
and	NN	O	I-OUT
objective	NN	O	I-OUT
ocular	NN	O	I-OUT
symptoms	NN	O	I-OUT
were	NN	O	O
documented	NN	O	O
over	NN	O	O
the	NN	O	O
treatment	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
Both	NN	O	O
eye	NN	O	O
drops	NN	O	O
reduced	NN	O	O
subjective	NN	O	B-OUT
and	NN	O	I-OUT
objective	NN	O	I-OUT
ocular	NN	O	I-OUT
symptoms	NN	O	I-OUT
effective	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
treatments	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.0395	NN	O	O
)	NN	O	O
was	NN	O	O
the	NN	O	O
faster	NN	O	O
onset	NN	O	B-OUT
of	NN	O	I-OUT
action	NN	O	I-OUT
of	NN	O	O
Antazolin/Tetryzolin	NN	O	B-INT
30	NN	O	O
minutes	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
drop	NN	O	O
of	NN	O	O
trial	NN	O	O
medication	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
A	NN	O	O
fast	NN	O	O
and	NN	O	O
effective	NN	O	O
onset	NN	O	O
of	NN	O	O
action	NN	O	O
is	NN	O	O
of	NN	O	O
high	NN	O	O
clinical	NN	O	O
relevance	NN	O	O
.	NN	O	O

Therefore	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
using	NN	O	O
Antazolin/Tetryzolin	NN	O	B-INT
eye	NN	O	O
drops	NN	O	O
was	NN	O	O
clearly	NN	O	O
outweigh	NN	O	O
.	NN	O	O



--DOCSTART-- (9394106)

Effect	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
paromomycin	NN	O	B-INT
on	NN	O	O
endotoxemia	NN	O	B-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
alcoholic	NN	O	I-PAR
liver	NN	O	I-PAR
disease	NN	O	I-PAR
--	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	B-INT
trial	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
experimental	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
gut-derived	NN	O	O
endotoxins	NN	O	O
might	NN	O	O
be	NN	O	O
of	NN	O	O
relevance	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
and	NN	O	O
course	NN	O	O
of	NN	O	O
alcoholic	NN	O	O
liver	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
nonabsorbable	NN	O	O
,	NN	O	O
broad-spectrum	NN	O	O
antibiotic	NN	O	O
on	NN	O	O
endotoxemia	NN	O	B-OUT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
alcoholic	NN	O	I-PAR
liver	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O

Fifty	NN	O	B-PAR
patients	NN	O	I-PAR
with	NN	O	I-PAR
alcoholic	NN	O	I-PAR
liver	NN	O	I-PAR
disease	NN	O	I-PAR
(	NN	O	I-PAR
27	NN	O	I-PAR
with	NN	O	I-PAR
cirrhosis	NN	O	I-PAR
,	NN	O	I-PAR
23	NN	O	I-PAR
without	NN	O	I-PAR
cirrhosis	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
paromomycin	NN	O	B-INT
sulfate	NN	O	I-INT
(	NN	O	O
3	NN	O	O
x	NN	O	O
1	NN	O	O
g/day	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
fashion	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
3	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
if	NN	O	O
possible	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Endotoxin	NN	O	B-OUT
concentration	NN	O	I-OUT
,	NN	O	I-OUT
liver	NN	O	I-OUT
function	NN	O	I-OUT
tests	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
other	NN	O	O
laboratory	NN	O	O
parameters	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
weekly	NN	O	O
intervals	NN	O	O
.	NN	O	O

Endotoxin	NN	O	B-OUT
concentration	NN	O	I-OUT
was	NN	O	O
also	NN	O	O
determined	NN	O	O
in	NN	O	O
15	NN	O	B-PAR
healthy	NN	O	I-PAR
controls	NN	O	I-PAR
.	NN	O	O

Groups	NN	O	O
receiving	NN	O	O
paromomycin	NN	O	B-INT
or	NN	O	O
placebo	NN	O	B-INT
were	NN	O	O
similar	NN	O	O
for	NN	O	O
clinical	NN	O	O
and	NN	O	O
biological	NN	O	O
items	NN	O	O
collected	NN	O	O
initially	NN	O	O
.	NN	O	O

Mean	NN	O	O
initial	NN	O	O
endotoxin	NN	O	B-OUT
concentrations	NN	O	I-OUT
were	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
(	NN	O	O
mean	NN	O	O
+/-	NN	O	O
SEM	NN	O	O
;	NN	O	O
paromomycin	NN	O	B-INT
,	NN	O	O
16.7	NN	O	O
+/-	NN	O	O
5.3	NN	O	O
pg/ml	NN	O	O
;	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
17.5	NN	O	O
+/-	NN	O	O
6.9	NN	O	O
pg/ml	NN	O	O
;	NN	O	O
healthy	NN	O	O
controls	NN	O	O
,	NN	O	O
2.3	NN	O	O
+/-	NN	O	O
0.4	NN	O	O
pg/ml	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
mean	NN	O	O
endotoxin	NN	O	B-OUT
concentration	NN	O	I-OUT
was	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
verum	NN	O	O
group	NN	O	O
after	NN	O	O
1	NN	O	O
week	NN	O	O
(	NN	O	O
paromomycin	NN	O	B-INT
,	NN	O	O
8.0	NN	O	O
+/-	NN	O	O
1.9	NN	O	O
pg/ml	NN	O	O
;	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
14.6	NN	O	O
+/-	NN	O	O
3.5	NN	O	O
pg/ml	NN	O	O
;	NN	O	O
p	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
,	NN	O	O
paromomycin	NN	O	B-INT
treatment	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
endotoxin	NN	O	B-OUT
concentration	NN	O	I-OUT
or	NN	O	O
liver	NN	O	B-OUT
function	NN	O	I-OUT
tests	NN	O	I-OUT
during	NN	O	O
the	NN	O	O
4-week	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
paromomycin	NN	O	B-INT
treatment	NN	O	O
on	NN	O	O
endotoxemia	NN	O	O
in	NN	O	O
cirrhotics	NN	O	O
reported	NN	O	O
in	NN	O	O
earlier	NN	O	O
studies	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
reproduced	NN	O	O
under	NN	O	O
the	NN	O	O
conditions	NN	O	O
of	NN	O	O
this	NN	O	O
trial	NN	O	O
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
alcoholic	NN	O	I-PAR
liver	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	O



--DOCSTART-- (9481998)

Effect	NN	O	O
of	NN	O	O
indomethacin	NN	O	B-INT
phonophoresis	NN	O	I-INT
on	NN	O	O
the	NN	O	O
relief	NN	O	O
of	NN	O	O
temporomandibular	NN	O	B-PAR
joint	NN	O	I-PAR
pain	NN	O	I-PAR
.	NN	O	O

The	NN	O	O
pain-relieving	NN	O	B-OUT
effect	NN	O	O
of	NN	O	O
indomethacin	NN	O	B-INT
phonophoresis	NN	O	I-INT
on	NN	O	O
temporomandibular	NN	O	O
(	NN	O	O
TMJ	NN	O	O
)	NN	O	O
joint	NN	O	O
pain	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	B-INT
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

Twenty	NN	O	B-PAR
subjects	NN	O	I-PAR
,	NN	O	I-PAR
who	NN	O	I-PAR
have	NN	O	I-PAR
TMJ	NN	O	I-PAR
pain	NN	O	I-PAR
,	NN	O	O
were	NN	O	O
included	NN	O	O
for	NN	O	O
this	NN	O	O
study	NN	O	O
and	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
either	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

Each	NN	O	O
treatment	NN	O	O
consisted	NN	O	O
of	NN	O	O
the	NN	O	O
application	NN	O	O
of	NN	O	O
ultrasound	NN	O	O
massage	NN	O	O
(	NN	O	O
1.0	NN	O	O
MHz	NN	O	O
,	NN	O	O
0.8	NN	O	O
to	NN	O	O
1.5	NN	O	O
W/cm2	NN	O	O
continuous	NN	O	O
output	NN	O	O
)	NN	O	O
for	NN	O	O
15	NN	O	O
minutes	NN	O	O
to	NN	O	O
the	NN	O	O
painful	NN	O	O
temporomandibular	NN	O	O
joint	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
conducting	NN	O	O
medium	NN	O	O
,	NN	O	O
1	NN	O	O
%	NN	O	O
indomethacin	NN	O	B-INT
cream	NN	O	O
was	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
and	NN	O	O
placebo	NN	O	B-INT
cream	NN	O	O
for	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
respectively	NN	O	O
.	NN	O	O

Pre-	NN	O	O
and	NN	O	O
post-treatment	NN	O	O
pain	NN	O	B-OUT
levels	NN	O	I-OUT
and	NN	O	I-OUT
pain	NN	O	I-OUT
sensitivity	NN	O	I-OUT
were	NN	O	O
assessed	NN	O	O
with	NN	O	O
visual	NN	O	B-OUT
analogue	NN	O	I-OUT
scales	NN	O	I-OUT
(	NN	O	I-OUT
VAS	NN	O	I-OUT
)	NN	O	I-OUT
and	NN	O	O
pressure	NN	O	B-OUT
pain	NN	O	I-OUT
threshold	NN	O	I-OUT
(	NN	O	I-OUT
PPT	NN	O	I-OUT
)	NN	O	I-OUT
.	NN	O	O

Mean	NN	O	O
data	NN	O	O
indicated	NN	O	O
that	NN	O	O
post-treatment	NN	O	B-OUT
VAS	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
and	NN	O	O
post-treatment	NN	O	B-OUT
PPT	NN	O	I-OUT
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
,	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
indomethacin	NN	O	B-INT
phonophoresis	NN	O	I-INT
provides	NN	O	O
significant	NN	O	O
pain	NN	O	B-OUT
relieving	NN	O	O
effect	NN	O	O
over	NN	O	O
the	NN	O	O
TMJ	NN	O	O
pain	NN	O	O
.	NN	O	O



--DOCSTART-- (9573502)

Systemic	NN	O	B-OUT
hemodynamic	NN	O	I-OUT
,	NN	O	I-OUT
neurohormonal	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
renal	NN	O	I-OUT
effects	NN	O	I-OUT
of	NN	O	O
a	NN	O	O
steady-state	NN	O	O
infusion	NN	O	O
of	NN	O	O
human	NN	O	B-INT
brain	NN	O	I-INT
natriuretic	NN	O	I-INT
peptide	NN	O	I-INT
in	NN	O	O
patients	NN	O	B-PAR
with	NN	O	I-PAR
hemodynamically	NN	O	I-PAR
decompensated	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
Human	NN	O	B-INT
brain	NN	O	I-INT
natriuretic	NN	O	I-INT
peptide	NN	O	I-INT
(	NN	O	I-INT
hBNP	NN	O	I-INT
)	NN	O	I-INT
is	NN	O	O
a	NN	O	O
promising	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
decompensated	NN	O	O
cardiac	NN	O	O
failure	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
systemic	NN	O	B-OUT
hemodynamic	NN	O	I-OUT
,	NN	O	I-OUT
neurohormonal	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
renal	NN	O	I-OUT
effects	NN	O	I-OUT
of	NN	O	O
hBNP	NN	O	B-INT
have	NN	O	O
been	NN	O	O
incompletely	NN	O	O
studied	NN	O	O
in	NN	O	O
human	NN	O	O
heart	NN	O	O
failure	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
The	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
continuous	NN	O	O
4-hour	NN	O	O
infusion	NN	O	O
of	NN	O	O
hBNP	NN	O	B-INT
were	NN	O	O
determined	NN	O	O
in	NN	O	O
16	NN	O	B-PAR
decompensated	NN	O	I-PAR
heart	NN	O	I-PAR
failure	NN	O	I-PAR
patients	NN	O	I-PAR
in	NN	O	O
an	NN	O	O
invasive	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	B-INT
study	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
evaluated	NN	O	O
during	NN	O	O
three	NN	O	O
4-hour	NN	O	O
study	NN	O	O
periods	NN	O	O
:	NN	O	O
baseline	NN	O	O
,	NN	O	O
treatment	NN	O	O
(	NN	O	O
placebo	NN	O	B-INT
[	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
]	NN	O	O
versus	NN	O	O
hBNP	NN	O	B-INT
0.025	NN	O	O
or	NN	O	O
0.05	NN	O	O
microgram/kg/min	NN	O	O
[	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
]	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
post-treatment	NN	O	O
.	NN	O	O

Urinary	NN	O	O
volume	NN	O	O
losses	NN	O	O
were	NN	O	O
replaced	NN	O	O
hourly	NN	O	O
to	NN	O	O
separate	NN	O	O
the	NN	O	O
vasodilatory	NN	O	O
and	NN	O	O
diuretic	NN	O	O
effects	NN	O	O
of	NN	O	O
hBNP	NN	O	B-INT
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
hBNP	NN	O	B-INT
group	NN	O	O
were	NN	O	O
excluded	NN	O	O
from	NN	O	O
the	NN	O	O
analysis	NN	O	O
because	NN	O	O
of	NN	O	O
adverse	NN	O	B-OUT
events	NN	O	I-OUT
.	NN	O	O

hBNP	NN	O	B-INT
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
reduced	NN	O	O
right	NN	O	B-OUT
atrial	NN	O	I-OUT
pressure	NN	O	I-OUT
and	NN	O	I-OUT
pulmonary	NN	O	I-OUT
capillary	NN	O	I-OUT
wedge	NN	O	I-OUT
pressure	NN	O	I-OUT
by	NN	O	O
approximately	NN	O	O
30	NN	O	O
%	NN	O	O
and	NN	O	O
40	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

hBNP	NN	O	B-INT
also	NN	O	O
significantly	NN	O	O
lowered	NN	O	O
systemic	NN	O	B-OUT
vascular	NN	O	I-OUT
resistance	NN	O	I-OUT
from	NN	O	O
1722	NN	O	O
+/-	NN	O	O
139	NN	O	O
to	NN	O	O
1101	NN	O	O
+/-	NN	O	O
83	NN	O	O
dynes.s.cm-5	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
unloading	NN	O	O
effects	NN	O	O
of	NN	O	O
hBNP	NN	O	B-INT
produced	NN	O	O
a	NN	O	O
28	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
cardiac	NN	O	B-OUT
index	NN	O	I-OUT
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
with	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
heart	NN	O	B-OUT
rate	NN	O	I-OUT
.	NN	O	O

Compared	NN	O	O
to	NN	O	O
placebo	NN	O	B-INT
,	NN	O	O
hBNP	NN	O	B-INT
decreased	NN	O	O
plasma	NN	O	B-OUT
norepinephrine	NN	O	I-OUT
and	NN	O	I-OUT
aldosterone	NN	O	I-OUT
.	NN	O	O

Renal	NN	O	B-OUT
hemodynamics	NN	O	I-OUT
were	NN	O	O
unaffected	NN	O	O
by	NN	O	O
hBNP	NN	O	B-INT
;	NN	O	O
however	NN	O	O
,	NN	O	O
most	NN	O	O
patients	NN	O	O
were	NN	O	O
resistant	NN	O	O
to	NN	O	O
its	NN	O	O
natriuretic	NN	O	B-OUT
effect	NN	O	I-OUT
.	NN	O	O

CONCLUSIONS	NN	O	O
1	NN	O	O
)	NN	O	O
The	NN	O	O
predominant	NN	O	O
hemodynamic	NN	O	B-OUT
effects	NN	O	I-OUT
of	NN	O	O
hBNP	NN	O	B-INT
were	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
cardiac	NN	O	B-OUT
preload	NN	O	I-OUT
and	NN	O	I-OUT
systemic	NN	O	I-OUT
vascular	NN	O	I-OUT
resistance	NN	O	I-OUT
.	NN	O	O

2	NN	O	O
)	NN	O	O
hBNP	NN	O	B-INT
also	NN	O	O
improved	NN	O	O
cardiac	NN	O	B-OUT
output	NN	O	I-OUT
without	NN	O	O
increasing	NN	O	O
heart	NN	O	B-OUT
rate	NN	O	I-OUT
.	NN	O	O

3	NN	O	O
)	NN	O	O
Plasma	NN	O	B-OUT
norepinephrine	NN	O	I-OUT
and	NN	O	I-OUT
aldosterone	NN	O	I-OUT
levels	NN	O	I-OUT
decreased	NN	O	O
during	NN	O	O
hBNP	NN	O	B-INT
infusion	NN	O	O
.	NN	O	O

4	NN	O	O
)	NN	O	O
hBNP	NN	O	B-INT
is	NN	O	O
pharmacologically	NN	O	O
active	NN	O	O
and	NN	O	O
has	NN	O	O
potential	NN	O	O
in	NN	O	O
the	NN	O	O
therapy	NN	O	O
for	NN	O	O
decompensated	NN	O	O
heart	NN	O	O
failure	NN	O	O
.	NN	O	O



--DOCSTART-- (9695300)

Salbutamol	NN	O	B-INT
or	NN	O	O
mist	NN	O	B-INT
in	NN	O	O
acute	NN	O	B-PAR
bronchiolitis	NN	O	I-PAR
.	NN	O	O

BACKGROUND	NN	O	O
The	NN	O	O
role	NN	O	O
of	NN	O	O
bronchodilators	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
bronchiolitis	NN	O	O
remains	NN	O	O
controversial	NN	O	O
.	NN	O	O

METHODS	NN	O	O
A	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
controlled	NN	O	O
trial	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
clinical	NN	O	O
response	NN	O	O
to	NN	O	O
nebulized	NN	O	O
salbutamol	NN	O	B-INT
.	NN	O	O

One	NN	O	B-PAR
hundred	NN	O	I-PAR
and	NN	O	I-PAR
fifty-six	NN	O	I-PAR
infants	NN	O	I-PAR
aged	NN	O	I-PAR
between	NN	O	I-PAR
7	NN	O	I-PAR
weeks	NN	O	I-PAR
and	NN	O	I-PAR
24	NN	O	I-PAR
months	NN	O	I-PAR
who	NN	O	I-PAR
had	NN	O	I-PAR
had	NN	O	I-PAR
an	NN	O	I-PAR
episode	NN	O	I-PAR
of	NN	O	I-PAR
wheezing	NN	O	I-PAR
and	NN	O	I-PAR
other	NN	O	I-PAR
signs	NN	O	I-PAR
and	NN	O	I-PAR
symptoms	NN	O	I-PAR
of	NN	O	I-PAR
bronchiolitis	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
three	NN	O	O
groups	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
nebulized	NN	O	O
salbutamol	NN	O	B-INT
was	NN	O	O
administered	NN	O	O
to	NN	O	O
52	NN	O	O
patients	NN	O	O
in	NN	O	O
group	NN	O	O
I	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0.15	NN	O	O
mg/kg	NN	O	O
in	NN	O	O
2	NN	O	O
mL	NN	O	O
saline	NN	O	B-INT
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
saline	NN	O	B-INT
was	NN	O	O
nebulized	NN	O	O
to	NN	O	O
52	NN	O	O
patients	NN	O	O
in	NN	O	O
group	NN	O	O
II	NN	O	O
and	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
III	NN	O	O
52	NN	O	O
patients	NN	O	O
received	NN	O	O
mist	NN	O	B-INT
in	NN	O	O
a	NN	O	O
tent	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
groups	NN	O	O
were	NN	O	O
administered	NN	O	O
oxygen	NN	O	B-INT
during	NN	O	O
the	NN	O	O
procedures	NN	O	O
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
repeated	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
agent	NN	O	O
after	NN	O	O
30	NN	O	O
min	NN	O	O
if	NN	O	O
the	NN	O	O
respiratory	NN	O	O
score	NN	O	O
was	NN	O	O
5	NN	O	O
or	NN	O	O
more	NN	O	O
.	NN	O	O

Respiratory	NN	O	B-OUT
rate	NN	O	I-OUT
,	NN	O	I-OUT
heart	NN	O	I-OUT
rate	NN	O	I-OUT
,	NN	O	I-OUT
oxygen	NN	O	I-OUT
saturation	NN	O	I-OUT
and	NN	O	I-OUT
presence	NN	O	I-OUT
of	NN	O	I-OUT
cyanosis	NN	O	I-OUT
,	NN	O	I-OUT
wheezing	NN	O	I-OUT
,	NN	O	I-OUT
retractions	NN	O	I-OUT
were	NN	O	O
recorded	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
each	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
The	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
respiratory	NN	O	B-OUT
score	NN	O	I-OUT
was	NN	O	O
5.2	NN	O	O
+/-	NN	O	O
1.8	NN	O	O
,	NN	O	O
0.82	NN	O	O
+/-	NN	O	O
2.4	NN	O	O
and	NN	O	O
1.7	NN	O	O
+/-	NN	O	O
1.3	NN	O	O
in	NN	O	O
group	NN	O	O
I	NN	O	O
,	NN	O	O
II	NN	O	O
and	NN	O	O
III	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
group	NN	O	O
I	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

Heart	NN	O	B-OUT
rate	NN	O	I-OUT
was	NN	O	O
similar	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

Oxygen	NN	O	B-OUT
saturation	NN	O	I-OUT
decreased	NN	O	O
in	NN	O	O
group	NN	O	O
I	NN	O	O
without	NN	O	O
reaching	NN	O	O
statistical	NN	O	O
significance	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
Salbutamol	NN	O	B-INT
was	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	B-OUT
and	NN	O	O
safe	NN	O	B-OUT
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
bronchiolitis	NN	O	O
.	NN	O	O



--DOCSTART-- (9730996)

Inhaled	NN	O	O
fluticasone	NN	O	B-INT
reduces	NN	O	O
sputum	NN	O	B-OUT
inflammatory	NN	O	I-OUT
indices	NN	O	I-OUT
in	NN	O	O
severe	NN	O	B-PAR
bronchiectasis	NN	O	I-PAR
.	NN	O	O

Although	NN	O	O
corticosteroid	NN	O	O
therapy	NN	O	O
might	NN	O	O
be	NN	O	O
clinically	NN	O	O
beneficial	NN	O	O
for	NN	O	O
bronchiectasis	NN	O	O
,	NN	O	O
very	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
of	NN	O	O
its	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
inflammatory	NN	O	B-OUT
and	NN	O	I-OUT
infective	NN	O	I-OUT
markers	NN	O	I-OUT
in	NN	O	O
bronchiectasis	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
therefore	NN	O	O
performed	NN	O	O
a	NN	O	O
double-blind	NN	O	O
,	NN	O	O
placebo-controlled	NN	O	B-INT
study	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
4-wk	NN	O	O
administration	NN	O	O
of	NN	O	O
inhaled	NN	O	O
fluticasone	NN	O	B-INT
in	NN	O	O
bronchiectasis	NN	O	O
.	NN	O	O

Twenty-four	NN	O	B-PAR
patients	NN	O	I-PAR
(	NN	O	I-PAR
12	NN	O	I-PAR
female	NN	O	I-PAR
;	NN	O	I-PAR
mean	NN	O	I-PAR
age	NN	O	I-PAR
51	NN	O	I-PAR
yr	NN	O	I-PAR
)	NN	O	I-PAR
were	NN	O	O
randomized	NN	O	O
into	NN	O	O
receiving	NN	O	O
either	NN	O	O
inhaled	NN	O	O
fluticasone	NN	O	B-INT
(	NN	O	O
500	NN	O	O
microgram	NN	O	O
twice	NN	O	O
daily	NN	O	O
)	NN	O	O
via	NN	O	O
the	NN	O	O
Accuhaler	NN	O	O
device	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	B-INT
.	NN	O	O

At	NN	O	O
each	NN	O	O
visit	NN	O	O
,	NN	O	O
spirometry	NN	O	B-OUT
,	NN	O	I-OUT
24-h	NN	O	I-OUT
sputum	NN	O	I-OUT
volume	NN	O	I-OUT
,	NN	O	I-OUT
sputum	NN	O	I-OUT
leukocyte	NN	O	I-OUT
density	NN	O	I-OUT
,	NN	O	I-OUT
bacterial	NN	O	I-OUT
densities	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
concentrations	NN	O	B-OUT
of	NN	O	I-OUT
interleukin	NN	O	I-OUT
(	NN	O	I-OUT
IL	NN	O	I-OUT
)	NN	O	I-OUT
-1beta	NN	O	I-OUT
,	NN	O	I-OUT
IL-8	NN	O	I-OUT
,	NN	O	I-OUT
tumor	NN	O	I-OUT
necrosis	NN	O	I-OUT
factor-alpha	NN	O	I-OUT
(	NN	O	I-OUT
TNF-alpha	NN	O	I-OUT
)	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
leukotriene	NN	O	B-OUT
B4	NN	O	I-OUT
(	NN	O	I-OUT
LTB4	NN	O	I-OUT
)	NN	O	I-OUT
were	NN	O	O
determined	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
sputum	NN	O	B-OUT
leukocyte	NN	O	I-OUT
density	NN	O	I-OUT
and	NN	O	O
IL-1beta	NN	O	B-OUT
,	NN	O	I-OUT
IL-8	NN	O	I-OUT
,	NN	O	O
and	NN	O	O
LTB4	NN	O	B-OUT
after	NN	O	O
fluticasone	NN	O	B-INT
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
fluticasone	NN	O	B-INT
group	NN	O	O
had	NN	O	O
one	NN	O	O
and	NN	O	O
the	NN	O	O
placebo	NN	O	B-INT
group	NN	O	O
three	NN	O	O
episodes	NN	O	O
of	NN	O	O
exacerbation	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
spirometry	NN	O	B-OUT
(	NN	O	O
p	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
or	NN	O	O
any	NN	O	O
reported	NN	O	O
adverse	NN	O	B-OUT
reactions	NN	O	I-OUT
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
show	NN	O	O
that	NN	O	O
high-dose	NN	O	O
fluticasone	NN	O	O
is	NN	O	O
effective	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
sputum	NN	O	B-OUT
inflammatory	NN	O	I-OUT
indices	NN	O	I-OUT
in	NN	O	O
bronchiectasis	NN	O	O
.	NN	O	O

Large-scale	NN	O	O
and	NN	O	O
long-term	NN	O	O
studies	NN	O	O
are	NN	O	O
indicated	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
inhaled	NN	O	O
steroid	NN	O	O
therapy	NN	O	O
on	NN	O	O
the	NN	O	O
inflammatory	NN	O	O
components	NN	O	O
in	NN	O	O
bronchiectasis	NN	O	B-PAR
.	NN	O	O



--DOCSTART-- (9816035)

Amonafide	NN	O	B-INT
:	NN	O	O
An	NN	O	O
active	NN	O	O
agent	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
previously	NN	O	B-PAR
untreated	NN	O	I-PAR
advanced	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
--	NN	O	O
a	NN	O	O
cancer	NN	O	O
and	NN	O	O
leukemia	NN	O	O
group	NN	O	O
B	NN	O	O
study	NN	O	O
(	NN	O	O
CALGB	NN	O	O
8642	NN	O	O
)	NN	O	O
.	NN	O	O

Amonafide	NN	O	B-INT
is	NN	O	O
a	NN	O	O
new	NN	O	O
imide	NN	O	O
derivative	NN	O	O
of	NN	O	O
naphthalic	NN	O	O
acid	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
had	NN	O	O
demonstrated	NN	O	O
significant	NN	O	O
activity	NN	O	O
in	NN	O	O
preclinical	NN	O	O
studies	NN	O	O
and	NN	O	O
some	NN	O	O
activity	NN	O	O
in	NN	O	O
Phase	NN	O	O
I	NN	O	O
trials	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
is	NN	O	O
extensively	NN	O	O
metabolized	NN	O	O
and	NN	O	O
detected	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
urine	NN	O	O
.	NN	O	O

Its	NN	O	O
toxicity	NN	O	O
has	NN	O	O
previously	NN	O	O
been	NN	O	O
correlated	NN	O	O
to	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
an	NN	O	O
active	NN	O	O
metabolite	NN	O	O
,	NN	O	O
N-acetyl-amonafide	NN	O	O
.	NN	O	O

Amonafide	NN	O	B-INT
was	NN	O	O
chosen	NN	O	O
for	NN	O	O
inclusion	NN	O	O
in	NN	O	O
the	NN	O	O
Cancer	NN	O	O
and	NN	O	O
Leukemia	NN	O	O
Group	NN	O	O
B	NN	O	O
(	NN	O	O
CALGB	NN	O	O
)	NN	O	O
master	NN	O	O
metastatic	NN	O	O
breast	NN	O	O
cancer	NN	O	O
protocol	NN	O	O
.	NN	O	O

CALGB	NN	O	O
8642	NN	O	O
randomizes	NN	O	O
previously	NN	O	B-PAR
untreated	NN	O	I-PAR
metastatic	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
either	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
several	NN	O	O
Phase	NN	O	O
II	NN	O	O
agents	NN	O	O
given	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
four	NN	O	O
cycles	NN	O	O
and	NN	O	O
then	NN	O	O
followed	NN	O	O
by	NN	O	O
standard	NN	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	NN	O	B-INT
,	NN	O	O
or	NN	O	O
to	NN	O	O
immediate	NN	O	O
treatment	NN	O	O
with	NN	O	O
standard	NN	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	NN	O	B-INT
.	NN	O	O

The	NN	O	O
end	NN	O	O
point	NN	O	O
of	NN	O	O
CALGB	NN	O	O
8642	NN	O	O
is	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
difference	NN	O	O
in	NN	O	O
survival	NN	O	B-OUT
,	NN	O	I-OUT
toxicity	NN	O	I-OUT
,	NN	O	I-OUT
and	NN	O	I-OUT
overall	NN	O	I-OUT
response	NN	O	I-OUT
when	NN	O	O
limited	NN	O	O
exposure	NN	O	O
to	NN	O	O
Phase	NN	O	O
II	NN	O	O
agents	NN	O	O
precedes	NN	O	O
standard	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
deals	NN	O	O
only	NN	O	O
with	NN	O	O
amonafide	NN	O	B-INT
as	NN	O	O
a	NN	O	O
Phase	NN	O	O
II	NN	O	O
agent	NN	O	O
.	NN	O	O

Comparisons	NN	O	O
with	NN	O	O
the	NN	O	O
cyclophosphamide-doxorubicin-5-fluorouracil	NN	O	B-INT
arm	NN	O	O
will	NN	O	O
not	NN	O	O
be	NN	O	O
addressed	NN	O	O
.	NN	O	O

Patients	NN	O	B-PAR
had	NN	O	I-PAR
to	NN	O	I-PAR
have	NN	O	I-PAR
histologically	NN	O	I-PAR
documented	NN	O	I-PAR
measurable	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
and	NN	O	I-PAR
a	NN	O	I-PAR
performance	NN	O	I-PAR
status	NN	O	I-PAR
of	NN	O	I-PAR
0-1	NN	O	I-PAR
.	NN	O	I-PAR
Patients	NN	O	I-PAR
could	NN	O	I-PAR
not	NN	O	I-PAR
have	NN	O	I-PAR
had	NN	O	I-PAR
prior	NN	O	I-PAR
chemotherapy	NN	O	I-PAR
for	NN	O	I-PAR
metastatic	NN	O	I-PAR
disease	NN	O	I-PAR
.	NN	O	I-PAR
Prior	NN	O	I-PAR
adjuvant	NN	O	I-PAR
chemotherapy	NN	O	I-PAR
was	NN	O	I-PAR
permitted	NN	O	I-PAR
.	NN	O	I-PAR
Patients	NN	O	I-PAR
could	NN	O	I-PAR
not	NN	O	I-PAR
have	NN	O	I-PAR
visceral	NN	O	I-PAR
crisis	NN	O	I-PAR
.	NN	O	I-PAR
Amonafide	NN	O	I-INT
was	NN	O	O
given	NN	O	O
at	NN	O	O
300	NN	O	O
mg/m2/day	NN	O	O
i.v	NN	O	O
.	NN	O	O

for	NN	O	O
5	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
repeated	NN	O	O
at	NN	O	O
21-day	NN	O	O
intervals	NN	O	O
for	NN	O	O
a	NN	O	O
maximum	NN	O	O
of	NN	O	O
four	NN	O	O
cycles	NN	O	O
.	NN	O	O

Escalation	NN	O	O
and	NN	O	O
reduction	NN	O	O
in	NN	O	O
dose	NN	O	O
was	NN	O	O
mandated	NN	O	O
dependent	NN	O	O
on	NN	O	O
hematotoxicity	NN	O	O
or	NN	O	O
lack	NN	O	O
thereof	NN	O	O
.	NN	O	O

Toxicity	NN	O	B-OUT
was	NN	O	O
primarily	NN	O	O
hematological	NN	O	O
and	NN	O	O
bimodal	NN	O	O
:	NN	O	O
32	NN	O	O
%	NN	O	O
had	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
leukopenia	NN	O	B-OUT
and	NN	O	O
24	NN	O	O
%	NN	O	O
had	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
thrombocytopenia	NN	O	B-OUT
;	NN	O	O
22	NN	O	O
%	NN	O	O
had	NN	O	O
no	NN	O	O
leukopenia	NN	O	B-OUT
and	NN	O	O
44	NN	O	O
%	NN	O	O
had	NN	O	O
no	NN	O	O
thrombocytopenia	NN	O	B-OUT
.	NN	O	O

The	NN	O	O
response	NN	O	B-OUT
rate	NN	O	I-OUT
was	NN	O	O
18	NN	O	O
%	NN	O	O
,	NN	O	O
including	NN	O	O
one	NN	O	O
complete	NN	O	O
response	NN	O	O
.	NN	O	O

When	NN	O	O
response	NN	O	O
was	NN	O	O
analyzed	NN	O	O
by	NN	O	O
hematological	NN	O	B-OUT
toxicity	NN	O	I-OUT
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
35.7	NN	O	O
%	NN	O	O
response	NN	O	O
if	NN	O	O
patients	NN	O	O
had	NN	O	O
leukopenia	NN	O	B-OUT
grade	NN	O	O
3/4	NN	O	O
(	NN	O	O
versus	NN	O	O
8.3	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0.08	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
response	NN	O	O
if	NN	O	O
patients	NN	O	O
had	NN	O	O
thrombocytopenia	NN	O	B-OUT
grade	NN	O	O
3/4	NN	O	O
(	NN	O	O
versus	NN	O	O
7.1	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
amonafide	NN	O	B-INT
is	NN	O	O
somewhat	NN	O	O
active	NN	O	O
in	NN	O	O
previously	NN	O	B-PAR
untreated	NN	O	I-PAR
breast	NN	O	I-PAR
cancer	NN	O	I-PAR
patients	NN	O	I-PAR
.	NN	O	O

There	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
steep	NN	O	O
dose-response	NN	O	O
curve	NN	O	O
,	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
significant	NN	O	O
correlation	NN	O	O
between	NN	O	O
myelosuppression	NN	O	O
and	NN	O	O
response	NN	O	O
.	NN	O	O

Rates	NN	O	B-OUT
of	NN	O	I-OUT
responses	NN	O	I-OUT
in	NN	O	O
patients	NN	O	O
adequately	NN	O	O
dosed	NN	O	O
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
with	NN	O	O
significant	NN	O	O
hematotoxicity	NN	O	O
)	NN	O	O
with	NN	O	O
amonafide	NN	O	O
ranged	NN	O	O
from	NN	O	O
35	NN	O	O
to	NN	O	O
50	NN	O	O
%	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
will	NN	O	O
incorporate	NN	O	O
individualized	NN	O	O
dosing	NN	O	O
based	NN	O	O
on	NN	O	O
pretreatment	NN	O	O
acetylator	NN	O	O
phenotyping	NN	O	O
.	NN	O	O



